ProtocolSection.IdentificationModule.NCTId,ProtocolSection.IdentificationModule.OrgStudyIdInfo.OrgStudyId,ProtocolSection.IdentificationModule.Organization.OrgFullName,ProtocolSection.IdentificationModule.Organization.OrgClass,ProtocolSection.IdentificationModule.BriefTitle,ProtocolSection.IdentificationModule.OfficialTitle,ProtocolSection.StatusModule.StatusVerifiedDate,ProtocolSection.StatusModule.OverallStatus,ProtocolSection.StatusModule.ExpandedAccessInfo.HasExpandedAccess,ProtocolSection.StatusModule.StartDateStruct.StartDate,ProtocolSection.StatusModule.StartDateStruct.StartDateType,ProtocolSection.StatusModule.PrimaryCompletionDateStruct.PrimaryCompletionDate,ProtocolSection.StatusModule.PrimaryCompletionDateStruct.PrimaryCompletionDateType,ProtocolSection.StatusModule.CompletionDateStruct.CompletionDate,ProtocolSection.StatusModule.CompletionDateStruct.CompletionDateType,ProtocolSection.StatusModule.StudyFirstSubmitDate,ProtocolSection.StatusModule.StudyFirstSubmitQCDate,ProtocolSection.StatusModule.StudyFirstPostDateStruct.StudyFirstPostDate,ProtocolSection.StatusModule.StudyFirstPostDateStruct.StudyFirstPostDateType,ProtocolSection.StatusModule.LastUpdateSubmitDate,ProtocolSection.StatusModule.LastUpdatePostDateStruct.LastUpdatePostDate,ProtocolSection.StatusModule.LastUpdatePostDateStruct.LastUpdatePostDateType,ProtocolSection.SponsorCollaboratorsModule.ResponsibleParty.ResponsiblePartyType,ProtocolSection.SponsorCollaboratorsModule.LeadSponsor.LeadSponsorName,ProtocolSection.SponsorCollaboratorsModule.LeadSponsor.LeadSponsorClass,ProtocolSection.OversightModule.IsFDARegulatedDrug,ProtocolSection.OversightModule.IsFDARegulatedDevice,ProtocolSection.OversightModule.IsUnapprovedDevice,ProtocolSection.OversightModule.IsUSExport,ProtocolSection.DescriptionModule.BriefSummary,ProtocolSection.ConditionsModule.ConditionList.Condition,ProtocolSection.DesignModule.StudyType,ProtocolSection.DesignModule.PhaseList.Phase,ProtocolSection.DesignModule.DesignInfo.DesignAllocation,ProtocolSection.DesignModule.DesignInfo.DesignInterventionModel,ProtocolSection.DesignModule.DesignInfo.DesignPrimaryPurpose,ProtocolSection.DesignModule.DesignInfo.DesignMaskingInfo.DesignMasking,ProtocolSection.DesignModule.EnrollmentInfo.EnrollmentCount,ProtocolSection.DesignModule.EnrollmentInfo.EnrollmentType,ProtocolSection.ArmsInterventionsModule.ArmGroupList.ArmGroup,ProtocolSection.ArmsInterventionsModule.InterventionList.Intervention,ProtocolSection.OutcomesModule.PrimaryOutcomeList.PrimaryOutcome,ProtocolSection.OutcomesModule.SecondaryOutcomeList.SecondaryOutcome,ProtocolSection.EligibilityModule.EligibilityCriteria,ProtocolSection.EligibilityModule.HealthyVolunteers,ProtocolSection.EligibilityModule.Gender,ProtocolSection.EligibilityModule.MinimumAge,ProtocolSection.EligibilityModule.MaximumAge,ProtocolSection.EligibilityModule.StdAgeList.StdAge,ProtocolSection.ContactsLocationsModule.LocationList.Location,ProtocolSection.SponsorCollaboratorsModule.CollaboratorList.Collaborator,ProtocolSection.OversightModule.OversightHasDMC,ProtocolSection.DescriptionModule.DetailedDescription,ProtocolSection.ConditionsModule.KeywordList.Keyword,ProtocolSection.DesignModule.PatientRegistry,ProtocolSection.DesignModule.DesignInfo.DesignObservationalModelList.DesignObservationalModel,ProtocolSection.DesignModule.DesignInfo.DesignTimePerspectiveList.DesignTimePerspective,ProtocolSection.EligibilityModule.StudyPopulation,ProtocolSection.EligibilityModule.SamplingMethod,ProtocolSection.IdentificationModule.SecondaryIdInfoList.SecondaryIdInfo,ProtocolSection.IdentificationModule.Acronym,ProtocolSection.SponsorCollaboratorsModule.ResponsibleParty.ResponsiblePartyInvestigatorFullName,ProtocolSection.SponsorCollaboratorsModule.ResponsibleParty.ResponsiblePartyInvestigatorTitle,ProtocolSection.SponsorCollaboratorsModule.ResponsibleParty.ResponsiblePartyInvestigatorAffiliation,ProtocolSection.DesignModule.DesignInfo.DesignMaskingInfo.DesignWhoMaskedList.DesignWhoMasked,ProtocolSection.OutcomesModule.OtherOutcomeList.OtherOutcome,ProtocolSection.ContactsLocationsModule.OverallOfficialList.OverallOfficial,ProtocolSection.IPDSharingStatementModule.IPDSharing,ProtocolSection.ReferencesModule.ReferenceList.Reference,ProtocolSection.StatusModule.ResultsFirstSubmitDate,ProtocolSection.StatusModule.ResultsFirstSubmitQCDate,ProtocolSection.StatusModule.ResultsFirstPostDateStruct.ResultsFirstPostDate,ProtocolSection.StatusModule.ResultsFirstPostDateStruct.ResultsFirstPostDateType,ProtocolSection.IPDSharingStatementModule.IPDSharingDescription,ProtocolSection.ContactsLocationsModule.CentralContactList.CentralContact,ProtocolSection.StatusModule.WhyStopped,ProtocolSection.DesignModule.BioSpec.BioSpecRetention,ProtocolSection.DesignModule.BioSpec.BioSpecDescription,ProtocolSection.ReferencesModule.SeeAlsoLinkList.SeeAlsoLink,DerivedSection.MiscInfoModule.RemovedCountryList.RemovedCountry,ProtocolSection.StatusModule.LastKnownStatus,ProtocolSection.StatusModule.DispFirstSubmitDate,ProtocolSection.StatusModule.DispFirstSubmitQCDate,ProtocolSection.StatusModule.DispFirstPostDateStruct.DispFirstPostDate,ProtocolSection.StatusModule.DispFirstPostDateStruct.DispFirstPostDateType,ProtocolSection.SponsorCollaboratorsModule.ResponsibleParty.ResponsiblePartyOldNameTitle,ProtocolSection.SponsorCollaboratorsModule.ResponsibleParty.ResponsiblePartyOldOrganization,ProtocolSection.IdentificationModule.NCTIdAliasList.NCTIdAlias,ProtocolSection.DesignModule.TargetDuration,ProtocolSection.DesignModule.DesignInfo.DesignInterventionModelDescription,ProtocolSection.DesignModule.DesignInfo.DesignMaskingInfo.DesignMaskingDescription,ProtocolSection.IdentificationModule.OrgStudyIdInfo.OrgStudyIdType,ProtocolSection.IdentificationModule.OrgStudyIdInfo.OrgStudyIdLink,ProtocolSection.IPDSharingStatementModule.IPDSharingInfoTypeList.IPDSharingInfoType,ProtocolSection.IPDSharingStatementModule.IPDSharingTimeFrame,ProtocolSection.IPDSharingStatementModule.IPDSharingAccessCriteria,ProtocolSection.IPDSharingStatementModule.IPDSharingURL,ProtocolSection.DesignModule.ExpandedAccessTypes.ExpAccTypeTreatment,DerivedSection.MiscInfoModule.VersionHolder,DerivedSection.ConditionBrowseModule.ConditionMeshList.ConditionMesh,DerivedSection.ConditionBrowseModule.ConditionAncestorList.ConditionAncestor,DerivedSection.ConditionBrowseModule.ConditionBrowseLeafList.ConditionBrowseLeaf,DerivedSection.ConditionBrowseModule.ConditionBrowseBranchList.ConditionBrowseBranch,DerivedSection.InterventionBrowseModule.InterventionMeshList.InterventionMesh,DerivedSection.InterventionBrowseModule.InterventionAncestorList.InterventionAncestor,DerivedSection.InterventionBrowseModule.InterventionBrowseLeafList.InterventionBrowseLeaf,DerivedSection.InterventionBrowseModule.InterventionBrowseBranchList.InterventionBrowseBranch,ResultsSection.ParticipantFlowModule.FlowPreAssignmentDetails,ResultsSection.ParticipantFlowModule.FlowRecruitmentDetails,ResultsSection.ParticipantFlowModule.FlowGroupList.FlowGroup,ResultsSection.ParticipantFlowModule.FlowPeriodList.FlowPeriod,ResultsSection.BaselineCharacteristicsModule.BaselinePopulationDescription,ResultsSection.BaselineCharacteristicsModule.BaselineGroupList.BaselineGroup,ResultsSection.BaselineCharacteristicsModule.BaselineDenomList.BaselineDenom,ResultsSection.BaselineCharacteristicsModule.BaselineMeasureList.BaselineMeasure,ResultsSection.OutcomeMeasuresModule.OutcomeMeasureList.OutcomeMeasure,ResultsSection.AdverseEventsModule.EventsFrequencyThreshold,ResultsSection.AdverseEventsModule.EventsTimeFrame,ResultsSection.AdverseEventsModule.EventsDescription,ResultsSection.AdverseEventsModule.EventGroupList.EventGroup,ResultsSection.AdverseEventsModule.OtherEventList.OtherEvent,ResultsSection.MoreInfoModule.CertainAgreement.AgreementPISponsorEmployee,ResultsSection.MoreInfoModule.CertainAgreement.AgreementRestrictiveAgreement,ResultsSection.MoreInfoModule.PointOfContact.PointOfContactTitle,ResultsSection.MoreInfoModule.PointOfContact.PointOfContactOrganization,ResultsSection.MoreInfoModule.PointOfContact.PointOfContactEMail,ResultsSection.MoreInfoModule.PointOfContact.PointOfContactPhone,ResultsSection.AdverseEventsModule.SeriousEventList.SeriousEvent,ResultsSection.MoreInfoModule.CertainAgreement.AgreementRestrictionType,ResultsSection.MoreInfoModule.CertainAgreement.AgreementOtherDetails,AnnotationSection.AnnotationModule.UnpostedAnnotation.UnpostedResponsibleParty,AnnotationSection.AnnotationModule.UnpostedAnnotation.UnpostedEventList.UnpostedEvent,DocumentSection.LargeDocumentModule.LargeDocList.LargeDoc,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04371159,CTP-Velieve-MC-02,Healthy.io Ltd.,INDUSTRY,"A Comparative, Controlled Study to Evaluate the Clinical Accuracy of the Velieve U.S. UTI Urine Analysis Test System","A Comparative, Controlled Study to Evaluate the Clinical Accuracy of the Velieve U.S. UTI Urine Analysis Test System",Jun-20,Completed,No,05-Feb-20,Actual,30-May-20,Actual,30-May-20,Actual,30-Apr-20,30-Apr-20,01-May-20,Actual,21-Jun-20,23-Jun-20,Actual,Sponsor,Healthy.io Ltd.,INDUSTRY,No,Yes,Yes,No,"The Velieve U.S. UTI Urine Analysis Test System (henceforth Velieve U.S.) is composed of a kit and a smartphone application. The device will be provided to the subject in a simulated home-use environment. All subjects will be asked to complete the urine test by following the application guidance,including providing a urine sample and scanning the urine strip after placing it on the Color-Board. The user will also complete a questionnaire to collect information regarding the use of the Velieve U.S. device. Following the usability test performed by the lay user, the subject's urine sample will be tested by the professional user using the comparator device.

The use of the Velieve U.S. device will be evaluated for identified risks. Additionally, measurable usability criteria for specific, critical steps will be evaluated.",['Urinary Tract Infections'],Interventional,['Not Applicable'],N/A,Single Group Assignment,Diagnostic,None (Open Label),125,Actual,"[{'ArmGroupLabel': 'Velieve U.S.', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Each participant will test their urine sample using the Velieve U.S. device', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Velieve U.S.']}}]","[{'InterventionType': 'Device', 'InterventionName': 'Velieve U.S.', 'InterventionDescription': 'The Velieve U.S. is a home use, in-vitro diagnostic (IVD) device. The device is used for the semi-quantitative detection of blood and leukocytes, and the qualitative detection of nitrites in urine.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Velieve U.S.']}}]","[{'PrimaryOutcomeMeasure': 'Evaluation of the % agreement of the Velieve U.S., tested by the lay user, as compared to a comparator device, tested by a professional user.', 'PrimaryOutcomeTimeFrame': '11 months'}]","[{'SecondaryOutcomeMeasure': 'Evaluation of the Velieve U.S. usability success rate, by potential lay users under actual use conditions.', 'SecondaryOutcomeTimeFrame': '11 months'}]","Inclusion Criteria:

Males and Females 18-80 years of age;
Subjects who are healthy or:

Subjects with a medical condition that normally present with an abnormal concentration of Leukocytes, Nitrites and Blood: (examples of such conditions include the following):

Urinary tract infection (UTI)
Patients with suspected or known occult blood in urine
Pregnant women
Other relevant conditions
Subjects with any pathological findings which might be identified by the urine test (according to the physician discretion)
Subject is capable and willing to provide informed consent;
Subject has facility with both hands;
Subject is capable and willing to adhere to the study procedures.
Subject is familiar with the use of a smartphone
Subject is capable of comprehending and following instructions in English

Exclusion Criteria:

Subject has dementia.
Subject has mental disorders.
Subject cannot collect urine in a receptacle.
Subject is visually impaired (cannot read the user manual).
Any additional reason the study physician believes disqualifies the subject from participating in the study.",Accepts Healthy Volunteers,All,18 Years,80 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'Comprehensive Clinical Trials, LLC', 'LocationCity': 'West Palm Beach', 'LocationState': 'Florida', 'LocationZip': '33409', 'LocationCountry': 'United States'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000014552', 'ConditionMeshTerm': 'Urinary Tract Infections'}]","[{'ConditionAncestorId': 'D000007239', 'ConditionAncestorTerm': 'Infection'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15885', 'ConditionBrowseLeafName': 'Urinary Tract Infections', 'ConditionBrowseLeafAsFound': 'Urinary Tract Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15902', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04474496,261131,University of Arkansas,OTHER,Impact of COVID-19 on Marshallese Communities in the U.S.,Impact of COVID-19 on Marshallese Communities in the U.S.,Sep-20,Enrolling by invitation,No,27-Jul-20,Actual,01-Nov-20,Anticipated,01-Nov-20,Anticipated,10-Jul-20,15-Jul-20,16-Jul-20,Actual,01-Sep-20,03-Sep-20,Actual,Sponsor,University of Arkansas,OTHER,No,No,,,"Up to 2000 Marshallese will complete an online or telephone survey. Among those who complete the survey, 40 participants will be randomly selected and invited to complete an in-depth qualitative interview. This survey will collect data describing the impact of COVID-19 on self-reported Marshallese persons in the United States. Data collected will help describe: 1) risk exposure, 2) knowledge of preventive recommendations, 3) barriers and facilitators to implementing preventative recommendations, 4) barriers and facilitators to COVID-19 testing when appropriate, and self-care behaviors during COVID-19.",['COVID-19'],Observational,,,,,,2000,Anticipated,"[{'ArmGroupLabel': 'Marshallese in the U.S.', 'ArmGroupDescription': 'Marshallese persons 18 years of age or older residing in the United States', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Assessing impact of COVID19']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Assessing impact of COVID19', 'InterventionDescription': 'Surveying Marshallese adults in the U.S. to determine impact of COVID19', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Marshallese in the U.S.']}}]","[{'PrimaryOutcomeMeasure': 'Effects of COVID-19 on social determinants of health', 'PrimaryOutcomeDescription': 'Respondents will be asked how COVID-19 has impacted mulitple facets of their lives, including housing, food security, and employment and income', 'PrimaryOutcomeTimeFrame': 'Baseline'}]","[{'SecondaryOutcomeMeasure': 'Effects of COVID-19 on general health status and mental health', 'SecondaryOutcomeDescription': 'Respondents will be asked to rate their general health and mental health now and compared with before the COVID-19 outbreak', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'Effects of COVID-19 on disease management', 'SecondaryOutcomeDescription': 'Respondents with type 2 diabetes will be asked to compare their current self-care behaviors with before the COVID-19 outbreak using multiple items, including the Summary of Diabetes Self-Care Activities (adapted to include retrospective pre-COVID-19 comparisons of behaviors)', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'Effects of COVID-19 on diet and physical activity behaviors', 'SecondaryOutcomeDescription': 'Using Behavioral Risk Factor Surveillance System items and relevant items from the Summary of Diabetes Self-Care Activities, respondents will be asked to compare their current diet and physical activity behaviors with before the COVID-19 outbreak', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'COVID-19 screening, testing, and prevention', 'SecondaryOutcomeDescription': 'Respondents will be asked to report whether they have been screened for COVID-19 (and how), whether they have been tested for COVID-19 (and how), whether they would accept a COVID-19 vaccine, and what specific actions they have taken to prevent being infected by COVID-19', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'Trusted sources of COVID-19 information', 'SecondaryOutcomeDescription': 'Respondents will be asked to report which sources of information they use the most and trust the most to stay informed about COVID-19', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'Impacts of COVID-19 on daily life', 'SecondaryOutcomeDescription': 'Respondents will be asked to report how the COVID-19 outbreak has impacted their daily lives, including health concerns, impacts on family, and access to healthcare', 'SecondaryOutcomeTimeFrame': 'Baseline'}, {'SecondaryOutcomeMeasure': 'COVID-19 attitudes, fears, and beliefs', 'SecondaryOutcomeDescription': 'Respondents will be asked to report how likely they feel they are to be infected, their chances of dying if infected, how easy it is to avoid being infected, and how concerned they are with what could result from being infected (e.g., losing a job, infecting others, being isolated)', 'SecondaryOutcomeTimeFrame': 'Baseline'}]","Inclusion Criteria:

Self-reported Marshallese
18 years of age or older
Live in the Continental U.S. or Hawaii

Exclusion Criteria:

- Does not meet inclusion criteria",,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Arkansas for Medical Sciences Northwest', 'LocationCity': 'Fayetteville', 'LocationState': 'Arkansas', 'LocationZip': '72703', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Patient-Centered Outcomes Research Institute', 'CollaboratorClass': 'OTHER'}]",No,"Specific Aims Aim 1: Document COVID-19 risk exposure for Marshallese community members. Aim 2: Document Marshallese community members' knowledge of preventive recommendations.

Aim 3: Document barriers and facilitators to implementing preventative recommendations.

Aim 4: Document Marshallese community members' barriers and facilitators to COVID-19 testing when appropriate.

Aim 5: Document self-care behaviors during COVID-19. Aim 6: Explore COVID-19 pandemic related barriers and facilitators to diabetes self-management among Marshallese adults with T2DM.

Aim 7: Assess the effect of the COVID-19 pandemic on diabetes self-management activities among Marshallese adults with T2DM.","['Marshallese', 'Pacific Islanders', 'Type 2 Diabetes', 'COVID-19']",No,['Other'],['Cross-Sectional'],Self-reported Marshallese persons 18 years of age or older who live in the continental United States or Hawaii.,Non-Probability Sample,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,"[{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5702', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02801266,FPRPA006057,New York University,OTHER,Improving Contraceptive Counseling in the United States,Improving Contraceptive Counseling in the United States,Jun-16,Completed,No,Oct-12,,Oct-14,Actual,Oct-15,Actual,02-Jun-16,11-Jun-16,15-Jun-16,Estimate,11-Jun-16,15-Jun-16,Estimate,Principal Investigator,New York University,OTHER,,,,,"This project develops a contraceptive counseling protocol (CCP) grounded in scientific evidence and evaluates the CCP for promoting behaviors conducive to preventing unintended pregnancy among women. The project develops and refines the CCP using focus groups and in-depth interviews with (a) key administrators in the national office of Planned Parenthood (b) key administrators in participating Title X clinics, (c) contraceptive counselors, and (d) clients of the health centers. The CCP uses scientifically grounded principles for guiding effective decision making and provider-client communication. Ten Title X clinics are randomly assigned to one of two conditions (5 clinics per condition): (1) treatment as usual (TAU) or (2) implementation of the CCP. Approximately 150 women are selected for study participation in each clinic, yielding about 1,400 participants (half control and half CCP). Immediately following their counseling session, women complete a computer-administered interview that serves as a fidelity check and permits evaluation of the effects of the CCP on variables associated with counseling satisfaction. All women are re-interviewed by phone 6 months later and 12 months later. The effect of the CCP on method-choice effectiveness, method switching, gaps in protection, and use accuracy are evaluated.","['New Behavioral Protocol', 'Treatment as Usual']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Prevention,Single,1418,Actual,"[{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention arm receives contraceptive counseling from counselors who underwent training on the use of evidence informed birth control counseling.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Evidence informed birth control counseling']}}, {'ArmGroupLabel': 'No intervention', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'The no intervention arm receives contraceptive counseling from counselors who underwent no additional training beyond what they normally receive.'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Evidence informed birth control counseling', 'InterventionDescription': 'Counselors underwent training on the use of 10 best practices for contraceptive counseling.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Improving contraceptive counseling in the United States']}}]","[{'PrimaryOutcomeMeasure': 'Patient satisfaction with counselors as assessed by 5 point Likert rating scales using questionnaire designed for this study at immediate posttest.', 'PrimaryOutcomeTimeFrame': 'immediately after counseling session'}, {'PrimaryOutcomeMeasure': 'Patient satisfaction with counseling session as assessed by 5 point Likert rating scales using a questionnaire designed for this study at immediate posttest.', 'PrimaryOutcomeTimeFrame': 'immediately after counseling session'}, {'PrimaryOutcomeMeasure': 'Patient satisfaction with clinic experience overall as assessed by 5 point Likert rating scales using a questionnaire designed for this study at immediate posttest.', 'PrimaryOutcomeTimeFrame': 'immediately after counseling session'}, {'PrimaryOutcomeMeasure': 'Patient satisfaction with clinic experience overall as assessed by 5 point Likert rating scales using a questionnaire designed for this study at 6 months.', 'PrimaryOutcomeTimeFrame': '6 months from initial clinic visit'}, {'PrimaryOutcomeMeasure': 'Patient satisfaction with clinic experience overall as assessed by 5 point Likert rating scales using a questionnaire designed for this study at 12 months.', 'PrimaryOutcomeTimeFrame': 'one year from initial clinic visit'}]","[{'SecondaryOutcomeMeasure': 'Type of contraceptive method currently using (including none and dual use) as assessed by a questionnaire designed for this study (e.g., what method of birth control are you currently using).', 'SecondaryOutcomeTimeFrame': 'six months to one year from initial clinic visit'}]","Inclusion Criteria:

Must be seeking contraception from clinic on day of recruitment

Exclusion Criteria:

Not seeking contraception from clinic on day of recruitment",Accepts Healthy Volunteers,Female,18 Years,30 Years,['Adult'],"[{'LocationFacility': 'New York University, Silver School of Social Work', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10001', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Planned Parenthood Federation of America', 'CollaboratorClass': 'OTHER'}]",No,,"['Contraception', 'Reproductive and Sexual Health', 'Counseling', 'Contraceptive Counseling']",,,,,,"[{'SecondaryId': '12-9103', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'NYU Committee on Activities Involving Human Subjects'}]",ICC,James Jaccard,Professor and Associate Dean for Research,New York University,['Participant'],"[{'OtherOutcomeMeasure': 'Method switching for pill users as assessed by a questionnaire designed for this study asking current method used at posttest to determine if it is no longer the pill using questions designed for this study', 'OtherOutcomeTimeFrame': 'six months to one year from initial clinic visit'}, {'OtherOutcomeMeasure': 'Gaps in pregnancy protection (number of weeks not using any birth control during contraceptive method switches as assessed by a questionnaire designed for this study using retrospective recall', 'OtherOutcomeTimeFrame': 'six months to one year from initial clinic visit'}, {'OtherOutcomeMeasure': 'Counselor behavior (topics covered during counseling) as assessed by a questionnaire designed for this study asking if counselor did or did not address key topics about method use', 'OtherOutcomeTimeFrame': 'six months to one year from initial clinic visit'}, {'OtherOutcomeMeasure': 'Pill users retrospective report of the number of missed pills using a questionnaire designed for this study', 'OtherOutcomeTimeFrame': 'six months to one year from initial clinic visit'}]","[{'OverallOfficialName': 'James J Jaccard, PhD', 'OverallOfficialAffiliation': 'New York University', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,"[{'InterventionMeshId': 'D000003270', 'InterventionMeshTerm': 'Contraceptive Agents'}]","[{'InterventionAncestorId': 'D000012102', 'InterventionAncestorTerm': 'Reproductive Control Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]","[{'InterventionBrowseLeafId': 'M5077', 'InterventionBrowseLeafName': 'Contraceptive Agents', 'InterventionBrowseLeafAsFound': 'Ipilimumab', 'InterventionBrowseLeafRelevance': 'high'}]","[{'InterventionBrowseBranchAbbrev': 'Repr', 'InterventionBrowseBranchName': 'Reproductive Control Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01599390,116730,GlaxoSmithKline,INDUSTRY,"Influenza Burden Assessment in the United States, July1997 - up to April 2009","Burden of Influenza in the United States, July 1997 up to April 2009",Feb-13,Completed,No,Jul-12,,Feb-13,Actual,Feb-13,Actual,14-May-12,14-May-12,16-May-12,Estimate,21-Feb-13,25-Feb-13,Estimate,Sponsor,GlaxoSmithKline,INDUSTRY,,,,,"The study will assess the burden of severe influenza outcomes by age, risk status, and influenza subtype, in order to create a profile of the burden of influenza-related morbidity and mortality in United States from July 1997 to April 2009.",['Influenza'],Observational,,,,,,1,Actual,"[{'ArmGroupLabel': 'Influenza Group', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Data collection']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Data collection', 'InterventionDescription': 'The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.\n\nWeekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Influenza Group']}}]","[{'PrimaryOutcomeMeasure': 'Occurrences of potentially influenza-attributable hospitalization or death by age, risk status, region and season.', 'PrimaryOutcomeTimeFrame': 'From July 1997 to April 2009 (i.e., up to almost 12 years)'}, {'PrimaryOutcomeMeasure': 'Amount of circulating influenza A and B, and RSV strains determined for each season.', 'PrimaryOutcomeTimeFrame': 'From July 1997 to April 2009 (i.e., up to almost 12 years)'}]","[{'SecondaryOutcomeMeasure': 'Influenza vaccine content and effectiveness by season.', 'SecondaryOutcomeTimeFrame': 'From July 1997 to April 2009 (i.e., up to almost 12 years)'}, {'SecondaryOutcomeMeasure': 'Influenza vaccine coverage by season.', 'SecondaryOutcomeTimeFrame': 'From July 1997 to April 2009 (i.e., up to almost 12 years)'}]","Inclusion Criteria:

Recorded in the US NIS hospitalization data or the US National Vital Statistics System (NVSS) mortality data with a pre-specified diagnostic code.

Exclusion Criteria:

Missing data in the following fields: age, primary discharge diagnosis, admission month (NIS) /month of death (NVSS), and status at discharge (alive / dead).",No,All,,,"['Child', 'Adult', 'Older Adult']",,"[{'CollaboratorName': 'Sage Analytica', 'CollaboratorClass': 'INDUSTRY'}]",No,This epidemiological study is a modelling of time series retrospectively extracted from multiple databases. Data will be extracted from existing electronic healthcare databases.,"['United States', 'Burden of Disease', 'Influenza']",,,['Retrospective'],All records of people in the US in the Nationwide Inpatient Sample (NIS) hospitalization data or in the US mortality data will be included in this study.,Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '28320361', 'ReferenceType': 'derived', 'ReferenceCitation': 'Matias G, Taylor R, Haguinet F, Schuck-Paim C, Lustig R, Shinde V. Estimates of hospitalization attributable to influenza and RSV in the US during 1997-2009, by age and risk status. BMC Public Health. 2017 Mar 21;17(1):271. doi: 10.1186/s12889-017-4177-z.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007251', 'ConditionMeshTerm': 'Influenza, Human'}]","[{'ConditionAncestorId': 'D000009976', 'ConditionAncestorTerm': 'Orthomyxoviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000012141', 'ConditionAncestorTerm': 'Respiratory Tract Infections'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]","[{'ConditionBrowseLeafId': 'M8878', 'ConditionBrowseLeafName': 'Influenza, Human', 'ConditionBrowseLeafAsFound': 'Influenza', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11485', 'ConditionBrowseLeafName': 'Orthomyxoviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13561', 'ConditionBrowseLeafName': 'Respiratory Tract Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00312702,WRAIR 1249,U.S. Army Medical Research and Development Command,FED,Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America,"A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS02A Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States",May-18,Completed,No,Apr-06,,Oct-06,Actual,Apr-07,Actual,06-Apr-06,06-Apr-06,10-Apr-06,Estimate,15-May-18,26-Nov-18,Actual,Sponsor,U.S. Army Medical Research and Development Command,FED,,,,,"Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.","['Malaria', 'Plasmodium Falciparum Malaria']",Interventional,"['Phase 1', 'Phase 2']",Randomized,Parallel Assignment,Prevention,None (Open Label),18,Actual,"[{'ArmGroupLabel': '10µg dose FMP011', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Falciparum Malaria Protein 11 with AS02A adjuvant']}}, {'ArmGroupLabel': '50µg dose FMP011', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Falciparum Malaria Protein 11 with AS02A adjuvant']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Falciparum Malaria Protein 11 with AS02A adjuvant', 'InterventionDescription': 'vaccine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['10µg dose FMP011', '50µg dose FMP011']}}]","[{'PrimaryOutcomeMeasure': 'Safety - Most Frequently Reported Adverse Events and Grade', 'PrimaryOutcomeDescription': 'An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to study drug or clinically significant.\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe', 'PrimaryOutcomeTimeFrame': '30 days post vaccination'}]","[{'SecondaryOutcomeMeasure': 'Anti-LSA-1 Antibody Response in Titer Units', 'SecondaryOutcomeDescription': 'Anti-LSA-1 Antibody Response in Titer Units on days 0, 28, 42 and 84', 'SecondaryOutcomeTimeFrame': 'days 0, 28, 42 (challenge day) and 84'}]","Inclusion Criteria:

A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening.
Written informed consent obtained from the subject before screening procedures.
Free of obvious health problems as established by medical history and clinical examination before entering into the study.*
Available to participate for duration of study (approximately 15 months).
If the subject is female, she must be currently using birth control, must be surgically sterilized, or must be at least 1-year post menopausal.
Pass a comprehension assessment test.

Exclusion Criteria:

Prior receipt of an investigational malaria vaccine.
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 28 days preceding the first dose of study vaccine, or planned use during the study period.
Administration of chronic immunosuppressants or other immune modifying drugs within six months of vaccination.
Chronic use of antibiotics with anti-malarial effects.
Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).
History of use of anti-malarial medication within 60 days prior to vaccination.
Any history of malaria.
Known exposure to malaria within the previous 12 months.
Planned travel to malarious areas during the study period.
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection.
A family history of congenital or hereditary immunodeficiency.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Chronic or active neurologic disease including seizures, but not including a single febrile seizure as a child.
History of splenectomy.
Acute disease at the time of enrollment.
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
Personal history of autoimmune disease or subjects who describe a first-degree relative with clearly documented autoimmune disease.
Seropositive for hepatitis B surface antigen.
Seropositive for Hepatitis C virus (antibodies to HCV).
Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period.
Pregnant or lactating female.
Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV.
Chronic or active intravenous drug use.
History of severe reactions to mosquito bites as defined as anaphylaxis.
Female who intends to become pregnant during the study.
Any history of anaphylaxis in reaction to vaccination.
A clinical history of sickle cell disease or sickle cell trait.
Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.",Accepts Healthy Volunteers,All,18 Years,50 Years,['Adult'],"[{'LocationFacility': 'Walter Reed Army Institute of Research', 'LocationCity': 'Silver Spring', 'LocationState': 'Maryland', 'LocationZip': '20910', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'GlaxoSmithKline', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'The PATH Malaria Vaccine Initiative (MVI)', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Walter Reed Army Institute of Research (WRAIR)', 'CollaboratorClass': 'FED'}]",Yes,"Controlled challenge, Phase I/IIa WRAIR study.
Healthy, malaria-naive adults aged 18 - 50 years.
2 groups, 5 subjects in group A (10µg dose) and 15 subjects in group B (50µg dose).
Control: none for immunization phase; infectivity controls for challenge and rechallenge phases. Six infectivity controls per day of challenge will be enrolled for the challenge phases, with 3 alternates available for challenge if needed.
Vaccination schedule of 0, 1 months.
Challenge of up to 15 subjects in Group B.
Contingent upon short term efficacy, rechallenge of initially protected subjects 6 months (+/- 2 months) after second dose of vaccine.
Self-contained study.
Duration of the study, per subject: approximately 15 months (screening, enrollment, vaccination, challenge and rechallenge).
Data collection will be by done at the site.","['Vaccine', 'Malaria', 'Liver Stage Antigen-1', 'Falciparum Malaria Protein-11', 'AS02A', 'adjuvant']",,,,,,"[{'SecondaryId': 'HSRRB A-13732', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'USAMRMC'}]",,,,,,,"[{'OverallOfficialName': 'James F Cummings, MD', 'OverallOfficialAffiliation': 'Walter Reed Army Institute of Research (WRAIR)', 'OverallOfficialRole': 'Principal Investigator'}]",,,09-Dec-16,15-May-18,26-Nov-18,Actual,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}, {'ConditionMeshId': 'D000016778', 'ConditionMeshTerm': 'Malaria, Falciparum'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17716', 'ConditionBrowseLeafName': 'Malaria, Falciparum', 'ConditionBrowseLeafAsFound': 'Plasmodium Falciparum Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9693', 'InterventionBrowseLeafName': 'Liver Extracts', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Hemat', 'InterventionBrowseBranchName': 'Hematinics'}]","18 subjects were randomly assigned to the immunization phase for each of the 2 vaccine formulations. 12 IC's from high does group and 1 non immunized infectivity control subject out of the 6 came from this phase 1 study, the other 5 came from the phase 2 study (WRAIR 1250, NCT00312663). Both studies were included in one final clinical study report.","18 immunized, 12 IC's from high dose group and 6 control subject","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': '10µg Dose FMP011', 'FlowGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': '50µg Dose FMP011', 'FlowGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': 'Infectivity Controls (IC)', 'FlowGroupDescription': ""12 Subjects from the high dose group and 1 non immunized subject enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.\n\n1 infectivity control subject out of the 6 came from this phase 1 study, the other 5 came from the phase 2 study (WRAIR 1250, NCT00312663). Both studies were included in one final clinical study report.""}]","[{'FlowPeriodTitle': 'Immunization Phase', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '5'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '13'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '5'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '12'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '1'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '0'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'}]}}]}}, {'FlowPeriodTitle': 'Challenge Phase', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementComment': ""low dose subjects didn't participate in the challenge phase"", 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementComment': '12 subjects from the high dose group participated in the challenge phase', 'FlowAchievementNumSubjects': '12'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementComment': '1 non-immunized subjects participated in the challenge phase.', 'FlowAchievementNumSubjects': '1'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '12'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '1'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}]}}]",12 Subjects from the high dose group and 1 non immunized subject enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': '10µg Dose FMP011', 'BaselineGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': '50µg Dose FMP011', 'BaselineGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Infectivity Control (IC)', 'BaselineGroupDescription': ""12 Subjects from the high dose group and 1 non immunized subject enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.\n\n1 infectivity control subject out of the 6 came from this phase 1 study, the other 5 came from the phase 2 study (WRAIR 1250, NCT00312663). Both studies were included in one final clinical study report.""}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '5'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '13'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '1'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '19'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '25.4', 'BaselineMeasurementSpread': '6.2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '32.8', 'BaselineMeasurementSpread': '8.2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '34.5', 'BaselineMeasurementSpread': '0.0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '30.7', 'BaselineMeasurementSpread': '8.2'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '10'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Ethnicity (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Not Hispanic or Latino', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '19'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '11'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '17'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '18'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Safety - Most Frequently Reported Adverse Events and Grade', 'OutcomeMeasureDescription': 'An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to study drug or clinically significant.\n\nGrade 1: Mild Grade 2: Moderate Grade 3: Severe', 'OutcomeMeasurePopulationDescription': ""The AE's were tabulated and summarized by subject and treatment groups. No additional analyses were performed. Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe Infectivity Controls were not included in this analysis."", 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Number of adverse events', 'OutcomeMeasureTimeFrame': '30 days post vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': '10µg Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': '50µg Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Infectivity Control', 'OutcomeGroupDescription': ""12 Subjects from the high dose group and 1 non immunized subject enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.\n\n1 infectivity control subject out of the 6 came from this phase 1 study, the other 5 came from the phase 2 study (WRAIR 1250, NCT00312663). Both studies were included in one final clinical study report.""}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '5'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '13'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '1'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Pain - Grade 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '10'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Pain - Grade 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '3'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Pain - Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Redness - Grade 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Redness - Grade 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Redness - Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Swelling - Grade 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Swelling - Grade 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Swelling - Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Anti-LSA-1 Antibody Response in Titer Units', 'OutcomeMeasureDescription': 'Anti-LSA-1 Antibody Response in Titer Units on days 0, 28, 42 and 84', 'OutcomeMeasurePopulationDescription': ""Low dose group didn't participate in challenge (day 42) and day 84"", 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Full Range', 'OutcomeMeasureUnitOfMeasure': 'Titer units', 'OutcomeMeasureTimeFrame': 'days 0, 28, 42 (challenge day) and 84', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': '10µg Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': '50µg Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '5'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '13'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Day 0', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '24.8', 'OutcomeMeasurementLowerLimit': '21.4', 'OutcomeMeasurementUpperLimit': '171.2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '47.1', 'OutcomeMeasurementLowerLimit': '18.5', 'OutcomeMeasurementUpperLimit': '220.2'}]}}]}}, {'OutcomeClassTitle': 'Day 28', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1629.9', 'OutcomeMeasurementLowerLimit': '82.3', 'OutcomeMeasurementUpperLimit': '2855.6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '834.8', 'OutcomeMeasurementLowerLimit': '51.4', 'OutcomeMeasurementUpperLimit': '2207.3'}]}}]}}, {'OutcomeClassTitle': 'Day 42 (challenge day)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementLowerLimit': 'NA', 'OutcomeMeasurementUpperLimit': 'NA', 'OutcomeMeasurementComment': ""Low dose group didn't participate in challenge (day 42)""}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '29851.5', 'OutcomeMeasurementLowerLimit': '10590.0', 'OutcomeMeasurementUpperLimit': '64250.0'}]}}]}}, {'OutcomeClassTitle': 'Day 84', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementLowerLimit': 'NA', 'OutcomeMeasurementUpperLimit': 'NA', 'OutcomeMeasurementComment': ""Low dose group didn't participate in day 84""}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '10378.5', 'OutcomeMeasurementLowerLimit': '3397.0', 'OutcomeMeasurementUpperLimit': '49800.0'}]}}]}}]}}]",0,Up to 6 months,"Evaluate the safety by 1) the occurrence of solicited AEs over a 7 day follow-up period (day of immunization and 6 days post-immunization); 2) the occurrence of unsolicited AEs over a 30 day follow-up period (day of immunization and 29 day follow-up period

); and 3) the occurrence of SAE's during the study period. Subjects in the Infectivity Control group were not included in this analysis and are not presented in the final clinical study report.","[{'EventGroupId': 'EG000', 'EventGroupTitle': '10µg Dose FMP011', 'EventGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '5', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '5', 'EventGroupOtherNumAffected': '5', 'EventGroupOtherNumAtRisk': '5'}, {'EventGroupId': 'EG001', 'EventGroupTitle': '50µg Dose FMP011', 'EventGroupDescription': 'Falciparum Malaria Protein 11 with AS02A adjuvant\n\nFalciparum Malaria Protein 11 with AS02A adjuvant: vaccine', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '13', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '13', 'EventGroupOtherNumAffected': '13', 'EventGroupOtherNumAtRisk': '13'}, {'EventGroupId': 'EG002', 'EventGroupTitle': 'Infecticvity Control (IC)', 'EventGroupDescription': ""12 Subjects from the high dose group and 1 non immunized subject enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.\n\n1 infectivity control subject out of the 6 came from this phase 1 study, the other 5 came from the phase 2 study (WRAIR 1250, NCT00312663). Both studies were included in one final clinical study report."", 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '1', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '1', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '1'}]","[{'OtherEventTerm': 'Local', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Redness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Malaise', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Local', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Redness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Local', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Redness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Malaise', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Chills', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Bruise at injection site', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Axilla lymphadenopathy', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Ringing in ears - bilateral', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Vasovagal event', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Ringing in ears - bilateral', 'OtherEventOrganSystem': 'Ear and labyrinth disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Bruise at injection site', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Axilla lymphadenopathy', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}, {'OtherEventTerm': 'Vasovagal event', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '1'}]}}]",No,No,"James F. Cummings, MD",Walter Reed Army Institute of Research,james.cummings@us.army.mil,301-319-9312,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00312663,WRAIR 1250,U.S. Army Medical Research and Development Command,FED,Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America,"A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS01B Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States",May-18,Completed,No,Apr-06,,Oct-06,Actual,Apr-07,Actual,06-Apr-06,06-Apr-06,10-Apr-06,Estimate,03-May-18,26-Nov-18,Actual,Sponsor,U.S. Army Medical Research and Development Command,FED,,,,,"Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.",['Plasmodium Falciparum Malaria'],Interventional,"['Phase 1', 'Phase 2']",Randomized,Single Group Assignment,Prevention,None (Open Label),24,Actual,"[{'ArmGroupLabel': '10ug dose FMP011', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.']}}, {'ArmGroupLabel': '50ug dose FMP011', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Falciparum Malaria Protein 11 with AS01B adjuvant.']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Falciparum Malaria Protein 11 with AS01B adjuvant.', 'InterventionDescription': 'malaria experimental vaccine', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['10ug dose FMP011', '50ug dose FMP011']}}]","[{'PrimaryOutcomeMeasure': 'Safety - Most Frequently Reported Adverse Events and Grade', 'PrimaryOutcomeDescription': 'An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to the study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe', 'PrimaryOutcomeTimeFrame': '30 days post vaccination'}]","[{'SecondaryOutcomeMeasure': 'Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84', 'SecondaryOutcomeDescription': 'Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84', 'SecondaryOutcomeTimeFrame': 'Days 0, 28, 42, and 84'}]","Inclusion Criteria:

A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening.
Written informed consent obtained from the subject before screening procedures.
Free of obvious health problems as established by medical history and clinical examination before entering into the study.*
Available to participate for duration of study (approximately 15 months).
If the subject is female, she must be currently using birth control, must be surgically sterilized, or must be at least 1-year post menopausal.
Pass a comprehension assessment test.

Exclusion Criteria:

Prior receipt of an investigational malaria vaccine.
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 28 days preceding the first dose of study vaccine, or planned use during the study period.
Administration of chronic immunosuppressants or other immune modifying drugs within six months of vaccination.
Chronic use of antibiotics with anti-malarial effects.
Planned administration/ administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of vaccine(s).
History of use of anti-malarial medication within 60 days prior to vaccination.
Any history of malaria.
Known exposure to malaria within the previous 12 months.
Planned travel to malarious areas during the study period.
Any confirmed or suspected immunosuppressive or immunodeficient condition, including HIV infection.
A family history of congenital or hereditary immunodeficiency.
History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
Chronic or active neurologic disease including seizures, but not including a single febrile seizure as a child.
History of splenectomy.
Acute disease at the time of enrollment.
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.
Personal history of autoimmune disease or subjects who describe a first-degree relative with clearly documented autoimmune disease.
Seropositive for hepatitis B surface antigen.
Seropositive for Hepatitis C virus (antibodies to HCV).
Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned. administration during the study period
Pregnant or lactating female.
Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV.
Chronic or active intravenous drug use.
History of severe reactions to mosquito bites as defined as anaphylaxis.
Female who intends to become pregnant during the study.
Any history of anaphylaxis in reaction to vaccination.
A clinical history of sickle cell disease or sickle cell trait.
Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study.",Accepts Healthy Volunteers,All,18 Years,50 Years,['Adult'],"[{'LocationFacility': 'Walter Reed Army Institute of Research', 'LocationCity': 'Silver Spring', 'LocationState': 'Maryland', 'LocationZip': '20910', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'GlaxoSmithKline', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'The PATH Malaria Vaccine Initiative (MVI)', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Walter Reed Army Institute of Research (WRAIR)', 'CollaboratorClass': 'FED'}]",Yes,"Controlled challenge, Phase I/IIa WRAIR study.
Healthy, malaria-naive adults aged 18 - 50 years.
2 groups, 5 subjects in group A (10µg dose) and 13 subjects in group B(50µg dose).
Control: none for immunization phase; infectivity controls for challenge and rechallenge phases. Six infectivity controls per day of challenge will be enrolled for the challenge phases, with 3 alternates available for challenge if needed.
Vaccination schedule of 0, 1 months.
Challenge of up to 13 subjects in Group B.
Contingent upon short term efficacy, rechallenge of initially protected subjects 6 months (+/- 2 months) after second dose of vaccine.
Self-contained study.
Duration of the study, per subject: approximately 15 months (screening, enrollment, vaccination, challenge and rechallenge).
Data collection will be by done onsite.","['Vaccine', 'Phase I/II', 'Malaria', 'Liver Stage Antigen -1', 'Falciparum Malaria Protein -11', 'AS01B', 'adjuvant']",,,,,,"[{'SecondaryId': 'HSRRB A-13734', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'USAMRMC'}]",,,,,,,"[{'OverallOfficialName': 'James F. Cummings, MD', 'OverallOfficialAffiliation': 'Walter Reed Army Institute of Research (WRAIR)', 'OverallOfficialRole': 'Principal Investigator'}]",Yes,,09-Dec-16,03-May-18,26-Nov-18,Actual,"GlaxoSmithKline, The PATH Malaria Vaccine Initiative (MVI), Walter Reed Army Institute of Research (WRAIR)",,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}, {'ConditionMeshId': 'D000016778', 'ConditionMeshTerm': 'Malaria, Falciparum'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17716', 'ConditionBrowseLeafName': 'Malaria, Falciparum', 'ConditionBrowseLeafAsFound': 'Plasmodium Falciparum Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9693', 'InterventionBrowseLeafName': 'Liver Extracts', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Hemat', 'InterventionBrowseBranchName': 'Hematinics'}]",18 subjects were randomly assigned to the immunization phase for each of the 2 vaccine formulations.,18 immunized subjects,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': '10ug Dose FMP011', 'FlowGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': '50ug Dose FMP011', 'FlowGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': 'Infectivity Controls (IC)', 'FlowGroupDescription': ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.""}]","[{'FlowPeriodTitle': 'Immunization Phase', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '5'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '13'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '5'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '12'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '1'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Adverse Event', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '0'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '0'}]}}]}}, {'FlowPeriodTitle': 'Challenge Phase', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementComment': ""low dose subjects didn't participate in the challenge phase"", 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementComment': '10 subjects from the high dose group participated in the challenge phase', 'FlowAchievementNumSubjects': '10'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementComment': '6 non-immunized subjects participated in the challenge phase', 'FlowAchievementNumSubjects': '6'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '10'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '6'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}]}}]",10 subjects from the high dose group and 6 non-immunized subjects participated in the Infectivity Control,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': '10ug Dose FMP011', 'BaselineGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': '50ug Dose FMP011', 'BaselineGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Infectivity Control (IC)', 'BaselineGroupDescription': ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge""}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '5'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '13'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '6'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '24'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30.8', 'BaselineMeasurementSpread': '7.9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '32.8', 'BaselineMeasurementSpread': '8.1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '24.5', 'BaselineMeasurementSpread': '4.9'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '32.2', 'BaselineMeasurementSpread': '7.9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '9'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '15'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '3'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '15'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '2'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '18'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Safety - Most Frequently Reported Adverse Events and Grade', 'OutcomeMeasureDescription': 'An AE was defined as any reaction, side effect, or untoward event that occurred during the course of the trial whether or not the event was considered related to the study drug or clinically significant. Grade 1: Mild Grade 2: Moderate Grade 3: Severe', 'OutcomeMeasurePopulationDescription': ""The AE's were tabulated and summarized by subject and treatment groups. No additional analyses were performed. Subjects from the IC group were not evaluated for AE's and there for not included in the data.\n\nGrade 1 = mild, Grade 2 = moderate, Grade 3 = severe"", 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'adverse events', 'OutcomeMeasureTimeFrame': '30 days post vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': '10ug Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': '50ug Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Infectivity Control (IC)', 'OutcomeGroupDescription': ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge""}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '5'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '13'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '0'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Pain - Grade 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '9'}]}}]}}, {'OutcomeClassTitle': 'Pain - Grade 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '4'}]}}]}}, {'OutcomeClassTitle': 'Pain - Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Redness - Grade 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Redness - Grade 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Redness - Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'Swelling - Grade 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'Swelling - Grade 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'Swelling - Grade 3', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84', 'OutcomeMeasureDescription': 'Anti-LSA-1 Antibody Response in Titer Units on Days 0, 28, 42, and 84', 'OutcomeMeasurePopulationDescription': 'nAnti-LSA-1 Antibody Response in Titer units on Days 0, 28, 42 and 84', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Median', 'OutcomeMeasureDispersionType': 'Full Range', 'OutcomeMeasureUnitOfMeasure': 'Titer units', 'OutcomeMeasureTimeFrame': 'Days 0, 28, 42, and 84', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': '10ug Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': '50ug Dose FMP011', 'OutcomeGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Infectivity Controls (IC)', 'OutcomeGroupDescription': ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge.""}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '5'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '13'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '6'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Day 0', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '36.2', 'OutcomeMeasurementLowerLimit': '23.7', 'OutcomeMeasurementUpperLimit': '644.0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '43.15', 'OutcomeMeasurementLowerLimit': '-10', 'OutcomeMeasurementUpperLimit': '475.9'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementLowerLimit': 'NA', 'OutcomeMeasurementUpperLimit': 'NA', 'OutcomeMeasurementComment': ""Didn't participate in phase""}]}}]}}, {'OutcomeClassTitle': 'Day 28', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '514.4', 'OutcomeMeasurementLowerLimit': '51.9', 'OutcomeMeasurementUpperLimit': '3523.3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '462.0', 'OutcomeMeasurementLowerLimit': '41.1', 'OutcomeMeasurementUpperLimit': '6161.0'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementLowerLimit': 'NA', 'OutcomeMeasurementUpperLimit': 'NA', 'OutcomeMeasurementComment': ""Didn't participate in phase""}]}}]}}, {'OutcomeClassTitle': 'Day 42', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementLowerLimit': 'NA', 'OutcomeMeasurementUpperLimit': 'NA', 'OutcomeMeasurementComment': ""Didn't' participate in Challenge Phase""}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '36527.0', 'OutcomeMeasurementLowerLimit': '1774.9', 'OutcomeMeasurementUpperLimit': '85080.0'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '21.1', 'OutcomeMeasurementLowerLimit': '-10', 'OutcomeMeasurementUpperLimit': '248.5'}]}}]}}, {'OutcomeClassTitle': 'Day 84', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': 'NA', 'OutcomeMeasurementLowerLimit': 'NA', 'OutcomeMeasurementUpperLimit': 'NA', 'OutcomeMeasurementComment': ""Didn't' participate in Challenge Phase""}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '9180.0', 'OutcomeMeasurementLowerLimit': '834.0', 'OutcomeMeasurementUpperLimit': '18131.0'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '30', 'OutcomeMeasurementLowerLimit': '14.0', 'OutcomeMeasurementUpperLimit': '235.4'}]}}]}}]}}]",0,Up to 6 months,Evaluate the safety by 1) occurrence of solicited AEs over a 7 day follow-up period (day of immunization and 6 days post-immunization); 2) the occurrence of unsolicited AEs over a 30 day follow-up period (day of immunization and 29 day follow-up period); and 3) the occurrence of SAEs during the study period. IC group was not included in AE evaluations and there for not reported in the FCSR.,"[{'EventGroupId': 'EG000', 'EventGroupTitle': '10ug Dose FMP011', 'EventGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '5', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '5', 'EventGroupOtherNumAffected': '5', 'EventGroupOtherNumAtRisk': '5'}, {'EventGroupId': 'EG001', 'EventGroupTitle': '50ug Dose FMP011', 'EventGroupDescription': 'Falciparum Malaria Protein 11 with AS01B adjuvant\n\nFalciparum Malaria Protein 11 with AS01B adjuvant.: malaria experimental vaccine', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '13', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '13', 'EventGroupOtherNumAffected': '13', 'EventGroupOtherNumAtRisk': '13'}, {'EventGroupId': 'EG002', 'EventGroupTitle': 'Infectivity Control (IC)', 'EventGroupDescription': ""10 Subject from the high dose group and six non immunized subjects enrolled prior to challenge to serve as IC's for malaria sporozoite challenge"", 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '0', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '0', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '0'}]","[{'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Redness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '10', 'OtherEventStatsNumAffected': '10', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Malaise', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Joint pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '13', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Redness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Joint pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 1', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '11', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Redness', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Fever', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Malaise', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Myalgia', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '9', 'OtherEventStatsNumAffected': '9', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Joint pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Chills', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Bruise', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Back pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Flu-like symptoms', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Stiffness', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Swollen glands', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Any', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Chills', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '7', 'OtherEventStatsNumAffected': '7', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Back pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Flu-like symptoms', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Stiffness', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}, {'OtherEventTerm': 'Swollen glands - neck and axillary', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MeDRA', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventNotes': 'Immunization 2', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '5'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '13'}, {'OtherEventStatsGroupId': 'EG002', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '0'}]}}]",No,No,"James Cummings, MD",WRAIR,james.cummings@us.army.mil,301-319-9312,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01153880,113158,GlaxoSmithKline,INDUSTRY,United States Pharmacovigilence Retapamulin-Prescribing,Pharmacovigilence for Retapamulin: Age-stratified Monitoring of Prescribed Use in the United States,May-13,Completed,No,Dec-08,,Aug-12,Actual,Aug-12,Actual,29-Jun-10,29-Jun-10,30-Jun-10,Estimate,06-Jun-13,10-Jun-13,Estimate,Sponsor,GlaxoSmithKline,INDUSTRY,,,,,"Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical antibiotics approved for human use. In the United States (US), retapamulin is approved for the treatment of impetigo in persons nine or more months of age and was launched on 12 April 2007. This five-year study is designed to examine use of retapamulin in the pediatric population less than nine months of age. We will conduct an annual assessment of prescription sales claims for retapamulin using the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database. For each year of reporting, the observed frequencies of the exposure, with or without same-day, co-prescribed sales claim of mupirocin, will be identified. The study objectives are to determine the frequency of retapamulin sales in a representative US population stratified by the designated age group and to determine the frequency of same-day sale of the topical agent, mupirocin.","['Skin Infections, Bacterial']",Observational,,,,,,1,Actual,"[{'ArmGroupLabel': 'Age <9 months definitive', 'ArmGroupDescription': 'Age at time of prescription was <9 months', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']}}, {'ArmGroupLabel': 'Age <9 months uncertain', 'ArmGroupDescription': 'Age at time of prescription was uncertain for <9 months', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']}}, {'ArmGroupLabel': '9 months to 6 years', 'ArmGroupDescription': 'Age at time of prescription was 9 months to 6 years', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']}}, {'ArmGroupLabel': '7 to 18 years', 'ArmGroupDescription': 'Age at time of prescription was 7 to 18 years', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']}}, {'ArmGroupLabel': '19 to 65 years', 'ArmGroupDescription': 'Age at time of prescription was 19 to 65 years', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']}}, {'ArmGroupLabel': '66 years and older', 'ArmGroupDescription': 'Age at time of prescription was 66 years and older', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Retapamulin', 'Drug: Co-prescription of retapamulin and topical mupirocin']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Retapamulin', 'InterventionDescription': 'Prescription sales claim of retapamulin', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['19 to 65 years', '66 years and older', '7 to 18 years', '9 months to 6 years', 'Age <9 months definitive', 'Age <9 months uncertain']}}, {'InterventionType': 'Drug', 'InterventionName': 'Co-prescription of retapamulin and topical mupirocin', 'InterventionDescription': 'Same day prescription sales claims for retapamulin and topical mupirocin', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['19 to 65 years', '66 years and older', '7 to 18 years', '9 months to 6 years', 'Age <9 months definitive', 'Age <9 months uncertain']}}]","[{'PrimaryOutcomeMeasure': 'Prescription of retapamulin', 'PrimaryOutcomeTimeFrame': 'First prescription in database for each calendar year between January 2007 and December 2011'}]","[{'SecondaryOutcomeMeasure': 'Prescription for retapamulin and topical mupirocin', 'SecondaryOutcomeTimeFrame': 'First same-day prescriptions for both medicines in database for each calendar year between Janaury 2007 and December 2011'}]","Inclusion Criteria:

The study population will consist of all 'eligible members' in the IHCIS database with a valid gender and age record who have at least 1 month enrolment and eligibility of pharmacy benefits.

Exclusion Criteria:

Membership in IHCIS without a valid gender or age record, enrolment less than 1 month, or ineligibility for pharmacy benefits will be excluded.",No,All,,,"['Child', 'Adult', 'Older Adult']",,,No,"The IHCIS is Health Insurance Portability and Accountability Act (HIPAA) compliant with encrypted member and provider identifiers; date of birth is restricted to year of birth. Based on year of birth and the prescription sales claim date, age at the time of the prescription(s) will be categorized as less than 9 months (definitive) and less than 9 months (uncertain).","['Altabax', 'United States', 'topical', 'Mupirocin', 'Retapamulin', 'Bactroban']",,,['Retrospective'],Members with enrollment and phamacy benefits eligibility in the Integrated Health Care Information Services (IHCIS) National Managed Care Benchmarked Database will be assessed annually for prescription sales claims for five years post-launch of retapamulin. The IHCIS is a US national managed care database which is Health Insurance Portability and Accountability Act (HIPAA) compliant and features encrypted member and provider identifiers.,Probability Sample,,,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000002481', 'ConditionMeshTerm': 'Cellulitis'}, {'ConditionMeshId': 'D000012874', 'ConditionMeshTerm': 'Skin Diseases, Infectious'}, {'ConditionMeshId': 'D000001424', 'ConditionMeshTerm': 'Bacterial Infections'}]","[{'ConditionAncestorId': 'D000007239', 'ConditionAncestorTerm': 'Infection'}, {'ConditionAncestorId': 'D000013492', 'ConditionAncestorTerm': 'Suppuration'}, {'ConditionAncestorId': 'D000003240', 'ConditionAncestorTerm': 'Connective Tissue Diseases'}, {'ConditionAncestorId': 'D000007249', 'ConditionAncestorTerm': 'Inflammation'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14260', 'ConditionBrowseLeafName': 'Skin Diseases, Infectious', 'ConditionBrowseLeafAsFound': 'Skin Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4313', 'ConditionBrowseLeafName': 'Cellulitis', 'ConditionBrowseLeafAsFound': 'Skin Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14257', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3303', 'ConditionBrowseLeafName': 'Bacterial Infections', 'ConditionBrowseLeafAsFound': 'Infections, Bacterial', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14856', 'ConditionBrowseLeafName': 'Suppuration', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5047', 'ConditionBrowseLeafName': 'Connective Tissue Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8876', 'ConditionBrowseLeafName': 'Inflammation', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]","[{'InterventionMeshId': 'D000016712', 'InterventionMeshTerm': 'Mupirocin'}, {'InterventionMeshId': 'C000508887', 'InterventionMeshTerm': 'Retapamulin'}]","[{'InterventionAncestorId': 'D000000900', 'InterventionAncestorTerm': 'Anti-Bacterial Agents'}, {'InterventionAncestorId': 'D000000890', 'InterventionAncestorTerm': 'Anti-Infective Agents'}, {'InterventionAncestorId': 'D000011500', 'InterventionAncestorTerm': 'Protein Synthesis Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}]","[{'InterventionBrowseLeafId': 'M17658', 'InterventionBrowseLeafName': 'Mupirocin', 'InterventionBrowseLeafAsFound': 'Toxoid', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M268755', 'InterventionBrowseLeafName': 'Retapamulin', 'InterventionBrowseLeafAsFound': 'Stage IV pancreatic cancer', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2803', 'InterventionBrowseLeafName': 'Anti-Bacterial Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02019732,117233,GlaxoSmithKline,INDUSTRY,Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States,"Burden of Mild Outcomes Due to Influenza in the United States, July 2000 Through April 2009 and October 2010 to May 2011",Jan-17,Completed,No,Jan-13,,Jun-13,Actual,Jun-13,Actual,27-Nov-13,19-Dec-13,24-Dec-13,Estimate,09-Jan-17,10-Jan-17,Estimate,Sponsor,GlaxoSmithKline,INDUSTRY,,,,,"This is a database study to quantify the burden of multiple mild outcomes (i.e., those that result in visits to a physician's office) attributable to influenza in the United States, stratified by age group, geographic region and influenza subtype for selected influenza seasons.",['Influenza'],Observational,,,,,,1,Actual,"[{'ArmGroupLabel': 'Study Group', 'ArmGroupDescription': 'Applicable subjects less than 65 years of age identified in the Marketscan Commercial database during the period from July 2000 through April 2009, and October 2010 to May 2011 and subjects 65 years of age and older identified in MarketScan Medicare Supplemental database during the period from July 2006 through April 2009, and October 2010 to May 2011.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Data collection']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Data collection', 'InterventionDescription': 'Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Study Group']}}]","[{'PrimaryOutcomeMeasure': ""Weekly occurrences of potentially influenza-attributable physician's office visits by age, region and season."", 'PrimaryOutcomeDescription': '- All the events contained within ""potentially influenza-attributable"" office visits. - Weekly proportion of circulating influenza A and B strains determined for each season.', 'PrimaryOutcomeTimeFrame': 'Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).'}]","[{'SecondaryOutcomeMeasure': 'Assessment of Influenza vaccine content and effectiveness by season.', 'SecondaryOutcomeTimeFrame': 'Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).'}, {'SecondaryOutcomeMeasure': 'Assessment of Influenza vaccine coverage by season and region.', 'SecondaryOutcomeTimeFrame': 'Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).'}, {'SecondaryOutcomeMeasure': 'Assessment of Influenza B vaccine mismatch (by region and season).', 'SecondaryOutcomeTimeFrame': 'Up to 10 years approximately (Marketscan Commercial Database) and up to 6 years approximately (Marketscan Medicare Supplemental Database).'}]","Inclusion Criteria:

• Recorded in a Marketscan database with any of the specified diagnostic codes.

Exclusion Criteria:

• Missing data in any of the following fields: age, diagnosis, region or visit date.",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20814', 'LocationCountry': 'United States'}]",,,"This is a retrospective database study to quantify the burden of multiple mild pre-defined influenza-attributable outcomes of interest, which resulted in physician office visits for persons who were less than 65 years of age, in the United States in the relevant Marketscan Commercial database in the period from July 2000 through April 2009, and October 2010 to May 2011. The corresponding physician office visits for persons 65 years of age and older, with a mild influenza-attributable outcome of interest, in the United States that were recorded in the relevant MarketScan Medicare Supplemental database in the period from July 2006 through April 2009, and October 2010 to May 2011 were also investigated. The period from April 2009 through September 2010 is excluded to avoid the H1N1 pandemic wave.","['Mild outcomes', 'Database', 'Influenza-attributable', 'Retrospective', 'Influenza', 'United States of America (USA)']",,,['Retrospective'],All records related to physician office visits of subjects less than 65 years of age and 65 years of age and older in the United States with an outcome of interest in the relevant Marketscan database.,Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '27821091', 'ReferenceType': 'derived', 'ReferenceCitation': 'Matias G, Haguinet F, Lustig RL, Edelman L, Chowell G, Taylor RJ. Model estimates of the burden of outpatient visits attributable to influenza in the United States. BMC Infect Dis. 2016 Nov 7;16(1):641.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007251', 'ConditionMeshTerm': 'Influenza, Human'}]","[{'ConditionAncestorId': 'D000009976', 'ConditionAncestorTerm': 'Orthomyxoviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000012141', 'ConditionAncestorTerm': 'Respiratory Tract Infections'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]","[{'ConditionBrowseLeafId': 'M8878', 'ConditionBrowseLeafName': 'Influenza, Human', 'ConditionBrowseLeafAsFound': 'Influenza', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11485', 'ConditionBrowseLeafName': 'Orthomyxoviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13561', 'ConditionBrowseLeafName': 'Respiratory Tract Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03972358,8002,Gynuity Health Projects,OTHER,Assessing Medical Menstrual Regulation in the United States,Assessing Acceptability and Use of Medical Menstrual Regulation in the United States,Jan-20,Recruiting,No,Jan-20,Anticipated,31-Dec-20,Anticipated,31-Dec-20,Anticipated,28-May-19,31-May-19,03-Jun-19,Actual,07-Jan-20,10-Jan-20,Actual,Sponsor,Gynuity Health Projects,OTHER,Yes,No,,No,This study will assess the acceptability and use of medical menstrual regulation among women in the United States.,['Menstrual Regulation'],Interventional,['Phase 2'],N/A,Single Group Assignment,Treatment,None (Open Label),284,Anticipated,"[{'ArmGroupLabel': 'Medical menstrual regulation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Mifepristone 200 mg orally on day 1.\n\nMisoprostol 800 mcg buccally on day 2 (24 hours after mifepristone).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Mifepristone', 'Drug: Misoprostol']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Mifepristone', 'InterventionDescription': 'All participants will receive 200 mg mifepristone, to be taken orally on day 1.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Medical menstrual regulation']}}, {'InterventionType': 'Drug', 'InterventionName': 'Misoprostol', 'InterventionDescription': 'All participants will receive 800 mcg misoprostol, to be taken buccally 24 hours after mifepristone (day 2)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Medical menstrual regulation']}}]","[{'PrimaryOutcomeMeasure': 'Number of participants who report that MMR was acceptable or highly acceptable during the exit interview', 'PrimaryOutcomeDescription': 'Acceptability of MMR', 'PrimaryOutcomeTimeFrame': 'Up to 28 days after mifepristone administration'}]","[{'SecondaryOutcomeMeasure': 'Number of participants not pregnant at follow-up', 'SecondaryOutcomeDescription': 'Efficacy', 'SecondaryOutcomeTimeFrame': 'Up to 28 days after mifepristone administration'}, {'SecondaryOutcomeMeasure': 'Number of participants with adverse events and/or side effects', 'SecondaryOutcomeDescription': 'Safety and side effects', 'SecondaryOutcomeTimeFrame': 'Up to 28 days after mifepristone administration'}, {'SecondaryOutcomeMeasure': 'Perceived advantages and disadvantages of MMR as reported by participants during the exit interview', 'SecondaryOutcomeDescription': 'Experiences, perceived advantages and disadvantages', 'SecondaryOutcomeTimeFrame': 'Up to 28 days after mifepristone administration'}]","Inclusion Criteria:

Age 18-49 years
General good health
Does not want to be pregnant
Does not want to verify pregnancy status at the study site
History of regular monthly menstrual cycles
Missed menses of 1-21 days
Sexual activity in the past 2 months
Willing and able to sign consent forms
Willing to provide urine sample at enrollment
Willing to return for a follow-up visit

Exclusion Criteria:

Known allergies or contraindications to mifepristone and/or misoprostol
Symptoms of or risk factors for ectopic pregnancy
Current use of an IUD, contraceptive implant or injectable",Accepts Healthy Volunteers,Female,18 Years,49 Years,['Adult'],"[{'LocationFacility': 'Carafem Health Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Skokie', 'LocationState': 'Illinois', 'LocationZip': '60076', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Grant', 'LocationContactRole': 'Contact', 'LocationContactPhone': '855-729-2272'}, {'LocationContactName': 'Melissa Grant', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Carafem Health Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chevy Chase', 'LocationState': 'Maryland', 'LocationZip': '20815', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Melissa Grant', 'LocationContactRole': 'Contact', 'LocationContactPhone': '855-729-2272'}, {'LocationContactName': 'Melissa Grant', 'LocationContactRole': 'Principal Investigator'}]}}]",,No,"Medical menstrual regulation (MMR) entails the use of uterine evacuation medications by women with late menses without confirming pregnancy status. Provision of MMR in the United States could expand reproductive choice and service options for women. This study will collect data on the acceptability, efficacy, safety and feasibility of MMR among women with missed menses of 1-21 days",,,,,,,,,,,,,,"[{'OverallOfficialName': 'Wendy R Sheldon, PhD', 'OverallOfficialAffiliation': 'Gynuity Health Projects', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,Sharing de-identified data will be considered upon individual request.,"[{'CentralContactName': 'Wendy R Sheldon, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '212-448-1230', 'CentralContactEMail': 'wsheldon@gynuity.org'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,"[{'InterventionMeshId': 'D000016595', 'InterventionMeshTerm': 'Misoprostol'}, {'InterventionMeshId': 'D000015735', 'InterventionMeshTerm': 'Mifepristone'}]","[{'InterventionAncestorId': 'D000000020', 'InterventionAncestorTerm': 'Abortifacient Agents, Nonsteroidal'}, {'InterventionAncestorId': 'D000000019', 'InterventionAncestorTerm': 'Abortifacient Agents'}, {'InterventionAncestorId': 'D000012102', 'InterventionAncestorTerm': 'Reproductive Control Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000000897', 'InterventionAncestorTerm': 'Anti-Ulcer Agents'}, {'InterventionAncestorId': 'D000005765', 'InterventionAncestorTerm': 'Gastrointestinal Agents'}, {'InterventionAncestorId': 'D000010120', 'InterventionAncestorTerm': 'Oxytocics'}, {'InterventionAncestorId': 'D000000021', 'InterventionAncestorTerm': 'Abortifacient Agents, Steroidal'}, {'InterventionAncestorId': 'D000003280', 'InterventionAncestorTerm': 'Contraceptives, Oral, Synthetic'}, {'InterventionAncestorId': 'D000003276', 'InterventionAncestorTerm': 'Contraceptives, Oral'}, {'InterventionAncestorId': 'D000003271', 'InterventionAncestorTerm': 'Contraceptive Agents, Female'}, {'InterventionAncestorId': 'D000003270', 'InterventionAncestorTerm': 'Contraceptive Agents'}, {'InterventionAncestorId': 'D000003283', 'InterventionAncestorTerm': 'Contraceptives, Postcoital, Synthetic'}, {'InterventionAncestorId': 'D000003281', 'InterventionAncestorTerm': 'Contraceptives, Postcoital'}, {'InterventionAncestorId': 'D000006727', 'InterventionAncestorTerm': 'Hormone Antagonists'}, {'InterventionAncestorId': 'D000006730', 'InterventionAncestorTerm': 'Hormones, Hormone Substitutes, and Hormone Antagonists'}, {'InterventionAncestorId': 'D000008186', 'InterventionAncestorTerm': 'Luteolytic Agents'}, {'InterventionAncestorId': 'D000008600', 'InterventionAncestorTerm': 'Menstruation-Inducing Agents'}]","[{'InterventionBrowseLeafId': 'M17562', 'InterventionBrowseLeafName': 'Misoprostol', 'InterventionBrowseLeafAsFound': 'Infected', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M16883', 'InterventionBrowseLeafName': 'Mifepristone', 'InterventionBrowseLeafAsFound': 'Data collection', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2769', 'InterventionBrowseLeafName': 'Antacids', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2800', 'InterventionBrowseLeafName': 'Anti-Ulcer Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7464', 'InterventionBrowseLeafName': 'Gastrointestinal Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M5077', 'InterventionBrowseLeafName': 'Contraceptive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M5083', 'InterventionBrowseLeafName': 'Contraceptives, Oral', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M5088', 'InterventionBrowseLeafName': 'Contraceptives, Postcoital', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8372', 'InterventionBrowseLeafName': 'Hormones', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8371', 'InterventionBrowseLeafName': 'Hormone Antagonists', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}, {'InterventionBrowseBranchAbbrev': 'Repr', 'InterventionBrowseBranchName': 'Reproductive Control Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00948233,2009-0222,M.D. Anderson Cancer Center,OTHER,Project COMBAT: Combating Tobacco Use in the United States Army,Combating Tobacco Use in the United States Army,Jul-16,Withdrawn,No,Jun-09,,Jul-16,Actual,Jul-16,Actual,16-Jul-09,28-Jul-09,29-Jul-09,Estimate,20-Jul-16,21-Jul-16,Estimate,Sponsor,M.D. Anderson Cancer Center,OTHER,,,,,"The goal of this behavioral research study is to test a new multimedia anti-tobacco video game tailored to the U.S. Army. Researchers want to study how using the program affects tobacco use in soldiers, as compared to standard anti-tobacco programs.","['Smoking', 'Smoking Cessation']",Observational,,,,,,0,Actual,"[{'ArmGroupLabel': 'Intervention', 'ArmGroupDescription': 'Educational video game', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Video Game', 'Behavioral: Surveys']}}, {'ArmGroupLabel': 'Standard Care', 'ArmGroupDescription': 'Pamphlets on stopping tobacco use', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Pamphlet', 'Behavioral: Surveys']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Video Game', 'InterventionDescription': 'Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Pamphlet', 'InterventionDescription': 'Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Standard Care']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Surveys', 'InterventionDescription': 'Computer surveys taken at 4 points throughout the study.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention', 'Standard Care']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Questionnaire']}}]","[{'PrimaryOutcomeMeasure': 'Reductions in Smoking Initiation/Smokeless Tobacco Use and Smoking Cessation', 'PrimaryOutcomeTimeFrame': 'Baseline, immediately following completion of the program, and at 6- and 12-month follow-ups'}]",,"Inclusion Criteria:

Active duty service members, age 18 or above, who have entered the Army stationed at Joint Base San Antonio
Does not have to be a current smoker or user of alternative tobacco products
Must provide contact information including: an address, telephone number, and an email address
Willing to answer two questions regarding status of smoking and smokeless tobacco use on study survey
Have access to the Internet
Speak, read and write in English at a sixth-grade literacy level

Exclusion Criteria:

N/A",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']",,"[{'CollaboratorName': 'United States Department of Defense', 'CollaboratorClass': 'FED'}]",No,"Researchers in the M. D. Anderson Department of Behavioral Science are developing a new video game program for young U.S. Army service members. The game addresses stopping and preventing the use of cigarettes and smokeless tobacco. Soldiers (ages 18-35 years) stationed at Fort Hood, Texas, who are not scheduled to be mobilized for a 13-month period, will be invited to take part in the study.

The Study Groups:

If you choose to take part in this study, you will be assigned to a type of study intervention. The personnel companies on-base have been randomly assigned (as in the flip of a coin) to offer participating service members 1 of the following 2 programs: either the educational video game (called the ""intervention""), or pamphlets on stopping tobacco use (called ""standard care""). Each company will receive only 1 of the 2 programs, and all participating service members in the same company will receive the same program. Each company has an equal chance of being assigned to either program.

Intervention:

Participants in the intervention group will have a month to use the educational anti-tobacco video game located in areas that will provide convenient access. The game will be made available using an arcade-type kiosk which houses the computer game. After playing the video game on the kiosk for three 30-minute sessions, you will then be given a CD-ROM disc of the game to use as needed. After finishing these three 30-minute computer sessions, you will also receive a series of printed materials that go along with the computer sessions.

Standard Care:

The standard care participants will receive a self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.

Both Intervention and Standard Care Groups:

No matter which group your company is assigned to, if you choose to take part, you will be asked to complete surveys by computer at 4 points throughout the study. The survey will include questions about tobacco use, such as how much tobacco you use, how many times you have tried to quit, how ready you are to quit, how dependent you are on nicotine, any withdrawal and breathing symptoms you experience, your level of alcohol use, and support from family and friends. Each survey should take about 30 minutes to complete.

The first surveys will take place at the start of study participation. The intervention group will complete the second survey right after finishing the program. The standard care group will complete this second survey at about the same time as the intervention group. Both groups will also complete the third and fourth surveys at 6- and 12-month follow-ups.

You will be asked to provide saliva samples at the 12-month follow-up visit. Researchers will use these saliva samples to measure the level of cotinine, a chemical in your saliva that is related to tobacco use. You will be asked to spit into a clean plastic container. A dipstick will be placed in the container for at least 30 minutes. After reading the dipstick and recording the result, the study staff will throw away the saliva sample right away.

You will also be told about the nicotine replacement therapy and other tobacco cessation services available at no cost through the Carl R. Darnall Army Medical Center (CRDAMC) Tobacco Cessation Program at Fort Hood. M. D. Anderson is collaborating with the CRDAMC Tobacco Cessation Program on this study.

This is an investigational study. Up to 2050 soldiers will be asked to take part in this study.","['Tobacco', 'Smoking Cessation', 'Prevention', 'Smokeless tobacco', 'Habit']",,['Case-Only'],['Prospective'],"Soldiers stationed at Fort Hood, Texas, who are not scheduled to be mobilized for a 13-month period.",Non-Probability Sample,"[{'SecondaryId': 'W81XWH-09-2-0033', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'DOD'}]",,,,,,,"[{'OverallOfficialName': 'Alex Prokhorov, MD, PHD', 'OverallOfficialAffiliation': 'M.D. Anderson Cancer Center', 'OverallOfficialRole': 'Study Chair'}]",,,,,,,,,Military related changes led to to no initiation of recruitment.,Samples Without DNA,"Saliva samples at the 12-month follow-up visit to measure level of cotinine, a chemical related to tobacco use.","[{'SeeAlsoLinkLabel': 'University of Texas MD Anderson Cancer Center Website', 'SeeAlsoLinkURL': 'http://www.mdanderson.org'}]",['United States'],,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,,,"[{'InterventionBrowseLeafId': 'M15342', 'InterventionBrowseLeafName': 'Tin Fluorides', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M9703', 'InterventionBrowseLeafName': 'Lobeline', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Resp', 'InterventionBrowseBranchName': 'Respiratory System Agents'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00026728,10073,National Institutes of Health Clinical Center (CC),NIH,Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States,The Seroprevalence of Kaposi's Sarcoma Herpesvirus in the United States,Dec-05,Completed,No,Feb-01,,,,Dec-05,,14-Nov-01,14-Nov-01,15-Nov-01,Estimate,03-Mar-08,04-Mar-08,Estimate,,National Cancer Institute (NCI),NIH,,,,,"This study will investigate patterns of Kaposi's sarcoma herpes virus (KSHV) in the United States and its potential impact on the U.S. population. KSHV is a newly discovered virus that is strongly associated with Kaposi's sarcoma and primary effusion lymphoma. The high prevalence of KS and KSHV among HIV-infected homosexual men suggests sexual contact as a primary mode of transmission. Reports of non-sexual transmission in parts of Africa and the Mediterranean where Kaposi's sarcoma is endemic, and the identification of viral DNA in saliva and other bodily fluids, however, indicate the virus is also transmitted non-sexually. This study will:

Compare the prevalence of KSHV among different demographic groups in the United States
Examine the association between KSHV and high risk behaviors such as drug use (marijuana and cocaine), sexual behavior (age at first sexual intercourse and number of sexual partners), and medical risk factors (herpes simplex virus II, hepatitis B and hepatitis C)
Estimate the prevalence of KSHV in the United States.

Data and blood samples for the study will be taken from the NHANES III survey. NHANES is a program of periodic surveys conducted by the Centers for Disease Control and Prevention's National Center for Health Statistics. The survey is designed to provide national estimates of health status for the United States non-institutionalized civilian population by means of household interviews, standardized physical examinations, and blood sample collection and testing. NHANES III-the seventh in a series of national examination studies-was conducted from 1988 to 1994.

This study will use the HANES data to identify risks associated with a KSHV-positive blood test in the survey population. The study plans to include all 19,754 participants (67% of the 29,314 participants originally examined) for whom blood samples were collected and remain available.","[""Kaposi's Sarcoma"", 'Herpesviridae Infection']",Observational,,,,,,20169,,,,,,No specific eligibility criteria was provided for this protocol.,No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'National Cancer Institute (NCI)', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20892', 'LocationCountry': 'United States'}]",,,"Kaposi sarcoma herpesvirus (KSHV) is the viral cause of Kaposi sarcoma. Although infection with this virus appears to be uncommon in the United States, the prevalence in the general population in uncertain, and routes for transmission are poorly characterized. This study makes use of questionnaire data and serum specimens obtained in the third National Health and Nutrition Survey (NHAnes III). Sera from 18,168 individuals in this study were tested for antibodies to the KSHV proteins K8.1 and LANA. We will use these measurements to estimate KSHV seroprevalence for the overall U.S. general population and for demographic subgroups. To characterize potential transmission routes, we will also examine whether KSHV seroprevalence is related to sexual activity and exposures to blood, as indicated by responses to questionnaire items and previous NHANES III measurements of markers of relevant viral infections.","['Human Herpesvirus B', 'NHANES', 'Epidemiology', 'Population-Based Study', ""Kaposi's Sarcoma Herpes Virus""]",,,,,,[{'SecondaryId': '01-C-0073'}],,,,,,,,,"[{'ReferencePMID': '7891487', 'ReferenceType': 'background', 'ReferenceCitation': ""Huang YQ, Li JJ, Kaplan MH, Poiesz B, Katabira E, Zhang WC, Feiner D, Friedman-Kien AE. Human herpesvirus-like nucleic acid in various forms of Kaposi's sarcoma. Lancet. 1995 Mar 25;345(8952):759-61.""}]",,,,,,,,,,"[{'SeeAlsoLinkLabel': 'NIH Clinical Center Detailed Web Page', 'SeeAlsoLinkURL': 'http://clinicalstudies.info.nih.gov/detail/B_2001-C-0073.html'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012514', 'ConditionMeshTerm': 'Sarcoma, Kaposi'}, {'ConditionMeshId': 'D000006566', 'ConditionMeshTerm': 'Herpesviridae Infections'}, {'ConditionMeshId': 'D000012509', 'ConditionMeshTerm': 'Sarcoma'}]","[{'ConditionAncestorId': 'D000018204', 'ConditionAncestorTerm': 'Neoplasms, Connective and Soft Tissue'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004266', 'ConditionAncestorTerm': 'DNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000009383', 'ConditionAncestorTerm': 'Neoplasms, Vascular Tissue'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13910', 'ConditionBrowseLeafName': 'Sarcoma', 'ConditionBrowseLeafAsFound': 'Sarcoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8226', 'ConditionBrowseLeafName': 'Herpesviridae Infections', 'ConditionBrowseLeafAsFound': 'Herpesviridae Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M13915', 'ConditionBrowseLeafName': 'Sarcoma, Kaposi', 'ConditionBrowseLeafAsFound': ""Kaposi's Sarcoma"", 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M18933', 'ConditionBrowseLeafName': 'Neoplasms, Connective and Soft Tissue', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10898', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6025', 'ConditionBrowseLeafName': 'DNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5296', 'ConditionBrowseLeafName': 'Soft Tissue Sarcoma', 'ConditionBrowseLeafAsFound': 'Sarcoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T3204', 'ConditionBrowseLeafName': 'Kaposi Sarcoma', 'ConditionBrowseLeafAsFound': ""Kaposi's Sarcoma"", 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01211990,100192,National Institutes of Health Clinical Center (CC),NIH,An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States,An Exploratory Study of the Characteristics of and Challenges for International Families Seeking Medical Care in the United States,13-May-13,Completed,No,31-Aug-10,,,,13-May-13,,29-Sep-10,29-Sep-10,30-Sep-10,Estimate,05-Oct-17,06-Oct-17,Actual,,National Institute of Mental Health (NIMH),NIH,,,,,"Background:

- State-of-the art care for children with cancer or rare diseases is not available in all countries. Owing to the proximity of Latin America and the growing numbers of Latinos already in the United States, many international patients receiving specialized medical care in U.S. hospitals are from Spanish-speaking countries. Although there are benefits associated with obtaining specialized care in the United States, linguistic barriers and cultural differences as well as the general stresses of caring for a child with a serious illness may affect families ability to obtain adequate care for their children. Researchers are interested in exploring the experiences and needs of international Latino families receiving medical care for their child in the United States in order to help health care centers provide more appropriate resources and improve the overall quality of culturally sensitive care.

Objectives:

- To understand the experiences of international Latino families who are receiving treatment for their child or have enrolled their child in a research study in the United States.

Eligibility:

Caregivers of a child between birth and 25 years of ages who are from Latin America (which includes Mexico, all countries in Central America and South America, and Spanish-speaking Caribbean countries) and who have traveled to the United States to enroll their child in a research protocol and/or seek treatment for their child s medical condition.
Caregivers must have a child enrolled on a research protocol at the time of this study.
Caregivers must have been away from their country of origin for a minimum of 3 months.

Design:

This study requires a single interview that should take approximately 1 hour.
Participants will complete the interview with a member of the research team who is bilingual or fluent in Spanish.
Participants will be asked open-ended questions about why they chose to come to the United States, how they are adjusting to living and getting medical care for their child in the United States, and what hopes they have for treatment outcomes and future medical care.
Researchers will record the interviews to be reviewed later. The recordings will be used for this study only.","['Cancer', 'Allogeneic Peripheral Blood Stem Cell Transplant', 'Bone Marrow Transplantation']",Observational,,,,,,22,Actual,,,,,"INCLUSION CRITERIA:
Caregivers of children aged 0-25.
The children of the participants must be involved in clinical research or be receiving treatment for their child s medical condition. This includes but is not limited to oncological and hematological diseases, conditions requiring transplant, and rare immunodeficiency or genetic conditions.
The family traveled to the US for the purpose of addressing their child s medical condition.
Caregivers must be from a country outside of the United States. Care givers must be fluent in Spanish or English.
Caregiver has been away from the country of origin for a minimum of three months.
The child s treatment protocol PI must agree to have the research team contact potential participants in order to explore their interest in this protocol.

EXCLUSION CRITERIA:

The caregiver participant immigrated to the US for reasons other than enrolling in a research study or addressing their child s medical condition.
Presence of psychotic symptoms or severe psychological distress, which in the judgment of the Principal or Associate Investigator or consulting psychiatrist would compromise the caregiver s ability to engage in the interview or is likely to interfere with the study procedures or results.",Accepts Healthy Volunteers,All,18 Years,100 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'National Institutes of Health Clinical Center, 9000 Rockville Pike', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20892', 'LocationCountry': 'United States'}]",,,"Background:

The number of individuals who choose to travel out of their native country for medical treatment in the United States has been growing (Purnell & Paulanka, 1998). State-of-the art care for children with cancer or rare diseases is not available in all countries, especially those where the ubiquity of cancer is a new phenomenon (Granda-Cameron, 1999). Due to the proximity of Latin America and the growing numbers of Latinos already in the United States, many, though not all, of the international patients being treated in U.S. hospitals are from Spanish-speaking countries (Coatsworth, Duncan, Pantin, & Szapocznik, 2006). While there are benefits associated with obtaining care in the United States such as improved access to specialized medical services, barriers posed by linguistic and cultural differences may play a role in the provision of adequate care for these children and their families. Additional challenges associated with receiving care in another country include failure to adhere to medical regimen due to breakdowns in communication, increased stress upon the caregiver to navigate a foreign health system and adjust to a foreign culture, and being uprooted from supportive social networks and family members (Flores, Abreu, Schwartz, & Hill, 2000). Parents of children with more severe and/or complex diseases may find themselves settling in the United States at the cost of leaving behind loved ones and careers in their country of origin. Provision of optimal care for these patients includes addressing the adjustment needs of their families; the caregiver-patient relationship has a significant influence on the child s physical and psychological outcomes (Brown et al., 2008). Exploring the experiences and needs of internationalfamilies that come to the United States seeking medical care for their child may help health care centers to provide more appropriate resources and may improve the overall quality of culturally-sensitive care provided to these families.

Objective: This is a pilot, exploratory study designed to obtain greater understanding about the unique experiences of international families, mostly Latino families, who choose to participate in clinical research or seek medical treatment in the United States. Due to the lack of research on this phenomenon, the study will utilize qualitative methods to extrapolate the main themes that characterize this experience. The end goal of the study is to identify unique risk and protective factors that link directly to feasible interventions, so that we can provide this growing population with the standard of care expected by the mission of the NIH.

Aims:

To identify factors affecting the decision by international caregivers to seek treatment in the United States, with a specific focus on how medical information is obtained and utilized in the decision-making process.

To explore the experience of international caregivers in adapting to the medical and social culture of the United States.

To explore the thoughts and concerns of international caregivers regarding termination of treatment and subsequent re-entry into their native country.

To identify the presence and kind of positive growth experiences that occur in international families seeking medical care in the United States

To develop a set of concrete risk and protective factors associated with this experience in order to link to feasible interventions.

(The term caregiver in this protocol is used to encapsulate any individual, such as a parent, close relative, foster parent, or head of household, who attends to the needs of the ill child.)

Study Population:

This is a study taking place at the National Institutes of Health (NIH). All caregivers of a child between the ages of 0-25 from a foreign country who have traveled to the United States for the purpose of enrolling in a research protocol and/or seeking treatment for their child s medical condition will be invited to participate in this study. Caregivers who immigrated to the United States for reasons other than obtaining these services for their child s condition will not be eligible to enroll in this study. Given the present demographic populations at NIH, it is expected that participants will include, but not be limited to, individuals from the Caribbean, Dominican Republic, Puerto Rico, Chile, Peru, Guatemala, and Mexico. This sampling frame ensures that the presence of black, white, and mixed race individuals will be represented, acknowledging ethnicities that are often overlooked in studies focusing specifically on the experience of a given ethnic or racial group.

Socioeconomic situation of the families is expected to vary widely; at NIH, individuals who meet the criteria for this study are from all different socioeconomic strata and have varying levels of education.

Design:

This is a qualitative study that will utilize narrative interview techniques to gather data, and content analysis techniques to analyze data. Data will be gathered according to theories of saturation of content, while collecting sufficient data to ensure credibility and face validity (Mays & Pope, 2000). NVivo, a validated quantitative research tool will be used for data analysis.","['Pediatric', 'Children', 'Cancer', 'Bone Marrow Transplant']",,,['Prospective'],,,[{'SecondaryId': '10-M-0192'}],,,,,,,"[{'OverallOfficialName': 'Maryland Pao, M.D.', 'OverallOfficialAffiliation': 'National Institute of Mental Health (NIMH)', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '16615062', 'ReferenceType': 'background', 'ReferenceCitation': 'Abbe M, Simon C, Angiolillo A, Ruccione K, Kodish ED. A survey of language barriers from the perspective of pediatric oncologists, interpreters, and parents. Pediatr Blood Cancer. 2006 Nov;47(6):819-24.'}, {'ReferencePMID': '12461214', 'ReferenceType': 'background', 'ReferenceCitation': 'Alegría M, Canino G, Ríos R, Vera M, Calderón J, Rusch D, Ortega AN. Inequalities in use of specialty mental health services among Latinos, African Americans, and non-Latino whites. Psychiatr Serv. 2002 Dec;53(12):1547-55.'}, {'ReferencePMID': '9494321', 'ReferenceType': 'background', 'ReferenceCitation': 'Barakat LP, Kazak AE, Meadows AT, Casey R, Meeske K, Stuber ML. Families surviving childhood cancer: a comparison of posttraumatic stress symptoms with families of healthy children. J Pediatr Psychol. 1997 Dec;22(6):843-59.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02663219,HPTN 078,HIV Prevention Trials Network,NETWORK,"Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected MSM in the United States","Enhancing Recruitment, Linkage to Care and Treatment for HIV-Infected Men Who Have Sex With Men (MSM) in the United States",Jan-18,Unknown status,No,06-Jun-16,Actual,Feb-19,Anticipated,Feb-19,Anticipated,13-Jan-16,21-Jan-16,26-Jan-16,Estimate,08-Jan-18,10-Jan-18,Actual,Sponsor,HIV Prevention Trials Network,NETWORK,,,,,"The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable interventions to identify, recruit, link to care, retain in care, attain, and maintain viral suppression among HIV-infected men who have sex with men (MSM) in the United States (US).",['HIV'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Prevention,None (Open Label),356,Anticipated,"[{'ArmGroupLabel': 'Intervention', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Intervention']}}, {'ArmGroupLabel': 'Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Standard of care'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Intervention', 'InterventionDescription': 'The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Intervention']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Case Management']}}]","[{'PrimaryOutcomeMeasure': 'HIV status at screening for each MSM recruited', 'PrimaryOutcomeTimeFrame': 'UP to 24 months'}, {'PrimaryOutcomeMeasure': 'HIV viral load at screening for each MSM recruited', 'PrimaryOutcomeTimeFrame': 'Up to 24 months'}]","[{'SecondaryOutcomeMeasure': 'HIV prevalence', 'SecondaryOutcomeDescription': 'comparison between those who enrolled', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'HIV viral load after enrollment', 'SecondaryOutcomeTimeFrame': 'Up to 24 months measured at months 3, 6, 9, 12, 18 and 24'}, {'SecondaryOutcomeMeasure': 'Number of times participants are linked to care', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'HCV status at baseline', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'HIV viral load at end of study', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'Baseline Demographics', 'SecondaryOutcomeDescription': 'participant-administered questionnaire', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'CD4 status at baseline', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'Self-reported sexual risk behavior of unprotected anal intercourse, characteristics of 3 most recent partners) at baseline and 24 months', 'SecondaryOutcomeDescription': 'participant-administered questionnaire', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}, {'SecondaryOutcomeMeasure': 'Antiretroviral adherence at 24 months', 'SecondaryOutcomeDescription': 'viral load and cd4 are the biomarkers for adherence', 'SecondaryOutcomeTimeFrame': 'Up to 24 months'}]","Inclusion Criteria:

Individuals who meet all of the following criteria are eligible for study screening:

Biological male (at birth)
Self-report of history of anal intercourse with another man
16 years or older

Individuals who are eligible for screening and who meet all of the following criteria are eligible for enrollment into the CM intervention and SOC control arms:

HIV-infected, as defined in the HPTN 078 Study-Specific Procedures (SSP) Manual
Not virally suppressed (defined as HIV VL ≥ 1000 copies/ml)
Can receive HIV care at one of the participating clinics (as chosen by each site)
No current plan to relocate in the 24 months following enrollment

Exclusion Criteria:

Individuals who meet any of the following criteria will be excluded from study screening:

Unable or unwilling to provide consent/assent for study participation.
Active or previous participation in an HIV vaccine trial.
Any condition that, in the opinion of the Investigator of Record (IoR), would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

Individuals who are eligible for screening, but who meet the following criteria are excluded from enrollment into the CM intervention and SOC control arms:

• Current participation in a linkage or ART adherence study",No,Male,16 Years,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Alabama CRS', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35294', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ponce de Leon CRS', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30308-2012', 'LocationCountry': 'United States'}, {'LocationFacility': 'Johns Hopkins Baltimore CRS', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21287', 'LocationCountry': 'United States'}, {'LocationFacility': 'Fenway Health CRS', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02215-4302', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'CollaboratorClass': 'NIH'}]",No,"This study will use deep-chain respondent driven sampling (DC-RDS) and direct recruitment (DR) to identify and recruit HIV-infected MSM who are not virally suppressed. A subset of these men will be enrolled into one of two study arms. The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care. The control arm will provide the standard of care (SOC) for linkage to care, initiation of ART, treatment adherence and retention in care. The primary outcome of the study is viral suppression 24 months after enrollment. Phylogenetic methods will be used to evaluate the relationship between viruses in study participants. Mathematical modeling will be performed using demographic, behavioral, and clinical data generated from this study and other sources to estimate the population-level impact of the CM intervention on HIV incidence and to estimate the level of identification, linkage, ART coverage and viral suppression that would be required to achieve a substantial reduction in HIV incidence among MSM in the US settings where the study is conducted.","['MSM', 'ART', 'CCM', 'DAIDS', 'HPTN', 'ACA', 'PAF', 'PEP', 'RDS']",,,,,,"[{'SecondaryId': 'UM1AI068619', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=UM1AI068619&Fy=all'}, {'SecondaryId': '11995', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'DAIDS'}]",,,,,,"[{'OtherOutcomeMeasure': 'Health care utilization at baseline and 24 months', 'OtherOutcomeDescription': 'computer assisted self interview', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'Stigma at baseline and 24 months', 'OtherOutcomeDescription': 'computer assisted self interview', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'Number of contacts (text message, email, phone, in person) for each participant randomized to the CM intervention arm over follow-up', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'Satisfaction with the CM intervention components, as measured on a Likert scale during a standardized exit interview', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'Usefulness of the CM intervention components, as measured on a Likert scale during a standardized exit interview', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'Open-ended questions regarding linkage to HIV care', 'OtherOutcomeDescription': 'open ended qualitative data compiled and coded', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'The phylogenetic relationship between HIV sequences', 'OtherOutcomeDescription': 'relationship between HIV strains in different men', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'HIV viral load at baseline', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'Syphilis positive or negative at baseline', 'OtherOutcomeTimeFrame': 'Up to 24 months'}, {'OtherOutcomeMeasure': 'HIV viral suppression', 'OtherOutcomeTimeFrame': 'Up to 24 months'}]","[{'OverallOfficialName': 'Chris Beyrer, MD/MPH', 'OverallOfficialAffiliation': 'Johns Hopkins University', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Robert H Remien, PhD', 'OverallOfficialAffiliation': 'Columbia University', 'OverallOfficialRole': 'Study Chair'}]",No,"[{'ReferenceType': 'background', 'ReferenceCitation': 'KM Mitchell, B Hoots, D Dimitrov, et al. Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV- positive MSM in Baltimore: Mathematical Modelling for HPTN 078. HIV Research for Prevention (HIVR4P 2016). Chicago, October 17-21, 2016. Abstract OA10.04'}]",,,,,,,,,,"[{'SeeAlsoLinkLabel': 'Potential Impact on HIV Incidence of Increasing Viral Suppression among HIV- positive MSM in Baltimore: Mathematical Modelling for HPTN 078', 'SeeAlsoLinkURL': 'https://www.hptn.org/sites/default/files/2016-10/R4P_slides_KM_078_modelling_181016_FINAL.pdf'}]",,"Active, not recruiting",,,,,,,,,,,,,,,,,,26-Oct-20,,,"[{'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M24015', 'InterventionBrowseLeafName': 'Anti-Retroviral Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00121108,MI-CP117,MedImmune LLC,INDUSTRY,MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States,A Phase 3 Study of MEDI-524 (Motavizumab) for the Prevention of RSV Disease Among Native American Infants in the Southwestern United States,Jun-12,Completed,No,Nov-04,,Dec-10,Actual,Mar-11,Actual,13-Jul-05,19-Jul-05,21-Jul-05,Estimate,27-Jun-12,02-Jul-12,Estimate,,MedImmune LLC,INDUSTRY,,,,,"This study (MI-CP117) is a Phase 3, randomized, double-blind, placebo-controlled trial designed to determine if MEDI-524 compared to placebo will result in clinical efficacy in the reduction of RSV hospitalization in otherwise healthy Native American Indian Infants in the Southwestern United States during their first RSV season.",['Healthy'],Interventional,['Phase 3'],Randomized,Single Group Assignment,Treatment,Double,2127,Actual,"[{'ArmGroupLabel': '2', 'ArmGroupType': 'Placebo Comparator', 'ArmGroupDescription': 'Placebo', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Placebo']}}, {'ArmGroupLabel': '1', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'MEDI-524', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: MEDI-524']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'MEDI-524', 'InterventionDescription': '15 mg/kg motavizumab administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo', 'InterventionDescription': '15 mg/kg placebo administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]","[{'PrimaryOutcomeMeasure': 'The incidence of RSV hospitalization from Study Day 0 through Study Day 150 of the 1st RSV season will be the primary endpoint.', 'PrimaryOutcomeTimeFrame': 'Through Day 150'}]","[{'SecondaryOutcomeMeasure': 'Safety and tolerability of MEDI-524 will be assessed primarily by summarizing adverse events and serious adverse events occurring through Study Day 150.', 'SecondaryOutcomeTimeFrame': 'Through Day 150'}]","Inclusion Criteria:

6 months of age or younger at randomization (child must be randomized on or before their 6-month birthday)
Male or female Native American
General state of good health
Written informed consent obtained from the patient's parent(s) or legal guardian

Exclusion Criteria:

Gestational age less than or equal to 35 weeks
Chronic lung disease of prematurity
A bleeding diathesis that would preclude IM injections
Hospitalization at the time of randomization (unless discharge is anticipated within 10 days)
Active RSV infection (a child with signs/symptoms of respiratory infection must have negative RSV testing) or known prior history of RSV infection
A documented wheezing episode before enrollment
Known renal impairment
Known hepatic dysfunction
Clinically significant congenital anomaly of the respiratory tract
Chronic seizure or evolving or unstable neurologic disorder
Congenital heart disease (children with uncomplicated CHD [e.g., PDA, small septal defect] and children with complicated CHD who are currently anatomically and hemodynamically)
Known immunodeficiency
Mother with HIV infection (unless the child has been proven to be not infected)
Known allergy to Ig products
Receipt of palivizumab, RSV-IGIV, or other RSV-specific monoclonal antibody, or any other polyclonal antibody (for example, hepatitis B IG, IVIG) within 3 months prior to randomization
Anticipated use of palivizumab or IVIG during the study (blood transfusions permitted)
Previous receipt of RSV vaccines
Participation in other investigational drug product studies
Any medical or social condition which, in the opinion of the investigator, would adversely affect monitoring the infant
Inability to complete the study follow-up period through up to 5 years of age",Accepts Healthy Volunteers,All,1 Month,6 Months,['Child'],"[{'LocationFacility': 'Johns Hopkins University Bloomberg School of Public Health', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21205', 'LocationCountry': 'United States'}]",,Yes,,,,,,,,,,,,,"['Participant', 'Investigator']",,"[{'OverallOfficialName': 'Hason Jafri, M.D.', 'OverallOfficialAffiliation': 'MedImmune LLC', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '26511956', 'ReferenceType': 'derived', 'ReferenceCitation': ""O'Brien KL, Chandran A, Weatherholtz R, Jafri HS, Griffin MP, Bellamy T, Millar EV, Jensen KM, Harris BS, Reid R, Moulton LH, Losonsky GA, Karron RA, Santosham M; Respiratory Syncytial Virus (RSV) Prevention study group. Efficacy of motavizumab for the prevention of respiratory syncytial virus disease in healthy Native American infants: a phase 3 randomised double-blind placebo-controlled trial. Lancet Infect Dis. 2015 Dec;15(12):1398-408. doi: 10.1016/S1473-3099(15)00247-9. Epub 2015 Nov 4.""}]",,,,,,,,,,,,,08-Mar-12,27-Jun-12,02-Jul-12,Estimate,"Hasan Jafri, M.D.",MedImmune Inc.,,,,,,,,,,,,26-Oct-20,,,"[{'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01861210,IRB00043714,Emory University,OTHER,Couples HIV Counseling and Testing for Male Couples in the United States,Couples HIV Counseling and Testing for Male Couples in the United States,May-15,Completed,No,Sep-10,,May-12,Actual,Jun-12,Actual,21-May-13,22-May-13,23-May-13,Estimate,20-May-15,22-May-15,Estimate,Principal Investigator,Emory University,OTHER,,,,,"This is a study to determine whether testing for HIV together as a couple, as opposed to testing separately, in acceptable to men in male couples, and is a safe prevention service. Testing of couples together has been provided for decades in Africa, but has never been tested in the United States. In this study, male couples will be enrolled and randomly assigned to be tested together in the same room, or separately. At the time of testing, investigators will ask questions about how they felt about the service they received. Three months later, investigators will survey the men again, and determine whether they had any problems after the testing, like violence in the relationship or the relationship breaking up. The main outcomes are being satisfied with the testing service, and safety (lack of intimate partner violence or relationship termination). Although the study is not designed to determine if the service reduces risk behaviors for HIV transmission, investigators will examine data on risks just to explore that topic. The main hypotheses are: (1) men will be at least as satisfied with couples testing as they are with individual testing; and (2) men tested as couples will not experience higher rates of intimate partner violence or relationship dissolution, relative to men tested separately.",['HIV'],Interventional,['Not Applicable'],Randomized,Single Group Assignment,Prevention,None (Open Label),216,Actual,"[{'ArmGroupLabel': 'Couples Counseling and Testing', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Couples Voluntary HIV Counseling and Testing, adapted for use with male couples from the standard African couples testing service.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Couples Voluntary HIV Counseling and Testing']}}, {'ArmGroupLabel': 'Individudal Counseling and Testing', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Individual Voluntary Counseling and Testing involves HIV testing and individual, client-centered HIV prevention counseling. This service is provided by counselors trained in Centers for Disease Control and Prevention\'s ""Fundamentals of HIV Prevention Counseling"" training.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Individual Counseling and Testing']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Couples Voluntary HIV Counseling and Testing', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Couples Counseling and Testing']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Couples HIV Testing and Counseling']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Individual Counseling and Testing', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Individudal Counseling and Testing']}}]","[{'PrimaryOutcomeMeasure': 'Intimate partner violence', 'PrimaryOutcomeDescription': 'Having been punched, hit, or kicked by the partner he tested with, injured to the point of feeling physical pain the day after a fight, or inflicting any of these acts on his partner in the preceding three months.', 'PrimaryOutcomeTimeFrame': '3 months'}]","[{'SecondaryOutcomeMeasure': 'Relationship dissolution', 'SecondaryOutcomeDescription': 'Either or both partners reported that the relationship ended after their participation in the study', 'SecondaryOutcomeTimeFrame': '3 months, or at the time of followup survey'}]","Inclusion Criteria:

male at birth
currently self-identify as male
at least 18 years of age
have been in a couple with a man for at least 3 months
willing to complete a follow-up study visit in 3 months
able to complete study assessments in English.

Exclusion Criteria:

known to be HIV-positive
over 39 years of age
either partner being unwilling to accept randomization to the couples testing arm
either partner planning to move from the Atlanta area within 3 months of the initial study visit
either partner reporting a history of intimate partner violence
either partner reporting feeling coerced to tested with his partner",Accepts Healthy Volunteers,Male,18 Years,39 Years,['Adult'],"[{'LocationFacility': 'AID Atlanta', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30309', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]",No,,"['Homosexuality, Male']",,,,,,"[{'SecondaryId': 'R34MH086331', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R34MH086331&Fy=all'}, {'SecondaryId': 'CVCTMSM', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Other'}]",CVCT,Patrick S Sullivan,Professor,Emory University,,"[{'OtherOutcomeMeasure': 'Satisfaction with counseling service', 'OtherOutcomeDescription': 'Seven items asked on a 5-point Likert scale:\n\nQuality of the session\nRelevance of the session\nAppropriateness of the format\nDegree to which the session met personal needs\nUsefulness of the session\nSatisfaction with the session\nLikelihood of recommending the service to a friend', 'OtherOutcomeTimeFrame': 'Within 30 minutes after the service'}]","[{'OverallOfficialName': 'Patrick S Sullivan, PhD', 'OverallOfficialAffiliation': 'Emory University Rollins School of Public Health', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,"[{'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02911155,999916141,National Institutes of Health Clinical Center (CC),NIH,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists,May-20,Completed,No,21-Sep-16,,01-May-20,Actual,01-May-20,Actual,21-Sep-16,21-Sep-16,22-Sep-16,Estimate,01-May-20,05-May-20,Actual,Sponsor,National Cancer Institute (NCI),NIH,,,,,"Background:

The field of nuclear medicine has changed a lot in the past decades. Technology has gotten better, so patients are exposed to less radiation. But now workers are doing procedures more often and using lead aprons less. So they may be exposed to more radiation. This may put them at higher risk for cancers and other health problems that are related to radiation. Researchers want to collect data from technologists to learn more about the risks and appropriate doses of radiation.

Objective:

To learn more about the risks and appropriate doses of radiation for nuclear medicine technologists.

Eligibility:

Adults who were first certified in nuclear medicine technology in the United States after 1980. They must be living in the United States. They must not be participants in the USRT study.

Design:

Participants will be recruited online.

Participants will complete an online survey. It will take about a half hour. This will have questions about their work with nuclear medicine procedures. There will be questions about the kinds of procedures and how often they do them.

Participants will give a short work history. This will include the names of current and past employers.

Participants will allow researchers to get records of their film badge dose readings. These will come from dosimetry providers.

Dosimetry data will not be shared with participants. Researchers can t ensure the how accurate or complete the data are.","['Brain Cancer', 'Thyroid Cancer', 'Circulatory Disease', 'Breast Cancer']",Observational,,,,,,229,Actual,"[{'ArmGroupLabel': 'US Nuclear Medicine Technologist', 'ArmGroupDescription': 'radiologic technologists certified in nuclear medicine'}]",,"[{'PrimaryOutcomeMeasure': 'U.S. nuclear medicine tecnologist', 'PrimaryOutcomeDescription': 'Cancer and other disease risks associated with occupational nuclear medicine radiation exposures', 'PrimaryOutcomeTimeFrame': '2016-2022'}]","[{'SecondaryOutcomeMeasure': 'Administer questionnaire', 'SecondaryOutcomeDescription': 'Collect data on nuclear medicine procedures performed, radioisotopes used, related work and safety practices, and places of employment over time.', 'SecondaryOutcomeTimeFrame': '2016-2018'}, {'SecondaryOutcomeMeasure': 'Obtain badge doses', 'SecondaryOutcomeDescription': ""Collect badge doses from the nation's largest commercial dosimetry provider for use in estimating occupational radiation exposures."", 'SecondaryOutcomeTimeFrame': '2016-2019'}]","ELIGIBILITY CRITERIA:
Technologists from the target population of approximately 25,000 individuals who were first certified in nuclear medicine technology in the U.S. after 1980, are currently alive and residing in the U.S., and are not participants of the USRT study.",No,All,18 Years,100 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Minnesota, School of Public Health Environmental Health Sciences', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55455', 'LocationCountry': 'United States'}]",,,"The field of nuclear medicine has expanded rapidly since its inception in the mid-20th century, with nuclear medicine technologists now potentially experiencing higher levels of radiation exposure relative to other medical worker populations. Many radiopharmaceuticals and procedures used in previous decades are now obsolete and are being replaced by new and emerging radioisotopes and combined-modality and molecular imaging procedures. While improvements in imaging technologies and the introduction of certain radioisotopes have generally reduced patient exposure to radiation, nuclear medicine technologists have become increasingly specialized in these newer procedures and are performing these and other nuclear medicine procedures with increasing frequency. Furthermore, lead aprons are less effective in protecting workers during nuclear medicine procedures, specifically higher-energy procedures (e.g., positron emission tomography (PET)), compared to other radiation-related procedures, and are seldom used by technologists performing nuclear medicine. As a result, cumulative doses to nuclear medicine technologists are expected to have increased. We hypothesize that certified nuclear medicine technologists may experience higher risks of some radiation-related cancers and other adverse health outcomes compared to most other medical specialty groups. There is currently very little information about radiation-related risks associated with performing these procedures due, in part, to limited information on occupational doses associated with current nuclear medicine practices. To characterize organ-specific doses that could later be used to quantify risks for specific radiation-related disease outcomes, either directly (through subsequent follow-up) or indirectly (through risk projection methods), we plan to collect detailed work history information on nuclear medicine procedures and associated radiation safety practices, as well as badge doses, for a representative sample of 1,500 technologists certified in nuclear medicine in the U.S. This information will complement similar data collected in 2013-2014 from an independent sample of approximately 4,500 general radiologic technologists in the U.S. Radiologic Technologists Study (USRT) who had reported working with these procedures. However, unlike the USRT sample, the proposed sample is expected to be higher-risk, including only those workers with a specialty certification in nuclear medicine who will have been begun working with nuclear medicine procedures much earlier in their career, at ages associated with greater susceptibility to radiation-related carcinogenesis.","['Cohort Study', 'Radiation', 'Occupation']",,['Cohort'],['Prospective'],"This is an occupational cohort of 35,593 U.S. nuclear medicine technologists certified by the American Registry of Radiologic Technologist or the Nuclear Medicine Technology Certification Board in 1980 or later.",Probability Sample,[{'SecondaryId': '16-C-N141'}],,,,,,,"[{'OverallOfficialName': 'Cari M Kitahara', 'OverallOfficialAffiliation': 'National Cancer Institute (NCI)', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '25811150', 'ReferenceType': 'background', 'ReferenceCitation': 'Drozdovitch V, Brill AB, Callahan RJ, Clanton JA, DePietro A, Goldsmith SJ, Greenspan BS, Gross MD, Hays MT, Moore SC, Ponto JA, Shreeve WW, Melo DR, Linet MS, Simon SL. Use of radiopharmaceuticals in diagnostic nuclear medicine in the United States: 1960-2010. Health Phys. 2015 May;108(5):520-37. doi: 10.1097/HP.0000000000000261.'}, {'ReferencePMID': '26220810', 'ReferenceType': 'background', 'ReferenceCitation': 'Kitahara CM, Linet MS, Drozdovitch V, Alexander BH, Preston DL, Simon SL, Freedman DM, Brill AB, Miller JS, Little MP, Rajaraman P, Doody MM. Cancer and circulatory disease risks in US radiologic technologists associated with performing procedures involving radionuclides. Occup Environ Med. 2015 Nov;72(11):770-6. doi: 10.1136/oemed-2015-102834. Epub 2015 Jul 28.'}, {'ReferencePMID': '25162420', 'ReferenceType': 'background', 'ReferenceCitation': 'Drozdovitch V, Brill AB, Mettler FA Jr, Beckner WM, Goldsmith SJ, Gross MD, Hays MT, Kirchner PT, Langan JK, Reba RC, Smith GT, Bouville A, Linet MS, Melo DR, Lee C, Simon SL. Nuclear medicine practices in the 1950s through the mid-1970s and occupational radiation doses to technologists from diagnostic radioisotope procedures. Health Phys. 2014 Oct;107(4):300-10. doi: 10.1097/HP.0000000000000107.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000013964', 'ConditionMeshTerm': 'Thyroid Neoplasms'}, {'ConditionMeshId': 'D000001932', 'ConditionMeshTerm': 'Brain Neoplasms'}, {'ConditionMeshId': 'D000004194', 'ConditionMeshTerm': 'Disease'}]","[{'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000006258', 'ConditionAncestorTerm': 'Head and Neck Neoplasms'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000013959', 'ConditionAncestorTerm': 'Thyroid Diseases'}, {'ConditionAncestorId': 'D000016543', 'ConditionAncestorTerm': 'Central Nervous System Neoplasms'}, {'ConditionAncestorId': 'D000009423', 'ConditionAncestorTerm': 'Nervous System Neoplasms'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]","[{'ConditionBrowseLeafId': 'M3802', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15306', 'ConditionBrowseLeafName': 'Thyroid Neoplasms', 'ConditionBrowseLeafAsFound': 'Thyroid Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15301', 'ConditionBrowseLeafName': 'Thyroid Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3791', 'ConditionBrowseLeafName': 'Brain Neoplasms', 'ConditionBrowseLeafAsFound': 'Brain Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6446', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7931', 'ConditionBrowseLeafName': 'Head and Neck Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10950', 'ConditionBrowseLeafName': 'Nervous System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17520', 'ConditionBrowseLeafName': 'Central Nervous System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3786', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00724867,112233,GlaxoSmithKline,INDUSTRY,A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States,"A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States",Mar-16,Completed,No,Aug-08,,Mar-15,Actual,Mar-15,Actual,28-Jul-08,29-Jul-08,30-Jul-08,Estimate,10-Mar-16,28-Mar-16,Estimate,Sponsor,"Human Genome Sciences Inc., a GSK Company",INDUSTRY,,,,,"This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.",['Systemic Lupus Erythematosus'],Interventional,['Phase 3'],Non-Randomized,Parallel Assignment,Treatment,None (Open Label),268,Actual,"[{'ArmGroupLabel': 'Belimumab 1 mg/kg', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Belimumab 1 mg/kg IV every 28 days', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Belimumab 1 mg/kg']}}, {'ArmGroupLabel': 'Belimumab 10 mg/kg', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Belimumab 10 mg/kg IV every 28 days', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Belimumab 10 mg/kg']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Belimumab 1 mg/kg', 'InterventionDescription': 'Belimumab 1 mg/kg IV over one hour every 28 days', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Belimumab 1 mg/kg']}, 'InterventionOtherNameList': {'InterventionOtherName': ['BENLYSTA', 'HGS1006', 'LymphoStat-B™']}}, {'InterventionType': 'Biological', 'InterventionName': 'Belimumab 10 mg/kg', 'InterventionDescription': 'Belimumab 10 mg/kg IV over one hour every 28 days', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Belimumab 10 mg/kg']}, 'InterventionOtherNameList': {'InterventionOtherName': ['LymphoStat-B™', 'BENLYSTA', 'HGS1006']}}]","[{'PrimaryOutcomeMeasure': 'Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)', 'PrimaryOutcomeDescription': 'An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'AE Rates by System Organ Class (SOC) During the Study', 'PrimaryOutcomeDescription': 'AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / Participant Years. Participant years were calculated as sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'PrimaryOutcomeTimeFrame': 'Up Week 440'}, {'PrimaryOutcomeMeasure': 'SAE Rates by System Organ Class (SOC) During the Study', 'PrimaryOutcomeDescription': 'SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / participants Years. participants years were calculated as = sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Neutrophils Segmented and Platelets at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in basophils, eosinophils, lymphocytes, monocytes, neutrophils, neutrophils segmented and platelets is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Erythrocytes at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Hematology parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in erythrocytes is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Hematocrit at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hematocrit is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Hemoglobin at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in hemoglobin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Albumin and Protein at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in albumin and protein is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Blood Urea Nitrogen, Glucose, Calcium, Carbon Dioxide, Chloride, Magnesium, Phosphate, Potassium and Sodium at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in blood urea nitrogen, glucose, calcium, carbon dioxide, chloride, magnesium, phosphate, potassium and sodium is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Creatinine, Urate and Bilirubin at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in urate, creatinine and bilirubin is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Creatinine Clearance at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in creatinine clearance is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in BUN/Creatinine at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in BUN/creatinine is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Change From Baseline in Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Gamma Glutamyl Transferase and Lactate Dehydrogenase at the Indicated Time Points', 'PrimaryOutcomeDescription': 'Clinical chemistry parameters were assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Change from Baseline in alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, gamma glutamyl transferase and lactate dehydrogenase is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 432'}, {'PrimaryOutcomeMeasure': 'Number of Participants With the Indicated Immunogenic Response', 'PrimaryOutcomeDescription': 'Immunogenic response was assessed by binding confirmatory assay at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Number of participants with the indicated immunogenic response are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Results of binding confirmatory assay were categorized as negative, persistent positive (defined as a positive immunogenic response that occurs at least 2 consecutive assessments or a single result at the final assessment) or transient positive (defined as a single positive immunogenic response that does not occur at the final assessment). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Systolic Blood Pressure and Diastolic Blood Pressure at Indicated Time Points.', 'PrimaryOutcomeDescription': 'Systolic blood pressure (SBP) and diastolic blood pressure (DBP) was measured at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 432'}, {'PrimaryOutcomeMeasure': 'Percentage of Participants With at Least 25% Increase From Baseline in Creatinine at Indicated Time Points.', 'PrimaryOutcomeDescription': 'Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% increase from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}, {'PrimaryOutcomeMeasure': 'Percentage of Participants With at Least 25% Reduction From Baseline in Creatinine at Indicated Time Points. Amongst Subjects With Abnormal (>124 Umol/L) Creatinine at Baseline by Year Interval.', 'PrimaryOutcomeDescription': 'Serum creatinine was assessed at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Percentage of participants with at least 25% reduction from baseline in creatinine are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'PrimaryOutcomeTimeFrame': 'Up to Week 440'}]","[{'SecondaryOutcomeMeasure': 'Number of Participants With Serum Immunoglobulins Below the Lower Limit of Normal at Indicated Time Points.', 'SecondaryOutcomeDescription': 'Serum immunoglobulin G (IgG) was collected at Baseline (BL) (Day 0), at Week 24 and Week 48 in first year, at Week 48 in subsequent years up to 8 years and at follow-up (up to 8 weeks post last infusion). Number of participants with serum immunoglobulins below the lower limit of normal (LLN) (<0.5 nanograms per milliliter [ng/mL]) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 392'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants Achieving SRI Response at Indicated Time Points', 'SecondaryOutcomeDescription': 'The percentage of participants achieving a SLE Responder Index (SRI) response at Baseline (BL) (Day 0), at Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Response is defined as:>=4 point reduction from the BL in the safety of estrogen in lupus national assessment (SELENA) SLE disease activity index (SLEDAI) score and no worsening (increase of <0.30 points from the BL) in Physicians Global Assessment (PGA), and no new British Isles Lupus Assessment Group (BILAG) A organ domain score or 2 new BILAG B organ domain scores compared with the BL. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 440'}, {'SecondaryOutcomeMeasure': 'Observed Anti-double Stranded DNA Levels at Indicated Time Points.', 'SecondaryOutcomeDescription': 'Anti-double stranded deoxyribonucleic acid (anti-dsDNA) levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks in participants who were positive at baseline (anti-dsDNA >=30 International Units/milliliter [IU/mL]). Observed anti-dsDNA levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Median Percent Change From Baseline in Anti-double Stranded DNA at Indicated Time Points.', 'SecondaryOutcomeDescription': 'Anti-dsDNA levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants who were positive at baseline (anti-dsDNA ≥30 IU/mL). Median percent change from Baseline in anti-dsDNA levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Observed Complement C3 and C4 Levels at Indicated Time Points', 'SecondaryOutcomeDescription': 'Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), at Week 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligram per deciliter (mg/dL) and C4 <16 mg/dL). Observed complement C3 and C4 levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 440'}, {'SecondaryOutcomeMeasure': 'Median Percent Change From Baseline in Complement C3 and C4 Levels at Indicated Time Points', 'SecondaryOutcomeDescription': 'Complement C3 and C4 levels were assessed at Baseline (BL) (Day 0), 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit in participants with low complements at Baseline (C3 <90 milligrams per decilitre (mg/dL) and C4 <16 mg/dL). Median percent change from Baseline in complement C3 and C4 levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Percent of Participants With Daily Prednisone Dose Reduction at Indicated Time Points.', 'SecondaryOutcomeDescription': 'Trends for reduction in prednisone use in participants receiving belimumab were observed up to 432 weeks. Percentage of participants with daily prednisone dose reduced to <=7.5 mg/day from >7.5 mg/kg at the Baseline are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Percent of Participants With >= 50% Reduction in Proteinuria at Indicated Time Points.', 'SecondaryOutcomeDescription': 'Proteinuria is defined as the presence of an excess of serum proteins in the urine. Trends for reduction in proteinuria in participants receiving belimumab were assessed up to 432 weeks and at Exit visit. Percentage of participants with >= 50% reduction in proteinuria among participants with Baseline proteinuria >0.5 g/24 hour (hr) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Observed B-cell Levels at Indicated Time Points.', 'SecondaryOutcomeDescription': 'B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Observed absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Median Percent Change From Baseline in B Cell Levels at Indicated Time Points.', 'SecondaryOutcomeDescription': 'B-cell levels were assessed at Baseline (BL) (Day 0), Week (Wk) 24 and 48 in first year, at Week 24 and 48 in subsequent years up to 432 weeks and at exit visit. Median percent change from Baseline in absolute B cell subsets (CD20+), CD19+/27BRIGHT/38BRIGHT SLE subset, CD19+20-27hi+ short-lived plasma cells (SLPC), CD20+/138+ plasmacytoid, CD20+/27+ memory, CD20+/27- naïve, CD20+/69+activated, CD20-/138+ plasma cells, Total CD19+ B-cells (CD19+) levels are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Percent change from Baseline is calculated as: 100 x ([Post-Dose Visit Value - Baseline] / Baseline). Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'SecondaryOutcomeTimeFrame': 'Up to Week 432'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With Worsening in SLICC/ACR Damage Index at Indicated Time Points', 'SecondaryOutcomeDescription': 'Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) Damage Index is a tool used to assess non-reversible organ damage in SLE patients. Damage Index is used to assess 12 systems by 41 items. Score is given as 1 or sometimes 2, if occur more than once, so that that the maximum possible score is 47. Higher damage index scores early in disease are associated with a poor prognosis and with increased mortality. Damage index was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. Percentage of participants with worsening in damage index (change >0) are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Only those participants available at the specified time points were analyzed ( n=X).', 'SecondaryOutcomeTimeFrame': 'Up to Week 384'}, {'SecondaryOutcomeMeasure': 'Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Time Point', 'SecondaryOutcomeDescription': 'The SF-36v2 is a participant-reported short form survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).', 'SecondaryOutcomeTimeFrame': 'Up to Week 384'}, {'SecondaryOutcomeMeasure': 'Change From Baseline in SF-36 Healthy Survey Overall Component Scores at Indicated Timepoints', 'SecondaryOutcomeDescription': 'The SF-36v2 is a participant-reported survey to measure functional health and well-being. There are 36 items grouped into eight health domains: Vitality, physical functioning, bodily pain, general health perceptions, physical role functioning, emotional role functioning, social role functioning and mental health. SF-36v2 gives a score (0-100) for each of these domains as well as summary score for the physical component score (PCS) and mental component score (MCS) based on the responses by participants. The lower the score the more disability and the higher the score the less disability. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. Only those participants available at the specified time points were analyzed ( n=X).', 'SecondaryOutcomeTimeFrame': 'Up to Week 384'}, {'SecondaryOutcomeMeasure': 'Change From Baseline in FACIT-Fatigue Scale Total Score at Indicated Time Point', 'SecondaryOutcomeDescription': 'The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Wk 48 in first year, at Wk 48 in subsequent Yrs up to 8 Yrs.The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Change from BL in FACIT-Fatigue scale total score are summarized. The BL is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from BL was calculated as the individual post-BL value minus the BL value. A negative change from BL represents a worsening condition. Only those participants available at the specified time points were analyzed ( n=X).', 'SecondaryOutcomeTimeFrame': 'Up to Week 384'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With Improvement in FACIT-Fatigue Scale Score Exceeding the MCID at Indicated Time Points', 'SecondaryOutcomeDescription': 'The FACIT-F scale measures the severity and impact of fatigue on functioning and health related quality of life experienced in the past 7 days. FACIT-Fatigue scale total score was assessed at BL (Day 0), Week 48 in first year, at Week 48 in subsequent years up to 8 years. The level of fatigue is measured by 13 questions assessed on a four-point scale (0=not at all fatigued; 1=a little bit fatigued; 2=somewhat fatigued; 3=quite a bit fatigued; 4=very much fatigued; possible total score of 0 to 52). Percentage of participants with improvement in FACIT-Fatigue scale score exceeding the minimum clinically important difference (MCID) (>=4 points) are summarized. Only those participants available at the specified time points were analyzed ( n=X).', 'SecondaryOutcomeTimeFrame': 'Up to Week 384'}]","Inclusion Criteria:

Have completed the HGS1006-C1056 protocol in the United States through Week 72 visit.
Be able to receive 1st dose of belimumab for HGS 1006-c1066 four weeks after last dose in HGS1006-c1056.

Exclusion Criteria:

Have developed any other medical disease or condition that has made the subject unsuitable for this study in the opinion of their physician.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35249', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85032', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85724', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Long Beach', 'LocationState': 'California', 'LocationZip': '90806', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90033', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90048', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Upland', 'LocationState': 'California', 'LocationZip': '91786', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20010', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Aventura', 'LocationState': 'Florida', 'LocationZip': '33180', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Orlando', 'LocationState': 'Florida', 'LocationZip': '32806', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Tampa', 'LocationState': 'Florida', 'LocationZip': '33614', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30303', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60612', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60637', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Munster', 'LocationState': 'Indiana', 'LocationZip': '46321', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Kansas City', 'LocationState': 'Kansas', 'LocationZip': '66160', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationZip': '40202', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Baton Rouge', 'LocationState': 'Louisiana', 'LocationZip': '70809', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21205', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Cumberland', 'LocationState': 'Maryland', 'LocationZip': '21502', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Hagerstown', 'LocationState': 'Maryland', 'LocationZip': '21740', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109-5542', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Lansing', 'LocationState': 'Michigan', 'LocationZip': '48910', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10461', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Brooklyn', 'LocationState': 'New York', 'LocationZip': '11203', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Great Neck', 'LocationState': 'New York', 'LocationZip': '11021', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Manhasset', 'LocationState': 'New York', 'LocationZip': '11030', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10016', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '14618', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Smithtown', 'LocationState': 'New York', 'LocationZip': '11787', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Chapel Hill', 'LocationState': 'North Carolina', 'LocationZip': '27599', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Greenville', 'LocationState': 'North Carolina', 'LocationZip': '27834', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Winston-Salem', 'LocationState': 'North Carolina', 'LocationZip': '27157', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43203', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Dayton', 'LocationState': 'Ohio', 'LocationZip': '45417', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Oklahoma City', 'LocationState': 'Oklahoma', 'LocationZip': '74104', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Tulsa', 'LocationState': 'Oklahoma', 'LocationZip': '74104', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Bethlehem', 'LocationState': 'Pennsylvania', 'LocationZip': '18015', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15217', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationZip': '29406', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationZip': '29425', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Greenville', 'LocationState': 'South Carolina', 'LocationZip': '29601', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationZip': '78705', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77004', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77034', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77074', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78232', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Sugar Land', 'LocationState': 'Texas', 'LocationZip': '77479', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Arlington', 'LocationState': 'Virginia', 'LocationZip': '22205-3606', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98133', 'LocationCountry': 'United States'}, {'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Onalaska', 'LocationState': 'Wisconsin', 'LocationZip': '54650', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'GlaxoSmithKline', 'CollaboratorClass': 'INDUSTRY'}]",Yes,This is a long-term continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States. This study is to evaluate the long-term safety and efficacy of belimumab (LymphoStat-B™) in subjects with SLE disease.,"['Systemic Lupus Erythematosus', 'Belimumab', 'SLE', 'Antibodies', 'Lupus', 'Autoimmune Diseases']",,,,,,"[{'SecondaryId': 'HGS1006-C1066', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Human Genome Sciences'}]",,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '30320964', 'ReferenceType': 'derived', 'ReferenceCitation': 'Strand V, Berry P, Lin X, Asukai Y, Punwaney R, Ramachandran S. Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. Arthritis Care Res (Hoboken). 2019 Jun;71(6):829-838. doi: 10.1002/acr.23788. Epub 2019 Apr 29.'}, {'ReferencePMID': '29409143', 'ReferenceType': 'derived', 'ReferenceCitation': 'Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States. Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25.'}]",19-Nov-15,10-Mar-16,28-Mar-16,Estimate,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008180', 'ConditionMeshTerm': 'Lupus Erythematosus, Systemic'}]","[{'ConditionAncestorId': 'D000003240', 'ConditionAncestorTerm': 'Connective Tissue Diseases'}, {'ConditionAncestorId': 'D000001327', 'ConditionAncestorTerm': 'Autoimmune Diseases'}, {'ConditionAncestorId': 'D000007154', 'ConditionAncestorTerm': 'Immune System Diseases'}]","[{'ConditionBrowseLeafId': 'M3210', 'ConditionBrowseLeafName': 'Autoimmune Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9760', 'ConditionBrowseLeafName': 'Lupus Erythematosus, Systemic', 'ConditionBrowseLeafAsFound': 'Systemic Lupus Erythematosus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5047', 'ConditionBrowseLeafName': 'Connective Tissue Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8783', 'ConditionBrowseLeafName': 'Immune System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}]","[{'InterventionMeshId': 'C000511911', 'InterventionMeshTerm': 'Belimumab'}]","[{'InterventionAncestorId': 'D000007166', 'InterventionAncestorTerm': 'Immunosuppressive Agents'}, {'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]","[{'InterventionBrowseLeafId': 'M2806', 'InterventionBrowseLeafName': 'Antibodies', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8767', 'InterventionBrowseLeafName': 'Immunoglobulins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M230963', 'InterventionBrowseLeafName': 'Belimumab', 'InterventionBrowseLeafAsFound': 'Clip', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M8795', 'InterventionBrowseLeafName': 'Immunosuppressive Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8784', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",Participants with systemic lupus erythematosus who completed the Phase 3 HGS1006-C1056 were enrolled to receive belimumab,,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Belimumab 10 mg/kg IV', 'FlowGroupDescription': 'Participants, who had received belimumab 1milligram per kilogram (mg/kg) or 10 mg/kg or placebo in study HGS1006-C1056 , received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '268'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '140'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '128'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Adverse Event', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '25'}]}}, {'FlowDropWithdrawType': 'Lack of Efficacy', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '14'}]}}, {'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '12'}]}}, {'FlowDropWithdrawType': 'Non-compliance with study drug', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '6'}]}}, {'FlowDropWithdrawType': 'Physician Decision', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '17'}]}}, {'FlowDropWithdrawType': 'Protocol Violation', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '31'}]}}, {'FlowDropWithdrawType': 'Sponsor decision to end study', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '14'}]}}, {'FlowDropWithdrawType': 'Subject incarcerated', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Developed withdrawal criteria- pregnancy', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '4'}]}}, {'FlowDropWithdrawType': 'Subject moved out of state', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Elected to exit due to site closure', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '2'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Belimumab 10 mg/kg IV', 'BaselineGroupDescription': 'Participants, who had received belimumab 1milligram per kilogram (mg/kg) or 10 mg/kg or placebo in study HGS1006-C1056 , received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '268'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'Years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '42.8', 'BaselineMeasurementSpread': '11.33'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '250'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '18'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Black or African American/African Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '57'}]}}]}}, {'BaselineClassTitle': 'American Indian or Alaska Native', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '8'}]}}]}}, {'BaselineClassTitle': 'Asian: Central Asian Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}, {'BaselineClassTitle': 'Asian: East Asian Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}]}}]}}, {'BaselineClassTitle': 'Asian: Japanese Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}]}}]}}, {'BaselineClassTitle': 'Asian: South Asian Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}]}}, {'BaselineClassTitle': 'Asian: Southeast Asian Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}]}}]}}, {'BaselineClassTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}, {'BaselineClassTitle': 'White: Middle East/North African Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}]}}]}}, {'BaselineClassTitle': 'White: White/Caucasian/European Heritage', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '183'}]}}]}}, {'BaselineClassTitle': 'Mixed Race', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Participants With the Indicated Type of Adverse Event (AEs) and Serious Adverse Event (SAEs)', 'OutcomeMeasureDescription': 'An AE is defined as any untoward medical occurrence in a participant (par.) temporally associated with the use of a investigational product (IP), whether or not considered related to the IP. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of an IP. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is an important medical event that jeopardizes the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition, or is associated with liver injury and impaired liver function. Only those participants available at the specified time points (represented by n=X, in the category titles) were analyzed.', 'OutcomeMeasurePopulationDescription': 'Modified Intent to Treat (MIIT) Population: The MITT Population comprised of all the participants enrolled in the study who received at least one dose of IP.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to Week 440', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Belimumab 10 mg/kg IV', 'OutcomeGroupDescription': 'Participants, who had received belimumab 1milligram per kilogram (mg/kg) or 10 mg/kg or placebo in study HGS1006-C1056 , received intravenous (IV) infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received standard of care (SoC) for systemic lupus erythematosus (SLE) during study participation.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '268'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'AE, Any time post baseline, n=268', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '267'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 0-1, n=268', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '260'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 1-2, n=259', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '235'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 2-3, n=244', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '206'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 3-4, n=219', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '184'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 4-5, n=202', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '167'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 5-6, n=192', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '145'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 6-7, n=130', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '87'}]}}]}}, {'OutcomeClassTitle': 'AE, Year 7 plus, n=65', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '31'}]}}]}}, {'OutcomeClassTitle': 'SAE, Any time post baseline, n=268', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '112'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 0-1, n=268', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '33'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 1-2, n=259', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '30'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 2-3, n=244', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '25'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 3-4, n=219', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '22'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 4-5, n=202', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '24'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 5-6, n=192', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '16'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 6-7, n=130', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13'}]}}]}}, {'OutcomeClassTitle': 'SAE, Year 7 plus, n=65', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'AE Rates by System Organ Class (SOC) During the Study', 'OutcomeMeasureDescription': 'AE rates by SOC adjusting for participant-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent adverse events (AEs) are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an AE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / Participant Years. Participant years were calculated as sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). Participant years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'OutcomeMeasurePopulationDescription': 'MITT Population', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Adverse events/100 participant-years', 'OutcomeMeasureTimeFrame': 'Up Week 440', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Belimumab 10 mg/kg IV', 'OutcomeGroupDescription': 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '268'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Infections and infestations', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '134.4'}]}}]}}, {'OutcomeClassTitle': 'Musculoskeletal and connective tissue disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '75.5'}]}}]}}, {'OutcomeClassTitle': 'Gastrointestinal disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '53.6'}]}}]}}, {'OutcomeClassTitle': 'Injury, poisoning and procedural complications', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '32.3'}]}}]}}, {'OutcomeClassTitle': 'Skin and subcutaneous tissue disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '30'}]}}]}}, {'OutcomeClassTitle': 'Nervous system disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '29.7'}]}}]}}, {'OutcomeClassTitle': 'Respiratory, thoracic and mediastinal disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '28.5'}]}}]}}, {'OutcomeClassTitle': 'General disorders and administration sitecondition', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '27.9'}]}}]}}, {'OutcomeClassTitle': 'Psychiatric disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '12.4'}]}}]}}, {'OutcomeClassTitle': 'Metabolism and nutrition disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '10.1'}]}}]}}, {'OutcomeClassTitle': 'Vascular disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9.1'}]}}]}}, {'OutcomeClassTitle': 'Investigations', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9.1'}]}}]}}, {'OutcomeClassTitle': 'Eye disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '8.2'}]}}]}}, {'OutcomeClassTitle': 'Reproductive system and breast disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.7'}]}}]}}, {'OutcomeClassTitle': 'Cardiac disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.4'}]}}]}}, {'OutcomeClassTitle': 'Immune system disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}]}}]}}, {'OutcomeClassTitle': 'Renal and urinary disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5.3'}]}}]}}, {'OutcomeClassTitle': 'Neoplasms benign, malignant and unspecified', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}]}}]}}, {'OutcomeClassTitle': 'Blood and lymphatic system disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.4'}]}}]}}, {'OutcomeClassTitle': 'Ear and labyrinth disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.8'}]}}]}}, {'OutcomeClassTitle': 'Hepatobiliary disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.3'}]}}]}}, {'OutcomeClassTitle': 'Endocrine disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.8'}]}}]}}, {'OutcomeClassTitle': 'Social circumstances', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.8'}]}}]}}, {'OutcomeClassTitle': 'Congenital, familial and genetic disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.5'}]}}]}}, {'OutcomeClassTitle': 'Pregnancy, puerperium and perinatal conditions', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'SAE Rates by System Organ Class (SOC) During the Study', 'OutcomeMeasureDescription': 'SAE rates by SOC adjusting for participants-years on study drug anytime post Baseline are summarized, which included the follow up visits. Only treatment-emergent SAEs are summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. The event rate of an SAE was calculated as the number of events per 100 participant years: Event Rate = 100* Number of Events / participants Years. participants years were calculated as = sum across all participants ([last visit of interval day - first visit of interval day + 1]/365). participants years excluded between study gaps if participant had not started extension study on date of last visit of parent study.', 'OutcomeMeasurePopulationDescription': 'MITT Population', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Adverse events/100 participant-years', 'OutcomeMeasureTimeFrame': 'Up to Week 440', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Belimumab 10 mg/kg IV', 'OutcomeGroupDescription': 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '268'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Infections and infestations', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}]}}]}}, {'OutcomeClassTitle': 'Gastrointestinal disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.2'}]}}]}}, {'OutcomeClassTitle': 'Musculoskeletal and connective tissue disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'General disorders and administration sitecondition', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.7'}]}}]}}, {'OutcomeClassTitle': 'Nervous system disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.4'}]}}]}}, {'OutcomeClassTitle': 'Injury, poisoning and procedural complications', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.4'}]}}]}}, {'OutcomeClassTitle': 'Vascular disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Neoplasms benign, malignant and unspecified', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Respiratory, thoracic and mediastinal disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.7'}]}}]}}, {'OutcomeClassTitle': 'Cardiac disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.6'}]}}]}}, {'OutcomeClassTitle': 'Metabolism and nutrition disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.6'}]}}]}}, {'OutcomeClassTitle': 'Psychiatric disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.5'}]}}]}}, {'OutcomeClassTitle': 'Renal and urinary disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.5'}]}}]}}, {'OutcomeClassTitle': 'Hepatobiliary disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.4'}]}}]}}, {'OutcomeClassTitle': 'Blood and lymphatic system disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.3'}]}}]}}, {'OutcomeClassTitle': 'Reproductive system and breast disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.3'}]}}]}}, {'OutcomeClassTitle': 'Immune system disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}, {'OutcomeClassTitle': 'Investigations', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}, {'OutcomeClassTitle': 'Skin and subcutaneous tissue disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}, {'OutcomeClassTitle': 'Congenital, familial and genetic disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}, {'OutcomeClassTitle': 'Endocrine disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}, {'OutcomeClassTitle': 'Eye disorders', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}, {'OutcomeClassTitle': 'Pregnancy, puerperium and perinatal conditions', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.1'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Change From Baseline in Activated Partial Thromboplastin Time (APTT) and Prothrombin Time (PT) at the Indicated Time Points', 'OutcomeMeasureDescription': 'Hematology parameters were assessed at Baseline (BL) (Day 0), Week 4, 12, 24, 36 and 48 in first year, at Week 24 and 48 in subsequent years up to 440 weeks and at follow-up (up to 8 weeks post last infusion). Change from Baseline in APTT and PT is summarized. The Baseline is defined as the Year 1 Day 0 values for participants treated with placebo in the parent study and last pre-treatment value in the parent study for participants treated with belimumab in the parent study. Change from Baseline is defined as the difference between the post-dose post- Baseline visit value and the Baseline value. Only those participants available at the specified time points (represented by n=X in the category titles) were analyzed.', 'OutcomeMeasurePopulationDescription': 'MITT Population', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'Seconds', 'OutcomeMeasureTimeFrame': 'Up to Week 440', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Belimumab 10 mg/kg IV', 'OutcomeGroupDescription': 'Participants, who had received belimumab 1mg/kg or 10 mg/kg or placebo in study HGS1006-C1056 , received IV infusion of belimumab 10 mg/kg body weight over 1 hour every 28 days. The first dose of belimumab was given 4 weeks (2 to 8 weeks) after the last dose in the HGS1006-C1056 study. Treatment continued for five years from the time the last participant enrolled in the study or until there were 100 or fewer participants enrolled. All participants received SoC for systemic lupus erythematosus (SLE) during study participation.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '268'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'APTT, Year 1, Week 4, n= 82', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.3', 'OutcomeMeasurementSpread': '4.46'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 1, Week 12, n= 79', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1', 'OutcomeMeasurementSpread': '4.56'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 1, Week 24, n= 243', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.7', 'OutcomeMeasurementSpread': '4.81'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 1, Week 36, n= 71', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.4', 'OutcomeMeasurementSpread': '4.83'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 1, Week 48, n= 246', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.7', 'OutcomeMeasurementSpread': '5.37'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 2, Week 24, n= 231', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.7', 'OutcomeMeasurementSpread': '5.88'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 2, Week 48, n= 220', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.9', 'OutcomeMeasurementSpread': '5.39'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 3, Week 24, n= 206', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.5', 'OutcomeMeasurementSpread': '4.92'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 3, Week 48, n= 202', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4', 'OutcomeMeasurementSpread': '5.34'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 4, Week 24, n= 201', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.2', 'OutcomeMeasurementSpread': '6.51'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 4, Week 48, n= 185', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.7', 'OutcomeMeasurementSpread': '8.19'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 5, Week 24, n= 174', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.7', 'OutcomeMeasurementSpread': '7.03'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 5, Week 48, n= 171', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.6', 'OutcomeMeasurementSpread': '5.46'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 6, Week 24, n= 160', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.3', 'OutcomeMeasurementSpread': '6.37'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 6, Week 48, n= 126', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.8', 'OutcomeMeasurementSpread': '7.71'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 7, Week 24, n= 118', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.4', 'OutcomeMeasurementSpread': '4.77'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 7, Week 48, n= 92', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5', 'OutcomeMeasurementSpread': '9.55'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 8, Week 24, n= 59', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.7', 'OutcomeMeasurementSpread': '5.02'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 8, Week 48, n= 28', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.7', 'OutcomeMeasurementSpread': '5.51'}]}}]}}, {'OutcomeClassTitle': 'APTT, Year 9, Week 24, n= 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '8.5', 'OutcomeMeasurementSpread': '13.44'}]}}]}}, {'OutcomeClassTitle': 'APTT, Exit, n= 230', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.1', 'OutcomeMeasurementSpread': '6.72'}]}}]}}, {'OutcomeClassTitle': 'APTT, 8 Week, Follow-Up, n= 104', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.3', 'OutcomeMeasurementSpread': '8.58'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 1, Week 4, n= 82', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.05', 'OutcomeMeasurementSpread': '1.463'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 1, Week 12, n= 79', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.66', 'OutcomeMeasurementSpread': '3.502'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 1, Week 24, n= 244', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.04', 'OutcomeMeasurementSpread': '3.239'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 1, Week 36, n= 71', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '-0.42', 'OutcomeMeasurementSpread': '3.943'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 1, Week 48, n= 246', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.2', 'OutcomeMeasurementSpread': '4.493'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 2, Week 24, n= 233', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.52', 'OutcomeMeasurementSpread': '5.059'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 2, Week 48, n= 221', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.24', 'OutcomeMeasurementSpread': '2.693'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 3, Week 24, n= 206', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.26', 'OutcomeMeasurementSpread': '2.983'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 3, Week 48, n= 202', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.34', 'OutcomeMeasurementSpread': '3.77'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 4, Week 24, n= 201', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.39', 'OutcomeMeasurementSpread': '3.047'}]}}]}}, {'OutcomeClassTitle': 'PT, Year 4, Week 48, n= 186', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03973905,210031,GlaxoSmithKline,INDUSTRY,Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States,Effectiveness of Maternal Immunization With Boostrix at Preventing Pertussis Among Infants <2 Months Old in the United States: Analysis of a Dataset From a Case-control Study,Jul-20,Completed,No,15-Feb-19,Actual,15-May-19,Actual,15-May-19,Actual,13-Feb-19,03-Jun-19,04-Jun-19,Actual,03-Jul-20,07-Jul-20,Actual,Sponsor,GlaxoSmithKline,INDUSTRY,,,,,The purpose of this study is to estimate the effectiveness of maternal immunization with Boostrix at preventing pertussis in infants in the United States.,['Whooping Cough'],Observational,,,,,,290,Actual,"[{'ArmGroupLabel': 'Pertussis Case Group', 'ArmGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility).\n\nThis post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Not applicable / dataset analysis']}}, {'ArmGroupLabel': 'Control Group', 'ArmGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant).\n\nThis post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Not applicable / dataset analysis']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Not applicable / dataset analysis', 'InterventionDescription': 'Not applicable / dataset analysis', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control Group', 'Pertussis Case Group']}}]","[{'PrimaryOutcomeMeasure': 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During Third Trimester of Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'PrimaryOutcomeDescription': 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during the third pregnancy trimester in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'PrimaryOutcomeTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)'}]","[{'SecondaryOutcomeMeasure': 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (Before Pregnancy, During First or Second Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'SecondaryOutcomeDescription': 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second pregnancy trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'SecondaryOutcomeTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)'}, {'SecondaryOutcomeMeasure': 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During First, Second or Third Trimester) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'SecondaryOutcomeDescription': 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'SecondaryOutcomeTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)'}, {'SecondaryOutcomeMeasure': 'Number of Pertussis Cases Leading to Hospitalization and Matched Controls in Infants Born to Mothers Vaccinated With Boostrix (Before Pregnancy, During First or Second, Third Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'SecondaryOutcomeDescription': 'Vaccine effectiveness at preventing pertussis occurrence leading to hospitalization in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second, third trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'SecondaryOutcomeTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)'}]","Inclusion Criteria:

Inclusion criteria for case infants:

Case infants were eligible for the enrolment if they:
were at least 2 days old and < 2 months old on the cough onset date
resided in the catchment area on their cough onset date
were born in a hospital in their state of residence
were ≥37 weeks' gestational age at birth
were neither adopted nor in foster care
did not live in a residential care facility

Inclusion criteria for control infants:

Control infants were eligible for the enrolment if they:
were at least 2 days old and <2 months old on the case infant's cough onset date
were born in a hospital in their state of residence
were ≥37 weeks' gestational age at birth
were neither adopted nor in foster care
did not live in a residential care facility
were born at the same hospital as the case infant

did not have pertussis diagnosis prior to the cough onset date of the corresponding case infant

Exclusion Criteria:

Infants (case and controls) whose mothers have received Adacel or mothers without brand information available, as well as controls who were matched to a case whose mother received Adacel or mothers without brand information available, will be excluded from the analysis of the effectiveness of vaccination with Boostrix.",Accepts Healthy Volunteers,All,,2 Months,['Child'],"[{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Wavre', 'LocationZip': '1300', 'LocationCountry': 'Belgium'}]",,,,"['Whooping Cough', 'Boostrix', 'Tdap', 'effectiveness', 'pregnancy', 'infants']",No,['Case-Control'],['Retrospective'],"Infant subjects, born to mothers exposed, or unexposed to Boostrix or any Tdap vaccination, coming from 6 emerging program network sites.",Probability Sample,,,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",No,"[{'ReferencePMID': '29028938', 'ReferenceType': 'background', 'ReferenceCitation': 'Skoff TH, Blain AE, Watt J, Scherzinger K, McMahon M, Zansky SM, Kudish K, Cieslak PR, Lewis M, Shang N, Martin SW. Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation. Clin Infect Dis. 2017 Nov 29;65(12):1977-1983. doi: 10.1093/cid/cix724.'}]",29-May-20,03-Jul-20,07-Jul-20,Actual,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000014917', 'ConditionMeshTerm': 'Whooping Cough'}]","[{'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}, {'ConditionAncestorId': 'D000001885', 'ConditionAncestorTerm': 'Bordetella Infections'}, {'ConditionAncestorId': 'D000016905', 'ConditionAncestorTerm': 'Gram-Negative Bacterial Infections'}, {'ConditionAncestorId': 'D000001424', 'ConditionAncestorTerm': 'Bacterial Infections'}, {'ConditionAncestorId': 'D000012141', 'ConditionAncestorTerm': 'Respiratory Tract Infections'}, {'ConditionAncestorId': 'D000007239', 'ConditionAncestorTerm': 'Infection'}]","[{'ConditionBrowseLeafId': 'M5173', 'ConditionBrowseLeafName': 'Cough', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16239', 'ConditionBrowseLeafName': 'Whooping Cough', 'ConditionBrowseLeafAsFound': 'Whooping Cough', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3745', 'ConditionBrowseLeafName': 'Bordetella Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3303', 'ConditionBrowseLeafName': 'Bacterial Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17832', 'ConditionBrowseLeafName': 'Gram-Negative Bacterial Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13561', 'ConditionBrowseLeafName': 'Respiratory Tract Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T5937', 'ConditionBrowseLeafName': 'Whooping Cough', 'ConditionBrowseLeafAsFound': 'Whooping Cough', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]","The primary study was a case-control study evaluating the effectiveness of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccines (Boostrix and Adacel) administered during pregnancy in preventing pertussis in infants.","The present analysis has been performed on the data set of a case-control study conducted in 6 US Emerging Infection Program Network states, either statewide (4 states) or in select counties (2 states) by Skoff et al., 2017.","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Pertussis Case Group', 'FlowGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Control Group', 'FlowGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '107'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '183'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '107'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '183'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Pertussis Case Group', 'BaselineGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Control Group', 'BaselineGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '107'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '183'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '290'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'Weeks', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': ""Infant's age (weeks)"", 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5.0', 'BaselineMeasurementSpread': '1.9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4.8', 'BaselineMeasurementSpread': '2.0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4.9', 'BaselineMeasurementSpread': '2.0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '49'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '90'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '139'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '58'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '93'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '151'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'White', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '88'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '140'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '228'}]}}]}}, {'BaselineClassTitle': 'Black', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '22'}]}}]}}, {'BaselineClassTitle': 'Other-unspecified', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '30'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '40'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During Third Trimester of Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'OutcomeMeasureDescription': 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during the third pregnancy trimester in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasurePopulationDescription': 'The analysis includes cases and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Pertussis Case Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Control Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '106'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '180'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Unvaccinated', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '72'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '112'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated during third trimester', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '17'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix during third trimester of pregnancy (at least 14 days before delivery) at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '65.26', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-64.93', 'OutcomeAnalysisCIUpperLimit': '92.68', 'OutcomeAnalysisEstimateComment': 'Vaccine Effectiveness (VE) was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (Before Pregnancy, During First or Second Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'OutcomeMeasureDescription': 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second pregnancy trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasurePopulationDescription': 'The analysis includes cases and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Pertussis Case Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Control Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '106'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '180'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Unvaccinated', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '72'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '112'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, before pregnancy', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '4'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, during first or second trimester', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, after pregnancy', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '27'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '41'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix before pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '42.01', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-1071.80', 'OutcomeAnalysisCIUpperLimit': '97.13', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix during first or second trimester of pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '62.17', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-439.75', 'OutcomeAnalysisCIUpperLimit': '97.35', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix after pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '-12.89', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-166.37', 'OutcomeAnalysisCIUpperLimit': '52.16', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Pertussis Cases and Matched Controls Among Infants Born to Mothers Vaccinated With Boostrix Vaccine (During First, Second or Third Trimester) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'OutcomeMeasureDescription': 'Vaccine effectiveness at preventing pertussis occurrence in infants < 2 months old is assessed by comparing the Boostrix immunization status during pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasurePopulationDescription': 'The analysis includes cases and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Pertussis Case Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Control Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '106'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '180'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Unvaccinated', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '72'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '112'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, during pregnancy (Any trimester)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '23'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix at any time during pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '64.79', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-57.51', 'OutcomeAnalysisCIUpperLimit': '92.13', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Pertussis Cases Leading to Hospitalization and Matched Controls in Infants Born to Mothers Vaccinated With Boostrix (Before Pregnancy, During First or Second, Third Trimester, After Pregnancy) or Not Exposed to Any Tdap Vaccine During Pregnancy', 'OutcomeMeasureDescription': 'Vaccine effectiveness at preventing pertussis occurrence leading to hospitalization in infants < 2 months old is assessed by comparing the Boostrix immunization status before pregnancy, during first or second, third trimester, after pregnancy in mothers of infant pertussis cases and matched controls. The association between maternal Boostrix vaccination and pertussis in infants was analyzed using conditional logistic regression. The multivariate analysis was performed to obtain the adjusted values. Covariates that were statistically significant in the univariate analysis or considered as clinically significant were included in the multivariable conditional logistic regression model. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasurePopulationDescription': 'The analysis includes cases leading to hospitalization and at least one matched control born from mothers either unvaccinated or vaccinated with Boostrix. Subjects with missing or unknown values, if any, for at least one of the risk factors were excluded from the model.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'During the data collection period (from 1 January 2011 to 31 December 2014)', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Pertussis Case Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Control Group', 'OutcomeGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '69'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '121'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Unvaccinated', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '49'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '78'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, before pregnancy', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, during first or second trimester', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '5'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, during third trimester', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '11'}]}}]}}, {'OutcomeClassTitle': 'Vaccinated, after pregnancy', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '16'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '25'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix before pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '17.65', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-12529.0', 'OutcomeAnalysisCIUpperLimit': '99.46', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix during third trimester of pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '85.01', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-13.91', 'OutcomeAnalysisCIUpperLimit': '98.03', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'To assess the effectiveness of maternal vaccination with Boostrix after pregnancy at preventing pertussis in infants <2 months', 'OutcomeAnalysisNonInferiorityType': 'Other', 'OutcomeAnalysisParamType': 'Vaccine Effectiveness', 'OutcomeAnalysisParamValue': '37.64', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-87.40', 'OutcomeAnalysisCIUpperLimit': '79.25', 'OutcomeAnalysisEstimateComment': 'VE was estimated as (1-odds ratio) × 100%. The Confidence Interval was calculated based on the conditional binomial distribution of cases in the exposed group and the total number of cases.'}]}}]",0,,"All-Cause Mortality, Serious Adverse Events and Other Adverse Events were not collected/monitored in this observational study.","[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Pertussis Case Group', 'EventGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who met the pertussis diagnosis definition (laboratory confirmed pertussis, epidemiological linkage to a laboratory-confirmed case, clinically compatible illness), and who met the case infants inclusion criteria (resided in the catchment area on their cough onset date, were born in a hospital in their state of residence, had at least 37 weeks gestational age at birth, were neither adopted, nor in foster care and did not live in a residential care facility) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '0', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '0', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '0'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Control Group', 'EventGroupDescription': 'Infant subjects of at least 2 days old and less than (<) 2 months old, who did not have a pertussis diagnosis prior to the cough onset date and who met the inclusion criteria for control infants (were born on a hospital in their state of residence, were at least 37 weeks gestational age at birth, were neither adopted, nor in foster care, did not live in a residential care facility, were born at the same hospital as the case infant) This post-hoc analysis was limited to cases and controls whose mothers were either vaccinated with Boostrix or did not receive any Tdap vaccine. Cases with no remaining matched control were also excluded from the analysis and vice versa.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '0', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '0', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '0'}]",,No,Yes,GSK Response Center,GlaxoSmithKline,GSKClinicalSupportHD@gsk.com,866-435-7343,,OTHER,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single site data not precede the primary publication of the entire clinical trial.",,,"[{'LargeDocTypeAbbrev': 'SAP', 'LargeDocHasProtocol': 'No', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Statistical Analysis Plan', 'LargeDocDate': 'March 8, 2019', 'LargeDocUploadDate': '07/03/2020 10:24', 'LargeDocFilename': 'SAP_000.pdf'}, {'LargeDocTypeAbbrev': 'Prot', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol', 'LargeDocDate': 'June 24, 2020', 'LargeDocUploadDate': '07/03/2020 10:24', 'LargeDocFilename': 'Prot_001.pdf'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00340457,999902051,National Institutes of Health Clinical Center (CC),NIH,Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States,Case-Control Study of Renal Cell Cancer Among Caucasians and African Americans in the United States,05-Feb-20,Completed,No,15-Nov-01,,,,,,19-Jun-06,19-Jun-06,21-Jun-06,Estimate,02-Oct-20,05-Oct-20,Actual,Sponsor,National Cancer Institute (NCI),NIH,,,,,"Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries. In particular, rates among African Americans have risen more sharply than any other cancer site. We propose to conduct a population-based case-control study of renal cell cancer in areas of the U.S. with a high proportion of African American residents. We will include two study centers and one data coordinating center and will recruit study participants over a period of four years. We plan to conduct in-person interviews with 2,100 cases (1,400 whites and 700 blacks) and 2,800 controls (1,400 each of whites and blacks) to elicit information on demographic background and history of exposures. A 40 ml blood sample will be collected from living cases and controls to measure certain environmental exposures and for genetic analyses. Two buccal cell samples will be collected from living cases and controls for genetic analyses. Tumor tissue blocks will be collected from as many cases as possible for assays of tumor mutations. Diagnostic slides will be collected for standardized reclassification of tumors into clear cell, papillary, and other histologic subtypes. Medical records for all cases will be reviewed for health insurance coverage, concomitant conditions, presenting symptoms, tumor stage, size and grade, and methods leading to diagnosis of renal cell cancer.","['Kidney Cancer', 'Renal Cell Carcinoma']",Observational,,,,,,2424,Actual,"[{'ArmGroupLabel': 'Cases', 'ArmGroupDescription': 'African American patients with renal cancer from two geographic areas of the US'}, {'ArmGroupLabel': 'Controls', 'ArmGroupDescription': 'African American participants without renal cancer from two geographic areas of the US'}]",,,,"INCLUSION CRITERIA - CASES:

Residents of the study areas who are diagnosed with histologically confirmed renal cell carcinoma at ages 20 to 79 years over a four year study will be potentially eligible for the study.

In addition, only eligible patients who are mentally/physically able to provide informed consent and undergo interviews will be approached for participation.

INCLUSION CRITERIA - CONTROLS:

Population-based controls will be frequency-matched to the cases by study center, race, age and sex, at the ratio of one control per case for non-African Americans and two controls per case for African Americans.

Controls aged 65 years and older will be identified from Health Care Financing Administration (HCFA) files.

Controls under age 65 years will be identified from residents of the study areas by random telephone digit dialing (RDD).",No,All,20 Years,79 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Illinois at Chicago', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60612', 'LocationCountry': 'United States'}, {'LocationFacility': 'Wayne State University', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48201', 'LocationCountry': 'United States'}]",,,"Incidence rates of renal cell cancer have increased rapidly in the U.S. and other countries. In particular, rates among African Americans have risen more sharply than any other cancer site. We propose to conduct a population-based case-control study of renal cell cancer two areas of the U.S. with a high proportion of African American residents: Detroit, Michigan (Wayne State University), and Chicago, Illinois (University of Illinois at Chicago). Westat, Inc. is the coordinating center. Participants are being recruited over a period of four years. A total of 2,100 cases (1,400 Caucasian Americans and 700 African Americans) and 2,800 controls (1,400 each of Caucasian and African Americans) will be recruited. In-person interviews are conducted with cases and controls to elicit information on demographic background and history of exposures. A 40 ml blood sample and a buccal cell sample are collected from cases and controls for genetic analyses. Tumor tissue blocks will be collected from as many cases as possible for assays of tumor mutations. Diagnostic slides will be collected for standardized reclassification of tumors into clear cell, papillary, and other histologic subtypes. Medical records for all cases will be reviewed for presenting symptoms, tumor stage, size and grade, and methods leading to diagnosis of renal cell cancer. Telephone interviews are conducted with the nest-of-kin of eligible cases who died before we could interview them. Permission is being sought from the next-of-kin to assess the case's medical records and obtain tumor tissue samples.","['Case-Control Study', 'Renal Cell Carcinoma', 'Kidney Cancer', 'Diet', 'Occupation']",,['Case-Control'],['Retrospective'],"Cases and controls are residents of Chicago (Cook County), IL and Detroit (Wayne, Oakland, Macomb Counties), MI.",Probability Sample,[{'SecondaryId': '02-C-N051'}],,,,,,,"[{'OverallOfficialName': 'Mark P Purdue, M.D.', 'OverallOfficialAffiliation': 'National Cancer Institute (NCI)', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '10471525', 'ReferenceType': 'background', 'ReferenceCitation': 'Bergström A, Moradi T, Lindblad P, Nyrén O, Adami HO, Wolk A. Occupational physical activity and renal cell cancer: a nationwide cohort study in Sweden. Int J Cancer. 1999 Oct 8;83(2):186-91.'}, {'ReferencePMID': '10340905', 'ReferenceType': 'background', 'ReferenceCitation': 'Brauch H, Weirich G, Hornauer MA, Störkel S, Wöhl T, Brüning T. Trichloroethylene exposure and specific somatic mutations in patients with renal cell carcinoma. J Natl Cancer Inst. 1999 May 19;91(10):854-61.'}, {'ReferencePMID': '9285043', 'ReferenceType': 'background', 'ReferenceCitation': 'Brüning T, Lammert M, Kempkes M, Thier R, Golka K, Bolt HM. Influence of polymorphisms of GSTM1 and GSTT1 for risk of renal cell cancer in workers with long-term high occupational exposure to trichloroethene. Arch Toxicol. 1997;71(9):596-9.'}]",,,,,,,,,,,,,,,,,,,"['NCT00546338', 'NCT01338220']",,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000002292', 'ConditionMeshTerm': 'Carcinoma, Renal Cell'}, {'ConditionMeshId': 'D000007680', 'ConditionMeshTerm': 'Kidney Neoplasms'}]","[{'ConditionAncestorId': 'D000002277', 'ConditionAncestorTerm': 'Carcinoma'}, {'ConditionAncestorId': 'D000009375', 'ConditionAncestorTerm': 'Neoplasms, Glandular and Epithelial'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000000230', 'ConditionAncestorTerm': 'Adenocarcinoma'}, {'ConditionAncestorId': 'D000014571', 'ConditionAncestorTerm': 'Urologic Neoplasms'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000007674', 'ConditionAncestorTerm': 'Kidney Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}]","[{'ConditionBrowseLeafId': 'M4116', 'ConditionBrowseLeafName': 'Carcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4130', 'ConditionBrowseLeafName': 'Carcinoma, Renal Cell', 'ConditionBrowseLeafAsFound': 'Renal Cell Carcinoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9286', 'ConditionBrowseLeafName': 'Kidney Neoplasms', 'ConditionBrowseLeafAsFound': 'Kidney Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10903', 'ConditionBrowseLeafName': 'Neoplasms, Glandular and Epithelial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10898', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2166', 'ConditionBrowseLeafName': 'Adenocarcinoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15903', 'ConditionBrowseLeafName': 'Urologic Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15898', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9281', 'ConditionBrowseLeafName': 'Kidney Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15902', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4916', 'ConditionBrowseLeafName': 'Renal Cell Carcinoma', 'ConditionBrowseLeafAsFound': 'Renal Cell Carcinoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T1346', 'ConditionBrowseLeafName': 'Clear Cell Renal Cell Carcinoma', 'ConditionBrowseLeafAsFound': 'Renal Cell Carcinoma', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02429284,PH-2013-008,"University of California, San Diego",OTHER,U.S. CTEPH Registry,United States CTEPH Registry,Mar-20,Completed,No,Apr-15,Actual,May-19,Actual,Nov-19,Actual,13-Apr-15,28-Apr-15,29-Apr-15,Estimate,23-Mar-20,24-Mar-20,Actual,Principal Investigator,"University of California, San Diego",OTHER,,,,,"The U.S. CTEPH Registry is a multicenter, observational, U.S.-based study of the clinical course and treatment of patients diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension. The mission of the Registry will be to promote a greater understanding of the prevalence, pathophysiology, evaluation, and treatment of patients with CTEPH through shared information, education, and collaborative investigation among pulmonary hypertension (PH) centers of excellence throughout the U.S.","['Chronic Thromboembolic Pulmonary Hypertension (CTEPH)', 'Pulmonary Hypertension']",Observational,,,,,,754,Actual,"[{'ArmGroupLabel': 'Patients newly diagnosed with CTEPH', 'ArmGroupDescription': 'Patients newly diagnosed with chronic thromboembolic pulmonary hypertension (CTEPH), WHO Group IV Classification for Pulmonary Hypertension.'}]",,"[{'PrimaryOutcomeMeasure': 'Describe the patterns of evaluation of CTEPH Patients', 'PrimaryOutcomeTimeFrame': 'up to 5 years'}, {'PrimaryOutcomeMeasure': 'Describe the patters of risk factors and clinical presentation of CTEPH Patients', 'PrimaryOutcomeTimeFrame': 'up to 5 years'}, {'PrimaryOutcomeMeasure': 'Outcomes of medical and surgical therapy of CTEPH patients as assessed by hemodynamics, quality of life, and functional status', 'PrimaryOutcomeTimeFrame': 'up to 5 years, at 6 month intervals'}]",,"Inclusion Criteria:

Patients must be a permanent resident of the United States

Documentation of the following hemodynamic parameters by right heart catheterization

Mean pulmonary arterial pressure (PAPm) ≥ 25 mm Hg at rest and,
Pulmonary artery wedge pressure (PAWP) ≤ 15 mm Hg (or > 15 mmHg if justified)

Radiologic confirmation that chronic thromboembolic disease is the cause of the pulmonary hypertension by

One or more mismatched perfusion defect(s) by lung ventilation/perfusion scan, and
Confirmation of chronic thromboembolic disease by evidence of bands/webs, vessel narrowing or occlusion seen on CT pulmonary angiogram (CTA), conventional angiography or MR angiography (MRA).
Patients must be diagnosed with CTEPH within 6 months of being considered for study eligibility (signing of consent to participate). The date of diagnosis will be defined as when both hemodynamic criteria have been met and chronic thromboembolic disease is confirmed to be the cause of the pulmonary hypertension by an abnormal V/Q scan and the presence of chronic thromboembolic disease on CTA, MRA or pulmonary angiography. Hemodynamic and radiologic criteria can be met at separate time points; the most recently met criteria time point will be defined as the date of diagnosis.
Prior to enrollment all subjects must have the diagnosis of CTEPH confirmed by the Adjudication Committee.

Exclusion Criteria:

Patients unwilling or unable to provide written consent for participation in the study. Appropriate surrogate consent will be obtained for pediatric patients as defined by each investigational site's IRB.
Patients with an underlying medical disorder with an anticipated life expectancy less than 2 years.

Patients who do not meet inclusion criteria including:

Have not had documentation of hemodynamic criteria by right heart catheterization as outlined in the inclusion criteria
Do not have radiologic confirmation of chronic thromboembolic disease as outlined in the inclusion criteria
Meet the criteria for inclusion into WHO Groups I, II, III, or V",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'UCSD Health System', 'LocationCity': 'La Jolla', 'LocationState': 'California', 'LocationZip': '92037', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'E Squared Trials and Registries, Inc.', 'CollaboratorClass': 'INDUSTRY'}]",Yes,"Chronic thromboembolic pulmonary hypertension (CTEPH) is a subset of pulmonary hypertension (PH) characterized by the obstruction of pulmonary arteries with fibrotic material and vascular remodeling that leads to increased pulmonary arterial pressure and right ventricular failure.

A United States CTEPH Registry has been established under the guidance of a Steering Committee consisting of recognized physicians and scientists with expertise in CTEPH and related diseases. The mission of the Registry will be to promote a greater understanding of the prevalence, pathophysiology, evaluation, and treatment of patients with CTEPH through shared information, education, and collaborative investigation among PH centers of excellence throughout the U.S. The development of a national CTEPH registry will be an important element in the advancement of the understanding of CTEPH and improvement in the care of patients who suffer from this debilitating disease.

All consecutive consenting patients recently diagnosed (< 6 months) with CTEPH at participating study sites will be enrolled. At the time of study entry, data on prior history and evaluation will be obtained from patient interview and review of medical records. Patients will be followed biannually after enrollment until the conclusion of the study (minimum of 1 year follow-up for final patients enrolled).

Much of the data gathered by the Registry will be presented as descriptive statistics. The Registry will seek the assistance of a biostatistician to develop a statistical plan for within patient and between patient cohort analyses.

Approximately 750 patients with newly diagnosed (< 6 months) CTEPH will be enrolled.

TIME FRAME:

Participants will be followed from the time of their enrollment until 1 year after the final patient is enrolled. Short term outcome measures and medical history will be collected during the initial visit, and clinical data will be collected from the initial clinic visits, hospital says, or procedures (if applicable). Patients will then be followed every 6 months after their enrollment for long term outcome measures on quality of life, functional status, and medical treatments.

DATA ANALYSES:

Demographics and Clinical Course:

Demographics, risk factors, time to appropriate testing and diagnosis, PAH targeted medication use, functional status, and hemodynamics at the time of enrollment will be provided annually as aggregate data to all investigators.

Evaluating Outcomes of PTE Surgery:

Descriptive statistics of the peri-operative data collected will be provided as aggregate data to all investigators annually. Immediate post-operative and longitudinal follow-up of all patients undergoing PTE surgery will also be provided as aggregate data annually to all sites. Comparisons of hemodynamics, functional status, medication and supplemental oxygen use and healthcare utilization will be made between the pre-operative data and longitudinal post-operative data.

Evaluating Predictors of Successful PTE:

Using longitudinal data collected on post-operative PTE patients, a definition of ""successful PTE"" will be established based upon hemodynamics, functional status and QoL. Retrospective analysis of pre-, peri-, and post-operative data can then be analyzed to identify factors that predict a ""successful"" or ""unsuccessful"" PTE surgery.

Evaluating Outcomes of Nonsurgical Therapy of CTEPH:

Predominantly descriptive statistics will be used to describe why patients are not operative candidates and the nonsurgical therapies (medication, balloon pulmonary angioplasty) used for treatment. Changes in hemodynamics, functional status, QoL and healthcare utilization on therapy will be provided as aggregate data annually.

Evolving Research Needs:

To adapt to the evolving science and research needs of the CTEPH community, separate analysis plans will be developed for new objectives identified and minor changes in the eCRF may occur in response to new diagnostics and treatments, if approved by the Steering Committee. Ongoing assessment of enrollment and data captured will also be performed by the Steering Committee to be certain the goals of the Registry are being met.

COMMITTEES:

A Steering Committee, chaired by Dr. Kim Kerr, is comprised of thought leaders in the areas of cardiology, pulmonology, and cardiothoracic surgery with expertise in CTEPH. The committee will have the following responsibilities:

Provide advice and guidance on the U.S. CTEPH Registry study design and protocol
Provide advice and guidance on the variables to be captured by the eCRF
Provide guidance on study sites selection
Review data results and provide insights into interpretation of the data annually
Provide input on the planning and organization of abstracts and manuscripts
Review abstracts and papers for submission to scientific journals or conferences
Present data at conferences

An Adjudication Committee, consisting of physicians with expertise in the diagnosis of CTEPH, will review all patients felt by Investigators to be eligible for the Registry. The adjudication committee members must confirm the diagnosis of CTEPH before the subject can be enrolled in the Registry.","['Chronic Thromboembolic Pulmonary Hypertension (CTEPH)', 'Pulmonary Endarterectomy (PEA)', 'Pulmonary Thromboendarterectomy (PTE)', 'Pulmonary Hypertension', 'Balloon Pulmonary Angioplasty (BPA)']",Yes,['Cohort'],['Prospective'],All consecutive consenting patients recently diagnosed (< 6 months) with CTEPH at participating study sites will be enrolled. Patients must meet inclusion criteria and have the diagnosis of CTEPH confirmed by the Adjudication Committee (AC) to be enrolled. Adult and pediatric patients may be enrolled and prior medical therapy will not exclude patients from enrollment.,Non-Probability Sample,,,Kim Kerr,Clinical Professor of Medicine,"University of California, San Diego",,,"[{'OverallOfficialName': 'Kim M Kerr, MD', 'OverallOfficialAffiliation': 'University of California, San Diego', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '24355646', 'ReferenceType': 'background', 'ReferenceCitation': 'Kim NH, Delcroix M, Jenkins DP, Channick R, Dartevelle P, Jansa P, Lang I, Madani MM, Ogino H, Pengo V, Mayer E. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D92-9. doi: 10.1016/j.jacc.2013.10.024. Review.'}, {'ReferencePMID': '24355642', 'ReferenceType': 'background', 'ReferenceCitation': 'McGoon MD, Benza RL, Escribano-Subias P, Jiang X, Miller DP, Peacock AJ, Pepke-Zaba J, Pulido T, Rich S, Rosenkranz S, Suissa S, Humbert M. Pulmonary arterial hypertension: epidemiology and registries. J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D51-9. doi: 10.1016/j.jacc.2013.10.023. Review.'}, {'ReferencePMID': '21969018', 'ReferenceType': 'background', 'ReferenceCitation': ""Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, Treacy C, D'Armini AM, Morsolini M, Snijder R, Bresser P, Torbicki A, Kristensen B, Lewczuk J, Simkova I, Barberà JA, de Perrot M, Hoeper MM, Gaine S, Speich R, Gomez-Sanchez MA, Kovacs G, Hamid AM, Jaïs X, Simonneau G. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation. 2011 Nov 1;124(18):1973-81. doi: 10.1161/CIRCULATIONAHA.110.015008. Epub 2011 Oct 3.""}]",,,,,,,,,,"[{'SeeAlsoLinkLabel': 'The central website for the U.S. CTEPH Registry', 'SeeAlsoLinkURL': 'http://usctephregistry.com'}]",,,,,,,,,,4 Years,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006976', 'ConditionMeshTerm': 'Hypertension, Pulmonary'}, {'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}]","[{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]","[{'ConditionBrowseLeafId': 'M8607', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8610', 'ConditionBrowseLeafName': 'Hypertension, Pulmonary', 'ConditionBrowseLeafAsFound': 'Pulmonary Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9751', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1321', 'ConditionBrowseLeafName': 'Chronic Thromboembolic Pulmonary Hypertension', 'ConditionBrowseLeafAsFound': 'Chronic Thromboembolic Pulmonary Hypertension', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02889263,QUANTIN DGOS 2015,Centre Hospitalier Universitaire Dijon,OTHER,Comparison of Rehospitalization Rates in France and the United States,Comparison of Rehospitalization Rates in France and the United States,Aug-16,Completed,No,,,Sep-14,Actual,,,31-Aug-16,02-Sep-16,05-Sep-16,Estimate,02-Sep-16,05-Sep-16,Estimate,Sponsor,Centre Hospitalier Universitaire Dijon,OTHER,,,,,"The problem of rehospitalizations in the US is well documented but poorly understood. Although Medicare compares the rates of rehospitalization across the country, we have found no comparison of different countries. This is a first attempt to compare rehospitalization in the US with France where national health insurance (NHI) provides easy access to primary care but, like the US, policymakers struggle to improve coordination between hospitals and community-based health care providers.Although France's NHI system with central state intervention differs from the United States' tradition of federalism, private health insurance and pluralism, policymakers seek to achieve cost savings and to reform the health care system. A recent literature review on avoidable rehospitalization of older persons in France cited studies on the topic and relied largely on ones from the US. Starting in 2013, the Center for Medicare and Medicaid Services' (CMS) 'Hospitals Readmissions Reductions Program' withheld up to 1% of regular reimbursements for hospitals with higher than expected (by CMS) rates of rehospitalization, within 30 days of discharge, due to heart attacks, heart failure and pneumonia. CMS increased this to 2% in 2014, will raise it to 3% in 2015 and may subsequently expand the list of conditions for which it will penalize early rehospitalizations. Policymakers in France have been reluctant to implement a hospital pay for performance system based on a rehospitalization indicator whose validity is a subject of considerable controversy. Despite the controversy and differences in approach, a comparison of rehospitalizations between the US and France provides a cross-national perspective on a timely policy issue facing both countries.",['Individuals Hospitalized for Any Disease'],Observational,,,,,,1944566,Actual,,,"[{'PrimaryOutcomeMeasure': 'The total number of rehospitalizations within 30 days of discharge, as a percent of total hospital discharges for all acute-care hospitals', 'PrimaryOutcomeTimeFrame': '30 days'}]","[{'SecondaryOutcomeMeasure': 'the most common diagnoses associated with the rehospitalizations for initial medical and surgical discharges', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'regional patterns of rehospitalization', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'the proportion of rehospitalized patients who received outpatient visits between the time of discharge and rehospitalization', 'SecondaryOutcomeTimeFrame': '30 days'}]","Inclusion Criteria:

Hospitalized patients aged over 65 years in France in 2010",No,All,65 Years,,['Older Adult'],,,No,"Data sources :

The hospital administrative data for this study are from the SNIIRAM (Syste'me National d'Informations Inter Regimes de l'Assurance Maladie) which also includes the national hospital reporting system (PMSI - Programme de Medicalisation des Systemes d'Information. The SNIIRAM is a centralized administrative database of all health services reimbursed under France's NHI program. The PMSI, based on diagnosis-related groups (DRGs), is a centralized administrative database of hospital discharge records by diagnosis, procedure, age and residence of patients from all hospitals in France. It is managed by a national agency (ATIH).

To calculate the proportion of rehospitalized patients (65þ) who received outpatient visits (all physician consultations in community-based practice, as well as hospital outpatient visits) between the time of discharge and rehospitalization, we collaborated with analysts at the French NHI fund (CNAMTS). We linked the individual identifying variable for rehospitalized patients and extracted the outpatient visits from the SNIIRAM database for all medical and surgical admissions. Of the total number of hospitalized French patients aged 18 years and over (5,804,677) with identifiers in 2010, only 299,364 (5%) were unidentified after linking these datasets. These patients are most likely to have been foreigners and newborns who had not yet received an identifier. Outpatient visits include all physician consultations in community-based practice, as well as hospital outpatient visits.",,No,['Cohort'],['Retrospective'],Hospitalized patients aged over 65 years in France in 2010,Non-Probability Sample,,REHOSP,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03995745,831689,University of Pennsylvania,OTHER,Medication Adherence and Outcomes Among Patients in United States With HIV,Behavioral Economic Incentives to Improve Medication Adherence and Outcomes Among Patients in United States With HIV: A Feasibility Study,Oct-20,Completed,No,16-May-19,Actual,27-Sep-19,Actual,13-Oct-20,Actual,23-May-19,20-Jun-19,24-Jun-19,Actual,14-Oct-20,19-Oct-20,Actual,Sponsor,University of Pennsylvania,OTHER,No,No,,,"With support from the NIH, this pilot study will assess the feasibility of using wireless devices and financial incentives to motivate medication adherence among HIV-positive adults in the U.S., focusing on those with non-suppressed viral loads.

While daily lotteries using wireless devices may have great potential for improving adherence to ART regimens, substantial questions exist as to whether it is: 1) possible to achieve high rates of uptake for a pilot offering wireless devices to high-risk populations; 2) achieve high rates of sustained engagement.","['Human Immunodeficiency Virus', 'Medication Adherence']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),40,Actual,"[{'ArmGroupLabel': 'adherence based financial incentives', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': ""Participants randomized to this arm will receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will be randomly assigned a 2-digit number to be used as part of the lottery-based engagement incentives in which eligibility to win will be conditional on medication adherence. Participants will also be eligible for a financial bonus if participant's viral load is suppressed at the end of the intervention period. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period."", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Medication adherence and financial incentives']}}, {'ArmGroupLabel': 'control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Of the 20 participants randomized to the control arm, 10 will be randomly assigned to receive an electronic pill bottle, AdhereTech. The AdhereTech bottle will be remotely monitored by the Way to Health platform. Participants will also receive an enrollment incentive and an incentive to complete a lab visit at the end of the intervention period.'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Medication adherence and financial incentives', 'InterventionDescription': 'Provision of wireless devices and financial incentives to motivate medication adherence among HIV-positive adults who have not reached viral suppression.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['adherence based financial incentives']}}]","[{'PrimaryOutcomeMeasure': 'Number of patients with viral suppression', 'PrimaryOutcomeDescription': 'viral load less than 400', 'PrimaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}]","[{'SecondaryOutcomeMeasure': 'viral suppression by arm', 'SecondaryOutcomeDescription': 'viral load less than 400', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'medication adherence by arm', 'SecondaryOutcomeDescription': 'electronic pill bottle openings by day', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'Recruitment rates by arm', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'Attrition rates by arm', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'Percent of patients that use electronic pill bottle', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'Completion rates of lab visit by arm', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}, {'SecondaryOutcomeMeasure': 'number of clinic visits by arm', 'SecondaryOutcomeTimeFrame': 'approximately 3 months after enrollment'}]","Inclusion Criteria:

Diagnosis of HIV, established in 2017 or earlier
Patients at least 18 years of age or older
Currently prescribed first or second line ART medications
Non-suppressed viral loads, with two consecutive non-suppressed viral loads (VL>400 copies/ml) for the past two lab readings.

Exclusion Criteria:

Pregnant
Prescribed Maraviroc or Fuzeon
More than 5 additional medications
Diagnosed with insulin dependent diabetes
Unable to provide consent
Non-English speaker
Cognitive impairment, per PI discretion
Does not have stable residence",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Drexel University', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19104', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Drexel University', 'CollaboratorClass': 'OTHER'}]",No,"The goal of this study is to explore the feasibility of using wireless devices and financial incentives to motivate medication adherence among high-risk HIV positive patients. By partnering with the Drexel Partnership Comprehensive Care Clinic at Drexel University, the investigators will be able to identify such patients using clinic patient data, use clinic and physician communication channels to enroll them, and maintain high levels of ongoing participation through the use of incentives. The aim is to improve antiretroviral medication adherence among high-risk HIV positive patients by providing patients with a AdhereTech device (electronic pill bottle), daily adherence notifications tracked by the Way to Health platform, as well as daily lotteries and financial incentives. Upon completion, this study will answer questions important to the feasibility of conducting well-powered randomized controlled trials to improve adherence among HIV patients within the U.S. who have sub-optimal adherence.",,,,,,,,CHANGE,,,,,,,No,,,,,,,,,,,,,,,,,,,,,,"HIV-positive patients in Philadelphia with non-suppressed viral loads will be randomly assigned to receive the intervention (electronic-pill bottle with adherence based daily financial incentives, and incentive for reaching viral suppression) or control. About 40 patients will be enrolled in the study, 20 in each arm.",,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000000163', 'ConditionMeshTerm': 'Acquired Immunodeficiency Syndrome'}, {'ConditionMeshId': 'D000015658', 'ConditionMeshTerm': 'HIV Infections'}]","[{'ConditionAncestorId': 'D000007153', 'ConditionAncestorTerm': 'Immunologic Deficiency Syndromes'}, {'ConditionAncestorId': 'D000007154', 'ConditionAncestorTerm': 'Immune System Diseases'}, {'ConditionAncestorId': 'D000016180', 'ConditionAncestorTerm': 'Lentivirus Infections'}, {'ConditionAncestorId': 'D000012192', 'ConditionAncestorTerm': 'Retroviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000015229', 'ConditionAncestorTerm': 'Sexually Transmitted Diseases, Viral'}, {'ConditionAncestorId': 'D000012749', 'ConditionAncestorTerm': 'Sexually Transmitted Diseases'}, {'ConditionAncestorId': 'D000012897', 'ConditionAncestorTerm': 'Slow Virus Diseases'}]","[{'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafAsFound': 'Human Immunodeficiency Virus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafAsFound': 'Human Immunodeficiency Virus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8782', 'ConditionBrowseLeafName': 'Immunologic Deficiency Syndromes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14938', 'ConditionBrowseLeafName': 'Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8783', 'ConditionBrowseLeafName': 'Immune System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17223', 'ConditionBrowseLeafName': 'Lentivirus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13609', 'ConditionBrowseLeafName': 'Retroviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14141', 'ConditionBrowseLeafName': 'Sexually Transmitted Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16516', 'ConditionBrowseLeafName': 'Sexually Transmitted Diseases, Viral', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14283', 'ConditionBrowseLeafName': 'Slow Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00928694,0767-031,Merck Sharp & Dohme Corp.,INDUSTRY,Fenofibrate Bioequivalence Study (0767-031),"An Open-Label, Randomized, 2-Period, Crossover Study to Determine Definitive Bioequivalence After Administration of Single 160 mg Doses of the U.S. and UK Formulations of Fenofibrate in Healthy Adult Subjects",Aug-15,Completed,No,Feb-03,,Apr-03,Actual,Apr-04,Actual,25-Jun-09,25-Jun-09,26-Jun-09,Estimate,18-Aug-15,19-Aug-15,Estimate,Sponsor,Merck Sharp & Dohme Corp.,INDUSTRY,,,,,This study will determine definitive bioequivalence of the United States (U.S.) and United Kingdom (UK) formulations of fenofibrate following administration of single doses in healthy adult subjects.,['Dyslipidemia'],Interventional,['Phase 1'],Randomized,Crossover Assignment,Treatment,None (Open Label),14,Actual,"[{'ArmGroupLabel': '1', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Fenofibrate U.S. Formulation', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: fenofibrate (U.S. formulation)']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Fenofibrate UK Formulation', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: fenofibrate (UK formulation)']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'fenofibrate (U.S. formulation)', 'InterventionDescription': 'Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Tricor®']}}, {'InterventionType': 'Drug', 'InterventionName': 'fenofibrate (UK formulation)', 'InterventionDescription': 'Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Supralip®']}}]","[{'PrimaryOutcomeMeasure': 'Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid', 'PrimaryOutcomeTimeFrame': 'Predose and up to 168 hours postdose'}, {'PrimaryOutcomeMeasure': 'Maximum Plasma Concentration (Cmax) of Fenofibric Acid', 'PrimaryOutcomeTimeFrame': 'Predose and up to 168 hours postdose'}]",,"Inclusion Criteria:

Subject is in good health
Subject is willing to follow all study guidelines

Exclusion Criteria:

Subject has uncontrolled high blood pressure, impaired glucose tolerance, diabetes, or other major diseases or chronic conditions that would confound the results of the study or make participation unsafe
Female subject is receiving oral contraceptives or hormone replacement therapy",Accepts Healthy Volunteers,All,18 Years,45 Years,['Adult'],,,,,,,,,,,"[{'SecondaryId': 'MK0767-031'}, {'SecondaryId': '2009_606'}]",,,,,,,"[{'OverallOfficialName': 'Medical Monitor', 'OverallOfficialAffiliation': 'Merck Sharp & Dohme Corp.', 'OverallOfficialRole': 'Study Director'}]",,,10-Nov-09,10-Nov-09,11-Dec-09,Estimate,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000050171', 'ConditionMeshTerm': 'Dyslipidemias'}]","[{'ConditionAncestorId': 'D000052439', 'ConditionAncestorTerm': 'Lipid Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]","[{'ConditionBrowseLeafId': 'M24768', 'ConditionBrowseLeafName': 'Dyslipidemias', 'ConditionBrowseLeafAsFound': 'Dyslipidemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M25616', 'ConditionBrowseLeafName': 'Lipid Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]","[{'InterventionMeshId': 'D000011345', 'InterventionMeshTerm': 'Fenofibrate'}]","[{'InterventionAncestorId': 'D000000960', 'InterventionAncestorTerm': 'Hypolipidemic Agents'}, {'InterventionAncestorId': 'D000000963', 'InterventionAncestorTerm': 'Antimetabolites'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000057847', 'InterventionAncestorTerm': 'Lipid Regulating Agents'}]","[{'InterventionBrowseLeafId': 'M12801', 'InterventionBrowseLeafName': 'Fenofibrate', 'InterventionBrowseLeafAsFound': 'OCT', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2859', 'InterventionBrowseLeafName': 'Hypolipidemic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2862', 'InterventionBrowseLeafName': 'Antimetabolites', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M27470', 'InterventionBrowseLeafName': 'Lipid Regulating Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Lipd', 'InterventionBrowseBranchName': 'Lipid Regulating Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'TRICOR™ First, Then SUPRALIP™', 'FlowGroupDescription': 'U.S. formulation (TRICOR™) 160 mg tablet/ UK formulation (SUPRALIP™) 160 mg tablet'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'SUPRALIP™ First, Then TRICOR™', 'FlowGroupDescription': 'UK formulation (SUPRALIP™) 160 mg tablet / U.S. formulation (TRICOR™) 160 mg tablet'}]","[{'FlowPeriodTitle': 'First Intervention', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}, {'FlowPeriodTitle': 'Second Intervention', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '7'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '7'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'All Participants'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '14'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '36.7', 'BaselineMeasurementLowerLimit': '23', 'BaselineMeasurementUpperLimit': '45'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}]}}]}}]}}, {'BaselineMeasureTitle': 'Height', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'Centimeters', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '169.64', 'BaselineMeasurementLowerLimit': '154.94', 'BaselineMeasurementUpperLimit': '187.96'}]}}]}}]}}, {'BaselineMeasureTitle': 'Weight', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Full Range', 'BaselineMeasureUnitOfMeasure': 'Kilograms', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '73.94', 'BaselineMeasurementLowerLimit': '51.71', 'BaselineMeasurementUpperLimit': '93.90'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Area Under the Curve (AUC(0 to Infinity)) of Fenofibric Acid', 'OutcomeMeasurePopulationDescription': 'Healthy Male and Female subjects Aged 18 to 45', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'μg·hr/mL', 'OutcomeMeasureTimeFrame': 'Predose and up to 168 hours postdose', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'U.S. Formulation (TRICOR™)', 'OutcomeGroupDescription': 'U.S. Formulation: single oral 160 mg dose of the U.S. formulation of fenofibrate with food.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'UK Formulation (SUPRALIP™)', 'OutcomeGroupDescription': 'UK Formulation: single oral 160 mg dose of the UK formulation of fenofibrate with food.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '14'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '14'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '116', 'OutcomeMeasurementSpread': '35.1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '121', 'OutcomeMeasurementSpread': '36.4'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'Yes', 'OutcomeAnalysisNonInferiorityType': 'Non-Inferiority or Equivalence', 'OutcomeAnalysisNonInferiorityComment': 'Bioequivalence bounds = (0.80, 1.25) Study Primary Hypothesis: Single 160 mg doses of the U.S. and UK formulations of fenofibrate following consumption of a standard breakfast are bioequivalent (the true geometric mean ratios (GMRs) [U.S./UK] for the AUC(0 to infinity) and maximum plasma concentration (Cmax) of fenofibric acid after administration of the U.S. and UK formulations of fenofibrate with food are contained in the interval [0.80, 1.25]).', 'OutcomeAnalysisParamType': 'Geometric Mean Ratio', 'OutcomeAnalysisParamValue': '0.96', 'OutcomeAnalysisCIPctValue': '90', 'OutcomeAnalysisCILowerLimit': '0.90', 'OutcomeAnalysisCIUpperLimit': '1.02'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Maximum Plasma Concentration (Cmax) of Fenofibric Acid', 'OutcomeMeasurePopulationDescription': 'Healthy Male and Female subjects Aged 18 to 45', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'μg/mL', 'OutcomeMeasureTimeFrame': 'Predose and up to 168 hours postdose', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'U.S. Formulation (TRICOR™)', 'OutcomeGroupDescription': 'U.S. Formulation: single oral 160 mg dose of the U.S. formulation of fenofibrate with food.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'UK Formulation (SUPRALIP™)', 'OutcomeGroupDescription': 'UK Formulation: single oral 160 mg dose of the UK formulation of fenofibrate with food.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '14'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '14'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.35', 'OutcomeMeasurementSpread': '1.61'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6.48', 'OutcomeMeasurementSpread': '1.80'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'Yes', 'OutcomeAnalysisNonInferiorityType': 'Non-Inferiority or Equivalence', 'OutcomeAnalysisNonInferiorityComment': 'Bioequivalence bounds = (0.80, 1.25) Study Primary Hypothesis: Single 160 mg doses of the U.S. and UK formulations of fenofibrate following consumption of a standard breakfast are bioequivalent (the true GMRs [U.S./UK] for the AUC(0 to infinity) and Cmax of fenofibric acid after administration of the U.S. and UK formulations of fenofibrate with food are contained in the interval [0.80, 1.25]).', 'OutcomeAnalysisParamType': 'Geometric Mean Ratio', 'OutcomeAnalysisParamValue': '0.98', 'OutcomeAnalysisCIPctValue': '90', 'OutcomeAnalysisCILowerLimit': '0.90', 'OutcomeAnalysisCIUpperLimit': '1.06'}]}}]",0,,,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Tricor™', 'EventGroupDescription': 'U.S. formulation (TRICOR™) 160 mg tablet', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '14', 'EventGroupOtherNumAffected': '1', 'EventGroupOtherNumAtRisk': '14'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Supralip™', 'EventGroupDescription': 'UK formulation (SUPRALIP™) 160 mg tablet', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '14', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '14'}]","[{'OtherEventTerm': 'Loose Stools', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 12.0', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '14'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '14'}]}}]",No,Yes,"Senior Vice President, Global Clinical Development",Merck Sharp & Dohme Corp.,ClinicalTrialsDisclosure@merck.com,1-800-672-6372,,OTHER,"Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02153996,140121,National Institutes of Health Clinical Center (CC),NIH,Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States,Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States,15-Mar-16,Terminated,No,15-May-14,,15-Mar-16,Actual,15-Mar-16,Actual,31-May-14,31-May-14,03-Jun-14,Estimate,14-Dec-19,17-Dec-19,Actual,Sponsor,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,,,,"Plasmodium falciparum malaria is a major cause of morbidity and mortality in tropical and sub-tropical areas worldwide. Repeated P. falciparum infections in endemic areas induce protective immunity, thus providing optimism that an effective malaria vaccine can be developed. Key to the development of such a vaccine is an understanding of the immune mechanisms underlying protection and the longevity of these responses in the absence of continuous P. falciparum exposure. Anecdotal evidence suggests clinical immunity to malaria wanes within months to years after an immune individual leaves an endemic area. A detailed, systematic description of the quality and longevity of the P. falciparum-specific humoral and cellular immune responses in such individuals over time in the absence of ongoing exposure is lacking.

This protocol will attempt to fill this knowledge gap through comprehensive longitudinal immunological analyses of two populations of healthy adult volunteers: 1) naive travelers returning from malaria endemic areas recently treated (within 2 weeks) for acute P. falciparum malaria and referred from hospitals in the metropolitan Washington DC area; and 2) immigrants from malaria endemic areas living in the metropolitan Washington DC area with serologic evidence of past P. falciparum exposure. In both groups, venipuncture and possibly apheresis will be performed for the isolation of plasma, RNA and peripheral blood mononuclear cells (PBMCs) which will be analysed to understand the components of innate and adaptive immunity to malaria. Na(SqrRoot) ve travelers returning from malaria endemic areas recently treated for acute malaria will undergo venipuncture at enrollment, then once every 2 weeks for 2 months, then every 3 months for 1 year, and then every 6 months for up to 5 years. Immigrants will be seen every three months for one year and then every six months for up to 5 years. All subjects who return to the U.S. from a malaria endemic area will be evaluated within two weeks of return for repeat venipuncture and will restart the same sequence of blood draws as naive travelers. Optional apheresis will be performed on both na(SqrRoot) ve travelers and immigrants at enrollment, at 1, 6, and 12 months, then yearly therafter.

The primary objective is to estimate the quality and longevity of P. falciparum-specific humoral and cellular immune responses in the absence of ongoing P. falciparum exposure in both returned na(SqrRoot) ve travelers and immigrants. The secondary objective is to compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali.

...",['Malaria'],Observational,,,,,,3,Actual,,,"[{'PrimaryOutcomeMeasure': 'Estimate the quality and longevity of P. falciparum-specific humoral and cellular immune responses in the absence of ongoing P. falciparum exposure.', 'PrimaryOutcomeTimeFrame': 'Five years'}]","[{'SecondaryOutcomeMeasure': 'Compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to age and sex matched individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali.', 'SecondaryOutcomeTimeFrame': '5 years'}]","INCLUSION CRITERIA:
All Subjects: Age 18-65
Agree to have blood specimens stored for future research and genetic studies

Malaria endemicity will be defined according to CDC Yellow Book criteria available at:

http://wwwnc.cdc.gov/travel/yellowbook/2014/chapter-3-infectious-diseases-related-totravel/malaria#3929

NaIve travelers returning from malaria endemic areas recently treated for malaria:

-Treated for acute P. falciparum malaria within 4 weeks of enrolling in this study as determined by clinical and microbiologic evidence (including blood smear) of infection as indicated by medical records

Immigrants from malaria endemic areas:

Confirmation of having lived in a malaria endemic area through documentation or verifiable detailed immigration history.
Evidence of past P. falciparum exposure with positive AMA -1 ELISA.

SUBJECT EXCLUSION CRITERIA:

History of HIV and/or hepatitis C.
Inadequate peripheral venous access
Current use of the steroid equivalent of prednisone 20mg/day or more or other systemic immunosuppressants
Underlying heart disease, lung disease, bleeding disorder, or other conditions that, in the judgment of the investigator, contraindicates study participation
Temperature greater than or equal to 37.5 (Infinite)C or other clinical evidence of an acute infection
Currently pregnant (positive urine beta-HCG) or breastfeeding",Accepts Healthy Volunteers,All,18 Years,65 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'National Institutes of Health Clinical Center, 9000 Rockville Pike', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20892', 'LocationCountry': 'United States'}]",,,"Plasmodium falciparum malaria is a major cause of morbidity and mortality in tropical and sub-tropical areas worldwide. Repeated P. falciparum infections in endemic areas induce protective immunity, thus providing optimism that an effective malaria vaccine can be developed. Key to the development of such a vaccine is an understanding of the immune mechanisms underlying protection and the longevity of these responses in the absence of continuous P. falciparum exposure. Anecdotal evidence suggests clinical immunity to malaria wanes within months to years after an immune individual leaves an endemic area. A detailed, systematic description of the quality and longevity of the P. falciparum-specific humoral and cellular immune responses in such individuals over time in the absence of ongoing exposure is lacking.

This protocol will attempt to fill this knowledge gap through comprehensive longitudinal immunological analyses of two populations of healthy adult volunteers: 1) naive travelers returning from malaria endemic areas recently treated (within 2 weeks) for acute P. falciparum malaria and referred from hospitals in the metropolitan Washington DC area; and 2) immigrants from malaria endemic areas living in the metropolitan Washington DC area with serologic evidence of past P. falciparum exposure. In both groups, venipuncture and possibly apheresis will be performed for the isolation of plasma, RNA and peripheral blood mononuclear cells (PBMCs) which will be analysed to understand the components of innate and adaptive immunity to malaria. Na(SqrRoot) ve travelers returning from malaria endemic areas recently treated for acute malaria will undergo venipuncture at enrollment, then once every 2 weeks for 2 months, then every 3 months for 1 year, and then every 6 months for up to 5 years. Immigrants will be seen every three months for one year and then every six months for up to 5 years. All subjects who return to the U.S. from a malaria endemic area will be evaluated within two weeks of return for repeat venipuncture and will restart the same sequence of blood draws as naive travelers. Optional apheresis will be performed on both na(SqrRoot) ve travelers and immigrants at enrollment, at 1, 6, and 12 months, then yearly therafter.

The primary objective is to estimate the quality and longevity of P. falciparum-specific humoral and cellular immune responses in the absence of ongoing P. falciparum exposure in both returned na(SqrRoot) ve travelers and immigrants. The secondary objective is to compare the P. falciparum-specific humoral and cellular immune response in na(SqrRoot) ve travelers and immigrants to individuals in malaria-endemic areas enrolled in ongoing LIG protocols in Mali.",['Malaria Immunity Longevity'],,['Cohort'],['Prospective'],,,[{'SecondaryId': '14-I-0121'}],,,,,,,"[{'OverallOfficialName': 'Eugene W Liu, M.D.', 'OverallOfficialAffiliation': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '8074247', 'ReferenceType': 'background', 'ReferenceCitation': 'Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, Badji A, Ndiaye G, Ndiaye P, et al. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg. 1994 Aug;51(2):123-37.'}, {'ReferencePMID': '7565132', 'ReferenceType': 'background', 'ReferenceCitation': 'Pérignon JL, Druilhe P. Immune mechanisms underlying the premunition against Plasmodium falciparum malaria. Mem Inst Oswaldo Cruz. 1994;89 Suppl 2:51-3. Review.'}, {'ReferencePMID': '15463545', 'ReferenceType': 'background', 'ReferenceCitation': 'Deloron P, Chougnet C. Is immunity to malaria really short-lived? Parasitol Today. 1992 Nov;8(11):375-8.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00413673,WRAMC WU # 2335-99,Walter Reed Army Medical Center,FED,Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel,Initial Evaluation of Photorefractive Keratectomy in U.S. Army Personnel,Nov-07,Completed,No,Aug-01,,,,Mar-08,,19-Dec-06,19-Dec-06,20-Dec-06,Estimate,31-Mar-08,01-Apr-08,Estimate,,Walter Reed Army Medical Center,FED,,,,,"The objective of this study is to conduct a prospective clinical trial to evaluate the safety and efficacy fo the VISX Excimer Laser system for the treatment of naturally occurring low to moderate myopia, with or without low levels of astigmatism, in U.S. Army personnel.",['Myopia'],Interventional,['Not Applicable'],Non-Randomized,Single Group Assignment,Treatment,None (Open Label),100,Anticipated,"[{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'PRK', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: PRK']}}]","[{'InterventionType': 'Procedure', 'InterventionName': 'PRK', 'InterventionDescription': 'PRK', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}]","[{'PrimaryOutcomeMeasure': 'safety and efficacy of PRK', 'PrimaryOutcomeTimeFrame': '12 months after surgery'}]",,"Inclusion Criteria:

Informed consent.
Normal, healthy active adults with access to medical care at Walter Reed Health Care System.
Age 21 years or older.
Spherical equivalent of the manifest refractive error between -1.0 to -6.0 diopters (D), inclusive, with no more than 3.0D of cylinder. The absolute value of the cylinder (expressed in minus cylinder) will be limited such that the short axis of the elliptical ablation will be no smaller than 4.9mm. The following specifies the maximum cylinder for a given spherical component of the manifest refraction:

Spherical component / Maximum cylinder

1.0D / -0.5D
2.0D / -1.0D
3.0D / -1.5D
4.0D / -2.0D
5.0D / -2.5D
6.0D / -3.0D
Corrected vision of at least 20/20
Soft contact lens users must havE removed their lenses at least two weeks prior to baseline measurements.
Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least four weeks prior to baseline measurements. At least two weekly manifest refractions and keratometry measurements will be required in this interval. The last two measurements must not vary by more than 0.50D in any meridian.
Patients undergoing orthokeratology must have their lenses removed at least 6 months prior to the baseline examination. At least two monthly manifest refractions and keratometry measurements taken after the third month out of lenses must not vary by more than 0.50D in any meridian.
Refractive stability must be documented by previous refractions. Spherical and cylindrical portion of the manifest refraction must not have varied by more than 0.50D over the previous 12 months.
Exhibits strong motivation for keeping the follow-up visits.
Available for evaluation at Walter Reed during the two-year follow-up period.
Service members must have their command approval to participate in the study.
Access to transportation to meet follow-up requirements.

Exclusion Criteria:

Residual, recurrent or active ocular diseases or corneal abnormalities in either eye such as iritis, uveitis, keratoconjunctivitis sicca, herpetic keratitis, vernal conjunctivitis, lagophthalmos, corneal scarring, glaucoma, previous steroid responder, occludable chamber angles, visually significant cataracts.
Either one or both eyes suffering from chronic dryness.
Taking any systemic medications that may affect wound healing such as corticosteroids or antimetabolites.
Patient corneal neovascularization within one mm of the ablation zone.
History of any previous eye surgery, including previous refractive surgery.
Best corrected visual acuity of less than 20/20.
Progressive myopia or keratoconus.
Any systemic disease that may affect wound healing, such as connective tissue disorders (rheumatoid arthritis, systemic lupus erythematosus, etc.), diabetes, or severe atopic disease.
Any physical or mental impairment that would preclude participation in any of the examinations.
For contact lens users there must be no evidence of contact lens corneal warpage on computerized topography.
Currently on flight status or projected to be on flight status within ten years.
Pregnant or breast-feeding an infant. Women of childbearing age must take a urine blood pregnancy test before starting this study",Accepts Healthy Volunteers,All,21 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Walter Reed Army Medical Center, Center For Refractive Surgery', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20307', 'LocationCountry': 'United States'}]",,,,"['Naturally occurring low to moderate myopia, with or without low levels of astigmatism in U.S. Army personnel']",,,,,,,,,,,,,"[{'OverallOfficialName': 'KRAIG S. BOWER, MD', 'OverallOfficialAffiliation': 'Walter Reed Army Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000009216', 'ConditionMeshTerm': 'Myopia'}]","[{'ConditionAncestorId': 'D000012030', 'ConditionAncestorTerm': 'Refractive Errors'}, {'ConditionAncestorId': 'D000005128', 'ConditionAncestorTerm': 'Eye Diseases'}]","[{'ConditionBrowseLeafId': 'M10751', 'ConditionBrowseLeafName': 'Myopia', 'ConditionBrowseLeafAsFound': 'Myopia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3139', 'ConditionBrowseLeafName': 'Astigmatism', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13455', 'ConditionBrowseLeafName': 'Refractive Errors', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6854', 'ConditionBrowseLeafName': 'Eye Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC11', 'ConditionBrowseBranchName': 'Eye Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03867409,IRB201801473 -N,University of Florida,OTHER,The United States Healthy Living Study,The United States Healthy Living Study,Mar-20,Completed,No,05-Nov-18,Actual,14-Mar-19,Actual,14-Mar-19,Actual,01-Mar-19,05-Mar-19,08-Mar-19,Actual,25-Mar-20,26-Mar-20,Actual,Sponsor,University of Florida,OTHER,No,No,,,"The purpose of this study is to pilot test the efficacy of a patient-centered, tailored message intervention delivered via virtual human technology for increasing colorectal cancer (CRC) screening within guidelines. Although participation is not limited to these groups, the study team is particularly interested in the feasibility of the intervention for reaching racial/ethnic minority and rural patients.",['Colo-rectal Cancer'],Interventional,['Not Applicable'],Randomized,Factorial Assignment,Screening,Single,2218,Actual,"[{'ArmGroupLabel': 'Concordant virtual human', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: message delivered via virtual technology']}}, {'ArmGroupLabel': 'Dis-concordant virtual human', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered by virtual human technology.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: message delivered via virtual technology']}}, {'ArmGroupLabel': 'Concordant text', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participant is exposed to a demographically concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: message delivered via virtual technology']}}, {'ArmGroupLabel': 'Dis-concordant text', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participant is exposed to a demographically dis-concordant (i.e. gender and race matched with patient) colon cancer screening message delivered in a text-based format.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: message delivered via virtual technology']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'message delivered via virtual technology', 'InterventionDescription': 'The intervention is precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Concordant text', 'Concordant virtual human', 'Dis-concordant text', 'Dis-concordant virtual human']}}]","[{'PrimaryOutcomeMeasure': 'Perceived susceptibility', 'PrimaryOutcomeDescription': 'Perceived susceptibility (Birmingham et al., 2015) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\nI am at risk for getting colon cancer in my lifetime.\nIt is possible that I will get colon cancer in my lifetime.\nI am susceptible to getting colon cancer in my lifetime.\nIt is likely that I will get colon cancer in my lifetime.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Perceived severity', 'PrimaryOutcomeDescription': 'Perceived severity (Boonyasiriwat et al., 2013; Hsien Cheah, 2006; Lipkus & Klein, 2006) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n5. I believe that colon cancer is harmful. 6. I believe that colon cancer is a significant disease. 7. I believe that colon cancer has serious negative consequences. 8. I believe that colon cancer is serious. 9. I believe that colon cancer is dangerous. 10. I believe that colon cancer is life-threatening.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Perceived benefits', 'PrimaryOutcomeDescription': ""Perceived benefits (Christy et al., 2013; Purnell, Katz, Andersen, & Bennett, 2010; Rawl et al., 2001; Vernon, Myers, & Tilley, 1997) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n13. The FIT will decrease your chances of dying from colon cancer. 14. The FIT will help you not worry as much about colon cancer. 15. I believe that if I had a normal screening test result, I wouldn't have to worry about developing colon cancer.\n\n16. I believe that when colon cancer is found early, it can be cured."", 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Perceived barriers', 'PrimaryOutcomeDescription': 'Perceived barriers (Champion & Skinner, 2003; Gwede et al., 2011; James, Campbell, & Hudson, 2002) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n17. My doctor would never recommend the FIT. 18. The FIT would be too expensive. 19. The FIT would be too embarrassing. 20. Preparation for the FIT is too hard. 21. The FIT takes too much time. 22. The FIT is difficult because it is too hard to understand all the instructions.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Attitudes towards Fecal immunochemical test (FIT)', 'PrimaryOutcomeDescription': 'Attitudes towards FIT/colonoscopy (Rydell, Sherman, Boucher, & Macy, 2012) Please indicate your feelings about FIT. Numbers 1 and 5 indicate a very strong feeling. Numbers 2 and 4 indicate a weak feeling. Number 3 indicates you are undecided.\n\nFIT is… 23. Awful-Nice 24. Unpleasant-Pleasant 25. Fun-Not Fun', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Attitudes towards colonoscopy', 'PrimaryOutcomeDescription': 'Attitudes towards FIT/colonoscopy (Rydell, Sherman, Boucher, & Macy, 2012) Please indicate your feelings about colonoscopy. Numbers 1 and 5 indicate a very strong feeling. Numbers 2 and 4 indicate a weak feeling. Number 3 indicates you are undecided.\n\nColonoscopy is… 26. Awful-Nice 27. Unpleasant-Pleasant 28. Fun-Not Fun', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Self-efficacy', 'PrimaryOutcomeDescription': 'Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\nI am confident that I can use the FIT. Arranging my schedule to use the FIT is an easy thing to do. FIT screening would be easy for me to do. It would be easy for me to take a stool sample. It would be easy for me to mail my kit back. It would be easy for me to use all the tools in the kit. I know how to collect a stool sample. I am confident that I can get a colonoscopy. Arranging my schedule to get a colonoscopy is an easy thing to do. Finding time to get a colonoscopy would be difficult for me to do. Screening for colon cancer with a colonoscopy would be easy for me to do. It would be easy for me to get a colonoscopy.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Response efficacy', 'PrimaryOutcomeDescription': 'Response efficacy (Boer & Seydel, 1996; Duncan et al., 2014; Hwang et al., 2012, 2013; Vernon et al., 1997) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n7. FIT screening leads to early detection if something is wrong. 8. FIT screening leads to the detection of small abnormalities. 9. FIT screening will help me find cancer early. (What has Nick gotten from something like this?) 10. FIT screening will decrease my chances of dying from colon cancer', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Comparative risk feedback', 'PrimaryOutcomeDescription': 'Comparative risk feedback (Dillard, Ferrer, Ubel, & Fagerlin, 2012; Weinstein et al., 2004) 11. Compared to the average person-your age, gender, and race-how would you rate your chances of developing colon cancer in your life? (Very much higher, much higher, higher, average, lower, much lower, very much lower)', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Cancer Information Overload', 'PrimaryOutcomeDescription': ""Cancer Information Overload (Jensen, Carcioppolo, et al., 2014) Below are some statements about the information you read and hear about cancer. For each statement, please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n12. There are so many different recommendations about preventing cancer, it's hard to know which ones to follow.\n\n13. There is not enough time to do all of the things recommended to prevent cancer.\n\n14. It has gotten to the point where I don't even care to hear new information about cancer.\n\n15. I feel overwhelmed by the amount of cancer information I am supposed to know."", 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Cancer fatalism', 'PrimaryOutcomeDescription': 'Cancer fatalism (Powe, 1995; Shen, Condit, & Wright, 2009) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n11. I will die if I get colon cancer. 12. If I am diagnosed with colon cancer, I have little chance of surviving the disease.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Perceived Message Relevance Scale', 'PrimaryOutcomeDescription': 'Perceived Message Relevance Scale (Jensen, King, et al., 2014; Jensen, King, Carcioppolo, & Davis, 2012) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n16. The message seemed to be written personally for me. 17. The message was very relevant to my situation. 18. The message was applicable to me. 19. The message was very customized to me. 20. This message was manipulative. 21. This message was misleading.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Argument strength', 'PrimaryOutcomeDescription': 'Argument strength (Zhao, Strasser, Cappella, Lerman, & Fishbein, 2011) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree) about colon cancer screening.\n\n22. The visit is a reason for screening with FIT that is believable. 23. The visit is a reason for screening with FIT that is convincing. 24. The visit is gives me a reason for screening with FIT that is important to me.\n\n25. The visit helped me feel confident about how best to screen with FIT. 26. The visit would help my friends screen with FIT. 27. The visit put thoughts in my mind about wanting to screen with FIT. 28. The statement put thoughts in my mind about not wanting to avoid screening. 29. Overall, how much do you agree or disagree with the visit? 30. Is the reason the visit gave for screening with FIT a strong reason or weak reason?', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Source credibility', 'PrimaryOutcomeDescription': ""Source credibility (McCroskey & Teven, 1999) Please indicate your feelings about Alex. Numbers 1 and 5 indicate a very strong feeling. Numbers 2 and 4 indicate a weak feeling. Number 3 indicates you are undecided.\n\n37. Intelligent-Unintelligent 38. Trained-Untrained 39. Cares about me-Doesn't care about me 40. Honest-Dishonest 41. Has my interests at heart-Doesn't have my interests at heart 42. Trustworthy-Untrustworthy 43. Expert-Inexpert 44. Not self-centered-Self-centered 45. Concerned with me-Not concerned with me 46. Honorable-Dishonorable 47. Informed-Uninformed 48. Moral-Immoral 49. Competent-Incompetent 50. Ethical-Unethical 51. Sensitive-Insensitive 52. Bright-Stupid 53. Genuine-Phony 54. Understanding-Not understanding"", 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Trust in Physician Scale', 'PrimaryOutcomeDescription': ""Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\nI doubt that my doctor really cares about me as a person. My doctor usually puts my needs first. I trust my doctor so much I always try to follow his/her advice. If my doctor tells me something is so, then it must be true. I sometimes distrust my doctor's opinion. I trust my doctor's judgments about my medical care. I feel my doctor does not do everything he/she should about my medical care. I trust my doctor to put my medical needs above all other considerations when treating my medical problems.\n\nMy doctor is well qualified to manage (diagnose and treat or make an appropriate referral) medical problems like mine.\n\nI trust my doctor to tell me if a mistake was made about my treatment. I sometimes worry that my doctor may not keep the information we discuss totally private."", 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Patient-provider communication scale', 'PrimaryOutcomeDescription': ""Patient-provider communication scale (Katz et al., 2004) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n66. I receive enough understandable information from my doctor/healthcare provider to make good decisions about my health.\n\n67. I feel rushed during visits. 68. My doctor/healthcare provider involves me in decisions about my health care treatment.\n\n69. I feel uncomfortable asking my doctor for tests or information if he/she doesn't mention it.\n\n70. My doctor/healthcare provider understands my health needs."", 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Patient general health (SF-36)', 'PrimaryOutcomeDescription': 'Patient general health (SF-36) (Fan, Burman, McDonell, & Fihn, 2005; Jenkinson, Coulter, & Wright, 1993; RAND Corporation, n.d.) 71. In general, would you say your health is:\n\nExcellent\nVery good\nGood\nFair\nPoor 72. How much bodily pain have you had during the past 4 weeks?\nNone\nVery mild\nMild\nModerate\nSevere\nVery severe 73. During the past 4 weeks, how much did pain interfere with your normal work (including both work outside the home and housework)?\nNot at all\nA little bit\nModerately\nQuite a bit\nExtremely', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'eHeals Health Literacy', 'PrimaryOutcomeDescription': 'eHeals Health Literacy (Norman & Skinner, 2006) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n74. I know how to find helpful health resources on the Internet. 75. I know how to use the Internet to answer my health questions. 76. I know what health resources are available on the Internet. 77. I know where to find helpful health resources on the Internet. 78. I know how to use the health information I find on the Internet to help me. 79. I have the skills I need to evaluate the health resources I find on the Internet.\n\n80. I can tell high quality from low quality health resources on the Internet. 81. I feel confident in using information from the Internet to make health decisions.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Transportation', 'PrimaryOutcomeDescription': 'Transportation (Green & Brock, 2000) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n82. During the appointment, I could easily picture myself in the exam room. 83. While I was reading the narrative, activity going on in the room around me was not on my mind.\n\n84. I could picture myself in the scene of the events described in the narrative.\n\n85. I was mentally involved in the conversation while reading it. 86. After finishing the appointment, I found it easy to put it out of my mind. 87. I wanted to learn how the narrative ended. 88. The appointment affected me emotionally. 89. I found myself thinking of ways the narrative could have turned out differently.\n\n90. I found my mind wandering while reading the narrative. 91. The events in the narrative are relevant to my everyday life. 92. The events in the narrative have changed my life.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Usability of App', 'PrimaryOutcomeDescription': 'In the last 12 months, how often have you used a secure website or application (""app"") to track your health information online?\n\nDaily\nWeekly\nMonthly\nA few times a year\nI don\'t use websites or applications for this. What device(s) do you use to access your personal health information online? (Please circle all that apply)\nPhone\nTablet\nLaptop/desktop Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n-Various statements about PHI, electronic storage, and access-\n\nPlease rate how similar you are to Alex on the following dimensions:\n\nGender Race Age Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n-Various questions about the virtual assistant\'s usefulness-', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Homophily', 'PrimaryOutcomeDescription': ""Homophily (Lin & Guan, 2003; McCroskey, Richmond, & Daly, 1975; Z. Wang, Walther, Pingree, & Hawkins, 2008) Alex, my healthcare assistant… 129. Thinks like me-doesn't think like me 130. Behaves like me-doesn't behave like me 131. Is similar to me-is different from me 132. Is like me-is unlike me 133. Has a background similar from mine-has a background different to mine 134. Has morals like mine-has morals unlike mine 135. Looks similar to me-looks different from me 136. Has the same body size as I do-is a different body size than I am"", 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}, {'PrimaryOutcomeMeasure': 'Interpersonal Distance', 'PrimaryOutcomeDescription': 'Interpersonal Distance (Bailenson, Blascovich, Beall, & Loomis, 2003) Please indicate how strongly you agree or disagree with the following statements (5=strongly agree; 1=strongly disagree).\n\n137. I perceive that I am in the presence of Alex in the room with me. 138. I feel that Alex is aware of my presence. 139. The thought that Alex is not a real person crosses my mind often. 140. I perceive Alex as being only a computerized image, not as a real person.', 'PrimaryOutcomeTimeFrame': 'immediately after the intervention'}]",,"Inclusion Criteria:

reside within the United States but outside of Florida
speak English
are of either black or white racial background.
are out-of-guidelines for colorectal cancer screening (>10 years for colonoscopy, >3 years for Cologuard, > 1 year for fecal immunochemical test)

Exclusion Criteria:

does not meet the above criteria",Accepts Healthy Volunteers,All,50 Years,73 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Florida', 'LocationCity': 'Gainesville', 'LocationState': 'Florida', 'LocationZip': '32611', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]",Yes,"The primary goal of the study is to reduce colorectal cancer (CRC) morbidity and mortality by increasing CRC screening rates among the at-risk patient community and to reduce racial and geographic (rural vs. urban) disparities in CRC screening and mortality rates. To accomplish this long-term goal, this study aims to develop and test precision messaging tailored to target audiences through development and evaluation of culturally sensitive, interactive messages about CRC screening delivered using VHT. The study will investigate whether interactive, tailored messages contribute to an overall enhancement of knowledge of CRC and screening options by eliciting positive attitudes and behaviors toward FIT screening.

To date, there is no other study that has looked to partner specific message strategies and colorectal cancer screening with an emphasis on racial concordance and modality. As such, the researchers hope to shed new light on how, as health communicators, to more successfully engage target audiences to change attitudes and/or behaviors towards getting screened for colorectal cancer.",,,,,,,"[{'SecondaryId': '5R01CA207689-02', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=5R01CA207689-02&Fy=all'}, {'SecondaryId': 'OCR19177', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'UF OnCore'}]",,,,,['Participant'],,"[{'OverallOfficialName': 'Janice Krieger, PhD', 'OverallOfficialAffiliation': 'University of Florida', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,,,,,,,,,,,,,,,,,"The study design will be a fractional factorial design for delivering a CRC intervention. Patients will either see a racially concordant virtual human message, a racially discordant virtual human message, a racially concordant text-based message, a racially discordant text-based message, or an attention control message.",,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012004', 'ConditionMeshTerm': 'Rectal Neoplasms'}]","[{'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}, {'ConditionAncestorId': 'D000012002', 'ConditionAncestorTerm': 'Rectal Diseases'}]","[{'ConditionBrowseLeafId': 'M13429', 'ConditionBrowseLeafName': 'Rectal Neoplasms', 'ConditionBrowseLeafAsFound': 'Rectal Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16473', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9031', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7469', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5839', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9027', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13427', 'ConditionBrowseLeafName': 'Rectal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'T120', 'InterventionBrowseLeafName': 'Cola', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04004260,R21DC017214,Lamar University,OTHER,CBT-based Internet Intervention for Adults With Tinnitus in the United States,Cognitive Behavior Therapy Based Self-help Delivered Via the Internet for Tinnitus Sufferers: Efficacy Trial in the U.S. Population,Apr-20,"Active, not recruiting",No,01-Mar-20,Actual,31-Aug-21,Anticipated,31-Aug-21,Anticipated,26-Jun-19,27-Jun-19,02-Jul-19,Actual,31-Aug-20,01-Sep-20,Actual,Principal Investigator,Lamar University,OTHER,No,No,,,"Nearly 50 million people in the U.S. experience tinnitus, of which about 20 million people have burdensome chronic tinnitus. Tinnitus can be very debilitating as many aspects of daily life can be affected, such as sleep, mood, and concentration. Currently, there is no cure for tinnitus. Pharmacological or sound-therapy based interventions are sometimes provided, but may be of limited value to certain individuals. Research suggests that Cognitive Behavior Therapy (CBT) based approaches have the most evidence of effectiveness in the management of tinnitus. However, CBT is rarely offered in the U.S. (less than 1%), partly attributed to a lack of trained professionals who can deliver CBT. To improve access to CBT for tinnitus, and online CBT program has been developed. The purpose of this study is to determine the feasibility and efficacy of a CBT Internet-based intervention for adults with tinnitus in the United States.",['Tinnitus'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),158,Actual,"[{'ArmGroupLabel': 'Experimental group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The intervention offered is a guided Internet-based CBT intervention. The intervention is similar to a self-help program, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is a 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice the techniques learned.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Internet-based Cognitive Behavior Therapy']}}, {'ArmGroupLabel': 'Weekly check-in control group', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'The weekly check-in control group will be monitored weekly by means of the Tinnitus Handicap Inventory-Screening version (THI-S) and the Tinnitus Qualities Questionnaire (TQQ). Once the experimental group completes the ICBT intervention, the control group undertake the same ICBT intervention.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Internet-based Cognitive Behavior Therapy']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Internet-based Cognitive Behavior Therapy', 'InterventionDescription': 'The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Experimental group', 'Weekly check-in control group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['ICBT']}}]","[{'PrimaryOutcomeMeasure': 'Change in Tinnitus Functional Index (TFI)', 'PrimaryOutcomeDescription': 'The TFI is a 25-item questionnaire that evaluates treatment responsiveness (i.e., changes in functional effects of tinnitus over time). Total possible score ranges from 0-to-100 (scores >25 indicate tinnitus is a significant problem).', 'PrimaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}]","[{'SecondaryOutcomeMeasure': 'Change in Tinnitus and Hearing Survey (THS)', 'SecondaryOutcomeDescription': ""THS is a 10-item questionnaire that helps in determining how much of a patient's complaint about tinnitus is due to a hearing problem and how much is due specifically to the tinnitus. THS has three sections/subscales (A, B, and C). Section A consists of four items that address common tinnitus problems. Section B contains four items that address hearing. Section C, which includes two items, which focus on sound tolerance problem and ability to participate in group therapy. Responses for each item can range from 0 (not a problem) to 4 (very big problem). The total THS score can range from 0 to 40 (sections A and B range 0 to 16 and section C range from 0 to 8)."", 'SecondaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}, {'SecondaryOutcomeMeasure': 'Change in Tinnitus Cognition Questionnaire (TCQ)', 'SecondaryOutcomeDescription': 'TCQ is a 26-item questionnaire that assesses positive and negative cognitions associated with tinnitus. The first 13 items refer to negative thoughts and the second 13 items refer to positive thoughts. Responses are marked on a five-point Likert scale (0 to 4). The negative items (1-13) are scored 0-4, whereas the positive items (14-26) are reverse-scored: 4-0. The scoring procedure involves the simple addition of the number circled by the respondent for items 1-13 and the addition of reverse-scored items 14-26. The total score of the TCQ has a potential range from 0 to 104. A high score represents a greater tendency to engage in negative cognitions in response to tinnitus and low engagement in positive cognitions.', 'SecondaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}, {'SecondaryOutcomeMeasure': 'Change in Patient Health Questionnaire (PHQ-9)', 'SecondaryOutcomeDescription': 'PHQ-9 is a 9-item questionnaire that assesses depression severity. Responses are marked on a four-point Likert scale (0 to 3). The total score can range from 0 to 27 with higher scores indicating more severe depression.', 'SecondaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}, {'SecondaryOutcomeMeasure': 'Change in Generalized Anxiety Disorder (GAD-7)', 'SecondaryOutcomeDescription': 'GAD-7 is a 7-item questionnaire that assesses the severity of anxiety. Responses are marked on a four-point Likert scale (0 to 3). The total score can range from 0 to 21 with higher scores indicating more severe anxiety.', 'SecondaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}, {'SecondaryOutcomeMeasure': 'Change in Insomnia Severity Index (ISI)', 'SecondaryOutcomeDescription': 'ISI is a 7-item questionnaire that evaluates insomnia. Responses are marked on a five-point Likert scale (0 to 4). The total score can range from 0 to 28 with higher scores indicating more severe insomnia.', 'SecondaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}, {'SecondaryOutcomeMeasure': 'Change in EuroQol EQ-5D-5L', 'SecondaryOutcomeDescription': ""EQ-5D-5L is a 5-item questionnaire that evaluates health-related quality of life. Responses are marked on a five-point scale: no problems (Level 1); slight; moderate; severe; and extreme problems (Level 5). The total score can range from 0 to 28 with higher scores indicating more severe insomnia. Possible health states is defined by combining one level from each dimension, ranging from 11111 (full health) to 55555 (worst health). EQ-5D-5L health states are converted into a single index 'utility' score using a scoring algorithm based on public preferences."", 'SecondaryOutcomeTimeFrame': '8 weeks [Baseline; 2 month (last treatment session)]'}]","Inclusion Criteria:

aged 18 years and older living in the State of Texas, USA;
the ability to read and type in English or Spanish;
no barriers to using a computer (e.g. no significant fine motor control or visual problems);
Internet and e-mail access and the ability to use it;
commitment to completing the program;
completion of the online screening and outcome questionnaires;
agreeing to participate in either group and be randomized to one of these groups;
understanding and working towards the end goal of reducing the impact and distress of tinnitus, although the strength of the tinnitus may remain the same;
be available for 12 months after starting the study to complete a 1-year follow-up questionnaire;
suffering with experiencing tinnitus for a minimum period of 3 months; and
tinnitus outcome measure scores indicating the need for tinnitus care [25 or above on the Tinnitus Functional Index (TFI)].

Exclusion Criteria:

reporting any major medical or psychiatric conditions;
reporting pulsatile, objective or unilateral tinnitus, which has not been investigated medically;
tinnitus as a consequence of a medical disorder, still under investigation; and
undergoing any other tinnitus therapy while participating in this study.",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Lamar University', 'LocationCity': 'Beaumont', 'LocationState': 'Texas', 'LocationZip': '77705', 'LocationCountry': 'United States'}]",,Yes,"Objective: This study aims to determine the feasibility and efficacy of an Internet-based Cognitive Behavior Therapy (ICBT) in reducing the impact associated with tinnitus in the United States.

Hypothesis: It is hypothesized that ICBT will result in reduced tinnitus-related distress, decreased sleep disturbance, decreased anxiety and depression, and improved health-related quality of life in a treatment group as compared with adults in the weekly check-in control-group in the U.S. population. The investigators also hypothesize that these results will be stable in both short- and long-term post-intervention.

Design: A two-armed Randomized Control Trial (RCT), with a one-year follow-up design will be used to evaluate the efficacy of ICBT on tinnitus distress.

Setting: This will be an Internet-based study for adults with tinnitus living in the State of Texas, USA.

Participants: Eligible participants will include adults with tinnitus for a minimum period of 3 months with internet access and no major medical or psychiatric conditions. 80 participants will be recruited for each group and will be randomly assigned using a computer-generated randomization schedule by an independent research assistant after being pre-stratified for language and tinnitus severity.

Intervention: The intervention offered is a guided CTB-based internet intervention (ICBT), providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8-week long e-learning intervention, with new modules introduced weekly and assignments are given to practice techniques learned.

Outcome measures: The main outcome measure is the Tinnitus Functional Index (TFI). Secondary outcome measures are the Tinnitus and Hearing Survey (THS), Tinnitus Cognition Questionnaire (TCQ), Patient Health Questionnaire (PHQ-9), Generalized Anxiety Disorder (GAD-7), Insomnia Severity Index (ISI), and EuroQol EQ-5D-5L.",,,,,,,,,Vinaya Manchaiah,Jo Mayo Endowed Professor,Lamar University,,,"[{'OverallOfficialName': 'Vinaya Manchaiah, PhD', 'OverallOfficialAffiliation': 'Lamar University', 'OverallOfficialRole': 'Principal Investigator'}]",Yes,"[{'ReferencePMID': '29095725', 'ReferenceType': 'background', 'ReferenceCitation': 'Beukes EW, Baguley DM, Allen PM, Manchaiah V, Andersson G. Audiologist-Guided Internet-Based Cognitive Behavior Therapy for Adults With Tinnitus in the United Kingdom: A Randomized Controlled Trial. Ear Hear. 2018 May/Jun;39(3):423-433. doi: 10.1097/AUD.0000000000000505.'}, {'ReferencePMID': '30286238', 'ReferenceType': 'background', 'ReferenceCitation': 'Beukes EW, Andersson G, Allen PM, Manchaiah V, Baguley DM. Effectiveness of Guided Internet-Based Cognitive Behavioral Therapy vs Face-to-Face Clinical Care for Treatment of Tinnitus: A Randomized Clinical Trial. JAMA Otolaryngol Head Neck Surg. 2018 Dec 1;144(12):1126-1133. doi: 10.1001/jamaoto.2018.2238.'}, {'ReferencePMID': '30452747', 'ReferenceType': 'background', 'ReferenceCitation': 'Beukes EW, Allen PM, Baguley DM, Manchaiah V, Andersson G. Long-Term Efficacy of Audiologist-Guided Internet-Based Cognitive Behavior Therapy for Tinnitus. Am J Audiol. 2018 Nov 19;27(3S):431-447. doi: 10.1044/2018_AJA-IMIA3-18-0004.'}, {'ReferencePMID': '31328660', 'ReferenceType': 'background', 'ReferenceCitation': 'Beukes EW, Manchaiah V, Allen PM, Baguley DM, Andersson G. Internet-Based Interventions for Adults With Hearing Loss, Tinnitus, and Vestibular Disorders: A Systematic Review and Meta-Analysis. Trends Hear. 2019 Jan-Dec;23:2331216519851749. doi: 10.1177/2331216519851749.'}, {'ReferencePMID': '32105512', 'ReferenceType': 'background', 'ReferenceCitation': 'Beukes EW, Fagelson M, Aronson EP, Munoz MF, Andersson G, Manchaiah V. Readability Following Cultural and Linguistic Adaptations of an Internet-Based Intervention for Tinnitus for Use in the United States. Am J Audiol. 2020 Jun 8;29(2):97-109. doi: 10.1044/2019_AJA-19-00014. Epub 2020 Feb 26.'}]",,,,,The de-identified individual participant data for all primary and secondary outcome measures will be made available,,,,,"[{'SeeAlsoLinkLabel': 'Study website', 'SeeAlsoLinkURL': 'http://www.tacklingtinnitus.org'}]",,,,,,,,,,,"The experimental group will initially undergo the ICBT intervention while the control group are monitored weekly. Once the experimental group has completed the intervention, the control group will undertake the ICBT intervention.",,U.S. NIH Grant/Contract,https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R21DC017214&Fy=all,"['Study Protocol', 'Statistical Analysis Plan (SAP)']",Data will be available within 1-year of the study completion.,Data access requests will be reviewed by the research team. Requestors will be required to sign a Data Access Agreement.,,,26-Oct-20,"[{'ConditionMeshId': 'D000014012', 'ConditionMeshTerm': 'Tinnitus'}]","[{'ConditionAncestorId': 'D000006311', 'ConditionAncestorTerm': 'Hearing Disorders'}, {'ConditionAncestorId': 'D000004427', 'ConditionAncestorTerm': 'Ear Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}, {'ConditionAncestorId': 'D000012678', 'ConditionAncestorTerm': 'Sensation Disorders'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]","[{'ConditionBrowseLeafId': 'M15352', 'ConditionBrowseLeafName': 'Tinnitus', 'ConditionBrowseLeafAsFound': 'Tinnitus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7983', 'ConditionBrowseLeafName': 'Hearing Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6184', 'ConditionBrowseLeafName': 'Ear Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11544', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14073', 'ConditionBrowseLeafName': 'Sensation Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04205877,The U.S. PDA Registry,Le Bonheur Children's Hospital,OTHER,The U.S. PDA Registry,The United States Patent Ductus Arteriosus Registry,Dec-19,Not yet recruiting,No,01-Jan-20,Anticipated,01-Jan-30,Anticipated,01-Dec-31,Anticipated,16-Dec-19,17-Dec-19,20-Dec-19,Actual,17-Dec-19,20-Dec-19,Actual,Principal Investigator,Le Bonheur Children's Hospital,OTHER,No,Yes,,No,The objective of this study is to demonstrate the continued safety and efficacy in a real-world setting of transcatheter device closure of the PDA in premature infants less than 2kg in weight at the time of device implant using the Amplatzer Piccolo Occluder device and other devices performed in the USA.,"['Ductus Arteriosus, Patent']",Observational,,,,,,5000,Anticipated,"[{'ArmGroupLabel': 'Registry Group', 'ArmGroupDescription': 'All participants will have the same data collected at the same time points.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Transcatheter PDA Closure']}}]","[{'InterventionType': 'Device', 'InterventionName': 'Transcatheter PDA Closure', 'InterventionDescription': 'Device utilized for closure of PDA, study is to help assure continued safety and effectiveness of FDA approved Amplatzer Piccolo Occluder device as well as other devices used off label for PDA closure in premature infants less than 2 kg at the time of device implant.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Registry Group']}}]","[{'PrimaryOutcomeMeasure': 'Vascular Access Complications (Safety)', 'PrimaryOutcomeDescription': 'Access vessel complications include femoral arterial or femoral/jugular venous complications noted during the procedure, immediately after the procedure or delayed (>24 hours). They range from bleeding from access sites, arterial or venous thrombosis with or without the need for treatment to loss of limb secondary to arterial occlusion.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Valvular Injury (Safety)', 'PrimaryOutcomeDescription': 'Valvular injury includes damage to the tricuspid valve or other cardiac valve resulting in immediate post-procedural valvular dysfunction.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Device Embolization (Safety)', 'PrimaryOutcomeDescription': 'Device embolization includes malposition of the device either during or after the procedure or delayed (>24 hours). The outcome of device embolization ranges from observation, transcatheter retrieval at time of procedure or at a separate time, surgical retrieval, other end organ damage, to mortality.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Pulmonary or Aortic Vessel Stenosis (Safety)', 'PrimaryOutcomeDescription': 'Adjacent vessel stenosis includes a narrowing of the aorta or the left pulmonary artery directly as a consequence of device implantation for PDA closure. Vessel stenosis could happen either during or after the procedure or delayed (>24 hours). The outcome of vessel stenosis ranges from no intervention needed to repeated transcatheter and surgical therapies.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Rate of Effective PDA Closure (Effectiveness)', 'PrimaryOutcomeDescription': 'The effectiveness endpoint is the rate of effective closure of the PDA using a transcatheter device within six months post procedure. If more than one attempt is required, or multiple devices are required during the same procedure, it is still considered effective if there is Grade 0 or Grade 1 shunt, as defined below, at follow-up by transthoracic echocardiography or if a second procedure is not required following the initial attempt. If there is device embolization, adjacent vessel stenosis that required retrieval of the device and replacement during the same procedure with less than Grade 1 shunt during follow-up, it is still considered effective. Conversely, if an AE is noted after the procedure that requires a second procedure for treatment that results in greater than Grade 1 shunt, then the procedure is considered not effective, even if the initial attempt was effective. See protocol for PDA shunt definitions.', 'PrimaryOutcomeTimeFrame': '6 months'}]","[{'SecondaryOutcomeMeasure': 'Significant obstruction of the left pulmonary artery', 'SecondaryOutcomeDescription': 'Significant obstruction of the left pulmonary artery is defined as less than 30% flow to the left lung by lung perfusion scan or a peak instantaneous gradient in left pulmonary artery\n\n≥35 mmHg by echocardiogram if lung perfusion scan is not available or as determined by the interventional cardiologist based on angiographic appearance.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Significant obstruction of the aorta', 'SecondaryOutcomeDescription': 'Significant obstruction of the aorta is defined as a gradient of ≥20 mmHg in the aortic isthmus by invasive aortic catheterization or a mean gradient ≥20 mmHg in the aortic isthmus by echocardiogram if invasive aortic catheterization is not available.', 'SecondaryOutcomeTimeFrame': '6 months'}]","Inclusion Criteria:

Diagnosis of PDA.
Clinical indication for transcatheter PDA closure (discretion of the physician).
Weight <2 kg at the time of device implant.

Exclusion Criteria:

Weight <700 gm or greater than or equal to 2 kg at the time of device implant.
Age < 3 days at the time of device implant.
Pre-existing coarctation of the aorta.
Pre-existing left pulmonary artery stenosis.
Cardiac output that is dependent on right to left shunt through the PDA due to pulmonary hypertension.
Intracardiac thrombus that interferes with device implant.
Active infection requiring treatment at the time of impant.",,All,,1 Year,['Child'],"[{'LocationFacility': ""LeBonheur Children's Hospital"", 'LocationCity': 'Memphis', 'LocationState': 'Tennessee', 'LocationZip': '38103', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shyam K Sathanandam, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '901-287-6380', 'LocationContactEMail': 'ssathan@uthsc.edu'}, {'LocationContactName': 'Jorden Cunningham, BSN', 'LocationContactRole': 'Contact', 'LocationContactPhone': '901-287-7457', 'LocationContactEMail': 'jorden.cunningham@lebonheur.org'}]}}]","[{'CollaboratorName': 'Abbott', 'CollaboratorClass': 'INDUSTRY'}]",No,"Based on the IMPACT registry, there are over 6000 transcatheter device closures of PDA that occurs in the United States annually. However, there are no comprehensive data collection tools for this procedure. The current databases do not include multiple data points, or follow-up data, or a section for specific adverse events to be documented. Moreover, until now, there has been no approved devices for PDA closure in children < 2kg. This clinical study is the first of its kind to collect data from all transcatheter device closure of PDA in children < 2kg performed in the USA.This study will be limited to children between 700 to 2000 grams who are the most vulnerable population undergoing this procedure. This will allow us to understand the real world experience (efficacy and safety) of using the Amplatzer Piccolo Occluder and other devices in an extremely vulnerable, yet highly underserved population. The study will allow for standardization of this procedure throughout the country for the small children (<2 kg) with a PDA. This is a multi-center, single arm, observational data collection study. This will be a large population study to help analyze outcomes in subjects <2 kg. The trial has two primary endpoints for safety and effectiveness without formal hypothesis. The safety and effectiveness results will be compared with data reported in the ADO II AS IDE and Continued Access Protocol studies.",,No,['Case-Only'],['Other'],"The study population is patients with diagnosis of PDA with clinical indication for transcatheter PDA closure, and weigh less than 2 kg at the time of device implant.",Non-Probability Sample,,,"Shyam K. Sathanandam, MD","Associate Professor of Pediatrics, University of Tennessee. Director of Cath Lab, Le Bonheur Children's Hospital.",Le Bonheur Children's Hospital,,,"[{'OverallOfficialName': 'Shyam Sathanandam, MD', 'OverallOfficialAffiliation': 'National Principal Investigator', 'OverallOfficialRole': 'Principal Investigator'}]",Yes,"[{'ReferencePMID': '25822689', 'ReferenceType': 'result', 'ReferenceCitation': 'Tashiro J, Perez EA, Sola JE. Reduced Hospital Mortality With Surgical Ligation of Patent Ductus Arteriosus in Premature, Extremely Low Birth Weight Infants: A Propensity Score-matched Outcome Study. Ann Surg. 2016 Mar;263(3):608-14. doi: 10.1097/SLA.0000000000001228.'}, {'ReferencePMID': '22414886', 'ReferenceType': 'result', 'ReferenceCitation': 'Schneider DJ. The patent ductus arteriosus in term infants, children, and adults. Semin Perinatol. 2012 Apr;36(2):146-53. doi: 10.1053/j.semperi.2011.09.025. Review.'}, {'ReferencePMID': '4031274', 'ReferenceType': 'result', 'ReferenceCitation': 'Mahoney LT, Coryell KG, Lauer RM. The newborn transitional circulation: a two-dimensional Doppler echocardiographic study. J Am Coll Cardiol. 1985 Sep;6(3):623-9.'}, {'ReferencePMID': '26525611', 'ReferenceType': 'result', 'ReferenceCitation': 'Philip R, Waller BR 3rd, Agrawal V, Wright D, Arevalo A, Zurakowski D, Sathanandam S. Morphologic characterization of the patent ductus arteriosus in the premature infant and the choice of transcatheter occlusion device. Catheter Cardiovasc Interv. 2016 Feb 1;87(2):310-7. doi: 10.1002/ccd.26287. Epub 2015 Nov 3.'}, {'ReferencePMID': '2929450', 'ReferenceType': 'result', 'ReferenceCitation': 'Krichenko A, Benson LN, Burrows P, Möes CA, McLaughlin P, Freedom RM. Angiographic classification of the isolated, persistently patent ductus arteriosus and implications for percutaneous catheter occlusion. Am J Cardiol. 1989 Apr 1;63(12):877-80.'}, {'ReferencePMID': '16681450', 'ReferenceType': 'result', 'ReferenceCitation': 'Pass RH. Amplatzer Duct Occluder device: a new technology for the closure of the moderate-to-large-sized patent ductus arteriosus. Expert Rev Med Devices. 2006 May;3(3):291-6.'}, {'ReferencePMID': '15619281', 'ReferenceType': 'result', 'ReferenceCitation': 'Moore JW, Levi DS, Moore SD, Schneider DJ, Berdjis F. Interventional treatment of patent ductus arteriosus in 2004. Catheter Cardiovasc Interv. 2005 Jan;64(1):91-101. Review.'}, {'ReferenceType': 'result', 'ReferenceCitation': 'Perlo f, Joseph K.The Clinical Recognition of Congenital Heart Disease. Philadelphia: Saunders. Print.'}, {'ReferencePMID': '6363741', 'ReferenceType': 'result', 'ReferenceCitation': 'Gross RE, Hubbard JP. Landmark article Feb 25, 1939: Surgical ligation of a patent ductus arteriosus. Report of first successful case. By Robert E. Gross and John P. Hubbard. JAMA. 1984 Mar 2;251(9):1201-2.'}, {'ReferencePMID': '17307535', 'ReferenceType': 'result', 'ReferenceCitation': 'Kabra NS, Schmidt B, Roberts RS, Doyle LW, Papile L, Fanaroff A; Trial of Indomethacin Prophylaxis in Preterms Investigators. Neurosensory impairment after surgical closure of patent ductus arteriosus in extremely low birth weight infants: results from the Trial of Indomethacin Prophylaxis in Preterms. J Pediatr. 2007 Mar;150(3):229-34, 234.e1.'}, {'ReferencePMID': '17545385', 'ReferenceType': 'result', 'ReferenceCitation': 'Chorne N, Leonard C, Piecuch R, Clyman RI. Patent ductus arteriosus and its treatment as risk factors for neonatal and neurodevelopmental morbidity. Pediatrics. 2007 Jun;119(6):1165-74.'}, {'ReferencePMID': '18615091', 'ReferenceType': 'result', 'ReferenceCitation': 'Teixeira LS, Shivananda SP, Stephens D, Van Arsdell G, McNamara PJ. Postoperative cardiorespiratory instability following ligation of the preterm ductus arteriosus is related to early need for intervention. J Perinatol. 2008 Dec;28(12):803-10. doi: 10.1038/jp.2008.101. Epub 2008 Jul 10.'}, {'ReferencePMID': '4938290', 'ReferenceType': 'result', 'ReferenceCitation': 'Porstmann W, Wierny L, Warnke H, Gerstberger G, Romaniuk PA. Catheter closure of patent ductus arteriosus. 62 cases treated without thoracotomy. Radiol Clin North Am. 1971 Aug;9(2):203-18.'}, {'ReferencePMID': '25024972', 'ReferenceType': 'result', 'ReferenceCitation': 'Weisz DE, McNamara PJ. Patent ductus arteriosus ligation and adverse outcomes: causality or bias? J Clin Neonatol. 2014 Apr;3(2):67-75. doi: 10.4103/2249-4847.134670. Review.'}, {'ReferencePMID': '28258658', 'ReferenceType': 'result', 'ReferenceCitation': 'Gruenstein DH, Ebeid M, Radtke W, Moore P, Holzer R, Justino H. Transcatheter closure of patent ductus arteriosus using the AMPLATZER™ duct occluder II (ADO II). Catheter Cardiovasc Interv. 2017 May;89(6):1118-1128. doi: 10.1002/ccd.26968. Epub 2017 Mar 4.'}, {'ReferencePMID': '22718329', 'ReferenceType': 'result', 'ReferenceCitation': 'Kenny D, Morgan GJ, Bentham JR, Wilson N, Martin R, Tometzki A, Oslizlok P, Walsh KP. Early clinical experience with a modified Amplatzer ductal occluder for transcatheter arterial duct occlusion in infants and small children. Catheter Cardiovasc Interv. 2013 Oct 1;82(4):534-40. doi: 10.1002/ccd.24522. Epub 2013 Jun 29.'}, {'ReferencePMID': '23460349', 'ReferenceType': 'result', 'ReferenceCitation': 'Sungur M, Karakurt C, Ozbarlas N, Baspinar O. Closure of patent ductus arteriosus in children, small infants, and premature babies with Amplatzer duct occluder II additional sizes: multicenter study. Catheter Cardiovasc Interv. 2013 Aug 1;82(2):245-52. doi: 10.1002/ccd.24905. Epub 2013 Apr 8.'}, {'ReferencePMID': '24532416', 'ReferenceType': 'result', 'ReferenceCitation': 'Bruckheimer E, Godfrey M, Dagan T, Levinzon M, Amir G, Birk E. The Amplatzer Duct Occluder II Additional Sizes device for transcatheter PDA closure: initial experience. Catheter Cardiovasc Interv. 2014 Jun 1;83(7):1097-101. doi: 10.1002/ccd.25445. Epub 2014 Mar 4.'}, {'ReferencePMID': '25832591', 'ReferenceType': 'result', 'ReferenceCitation': 'Baspinar O, Sahin DA, Sulu A, Irdem A, Gokaslan G, Sivasli E, Kilinc M. Transcatheter closure of patent ductus arteriosus in under 6 kg and premature infants. J Interv Cardiol. 2015 Apr;28(2):180-9. doi: 10.1111/joic.12196. Epub 2015 Apr 2.'}]",,,,,"A Data Management Plan (DMP) will describe procedures used for data review, database cleaning, and issuing and resolving data queries. If appropriate, the DMP may be updated throughout the clinical investigation duration. All revisions will be tracked and document controlled. Subject data will be captured in a validated electronic data capture (EDC) system. Only authorized site personnel will be permitted to enter the CRF data through the EDC system. An electronic audit trail will be used to track any subsequent changes of the entered data.","[{'CentralContactName': 'Shyam K Sathanandam, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '901-287-6380', 'CentralContactEMail': 'ssathan@uthsc.edu'}, {'CentralContactName': 'Jorden Cunningham, BSN', 'CentralContactRole': 'Contact', 'CentralContactPhone': '901-287-7457', 'CentralContactEMail': 'jorden.cunningham@lebonheur.org'}]",,,,,,,,,,,,,,,,,,,"['Study Protocol', 'Clinical Study Report (CSR)']",Data will become available when it is collected and added to the national database. It will be available for 12 years.,"Investigators will submit proposal to request data to the Proposal Review Committee. If approved, de-identified data will be shared.",,,26-Oct-20,"[{'ConditionMeshId': 'D000004374', 'ConditionMeshTerm': 'Ductus Arteriosus, Patent'}]","[{'ConditionAncestorId': 'D000006330', 'ConditionAncestorTerm': 'Heart Defects, Congenital'}, {'ConditionAncestorId': 'D000018376', 'ConditionAncestorTerm': 'Cardiovascular Abnormalities'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000000013', 'ConditionAncestorTerm': 'Congenital Abnormalities'}]","[{'ConditionBrowseLeafId': 'M6131', 'ConditionBrowseLeafName': 'Ductus Arteriosus, Patent', 'ConditionBrowseLeafAsFound': 'Ductus Arteriosus, Patent', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8001', 'ConditionBrowseLeafName': 'Heart Defects, Congenital', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12', 'ConditionBrowseLeafName': 'Congenital Abnormalities', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19087', 'ConditionBrowseLeafName': 'Cardiovascular Abnormalities', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4461', 'ConditionBrowseLeafName': 'Patent Ductus Arteriosus', 'ConditionBrowseLeafAsFound': 'Ductus Arteriosus', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC16', 'ConditionBrowseBranchName': 'Diseases and Abnormalities at or Before Birth'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"[{'LargeDocTypeAbbrev': 'Prot', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol', 'LargeDocDate': 'October 18, 2018', 'LargeDocUploadDate': '12/12/2019 17:14', 'LargeDocFilename': 'Prot_000.pdf'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01262079,VRC 700,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.,Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.,Aug-11,Completed,No,Dec-10,,Jul-11,Actual,Aug-11,Actual,15-Dec-10,15-Dec-10,17-Dec-10,Estimate,11-Aug-11,15-Aug-11,Estimate,,National Institute of Allergy and Infectious Diseases (NIAID),NIH,,,,,"This is a specimen collection protocol designed with the purpose of understanding the immune responses to influenza in children and adult subjects through collection of blood specimens and influenza medical history data. This protocol will allow the investigators to evaluate influenza-specific immune responses to a variety of influenza strains in a broad age range of the U.S. population early and late in the 2010-2011 influenza season. Immune responses will be evaluated using blood samples. The underlying hypothesis for this protocol is that the detailed characterization of immune responses to influenza in subjects from different age groups will further the understanding of immune responses cross-reactivity and advance development of influenza vaccines that are cross-reactive against old, new and re-emerging influenza strains.",['Influenza'],Observational,,,,,,180,Anticipated,"[{'ArmGroupLabel': 'Group 1: 6-15 years old'}, {'ArmGroupLabel': 'Group 2: 16-25 years old'}, {'ArmGroupLabel': 'Group 3: 26-35 years old'}, {'ArmGroupLabel': 'Group 4: 36-45 years old'}, {'ArmGroupLabel': 'Group 5: 46-55 years old'}, {'ArmGroupLabel': 'Group 6: 56-65 years old'}, {'ArmGroupLabel': 'Group 7: 66-75 years old'}, {'ArmGroupLabel': 'Group 8: 76-85 years old'}, {'ArmGroupLabel': 'Group 9: > 85 years old'}]",,"[{'PrimaryOutcomeMeasure': 'Influenza-specific antibody responses', 'PrimaryOutcomeDescription': 'To evaluate antibody responses to a panel of influenza strains across a broad age range of the U.S. population early as compared to late in the 2010-2011 influenza season.', 'PrimaryOutcomeTimeFrame': '2010-2011 influenza season'}]","[{'SecondaryOutcomeMeasure': 'Influenza-specific T-cell responses', 'SecondaryOutcomeDescription': 'To evaluate influenza-specific T-cell responses to a panel of influenza strains across a broad age range of the U.S. population early as compared to late in the 2010-2011 influenza season.', 'SecondaryOutcomeTimeFrame': '2010-2011 influenza season'}]","Inclusion Criteria:

Children ages 6 through 17 years and adults 18 years of age or older
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process
Able and willing to complete the informed consent/assent process
Willing to donate blood for storage and for research, at least at three study visits
Willing to have genetic tests performed on stored blood for research purposes

Exclusion Criteria:

Known to be pregnant.
Medical, psychiatric, occupational or other condition that, in the judgment of the site investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent.
Bleeding disorder diagnosis or any contraindications to blood drawing as assessed by the site investigator
Immune system known to be compromised by HIV or other active infection, active cancer, or systemic immunosuppressive treatments.
Seasonal influenza vaccine within the 12 weeks prior to enrollment.
Another subject from the same household enrolled into the same age group.",Accepts Healthy Volunteers,All,6 Years,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Hope Clinic of the Emory Vaccine Center', 'LocationCity': 'Decatur', 'LocationState': 'Georgia', 'LocationZip': '30030', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Louis University - Doisy Research Center', 'LocationCity': 'St. Louis', 'LocationState': 'Missouri', 'LocationZip': '63104', 'LocationCountry': 'United States'}, {'LocationFacility': ""Cincinatti Children's Hospital Medical Center"", 'LocationCity': 'Cincinatti', 'LocationState': 'Ohio', 'LocationZip': '45229', 'LocationCountry': 'United States'}, {'LocationFacility': 'Baylor College of Medicine', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'The Emmes Company, LLC', 'CollaboratorClass': 'INDUSTRY'}]",No,,"['influenza', 'healthy volunteer', 'immunity', 'antibody', 'blood sample']",,['Cohort'],['Prospective'],Healthy participants ages 6 years and older who are available for 3 clinic study visits over approximately eight months. Participants must be willing and able to donate blood for storage and research. Females must not be or become pregnant during the study. Multiple subjects from the same household may not be enrolled into the same age group.,Probability Sample,"[{'SecondaryId': 'HHSN272201000049I', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Department of Health and Human Services'}]",,,,,,,"[{'OverallOfficialName': 'Barney S. Graham, M.D., Ph.D.', 'OverallOfficialAffiliation': 'Chief: Clinical Trials Core', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '16413916', 'ReferenceType': 'background', 'ReferenceCitation': 'Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity. 2006 Jan;24(1):5-9.'}, {'ReferencePMID': '20647428', 'ReferenceType': 'background', 'ReferenceCitation': 'Wei CJ, Boyington JC, McTamney PM, Kong WP, Pearce MB, Xu L, Andersen H, Rao S, Tumpey TM, Yang ZY, Nabel GJ. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science. 2010 Aug 27;329(5995):1060-4. doi: 10.1126/science.1192517. Epub 2010 Jul 15.'}, {'ReferencePMID': '19478718', 'ReferenceType': 'background', 'ReferenceCitation': 'Centers for Disease Control and Prevention (CDC). Serum cross-reactive antibody response to a novel influenza A (H1N1) virus after vaccination with seasonal influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009 May 22;58(19):521-4.'}]",,,,,,,,Samples With DNA,Serum Plasma PBMC Whole-blood,"[{'SeeAlsoLinkLabel': 'NIAID', 'SeeAlsoLinkURL': 'http://www.niaid.nih.gov/Volunteer/VRC/Pages/default.aspx'}]",,,,,,,"Vaccine Research Center, NIAID, NIH contact: Chief, Clinical Trials Core","Vaccine Research Center, NIAID, NIH",,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007251', 'ConditionMeshTerm': 'Influenza, Human'}]","[{'ConditionAncestorId': 'D000009976', 'ConditionAncestorTerm': 'Orthomyxoviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000012141', 'ConditionAncestorTerm': 'Respiratory Tract Infections'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]","[{'ConditionBrowseLeafId': 'M8878', 'ConditionBrowseLeafName': 'Influenza, Human', 'ConditionBrowseLeafAsFound': 'Influenza', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11485', 'ConditionBrowseLeafName': 'Orthomyxoviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13561', 'ConditionBrowseLeafName': 'Respiratory Tract Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M2806', 'InterventionBrowseLeafName': 'Antibodies', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8767', 'InterventionBrowseLeafName': 'Immunoglobulins', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00646438,USCDP,Providence Heart & Vascular Institute,OTHER,United States Coronary Artery Bypass Surgery (CABG) Diabetes Project (USCDP) Pilot Study,United States CABG Diabetes Project (USCDP) Pilot Study,Mar-08,Unknown status,No,Mar-09,,Feb-12,Anticipated,Dec-12,Anticipated,25-Mar-08,27-Mar-08,28-Mar-08,Estimate,03-Feb-09,04-Feb-09,Estimate,,Providence Heart & Vascular Institute,OTHER,,,,,"Standard care for patients with diabetes having CABG surgery at Providence St. Vincent Medical Center includes strict control of blood sugar (glucose) levels for 3 days after surgery. This is done through frequent monitoring of blood sugar levels and by giving insulin continuously through a needle into a vein (intravenously). This intensive glucose control has resulted in fewer complications such as serious infections and death, and has shortened the length of the hospital stay for patients.

This study treatment is different from standard treatment in that it extends the intensive glucose control beyond the third postoperative day to one full year. Once discharged from the hospital following the CABG procedure, the intense glucose control is done using subcutaneous insulin (a shot under the skin), oral medications, and by measuring blood sugar levels frequently.

The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year. Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.","['Diabetes', 'Coronary Artery Disease']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),120,Anticipated,"[{'ArmGroupLabel': '1', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'strict glucose control (study arm)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Strict Glycemic Control for one year post-op CABG']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'standard insulin treatment (control arm)'}]","[{'InterventionType': 'Drug', 'InterventionName': 'Strict Glycemic Control for one year post-op CABG', 'InterventionDescription': 'The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.\n\nPost-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.\n\nFor all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}, 'InterventionOtherNameList': {'InterventionOtherName': ['USCDP', 'Portlan Protocol']}}]","[{'PrimaryOutcomeMeasure': 'The purpose of this study is to see how safe and effective strict glucose control is when extended beyond 3 days and hospital discharge for one year.', 'PrimaryOutcomeTimeFrame': '3 years'}]","[{'SecondaryOutcomeMeasure': 'Another purpose is to see how well patients can comply with the daily management of intensive glucose control for one-year as well as the study follow-up schedule.', 'SecondaryOutcomeTimeFrame': '3 Years'}]","Inclusion Criteria:

Patients 18 - 80 years old
Pre-op diagnosis of diabetes
Scheduled for elective or urgent CABG surgery
Able to sign informed consent for research study

Exclusion Criteria:

Patients less than 18 years old or greater than 80 years old
Emergent or salvage CABG surgery
Other surgical intervention planned in same setting ( Valve surgery, TMR, MAZE...)",No,All,18 Years,80 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'Providence St. Vincent Medical Center', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97225', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Eric M. Johnson, BA/CCRC', 'LocationContactRole': 'Contact', 'LocationContactPhone': '503-216-2075', 'LocationContactEMail': 'eric.johnson@providence.org'}, {'LocationContactName': 'Tony Furnary, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '503-297-1419', 'LocationContactEMail': 'tfurnary@mac.com'}, {'LocationContactName': 'Anthony Furnary, MD', 'LocationContactRole': 'Principal Investigator'}]}}]","[{'CollaboratorName': 'Sanofi', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'LifeScan', 'CollaboratorClass': 'INDUSTRY'}]",No,"Purpose Pilot study to gather information for ""United States CABG Diabetes Project"" (USCDP) Multi-center Randomized Trial.

For 14 years our research team has successfully implemented an increasingly aggressive series of intravenous insulin protocols that normalize blood glucose levels for 3 postoperative days in patients with diabetes who undergo cardiac surgery. This has resulted in significant reductions in mortality, infection and length of stay (LOS) and has normalized those outcomes to those of the population without diabetes (DM). The current protocol ends on the morning of the 3rd postoperative day.

We believe that a logical expansion of this groundbreaking work is to extend the duration of intensive glycemic control beyond the third postoperative day and into the outpatient period. However it would be impossible to do so with the continued use of CII therapy. Therefore, we propose to employ intensive subcutaneous insulin therapies and oral hypoglycemic agents to affect continued tight glycemic control following discontinuation of CII and continue such therapy beyond hospital discharge for a period of at least one year.

We hypothesize that this will lead to further reductions in major adverse cardiac outcomes in the high-risk diabetes coronary artery bypass grafts (CABG) subgroup. The optimal method to test this hypothesis is with a very large, multi-center clinical trial. However, before embarking on such a resource-consuming endeavor, we intend to test the concepts, methods, implementation strategies, patient acceptability and compliance, proposed biomarkers and clinical outcomes of such a trial with this proposed limited pilot study.

If the information obtained from this pilot study is favorable, we will submit for full funding of the multicenter USCDP clinical trial to the NIDDK and NHLBI divisions of the NIH. In order to test all aspects of the proposed trial, we intend to randomize patients into this pilot study.","['Diabetes', 'CABG']",,,,,,,USCDP,,,,,,"[{'OverallOfficialName': 'Anthony Furnary, MD', 'OverallOfficialAffiliation': 'Providence Heart & Vascular Institute', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,"[{'CentralContactName': 'Eric M. Johnson, BA/CCRC', 'CentralContactRole': 'Contact', 'CentralContactPhone': '503-216-2075', 'CentralContactEMail': 'eric.johnson@providence.org'}, {'CentralContactName': 'Tony Furnary, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '503-297-1419', 'CentralContactEMail': 'tfurnary@mac.com'}]",,,,,,Not yet recruiting,,,,,"Anthony Furnary, MD / Principal Investigator",Providence Heart & Vascular Institute,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003324', 'ConditionMeshTerm': 'Coronary Artery Disease'}, {'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}]","[{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000003327', 'ConditionAncestorTerm': 'Coronary Disease'}, {'ConditionAncestorId': 'D000017202', 'ConditionAncestorTerm': 'Myocardial Ischemia'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000001161', 'ConditionAncestorTerm': 'Arteriosclerosis'}, {'ConditionAncestorId': 'D000001157', 'ConditionAncestorTerm': 'Arterial Occlusive Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}]","[{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5132', 'ConditionBrowseLeafName': 'Coronary Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5129', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafAsFound': 'Coronary Artery Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M18089', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23990', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9126', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3050', 'ConditionBrowseLeafName': 'Arteriosclerosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3046', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]",,,"[{'InterventionBrowseLeafId': 'M8948', 'InterventionBrowseLeafName': 'Insulin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M178017', 'InterventionBrowseLeafName': 'Insulin, Globin Zinc', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Hypo', 'InterventionBrowseBranchName': 'Hypoglycemic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00341588,999902113,National Institutes of Health Clinical Center (CC),NIH,A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen,A Case-Control Study of Testicular Germ Cell Tumors Among U.S. Military Servicemen,Aug-20,Completed,No,18-Jan-02,Actual,01-Oct-08,Actual,18-Aug-20,Actual,19-Jun-06,19-Jun-06,21-Jun-06,Estimate,19-Aug-20,21-Aug-20,Actual,Sponsor,National Cancer Institute (NCI),NIH,,,,,"The incidence of testicular germ cell tumors (TGCT) has increased during the twentieth century and is of particular concern as it primarily affects young men. It is the most common cancer among U.S. males ages 25-34. The only well-described risk factors are cryptorchism (undescended testis), family history of TGCT, and personal history of TGCT. To better understand the environmental and genetic determinants of TGCT risk, a case-control study will be conducted among members of the U.S. armed forces. The study will include men who have donated a blood sample to the Department of Defense Serum Repository (DoDSR) between 1989 and 2000. All DoDSR donors who have developed GCT will be matched to DoDSR donors who have not developed TGCT. Approximately 1,080 men with TGCT, 1,080 controls, and 2,160 mothers will be included in the study.

The DoDSR serum sample will be tested for organochlorines levels, gonadotropin levels, and viral antibody titres. Each participant will donate a saliva specimen that will be used in an examination of genetic susceptibility. Each participant will also complete a questionnaire concerning a variety of possible risk factors such as physical activity, medical history, medication history, and other risk factors. The mothers of all participants will be invited to participate by completing a questionnaire concerning perinatal exposures and events and by donating a saliva sample.

The three main objectives of this study are to:

determine whether environmental endocrine modulators (i.e., chlorinated pesticides and polychlorinated biphenyls) are related to risk of GCT and, if so, whether their effects are augmented by other risk factors.
determine whether genetic susceptibility to GCT exists and to characterize the environmental risk factors related to that susceptibility.
determine whether there are distinct causes of GCT by relating the tissue structures of the tumors to the risk factors.",['Testicular Cancer'],Observational,,,,,,2772,Actual,"[{'ArmGroupLabel': 'Cases', 'ArmGroupDescription': 'Male U.S. serviceman, age 18-45 years old with TGCT'}, {'ArmGroupLabel': 'Controls', 'ArmGroupDescription': 'Male U.S. serviceman, age 18-45 years old without TGCT'}]",,"[{'PrimaryOutcomeMeasure': 'environmental and genetic determinants of TGCT risk', 'PrimaryOutcomeTimeFrame': '16 years'}]",,"INCLUSION CRITERIA:

The identification of men who have had a diagnosis of testicular germ cell tumor (TCGT) will be accomplished by the linking of databases maintained by the Department of Defense. Potential cases will be initially identified through the Defense Medical Surveillance System (DMSS).

Matched controls will be identified through the DMSS.

Criteria for Cases include:

Age between 17 and 45 years at time of confirmed TGCT diagnosis.

Age of at least 18 years at time of study enrollment.

The existence of a pre-diagnostic serum sample of 1mL or greater in the DoDSR.

On active duty at time of diagnosis.

Donated a serum sample to the DoDSR between the years 1989 and 2003.

Criteria for Control Identification:

Case subjects will be matched with case men on age, ethnicity, and date of serum donation to men in the DoDSR who have never had a diagnosis of TGCT (control men).

Criteria for Control Men include:

No previous diagnosis of TGCT.

Donated a serum sample to the DpDSR between the years 1989 and 2003.

Alive at study initiation.

On active duty at time of case's diagnosis.",No,Male,18 Years,120 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'National Cancer Institute (NCI), 9000 Rockville Pike', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20892', 'LocationCountry': 'United States'}]",,,"The incidence of testicular germ cell tumors (TGCT) has increased during the better part of the twentieth century and is of particular concern as it primarily affects young men. Though the tumor is relatively infrequent in the population as a whole, TGCT is the most common cancer among U.S. males in the age group 15-34 years. Despite the increases in TGCT rates, the etiology is still poorly understood. The only well described risk factors for TGCT are cryptorchism, family history of TGCT and personal history of TGCT. Therefore, in order to understand better the environmental and genetic determinants of TGCT risk, a case-control study will be conducted among members of the U.S. Armed Forces. The study will include men who have donated a blood sample to the Department of Defense Serum Repository (DoDSR) between the years 1989 and 2003. All DoDSR donors who have developed GCT will be matched to DoDSR donors who have not developed TGCT.

A total of 1682 servicemen were enrolled in the study; 754 cases and 928 controls. Of these participants, 1303 men (77%, 590 cases, 713 controls) donated buccal cell samples. In addition to the servicemen, a total of 1090 mothers of servicemen were enrolled and 952 (87%) provided a buccal specimen. The DoDSR serum samples have been assayed for levels of organochlorines pesticides, polychlorinated biphenyl congeners, insulin-like growth factors and gonadotropins and steroid hormones. DNA isolated from the buccal cell specimens have thus far been genotyped for polymorphysms in the hormone metabolism and immune function pathway, immune function pathway, insulin-like growth factor pathway and for single nucleotide polymorphisms in the 8q24 locus. In addition, a genome-wide association study has completed. Statistical analyses of the questionnaire data are continuing.","['Testicular Cancer', 'Epidemiology', 'Testicular Germ Cell Cancer', 'TGCT', 'Healthy Volunteer']",,['Case-Control'],['Retrospective'],"Male U.S. servicemen, age 18-45 years old, with atleast one serum sample stored in the DoD Serum Repository.",Non-Probability Sample,[{'SecondaryId': '02-C-N113'}],,,,,,,"[{'OverallOfficialName': 'Katherine A McGlynn, Ph.D.', 'OverallOfficialAffiliation': 'National Cancer Institute (NCI)', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000009373', 'ConditionMeshTerm': 'Neoplasms, Germ Cell and Embryonal'}, {'ConditionMeshId': 'D000013736', 'ConditionMeshTerm': 'Testicular Neoplasms'}]","[{'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004701', 'ConditionAncestorTerm': 'Endocrine Gland Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000013733', 'ConditionAncestorTerm': 'Testicular Diseases'}, {'ConditionAncestorId': 'D000006058', 'ConditionAncestorTerm': 'Gonadal Disorders'}]","[{'ConditionBrowseLeafId': 'M15089', 'ConditionBrowseLeafName': 'Testicular Neoplasms', 'ConditionBrowseLeafAsFound': 'Testicular Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10901', 'ConditionBrowseLeafName': 'Neoplasms, Germ Cell and Embryonal', 'ConditionBrowseLeafAsFound': 'Germ cell tumor', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10898', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6446', 'ConditionBrowseLeafName': 'Endocrine Gland Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7529', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15898', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15086', 'ConditionBrowseLeafName': 'Testicular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7746', 'ConditionBrowseLeafName': 'Gonadal Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2481', 'ConditionBrowseLeafName': 'Germ Cells Tumors', 'ConditionBrowseLeafAsFound': 'Germ cell tumor', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T5614', 'ConditionBrowseLeafName': 'Testicular Germ Cell Tumor', 'ConditionBrowseLeafAsFound': 'Testicular germ cell tumor', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04562636,20-2552,"University of North Carolina, Chapel Hill",OTHER,Evaluating a Messaging Campaign in the United States,Evaluating a Messaging Campaign in the United States,Sep-20,Completed,No,29-Sep-20,Actual,01-Oct-20,Actual,01-Oct-20,Actual,14-Sep-20,18-Sep-20,24-Sep-20,Actual,02-Oct-20,05-Oct-20,Actual,Sponsor,"University of North Carolina, Chapel Hill",OTHER,No,No,,,"Purpose: To evaluate reactions to and opinions of a messaging campaign.

Participants: Participants will be recruited through Prime Panels and will be US-based adults (18 years old and older) who consumed red meat in the past 30 days.

Procedures (methods): After completing a screening question about meat consumption, participants will review a consent form. If they select to participate in the study, participants will be randomly assigned to view control messages, red meat-related environment messages, or red meat-related health messages. They will be asked a series of questions about these messages.

Participants will also be asked about grocery shopping preferences and standard demographics questions.","['Obesity', 'Heart Diseases', 'Cancer']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Prevention,None (Open Label),1244,Actual,"[{'ArmGroupLabel': 'Environment-focused Meatless Monday messages', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Four environmental messages from the Meatless Monday campaign.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Environmental message']}}, {'ArmGroupLabel': 'Health-focused Meatless Monday messages', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Four health messages from the Meatless Monday campaign.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Health message']}}, {'ArmGroupLabel': 'Neutral Message', 'ArmGroupType': 'Other', 'ArmGroupDescription': ""Four neutral messages about checking one's credit score."", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Neutral Message']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Environmental message', 'InterventionDescription': 'Participants will be randomized to view a set of four messages about the environmental harms of meat production from the Meatless Monday campaign.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Environment-focused Meatless Monday messages']}}, {'InterventionType': 'Other', 'InterventionName': 'Health message', 'InterventionDescription': 'Participants will be randomized to view a set of four messages about the health harms of meat consumption from the Meatless Monday campaign.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Health-focused Meatless Monday messages']}}, {'InterventionType': 'Other', 'InterventionName': 'Neutral Message', 'InterventionDescription': 'Participants will be randomized to view a set of four messages about checking their credit score.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Neutral Message']}}]","[{'PrimaryOutcomeMeasure': 'Perceived Message Effectiveness (PME)', 'PrimaryOutcomeDescription': 'Perceived effectiveness of the messages will be measured during the message using 4 items adapted from Baig et al. (2018): concern, unpleasantness, and discouragement. The averaged responses on the 4 items will be used to create a PME score. All 4 items are measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.\n\nQuestions: How much do these messages...\n\nmake you concerned about the health effects of eating red meat?\nmake you concerned about the environmental effects of eating red meat?\ndiscourage you from wanting to eat red meat?\n\nmake eating red meat seem unpleasant to you?\n\nNot at all, 2=Very little, 3=Somewhat, 4=Quite a bit, 5=A great deal).', 'PrimaryOutcomeTimeFrame': '~10 minute computer survey immediately after seeing messages'}]","[{'SecondaryOutcomeMeasure': 'Attention', 'SecondaryOutcomeDescription': ""How much the message grabs one's attention. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct."", 'SecondaryOutcomeTimeFrame': '~10 minute computer survey immediately after seeing messages'}, {'SecondaryOutcomeMeasure': 'Negative affect', 'SecondaryOutcomeDescription': 'How much the messages make one feel scared. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'SecondaryOutcomeTimeFrame': '~10 minute computer survey immediately after seeing messages'}, {'SecondaryOutcomeMeasure': 'Cognitive elaboration', 'SecondaryOutcomeDescription': 'How much the messages make one think about the environmental/health harms caused by eating meat. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'SecondaryOutcomeTimeFrame': '~10 minute computer survey immediately after seeing messages'}, {'SecondaryOutcomeMeasure': 'Social interactions', 'SecondaryOutcomeDescription': 'How much one is likely to talk about the message with others in the next week. Measured using a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'SecondaryOutcomeTimeFrame': '~10 minute computer survey immediately after seeing messages'}, {'SecondaryOutcomeMeasure': 'Intention to reduce meat consumption', 'SecondaryOutcomeDescription': 'How much one intends to reduce red meat consumption in the next 30 days. Measured using a a 1 to 5 likert scale, with higher scores representing a higher amount of the construct.', 'SecondaryOutcomeTimeFrame': '~10 minute computer survey immediately after seeing messages'}]","Inclusion Criteria:

Be 18 years or older
Be able to read and speak English
Be able to take a computer survey in English
Currently reside in the United States
Consumed red meat in the past 30 days

Exclusion Criteria:

Non red-meat eater",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Carolina Population Center', 'LocationCity': 'Chapel Hill', 'LocationState': 'North Carolina', 'LocationZip': '27599', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Wellcome Trust', 'CollaboratorClass': 'OTHER'}]",No,"Excess consumption of red and processed meat is a growing problem, especially in the United States where meat is consumed more than three times the global average. Epidemiological evidence for the association between excess meat intake and negative health outcomes (such as cancer, cardiovascular disease, and type 2 diabetes) as well as negative environmental impacts (such as pollution, overuse of resources, and carbon emissions) indicates that reducing meat consumption should be particularly pertinent to researchers and other public health professionals.

The potential of using widespread communication campaigns, such as Meatless Monday, to reduce meat consumption by educating individuals on the associated health and environmental risks appears to be promising. However, the current literature is missing information regarding what types of messages are most effective (e.g. negative environmental messages vs. negative health messages). To address this knowledge gap, our study will collect quantitative data in measurable outcomes to understand effectiveness and comprehension of environmental messages and health messages to reduce meat consumption.

Setting: This is an online study using Qualtrics, so this research does not involve talking to human participants.

Recruitment: Participants will be recruited through Prime Panels, a survey research firm through which participants voluntarily sign up to participate in research studies.

Informed Consent: Participants will read a written consent document that includes information about the study's purpose, expectations, and possible risks and benefits. Participants will acknowledge that they have read and agreed to the terms by clicking forward.

Randomization: Participants will be randomly assigned to one of three groups: 1) control (about checking their credit score), 2) environment-focused Meatless Monday messages, or 3) health-focused Meatless Monday messages.

Assessment: Using an online platform (Qualtrics), participants will answer a screening question about red meat consumption. If they are eligible (consumption of red meat 1 time per week or more), they will proceed to the main study after reading and agreeing to the written consent form. Participants will then answer two questions about their belief in climate change. Participants will then view four messages in their ascribed conditions. After viewing all 4 messages, participants will answer a series of questions about the messages they viewed. Then, participants will answer a series of demographic questions. Participants will also answer questions about grocery shopping preferences.

Detailed description of the trial arms: This study is a three-armed between subjects' design. Participants will be randomized to view a set of four messages either about the environmental harms of meat production (intervention), the health harms of meat consumption (intervention), or about checking their credit score (control). The environmental and health harms messages were obtained from existing publicly available messages from the Meatless Monday campaign.","['Red meat', 'Processed meat', 'Sustainability', 'Meat reduction']",,,,,,"[{'SecondaryId': '14380', 'SecondaryIdType': 'Other Grant/Funding Number', 'SecondaryIdDomain': 'Wellcome Trust'}]",,,,,,,"[{'OverallOfficialName': 'Hannah Rayala', 'OverallOfficialAffiliation': 'University of North Carolina, Chapel Hill', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Lindsey Smith Taillie, PhD', 'OverallOfficialAffiliation': 'University of North Carolina, Chapel Hill', 'OverallOfficialRole': 'Study Chair'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006331', 'ConditionMeshTerm': 'Heart Diseases'}]","[{'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]","[{'ConditionBrowseLeafId': 'M11284', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafAsFound': 'Heart Disease', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,"[{'LargeDocTypeAbbrev': 'SAP', 'LargeDocHasProtocol': 'No', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Statistical Analysis Plan', 'LargeDocDate': 'September 25, 2020', 'LargeDocUploadDate': '09/25/2020 13:28', 'LargeDocFilename': 'SAP_000.pdf'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03924505,INOD,RTI International,OTHER,Preventing Opioid Overdose Mortality in the United States,Preventing Opioid Overdose Mortality in the United States,Sep-20,Recruiting,No,03-Sep-19,Actual,Sep-21,Anticipated,Sep-21,Anticipated,19-Apr-19,22-Apr-19,23-Apr-19,Actual,15-Sep-20,17-Sep-20,Actual,Sponsor,RTI International,OTHER,No,No,,,"This study aims to generate knowledge regarding the process of implementing naloxone within syringe service programs (SSPs), and to test whether external facilitation can improve implementation of naloxone within SSPs throughout the country. Together, these efforts can improve access to naloxone for people at high risk of overdose, thereby improving our nation's response to the opioid overdose epidemic.",['Opioid Overdose'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Prevention,None (Open Label),100,Anticipated,"[{'ArmGroupLabel': 'Implementation Manual and External Facilitation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'This arm will receive the naloxone intervention implementation manual and the External Facilitation (EF) intervention. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs. The EF intervention is a collaborative, organization-centered form of guiding to navigate barriers and leverage facilitators to advance an evidence-based intervention along the EPIS continuum. Guidance will be conducted by an External Facilitator.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Implementation Manual with External Facilitation Intervention']}}, {'ArmGroupLabel': 'Implementation Manual - only', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'This arm will receive the naloxone intervention implementation manual. The manual provides details for developing, implementing, and managing a naloxone intervention program within different types of organizations that serve people who use opioids, including SSPs.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Implementation Manual only']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Implementation Manual with External Facilitation Intervention', 'InterventionDescription': 'Participating organizations will receive the implementation manual and the external facilitation (EF) intervention. The manual provides instructions for organizations wanting to implement a high quality naloxone program. The EF will assist syringe service programs to integrate naloxone delivery within their organization. As part of these efforts, we will use a measurement framework to understand naloxone delivery within SSPs along the four phases of the implementation process-exploration, preparation, implementation and sustainment (EPIS).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Implementation Manual and External Facilitation']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Implementation Manual only', 'InterventionDescription': 'Participating organizations will receive the implementation manual.The manual provides instructions for organizations wanting to implement a high quality naloxone program.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Implementation Manual - only']}}]","[{'PrimaryOutcomeMeasure': 'Adoption of Best Practices', 'PrimaryOutcomeDescription': 'Number of Best Practices adopted by the SSP', 'PrimaryOutcomeTimeFrame': 'Baseline'}, {'PrimaryOutcomeMeasure': 'Adoption of Best Practices', 'PrimaryOutcomeDescription': 'Number of Best Practices adopted by the SSP', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Naloxone Coverage', 'PrimaryOutcomeDescription': 'Number of SSP participants receiving a dose of naloxone', 'PrimaryOutcomeTimeFrame': 'Baseline'}, {'PrimaryOutcomeMeasure': 'Naloxone Coverage', 'PrimaryOutcomeDescription': 'Number of SSP participants receiving a dose of naloxone', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Number of Naloxone Doses Distributed to SSP participants', 'PrimaryOutcomeDescription': 'Naloxone Dispensed', 'PrimaryOutcomeTimeFrame': 'Baseline'}, {'PrimaryOutcomeMeasure': 'Number of Naloxone Doses Distributed to SSP participants', 'PrimaryOutcomeDescription': 'Naloxone Dispensed', 'PrimaryOutcomeTimeFrame': '12 months'}]",,"Inclusion Criteria:

SSPs that participate in the on-line screening survey and fall into the implementation phase of the EPIS continuum will be recruited into the study.

Exclusion Criteria:

-",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'RTI International', 'LocationStatus': 'Recruiting', 'LocationCity': 'Berkeley', 'LocationState': 'California', 'LocationZip': '94704', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Barrot Lambdin, PhD, MPH', 'LocationContactRole': 'Contact', 'LocationContactPhone': '510-665-8254', 'LocationContactEMail': 'blambdin@rti.org'}, {'LocationContactName': 'Lynn D Wenger, MSW, MPH', 'LocationContactRole': 'Contact', 'LocationContactPhone': '510-665-8219', 'LocationContactEMail': 'lynndee@rti.org'}]}}]","[{'CollaboratorName': 'National Institute on Drug Abuse (NIDA)', 'CollaboratorClass': 'NIH'}]",No,"The purpose of this study is to understand and improve naloxone implementation within Syringe Service Programs (SSPs) to reduce opioid overdose mortality in the United States. To achieve this goal, we will implement an external facilitation intervention that has been shown to improve implementation in HIV service settings. The intervention will leverage a naloxone implementation expert who will work with SSP organizational directors to identify barriers to and facilitators of achieving naloxone implementation quality and maximizing reach. We propose to assess the effectiveness of external facilitation, compared to dissemination of an implementation manual, in a national sample of SSPs in a randomized controlled trial (RCT). Our proposed specific aims are as follows:

Aim 1: To characterize United States syringe service programs along the exploration, preparation, implementation and sustainment (EPIS) continuum for delivering naloxone.

Aim 2: To test the effectiveness of external facilitation + dissemination of the naloxone implementation manual, compared with dissemination of the naloxone implementation manual alone, to improve the advancement of naloxone along the EPIS continuum among United States syringe service programs.

Hypothesis. The dissemination and external facilitation arm will be more effective in advancing naloxone implementation along the EPIS continuum between baseline and 12-month follow-up, than the dissemination-only arm.

To achieve these aims, 425 SSPs that are registered with the North American Syringe Exchange Network (NASEN) and /or receive information from harm reduction related web-based forums (e.g., online discussion groups, newsletters and listservs)will be asked to participate in an on-line cross-sectional survey and will be sent a hyperlink to the initial screening survey. We will use the on-line survey results to characterize the SSPs along the exploration, preparation, implementation and sustainment (EPIS) continuum for delivering the naloxone intervention (AIM 1).

The on-line survey includes a set of questions designed to collect information to evaluate where the SSP falls along the EPIS continuum for naloxone delivery. SSPs in the Implementation (I) phase of the EPIS continuum (estimated n = 100) will be contacted by research staff and offered the opportunity to participate in the RCT. SSPs that are interested in participating in the RCT will be enrolled in the study. For those SSPs who agree to participate, study staff will confirm eligibility by reviewing and documenting responses to the screening survey.

Following informed consent procedures, the study staff will administer the baseline survey to the SSP representative. The baseline survey will include questions about programmatic capacity, organizational culture, potential for internal champion or leader, perceived need for naloxone distribution within their community, and community acceptance of peer naloxone distribution programming. The study staff will then randomize SSPs into one of the one of the two study arms: (1) dissemination of the implementation manual and external facilitation for 12 months (experimental arm; n=50) and (2) dissemination of the implementation manual only (control arm; n=50).

All SSPs enrolled in the RCT will be sent a copy of the naloxone implementation manual either via email, hyperlink or the U.S. postal service depending on the preference of the participant. Those SSPs in the experimental arm will be enrolled in the EF intervention during which they will work directly with an OC to advance naloxone delivery as far along the EPIS continuum as possible during a 12-month period. The intervention will be delivered via phone calls, web-enabled audio and screen-sharing technology, and site visits. The key activities of the EF intervention include, initial SSP engagement, knowledge enhancement, capacity assessment, information gathering, identification of barriers and facilitators, development of action plans and provision of feedback, identification of funding and linkage to resources, and training of SSP staff.

At the end of the 12-month intervention period, SSPs in both study arms will participate in a follow-up survey, conducted by study staff, to evaluate advancement of naloxone implementation along the EPIS continuum.","['Opioid Overdose Prevention', 'Naloxone Implementation', 'Implementation Science']",,,,,,"[{'SecondaryId': '1R01DA046867-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01DA046867-01&Fy=all'}]",,,,,,,"[{'OverallOfficialName': 'Barrot Lambdin, PhD, MPH', 'OverallOfficialAffiliation': 'RTI International', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,"[{'CentralContactName': 'Barrot Lambdin, PhD, MPH', 'CentralContactRole': 'Contact', 'CentralContactPhone': '510-665-8254', 'CentralContactEMail': 'blambdin@rti.org'}, {'CentralContactName': 'Lynn Wenger', 'CentralContactRole': 'Contact', 'CentralContactPhone': '510-665-8219', 'CentralContactEMail': 'lynndee@rti.org'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000062787', 'ConditionMeshTerm': 'Drug Overdose'}]","[{'ConditionAncestorId': 'D000019966', 'ConditionAncestorTerm': 'Substance-Related Disorders'}, {'ConditionAncestorId': 'D000064419', 'ConditionAncestorTerm': 'Chemically-Induced Disorders'}]","[{'ConditionBrowseLeafId': 'M28598', 'ConditionBrowseLeafName': 'Drug Overdose', 'ConditionBrowseLeafAsFound': 'Overdose', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20421', 'ConditionBrowseLeafName': 'Substance-Related Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28889', 'ConditionBrowseLeafName': 'Chemically-Induced Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC25', 'ConditionBrowseBranchName': 'Substance Related Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}]",,,"[{'InterventionBrowseLeafId': 'M2614', 'InterventionBrowseLeafName': 'Analgesics, Opioid', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M10804', 'InterventionBrowseLeafName': 'Naloxone', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}, {'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'NarcAntag', 'InterventionBrowseBranchName': 'Narcotic Antagonists'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02334462,150044,National Institutes of Health Clinical Center (CC),NIH,"Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali","Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali",22-Oct-18,Completed,No,07-Jan-15,,31-Mar-16,Actual,22-Oct-18,Actual,07-Jan-15,07-Jan-15,08-Jan-15,Estimate,10-Apr-19,11-Apr-19,Actual,Sponsor,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Yes,,,,"Background:

- Malaria is a severe infection caused by a parasite. People can get malaria if a mosquito that carries the parasite bites them. Malaria infection does not happen in the United States, but many people in Africa, Asia, and South America are at risk for it. Researchers want to test two vaccines that may help decrease malaria infection.

Objective:

- To see if two vaccines (Pfs25M-EPA/Alhydrogel and Pfs230DIM-EPA/Alhydrogel ) are safe in humans and cause an immune response that will prevent malaria parasites from correctly growing in the mosquito.

Eligibility:

- Healthy adults ages 18 50.

Design:

There are several groups in this study. Each group will receive a different dose of the vaccine and some groups will received both vaccines.
Vaccinations will be given on two days about 4 weeks apart.
Participants will receive each vaccine as an injection into the arm. Blood will be drawn on the day of vaccination.
In the 4 weeks after receiving a vaccination, participants will have at least 3 clinic visits and 1 phone contact. They will have at least 3 more visits and 3 phone contacts over the next 6 months.
At each visit, participants will be evaluated for side effects to the vaccine and any new health changes or problems. They will be asked how they are feeling and if they have taken any medicine. Blood and urine samples may be taken at the visit. More follow-up visits may be needed to follow up on changes or problems.",['Malaria'],Interventional,['Phase 1'],Randomized,Parallel Assignment,Prevention,Double,538,Actual,"[{'ArmGroupLabel': 'Group 1- Mali', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Arm A1 (N=5) to receive 16 micrograms Pfs25M on D0, D28 Arm A2 (N=50) to receive 47 micrograms Pfs25M and Normal Saline on D0, D28, D168, D530', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Pfs25M-EPA/Alhydrogel']}}, {'ArmGroupLabel': 'Group 1-U.S', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Arm 1a (N=5) to receive 16 micrograms Pfs25M on D0, D28. Arm 1b (N=5) to receive 47 micrograms Pfs25M on D0, D28.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Pfs25M-EPA/Alhydrogel']}}, {'ArmGroupLabel': 'Group 2- Mali', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Arm B1 (N=5) to receive 15 micrograms Pfs230D1M on D0, D28 Pfs230D1M-EPA/Alhydrogel Arm B2 (N=50) to receive 40 micrograms Pfs230D1M and Normal Saline on D0, D28, D168, D530', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Pfs230D1M-EPA/Alhydrogel']}}, {'ArmGroupLabel': 'Group 2-U.S', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Arm 2a (N=5) to receive 5 micrograms Pfs230D1M on D0, D28.Arm 2b (N=5) to receive 15 micrograms Pgs230D1M on D0, D28. Arm 2c (N=5) to receive 40 micrograms Pfs230D1M on D0, D28.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Pfs230D1M-EPA/Alhydrogel']}}, {'ArmGroupLabel': 'Group 3- Mali', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Arm C1 (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28Arm C2 (N=50) to receive 47 micrograms Pfs25M and 40 microgramsPfs230D1M on D0, D28, D168, D530', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel']}}, {'ArmGroupLabel': 'Group 3- U.S.', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Arm 3a (N=5) to receive 16 micrograms Pfs25M and 15 micrograms Pfs230D1M on D0, D28. Arm 3b (N=5) to receive 47 micrograms Pfs25M and 40 micrograms Pfs230D1M on D0, D28.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Pfs230D1M-EPA/Alhydrogel', 'Biological: Pfs25M-EPA/Alhydrogel']}}, {'ArmGroupLabel': 'Group 4- Mali', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Arm D1 (N=5) to receive TWINRIX on D0, D28Arm D2 (N=5) to receive TWINRIX and NormalSaline on D0, D28Arm D3 (N=50) to receive TWINRIX and NormalSaline on D0, D28, D168; to receive Menactra andNormal Saline on D530', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: TWINRIX', 'Drug: Menactra']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Pfs230D1M-EPA/Alhydrogel', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 2- Mali', 'Group 2-U.S', 'Group 3- Mali', 'Group 3- U.S.']}}, {'InterventionType': 'Biological', 'InterventionName': 'Pfs25M-EPA/Alhydrogel', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 1- Mali', 'Group 1-U.S', 'Group 3- Mali', 'Group 3- U.S.']}}, {'InterventionType': 'Drug', 'InterventionName': 'TWINRIX', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 4- Mali']}}, {'InterventionType': 'Drug', 'InterventionName': 'Menactra', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 4- Mali']}}]","[{'PrimaryOutcomeMeasure': 'Incidence of local and systemic adverse events and serious advents in U.S. adults and in exposed Malian adults.', 'PrimaryOutcomeTimeFrame': 'U.S. Study: Days 1,3,7,14,28,29,31,35,42,56,84,112,140,168 and 196. Same as U.S. plus Days 169,171,175,182,189,196,203,210,217,240,2 70,300,330,360,390,420,450,480,510,540,541,543,547,554,561,568,575,582,589,610,640,670,700,730'}]","[{'SecondaryOutcomeMeasure': 'Anti -Pfs25 and Anti-Pfs230 antibody levels elicited by as measured by ELISA in U.S. adults and in exposed Malian adults', 'SecondaryOutcomeTimeFrame': 'U.S. Study: D. 14,28,42,84,140,196 Mali (Safety Arm: Same as the U.S. Mali (Functional Arm): D. 14,28,42,84,140,168,182,196,210,240,300,360,420,480,540,554,568,582,610,670,730'}]","INCLUSION CRITERIA: (US & Mali)

All of the following criteria must be fulfilled for a volunteer to participate in this trial:

Age greater than or equal to18 and less than or equal to 50 years.
Available for the duration of the trial.
Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.
In good general health and without clinically significant medical history.

Females of childbearing potential must be willing to use reliable contraception (as defined below) from 21 days prior to Study Day 0 to 3 months after the last vaccination.

Reliable methods of birth control include one of the following: confirmed pharmacologic contraceptives (parenteral) delivery; intrauterine or implantable device.
Reliable methods of birth control include concurrent use of a pharmacologic and a barrier method, i.e. two of the following: confirmed pharmacologic contraceptives (oral, transdermal) delivery or vaginal ring AND condoms with spermicide or diaphragm with spermicide.
Abstinence of potentially reproductive sexual activity.
Non-childbearing women will also be required to report date of last menstrual period, history of surgical sterility (i.e. tubal ligation, hysterectomy) or premature ovarian insufficiency (POI), and will have a baseline urine or serum pregnancy test performed.
Willingness to have blood samples stored for future research.
Willingness to undergo direct skin feeds (Mali only).
Known resident of Bancoumana or surrounding area (Mali only).

EXCLUSION CRITERIA: (US & Mali)

A subject will be excluded from participating in this trial if any one of the following criteria is

fulfilled:

Pregnancy as determined by a positive urine or serum human choriogonadotropin ( <=- hCG) test (if female).

NOTE: Pregnancy is also a criteria for discontinuation of any further dosing or nonsafety related interventions for that subject.

Currently breast-feeding (if female).
Behavioral, cognitive, or psychiatric disease that in the opinion of the investigator affects the ability of the participant to understand and comply with the study protocol.
Hemoglobin, WBC, absolute neutrophils, and platelets outside the local laboratorydefined limits of normal (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range).
Alanine transaminase (ALT) or creatinine (Cr) level above the local laboratory-defined upper limit of normal (subjects may be included at the investigator s discretion for not clinically significant values outside of normal range).

Infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or

hepatitis B (HBV).

Evidence of clinically significant neurologic, cardiac, pulmonary, hepatic, endocrine, rheumatologic, autoimmune, hematological, oncologic, or renal disease by history, physical examination, and/or laboratory studies including urinalysis.
History of receiving any investigational product within the past 30 days.
Participation or planned participation in a clinical trial with an investigational product prior to completion of the follow up visit 28 days following last vaccination OR planned participation in an investigational vaccine study until the last required protocol visit
Subject has had medical, occupational, or family problems as a result of alcohol or illicit drug use during the past 12 months.
History of a severe allergic reaction or anaphylaxis.
Severe asthma, defined as asthma that is unstable or required emergent care, urgent care, hospitalization, or intubation during the past 2 years, or that has required the use of oral or parenteral corticosteroids at any time during the past 2 years.
Pre-existing autoimmune or antibody-mediated diseases including but not limited to: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sj(SqrRoot)(Delta)gren s syndrome, or autoimmune thrombocytopenia.
Known immunodeficiency syndrome.
Known asplenia or functional asplenia.
Use of chronic (greater than or equal to 14 days) oral or intravenous corticosteroids (excluding topical or nasal) at immunosuppressive doses (i.e., prednisone >10 mg/day) or immunosuppressive drugs within 30 days of Study Day 0.
Prior to Study Day 0 and every subsequent vaccination day, receipt of a live vaccine within the past 4 weeks or a killed vaccine within the past 2 weeks.
Receipt of immunoglobulins and/or blood products within the past 6 months.
Previous receipt of an investigational malaria vaccine in the last 5 years.
Other condition that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.
Prior malaria infection by history in the last 10 years (US only).
Prior travel to a malaria transmission area in the last 5 years or planned travel during the course of the study (US only).
History of severe reaction to mosquito bites (Mali only).

History of allergy to any component of the comparator vaccine (e.g. neomycin) (Mali only).

INCLUSION AND EXCLUSION FOR LARGE VOLUME BLOOD DRAW:

- Individuals previously enrolled in Arms A2, B2, or C2 may be asked to return to the clinic for a single additional visit. This visit would be to collect a single large volume blood sample for additional serological analysis and characterization of B cell receptor usage.

INCLUSION CRITERIA (LARGE VOLUME BLOOD DRAW):

-The following criteria must be fulfilled for a volunteer to participate in the large volume blood draw addendum:

-- Previously enrolled in 15-I-0044 in Arms A2, B2, or C2

EXCLUSION CRITERIA (LARGE VOLUME BLOOD DRAW):

- A subject will be excluded from participating in the large volume blood draw addendum if any one of the following criteria is fulfilled:

Pregnancy as determined by self report (if female).
Within the past 30 days has received a research drug or vaccine or been enrolled in another research drug or vaccine trial.
Condition or on a medication that in the opinion of the investigator would jeopardize the safety or rights of a participant participating in the trial, interfere with the evaluation of the study objectives, or would render the subject unable to comply with the protocol.",No,All,18 Years,50 Years,['Adult'],"[{'LocationFacility': 'National Institutes of Health Clinical Center, 9000 Rockville Pike', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20892', 'LocationCountry': 'United States'}, {'LocationFacility': 'Malaria Research and Training Center', 'LocationCity': 'Bamako', 'LocationCountry': 'Mali'}]","[{'CollaboratorName': 'Rodolphe Merieux Laboratory@@@Bamako, Mali', 'CollaboratorClass': 'UNKNOWN'}]",,"A vaccine to interrupt malaria transmission would be a valuable tool for local elimination or

eradication of this disease. Pfs25 and Pfs230, surface antigens of zygotes and ookinetes in the mosquito stage of Plasmodium falciparum, are the lead candidates for a malaria transmission blocking vaccine. Recombinant Pfs25M and recombinant Pfs230D1M have each been conjugated to Pseudomonas aeruginosa ExoProtein A (EPA) and adjuvanted with Alhydrogel . This dose-escalating phase 1 study will determine safety and immunogenicity of these vaccines in US adults and subsequently in Malian adults.

A total of 260 subjects will be enrolled at sites in the US and Mali to receive escalating doses of Pfs25M- EPA/Alhydrogel , Pfs230D1M-EPA/Alhydrogel , or simultaneous Pfs25MEPA/Alhydrogel and Pfs230D1M-EPA/Alhydrogel . Enrollment within each group will be staggered for additional safety, and subjects will only be enrolled into the simultaneous administration group once each individual dose has been administered and reviewed for safety. Subjects will be followed for at least 6 months after the last vaccination. Safety outcomes will be local and systemic adverse events (AEs) and serious adverse events (SAEs). Immunogenicity outcomes will be antibody responses as measured by ELISA against recombinant Pfs25, Pfs230, and EPA, and B cell responses. Functional activity of the induced antibodies will be assessed by membrane feeding assays conducted at the National Institute of Allergy and Infectious Diseases in the US.","['Assays', 'Antibody', 'Reactogenicity', 'Mosquito', 'Responses']",,,,,,[{'SecondaryId': '15-I-0044'}],,,,,"['Participant', 'Investigator']",,"[{'OverallOfficialName': 'Patrick E Duffy, M.D.', 'OverallOfficialAffiliation': 'National Institute of Allergy and Infectious Diseases (NIAID)', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '21715576', 'ReferenceType': 'background', 'ReferenceCitation': 'Farrance CE, Rhee A, Jones RM, Musiychuk K, Shamloul M, Sharma S, Mett V, Chichester JA, Streatfield SJ, Roeffen W, van de Vegte-Bolmer M, Sauerwein RW, Tsuboi T, Muratova OV, Wu Y, Yusibov V. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin Vaccine Immunol. 2011 Aug;18(8):1351-7. doi: 10.1128/CVI.05105-11. Epub 2011 Jun 29.'}, {'ReferencePMID': '3283563', 'ReferenceType': 'background', 'ReferenceCitation': 'Kaslow DC, Quakyi IA, Syin C, Raum MG, Keister DB, Coligan JE, McCutchan TF, Miller LH. A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains. Nature. 1988 May 5;333(6168):74-6.'}, {'ReferencePMID': '23623858', 'ReferenceType': 'background', 'ReferenceCitation': 'Shimp RL Jr, Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, Rausch KM, Kumar K, Wu Y, Jin AJ, Jones DS, Narum DL. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle. Vaccine. 2013 Jun 19;31(28):2954-62. doi: 10.1016/j.vaccine.2013.04.034. Epub 2013 Apr 24.'}, {'ReferencePMID': '31307393', 'ReferenceType': 'derived', 'ReferenceCitation': 'Guindo A, Sagara I, Ouedraogo B, Sallah K, Assadou MH, Healy S, Duffy P, Doumbo OK, Dicko A, Giorgi R, Gaudart J. ""Spatial heterogeneity of environmental risk in randomized prevention trials: consequences and modeling"". BMC Med Res Methodol. 2019 Jul 15;19(1):149. doi: 10.1186/s12874-019-0759-z.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}, {'ConditionMeshId': 'D000016778', 'ConditionMeshTerm': 'Malaria, Falciparum'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17716', 'ConditionBrowseLeafName': 'Malaria, Falciparum', 'ConditionBrowseLeafAsFound': 'Plasmodium Falciparum Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]","[{'InterventionMeshId': 'D000000536', 'InterventionMeshTerm': 'Aluminum Hydroxide'}]","[{'InterventionAncestorId': 'D000000276', 'InterventionAncestorTerm': 'Adjuvants, Immunologic'}, {'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000000863', 'InterventionAncestorTerm': 'Antacids'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000005765', 'InterventionAncestorTerm': 'Gastrointestinal Agents'}]","[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2458', 'InterventionBrowseLeafName': 'Aluminum Hydroxide', 'InterventionBrowseLeafAsFound': 'Dengue', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2806', 'InterventionBrowseLeafName': 'Antibodies', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8767', 'InterventionBrowseLeafName': 'Immunoglobulins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2209', 'InterventionBrowseLeafName': 'Adjuvants, Immunologic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8784', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2769', 'InterventionBrowseLeafName': 'Antacids', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2800', 'InterventionBrowseLeafName': 'Anti-Ulcer Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7464', 'InterventionBrowseLeafName': 'Gastrointestinal Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03311295,US042616,"Mvrx, Inc.",INDUSTRY,MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States,MitrAl ValvE RepaIr Clinical Trial (MAVERIC Trial) - United States,Aug-20,Recruiting,No,03-Apr-18,Actual,03-Apr-21,Anticipated,03-Apr-26,Anticipated,11-Oct-17,11-Oct-17,17-Oct-17,Actual,07-Aug-20,11-Aug-20,Actual,Sponsor,"Mvrx, Inc.",INDUSTRY,No,Yes,Yes,,The objective of the study is to evaluate the safety and feasibility of the ARTO System in patients with mitral valve regurgitation (MR) associated with congestive heart failure (CHF).,['Mitral Valve Insufficiency'],Interventional,['Not Applicable'],N/A,Single Group Assignment,Treatment,None (Open Label),15,Anticipated,"[{'ArmGroupLabel': 'ARTO System', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: ARTO System']}}]","[{'InterventionType': 'Device', 'InterventionName': 'ARTO System', 'InterventionDescription': 'The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['ARTO System']}}]","[{'PrimaryOutcomeMeasure': 'Safety: Major Adverse Event Rate to 30 Days post-procedure', 'PrimaryOutcomeDescription': 'Major Adverse Events (MAEs) will be categorized and defined in accordance with the relation to the procedure and device.', 'PrimaryOutcomeTimeFrame': '30 days post procedure'}, {'PrimaryOutcomeMeasure': 'Efficacy: Mitral regurgitation grade by ASE criteria and change from baseline to 1 year', 'PrimaryOutcomeDescription': 'Mitral regurgitation grade by ASE criteria and change from baseline to 1 year evaluated by 2-D transthoracic echocardiogram', 'PrimaryOutcomeTimeFrame': 'Baseline to 1 year'}]",,"Inclusion Criteria:

Candidates must meet ALL of the following criteria to be enrolled in the study.

Is ambulatory, able and willing to comply with the study protocol and has provided written informed consent
Age 21-85, inclusive
Trans-septal catheterization is determined to be feasible by the treating physician
NYHA class II-IV heart failure of any etiology
Symptomatic with MR grade ≥ 2+
LVEF < 40%
LVEDD > 50 mm and ≤ 75 mm
No anticipated change in patient's cardiac medication regimen anticipated throughout the course of the study.
In the opinion of the investigator and heart surgery team, the patient is not an appropriate candidate for surgery, and the use of the ARTO System is technically feasible

Exclusion Criteria:

Candidates will be excluded from enrollment in the study if ANY of the following conditions apply.

In the opinion of the Investigator, the femoral vein and internal jugular vein cannot accommodate a 16 F catheter or the presence of an inferior vena cava (IVC) filter would interfere with advancement of the catheter or ipsilateral DVT is present
Significant structural abnormality of the mitral valve (e.g., flail, prolapse, leaflet calcification)
Significant mitral annular calcification
Hemodynamic instability (systolic pressure < 90 mmHg without afterload reduction or cardiogenic shock or the need for inotropic support or intra-aortic balloon pump)
Prior mitral valve surgery or valvuloplasty or any currently implanted prosthetic valve or VAD
History of, or active, rheumatic heart disease
History of Atrial Septal Defects (ASD), whether repaired or not
History of previously repaired PFO or PFO associated with clinical symptoms (e.g., cerebral ischemia) within 6 months of the planned investigational procedure
In the opinion of the investigator, an atrial septal aneurysm is present that may interfere with transseptal crossing
Serum creatinine > 2.5 mg/dL or dialysis dependent
No access to coronary sinus and/or great cardiac vein
Platelet count < 100 x 103 cells/mm3
Evidence of active infection (fever with temperature > 38°C and/or WBC > 15,000) or endocarditis
Echocardiographic evidence of mass intracardiac thrombus
Patients on prescribed dual antiplatelet therapy (asprin + any P2Y12 inhibitor) that cannot be discontinued.
Percutaneous coronary intervention or surgery anticipated within the 6 month follow up period following the investigational procedure
Biventricular pacing initiated or anticipated within 6 months of the planned investigational procedure
Evidence of an acute myocardial infarction within 12 weeks of the planned investigational procedure
Stroke or TIA within 6 months of the planned investigational procedure
GI bleeding within 6 months of the planned investigational procedure
Intravenous drug abuse or suspected inability to adhere to follow-up
Patients in whom TTE, TEE or ICE is contraindicated
Contraindication to CT scan
A known hypersensitivity or contraindication to study or procedure medications (specifically aspirin, clopidogrel and heparin) that cannot be adequately managed medically
A known allergy or hypersensitivity to nickel
A known need for any other cardiac surgery including surgery for coronary artery disease, atrial fibrillation, pulmonic, aortic or tricuspid valve disease
In the judgment of the Investigator, patients in whom the presence of a permanent pacemaker or pacing leads would interfere with placement of the test device or the placement of the test device would disrupt the leads
Irreversible bleeding disorder, history of bleeding diathesis or coagulopathy or refuses blood transfusion
Evidence of disease or condition expected to compromise survival (< 1 year) or ability to complete follow-up assessments
Pregnant or breastfeeding women
Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. [Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials]
Patient not a candidate for emergent surgical bailout in case of need",No,All,21 Years,85 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'UC Davis Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95817', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kimberly Book, BS, RN, CCRP', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Columbia University Medical Center/NewYork Presbyterian Hospital', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Tamir Nazif, MD', 'LocationContactRole': 'Contact'}]}}]",,Yes,,,,,,,,,MAVERIC US,,,,,,"[{'OverallOfficialName': 'Reginald Low, MD', 'OverallOfficialAffiliation': 'University California Davis', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,"[{'CentralContactName': 'Samantha Greene', 'CentralContactRole': 'Contact', 'CentralContactPhone': '949 910 8948', 'CentralContactEMail': 'sgreene@mvrxinc.com'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008944', 'ConditionMeshTerm': 'Mitral Valve Insufficiency'}]","[{'ConditionAncestorId': 'D000006349', 'ConditionAncestorTerm': 'Heart Valve Diseases'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]","[{'ConditionBrowseLeafId': 'M10493', 'ConditionBrowseLeafName': 'Mitral Valve Insufficiency', 'ConditionBrowseLeafAsFound': 'Mitral Valve Insufficiency', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8020', 'ConditionBrowseLeafName': 'Heart Valve Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03242278,18733,Bayer,INDUSTRY,Real-world Dosing Patterns of Rivaroxaban in the United States,Real-world Dosing Patterns of Rivaroxaban in the United States (RIVA-D),Aug-17,Completed,No,12-Feb-16,Actual,01-Mar-16,Actual,01-Mar-16,Actual,26-Jul-17,03-Aug-17,08-Aug-17,Actual,03-Aug-17,08-Aug-17,Actual,Sponsor,Bayer,INDUSTRY,No,No,,,"The primary objective is to assess the proportion of Non-valvular atrial fibrillation (NVAF) patients receiving the standard dose of 20 mg of rivaroxaban or the reduced dose of 15 mg of rivaroxaban.

The secondary objective is to determine if dosing patterns for rivaroxaban may be influenced by baseline chronic kidney disease (CKD) status (as a proxy for measured baseline renal function).",['Atrial Fibrillation'],Observational,,,,,,12507,Actual,"[{'ArmGroupLabel': 'NVAF patients receiving 20 mg rivaroxaban', 'ArmGroupDescription': 'NVAF patients who receive a standard dose of rivaroxaban (20 mg daily)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Rivaroxaban (Xarelto, BAY59-7939)']}}, {'ArmGroupLabel': 'NVAF patients receiving 15 mg rivaroxaban', 'ArmGroupDescription': 'NVAF patients who receive a reduced dose of rivaroxaban (15 mg daily)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Rivaroxaban (Xarelto, BAY59-7939)']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Rivaroxaban (Xarelto, BAY59-7939)', 'InterventionDescription': 'As prescribed by treating physicians', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['NVAF patients receiving 15 mg rivaroxaban', 'NVAF patients receiving 20 mg rivaroxaban']}}]","[{'PrimaryOutcomeMeasure': 'Number of NVAF patients receiving 20 mg Rivaroxaban', 'PrimaryOutcomeTimeFrame': 'At baseline'}, {'PrimaryOutcomeMeasure': 'Number of NVAF patients receiving 15 mg Rivaroxaban', 'PrimaryOutcomeTimeFrame': 'At baseline'}]","[{'SecondaryOutcomeMeasure': 'Baseline renal function', 'SecondaryOutcomeTimeFrame': 'At baseline'}]","Inclusion Criteria:

NVAF (non-valvular atrial fibrillation) will be defined as the occurrence of 2 or more inpatient or outpatient claims with International Classification of Disease ICD-9 427.31 as the diagnosis code at any time in the patient's data history prior to inclusion
Patients will be required to have 180 days of enrollment for the assessment of baseline characteristics
CHA2DS2-Vasc score ≥2 during the 180 days prior to index rivaroxaban use baseline period
Evidence of continuous enrollment in MarketScan during 180 days before the date of the first prescription of rivaroxaban

Exclusion Criteria:

Patients <18 years of age
Patients with valvular AF (atrial fibrillation)
Pregnancy
Malignant cancers
Transient cause of AF
Patients with VTE (Venous thromboembolism), pulmonary embolism or DVT (Deep Vein Thrombosis)
Patients with major surgery defined as hip or knee replacement
Prescriptions of OACs (Oral anticoagulants) (apixaban,warfarin, dabigatran, rivaroxaban) before index date
Prescription of more than one OAC on the index date",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationCity': 'New York', 'LocationState': 'New York', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Janssen Research & Development, LLC', 'CollaboratorClass': 'INDUSTRY'}]",No,,"['Non-valvular atrial fibrillation (NVAF)', 'Prevention', 'Stroke']",No,['Cohort'],['Retrospective'],Patients with non-valvular atrial fibrillation (NVAF),Non-Probability Sample,"[{'SecondaryId': 'XA1511US', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Company internal'}]",,,,,,,"[{'OverallOfficialName': 'Bayer Study Director', 'OverallOfficialAffiliation': 'Bayer', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,,,,"[{'SeeAlsoLinkLabel': 'Click here to find results for studies related to Bayer products.', 'SeeAlsoLinkURL': 'http://pharma.bayer.com/en/innovation-partnering/clinical-trials/trial-finder/'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001281', 'ConditionMeshTerm': 'Atrial Fibrillation'}]","[{'ConditionAncestorId': 'D000001145', 'ConditionAncestorTerm': 'Arrhythmias, Cardiac'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]","[{'ConditionBrowseLeafId': 'M3167', 'ConditionBrowseLeafName': 'Atrial Fibrillation', 'ConditionBrowseLeafAsFound': 'Atrial Fibrillation', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20890', 'ConditionBrowseLeafName': 'Stroke', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3034', 'ConditionBrowseLeafName': 'Arrhythmias, Cardiac', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}]","[{'InterventionMeshId': 'D000069552', 'InterventionMeshTerm': 'Rivaroxaban'}]","[{'InterventionAncestorId': 'D000065427', 'InterventionAncestorTerm': 'Factor Xa Inhibitors'}, {'InterventionAncestorId': 'D000000991', 'InterventionAncestorTerm': 'Antithrombins'}, {'InterventionAncestorId': 'D000015842', 'InterventionAncestorTerm': 'Serine Proteinase Inhibitors'}, {'InterventionAncestorId': 'D000011480', 'InterventionAncestorTerm': 'Protease Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000000925', 'InterventionAncestorTerm': 'Anticoagulants'}]","[{'InterventionBrowseLeafId': 'M463', 'InterventionBrowseLeafName': 'Rivaroxaban', 'InterventionBrowseLeafAsFound': 'Leg', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M29100', 'InterventionBrowseLeafName': 'Factor Xa Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2888', 'InterventionBrowseLeafName': 'Antithrombins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2887', 'InterventionBrowseLeafName': 'Antithrombin III', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M12926', 'InterventionBrowseLeafName': 'Protease Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M16974', 'InterventionBrowseLeafName': 'Serine Proteinase Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18192', 'InterventionBrowseLeafName': 'HIV Protease Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2825', 'InterventionBrowseLeafName': 'Anticoagulants', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T18', 'InterventionBrowseLeafName': 'Serine', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'AnCoag', 'InterventionBrowseBranchName': 'Anticoagulants'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'AA', 'InterventionBrowseBranchName': 'Amino Acids'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03683134,The Healthy Hearts Program,Auburn University,OTHER,A Mediterranean Diet Nutrition Education Program for the Reduction of Cardiovascular Disease Risk in the Southeastern U.S.,"A Pilot, Theory-Based, Nutrition Intervention Promoting a Mediterranean Diet for the Reduction of Cardiovascular Disease Risk Factors in a High-Risk Population of the Southeastern United States: The Healthy Hearts Program (HHP)",Sep-18,Completed,No,23-Jan-17,Actual,07-Sep-17,Actual,07-Sep-17,Actual,20-Sep-18,21-Sep-18,25-Sep-18,Actual,26-Sep-18,27-Sep-18,Actual,Principal Investigator,Auburn University,OTHER,No,No,,,"A 12-week, randomized nutrition intervention for the reduction of cardiovascular disease risk factors in a high-risk population in the southeastern United States. The primary objective of this pilot study was to assess the efficacy of a Mediterranean diet intervention (education + extra-virgin olive oil (EVOO) and mixed nut supplementation) versus that of an American Heart Association (AHA) nutrition intervention (education) on serum blood lipid levels as markers for cardiovascular disease risk. Researchers conducting this trial hypothesize that a greater reduction will be seen in cardiovascular disease risk factors in the Mediterranean diet intervention.","['Cardiovascular Diseases', 'Cardiovascular Risk Factor', 'Obesity']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,Double,58,Actual,"[{'ArmGroupLabel': 'Mediterranean diet group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive both nutrition education on patterns of a Mediterranean style diet as well as olive oil and mixed nuts.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Mediterranean diet', 'Dietary Supplement: Olive oil and mixed nuts']}}, {'ArmGroupLabel': 'American Heart Association group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants will receive nutrition education on the dietary recommendations for heart health from the American Heart Association.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: American Heart Association']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Mediterranean diet', 'InterventionDescription': 'Participants will receive nutrition education and educational materials from a registered dietitian on patients on the patterns of a Mediterranean style diet. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Mediterranean diet group']}}, {'InterventionType': 'Dietary Supplement', 'InterventionName': 'Olive oil and mixed nuts', 'InterventionDescription': 'Participants in the Mediterranean diet group will receive 3 liters of extra-virgin olive oil and 3 pounds of mixed nuts (1.5 pounds raw almonds and 1.5 pounds raw walnuts) at baseline and at 6 weeks. Participants will be educated by oral and written means, on consumption goals of the nuts and olive oil.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Mediterranean diet group']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'American Heart Association', 'InterventionDescription': 'Participants will receive nutrition education and educational materials from a registered dietitian on patients on the dietary recommendations from the American Heart Association for heart health. Seven education sessions will be delivered through an online platform. Participants will be asked to complete one education session per week for the first six weeks and the final session at week 9.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['American Heart Association group']}}]","[{'PrimaryOutcomeMeasure': 'Systolic Blood Pressure Measurement', 'PrimaryOutcomeDescription': 'Measured in mmHg', 'PrimaryOutcomeTimeFrame': 'Change from at baseline blood pressure to 6-weeks'}, {'PrimaryOutcomeMeasure': 'Systolic Blood Pressure Measurement', 'PrimaryOutcomeDescription': 'Measured in mmHg', 'PrimaryOutcomeTimeFrame': 'Change from at baseline blood pressure to 12-weeks'}]","[{'SecondaryOutcomeMeasure': 'Diastolic Blood Pressure Measurement', 'SecondaryOutcomeDescription': 'Measured in mmHg', 'SecondaryOutcomeTimeFrame': 'Change from at baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Change in Weight', 'SecondaryOutcomeDescription': 'Measured in kilograms (kg)', 'SecondaryOutcomeTimeFrame': 'Change from at baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'Calculation of Body Mass Index (BMI) (kg/m∧2)', 'SecondaryOutcomeDescription': 'Height in meters will be combined with weight in kilograms will be combined to report BMI in kg/m∧2)', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Calculation of BMI (kg/m∧2)', 'SecondaryOutcomeDescription': 'Height in meters will be combined with weight in kilograms will be combined to report BMI in kg/m∧2)', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted total cholesterol', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted total cholesterol', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted high-density lipoprotein (HDL) cholesterol', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted high-density lipoprotein (HDL) cholesterol', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted low-density lipoprotein (LDL) cholesterol', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted low-density lipoprotein (LDL) cholesterol', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted triglycerides', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted triglycerides', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio', 'SecondaryOutcomeDescription': 'Total cholesterol (mg/dL) will be used with HDL (mg/dL) to calculate total cholesterol to HDL ratio', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'A calculation of total cholesterol (mg/dL) to HDL (mg/dL) ratio', 'SecondaryOutcomeDescription': 'Total cholesterol (mg/dL) will be used with HDL (mg/dL) to calculate total cholesterol to HDL ratio', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted blood glucose', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Concentration of fasted blood glucose', 'SecondaryOutcomeDescription': 'Measured in mg/dL', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'A calculation of waist (inches) to height (inches) ratio', 'SecondaryOutcomeDescription': 'Waist circumference in inches will be calculated with height measurement in inches to report the waist-to-height ratio', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}, {'SecondaryOutcomeMeasure': 'A calculation of waist (inches) to height (inches) ratio', 'SecondaryOutcomeDescription': 'Waist circumference in inches will be calculated with height measurement in inches to report the waist-to-height ratio', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin', 'SecondaryOutcomeDescription': 'Fasting plasma glucose in mg/dL and fasting serum insulin in milliUnits (mU)/I will be used to calculate HOMA-IR as an indicator for insulin resistance.', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 6-weeks'}, {'SecondaryOutcomeMeasure': 'Calculation of homeostatic model assessment (HOMA)-insulin resistance (IR) from fasted blood concentrations of fasted blood glucose and fasted insulin', 'SecondaryOutcomeDescription': 'Fasting plasma glucose in mg/dL and fasting serum insulin in mU/I will be used to calculate HOMA-IR as an indicator for insulin resistance.', 'SecondaryOutcomeTimeFrame': 'Change from baseline weight to 12-weeks'}]","Inclusion Criteria:

Enrolled in Auburn University's health insurance program during the course of the study or a dependent of the enrollee during the course of the study
BMI >24.9 (kg/m2)
AND Meets two or more of the following
Screening values classified in the ""yellow"" or ""red"" zone for:
Systolic blood pressure (mmHg): Yellow zone: ≥140, Red zone: ≥160;
Diastolic Blood pressure (mmHg): Yellow zone: ≥90, Red zone: ≥ 100;
Fasting blood glucose (mm/dL): Yellow zone: ≥100, Red zone: ≥ 126
Blood glucose (random) (mg/dL): Yellow zone: 140-200, Red zone > 200
Total Cholesterol (mg/dL): Yellow zone: ≥200, red zone: ≥250
Have a pre-existing diagnosis of hypertension, pre-diabetes, or hypercholesterolemia
Current smoker (≥1 cigarette/day)
Are: male (age: 55-80) or female (age: 60-80)
A family history of premature coronary heart disease
High risk ethnicity: Black, African American, American Indians/Alaska Natives, Non-Hispanic blacks, Mexican-Americans, Asian, Hispanic/Latino

Exclusion Criteria:

Minors that are less than 19 years of age
Individuals who are not enrolled in the Auburn University health insurance program for the 2016 plan year at baseline and have not yet completed initial visit
Individuals who have not completed their 2015 ""Healthy Tigers"" biometric screening between January 1st and December 31st, 2015 (these can be completed by the ""Healthy Tigers"" staff or by submitting a healthcare provider form from the individuals' physician to the ""Healthy Tigers"" office), unless enrolled in ""TigerMeds"".
Individuals who are pregnant or who intend to become pregnant during the 12-week health and wellness challenge.
Individuals who anticipate absence or travel throughout the study that would interfere with their ability to complete the analysis at the mid-point and end of challenge.
Patients with a peanut, tree nut, or olive oil food allergy or intolerance.
Patients who are unable or unwilling to travel to Auburn University main campus for live health and wellness challenge events, individual assessments, personal appointments, and pre- and post- data collection
Individuals who have NOT been stabilized on medication to treat or manage high blood pressure, high cholesterol, dyslipidemia, or pre diabetes for at least 12 weeks prior to the study.
Patients who do not have access to the internet and therefore unable to complete the education portion of the study
Individuals who have a pacemaker
Patients who decline participation during informed consent",No,All,19 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Auburn University Pharmaceutical Care Center', 'LocationCity': 'Auburn', 'LocationState': 'Alabama', 'LocationZip': '36849', 'LocationCountry': 'United States'}]",,No,,"['Cardiovascular Disease', 'Mediterranean Diet', 'Nutrition education']",,,,,,,HHP,Michael W. Greene,"Director, Auburn University Metabolic Phenotyping Laboratory",Auburn University,"['Care Provider', 'Investigator']",,"[{'OverallOfficialName': 'Michael W Greene, PhD', 'OverallOfficialAffiliation': 'Auburn University', 'OverallOfficialRole': 'Study Chair'}, {'OverallOfficialName': 'Amy W Willis, MS, RD', 'OverallOfficialAffiliation': 'Auburn University', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000002318', 'ConditionMeshTerm': 'Cardiovascular Diseases'}]",,"[{'ConditionBrowseLeafId': 'M11284', 'ConditionBrowseLeafName': 'Obesity', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'T242', 'InterventionBrowseLeafName': 'Olive', 'InterventionBrowseLeafAsFound': 'Consolidation', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'T143', 'InterventionBrowseLeafName': 'English Walnut', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,"[{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'June 9, 2017', 'LargeDocUploadDate': '09/21/2018 13:56', 'LargeDocFilename': 'Prot_SAP_000.pdf'}, {'LargeDocTypeAbbrev': 'ICF', 'LargeDocHasProtocol': 'No', 'LargeDocHasSAP': 'No', 'LargeDocHasICF': 'Yes', 'LargeDocLabel': 'Informed Consent Form', 'LargeDocDate': 'June 9, 2017', 'LargeDocUploadDate': '09/21/2018 14:05', 'LargeDocFilename': 'ICF_001.pdf'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04047316,CI-PROT-0029,Barco NV,INDUSTRY,Development and Validation of a New Digital Dermatoscope in the United States,Development and Validation of a New Digital Dermatoscope in the United States,Jun-20,Completed,No,27-Aug-19,Actual,15-Apr-20,Actual,15-Apr-20,Actual,02-Aug-19,05-Aug-19,06-Aug-19,Actual,18-Jun-20,18-Jun-20,Actual,Sponsor,Barco NV,INDUSTRY,No,Yes,Yes,No,A completely new type of digital dermatoscope has been developed in order to take a significant step forward in technology for skin cancer imaging. By means of this study a better insight can be gained of the current performance and workflow in clinical dermatoscopy. This knowledge will be used to further improve the developed technology.,['Skin Cancer'],Observational,,,,,,60,Actual,,"[{'InterventionType': 'Device', 'InterventionName': 'Digital dermoscopy', 'InterventionDescription': 'Acquire skin images with a new digital dermatoscope'}]","[{'PrimaryOutcomeMeasure': 'Performance of the new device in its normal conditions of use', 'PrimaryOutcomeDescription': 'The outcome will be measured by a questionnaire with performance-related questions for clinicians to answer about a set of images from the collected database. A Likert-based scale will be used for the answers: from highly agree to highly disagree.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Usability of the new device', 'PrimaryOutcomeDescription': 'The outcome will be measured by a questionnaire with usability-related questions for clinicians.', 'PrimaryOutcomeTimeFrame': '1 month'}, {'PrimaryOutcomeMeasure': 'Safety of the new device in its normal conditions of use', 'PrimaryOutcomeDescription': 'The number of adverse events will be reported to assess safety of the device.', 'PrimaryOutcomeTimeFrame': '1 year'}]","[{'SecondaryOutcomeMeasure': 'Develop a database of skin images with the new device with metadata and histopathology of excised lesions', 'SecondaryOutcomeDescription': 'The outcome of the secondary objective will be an anonymized database of digital skin lesion images and corresponding metadata and a set of high quality images amenable to clinician evaluation.', 'SecondaryOutcomeTimeFrame': '1 year'}]","Inclusion Criteria:

Participant is willing and able to give informed consent for participation in the study.
Male or Female, aged 18 years or above.
Male or Female, aged less than 18 years, with informed consent of their legally authorized representative.
Patient presenting with any visible skin lesion for dermatologist review on a body site amenable to optimal photographic imaging.
Able and willing to comply with all study requirements.
Patient with a skin lesion that is clinically diagnosed by a dermatologist as benign, malignant or a suspicious skin lesion requiring excisional biopsy for histological diagnosis.

Exclusion Criteria:

Patients aged under 18 years old where the legally authorized representative is unable or unwilling to provide their informed consent.
Patients unable to provide informed consent.
Skin lesions in an anatomical site which is not suitable for photography including hair-obscured site, subungual lesion or inaccessible mucosal site.
Lesion is at a site where previous surgery was undertaken.",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Dermatologic Surgery Center of Washington LLC', 'LocationCity': 'Chevy Chase', 'LocationState': 'Maryland', 'LocationZip': '20815', 'LocationCountry': 'United States'}, {'LocationFacility': 'Silver Falls Dermatology', 'LocationCity': 'Salem', 'LocationState': 'Oregon', 'LocationZip': '97302', 'LocationCountry': 'United States'}]",,,,,No,['Other'],['Prospective'],Patients will be considered for enrollment in the study when they have a lesion that is accessible to the new digital dermatoscope and are able to give informed consent (guardian in case of patients under 18 years).,Non-Probability Sample,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012878', 'ConditionMeshTerm': 'Skin Neoplasms'}]","[{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]","[{'ConditionBrowseLeafId': 'M14264', 'ConditionBrowseLeafName': 'Skin Neoplasms', 'ConditionBrowseLeafAsFound': 'Skin Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14257', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03952364,The Precious Study,PredictImmune Ltd,INDUSTRY,The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States,The PRECIOUS Study: Predicting Crohn's & ColitIs Outcomes in the United States,Sep-20,Recruiting,No,10-Oct-19,Actual,Jun-21,Anticipated,Jun-21,Anticipated,14-May-19,14-May-19,16-May-19,Actual,15-Sep-20,17-Sep-20,Actual,Sponsor,PredictImmune Ltd,INDUSTRY,No,No,,,"A multi-center observational study based at referral centers and community hospitals within the US. Patients' blood will be collected at enrollment for testing with PredictSURE IBD™, which will occur at a later date. Patients will be prospectively followed up for 12 months with clinicians treating according to local standard of care, with a step-up or accelerated step-up regimen. Clinicians and patients will be blinded to the biomarker results.","['Crohn Disease', 'Ulcerative Colitis', 'IBD', 'Inflammatory Bowel Diseases']",Observational,,,,,,200,Anticipated,,"[{'InterventionType': 'Other', 'InterventionName': 'PredictSURE IBD™', 'InterventionDescription': 'To evaluate a test called PredictSURE IBD™ in the US population'}]","[{'PrimaryOutcomeMeasure': 'To stratify patients at diagnosis into high and low- risk cohorts', 'PrimaryOutcomeDescription': 'Stratifying patients into high or low risk of following an aggressive disease course requiring frequent treatment escalations.', 'PrimaryOutcomeTimeFrame': '12 month follow up'}]",,"Inclusion Criteria:

Active UC or CD with typical symptoms in conjunction with at least one objective measure of disease activity: elevated CRP, calprotectin, endoscopic evidence.
Not currently receiving systemic therapy* with steroids, immunomodulators or biologics, and at least 7 days since the last steroid dose.
Due to be managed using a ""step-up"" or ""accelerated step-up"" approach (so will not receive biologics as first line therapy).
Aged 16-80 years old.

Note, the ideal patients for this study are newly diagnosed patients who are treatment-naïve.

Exclusion Criteria:

The presence of any of the following will preclude patient inclusion:
Patients with fistulating peri-anal Crohn's disease or active perianal sepsis.
Obstructive symptoms and evidence of a fixed stricture on radiology or colonoscopy.
Patients who are scheduled to start on ""top-down"" therapy or receive biologics as a first line therapy",No,All,16 Years,80 Years,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'NYU Langone Health/Bellevue', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10016', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lily Deng', 'LocationContactRole': 'Contact', 'LocationContactPhone': '212-263-4163', 'LocationContactEMail': 'lily.deng@nyulangone.org'}, {'LocationContactName': 'Lea Ann Chen, MD', 'LocationContactRole': 'Principal Investigator'}]}}]","[{'CollaboratorName': ""The Crohn's and Colitis Foundation"", 'CollaboratorClass': 'UNKNOWN'}]",Yes,"This is a multi-center, observational study of newly diagnosed IBD (CD or UC) patients. The Study aims to assess whether a prognostic biomarker can stratify IBD patients in the US.","[""Crohn's Disease"", 'Ulcerative Colitis', 'IBD', 'Inflammatory Bowel Disease', 'Precious']",No,['Ecologic or Community'],['Prospective'],"The target patient populations are newly diagnosed, active CD or UC in patients who are immunomodulator and anti-TNFα treatment naïve.",Probability Sample,,,,,,,,"[{'OverallOfficialName': 'James Lee, MD', 'OverallOfficialAffiliation': 'PredictImmune Ltd', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,"[{'CentralContactName': 'Karen Hills, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '+44 (0) 1223 804195', 'CentralContactEMail': 'khills@predictimmune.com'}]",,Samples With DNA,"Following patient consent and recruitment to the study, a 2.5 ml blood sample will be collected in a PAXgene tube.",,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003424', 'ConditionMeshTerm': 'Crohn Disease'}, {'ConditionMeshId': 'D000003092', 'ConditionMeshTerm': 'Colitis'}, {'ConditionMeshId': 'D000003093', 'ConditionMeshTerm': 'Colitis, Ulcerative'}, {'ConditionMeshId': 'D000007410', 'ConditionMeshTerm': 'Intestinal Diseases'}, {'ConditionMeshId': 'D000015212', 'ConditionMeshTerm': 'Inflammatory Bowel Diseases'}, {'ConditionMeshId': 'D000014456', 'ConditionMeshTerm': 'Ulcer'}]","[{'ConditionAncestorId': 'D000005759', 'ConditionAncestorTerm': 'Gastroenteritis'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]","[{'ConditionBrowseLeafId': 'M9027', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafAsFound': 'Bowel Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16500', 'ConditionBrowseLeafName': 'Inflammatory Bowel Diseases', 'ConditionBrowseLeafAsFound': 'Inflammatory Bowel Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5221', 'ConditionBrowseLeafName': 'Crohn Disease', 'ConditionBrowseLeafAsFound': ""Crohn's Disease"", 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4904', 'ConditionBrowseLeafName': 'Colitis, Ulcerative', 'ConditionBrowseLeafAsFound': 'Ulcerative Colitis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4903', 'ConditionBrowseLeafName': 'Colitis', 'ConditionBrowseLeafAsFound': 'Colitis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15789', 'ConditionBrowseLeafName': 'Ulcer', 'ConditionBrowseLeafAsFound': 'Ulcerative', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7458', 'ConditionBrowseLeafName': 'Gastroenteritis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4919', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04021030,HUM00122412,University of Michigan,OTHER,Building Collaborations to Address Drug Problems in the United States and China,Building Collaborations to Address Drug Problems in the United States and China,Oct-20,"Active, not recruiting",No,04-Oct-19,Actual,31-Dec-20,Anticipated,31-Dec-20,Anticipated,12-Jul-19,12-Jul-19,16-Jul-19,Actual,15-Oct-20,19-Oct-20,Actual,Principal Investigator,University of Michigan,OTHER,No,No,,,The purpose of this study is to evaluate the impact of a Cognitive Behavioral Therapy (CBT) intervention on the distribution and variability of pain level before and after intervention receipt among people with co-occurring chronic pain and Substance Use Disorders (SUDs) over a three-month follow-up period.,['Chronic Pain'],Interventional,['Not Applicable'],N/A,Single Group Assignment,Treatment,None (Open Label),12,Actual,"[{'ArmGroupLabel': 'Cognitive Behavioral Therapy (CBT)', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Cognitive Behavioral Therapy (CBT)']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Cognitive Behavioral Therapy (CBT)', 'InterventionDescription': 'The therapeutic intervention consists of 8, one-hour individual therapy sessions delivered over the course of 2 to 4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both chronic pain and substance use.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Cognitive Behavioral Therapy (CBT)']}}]","[{'PrimaryOutcomeMeasure': 'Proportion of participants with decrease in pain level ≥ 18 % (or two points) on the Numeric Rating Scale (NRS)', 'PrimaryOutcomeDescription': 'Pain level will be assessed using the Numeric Rating Scale (NRS). The NRS is a 0-10 scale, with higher scores indicating greater intensity of pain.', 'PrimaryOutcomeTimeFrame': '3 months post-intervention'}]",,"Inclusion Criteria:

At least 18 years of age
Currently receiving detoxification treatment
Report pain of at least moderate or greater intensity over the three months prior to baseline assessment as indicated by an average score of four or greater on the Numeric Rating Scale (NRS)
Have access to a phone for confidential personal therapy after the completion of detoxification treatment. For individuals who enter the residential treatment at the facility following the detoxification treatment, a research therapist will meet with them in person at a private office at the facility during their stay due to program's restriction on phone usage.

Exclusion Criteria:

Inability to speak and understand English
Inability to give informed, voluntary, written consent",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Meridian Health Services', 'LocationCity': 'Waterford', 'LocationState': 'Michigan', 'LocationZip': '48327', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Michigan Medicine - PKUHSC Joint Institute for Translational and Clinical Research', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Peking University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Meridian Health Services', 'CollaboratorClass': 'UNKNOWN'}]",,"The project is an open trial of the CBT intervention for 20 adults receiving detoxification treatment with comorbid pain. Participants will be screened for pain and other conditions by completing a self-report survey questionnaire. Eligible participants will be asked to complete a baseline assessment. A trained research therapist will conduct individual therapy with participants twice a week for 2-4 weeks. Participants will be re-assessed at 1- and 3-month post-intervention follow-ups to track changes in their pain, functioning, and substance use.",['Cognitive Behavioral Therapy'],,,,,,,,Mark A. Ilgen,Professor of Psychiatry,University of Michigan,,,"[{'OverallOfficialName': 'Mark Ilgen, Ph.D.', 'OverallOfficialAffiliation': 'University of Michigan', 'OverallOfficialRole': 'Principal Investigator'}]",Yes,,,,,,"Individual participant data that underlie the results reported in this article, after deidentiﬁcation (text, tables, ﬁgures, and appendices).",,,,,,,,,,,,,,,,,,,,"['Study Protocol', 'Informed Consent Form (ICF)']",Beginning 6 months and ending 36 months following article publication.,"Data access requests should be directed to Mark Ilgen (PI) at marki@umich.edu up to 36 months following article publication. To gain access, requestors will be required to sign a Data Access Agreement.",,,26-Oct-20,"[{'ConditionMeshId': 'D000059350', 'ConditionMeshTerm': 'Chronic Pain'}]","[{'ConditionAncestorId': 'D000010146', 'ConditionAncestorTerm': 'Pain'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}]","[{'ConditionBrowseLeafId': 'M28029', 'ConditionBrowseLeafName': 'Chronic Pain', 'ConditionBrowseLeafAsFound': 'Chronic Pain', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11649', 'ConditionBrowseLeafName': 'Pain', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02959827,19185,Bayer,INDUSTRY,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Iodinated Contrast Agents and Risk of Hypothyroidism in Young Children in the United States,Jan-19,Completed,No,15-Oct-16,Actual,15-Jun-17,Actual,15-Jun-17,Actual,11-Oct-16,07-Nov-16,09-Nov-16,Estimate,29-Jan-19,30-Jan-19,Actual,Sponsor,Bayer,INDUSTRY,Yes,No,,,"This study will estimate the incidence of hypothyroidism in a pediatric population of children under age 4, based on data from the US-based Kaiser Permanente Northern California database, which were exposed to iodinated contrast agent through having a diagnostic procedure.",['Hypothyroidism'],Observational,,,,,,2320,Actual,"[{'ArmGroupLabel': 'Iodinated contrast agents', 'ArmGroupDescription': 'Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Iodinated contrast agents']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Iodinated contrast agents', 'InterventionDescription': 'Use of iodine contrast agents and doses following the decision of the treating physician.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Iodinated contrast agents']}}]","[{'PrimaryOutcomeMeasure': 'Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice', 'PrimaryOutcomeDescription': 'Incidence density rates (IDR) were calculated as the number of cases over the person time at risk where the numerator was the number of cases and the denominator was the person years at risk.', 'PrimaryOutcomeTimeFrame': 'In the 365 days post exposure to an iodinated contrast agent'}]","[{'SecondaryOutcomeMeasure': 'Baseline Characteristics (Age) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Baseline Characteristics (Year of Hypothyroidism Diagnosis) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Baseline Characteristics (Type of Iodine Contrast Exposure) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Baseline Characteristics (Race/Ethnicity) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Time From First Iodinated Contrast to First Hypothyroidism Event', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Classification of Subclinical/Manifest Hypothyroidism by Type of Exposure', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}, {'SecondaryOutcomeMeasure': 'Classification of Hypothyroidism by Etiology', 'SecondaryOutcomeTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent'}]","Inclusion Criteria:

Children under age 4 in the Kaiser Permanente Northern California (KPNC) database, who had a diagnostic procedure with an iodinated contrast agent.
Participants should be member of the KPNC for at least 3 months before the iodinated contrast exposure, except where the child is under 3 months of age at time of initial exposure, and 2 weeks after the exposure.

Exclusion Criteria:

Diagnosis of hypothyroid any time prior to the iodine contrast exposure.
Lab values for low thyroid (TSH > 5 mU/L for children) any time before the exposure
Thyroid replacement therapy, Hashimoto thyroiditis, or congenital hypothyroidism any time prior to exposure.",No,All,,3 Years,['Child'],"[{'LocationFacility': 'Oakland', 'LocationCity': 'Oakland', 'LocationState': 'California', 'LocationZip': '94612', 'LocationCountry': 'United States'}]",,No,,"['Hypothyroidism,', 'children,', 'iodinated contrast agents,', 'retrospective cohort,', 'database']",No,['Cohort'],['Retrospective'],"Children under age 4 in the Kaiser Permanente Northern California database, who had a diagnostic procedure with an iodinated contrast agent",Non-Probability Sample,,,,,,,,,,,24-May-18,29-Jan-19,30-Jan-19,Actual,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007037', 'ConditionMeshTerm': 'Hypothyroidism'}]","[{'ConditionAncestorId': 'D000013959', 'ConditionAncestorTerm': 'Thyroid Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]","[{'ConditionBrowseLeafId': 'M8670', 'ConditionBrowseLeafName': 'Hypothyroidism', 'ConditionBrowseLeafAsFound': 'Hypothyroidism', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15301', 'ConditionBrowseLeafName': 'Thyroid Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M9071', 'InterventionBrowseLeafName': 'Iodine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M237459', 'InterventionBrowseLeafName': 'Cadexomer iodine', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]","There were 2320 children identified in Kaiser Permanente Northern California who met our study population criteria: patients who had a procedure that used iodinated contrast agent and were under the age of 4, during the years 2008 to June of 2016.","This study was a retrospective cohort study, using the data from the years 2008 to June of 2016 in the database of Kaiser Permanente Northern California.","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Iodine Contrast Agent', 'FlowGroupDescription': 'Children under age 4, from the US-based Kaiser Permanente Northern California database, who were exposed to iodinated contrast agent through having a diagnostic procedure.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2320'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2320'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Iodine Contrast Agent', 'BaselineGroupDescription': 'Children under age 4, from the US-based Kaiser Permanente Northern California database, who were exposed to iodinated contrast agent through having a diagnostic procedure.'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '2320'}]}}]","[{'BaselineMeasureTitle': 'Age, Customized', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<1 month', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '197'}]}}, {'BaselineCategoryTitle': '1 to 3 months', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '174'}]}}, {'BaselineCategoryTitle': '3 to 6 months', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '174'}]}}, {'BaselineCategoryTitle': '6 months to 1 year', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '257'}]}}, {'BaselineCategoryTitle': '1 to 4 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1518'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1032'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1288'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '800'}]}}, {'BaselineCategoryTitle': 'African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '174'}]}}, {'BaselineCategoryTitle': 'Hispanic', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '726'}]}}, {'BaselineCategoryTitle': 'Asian/Pacific islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '425'}]}}, {'BaselineCategoryTitle': 'Other or missing', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '195'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Incidence Rate of Hypothyroidism Detected in Routine Clinical Practice', 'OutcomeMeasureDescription': 'Incidence density rates (IDR) were calculated as the number of cases over the person time at risk where the numerator was the number of cases and the denominator was the person years at risk.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'events per 1,000 person years', 'OutcomeMeasureTimeFrame': 'In the 365 days post exposure to an iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Iodine Contrast Agent', 'OutcomeGroupDescription': 'Children under age 4, from the US-based Kaiser Permanente Northern California database, who were exposed to iodinated contrast agent through having a diagnostic procedure.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '2320'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '15.9', 'OutcomeMeasurementLowerLimit': '11.2', 'OutcomeMeasurementUpperLimit': '22.0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Baseline Characteristics (Age) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Non-hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2286'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': '<1 month', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '193'}]}}, {'OutcomeCategoryTitle': '1 to 3 months', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '168'}]}}, {'OutcomeCategoryTitle': '3 to 6 months', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '168'}]}}, {'OutcomeCategoryTitle': '6 months to 1 year', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '253'}]}}, {'OutcomeCategoryTitle': '1 to 4 years', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '14'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1504'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Baseline Characteristics (Sex) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Non-hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2286'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'Male', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '24'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1264'}]}}, {'OutcomeCategoryTitle': 'Female', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '10'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1022'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Baseline Characteristics (Year of Hypothyroidism Diagnosis) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Non-hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2286'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': '2008', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '300'}]}}, {'OutcomeCategoryTitle': '2009', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '320'}]}}, {'OutcomeCategoryTitle': '2010', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '297'}]}}, {'OutcomeCategoryTitle': '2011', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '260'}]}}, {'OutcomeCategoryTitle': '2012', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '266'}]}}, {'OutcomeCategoryTitle': '2013', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '263'}]}}, {'OutcomeCategoryTitle': '2014', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '234'}]}}, {'OutcomeCategoryTitle': '2015', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '241'}]}}, {'OutcomeCategoryTitle': 'through August 2016', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '105'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Baseline Characteristics (Type of Iodine Contrast Exposure) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Units', 'OutcomeMeasureUnitOfMeasure': 'Iodine contrast exposure', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeMeasureTypeUnitsAnalyzed': 'Iodine contrast exposure', 'OutcomeMeasureDenomUnitsSelected': 'Iodine contrast exposure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Non-hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2286'}]}}, {'OutcomeDenomUnits': 'Iodine contrast exposure', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2290'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'CT scan', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '18'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1762'}]}}, {'OutcomeCategoryTitle': 'Heart catheterization', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '16'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '528'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Baseline Characteristics (Race/Ethnicity) of the Cases With Hypothyroidism and of the Rest of the Cohort', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Non-hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who did not meet the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2286'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'White', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '787'}]}}, {'OutcomeCategoryTitle': 'African American', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '170'}]}}, {'OutcomeCategoryTitle': 'Hispanic', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '720'}]}}, {'OutcomeCategoryTitle': 'Asian/Pacific islander', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '416'}]}}, {'OutcomeCategoryTitle': 'Other or missing', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '193'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Time From First Iodinated Contrast to First Hypothyroidism Event', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases With CT Scan', 'OutcomeGroupDescription': 'Participants who had CT scan and met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Hypothyroidism Cases With Cardiac Catheterization', 'OutcomeGroupDescription': 'Participants who had cardiac catheterization and met the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '18'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '16'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': '<30 days', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '3'}]}}, {'OutcomeCategoryTitle': '30 - 59 days', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '3'}]}}, {'OutcomeCategoryTitle': '60+ days', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '10'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '10'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Classification of Subclinical/Manifest Hypothyroidism by Type of Exposure', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases With CT Scan', 'OutcomeGroupDescription': 'Participants who had CT scan and met the criteria to be a case of hypothyroidism were identified.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Hypothyroidism Cases With Cardiac Catheterization', 'OutcomeGroupDescription': 'Participants who had cardiac catheterization and met the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '18'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '16'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'Subclinical hypothyroidism', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '15'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '9'}]}}, {'OutcomeCategoryTitle': 'Manifest hypothyroidism', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}, {'OutcomeCategoryTitle': 'Treatment or diagnosis with no TSH test', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Classification of Hypothyroidism by Etiology', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': 'Up to 365 days after a diagnostic scan with iodinated contrast agent', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Hypothyroidism Cases', 'OutcomeGroupDescription': 'Participants who met the criteria to be a case of hypothyroidism were identified.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '34'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeCategoryTitle': 'Iodine induced cases', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '23'}]}}, {'OutcomeCategoryTitle': 'Other etiology cases', 'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '11'}]}}]}}]}}]",0,Incidence of hypothyroidism was assessed up to one year after iodine contrast exposure,"This study is a retrospective study using data from the database in United States. The safety outcome focused on the incidence of hypothyroidism for up to one year after iodine contrast exposure. Please refer to the result of primary outcome measure. All-Cause Mortality, Serious, and Other (Not Including Serious) Adverse Events were not monitored/assessed during this retrospective observation study. Only retrospective safety outcome data were assessed, which are on the outcome measures module.","[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Iodine Contrast Agent', 'EventGroupDescription': 'Children under age 4, from the US-based Kaiser Permanente Northern California database, who were exposed to iodinated contrast agent through having a diagnostic procedure.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '0', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '0', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '0'}]",,No,Yes,Therapeutic Area Head,Bayer,clinical-trials-contact@bayer.com,(+) 1-888-8422937,,OTHER,,,,"[{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'October 11, 2016', 'LargeDocUploadDate': '05/23/2018 22:29', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02395536,"Version 1.0, 23 January 2015",Medtronic Cardiac Rhythm and Heart Failure,INDUSTRY,Medtronic Reveal LINQ™ In-Office 2 (RIO 2) Study United States,Reveal LINQ™ In-Office 2 (RIO 2) Study United States,May-17,Completed,No,30-Mar-15,Actual,31-May-16,Actual,31-May-16,Actual,17-Mar-15,20-Mar-15,23-Mar-15,Estimate,09-May-17,04-Oct-17,Actual,Sponsor,Medtronic Cardiac Rhythm and Heart Failure,INDUSTRY,,,,,"The primary purpose of the RIO 2 study is to demonstrate that when the Reveal LINQ™ insertable cardiac monitoring (ICM) system that records subcutaneous ECG insertion procedure performed in the in-office setting is as safe as LINQ™ insertions performed in the traditional hospital setting (operating room, cardiac catheterization or electrophysiology (EP) laboratory).",['Arrhythmia'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Health Services Research,None (Open Label),525,Actual,"[{'ArmGroupLabel': 'In office Outside walls of hospital', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Reveal LINQ insertions will be performed in office setting. The in office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not an ambulatory surgery center.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: office setting']}}, {'ArmGroupLabel': 'Traditional Hospital Setting', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'Reveal LINQ insertions will be performed in a traditional setting. The traditional hospital setting includes an operating room or electrophysiology laboratory.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: hosptial setting']}}]","[{'InterventionType': 'Other', 'InterventionName': 'office setting', 'InterventionDescription': 'An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['In office Outside walls of hospital']}}, {'InterventionType': 'Other', 'InterventionName': 'hosptial setting', 'InterventionDescription': 'A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Traditional Hospital Setting']}}]","[{'PrimaryOutcomeMeasure': 'Untoward Event Rate Associated With LINQ™ Insertions Performed', 'PrimaryOutcomeDescription': 'Demonstrate that the untoward event rate associated with Reveal LINQ™ insertions performed in-office or in the traditional hospital setting (operating room, cardiac catheterization or EP laboratory) are comparable.\n\nUntoward events are a composite of unsuccessful Reveal LINQ™ or complications related to the Reveal LINQ™ insertion procedure or system.', 'PrimaryOutcomeTimeFrame': '3 Months post insertion'}]",,"Inclusion Criteria:

Patient is indicated for continuous arrhythmia monitoring with a Reveal LINQ™ Insertable Cardiac Monitor
Patient is 18 years of age or older
Patient is willing to undergo ICM insertion procedure outside of the cath lab, OR, EP lab setting with only local anesthetic
Patient is willing and able to provide consent and authorize the use and disclosure of health information
Patient is willing and able to comply with the protocol including the required follow-up

Exclusion Criteria:

Patient has unusual thoracic anatomy or scarring at the implant site which may adversely affect the success of the implant procedure
Patient has reduced immune function or is otherwise at high risk for infection per physician discretion
Current therapy with immunosuppressive agents or chronic steroid use e.g. Prednisone greater than 20mg per day
Patient requires hemodialysis
Patient with active malignancy or history of chemotherapy or radiation treatment Patient has had a recent (within 30 days) or an active infection including but not limited to pneumonia, urinary tract, cellulitis, or bacteremia.
Patient has had major surgery (in the past 6 months)
Patient has undergone a procedure which required central venous or intraarterial access (e.g. AF/VT ablation, EP study, coronary angio) within the last 3 months or is scheduled for such a procedure while enrolled in the study.
Prior history of surgical infection, prosthetic device infection, or endovascular infection, including endocarditis, in the past 12 months.
Patient has a central venous port, an atrio-venous fistula, or a prosthetic valve
Patient requires conscious or moderate sedation to receive LINQ™
Patient is already implanted with a loop recorder
Patient is implanted or indicated for implant with a pacemaker, ICD, CRT device
Patient is enrolled in another study that could confound the results of this study, without documented pre-approval from a Medtronic study manager.
Patient's life expectancy is less than 6 months
Patient is pregnant",No,All,18 Years,99 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'Scripps Green Hospital', 'LocationCity': 'La Jolla', 'LocationState': 'California', 'LocationZip': '92037', 'LocationCountry': 'United States'}, {'LocationFacility': 'Saint Joseph Heritage Healthcare', 'LocationCity': 'Mission Viejo', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationFacility': 'Regional Cardiology Associates (Sacramento CA)', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationCountry': 'United States'}, {'LocationFacility': 'Colorado Heart and Vascular, PC', 'LocationCity': 'Lakewood', 'LocationState': 'Colorado', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cardiac Arrhythmia Service', 'LocationCity': 'Boca Raton', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationFacility': 'Clearwater Cardiovascular Consultants - Clearwater Office', 'LocationCity': 'Clearwater', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationFacility': 'Jim Moran Heart & Vascular-Holy Cross Hospital', 'LocationCity': 'Fort Lauderdale', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationFacility': 'Tallahassee Research Institute Inc', 'LocationCity': 'Tallahassee', 'LocationState': 'Florida', 'LocationCountry': 'United States'}, {'LocationFacility': 'Georgia Arrhythmia Consultants', 'LocationCity': 'Macon', 'LocationState': 'Georgia', 'LocationCountry': 'United States'}, {'LocationFacility': 'Saint Elizabeth Healthcare', 'LocationCity': 'Edgewood', 'LocationState': 'Kentucky', 'LocationCountry': 'United States'}, {'LocationFacility': 'Delmarva Heart Research Foundation Inc', 'LocationCity': 'Salisbury', 'LocationState': 'Maryland', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sparrow Clinical Research Institute', 'LocationCity': 'Lansing', 'LocationState': 'Michigan', 'LocationZip': '48912', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cardiology Associates of North Mississippi', 'LocationCity': 'Tupelo', 'LocationState': 'Mississippi', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mid America Heart Institute (MAHI)', 'LocationCity': 'Kansas City', 'LocationState': 'Missouri', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lester E Cox Medical Center', 'LocationCity': 'Springfield', 'LocationState': 'Missouri', 'LocationCountry': 'United States'}, {'LocationFacility': 'Morristown Memorial Hospital', 'LocationCity': 'Newark', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lourdes Cardiology Services', 'LocationCity': 'Voorhees', 'LocationState': 'New Jersey', 'LocationCountry': 'United States'}, {'LocationFacility': 'Northwell Health', 'LocationCity': 'Great Neck', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Mount Sinai Medical Center (New York NY)', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cone Health Medical Group HeartCare at Church Street', 'LocationCity': 'Greensboro', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationFacility': 'Raleigh Cardiology Associates', 'LocationCity': 'Raleigh', 'LocationState': 'North Carolina', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oklahoma Heart Institute', 'LocationCity': 'Tulsa', 'LocationState': 'Oklahoma', 'LocationCountry': 'United States'}, {'LocationFacility': 'Diagnostic Cardiology Group', 'LocationCity': 'Chattanooga', 'LocationState': 'Tennessee', 'LocationCountry': 'United States'}, {'LocationFacility': 'Amarillo Heart Group', 'LocationCity': 'Amarillo', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Cardiac Arrhythmia Research Foundation', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationFacility': 'Baylor Research Institute (Dallas TX)', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sentara Norfolk General Hospital', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationCountry': 'United States'}]",,No,"RIO 2 is a two arm, randomized, prospective, un-blinded, multicenter, non-significant risk study. The primary objective for RIO 2 will be assessed by randomizing subjects to receive their LINQ™ insertion in the office setting or in the traditional hospital environment. Moving the LINQ™ insertion procedure to the office setting is not expected to decrease the complication rate compared to in hospital insertion procedures, however, moving the LINQ™ insertion procedure out of the traditional hospital setting may benefit the patient and reduce the burden to the healthcare system.",,,,,,,,RIO 2,,,,,,,No,"[{'ReferencePMID': '32207636', 'ReferenceType': 'derived', 'ReferenceCitation': 'Rogers JD, Piorkowski C, Sohail MR, Anand R, Kowalski M, Rosemas S, Stromberg K, Sanders P. Resource utilization associated with hospital and office-based insertion of a miniaturized insertable cardiac monitor: results from the RIO 2 randomized US study. J Med Econ. 2020 Jul;23(7):706-713. doi: 10.1080/13696998.2020.1746548. Epub 2020 May 1.'}, {'ReferencePMID': '27825975', 'ReferenceType': 'derived', 'ReferenceCitation': 'Rogers JD, Sanders P, Piorkowski C, Sohail MR, Anand R, Crossen K, Khairallah FS, Kaplon RE, Stromberg K, Kowal RC. In-office insertion of a miniaturized insertable cardiac monitor: Results from the Reveal LINQ In-Office 2 randomized study. Heart Rhythm. 2017 Feb;14(2):218-224. doi: 10.1016/j.hrthm.2016.11.001. Epub 2016 Nov 4.'}]",09-May-17,09-May-17,04-Oct-17,Actual,,,,,,,,,,,,,,,,,,The site of the Reveal LINQ insertion was randomized. Therefore it was not possible to blind the subject or the investigator.,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001145', 'ConditionMeshTerm': 'Arrhythmias, Cardiac'}]","[{'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]","[{'ConditionBrowseLeafId': 'M3034', 'ConditionBrowseLeafName': 'Arrhythmias, Cardiac', 'ConditionBrowseLeafAsFound': 'Arrhythmia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,4 subjects excluded prior to randomization for not meeting inclusion/exclusion criteria,525 subjects were assessed for eligibility,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'In Office Outside Walls of Hospital', 'FlowGroupDescription': 'Reveal LINQ insertions will be performed in office setting.\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Traditional Hospital Setting', 'FlowGroupDescription': 'Reveal LINQ insertions will be performed in IN-a traditional setting\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '264'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '257'}]}}, {'FlowMilestoneType': 'REVEAL LINQ Insertion', 'FlowMilestoneComment': 'Number of subjects randomized that actually had a REVEAL LINQ insertion attempt', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '251'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '231'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '244'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '227'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '20'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '30'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '4'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'}]}}, {'FlowDropWithdrawType': 'Death', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '2'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}, {'FlowDropWithdrawType': 'Physician Decision', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '4'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '6'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '9'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '17'}]}}, {'FlowDropWithdrawType': 'Inclusion/Excusion Criteria Violation', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '2'}]}}, {'FlowDropWithdrawType': 'Insurance issue', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '0'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}]}}]",The baseline analysis population is the number of randomized subjects that had a REVEAL LINQ insertion attempt,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'In Office Outside Walls of Hospital', 'BaselineGroupDescription': 'Reveal LINQ insertions will be performed in office setting.\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Traditional Hospital Setting', 'BaselineGroupDescription': 'Reveal LINQ insertions will be performed in IN-a traditional setting\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '251'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '231'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '482'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '64.3', 'BaselineMeasurementSpread': '14.0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '63.9', 'BaselineMeasurementSpread': '14.9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '64.1', 'BaselineMeasurementSpread': '14.4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '117'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '125'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '242'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '134'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '106'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '240'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race and Ethnicity Not Collected', 'BaselineMeasurePopulationDescription': 'Race and Ethnicity were not collected from any participant.', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '0'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '0'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '0'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '251'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '231'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '482'}]}}]}}]}}, {'BaselineMeasureTitle': 'Body mass index (kg/m^2)', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'kg/m^2', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30.3', 'BaselineMeasurementSpread': '7.5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '29.6', 'BaselineMeasurementSpread': '7.1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '30.0', 'BaselineMeasurementSpread': '7.3'}]}}]}}]}}, {'BaselineMeasureTitle': 'Cardiomyopathy', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '17'}]}}]}}]}}, {'BaselineMeasureTitle': 'Congestive heart failure', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '9'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '14'}]}}]}}]}}, {'BaselineMeasureTitle': 'Hypertension', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '162'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '146'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '308'}]}}]}}]}}, {'BaselineMeasureTitle': 'Myocardial infarction', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '13'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '23'}]}}]}}]}}, {'BaselineMeasureTitle': 'Prior stroke or transient ischemic attack', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '69'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '58'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '127'}]}}]}}]}}, {'BaselineMeasureTitle': 'Unexplained syncope', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '48'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '76'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '124'}]}}]}}]}}, {'BaselineMeasureTitle': 'Paroxysmal atrial fibrillation', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '81'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '68'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '149'}]}}]}}]}}, {'BaselineMeasureTitle': 'Persistent/permanent atrial fibrillation', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '28'}]}}]}}]}}, {'BaselineMeasureTitle': 'Diabetes', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '43'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '53'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '96'}]}}]}}]}}, {'BaselineMeasureTitle': 'Renal dysfunction', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '251'}, {'BaselineClassDenomCountGroupId': 'BG001', 'BaselineClassDenomCountValue': '231'}, {'BaselineClassDenomCountGroupId': 'BG002', 'BaselineClassDenomCountValue': '482'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '14'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '21'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Untoward Event Rate Associated With LINQ™ Insertions Performed', 'OutcomeMeasureDescription': 'Demonstrate that the untoward event rate associated with Reveal LINQ™ insertions performed in-office or in the traditional hospital setting (operating room, cardiac catheterization or EP laboratory) are comparable.\n\nUntoward events are a composite of unsuccessful Reveal LINQ™ or complications related to the Reveal LINQ™ insertion procedure or system.', 'OutcomeMeasurePopulationDescription': 'Subjects exiting prematurely (prior to 3-month visit) without an untoward event were excluded from primary analysis. There were 7 excluded from the In office arm (2 deaths unrelated to the REVEAL LINQ and 5 premature exits) and 4 excluded from the traditional hospital setting arm (all 4 due to premature exit)', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Count of Participants', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': '3 Months post insertion', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'In Office Outside Walls of Hospital', 'OutcomeGroupDescription': 'Reveal LINQ insertions will be performed in office setting.\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Traditional Hospital Setting', 'OutcomeGroupDescription': 'Reveal LINQ insertions will be performed in IN-a traditional setting\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '244'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '227'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'The null hypothesis was that Reveal LINQ insertions performed in-office would have a higher untoward event rate than insertions performed in the traditional hospital setting. A sample size of 476 subjects was estimated to provide at least 90% power at a 1-sided alpha level of 2.5% and 5% non-inferiority margin. For the sample size calculation, an event rate of 2.0% was assumed in both arms. The Farrington-Manning test of two indepent proportions was used to compare study arms.', 'OutcomeAnalysisNonInferiorityType': 'Non-Inferiority', 'OutcomeAnalysisNonInferiorityComment': 'A non-inferiority margin of 5% was chosen since the inability to rule out a 5% increase in untoward event rate associated with moving the Reveal LINQ procedure in-office may suggest that in-office procedures would too high of a complication rate compared procedures performed in the traditional office setting.', 'OutcomeAnalysisPValue': '<0.001', 'OutcomeAnalysisPValueComment': 'P-value for non-inferiority versus a 5% non-inferiority margin.', 'OutcomeAnalysisStatisticalMethod': 'Farrington-Manning test', 'OutcomeAnalysisParamType': 'Risk Difference (RD)', 'OutcomeAnalysisParamValue': '-0.001', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '-0.030', 'OutcomeAnalysisCIUpperLimit': '0.029', 'OutcomeAnalysisEstimateComment': 'The estimated value and its associated confidence interval are for the in-office minus traditional hospital setting difference in the untoward event rates. The point estimate is negative since the in-office rate was lower than the hospital rate.'}]}}]",0,All adeverse events potentially related to the REVEAL LINQ insertion procedure or system were collected from consent through the end of study participation (3-months post-procedure). Additionally all deaths were collected.,An independent clinical events committee comprised on independent physicians who are not sponsor employees or study investigators and blinded to the subject's treatment arm adjudicated the relationship of each event to the REVEAL LINQ insertion procedure or system.,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'In Office Outside Walls of Hospital', 'EventGroupDescription': 'Reveal LINQ insertions will be performed in office setting.\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.', 'EventGroupDeathsNumAffected': '2', 'EventGroupDeathsNumAtRisk': '251', 'EventGroupSeriousNumAffected': '3', 'EventGroupSeriousNumAtRisk': '251', 'EventGroupOtherNumAffected': '8', 'EventGroupOtherNumAtRisk': '251'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Traditional Hospital Setting', 'EventGroupDescription': 'Reveal LINQ insertions will be performed in IN-a traditional setting\n\nInsertion of Reveal LINQ device in office or traditional hospital setting: The insterions will be performed in a Physician office setting or in Traditional Hospital Setting as per the arm the patient is randomized in.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '231', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '231', 'EventGroupOtherNumAffected': '11', 'EventGroupOtherNumAtRisk': '231'}]","[{'OtherEventTerm': 'Atrioventricular block complete', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Supraventricular tachycardia', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Device dislocation', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Device extrusion', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Implant site bruising', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Implant site rash', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Incision site complication', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Incision site haemorrhage', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '3', 'OtherEventStatsNumAffected': '3', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Procedural dizziness', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '2', 'OtherEventStatsNumAffected': '2', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Wound dehiscence', 'OtherEventOrganSystem': 'Injury, poisoning and procedural complications', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Cerebral haemorrhage', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Presyncope', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 18.1', 'OtherEventAssessmentType': 'Non-systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '0', 'OtherEventStatsNumAffected': '0', 'OtherEventStatsNumAtRisk': '251'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '1', 'OtherEventStatsNumAffected': '1', 'OtherEventStatsNumAtRisk': '231'}]}}]",No,Yes,"Lindsay Werder, Senior Clinical Research Specialist","Medtronic, PLC",lindsay.k.werder@medtronic.com,7635268168,"[{'SeriousEventTerm': 'Atrioventricular block complete', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 18.1', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '251'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '231'}]}}, {'SeriousEventTerm': 'Incision Site Haemorrhage', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 18.1', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '251'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '231'}]}}, {'SeriousEventTerm': 'Cerebral Haemorrhage', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 18.1', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '251'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '231'}]}}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03628235,C-001117-1,"CHDI Foundation, Inc.",OTHER,HD-Charge: Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States,Indirect and Out-of-Pocket Costs of Huntington's Disease in the United States,Sep-20,Recruiting,No,21-May-20,Actual,31-Dec-21,Anticipated,31-Dec-21,Anticipated,29-May-18,09-Aug-18,14-Aug-18,Actual,30-Sep-20,05-Oct-20,Actual,Sponsor,"CHDI Foundation, Inc.",OTHER,No,No,,,"Huntington's disease (HD) is a rare, inherited and progressive neurodegenerative disorder for which hallmark symptoms include movement disorders, loss of cognitive faculties and psychiatric disturbances. With the progression of the disease, patients require increasing level of medical care, caregiver support, and long-term care, which lead to substantial burden of illness. Very little data are available on the direct or indirect costs for HD. The direct medical costs of HD in the US have been summarized from retrospective commercial and Medicaid claims data analysis. The indirect and out-of-pocket costs of HD in the US have not been quantified. This study will help to bridge these gaps.

This study is a single-assessment, cross-sectional online survey administered to Huntington disease gene expansion carriers (HDGECs) and companions of HDGECs by HD stage to understand the indirect and out-of-pocket costs of Huntington's disease in the US.","[""Huntington's Disease""]",Observational,,,,,,240,Anticipated,"[{'ArmGroupLabel': 'Early stage HDGECs', 'ArmGroupDescription': 'CAG length ≥ 40; DCL = 4, TFC ≥ 11', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Online survey']}}, {'ArmGroupLabel': 'Middle stage HDGECs', 'ArmGroupDescription': 'CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Online survey']}}, {'ArmGroupLabel': 'Late stage HDGECs', 'ArmGroupDescription': 'CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Online survey']}}, {'ArmGroupLabel': 'Companions of early stage HDGECs', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Online survey']}}, {'ArmGroupLabel': 'Companions of middle stage HDGECs', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Online survey']}}, {'ArmGroupLabel': 'Companions of late stage HDGECs', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Online survey']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Online survey', 'InterventionDescription': ""Online survey to capture indirect and out of pocket costs of Huntington's Disease in HDGECs and companions"", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Companions of early stage HDGECs', 'Companions of late stage HDGECs', 'Companions of middle stage HDGECs', 'Early stage HDGECs', 'Late stage HDGECs', 'Middle stage HDGECs']}}]","[{'PrimaryOutcomeMeasure': 'Quantify the indirect costs associated with productivity loss for HDGECs and companions', 'PrimaryOutcomeDescription': ""Productivity loss is measured by annual lost wages and it is collected in the survey's employment questionnaires and WPAI"", 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Quantify out-of-pocket expenses for HDGECs and companions', 'PrimaryOutcomeDescription': 'The indirect costs associated with the total annual out-of-pocket expenses.', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Identify the indirect costs associated with informal care received for HDGECs', 'PrimaryOutcomeDescription': 'The total informal care time received during a typical week', 'PrimaryOutcomeTimeFrame': '12 months'}, {'PrimaryOutcomeMeasure': 'Quantify the indirect costs associated with non-work caregiving time for companions', 'PrimaryOutcomeDescription': 'The indirect costs associated with the annual opportunity costs of companion', 'PrimaryOutcomeTimeFrame': '12 months'}]","[{'SecondaryOutcomeMeasure': ""Identify the reasons for HDGEC and companion's unemployment or underemployment"", 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'The proportion of Dual Role Companions, differentiated by HD stage of the companion', 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': 'To understand traditional disease staging system based on total functional capacity (TFC)', 'SecondaryOutcomeDescription': 'For HDGECs and Companions: Understand how the traditional disease staging system, based on the TFC score, relates to a staging system based on resource utilization questionnaire and comorbid conditions developed in Divino et al. (2013)', 'SecondaryOutcomeTimeFrame': '12 months'}]","Inclusion Criteria for HDGECs:

Identified as an active participant in Enroll-HD (participants who have completed their last on site Enroll-HD visit within approximately 15 months)
Able to provide online or written informed consent. A LAR for HDGEC can provide written consent, if applicable
Identified as a participant with clinically diagnosed HD and has a CAG length ≥ 40
Site PI has access to HDGEC's medical records for the purpose of completing the Resource Utilization Questionnaire
Able to speak and understand both verbal and written English
Has adult onset of disease (disease symptoms manifested at age 20 years or older)
Has access to a computer/tablet/smartphone (if compatible) and internet services

Stage classification of HDGECs:

Early stage HDGEC: CAG length ≥ 40; DCL = 4, TFC ≥ 11
Middle stage HDGEC: CAG length ≥ 40; DCL = 4, 7 ≤ TFC ≤ 10
Late stage HDGEC: CAG length ≥ 40; DCL = 4, 0 ≤ TFC ≤ 6

Exclusion Criteria for HDGECs:

HDGECs will be excluded from the study if they have significant cognitive or any other impairment sufficient to interfere with study associated tasks as judged by the Site PI or Site PI's designee (exceptions will be made if a companion/LAR completes the survey on their behalf).

Inclusion criteria for companions:

Able to provide online or written informed consent
Identified as the primary provider (unpaid) of supportive care of an HDGEC (HDGEC must be an Enroll-HD participant and have a CAG length ≥ 40 and have adult onset of disease (disease symptoms manifested at age 20 years or older))
Able to speak and understand both verbal and written English
Aged 21 years or older at time of survey
Has access to a computer/tablet/smartphone (if compatible) and internet services and has the technical skills required to complete an online survey

Exclusion Criteria for companions:

Companions will be excluded from the study if they are identified as paid or salaried caregivers; however, the HDGECs for whom they care may still be included in the study.",No,All,21 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Rocky Mountain Movement Disorder, P.C.', 'LocationStatus': 'Recruiting', 'LocationCity': 'Englewood', 'LocationState': 'Colorado', 'LocationZip': '80113', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rajeev Kumar, MD', 'LocationContactRole': 'Contact', 'LocationContactPhone': '303-357-5455', 'LocationContactEMail': 'rajeev_kumar@msn.com'}, {'LocationContactName': 'Rajeev Kumar, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Hereditary Neurological Disease Centre, Inc.', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wichita', 'LocationState': 'Kansas', 'LocationZip': '66226', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Greg M Suter', 'LocationContactRole': 'Contact', 'LocationContactPhone': '316-609-3020', 'LocationContactEMail': 'hndcentre@aol.com'}, {'LocationContactName': 'William Mallonee', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Columbia University Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Paula Wasserman, MA', 'LocationContactRole': 'Contact', 'LocationContactPhone': '212-305-4597', 'LocationContactEMail': 'pl2032@cumc.columbia.edu'}, {'LocationContactName': 'Hiral Shah, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Karen Marder, MD', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'University of Washington', 'LocationStatus': 'Recruiting', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98115', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ethan Hendrix', 'LocationContactRole': 'Contact', 'LocationContactPhone': '206-685-6602', 'LocationContactEMail': 'e713@uw.edu'}, {'LocationContactName': 'Debra Del Castillo', 'LocationContactRole': 'Contact', 'LocationContactPhone': '206-543-3647', 'LocationContactEMail': 'debradel@uw.edu'}, {'LocationContactName': 'Ali Samii, MD', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Anny Lin, MD', 'LocationContactRole': 'Principal Investigator'}]}}]","[{'CollaboratorName': 'IQVIA Company', 'CollaboratorClass': 'UNKNOWN'}]",No,"The survey collects the following data from each HDGEC and companion:

Participant demographics (for HDGECs and companion)
Informal care received (for HDGECs only)
Out of pocket HD costs (for HDGECs and companion)
Current employment status (for HDGECs and companion)
Non-work and work care giving time that companion spends taking care of HDGEC (for companion only)
Work Productivity and Activity Impairment (WPAI) Questionnaire (for HDGECs and companion)","['online survey', 'indirect costs', 'out-of-pocket costs', 'HD', ""Huntington's disease"", 'companions', 'Enroll-HD']",No,['Other'],['Prospective'],"HDGECs: Participant in Enroll-HD with clinically diagnosed HD and a cytosine, adenine, guanine (CAG) length ≥ 40, who meets the protocol inclusion criteria and none of the exclusion criteria.

Companions: Primary provider (unpaid) of supportive care for an HDGEC (this HDGEC must be an active participant of Enroll-HD Study, have a CAG ≥ 40, have an adult onset of disease (disease symptoms manifested at age 20 years or older), and a DCL=4)), who meets the protocol's companion inclusion criteria and none of the exclusion criteria.",Non-Probability Sample,,,,,,,,,Undecided,,,,,,,"[{'CentralContactName': 'Jamie Hamilton, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '609-945-9627', 'CentralContactEMail': 'jamie.hamilton@chdifoundation.org'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006816', 'ConditionMeshTerm': 'Huntington Disease'}]","[{'ConditionAncestorId': 'D000001480', 'ConditionAncestorTerm': 'Basal Ganglia Diseases'}, {'ConditionAncestorId': 'D000001927', 'ConditionAncestorTerm': 'Brain Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000003704', 'ConditionAncestorTerm': 'Dementia'}, {'ConditionAncestorId': 'D000002819', 'ConditionAncestorTerm': 'Chorea'}, {'ConditionAncestorId': 'D000020820', 'ConditionAncestorTerm': 'Dyskinesias'}, {'ConditionAncestorId': 'D000009069', 'ConditionAncestorTerm': 'Movement Disorders'}, {'ConditionAncestorId': 'D000020271', 'ConditionAncestorTerm': 'Heredodegenerative Disorders, Nervous System'}, {'ConditionAncestorId': 'D000019636', 'ConditionAncestorTerm': 'Neurodegenerative Diseases'}, {'ConditionAncestorId': 'D000030342', 'ConditionAncestorTerm': 'Genetic Diseases, Inborn'}, {'ConditionAncestorId': 'D000003072', 'ConditionAncestorTerm': 'Cognition Disorders'}, {'ConditionAncestorId': 'D000019965', 'ConditionAncestorTerm': 'Neurocognitive Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]","[{'ConditionBrowseLeafId': 'M8458', 'ConditionBrowseLeafName': 'Huntington Disease', 'ConditionBrowseLeafAsFound': ""Huntington's Disease"", 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24190', 'ConditionBrowseLeafName': 'Ganglion Cysts', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14941', 'ConditionBrowseLeafName': 'Synovial Cyst', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3355', 'ConditionBrowseLeafName': 'Basal Ganglia Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3786', 'ConditionBrowseLeafName': 'Brain Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5487', 'ConditionBrowseLeafName': 'Dementia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4642', 'ConditionBrowseLeafName': 'Chorea', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21158', 'ConditionBrowseLeafName': 'Dyskinesias', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10612', 'ConditionBrowseLeafName': 'Movement Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20676', 'ConditionBrowseLeafName': 'Heredodegenerative Disorders, Nervous System', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20142', 'ConditionBrowseLeafName': 'Neurodegenerative Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M22270', 'ConditionBrowseLeafName': 'Genetic Diseases, Inborn', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4884', 'ConditionBrowseLeafName': 'Cognition Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20420', 'ConditionBrowseLeafName': 'Neurocognitive Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2858', 'ConditionBrowseLeafName': 'Huntington Disease', 'ConditionBrowseLeafAsFound': ""Huntington's Disease"", 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC16', 'ConditionBrowseBranchName': 'Diseases and Abnormalities at or Before Birth'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02787538,2015P002116,Massachusetts General Hospital,OTHER,Supporting Patient Care With Electronic Resources in the United States,Supporting Patient Care With Electronic Resources in the United States (SuPER-US): Effectiveness of an Online Decision Aid for Patients Considering Biologic Therapy for Rheumatoid Arthritis,May-16,Unknown status,No,Jan-16,,Dec-17,Anticipated,Dec-18,Anticipated,26-May-16,31-May-16,01-Jun-16,Estimate,31-May-16,01-Jun-16,Estimate,Principal Investigator,Massachusetts General Hospital,OTHER,,,,,This proof-of-concept randomized trial evaluates the effectiveness of using an online decision aid (US-ANSWER-2) in the decision-making to start or switch biologic therapy in US patients with rheumatoid arthritis.,['Rheumatoid Arthritis'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Supportive Care,Single,80,Anticipated,"[{'ArmGroupLabel': 'US-ANSWER-2 decision aid', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': ""The intervention group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own computers within two days. At the end of the session, US-ANSWER-2 will produce a one-page summary with the participant's questions, concerns, and preferred medication option."", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: US-ANSWER-2 decision aid']}}, {'ArmGroupLabel': 'Control group (Online medication guide)', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The control group will receive the online medication guide, reflective of usual practice. The online medication guide contains standard information about biologics, including an introduction about biologic options, dosages, and effects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Control group (Online medication guide)']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'US-ANSWER-2 decision aid', 'InterventionDescription': 'US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['US-ANSWER-2 decision aid']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Control group (Online medication guide)', 'InterventionDescription': 'Standard online medication guide.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Control group (Online medication guide)']}}]","[{'PrimaryOutcomeMeasure': 'Decisional Conflict Scale (DCS)', 'PrimaryOutcomeDescription': 'The Decisional Conflict Scale (short version) measures personal perceptions of uncertainty in choosing options, factors contributing to uncertainty, and effective decision-making. It is one-dimensional and has 10 questions and three response categories (yes/no/unsure) used to compute one score.', 'PrimaryOutcomeTimeFrame': 'Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1)'}]","[{'SecondaryOutcomeMeasure': 'Medication Education Impact Questionnaire (MeiQ)', 'SecondaryOutcomeDescription': 'The MeiQ consists of 6 subscales and a total of 29 items. MeiQ was developed and tested in three different samples of patients with rheumatic conditions on their knowledge of medications.', 'SecondaryOutcomeTimeFrame': 'Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2'}, {'SecondaryOutcomeMeasure': 'Partners in Health Scale (PHS)', 'SecondaryOutcomeDescription': 'The Partners in Health Scale is an 11-item measure designed to assess self-efficacy, knowledge of RA and treatment, and self-management behaviours such as taking medication appropriately and adopting a healthy lifestyle.', 'SecondaryOutcomeTimeFrame': 'Change measure (baseline score compared to after using the US-ANSWER-2 intervention at Month 1 and at Month 2'}, {'SecondaryOutcomeMeasure': 'Health Resource Utilization (HRU) Questionnaire', 'SecondaryOutcomeDescription': ""The HRU questionnaire was developed for both self and interviewer administration in people with arthritis and other chronic conditions. It consists of a series of open-ended questions about individuals' visits to health professionals, use of investigative tests, hospital visits, use of medications, purchases of adaptive aids, and estimable productivity loss incurred by the individual and their caregivers due to his/her health."", 'SecondaryOutcomeTimeFrame': 'Change measure (baseline score compared to after using the US-ANSWER-2 at Month 2)'}]","Inclusion Criteria:

The inclusion criteria are as follows:

with a diagnosis of RA from a rheumatologist
whose rheumatologists have recommended initiating a biologic or switching to another biologic
who have internet access and email.

Exclusion Criteria:

Patients who do not meet the inclusion criteria.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Massachusetts General Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sharan Rai, BSc', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'srai1@mgh.harvard.edu'}, {'LocationContactName': 'Hyon K Choi, MD, DrPH', 'LocationContactRole': 'Principal Investigator'}]}}]","[{'CollaboratorName': 'Arthritis Research Centre of Canada', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': ""Brigham and Women's Hospital"", 'CollaboratorClass': 'OTHER'}]",No,"The proposed project aims to improve the process of making evidence-informed treatment decisions by patients with rheumatoid arthritis (RA) and ultimately empower patient self-management. Current RA treatment emphasizes: 1) the need for early and aggressive treatment, and 2) the use of a treat-to-target approach. However, patients often struggle with treatment decisions, especially when the options have both benefits and risks. To address this challenge, investigators based at Arthritis Research Canada have previously developed an online decision aid called ANSWER-2 (ANimated, Self-serve, WEb-based, Research Tool: Version 2) for RA patients who are considering a biologic, and this tool has been recently adapted for the US healthcare setting (called US-ANSWER-2).

Objectives: 1) To evaluate the effectiveness of US-ANSWER-2 in reducing patients' decisional conflict. 2) To assess the extent to which US-ANSWER-2 improves patients' knowledge about RA medications and confidence in managing their health. 3) To examine the experiences of patients and rheumatologists in using US-ANSWER-2.

The investigators will conduct a proof-of-concept randomized controlled trial with 80 patients with RA. Eligible individuals are those: 1) with a diagnosis of RA from a rheumatologist, 2) whose rheumatologists have recommended initiating a biologic or switching to another biologic, and 3) who have internet access and email. The Intervention Group will receive simple instructions to access the US-ANSWER-2 decision aid and complete the program on their own within two days. At the end of the session, a one-page summary will be produced to help them discuss their questions, concerns, and preferred choices with their health care providers. The Control Group will receive a standard online medication guide, reflective of usual practice. Participants will complete the Decisional Conflict Scale (primary outcome) before and after the intervention (US-ANSWER-2 or standard online medication guide). The following secondary outcome measures will be collected at baseline, Month 1, and Month 2: 1) Medication Education Impact Questionnaire, and 2) Partners in Health Scale. In addition, the use of healthcare resources will be collected at baseline and Month 2, and the use of biologics will be collected at Month 6. All participants and their rheumatologists will be invited to participate in a qualitative interview about their experience with the patient decision aid.","['Rheumatoid Arthritis', 'Decision Aids', 'Biologics']",,,,,,,SuPER-US,Hyon Choi,Professor of Medicine,Massachusetts General Hospital,['Outcomes Assessor'],"[{'OtherOutcomeMeasure': 'Use of biologics', 'OtherOutcomeDescription': 'Patients will be asked whether they started or switched a biologic, and the name, since using the US-ANSWER-2.', 'OtherOutcomeTimeFrame': '6 months from baseline'}]","[{'OverallOfficialName': 'Hyon K Choi, MD, DrPH', 'OverallOfficialAffiliation': 'Massachusetts General Hospital', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,"[{'CentralContactName': 'Sharan K Rai, BSc', 'CentralContactRole': 'Contact', 'CentralContactEMail': 'srai1@mgh.harvard.edu'}]",,,,,,Recruiting,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001168', 'ConditionMeshTerm': 'Arthritis'}, {'ConditionMeshId': 'D000001172', 'ConditionMeshTerm': 'Arthritis, Rheumatoid'}]","[{'ConditionAncestorId': 'D000007592', 'ConditionAncestorTerm': 'Joint Diseases'}, {'ConditionAncestorId': 'D000009140', 'ConditionAncestorTerm': 'Musculoskeletal Diseases'}, {'ConditionAncestorId': 'D000012216', 'ConditionAncestorTerm': 'Rheumatic Diseases'}, {'ConditionAncestorId': 'D000003240', 'ConditionAncestorTerm': 'Connective Tissue Diseases'}, {'ConditionAncestorId': 'D000001327', 'ConditionAncestorTerm': 'Autoimmune Diseases'}, {'ConditionAncestorId': 'D000007154', 'ConditionAncestorTerm': 'Immune System Diseases'}]","[{'ConditionBrowseLeafId': 'M3057', 'ConditionBrowseLeafName': 'Arthritis', 'ConditionBrowseLeafAsFound': 'Arthritis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3061', 'ConditionBrowseLeafName': 'Arthritis, Rheumatoid', 'ConditionBrowseLeafAsFound': 'Rheumatoid Arthritis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9204', 'ConditionBrowseLeafName': 'Joint Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10680', 'ConditionBrowseLeafName': 'Musculoskeletal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13628', 'ConditionBrowseLeafName': 'Rheumatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4906', 'ConditionBrowseLeafName': 'Collagen Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5047', 'ConditionBrowseLeafName': 'Connective Tissue Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3210', 'ConditionBrowseLeafName': 'Autoimmune Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8783', 'ConditionBrowseLeafName': 'Immune System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC05', 'ConditionBrowseBranchName': 'Muscle, Bone, and Cartilage Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01290393,114176,GlaxoSmithKline,INDUSTRY,Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada,Post-marketing Safety Study to Assess the Risk of Spontaneous Abortion Following Administration of CERVARIX in the United States and Canada,Jul-18,Terminated,No,26-Sep-11,Actual,20-Dec-12,Actual,20-Dec-12,Actual,03-Feb-11,03-Feb-11,07-Feb-11,Estimate,25-Jul-18,26-Jul-18,Actual,Sponsor,GlaxoSmithKline,INDUSTRY,,,,,"This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort, i.e. women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose.","['Infections, Papillomavirus']",Observational,,,,,,2,Actual,"[{'ArmGroupLabel': 'Exposed vaccinated cohort', 'ArmGroupDescription': 'Women with last menstrual period between 30 days before and 90 days after any CERVARIX dose. The target sample size of the Exposed vaccinated cohort is 150 subjects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Data collection']}}, {'ArmGroupLabel': 'Non-exposed vaccinated cohort', 'ArmGroupDescription': 'Women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose. The target sample size of the Non-exposed vaccinated cohort is 300 subjects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Data collection']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Data collection', 'InterventionDescription': 'Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Exposed vaccinated cohort', 'Non-exposed vaccinated cohort']}}]","[{'PrimaryOutcomeMeasure': 'Occurrence of spontaneous abortion during weeks 1-19 of gestation', 'PrimaryOutcomeTimeFrame': 'This outcome measure will be recorded between zero and six weeks after end of pregnancy'}]","[{'SecondaryOutcomeMeasure': 'Occurrence of other adverse pregnancy outcomes', 'SecondaryOutcomeTimeFrame': 'This outcome measure will be recorded between zero and six weeks after end of pregnancy'}]","Inclusion Criteria:

For Exposed vaccinated cohort:

Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.
Aged between, and including, 15 and 25 years of age.
Residing within the US or Canada.
Subjects who received at least one dose of CERVARIX.
Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less.
Last menstrual period between 30 days before and 90 days after any dose of CERVARIX with a maximum of 20% of subjects with last menstrual period between 46 and 90 days after any dose of CERVARIX.
Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol.

For Non-exposed vaccinated cohort:

Written informed consent, and assent in case of minors, obtained from the subject/from the parent(s)/legally acceptable representative(s) of the subject.
Aged between, and including, 15 and 25 years of age.
Residing within the US or Canada.
Subjects who received at least one dose of CERVARIX or at least one dose of GARDASIL.
Gestational age at inclusion should be 19 completed weeks (i.e. 133 days of gestation) or less.
Last menstrual period between 120 days and 18 months after the last dose of CERVARIX/ GARDASIL.
Subjects who the Investigator believes can and will comply with the requirements of the protocol (e.g. available for phone interviews). Or subjects who the Investigator believes that parent(s)/legally acceptable representative(s) can and will comply with the requirements of the protocol.

Exclusion Criteria:

For Exposed vaccinated cohort:

Last menstrual period between 30 days before and 90 days after any GARDASIL dose.
Ongoing pregnancy with foetus known to be non-viable.
Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect.
Use of any investigational or non-registered product (drug or vaccine) during the study period.

For Non-exposed vaccinated cohort:

Ongoing pregnancy with foetus known to be non-viable.
Ongoing pregnancy with pre-enrolment knowledge by prenatal diagnosis of a major structural defect.
Use of any investigational or non-registered product (drug or vaccine) during the study period.",Accepts Healthy Volunteers,Female,15 Years,25 Years,"['Child', 'Adult']","[{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92123', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'The Organization of Teratology Information Specialists', 'CollaboratorClass': 'OTHER'}]",,"The present study will be conducted by the OTIS (Organization of Teratology Information Specialists) network. OTIS is a non-profit organization specialised to assess exposures during pregnancy and dedicated to providing accurate evidence-based, clinical information to patients and health care professionals about exposures during pregnancy and lactation. OTIS is based on voluntary phone calls. Women call when they have questions and concerns about risks potentially associated with any kind of exposure during pregnancy or breastfeeding, including medications, chemicals, pesticides, diseases, infections, and vaccinations.","['vaccine', 'Spontaneous abortions', 'Human papillomavirus', 'HPV', 'Cervarix', 'pregnancy']",,['Cohort'],['Prospective'],Women aged 15 to 25 years and residing in the United States or in Canada,Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,Low accrual of subjects primarily attributable to the low uptake of Cervarix in the US and Canada in women aged 15 to 25 years of age.,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000000022', 'ConditionMeshTerm': 'Abortion, Spontaneous'}]","[{'ConditionAncestorId': 'D000011248', 'ConditionAncestorTerm': 'Pregnancy Complications'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21', 'ConditionBrowseLeafName': 'Abortion, Spontaneous', 'ConditionBrowseLeafAsFound': 'Spontaneous Abortion', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12710', 'ConditionBrowseLeafName': 'Pregnancy Complications', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04263311,19-01192,NYU Langone Health,OTHER,Scaling Community-Clinical Linage Models to Address Diabetes and Hypertension Disparities in the Southeast United States,Scaling Community-Clinical Linage Models to Address Diabetes and Hypertension Disparities in the Southeast United States,Aug-20,Recruiting,No,06-Jul-20,Actual,Jun-21,Anticipated,Jun-21,Anticipated,31-Jan-20,07-Feb-20,10-Feb-20,Actual,21-Aug-20,24-Aug-20,Actual,Sponsor,NYU Langone Health,OTHER,No,No,,,"The purpose of this study is to work with primary care physicians and their staff, and with community health workers (CHWs) to improve diabetes and hypertension management, health behaviors and improve blood pressure for South Asian patients with uncontrolled diabetes and hypertension in primary care clinics in Atlanta, Georgia. The CHWs are community members who are trained to work with patients to address health needs holistically by providing information on wellness, nutrition, stress relief, and blood pressure management in a culturally-appropriate and language-appropriate manner.",['Hypertension'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),162,Anticipated,"[{'ArmGroupLabel': 'Community Health Workers (CHW) treatment group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'There will be 81 treatment participants who will receive the Community Health Workers (CHW) intervention. Once recruited and consented, surveys will be administered and collected at baseline and 6 months in person or by a study coordinator within two weeks of completion of the CHW coaching component of the intervention. Participants enrolled in the intervention will receive monthly text and phone call reminders. in addition, multiple sessions will be hosted at varying times/days of the week to accommodate schedules of both working individuals and at-home caretakers. Finally, small incentives will be provided at each session to encourage ongoing attendance, and a cash raffle prize will be distributed at program completion for individuals who attend all five sessions.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: CHW']}}, {'ArmGroupLabel': 'Control group', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'There will be 81 control participants who will be offered the health education sessions as a point of service and not for research purposes'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'CHW', 'InterventionDescription': 'Participants will undergo 5 group-based health education sessions on hypertension and diabetes management and provide culturally and linguistically tailored health information and resources There will be 2 one-on-one in-person meetings and up to 7 follow-up calls/meetings to engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to diabetes prevention as identified jointly by patient and CHW. Participants will develop with the CHW and receive a copy of their long-term and short-term Participant Action Plan. Referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Community Health Workers (CHW) treatment group']}}]","[{'PrimaryOutcomeMeasure': 'Change in BP control', 'PrimaryOutcomeDescription': 'The primary outcome will be the proportion of eligible patients at a practice site to achieve BP control (130/80 mmHg) six months following the index office visit. Individuals receiving care during the implementation of the intervention will be more likely achieve BP control six months following the index office visit than individuals receiving care as usual. The primary outcome of interest is the proportion of patients who achieve BP control. this will be measured by the treatment participants and providers surveys.', 'PrimaryOutcomeTimeFrame': 'Baseline Visit, 6 months visits'}]","[{'SecondaryOutcomeMeasure': 'Change in Hemoglobin A1c (HbA1c)', 'SecondaryOutcomeDescription': 'Change in HbA1c will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Change in systolic blood pressure (SBP)', 'SecondaryOutcomeDescription': 'Change in SBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Change in diastolic blood pressure (DBP)', 'SecondaryOutcomeDescription': 'Change in DBP will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Change in body mass index (BMI)', 'SecondaryOutcomeDescription': 'Change in BMI will be measured in participants of CHW intervention versus the control participants. Clinical data will be retrieved from EHR.', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'Physicians Attitudes Regarding the Integrated Intervention', 'SecondaryOutcomeDescription': 'Physician attitudes will be primarily assessed with data from brief surveys collected from the participating clinicians. Survey items with response scales will be designed to capture data on each of the research questions above. For instance, participants may be asked to respond on a five-point scale (from 1=strongly agree to 5=strongly disagree) to the following statement: ""CHWs are helpful tome"". The survey data come from a small sample (n=approximately 10) and are only intended to quantify descriptive information and not for extensive statistical analyses. The data will be tabulated and summarized descriptively to assess change in attitudes from baseline to 6 months.', 'SecondaryOutcomeTimeFrame': 'Baseline Visit, 6 months'}, {'SecondaryOutcomeMeasure': 'Barriers and Facilitators to Implementation Adoption and Implications for Scalability', 'SecondaryOutcomeDescription': 'At baseline, qualitative interviews of key informants will assess current satisfaction and usage of CHWs and organizational workflows. At follow-up the interviews will assess barriers and facilitators to the implementation and adoption process of the integrated intervention appropriates, fidelity to the interventions and the solicit recommendations for the replication and scalability of the intervention to other sites. Satisfaction and outcomes from the partnership and capacity building process will also be assessed. Audio-recordings and interview transcripts will be stripped of all identifying data. Using a qualitative approach, interview data will be transcribed and analysis will follow ""constant comparison"" analytic approach. Using ""thematic"" coding, initial set of codes will be created which will be reviewed by the CAB to ensure they are relevant and complete. The coded transcripts will be analyzed with ATLAS.ti, a qualitative data analysis software.', 'SecondaryOutcomeTimeFrame': 'Baseline Visit, 6 months visit, 12 month visit'}]","CHW intervention:

Inclusion Criteria:

identified as of South Asian ethnicity
are at least 21 years of age and younger than age 75
had an appointment with a physician or mid-level clinician for routine non-emergent primary care in the last 12 months
a diagnosis of diabetes
a diagnosis of hypertension
an uncontrolled BP reading (>130/80mmHg) in the last 6 months

Provider Surveys Inclusion criteria

clinicians employed by the clinic
have enrolled into the study.

Key Informant Interviews Inclusion criteria

must be a provider, clinic manager, or community health worker.

CHW intervention

Exclusion Criteria:

under the age of 21 and older than 75
pregnant
Type 1 diabetes or diabetes secondary to other conditions
malignancy or life threatening illness with life expectancy of <5 years
inability to perform unsupervised physical activity
diagnosed cognitive deficits or limited decision-making capacity

Provider Surveys Inclusion criteria

clinicians who are unable to complete the survey in the English language.

Key Informant Interviews Inclusion criteria

who are unable to participate in the interview conducted in the English language.",Accepts Healthy Volunteers,All,21 Years,75 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'NYU Langone', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10016', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jennifer Zanowiak', 'LocationContactRole': 'Contact', 'LocationContactPhone': '646-501-3502', 'LocationContactEMail': 'jennifer.zanowiak@nyulangone.org'}, {'LocationContactName': 'Nadia Islam', 'LocationContactRole': 'Contact'}]}}]",,No,"The study will provide research training, technical assistance, and capacity-building to community and clinical sites in Georgia for implementation of culturally tailored, evidenced-based CHW programs to improve HTN and diabetes management for South Asians. In addition, the use a multi-theoretical framework to test the effectiveness of a CHW-led intervention compared to usual care among South Asian individuals with diabetes and uncontrolled HTN in Atlanta. The primary outcome is blood pressure control, defined as 130/80 mmHg. It is hypothesized that, compared to usual care, individuals receiving the CHW intervention will be 20% more likely to achieve blood pressure control at 6 months.

And to apply RE-AIM and CFIR frameworks to delineate factors influencing appropriateness, fidelity, adoption, and maintenance of the intervention within clinical and community settings to optimize intervention replication.

In addition, this study will serve as a national information and dissemination resource in the adaptation of evidence-based strategies to reduce geographic disparities in HTN and diabetes across Asian American groups.",,,,,,,,,,,,,,"[{'OverallOfficialName': 'Nadia Islam', 'OverallOfficialAffiliation': 'NYU Langone', 'OverallOfficialRole': 'Principal Investigator'}]",Yes,,,,,,"Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).","[{'CentralContactName': 'Jennifer Zanowiak', 'CentralContactRole': 'Contact', 'CentralContactPhone': '(646) 501-3502', 'CentralContactEMail': 'Jennifer.Zanowiak@nyulangone.org'}]",,,,,,,,,,,,,,,,,,,"['Study Protocol', 'Statistical Analysis Plan (SAP)']",Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.,"The investigator who proposed to use the data. Researchers who provide a methodologically sound proposal. Upon reasonable request Requests should be directed to laura.wyatt@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.",,,26-Oct-20,"[{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}]","[{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]","[{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8607', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00875641,112229,GlaxoSmithKline,INDUSTRY,Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States,"Safety Study of GSK Biologicals' Rotarix® (Rotavirus Vaccine, Live, Oral) Administered to a Birth Cohort in United States Health Insurance Plans",Jun-18,Completed,No,20-Apr-09,Actual,04-Nov-16,Actual,04-Nov-16,Actual,02-Apr-09,02-Apr-09,03-Apr-09,Estimate,02-Aug-18,25-Jan-19,Actual,Sponsor,GlaxoSmithKline,INDUSTRY,No,No,,,"This observational cohort study, conducted through two existing large administrative health databases in the US (outside the Vaccine Safety Datalink) is planned to confirm the safety profile regarding lack of any association of intussusception with Rotarix within 60 days of vaccination in a real life setting (routine use) in the US. This study will also include monitoring of Kawasaki disease, convulsions, hospitalizations due to acute lower respiratory tract infections and all-cause deaths within 60-days of vaccination.

This study involves three cohorts, one exposed and two control cohorts: infants who receive Rotarix (Exposed cohort) and infants who receive IPV vaccination (Unexposed cohort A and B).

This is a combined prospective and retrospective cohort study. Prospective component of the study identifies and compares study outcomes following Rotarix and IPV vaccination in the Exposed cohort and Unexposed cohort A, respectively.

Retrospective component of the study identifies and compares study outcomes following IPV vaccination in the Unexposed cohort B.","['Infections, Rotavirus']",Observational,,,,,,390659,Actual,"[{'ArmGroupLabel': 'HRV cohort', 'ArmGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Health Insurance Database']}}, {'ArmGroupLabel': 'Concurrent Control cohort', 'ArmGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Health Insurance Database']}}, {'ArmGroupLabel': 'Recent Historical Control cohort', 'ArmGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Health Insurance Database']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Health Insurance Database', 'InterventionDescription': 'Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Concurrent Control cohort', 'HRV cohort', 'Recent Historical Control cohort']}}]","[{'PrimaryOutcomeMeasure': 'Incidence Rates of Intussusceptions (IS) Among the HRV Cohort and Comparator Cohorts', 'PrimaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'PrimaryOutcomeTimeFrame': '60 days following each vaccination'}, {'PrimaryOutcomeMeasure': 'Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts', 'PrimaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'PrimaryOutcomeTimeFrame': '7 days following each vaccination'}, {'PrimaryOutcomeMeasure': 'Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts', 'PrimaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'PrimaryOutcomeTimeFrame': '30 days following each vaccination'}]","[{'SecondaryOutcomeMeasure': 'Incidence Rates of Kawasaki Disease Among the HRV Cohort and Comparator Cohorts', 'SecondaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'SecondaryOutcomeTimeFrame': '60 days following each vaccination'}, {'SecondaryOutcomeMeasure': 'Incidence Rates of Convulsions Among the HRV Cohort and Comparator Cohorts', 'SecondaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'SecondaryOutcomeTimeFrame': '60 days following each vaccination'}, {'SecondaryOutcomeMeasure': 'Incidence Rates of Acute Lower Respiratory Tract Infection (LRTI) Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'SecondaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'SecondaryOutcomeTimeFrame': '60 days following each vaccination'}, {'SecondaryOutcomeMeasure': 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'SecondaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'SecondaryOutcomeTimeFrame': '7 days following each vaccination'}, {'SecondaryOutcomeMeasure': 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'SecondaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'SecondaryOutcomeTimeFrame': '30 days following each vaccination'}, {'SecondaryOutcomeMeasure': 'Incidence Rates of All-cause Mortality Among the HRV Cohort and Comparator Cohorts', 'SecondaryOutcomeDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'SecondaryOutcomeTimeFrame': '60 days following each vaccination'}]","Inclusion Criteria:

For Exposed cohort:

Infants aged less than 1 year at study entry.
Infants who are enrolled in one of the two participating health insurance plans databases within 30 days of birth.
Have complete medical coverage and pharmacy benefits.
Received at least one dose of Rotarix from 1 August 2008.
Infants receiving Rotarix liquid formulation will also be eligible.

For Unexposed cohort A:

Infants aged less than 1 year at study entry.
Infants who are enrolled in one of the two participating health insurance plans databases within 30 days of birth.
Have complete medical coverage and pharmacy benefits.
Received at least one dose of IPV vaccine from 1 August 2008, with or without RotaTeq vaccination.
Frequency-matched to the Rotarix cohort by gender, age at first vaccination (±1 week) and calendar quarter of vaccination within the same year.

For Unexposed cohort B:

Infants who are enrolled in one of the two participating health insurance plans databases within 30 days of birth.
Had complete medical coverage and pharmacy benefits.
Received at least one dose of IPV vaccine.
Vaccinated between 1 January 2006 (inclusive) and 31 July 2008 (inclusive).
Not received any dose of rotavirus vaccination.
Frequency-matched to the Rotarix cohort by gender, age at first vaccination (±1 week) and calendar quarter of vaccination.

Exclusion Criteria:

For Exposed cohort:

• Subject has received any dose of RotaTeq prior to the first Rotarix vaccine during the study period.

For Unexposed cohort A:

• Subject has received any dose of Rotarix prior to the first IPV vaccine during the study period.

For Unexposed cohort B:

• Subject has received any dose of rotavirus vaccines prior to the first IPV vaccine.",Accepts Healthy Volunteers,All,,1 Year,['Child'],"[{'LocationFacility': 'GSK Investigational Site', 'LocationCity': 'Waltham', 'LocationState': 'Massachusetts', 'LocationZip': '02451', 'LocationCountry': 'United States'}]",,,,,,['Cohort'],['Other'],Children affiliated to two participating health insurance plans.,Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'GSK Clinical Trials', 'OverallOfficialAffiliation': 'GlaxoSmithKline', 'OverallOfficialRole': 'Study Director'}]",,,30-Oct-17,02-Aug-18,25-Jan-19,Actual,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012400', 'ConditionMeshTerm': 'Rotavirus Infections'}]","[{'ConditionAncestorId': 'D000012088', 'ConditionAncestorTerm': 'Reoviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13803', 'ConditionBrowseLeafName': 'Rotavirus Infections', 'ConditionBrowseLeafAsFound': 'Infections, Rotavirus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,"Subjects were identified through the automated corresponding health insurance plan databases, OptumInsight Life Sciences Research Database (from United Healthcare) and the HealthCore Integrated Research Database (HIRDSM) (part of Anthem, formerly known as WellPoint).","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'HRV Cohort', 'FlowGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Concurrent Control Cohort', 'FlowGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': 'Recent Historical Control Cohort', 'FlowGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '57931'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '173384'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '159344'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '57931'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '173384'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '159344'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '0'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'HRV Cohort', 'BaselineGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Concurrent Control Cohort', 'BaselineGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Recent Historical Control Cohort', 'BaselineGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '57931'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '173384'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '159344'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '390659'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'Months', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2.0', 'BaselineMeasurementSpread': '0.7'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2.0', 'BaselineMeasurementSpread': '0.7'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2.0', 'BaselineMeasurementSpread': '0.7'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '2.0', 'BaselineMeasurementSpread': '0.7'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '27929'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '83528'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '77128'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '188585'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '30002'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '89856'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '82216'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '202074'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'US Geographic Region', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Northeast', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '8461'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '18093'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '22171'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '48725'}]}}, {'BaselineCategoryTitle': 'South/Southeast', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '19875'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '59167'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '61965'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '141007'}]}}, {'BaselineCategoryTitle': 'Midwest', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '17101'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '51046'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '41114'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '109261'}]}}, {'BaselineCategoryTitle': 'West', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '12494'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '45078'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '34094'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '91666'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Incidence Rates of Intussusceptions (IS) Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '60 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-59 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.021', 'OutcomeMeasurementLowerLimit': '0.006', 'OutcomeMeasurementUpperLimit': '0.055'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.022', 'OutcomeMeasurementLowerLimit': '0.012', 'OutcomeMeasurementUpperLimit': '0.037'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.021', 'OutcomeMeasurementLowerLimit': '0.010', 'OutcomeMeasurementUpperLimit': '0.037'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.028', 'OutcomeMeasurementLowerLimit': '0.006', 'OutcomeMeasurementUpperLimit': '0.082'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.012', 'OutcomeMeasurementLowerLimit': '0.003', 'OutcomeMeasurementUpperLimit': '0.032'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.017', 'OutcomeMeasurementLowerLimit': '0.006', 'OutcomeMeasurementUpperLimit': '0.040'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.013', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.070'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.032', 'OutcomeMeasurementLowerLimit': '0.015', 'OutcomeMeasurementUpperLimit': '0.061'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.025', 'OutcomeMeasurementLowerLimit': '0.009', 'OutcomeMeasurementUpperLimit': '0.054'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '7 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-6 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.161'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.014', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.075'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.056'}]}}]}}, {'OutcomeClassTitle': '0-6 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.278'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.093'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.101'}]}}]}}, {'OutcomeClassTitle': '0-6 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.383'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.029', 'OutcomeMeasurementLowerLimit': '0.001', 'OutcomeMeasurementUpperLimit': '0.162'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.124'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Incidence Rates of IS Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '30 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-29 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.010', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.058'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.026', 'OutcomeMeasurementLowerLimit': '0.011', 'OutcomeMeasurementUpperLimit': '0.050'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.022', 'OutcomeMeasurementLowerLimit': '0.008', 'OutcomeMeasurementUpperLimit': '0.047'}]}}]}}, {'OutcomeClassTitle': '0-29 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.066'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.006', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.033'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.020', 'OutcomeMeasurementLowerLimit': '0.004', 'OutcomeMeasurementUpperLimit': '0.057'}]}}]}}, {'OutcomeClassTitle': '0-29 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.025', 'OutcomeMeasurementLowerLimit': '0.001', 'OutcomeMeasurementUpperLimit': '0.137'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.048', 'OutcomeMeasurementLowerLimit': '0.019', 'OutcomeMeasurementUpperLimit': '0.099'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.024', 'OutcomeMeasurementLowerLimit': '0.005', 'OutcomeMeasurementUpperLimit': '0.070'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incidence Rates of Kawasaki Disease Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '60 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-59 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.020'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.008', 'OutcomeMeasurementLowerLimit': '0.003', 'OutcomeMeasurementUpperLimit': '0.019'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.009', 'OutcomeMeasurementLowerLimit': '0.003', 'OutcomeMeasurementUpperLimit': '0.022'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.034'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.006', 'OutcomeMeasurementLowerLimit': '0.001', 'OutcomeMeasurementUpperLimit': '0.023'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.014', 'OutcomeMeasurementLowerLimit': '0.004', 'OutcomeMeasurementUpperLimit': '0.035'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.000', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.046'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.011', 'OutcomeMeasurementLowerLimit': '0.002', 'OutcomeMeasurementUpperLimit': '0.031'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.004', 'OutcomeMeasurementLowerLimit': '0.000', 'OutcomeMeasurementUpperLimit': '0.023'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incidence Rates of Convulsions Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '60 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-59 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.230', 'OutcomeMeasurementLowerLimit': '0.166', 'OutcomeMeasurementUpperLimit': '0.310'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.142', 'OutcomeMeasurementLowerLimit': '0.113', 'OutcomeMeasurementUpperLimit': '0.175'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.146', 'OutcomeMeasurementLowerLimit': '0.116', 'OutcomeMeasurementUpperLimit': '0.183'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.252', 'OutcomeMeasurementLowerLimit': '0.166', 'OutcomeMeasurementUpperLimit': '0.366'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.121', 'OutcomeMeasurementLowerLimit': '0.086', 'OutcomeMeasurementUpperLimit': '0.166'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.124', 'OutcomeMeasurementLowerLimit': '0.087', 'OutcomeMeasurementUpperLimit': '0.171'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.200', 'OutcomeMeasurementLowerLimit': '0.115', 'OutcomeMeasurementUpperLimit': '0.326'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.165', 'OutcomeMeasurementLowerLimit': '0.121', 'OutcomeMeasurementUpperLimit': '0.220'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.174', 'OutcomeMeasurementLowerLimit': '0.125', 'OutcomeMeasurementUpperLimit': '0.235'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incidence Rates of Acute Lower Respiratory Tract Infection (LRTI) Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '60 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-59 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.518', 'OutcomeMeasurementLowerLimit': '1.346', 'OutcomeMeasurementUpperLimit': '1.705'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.320', 'OutcomeMeasurementLowerLimit': '1.230', 'OutcomeMeasurementUpperLimit': '1.415'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '1.669', 'OutcomeMeasurementLowerLimit': '1.561', 'OutcomeMeasurementUpperLimit': '1.782'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.696', 'OutcomeMeasurementLowerLimit': '1.459', 'OutcomeMeasurementUpperLimit': '1.962'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.529', 'OutcomeMeasurementLowerLimit': '1.397', 'OutcomeMeasurementUpperLimit': '1.671'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '2.008', 'OutcomeMeasurementLowerLimit': '1.848', 'OutcomeMeasurementUpperLimit': '2.177'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.278', 'OutcomeMeasurementLowerLimit': '1.042', 'OutcomeMeasurementUpperLimit': '1.551'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.079', 'OutcomeMeasurementLowerLimit': '0.961', 'OutcomeMeasurementUpperLimit': '1.208'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '1.260', 'OutcomeMeasurementLowerLimit': '1.123', 'OutcomeMeasurementUpperLimit': '1.410'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '7 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-6 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.397', 'OutcomeMeasurementLowerLimit': '0.955', 'OutcomeMeasurementUpperLimit': '1.972'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.932', 'OutcomeMeasurementLowerLimit': '0.725', 'OutcomeMeasurementUpperLimit': '1.180'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '1.406', 'OutcomeMeasurementLowerLimit': '1.135', 'OutcomeMeasurem",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
ntUpperLimit': '1.722'}]}}]}}, {'OutcomeClassTitle': '0-6 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.960', 'OutcomeMeasurementLowerLimit': '1.280', 'OutcomeMeasurementUpperLimit': '2.871'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.184', 'OutcomeMeasurementLowerLimit': '0.870', 'OutcomeMeasurementUpperLimit': '1.575'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '1.921', 'OutcomeMeasurementLowerLimit': '1.497', 'OutcomeMeasurementUpperLimit': '2.427'}]}}]}}, {'OutcomeClassTitle': '0-6 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.622', 'OutcomeMeasurementLowerLimit': '0.228', 'OutcomeMeasurementUpperLimit': '1.354'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.641', 'OutcomeMeasurementLowerLimit': '0.401', 'OutcomeMeasurementUpperLimit': '0.970'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.774', 'OutcomeMeasurementLowerLimit': '0.491', 'OutcomeMeasurementUpperLimit': '1.162'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incidence Rates of Acute LTRI Hospitalisation Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '30 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'HRV Cohort', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '57931'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '173384'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '159344'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '0-29 days, Any Dose', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.593', 'OutcomeMeasurementLowerLimit': '1.351', 'OutcomeMeasurementUpperLimit': '1.865'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.383', 'OutcomeMeasurementLowerLimit': '1.255', 'OutcomeMeasurementUpperLimit': '1.519'}, {'OutcomeClassTitle': '0-29 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.858', 'OutcomeMeasurementLowerLimit': '1.518', 'OutcomeMeasurementValue': '1.327', 'OutcomeMeasurementLowerLimit': '1.132', 'OutcomeMeasurementUpperLimit': '1.544'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incidence Rates of All-cause Mortality Among the HRV Cohort and Comparator Cohorts', 'OutcomeMeasureDescription': 'Incidence rates were calculated following the first 2 doses of study vaccine as the number of events divided by the sum of the person-time in that risk period. Person-time was defined as the number of days at risk for the study outcomes. Person-time was calculated in months by dividing the number of person-days by (365.25/12).', 'OutcomeMeasurePopulationDescription': 'Analysis was performed on study population comprising of birth cohorts affiliated with 2 participating health insurance plans, United Healthcare & WellPoint, which were eligible for rotavirus vaccination according to routine recommendations. Within this population of infants, HRV, Concurrent Control & Recent Historical Control cohorts were defined.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Concurrent Control Cohort', 'OutcomeGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Recent Historical Control Cohort', 'OutcomeGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '1.788', 'OutcomeMeasurementLowerLimit': '1.634', 'OutcomeMeasurementUpperLimit': '1.952'}]}}]}}, 'OutcomeMeasurementUpperLimit': '2.252'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.523', 'OutcomeMeasurementLowerLimit': '1.341', 'OutcomeMeasurementUpperLimit': '1.721'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '2.166', 'OutcomeMeasurementLowerLimit': '1.939', 'OutcomeMeasurementUpperLimit': '2.412'}]}}]}}, {'OutcomeClassTitle': '0-29 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.228', 'OutcomeMeasurementLowerLimit': '0.911', 'OutcomeMeasurementUpperLimit': '1.619'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.221', 'OutcomeMeasurementLowerLimit': '1.048', 'OutcomeMeasurementUpperLimit': '1.414'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasureUnitOfMeasure': 'Incidences/Person-Month', 'OutcomeMeasureTimeFrame': '60 days following each vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.'}]}, 'OutcomeGroupTitle': 'HRV Cohort', {'OutcomeClassTitle': '0-59 days, Dose 1', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.047', 'OutcomeMeasurementLowerLimit': '0.015', 'OutcomeMeasurementUpperLimit': '0.109'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.059', 'OutcomeMeasurementLowerLimit': '0.036', 'OutcomeMeasurementUpperLimit': '0.092'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.075', 'OutcomeMeasurementLowerLimit': '0.047', 'OutcomeMeasurementUpperLimit': '0.114'}]}}]}}, {'OutcomeClassTitle': '0-59 days, Dose 2', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.050', 'OutcomeMeasurementLowerLimit': '0.014', 'OutcomeMeasurementUpperLimit': '0.128'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.029', 'OutcomeMeasurementLowerLimit': '0.012', 'OutcomeMeasurementUpperLimit': '0.057'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '0.045', 'OutcomeMeasurementLowerLimit': '0.023'," 'OutcomeMeasurementUpperLimit': '0.081'}]}}]}}]}}]""",5,,,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'HRV Cohort', 'EventGroupDescription': 'HRV (Human Rotavirus) cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans within 30 days of birth and who received at least one dose of Rotarix vaccination as part of their normal health care (with no previous dose of RotaTeq prior to or concurrent with the first Rotarix vaccination).', 'EventGroupDeathsNumAffected': '9', 'EventGroupDeathsNumAtRisk': '57931', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '57931', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '57931'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Concurrent Control Cohort', 'EventGroupDescription': 'Concurrent control cohort consisted of infants aged less than 1 year, enrolled in the participating health insurance plans, who were contemporaneous with the Rotarix vaccinees and who received at least one dose of IPV (Inactivated Poliovirus vaccine) with or without RotaTeq vaccination (with no previous dose of Rotarix prior to or concurrent with the first IPV vaccination).', 'EventGroupDeathsNumAffected': '27', 'EventGroupDeathsNumAtRisk': '173384', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '173384', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '173384'}, {'EventGroupId': 'EG002', 'EventGroupTitle': 'Recent Historical Control Cohort', 'EventGroupDescription': 'Recent historical control cohort consisted of infants aged less than 1 year of age, enrolled in participating health insurance plans, vaccinated with at least one dose of IPV (Inactivated Poliovirus vaccine) between 1 January 2004 (OptumInsight) or 1 January 2006 (HealthCore) and 31 July 2008 and who did not receive any dose of rotavirus vaccination during the study period.', 'EventGroupDeathsNumAffected': '33', 'EventGroupDeathsNumAtRisk': '159344', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '159344', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '159344'}]",,No,Yes,GSK Response Center,GlaxoSmithKline,,866-435-7343,,,,,,,,,,,,,,,,OTHER,"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."
NCT03199846,CA209-983,Bristol-Myers Squibb,INDUSTRY,Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States,Treatment Patterns and Outcomes Study in Patients With Unresectable Stage III and Metastatic (Stage IV) Melanoma in the United States,Feb-18,Completed,No,25-Oct-16,Actual,30-Oct-17,Actual,31-Dec-17,Actual,23-Jun-17,23-Jun-17,27-Jun-17,Actual,05-Feb-18,06-Feb-18,Actual,Sponsor,Bristol-Myers Squibb,INDUSTRY,,,,,This study will collect real-world data from advanced melanoma diagnosis through most recent visit and data sourced from patient medical records following a 2-part study design consisting of a random sample (Part 1) and an oversample (Part 2).,['Melanoma'],Observational,,,,,,650,Actual,"[{'ArmGroupLabel': 'advanced melanoma patients', 'ArmGroupDescription': 'Part 1 will consist of a representative sample of advanced melanoma patients, irrespective of date of diagnosis of stage III unresectable and metastatic/stage IV, to address information objectives on treatment patterns, clinical outcomes, and resource use after the start of treatment post-launch of new drugs, ie, since 2011 for ipi and 2015 for ipi + nivo in advanced melanoma', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Non-Interventional']}}, {'ArmGroupLabel': 'Ipi monotherapy', 'ArmGroupDescription': 'Part 2: patients must have been prescribed Ipi monotherapy during the index period between 01-Jan-2015 and 31-May-2016.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Non-Interventional']}}, {'ArmGroupLabel': 'Ipi + nivo combination therapy', 'ArmGroupDescription': 'Part 2: patients must have been prescribed Ipi + nivo combination therapy during the index period between 01-Jan-2015 and 31-May-2016.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Non-Interventional']}}, {'ArmGroupLabel': 'Dabrafenib + trametinib combination therapy', 'ArmGroupDescription': 'Part 2: patients must have been prescribed Dabrafenib + trametinib combination therapy during the index period between 01-Jan-2015 and 31-May-2016.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Non-Interventional']}}, {'ArmGroupLabel': 'Pembro monotherapy', 'ArmGroupDescription': 'Part 2: patients must have been prescribed Pembro monotherapy during the index period between 01-Jan-2015 and 31-May-2016', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Non-Interventional']}}, {'ArmGroupLabel': 'Nivo monotherapy', 'ArmGroupDescription': 'Part 2: patients must have been prescribed Nivo monotherapy during the index period between 01-Jan-2015 and 31-May-2016', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Non-Interventional']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Non-Interventional', 'InterventionDescription': 'Non-Interventional', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Dabrafenib + trametinib combination therapy', 'Ipi + nivo combination therapy', 'Ipi monotherapy', 'Nivo monotherapy', 'Pembro monotherapy', 'advanced melanoma patients']}}]","[{'PrimaryOutcomeMeasure': 'Distribution of treatment patterns for advanced melanoma patients', 'PrimaryOutcomeDescription': 'Distribution of treatment patterns for advanced melanoma patients including, treatment regimen selection and rationale, as well as time to initiation of therapy and type of therapy', 'PrimaryOutcomeTimeFrame': 'Aproximately 6 months'}]","[{'SecondaryOutcomeMeasure': 'Distribution of prescribing patterns', 'SecondaryOutcomeDescription': 'Distribution of prescribing patterns by type of practice setting and melanoma patient volume', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Patient Age at index date', 'SecondaryOutcomeDescription': 'Patient Age at index date will be determined from Medical Records', 'SecondaryOutcomeTimeFrame': 'at baseline'}, {'SecondaryOutcomeMeasure': ""Distribution of Patient's Sex at Index Date"", 'SecondaryOutcomeDescription': ""Patient's sex will be determined from Medical Records"", 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Comorbidities at index date', 'SecondaryOutcomeDescription': 'Comorbidities will be determined using the Charlson Comorbidity Index (CCI)', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Healthcare Coverage type', 'SecondaryOutcomeDescription': 'Healthcare Coverage type will be determined using Medical Records', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Diagnosis Date', 'SecondaryOutcomeDescription': 'Melanoma Diagnosis Date will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Advanced Diagnosis Date', 'SecondaryOutcomeDescription': 'Date of advanced/ metastatic melanoma diagnosis will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Age at Onset', 'SecondaryOutcomeDescription': 'Diagnosis date-Date of Birth', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Disease stage at time of diagnosis', 'SecondaryOutcomeDescription': 'Disease stage at time of diagnosis will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of Disease stage at subsequent visits', 'SecondaryOutcomeDescription': 'Disease stage at subsequent visits will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of ECOG status at Baseline', 'SecondaryOutcomeDescription': 'Eastern Cooperative Oncology Group (ECOG) status at Baseline will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'At Baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of ECOG status at Last Visit', 'SecondaryOutcomeDescription': 'Eastern Cooperative Oncology Group (ECOG) status at Last Visit will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Biomarker status at baseline', 'SecondaryOutcomeDescription': 'Biomarker status will be determined using Medical Records', 'SecondaryOutcomeTimeFrame': 'at baseline'}, {'SecondaryOutcomeMeasure': 'Distribution of treatment-related adverse events', 'SecondaryOutcomeDescription': 'treatment-related adverse events will be determined using medical records', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Overall Survival (OS) from Advanced Diagnosis', 'SecondaryOutcomeDescription': 'Date of death minus advanced/metastatic diagnosis date, censoring for LTF or end of observation', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Progression-Free Survival (PFS) at Advanced Diagnosis', 'SecondaryOutcomeDescription': 'Date of progression (increase in tumor size or increase in cancer stage)/start of next line of therapy minus advanced/metastatic diagnosis date, censoring for LTF or end of observation', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Overall Response Rate (ORR)', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Overall Survival (OS) from Index Date', 'SecondaryOutcomeDescription': 'Date of death minus index treatment start date, censoring for LTF or end of observation', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of Progression-Free Survival (PFS) at Index Date', 'SecondaryOutcomeDescription': 'Date of progression (increase in tumor size or increase in cancer stage)/start of next line of therapy minus index treatment start date, censoring for LTF or end of observation', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}, {'SecondaryOutcomeMeasure': 'Distribution of melanoma related HCRU', 'SecondaryOutcomeTimeFrame': 'Approximately 16 months'}]","Inclusion Criteria:

Adults 18 years or older
Diagnosis of unresectable stage III and/or metastatic (stage IV) melanoma before 01-Nov-2015
Initiating a new line of therapy during the index period between 01-Jan-2015 and 31-May-2016, irrespective of advanced melanoma diagnosis date
Medical history available for medical chart abstraction from date of diagnosis through most recent or current therapy (defined as end of data collection period)

Exclusion Criteria:

Physicians unwilling or unable to follow study instructions
Patients who were previously enrolled in a cancer treatment-related clinical trial since the diagnosis of unresectable stage III and/or metastatic (stage IV) melanoma",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Local Institution', 'LocationCity': 'Morristown', 'LocationState': 'New Jersey', 'LocationZip': '07960', 'LocationCountry': 'United States'}]",,No,,,No,['Cohort'],['Retrospective'],Patients initiating a new line of therapy for unresectable stage III and/or metastatic (stage IV) melanoma during the index period between 01-Jan-2015 and 31-May-2016.,Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'Bristol-Myers Squibb', 'OverallOfficialAffiliation': 'Bristol-Myers Squibb', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,,,,"[{'SeeAlsoLinkLabel': 'Investigator Inquiry Form', 'SeeAlsoLinkURL': 'http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008545', 'ConditionMeshTerm': 'Melanoma'}]","[{'ConditionAncestorId': 'D000018358', 'ConditionAncestorTerm': 'Neuroendocrine Tumors'}, {'ConditionAncestorId': 'D000017599', 'ConditionAncestorTerm': 'Neuroectodermal Tumors'}, {'ConditionAncestorId': 'D000009373', 'ConditionAncestorTerm': 'Neoplasms, Germ Cell and Embryonal'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000009380', 'ConditionAncestorTerm': 'Neoplasms, Nerve Tissue'}, {'ConditionAncestorId': 'D000018326', 'ConditionAncestorTerm': 'Nevi and Melanomas'}]","[{'ConditionBrowseLeafId': 'M10111', 'ConditionBrowseLeafName': 'Melanoma', 'ConditionBrowseLeafAsFound': 'Melanoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M19079', 'ConditionBrowseLeafName': 'Neuroendocrine Tumors', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18428', 'ConditionBrowseLeafName': 'Neuroectodermal Tumors', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18971', 'ConditionBrowseLeafName': 'Neuroectodermal Tumors, Primitive', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10901', 'ConditionBrowseLeafName': 'Neoplasms, Germ Cell and Embryonal', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10898', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10908', 'ConditionBrowseLeafName': 'Neoplasms, Nerve Tissue', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11031', 'ConditionBrowseLeafName': 'Nevus, Pigmented', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11029', 'ConditionBrowseLeafName': 'Nevus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M19054', 'ConditionBrowseLeafName': 'Nevi and Melanomas', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4102', 'ConditionBrowseLeafName': 'Neuroendocrine Tumor', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4103', 'ConditionBrowseLeafName': 'Neuroepithelioma', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M225737', 'InterventionBrowseLeafName': 'Trametinib', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M224868', 'InterventionBrowseLeafName': 'Dabrafenib', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04587245,PIRStudy,"ND Sciences, LLC",INDUSTRY,The Provider Insurance Revenue Study in Healthcare Providers in the United States of America,The Provider Insurance Revenue Study,Oct-20,Recruiting,No,01-Oct-20,Actual,15-Oct-21,Anticipated,15-Oct-21,Anticipated,07-Oct-20,07-Oct-20,14-Oct-20,Actual,14-Oct-20,19-Oct-20,Actual,Sponsor,"ND Sciences, LLC",INDUSTRY,No,No,,,"The investigators are enrolling 100 healthcare Provider volunteers (n=100) from across the United States to help to evaluate and document the financial impact of COVID-19 on Physicians and other healthcare Providers. This investigation will compare individual Physician revenues before and after the advent of the COVID-19 pandemic. The investigators expect to be able to differentiate between revenues lost due to the COVID-19-driven business recession and revenues lost due to the manipulation of reimbursement processes by insurance companies. The inextricable linkage between Payer and Physician revenues suggests that Payer revenues are higher at the direct expense of Physicians, since both streams come from the same sources of funding. The secondary objective is aimed at revealing the methods Payers use to retain more money.","['Covid19', 'Financial Disclosure']",Observational,,,,,,100,Anticipated,"[{'ArmGroupLabel': 'Physicians', 'ArmGroupDescription': 'Physician or healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Online questionnaire and interviews']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Online questionnaire and interviews', 'InterventionDescription': 'Online questionnaire, financial statements (one month per quarter in 2020) submitted electronically, interview with professional accounting firm and review of data and exit Interview', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Physicians']}}]","[{'PrimaryOutcomeMeasure': 'Change in monthly income of healthcare Providers from baseline to 6, 9 and 12 months after the beginning of the COVID-related events', 'PrimaryOutcomeDescription': 'Change in monthly income of healthcare Providers from baseline to 6, 9 and 12 months after the beginning of the COVID-related events', 'PrimaryOutcomeTimeFrame': '12 months'}]","[{'SecondaryOutcomeMeasure': 'Differences in Accounts Receivable (AR) due to claim denials over 4 quarters: Differences in recoveries of AR.', 'SecondaryOutcomeDescription': 'Differences in Accounts Receivable (AR) due to claim denials over 4 quarters: Differences in recoveries of AR.', 'SecondaryOutcomeTimeFrame': '12 months'}]","Inclusion Criteria:

Healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients.
To agree to participate in this study

Exclusion Criteria:

Any condition that at the discretion of the principal investigator renders the subject ineligible to participate in this study.",,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'University of California Irvine Beall Applied Innovation', 'LocationStatus': 'Recruiting', 'LocationCity': 'Irvine', 'LocationState': 'California', 'LocationZip': '92617', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Henry Broeska', 'LocationContactRole': 'Contact', 'LocationContactPhone': '949-332-9638', 'LocationContactEMail': 'hbroeska0@saddleback.edu'}, {'LocationContactName': 'Charles Bronson', 'LocationContactRole': 'Contact', 'LocationContactPhone': '415-530-8742', 'LocationContactEMail': 'chasbronson@gmail.com'}, {'LocationContactName': 'Sheridan Merrick, BA', 'LocationContactRole': 'Sub-Investigator'}]}}]","[{'CollaboratorName': 'University of California, Irvine', 'CollaboratorClass': 'OTHER'}]",No,"Since the beginning of the COVID-19 pandemic in March, 2020, Physicians and other medical Providers have taken devastating hits to their practice revenues. Most of the losses are due to doctors being forced to curtail elective procedures and office visits as Americans were ordered to stay home during the height of the national health emergency.

As Physicians were able to return to work in the early Summer, even if only partially, many had to adjust to the newer medical practice of telehealth, and the lower revenues that came with it. The Centers for Medicare & Medicaid Services (CMS) gave assurances to Physicians that Medicare would reimburse telehealth encounters at 100% of the office visit rate. But private Payers were under no such obligation. Across the country, Physicians are reporting that they're being reimbursed at about 70% of an office visit rate despite the fact that telehealth requires both resources and expertise to implement effectively, and each encounter takes up to twice as long as an office visit.

Adding to financial hardships, Physicians across the nation are reporting that legitimate insurance claims are being held up and denied by the insurance companies at a higher rate than ever, cutting off the cash that they need so desperately. As of June 1, only half of Physician practices say they have enough cash to stay open for another month.

In just 2 months in the spring of 2020, over 45 million Americans lost their jobs and for many, that also meant the loss of their employment-related health insurance. Despite shedding a massive number of members from their rolls, health insurance companies are actually predicting record profits for 2020. The pandemic it seems, is very good indeed for the health insurance business. Private investors and executives are taking huge dividends and bonuses out of the system just at a time when US healthcare needs a vast new investment of healthcare resources into the system. The good fortune of a few individuals and corporations comes at an as yet untold expense to American society.

The formula for insurance company success in a pandemic only happens one way. By keeping member premiums, delaying payments, and denying treatment authorizations, the large health insurance companies are taking advantage of the profound misfortunes of both doctors and patients during a national health emergency.

The COVID-19 pandemic will have adverse effects on the health of Americans that will be sprawling and long-felt. However, it is not for this study to decide whether private interests will always be antithetical to public interests when it comes to healthcare. That is a public debate that will continue to evolve as the profound weaknesses of the American way of distributing healthcare are magnified and exposed in a time of social upheaval.

The investigators do know that in order to get a handle on the major damage we see occurring in real-time- and to inform that debate, it is first necessary to measure it.","['Healthcare providers', 'Covid19', 'Financial impact', 'Income']",No,['Cohort'],['Retrospective'],Healthcare Provider based anywhere in the United States who is eligible to submit claims to an insurance company on behalf of patients.,Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'Henry Broeska, PhD', 'OverallOfficialAffiliation': 'University of California Irvine Beall Applied Innovation', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,"[{'CentralContactName': 'Henry Broeska, PhD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '949-332-9638', 'CentralContactEMail': 'hbroeska0@saddleback.edu'}, {'CentralContactName': 'Charles Bronson, MBA', 'CentralContactRole': 'Contact', 'CentralContactPhone': '415-530-8742', 'CentralContactEMail': 'chasbronoson@gmail.com'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02773979,11-0042,National Institute of Allergy and Infectious Diseases (NIAID),NIH,PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States,"A Phase 1 Dose Escalation Trial to Assess the Safety and Efficacy of Infectious (Replication-intact), Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Direct Venous Inoculation Under Chloroquine Cover (PfSPZ-CVac) on Varying Schedules in Healthy Malaria-Naïve Adults in the United States",05-Apr-17,Completed,No,12-Sep-16,Actual,22-Jan-18,Actual,22-Jan-18,Actual,12-May-16,12-May-16,16-May-16,Estimate,24-Dec-19,27-Dec-19,Actual,Sponsor,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Yes,No,,No,"This phase I trial of the replication-intact PfSPZ Challenge vaccine given under CQ cover will enroll 28 healthy volunteers to receive PfSPZ or placebo, as well as suppressive doses of chloroquine (CQ)on varying schedules. 10 weeks post 3rd immunization subjects will be subjected to controlled human malarial infection. The primary objective of this study is to evaluate the safety and tolerability of escalating doses of Sanaria PfSPZ Challenge administered by DVI on varying schedules to healthy malaria-naïve adults taking suppressive doses of CQ (PfSPZ-CVac).",['Plasmodium Falciparum Infection'],Interventional,['Phase 1'],Randomized,Parallel Assignment,Prevention,Double,28,Actual,"[{'ArmGroupLabel': 'Group 1: PfSPZ 51200 sporozoites/Placebo', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Chloroquine (CQ)/PfSPZ Challenge 51200 sporozoites or CQ/normal saline (NS). N=12, randomized 3:1', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge', 'Other: Placebo']}}, {'ArmGroupLabel': 'Group 2: PfSPZ 102400 sporozoites/Placebo', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'CQ/PfSPZ Challenge 102400 sporozoites or CQ/NS. N=4, randomized 3:1', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge', 'Other: Placebo']}}, {'ArmGroupLabel': 'Group 3: PfSPZ 102400 sporozoites', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'CQ/PfSPZ Challenge 102400 sporozoites N=9', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Chloroquine', 'Biological: PfSPZ (NF54) Challenge']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Chloroquine', 'InterventionDescription': 'Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 1: PfSPZ 51200 sporozoites/Placebo', 'Group 2: PfSPZ 102400 sporozoites/Placebo', 'Group 3: PfSPZ 102400 sporozoites']}}, {'InterventionType': 'Biological', 'InterventionName': 'PfSPZ (NF54) Challenge', 'InterventionDescription': 'Cryopreserved Plasmodium falciparum (Pf) fully infectious sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ (NF54) Challenge contains a laboratory malaria strain isolated from a Dutch traveler to Africa.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 1: PfSPZ 51200 sporozoites/Placebo', 'Group 2: PfSPZ 102400 sporozoites/Placebo', 'Group 3: PfSPZ 102400 sporozoites']}}, {'InterventionType': 'Other', 'InterventionName': 'Placebo', 'InterventionDescription': 'Placebo', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group 1: PfSPZ 51200 sporozoites/Placebo', 'Group 2: PfSPZ 102400 sporozoites/Placebo']}}]","[{'PrimaryOutcomeMeasure': 'The number of serious adverse events (SAEs) related to study product.', 'PrimaryOutcomeTimeFrame': 'Days 1-203'}, {'PrimaryOutcomeMeasure': 'The number of solicited local adverse events (AEs)', 'PrimaryOutcomeTimeFrame': 'Days 1-93'}, {'PrimaryOutcomeMeasure': 'The number of solicited systemic adverse events(AEs)', 'PrimaryOutcomeTimeFrame': 'Day 1-116'}, {'PrimaryOutcomeMeasure': 'The number of unsolicited adverse events (AEs) related to study product', 'PrimaryOutcomeTimeFrame': 'Days 1-130'}, {'PrimaryOutcomeMeasure': 'The severity of solicited local adverse events (AEs) as assessed by grading scales', 'PrimaryOutcomeTimeFrame': 'Day 1-93'}, {'PrimaryOutcomeMeasure': 'The severity of solicited systemic adverse event (AEs) as assessed by grading scales', 'PrimaryOutcomeTimeFrame': 'Day 1-116'}, {'PrimaryOutcomeMeasure': 'The severity of unsolicited AEs related to study product as assessed by grading scales.', 'PrimaryOutcomeTimeFrame': 'Days 1-130'}]",,"Inclusion Criteria:

Healthy adults (males and non-pregnant, non-lactating females) between the ages of 18 and 45 years, inclusive.
Able and willing to participate for the duration of the study.
Able and willing to provide written (not proxy) informed consent.
Provides informed consent before any study procedures, correctly answers >/= 70% of questions on the post consent quiz and is available for all study visits.

Women of childbearing potential* must have a negative serum pregnancy test at screening and a negative urine pregnancy test prior to each vaccination and on the day of malaria challenge.

Not sterilized via bilateral tubal ligation, bilateral oophorectomy, hysterectomy, or menopausal and still menstruating or < 1 year of the last menses.

Women of childbearing potential must have used an acceptable method of contraception* in the 30 days prior to enrollment and must agree to continue use of the same method throughout the study.

Includes, but is not limited to, abstinence from sex with men, monogamous relationship with vasectomized partner who has been vasectomized for 6 months or more prior to enrollment, barrier methods such as condoms or diaphragms with spermicide or foam, effective intrauterine devices, NuvaRing, successful Essure placement (permanent, non-surgical, non-hormonal sterilization) with documented confirmation test at least 3 months after the procedure, and licensed hormonal methods such as implants, injectables, or oral contraceptives.
Is in good health, as judged by the investigator, and determined by vital signs (heart rate, blood pressure, and oral temperature), medical history and physical examination.
Able to understand and comply with planned study procedures.
Reachable (24/7) by mobile phone during the whole study period and willing to provide two close contacts to assist with making contact.
Lives in the greater Seattle area and within an approximately one hour commute to the study research clinic.
Willing to avoid non-study related blood donation for 3 years following P. falciparum challenge.
Agrees not to travel to a malaria endemic region during the entire course of the trial.
Agrees not to travel away from the greater Seattle area from the day of first study immunization through 20 days after the last study immunization, and during the 29 days after CHMI.

Exclusion Criteria:

History of malaria infection or vaccination, residence in a malaria-endemic area for > / =5 years, travel to a malaria-endemic area in the past 6 months, or participation in a malaria research study.
Is breastfeeding or plans to breastfeed at any time throughout the study.
Plans to become pregnant at any time throughout the study.
Use of any antimalarial antibiotic or drug within 28 days prior to Study Day 1 or planned use during the study period.

Any clinically significant acute or chronic medical condition* or need for chronic medications** that, in the opinion of the investigator, will interfere with immunity or affect safety.

Includes, but is not limited to, disorders of the liver, kidney, lung, heart, or nervous system, or other metabolic or autoimmune/inflammatory conditions.

Receipt of systemic, prescription medications for the treatment of chronic medical conditions or variations of normal physiologic functions are permissible if, in the opinion of the investigator, they are used for conditions that are not clinically significant and would not impact the effectiveness of the vaccine or the safety of the subject or the safety and immunogenicity outcomes of the protocol. Use of systemic, over-the-counter medications and PRN systemic, prescription medications are allowed if, in the opinion of the investigator, they pose no additional risk to subject safety, vaccine efficacy or assessment of immunogenicity/reactogenicity. Topical (except corticosteroid) medications, nasal (including corticosteroid) medications, vitamins, and supplements are permissible. Any drug with antimalarial properties is not permissible.

Asthma, other than mild, well-controlled asthma*.

Cold or exercise induced asthma controlled with inhaled medications other than inhaled corticosteroids is permissible. Subjects should be excluded if they require daily bronchodilator use, or have had an asthma exacerbation requiring oral/parenteral steroid use or have used theophylline or inhaled corticosteroids in the past year.
Diabetes mellitus.

History of a psychiatric condition that may make study compliance difficult, such as schizophrenia, or unstable bipolar disorder*.

Includes persons with psychoses or history of suicide attempt or gesture in the 3 years before study entry or an ongoing risk for suicide.

Any history of non-febrile seizures or complex febrile seizures*

History of simple febrile seizures or a family history of seizure disorder is not exclusionary
Autoimmune disease (autoimmune thyroid disease is permissible and vitiligo or mild eczema not requiring chronic therapy is permissible).
Known or suspected congenital or acquired immunodeficiency including anatomic or functional asplenia* or immunosuppression as a result of underlying illness or treatment. *Any splenectomy is exclusionary.
Abuse of alcohol or drugs that, in the opinion of the investigator, may interfere with the subject's ability to comply with the protocol.
Body mass index (BMI) > / = 35 kg/m^2.

Active neoplastic disease*.

Subjects with a history of malignancy may be included if treated by surgical excision or if treated by chemotherapy or radiation therapy and has been observed for a period that in the investigator's estimation provides a reasonable assurance of sustained cure (not less than 36 months).

Chronic topical or systemic corticosteroid use*.

Corticosteroid nasal sprays for allergic rhinitis are permissible. Persons using a topical corticosteroid for a limited duration for mild uncomplicated dermatitis such as poison ivy or contact dermatitis may be enrolled the day after their therapy is completed. Oral or parenteral (IV, SC, or IM) corticosteroids given for non-chronic conditions not expected to recur are permissible if, within the year prior to enrollment, the longest course of therapy was no more than 14 days and no oral or parenteral corticosteroids were given within 30 days prior to enrollment. Intraarticular, bursal, tendon, or epidural injections of corticosteroids are permissible if the most recent injection was at least 30 days prior to enrollment.
Receipt or planned receipt of inactivated vaccine or allergy desensitization injection from 14 days before the first immunization through 14 days after the last immunization.
Planned receipt of inactivated vaccine or allergy desensitization injection from 14 days prior to CHMI through 28 days after CHMI.
Receipt or planned receipt of live attenuated vaccine 30 days before or at any time during the study up to 28 days after CHMI.

Receipt of any experimental agent* within 30 days prior to enrollment or planned receipt prior to the end of the study.

Vaccine, drug, biologic, device, blood product, or medication.

Plans to enroll in another clinical trial* that could interfere with safety assessment of the investigational product at any time during the study period.

Includes trials that have a study intervention such as a drug, biologic, or device.
Receipt of blood products or immunoglobulin within six months prior to Study Day 1 or donation of a unit of blood within two months before Study Day 1.
Systolic blood pressure > / = 161 mm Hg or diastolic blood pressure > / = 96 mm Hg.
Resting heart rate < 55 or > 100 beats per minute.
Oral temperature > / = 38 degrees C (100.4 degrees F).
Positive serology for HIV 1/2.
Positive hepatitis B surface antigen (HBsAg).
Positive antibody to hepatitis C virus (HCV).

Any Grade 1 or higher screening clinical lab value* (see Toxicity Tables Section 9.2.3).

Screening clinical labs include blood tests (white blood cells [WBC], hemoglobin, platelets, creatinine, non-fasting glucose, potassium, alanine aminotransferase [ALT], aspartate aminotransferase [AST], alkaline phosphatase, and total bilirubin) and urine dipstick tests (protein, glucose, hemoglobin). Any Grade 1 or higher value for any screening test will exclude the subject from enrollment with the exception of hematuria > / = 1 + detected during menses or other endometrial bleeding for females. In this situation, the test can be repeated if clinically warranted but is not considered an indicator of poor health status or increased risk and so is not a contraindication to enrollment.
Acute febrile illness (oral temperature > / = 38 degrees C [100.4 degrees F]) or other acute illness within 3 days prior to vaccination (subject may be rescheduled).

A screening ECG with abnormalities consistent with underlying heart disease.*

Pathologic Q waves and significant ST-T wave changes; left ventricular hypertrophy; any non-sinus rhythm excluding isolated premature atrial or ventricular contractions; right or left bundle branch block; QT/QTc interval > 450 ms; or advanced (secondary or tertiary) A-V heart block.
Has a history of psoriasis or porphyria.
Has a known allergy to chloroquine, 4-aminoquinoline derivatives, atovaquone, proguanil,artemether-lumenfantrine, 8-aminoquinoline derivatives, non-steroidal anti- inflammatory drugs, or acetaminophen.

Is using or intends to use a medication that is cross-reactive with CQ** or atovaquone and proguanil, such as cimetidine or metoclopramide, during the study period.

Antacids and kaolin can be administered at least 4 hours from intake of chloroquine.

Does not apply to infectivity controls
History of retinal or visual field changes, clinically significant auditory damage, or G6PD deficiency.
Has history of or a positive test for sickle cell disease or trait or other hemoglobinopathy.
Plans to undergo surgery (elective or otherwise) between enrollment and the end of the study.
Known hypersensitivity to PfSPZ or its components.
Has any condition that would, in the opinion of the site investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol.",Accepts Healthy Volunteers,All,18 Years,45 Years,['Adult'],"[{'LocationFacility': 'Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98101-1466', 'LocationCountry': 'United States'}]",,,"This phase I trial of the replication-intact PfSPZ Challenge vaccine given under CQ (PfSPZ-CVac) cover will randomize 28 healthy adult participants to one of three cohorts. Group 1 (n=12) will be randomized to receive PfSPZ Challenge vaccine at a dose of 51,200 sporozoites or 0.5 mL of sterile normal saline placebo by DVI on Days 3, 10 and 17. Group 2 (n=4) will be randomized to receive PfSPZ Challenge vaccine at a dose of 102,400 sporozoites or 0.5 mL of sterile normal saline placebo by DVI on Days 3, 10, and 17. Within both groups, placebo will be assigned 1:3, with blinded allocation to the two treatments within each group. All subjects in Study Groups 1 and 2 will receive, by directly observed treatment (DOT), oral chloroquine (CQ) on Days 1, 8, 15, and 22 at a suppressive dose of 600 mg base on Day 1 and 300 mg base on Days 8, 15 and 22. All subjects in Group 3 (n=9) will receive PfSPZ Challenge vaccine at a dose of 102,400 sporozoites per administration, with vaccine given on a Day 1, 6, and 11 schedule. Subjects in Group 3 will also receive, by DOT, oral CQ, with a suppressive dose of 600 mg base on Day 1 and a dose of 300 mg base on Days 6, 11, and 16. At 10 weeks after the third administration of study vaccine or placebo, all subjects within the three groups will receive the PfSPZ Challenge by direct venous injection at a dose of 3,200 P. falciparum sporozoites to assess vaccine efficacy against controlled human malarial infection (CHMI). The primary objective of this study is to 1) evaluate the safety and tolerability of escalating doses of Sanaria PfSPZ Challenge administered by DVI on varying schedules to healthy malaria-naïve adults taking suppressive doses of CQ (PfSPZ-CVac).","['challenge', 'malaria', 'P. falciparum', 'PfSPZ', 'sporozoites', 'vaccine']",,,,,,[{'SecondaryId': 'HHSN272201300019I'}],,,,,"['Participant', 'Investigator']",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]","[{'InterventionMeshId': 'D000002738', 'InterventionMeshTerm': 'Chloroquine'}]","[{'InterventionAncestorId': 'D000000563', 'InterventionAncestorTerm': 'Amebicides'}, {'InterventionAncestorId': 'D000000981', 'InterventionAncestorTerm': 'Antiprotozoal Agents'}, {'InterventionAncestorId': 'D000000977', 'InterventionAncestorTerm': 'Antiparasitic Agents'}, {'InterventionAncestorId': 'D000000890', 'InterventionAncestorTerm': 'Anti-Infective Agents'}, {'InterventionAncestorId': 'D000000962', 'InterventionAncestorTerm': 'Antimalarials'}, {'InterventionAncestorId': 'D000018501', 'InterventionAncestorTerm': 'Antirheumatic Agents'}]","[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M4562', 'InterventionBrowseLeafName': 'Chloroquine', 'InterventionBrowseLeafAsFound': 'Band', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M151035', 'InterventionBrowseLeafName': 'Chloroquine diphosphate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2861', 'InterventionBrowseLeafName': 'Antimalarials', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2485', 'InterventionBrowseLeafName': 'Amebicides', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2879', 'InterventionBrowseLeafName': 'Antiprotozoal Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2875', 'InterventionBrowseLeafName': 'Antiparasitic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19188', 'InterventionBrowseLeafName': 'Antirheumatic Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'ARhu', 'InterventionBrowseBranchName': 'Antirheumatic Agents'}, {'InterventionBrowseBranchAbbrev': 'Infl', 'InterventionBrowseBranchName': 'Anti-Inflammatory Agents'}, {'InterventionBrowseBranchAbbrev': 'Analg', 'InterventionBrowseBranchName': 'Analgesics'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03274726,CDC-NCCDPHP-2011-17,Centers for Disease Control and Prevention,FED,Iron Status of Women and Young Children in the United States,"Iron Status of Toddlers, Non-pregnant, and Pregnant Women in the United States",Sep-17,Completed,No,01-Jan-99,Actual,01-Dec-10,Actual,01-Dec-10,Actual,05-Sep-17,05-Sep-17,07-Sep-17,Actual,06-Sep-17,11-Sep-17,Actual,Principal Investigator,Centers for Disease Control and Prevention,FED,No,No,,,"This analysis describes the distribution of TBI and the prevalence of iron deficiency (ID) and iron deficiency anemia (IDA) among toddlers, non-pregnant women, and pregnant women.","['Iron-deficiency', 'Nutritional Deficiency']",Observational,,,,,,5000,Actual,,,"[{'PrimaryOutcomeMeasure': 'Iron Deficiency', 'PrimaryOutcomeDescription': 'Total Body Iron <0 mg/kg', 'PrimaryOutcomeTimeFrame': '1999-2010'}]",,"Included:

Children ages 12-23 months and Women ages 12-49 years
Those who completed the MEC

Excluded:

- Those missing data on iron biomarkers",Accepts Healthy Volunteers,All,,,"['Child', 'Adult', 'Older Adult']",,,,"Background: Total body iron stores (TBI), which are calculated from serum ferritin (SF) and soluble transferrin receptor (sTfR) concentrations, can be used to assess the iron status of populations in the United States.

Objective: This analysis describes the distribution of TBI and the prevalence of iron deficiency (ID) and iron deficiency anemia (IDA) among toddlers, non-pregnant women, and pregnant women.

Design: Investigators analyzed data from NHANES; toddlers aged 12-23 mo (NHANES 2003-2010), non-pregnant women aged 15-49 y (NHANES 2007-2010), and pregnant women aged 12-49 y (NHANES 1999-2010). Investigators used SAS survey procedures to plot distributions of TBI and produce prevalence estimates of ID and IDA for each target population. All analyses were weighted to account for the complex survey design",,No,['Other'],['Cross-Sectional'],"NHANES is a nationally-representative, cross-sectional study of nutrition and health for individuals residing in the U.S.",Probability Sample,,NHANES,Priya Gupta,ORISE Fellow,Centers for Disease Control and Prevention,,,,,"[{'ReferencePMID': '29070559', 'ReferenceType': 'derived', 'ReferenceCitation': 'Gupta PM, Hamner HC, Suchdev PS, Flores-Ayala R, Mei Z. Iron status of toddlers, nonpregnant females, and pregnant females in the United States. Am J Clin Nutr. 2017 Dec;106(Suppl 6):1640S-1646S. doi: 10.3945/ajcn.117.155978. Epub 2017 Oct 25. Review.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]","[{'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]","[{'ConditionBrowseLeafId': 'M19441', 'ConditionBrowseLeafName': 'Anemia, Iron-Deficiency', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23893', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Nutritional Deficiency', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11267', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M9116', 'InterventionBrowseLeafName': 'Iron', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Micro', 'InterventionBrowseBranchName': 'Micronutrients'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01283828,7.2,Gynuity Health Projects,OTHER,Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States,Vaginal and Rectal Clostridial Carriage Among Women of Reproductive Age in the United States,Oct-13,Completed,No,Nov-10,,Apr-13,Actual,Apr-13,Actual,25-Jan-11,25-Jan-11,26-Jan-11,Estimate,04-Oct-13,07-Oct-13,Estimate,Sponsor,Gynuity Health Projects,OTHER,,,,,This primary goals of this study are to: estimate the prevalence of Clostridium sordellii and Clostridium perfringens carriage in the rectum and/or vagina among women of reproductive age; estimate duration of carriage of the two clostridium species; and estimate the incidence of carriage at 2 weeks after a negative test.,"['Clostridium Sordellii', 'Clostridium Perfringens']",Observational,,,,,,4977,Actual,,,"[{'PrimaryOutcomeMeasure': 'Prevalence of C sordellii or C perfringens carriage in the rectum/vagina', 'PrimaryOutcomeTimeFrame': '2 years'}]","[{'SecondaryOutcomeMeasure': 'Duration of carriage of C sordellii or C perfringens', 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'Incidence of C. sordelli or C. perfringens carriage at 2 weeks after a negative test', 'SecondaryOutcomeTimeFrame': '2 years'}]","Inclusion Criteria:

Willing and able to provide informed consent
Between ages 18 and 45

Exclusion Criteria:

-Seeking emergency or oncological care",Accepts Healthy Volunteers,Female,18 Years,45 Years,['Adult'],"[{'LocationFacility': ""Montgomery Women's Health Associates"", 'LocationCity': 'Montgomery', 'LocationState': 'Alabama', 'LocationZip': '36117', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Arizona', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85721', 'LocationCountry': 'United States'}, {'LocationFacility': 'Planned Parenthood of the Rocky Mountains', 'LocationCity': 'Boulder', 'LocationState': 'Colorado', 'LocationZip': '80302', 'LocationCountry': 'United States'}, {'LocationFacility': ""UC Denver- Comprehensive Women's Health Center"", 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80220', 'LocationCountry': 'United States'}, {'LocationFacility': ""Feminist Women's Center"", 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30329', 'LocationCountry': 'United States'}, {'LocationFacility': 'Family Planning Associates Medical Group', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60630', 'LocationCountry': 'United States'}, {'LocationFacility': 'Planned Parenthood League of Massachusetts', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02215', 'LocationCountry': 'United States'}, {'LocationFacility': ""Women's Health Research Center"", 'LocationCity': 'Plainsboro', 'LocationState': 'New Jersey', 'LocationZip': '08536', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mt Sinai Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10029', 'LocationCountry': 'United States'}, {'LocationFacility': ""Red River Women's Clinic"", 'LocationCity': 'Fargo', 'LocationState': 'North Dakota', 'LocationZip': '58102', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Cincinnati', 'LocationCity': 'Cincinnati', 'LocationState': 'Ohio', 'LocationZip': '45267', 'LocationCountry': 'United States'}, {'LocationFacility': 'Downtown Gynecology', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97205', 'LocationCountry': 'United States'}, {'LocationFacility': ""Downtown Women's Center"", 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97205', 'LocationCountry': 'United States'}, {'LocationFacility': ""Philadelphia Women's Center"", 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19106', 'LocationCountry': 'United States'}, {'LocationFacility': ""Whole Women's Health of Fort Worth"", 'LocationCity': 'Fort Worth', 'LocationState': 'Texas', 'LocationZip': '76110', 'LocationCountry': 'United States'}, {'LocationFacility': 'Dr Barry Troyan', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77043', 'LocationCountry': 'United States'}, {'LocationFacility': 'Dairy Ashford Family Practice', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77077', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cedar River Clinic', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98405', 'LocationCountry': 'United States'}]",,Yes,"Since 2000, clostridial pelvic infections have claimed the lives of at least 17 young, previously healthy women. The majority of infections detected by molecular methods were among women testing positive for Clostridium sordellii only; in 5 cases, deaths were due to Clostridium perfringens only; and in 3 cases, the women were positive for both. These deaths occurred among both non-pregnant and recently pregnant women. Clostridium has been isolated from the vagina in 4-18% of normal, health non-pregnant women, with Clostridium perfringens the most common isolate. Most studies do not differentiate the small percentage of other clostridia present in the vaginal microenvironment. The vaginal carriage rate for Clostridium sordellii remains unknown, but is probably very low, less than 1%.

The correlates of clostridial carriage are unknown, and data on the etiology and lethality of clostridial infection among women of reproductive age are insufficient to guide possible courses of safe and effective prevention. In women infected with strains of Clostridium perfringens and Clostridium sordellii that produce the lethal toxin, it is not clear whether there is an effective treatment.",,,['Cohort'],['Prospective'],"Approximately 5,000 women aged 18 to 45 years in the United States will be enrolled in the study. Women will be recruited from approximately 25 clinics and solo or group practices providing maternity care (pre- and post-natal), abortion, STI prevention & treatment, family planning, and student health services. All women will be recruited, excluding women seeking emergency or oncological care.",Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'Beverly Winikoff, M.D., M.P.H.', 'OverallOfficialAffiliation': 'Gynuity Health Projects', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '26942366', 'ReferenceType': 'derived', 'ReferenceCitation': 'Chong E, Winikoff B, Charles D, Agnew K, Prentice JL, Limbago BM, Platais I, Louie K, Jones HE, Shannon C; NCT01283828 Study Team. Vaginal and Rectal Clostridium sordellii and Clostridium perfringens Presence Among Women in the United States. Obstet Gynecol. 2016 Feb;127(2):360-8. doi: 10.1097/AOG.0000000000001239.'}]",,,,,,,,Samples With DNA,Vaginal and rectal swabs,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04191824,PRO00102997,Duke University,OTHER,Genetic Testing to Understand and Address Renal Disease Disparities Across the United States,Genetic Testing to Understand and Address Renal Disease Disparities Across the United States,Mar-20,Recruiting,No,06-Jul-20,Actual,15-Apr-22,Anticipated,15-Jul-22,Anticipated,05-Dec-19,05-Dec-19,10-Dec-19,Actual,04-Aug-20,05-Aug-20,Actual,Sponsor,Duke University,OTHER,No,No,,,"The primary aim is to determine the effect of participant and provider knowledge of a positive APOL1 status and accompanying guideline based clinical decision support (CDS) on blood pressure management on change in systolic blood pressure (SBP) from baseline to 3 months after randomization among the APOL1 positive participants. Secondary aims are to:

Determine the effect of participant and provider knowledge of a positive APOL1 status on the probability of appropriate CKD diagnosis.
Determine the effect of participant and provider knowledge of a positive APOL1 status on the probability of receiving a urine microalbumin/creatinine testing and ACE-I/ARB prescription based on results of the urine microalbumin level.
Explore cost effectiveness, mediators, moderators, psychobehavioral impact of results disclosure on participants, and effects of participant and provider knowledge of APOL1 status on provider treatment recommendations.

PGX Substudy

In addition, GUARDD-US will include a substudy to determine the effect of knowledge of genetic test results that predict efficacy of various antihypertensive medications on change in SBP from baseline to 3 months in APOL1 negative individuals.

Approximately 5,435 participants of African ancestry age 18-70 with hypertension that either: 1) do not have diabetes and do not have CKD, or 2) have CKD. Participants with diabetes may be included as long as they also have CKD.

Population for Main Study:

Participants from Randomized Population (above) who test positive for APOL1

Population for PGx Substudy:

Participants from Randomized Population (above) randomized to Intervention and who test negative for APOL1

Main Study Analyses:

To determine the effect of participant and provider knowledge of a positive APOL1 status on SBP, we will compare the change in SBP from baseline to 3 months of the Intervention - APOL1 positive group to the change in SBP from baseline to 3 months of the Control - APOL1 positive group using a two sided Mann Whitney test, as appropriate, with a two-sided type I error of 0.05.
The effect of knowledge of a positive APOL1 status on all secondary endpoints will be compared between Intervention - APOL1 positives to Control - APOL1 positives with the proportion difference test.
Additional analyses will include analysis of time trends in SBP, subset analyses, and exploratory analyses of cost effectiveness, mediators, moderators, psychobehavioral impact of results disclosure on participants, and effects of knowledge of APOL1 status on provider treatment recommendations.

Substudy Analyses:

All primary and secondary endpoint analyses conducted for the APOL1 main study will be repeated for the PGx substudy focusing on differences in outcomes between APOL1 negative individuals with immediate PGx ROR (PGx Intervention) and APOL1 negative individuals with delayed PGx ROR (PGx Control).",['Renal Disease'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),5435,Anticipated,"[{'ArmGroupLabel': 'Immediate Return of Results', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Immediate return of results to inform participant of APOL1 status (either positive or negative).', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: APOL1 status']}}, {'ArmGroupLabel': 'Delayed Return of Results', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Delayed return of results of APOL1 status (either positive or negative) after the completion of the 6 month final study visit.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Diagnostic Test: APOL1 status']}}]","[{'InterventionType': 'Diagnostic Test', 'InterventionName': 'APOL1 status', 'InterventionDescription': 'Participants will be randomized to immediate versus delayed return of results for positive or negative APOL1 status.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Delayed Return of Results', 'Immediate Return of Results']}}]","[{'PrimaryOutcomeMeasure': 'Change in systolic blood pressure from baseline to 3 months', 'PrimaryOutcomeDescription': 'Change in systolic blood pressure', 'PrimaryOutcomeTimeFrame': 'Baseline to 3 month study visit'}]","[{'SecondaryOutcomeMeasure': 'Change in urine microalbuminuria/proteinuria', 'SecondaryOutcomeDescription': 'Change in urine microalbuminuria/proteinuria', 'SecondaryOutcomeTimeFrame': 'From baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Appropriate order of microalbuminuria/proteinuria tests', 'SecondaryOutcomeDescription': 'Appropriate order of microalbuminuria/proteinuria tests', 'SecondaryOutcomeTimeFrame': 'baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Change in appropriate diagnosis for stage 3 CKD', 'SecondaryOutcomeDescription': 'Change in appropriate diagnosis for stage 3 CKD', 'SecondaryOutcomeTimeFrame': 'baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Appropriate diagnosis of CKD stage 3 and above', 'SecondaryOutcomeDescription': 'Appropriate diagnosis of CKD stage 3 and above', 'SecondaryOutcomeTimeFrame': 'baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Change in appropriate diagnosis for any stage CKD', 'SecondaryOutcomeDescription': 'Change in appropriate diagnosis for any stage CKD', 'SecondaryOutcomeTimeFrame': 'Baseline to 6 months'}, {'SecondaryOutcomeMeasure': 'Appropriate diagnosis of all stage CKD', 'SecondaryOutcomeDescription': 'Appropriate diagnosis of all stage CKD', 'SecondaryOutcomeTimeFrame': 'Baseline to 6 months'}]","Inclusion Criteria:

African American/Black
English Speaking
Age 18-70 years
Have diagnosis of hypertension

Diagnosis of hypertension is defined by either:

ICD10 diagnosis codes (i.e., I10; I11.x; I12.x; I13.x; I16.x) OR
On active antihypertensive therapy for indication of hypertension OR
Having systolic blood pressure of 140 mm Hg or greater in at least 2 of the last 3 consecutive recorded values in the EHR OR

Having hypertension in the patient's medical record problem list

Have been seen at ≥1 time in past year at a participating primary care site
Either: 1) do not have diabetes and do not have CKD, or 2) have CKD;

Participants with diabetes may be included as long as they also have CKD.

CKD is defined by either:

1) ICD10 codes (i.e., N18.x; E08.22; E09.22; E10.22; E11.22;E13.22 (exclude Z94.0; N18.6; Z99.2)) OR

15 ≤ eGFR ≤ 60 ml/min for 2 time periods ≥ 3 months
Diabetes is defined by:
HbA1c ≥ 6.5 at least one time in the last year OR
ICD10 diagnosis codes (see Appendix A) OR
Having diabetes in the patient's medical record problem list

Exclusion Criteria:

Have diabetes, but no CKD.
Are currently on dialysis (ICD 10 codes N18.6, Z99.2 and Z94.0)
Have ESRD (eGFR<15 ml/min)
Have a terminal illness
Have patient-reported known pregnancy at time of enrollment
Have had a liver, kidney, or bone marrow transplant
Too cognitively impaired to provide informed consent and/or complete the study protocol
Institutionalized or too ill to participate (i.e. incarcerated, psychiatric or nursing home facility)
Plan to move out of the area within 6 months of enrollment
Not a current patient seeing a provider who cares for their hypertension (i.e., family medicine, internal medicine, nephrology, HIV provider, cardiology, hypertension specialists) at a participating site
Previously participated in the GUARDD pilot study OR have previously undergone APOL1 testing",No,All,18 Years,70 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Florida (Gainesville and Jacksonville)', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gainesville', 'LocationState': 'Florida', 'LocationZip': '32610', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Erica Elwood', 'LocationContactRole': 'Contact', 'LocationContactPhone': '352-273-6007', 'LocationContactEMail': 'erica.elwood@cop.ufl.edu'}, {'LocationContactName': 'Rhonda Cooper-DeHoff, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Indiana University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46202', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sheryl Lynch', 'LocationContactRole': 'Contact', 'LocationContactPhone': '317-274-2765', 'LocationContactEMail': 'slynch@iu.edu'}, {'LocationContactName': 'Michael Eadon, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'University Medical Center New Orleans', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70112', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Brianne Voros', 'LocationContactRole': 'Contact', 'LocationContactPhone': '504-702-3143', 'LocationContactEMail': 'Brianne.Voros@lcmchealth.org'}, {'LocationContactName': 'Jyotsna Fuloria, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Icahn School of Medicine at Mount Sinai', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10029', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Michelle Ramos', 'LocationContactRole': 'Contact', 'LocationContactPhone': '212-659-9571', 'LocationContactEMail': 'michelle.ramos@mountsinai.org'}, {'LocationContactName': 'Carol Horowitz, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'The Institute for Family Health', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10035', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Nandini Shroff', 'LocationContactRole': 'Contact', 'LocationContactPhone': '212-633-0800', 'LocationContactPhoneExt': '1363', 'LocationContactEMail': 'Nshroff@institute.org'}, {'LocationContactName': 'Neil Calman, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Southeastern Healthcare', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Lumberton', 'LocationState': 'North Carolina', 'LocationZip': '28358', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lori Dove', 'LocationContactRole': 'Contact', 'LocationContactPhone': '910-674-9526', 'LocationContactEMail': 'dove01@srmc.org'}, {'LocationContactName': 'Joseph Roberts, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Meharry Medical College', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37208', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Rajbir Singh', 'LocationContactRole': 'Contact', 'LocationContactPhone': '615-327-6204', 'LocationContactEMail': 'henry.h.ong@vumc.org'}, {'LocationContactName': 'Rajbir Singh, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Vanderbilt University Medical Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37232', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Henry Ong', 'LocationContactRole': 'Contact', 'LocationContactPhone': '615-322-5000', 'LocationContactEMail': 'henry.h.ong@vumc.org'}, {'LocationContactName': 'Kerri Cavanaugh, MD', 'LocationContactRole': 'Principal Investigator'}]}}, {'LocationFacility': 'Baylor Research Institute', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75210', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Aisha Montgomery', 'LocationContactRole': 'Contact', 'LocationContactPhone': '214-865-3071', 'LocationContactEMail': 'Aisha.Montgomery@BSWHealth.org'}, {'LocationContactName': 'Heather Kitzman, MD', 'LocationContactRole': 'Principal Investigator'}]}}]",,Yes,,,,,,,,,GUARDD-US,,,,,,"[{'OverallOfficialName': 'Hrishikesh Chakraborty', 'OverallOfficialAffiliation': 'Duke University', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,"[{'CentralContactName': 'Teji Rakhra-Burris', 'CentralContactRole': 'Contact', 'CentralContactPhone': '919-684-9849', 'CentralContactEMail': 'teji.rb@duke.edu'}]",,,,,,,,,,,,,,,Immediate versus delayed return of Apolipoprotein L1 (APOL1) gene testing results to provider and participant.,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007674', 'ConditionMeshTerm': 'Kidney Diseases'}]","[{'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}]","[{'ConditionBrowseLeafId': 'M9281', 'ConditionBrowseLeafName': 'Kidney Diseases', 'ConditionBrowseLeafAsFound': 'Renal Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15902', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03197688,AC-055-510,Actelion,INDUSTRY,Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States,"Multicenter, Retrospective Chart Review of First-time Opsumit® (Macitentan) Users in the United States",Sep-18,Completed,No,03-Aug-17,Actual,06-Sep-18,Actual,06-Sep-18,Actual,12-May-17,21-Jun-17,23-Jun-17,Actual,25-Sep-18,26-Sep-18,Actual,Sponsor,Actelion,INDUSTRY,Yes,No,,No,The Opsumit Users registry (OPUS; NCT02126943) was developed to characterize the safety profile of Opsumit and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting. It is expected that the recruitment target of the OPUS registry cannot be achieved within the planned time period (5000 Opsumit new users by October 2018). The OrPHeUS study is designed to supplement the OPUS registry with retrospectively identified first-time Opsumit users in order to achieve the desired sample size.,['Pulmonary Arterial Hypertension'],Observational,,,,,,2200,Actual,"[{'ArmGroupLabel': 'Notapplicable', 'ArmGroupDescription': 'Not applicable as non-interventional study', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Notapplicable']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Notapplicable', 'InterventionDescription': 'Not applicable as non-interventional study', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Notapplicable']}}]","[{'PrimaryOutcomeMeasure': 'Estimation of incidence rates of adverse events', 'PrimaryOutcomeDescription': 'Incidence rates of liver test abnormalities, Occurrence of Hepatic Adverse Events (HAEs), Occurrence of any other Adverse Event (AE), Occurrence and reason for discontinuation of Opsumit treatment, hospitalization and death', 'PrimaryOutcomeTimeFrame': 'Observation period from 19 Oct 2013 to 31 March 2017, Data collection from 1 Apr 2017 to 30 Jun 2018'}]","[{'SecondaryOutcomeMeasure': 'Description of demographic characteristics of patients', 'SecondaryOutcomeDescription': 'To describe demographic characteristics of patients treated with Opsumit at beginning and during study time period', 'SecondaryOutcomeTimeFrame': 'Observation period from 19 Oct 2013 to 31 March 2017, Data collection from 1 Apr 2017 to 30 Jun 2018'}, {'SecondaryOutcomeMeasure': 'Description of clinical characteristics of patients', 'SecondaryOutcomeDescription': 'To describe clinical characteristics of patients treated with Opsumit at beginning and during study time period', 'SecondaryOutcomeTimeFrame': 'Observation period from 19 Oct 2013 to 31 March 2017, Data collection from 1 Apr 2017 to 30 Jun 2018'}]","Inclusion Criteria:

Patients who initiated Opsumit for the first time between 19 October 2013 and 31 December 2016 (inclusive)
Patients whose medical charts are available for data collection

Exclusion Criteria:

Patient participation in the OPUS registry
Patient participation in any clinical trial involving Opsumit treatment or macitentan investigational product",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Pulmonary Associates', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85006', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cardiovascular Consultants', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85032', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mayo Clinic - Arizona', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85054', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of California San Diego', 'LocationCity': 'La Jolla', 'LocationState': 'California', 'LocationZip': '93093', 'LocationCountry': 'United States'}, {'LocationFacility': 'Loma Linda University Medical Center', 'LocationCity': 'Loma Linda', 'LocationState': 'California', 'LocationZip': '92354', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Southern California', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90033', 'LocationCountry': 'United States'}, {'LocationFacility': 'David Geffen School of Medicine at University of California Los Angeles', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90095-1690', 'LocationCountry': 'United States'}, {'LocationFacility': 'UCSF School of Medicine', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94143', 'LocationCountry': 'United States'}, {'LocationFacility': 'Paloma Medical Group', 'LocationCity': 'San Juan Capistrano', 'LocationState': 'California', 'LocationZip': '92675', 'LocationCountry': 'United States'}, {'LocationFacility': 'Santa Barbara Cottage Hospital', 'LocationCity': 'Santa Barbara', 'LocationState': 'California', 'LocationZip': '93105', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Colorado', 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80045', 'LocationCountry': 'United States'}, {'LocationFacility': 'National Jewish Health', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80206', 'LocationCountry': 'United States'}, {'LocationFacility': 'Yale University', 'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520', 'LocationCountry': 'United States'}, {'LocationFacility': 'Christiana Care Health Services', 'LocationCity': 'Newark', 'LocationState': 'Delaware', 'LocationZip': '19718', 'LocationCountry': 'United States'}, {'LocationFacility': 'MedStar Georgetown University Hospital', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20007', 'LocationCountry': 'United States'}, {'LocationFacility': 'Bay Area Cardiology Associates', 'LocationCity': 'Brandon', 'LocationState': 'Florida', 'LocationZip': '33511', 'LocationCountry': 'United States'}, {'LocationFacility': 'Florida Lung, Asthma and Sleep Specialists', 'LocationCity': 'Celebration', 'LocationState': 'Florida', 'LocationZip': '34747', 'LocationCountry': 'United States'}, {'LocationFacility': 'Frank Hull, MD, PA', 'LocationCity': 'Fort Lauderdale', 'LocationState': 'Florida', 'LocationZip': '33316', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Florida', 'LocationCity': 'Gainesville', 'LocationState': 'Florida', 'LocationZip': '32610', 'LocationCountry': 'United States'}, {'LocationFacility': 'West Pasco Pulmonary Associates', 'LocationCity': 'Hudson', 'LocationState': 'Florida', 'LocationZip': '34667', 'LocationCountry': 'United States'}, {'LocationFacility': ""Saint Vincent's Medical Center"", 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32209', 'LocationCountry': 'United States'}, {'LocationFacility': 'Medical Research of Central Florida', 'LocationCity': 'Leesburg', 'LocationState': 'Florida', 'LocationZip': '34748', 'LocationCountry': 'United States'}, {'LocationFacility': 'Independent Lung Associates', 'LocationCity': 'Melbourne', 'LocationState': 'Florida', 'LocationZip': '32901', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mount Sinai Comprehensive Cancer Center', 'LocationCity': 'Miami Beach', 'LocationState': 'Florida', 'LocationZip': '33140', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Miami', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33136', 'LocationCountry': 'United States'}, {'LocationFacility': 'Central Florida Pulmonary Group, P.A. - Downtown Orlando Office', 'LocationCity': 'Orlando', 'LocationState': 'Florida', 'LocationZip': '32803', 'LocationCountry': 'United States'}, {'LocationFacility': 'Coastal Pulmonary and Critical Care', 'LocationCity': 'Saint Petersburg', 'LocationState': 'Florida', 'LocationZip': '33704', 'LocationCountry': 'United States'}, {'LocationFacility': 'Bassetti Medical Research Inc', 'LocationCity': 'Sebring', 'LocationState': 'Florida', 'LocationZip': '33870', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cardiovascular Medicine Associates', 'LocationCity': 'South Miami', 'LocationState': 'Florida', 'LocationZip': '33143', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of South Florida', 'LocationCity': 'Tampa', 'LocationState': 'Florida', 'LocationZip': '33606', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cleveland Clinic Florida Hospital', 'LocationCity': 'Weston', 'LocationState': 'Florida', 'LocationZip': '33331', 'LocationCountry': 'United States'}, {'LocationFacility': 'Florida Medical Clinic', 'LocationCity': 'Zephyrhills', 'LocationState': 'Florida', 'LocationZip': '33542', 'LocationCountry': 'United States'}, {'LocationFacility': 'Piedmont Healthcare', 'LocationCity': 'Austell', 'LocationState': 'Georgia', 'LocationZip': '30106', 'LocationCountry': 'United States'}, {'LocationFacility': 'Southeastern Cardiology Associates', 'LocationCity': 'Columbus', 'LocationState': 'Georgia', 'LocationZip': '31904', 'LocationCountry': 'United States'}, {'LocationFacility': 'Wellstar Marietta Pulmonary Medicine', 'LocationCity': 'Marietta', 'LocationState': 'Georgia', 'LocationZip': '30060', 'LocationCountry': 'United States'}, {'LocationFacility': 'Bingham Memorial Hospital', 'LocationCity': 'Shelley', 'LocationState': 'Idaho', 'LocationZip': '83274', 'LocationCountry': 'United States'}, {'LocationFacility': 'Northwestern University', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60611', 'LocationCountry': 'United States'}, {'LocationFacility': 'IU Health Physicians Pulmonary & Critical Care', 'LocationCity': 'Carmel', 'LocationState': 'Indiana', 'LocationZip': '46032', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lutheran Hospital', 'LocationCity': 'Fort Wayne', 'LocationState': 'Indiana', 'LocationZip': '46804', 'LocationCountry': 'United States'}, {'LocationFacility': 'Indiana Internal Medicine Consultants', 'LocationCity': 'Greenwood', 'LocationState': 'Indiana', 'LocationZip': '46143', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Vincent Medical Group, Inc.', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46260', 'LocationCountry': 'United States'}, {'LocationFacility': 'CIC Associates', 'LocationCity': 'Clive', 'LocationState': 'Iowa', 'LocationZip': '50325', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Iowa Hospitals and Clinics', 'LocationCity': 'Iowa City', 'LocationState': 'Iowa', 'LocationZip': '52242', 'LocationCountry': 'United States'}, {'LocationFacility': 'The University of Kansas Physicians', 'LocationCity': 'Kansas City', 'LocationState': 'Kansas', 'LocationZip': '66160', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Elizabeth Healthcare Clinical Research Institute', 'LocationCity': 'Erlanger', 'LocationState': 'Kentucky', 'LocationZip': '41018', 'LocationCountry': 'United States'}, {'LocationFacility': 'Kentuckiana Pulmonary Associates', 'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationZip': '40202', 'LocationCountry': 'United States'}, {'LocationFacility': 'LSU Health Sciences Center', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70112', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ochsner Medical Center', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70121', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pulmonary & Critical Care Specialists', 'LocationCity': 'Shreveport', 'LocationState': 'Louisiana', 'LocationZip': '71105', 'LocationCountry': 'United States'}, {'LocationFacility': 'Tufts Medical Center', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02111', 'LocationCountry': 'United States'}, {'LocationFacility': 'Massachusetts General Hospital', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}, {'LocationFacility': 'Boston University Medical Center', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02118', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Michigan Medical Center', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Henry Ford Health System', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48202', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sparrow Clinical Research Institute', 'LocationCity': 'Lansing', 'LocationState': 'Michigan', 'LocationZip': '48912', 'LocationCountry': 'United States'}, {'LocationFacility': 'Beaumont Medical Center', 'LocationCity': 'Troy', 'LocationState': 'Michigan', 'LocationZip': '48085', 'LocationCountry': 'United States'}, {'LocationFacility': 'Minneapolis Heart Institute', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55407-3799', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Mississippi Medical Center', 'LocationCity': 'Jackson', 'LocationState': 'Mississippi', 'LocationZip': '39216', 'LocationCountry': 'United States'}, {'LocationFacility': 'Saint Louis University', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63104', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pulmonary Consultants Inc-St. Louis', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63136', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mercy Hospital Saint Louis', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63141', 'LocationCountry': 'United States'}, {'LocationFacility': 'Nebraska Pulmonary Specialties, LLC', 'LocationCity': 'Lincoln', 'LocationState': 'Nebraska', 'LocationZip': '68506', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Nebraska Medical Center', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68198-5990', 'LocationCountry': 'United States'}, {'LocationFacility': 'Barnabas Health Ambulatory Care Center', 'LocationCity': 'Newark', 'LocationState': 'New Jersey', 'LocationZip': '07112', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pulmonary and Critical Care Associates', 'LocationCity': 'Union', 'LocationState': 'New Jersey', 'LocationZip': '07083', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of New Mexico', 'LocationCity': 'Albuquerque', 'LocationState': 'New Mexico', 'LocationZip': '87131-0001', 'LocationCountry': 'United States'}, {'LocationFacility': 'Albany Medical Center', 'LocationCity': 'Albany', 'LocationState': 'New York', 'LocationZip': '12208', 'LocationCountry': 'United States'}, {'LocationFacility': 'Montefiore Medical Center - Bronx', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10467', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pulmonary Health Physicians', 'LocationCity': 'Fayetteville', 'LocationState': 'New York', 'LocationZip': '13066', 'LocationCountry': 'United States'}, {'LocationFacility': 'Stony Brook University Hospital', 'LocationCity': 'Hauppauge', 'LocationState': 'New York', 'LocationZip': '11788', 'LocationCountry': 'United States'}, {'LocationFacility': 'Temple University Hospital', 'LocationCity': 'Middletown', 'LocationState': 'New York', 'LocationZip': '10941', 'LocationCountry': 'United States'}, {'LocationFacility': 'Winthrop University Hospital, Clinical Trials Center', 'LocationCity': 'Mineola', 'LocationState': 'New York', 'LocationZip': '11501', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mount Sinai', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10029', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of North Carolina Hospitals', 'LocationCity': 'Chapel Hill', 'LocationState': 'North Carolina', 'LocationZip': '27599', 'LocationCountry': 'United States'}, {'LocationFacility': 'Duke University Medical Center', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27710', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Cincinnati', 'LocationCity': 'Cincinnati', 'LocationState': 'Ohio', 'LocationZip': '45242', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ohio State University, Wexner Medical Center', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mount Carmel Medical Group', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43213', 'LocationCountry': 'United States'}, {'LocationFacility': 'Midwest Pulmonary & Sleep Research', 'LocationCity': 'Dayton', 'LocationState': 'Ohio', 'LocationZip': '45459', 'LocationCountry': 'United States'}, {'LocationFacility': 'Southwest General Health Center', 'LocationCity': 'Middleburg Heights', 'LocationState': 'Ohio', 'LocationZip': '44130', 'LocationCountry': 'United States'}, {'LocationFacility': 'The University of Toledo Medical Center', 'LocationCity': 'Toledo', 'LocationState': 'Ohio', 'LocationZip': '43614', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oklahoma Heart Hospital', 'LocationCity': 'Oklahoma City', 'LocationState': 'Oklahoma', 'LocationZip': '73120', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oregon Health & Science University', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97201-3098', 'LocationCountry': 'United States'}, {'LocationFacility': 'Legacy Research Institute', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97210', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Oregon Clinic', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97225', 'LocationCountry': 'United States'}, {'LocationFacility': 'Doylestown Health Cardiology, a division of Doylestown Health Physicians', 'LocationCity': 'Doylestown', 'LocationState': 'Pennsylvania', 'LocationZip': '18907', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Pennsylvania Health System', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19104', 'LocationCountry': 'United States'}, {'LocationFacility': 'Thomas Jefferson University', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19107', 'LocationCountry': 'United States'}, {'LocationFacility': 'Allegheny General Hospital', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15212', 'LocationCountry': 'United States'}, {'LocationFacility': 'Lankenau Medical Center', 'LocationCity': 'Wynnewood', 'LocationState': 'Pennsylvania', 'LocationZip': '19096', 'LocationCountry': 'United States'}, {'LocationFacility': 'AnMed Health Medical Center', 'LocationCity': 'Anderson', 'LocationState': 'South Carolina', 'LocationZip': '29621', 'LocationCountry': 'United States'}, {'LocationFacility': 'Carolina Cardiology Associates', 'LocationCity': 'Rock Hill', 'LocationState': 'South Carolina', 'LocationZip': '29732', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sioux Falls Cardiovascular PC', 'LocationCity': 'Sioux Falls', 'LocationState': 'South Dakota', 'LocationZip': '57108', 'LocationCountry': 'United States'}, {'LocationFacility': 'Memorial Research Center', 'LocationCity': 'Chattanooga', 'LocationState': 'Tennessee', 'LocationZip': '37404', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mid-South Pulmonary Specialists', 'LocationCity': 'Memphis', 'LocationState': 'Tennessee', 'LocationZip': '38157', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Texas Southwestern Medical Center at Dallas', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75390-8550', 'LocationCountry': 'United States'}, {'LocationFacility': 'Premier Pulmonary CC and Sleep Medicine, PA', 'LocationCity': 'Denison', 'LocationState': 'Texas', 'LocationZip': '75020', 'LocationCountry': 'United States'}, {'LocationFacility': 'Houston Methodist Hospital', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Texas Health Science Center at Houston', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Baylor Regional Medical Center at Plano', 'LocationCity': 'Plano', 'LocationState': 'Texas', 'LocationZip': '75093', 'LocationCountry': 'United States'}, {'LocationFacility': 'Scott and White Memorial Hospital', 'LocationCity': 'Temple', 'LocationState': 'Texas', 'LocationZip': '76508-0001', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Washington', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98195', 'LocationCountry': 'United States'}, {'LocationFacility': 'Spokane Respiratory Consultants', 'LocationCity': 'Spokane', 'LocationState': 'Washington', 'LocationZip': '99204-4800', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cardiac Study Center', 'LocationCity': 'Tacoma', 'LocationState': 'Washington', 'LocationZip': '98405', 'LocationCountry': 'United States'}, {'LocationFacility': ""Aurora Health Care - Saint Luke's Medical Center"", 'LocationCity': 'Milwaukee', 'LocationState': 'Wisconsin', 'LocationZip': '53215', 'LocationCountry': 'United States'}, {'LocationFacility': 'CardioPulmonary Research Center', 'LocationCity': 'Guaynabo', 'LocationZip': '00968', 'LocationCountry': 'Puerto Rico'}]",,No,,,No,['Cohort'],['Retrospective'],"Patients who initiated Opsumit for the first time between 19 October 2013 and 31 December 2016 (inclusive) are eligible for OrPHeUS (i.e., eligibility period).",Non-Probability Sample,,OrPHeUS,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}]","[{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]","[{'ConditionBrowseLeafId': 'M8607', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'Arterial Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4818', 'ConditionBrowseLeafName': 'Pulmonary Arterial Hypertension', 'ConditionBrowseLeafAsFound': 'Pulmonary Arterial Hypertension', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M267028', 'InterventionBrowseLeafName': 'Macitentan', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02813577,CL0025-01,C. R. Bard,INDUSTRY,Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females (CONFIRM),"A Prospective, Multicenter, Single Arm, Post-Approval Study of the Lutonix Drug Coated Balloon for Treatment of Femoropopliteal Arteries in United States Females",Apr-20,Terminated,No,20-Apr-18,Actual,18-Feb-19,Actual,18-Feb-19,Actual,16-Jun-16,24-Jun-16,27-Jun-16,Estimate,10-Apr-20,24-Apr-20,Actual,Sponsor,C. R. Bard,INDUSTRY,No,Yes,,No,The post approval study will enroll US female patients presenting with claudication or ischemic rest pain and an angiographically significant lesion in the superficial femoral or popliteal artery. Subjects are treated per Instructions For Use (IFU) with the Lutonix® Catheter. Subjects will have a Duplex Ultrasound (DUS) and clinical follow-up through two (2) years.,"['Femoral Artery Stenosis', 'Popliteal Artery Stenosis', 'Femoral Artery Occlusion', 'Popliteal Artery Occlusion']",Interventional,['Not Applicable'],N/A,Single Group Assignment,Treatment,None (Open Label),4,Actual,"[{'ArmGroupLabel': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'ArmGroupType': 'Other', 'ArmGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Lutonix® 035 Drug Coated Balloon PTA Catheter']}}]","[{'InterventionType': 'Device', 'InterventionName': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'InterventionDescription': 'Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Lutonix® 035 Drug Coated Balloon PTA Catheter']}}]","[{'PrimaryOutcomeMeasure': 'Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure', 'PrimaryOutcomeDescription': 'Index limb amputation includes above or below the ankle amputations.', 'PrimaryOutcomeTimeFrame': '12 months post index procedure'}, {'PrimaryOutcomeMeasure': 'Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.', 'PrimaryOutcomeDescription': 'Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.', 'PrimaryOutcomeTimeFrame': '12 months post index procedure'}]","[{'SecondaryOutcomeMeasure': 'Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.', 'SecondaryOutcomeTimeFrame': '30 days post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Major Vascular Complications at 30 Days Post Index Procedure', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Number of Deaths (All Causes) at 30 Days Post Index Procedure', 'SecondaryOutcomeTimeFrame': '30 days post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months'}, {'SecondaryOutcomeMeasure': 'Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}, {'SecondaryOutcomeMeasure': 'Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline', 'SecondaryOutcomeTimeFrame': '1, 6, 12 and 24 months post index procedure'}]","Clinical Criteria

Non-pregnant female ≥18 years of age;
Rutherford Clinical Category 2-4;

Patient is willing to provide informed consent, is geographically stable, comply with the required follow up visits and testing schedule;

Angiographic Criteria

De novo or restenotic lesion(s) in native superficial femoral or popliteal arteries;
Lesion ≥70% stenosis by visual estimate;
Target reference vessel diameter of 4-7 mm;
A patent inflow artery free from significant lesion (≥50% stenosis) as confirmed by angiography; (Treatment of target lesion acceptable after successful treatment of inflow artery lesions. Successful inflow artery treatment is defined as attainment of residual diameter stenosis ≤30% without death or major vascular complication.)
At least one patent native outflow artery to the ankle, free from significant (≥50%) stenosis as confirmed by angiography after successful vessel preparation;
Successful antegrade wire crossing and vessel preparation (may include pre-dilatation) of the target lesion. Successful vessel preparation is defined by residual stenosis ≤30% without any major vascular complications;
No other prior vascular interventions within 2 weeks before and/or planned 30 days after the protocol treatment except for remote common femoral patch angioplasty separated by at least 2 cm from the lesion(s).

Exclusion Criteria

Life expectancy of <2 years;
Subject is currently participating in an investigational drug or device study, or previously enrolled in this study. Enrollment in another investigational drug or device study during the follow up period is not allowed;
History of stroke within 3 months;
History of myocardial infarction (MI), thrombolysis or angina within 2 weeks of index procedure;
Renal failure or chronic kidney disease with serum creatinine ≥2.5 mg/L within 30 days of index procedure or treated with dialysis;
Sudden symptom onset, acute vessel occlusion, or acute or sub-acute thrombus in target vessel.",No,Female,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'St. Vincent Medical Group', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46290', 'LocationCountry': 'United States'}, {'LocationFacility': 'Midwest Cardiovascular Research Foundation', 'LocationCity': 'Davenport', 'LocationState': 'Iowa', 'LocationZip': '52803', 'LocationCountry': 'United States'}, {'LocationFacility': 'Vascular Access Solutions', 'LocationCity': 'Orangeburg', 'LocationState': 'South Carolina', 'LocationZip': '29118', 'LocationCountry': 'United States'}, {'LocationFacility': 'Wellmont CVA Heart Institute', 'LocationCity': 'Kingsport', 'LocationState': 'Tennessee', 'LocationZip': '37660', 'LocationCountry': 'United States'}]",,No,"The Lutonix® 035 Drug Coated Balloon PTA Catheter (Lutonix® Catheter) has been approved by the Food and Drug Administration (P130024) for percutaneous transluminal angioplasty, after appropriate vessel preparation of de novo, restenotic, or in-stent restenotic lesions up to 300 mm in length in native superficial femoral or popliteal arteries with reference vessel diameters of 4-7 mm. The purpose of this post-approval study is to assess the safety and effectiveness of the Lutonix® Catheter in the US female population. This study will enroll approximately 165 female patients at a minimum of 10 US centers and a maximum of 25.","['Legs', 'Drug Coated Angioplasty Balloon', 'Experimental', 'Standard Angioplasty Balloon']",,,,,,,CONFIRM,,,,,,"[{'OverallOfficialName': 'Christopher Metzger, MD', 'OverallOfficialAffiliation': 'Wellmont CVA Heart Institute', 'OverallOfficialRole': 'Principal Investigator'}]",No,,10-Apr-20,10-Apr-20,24-Apr-20,Actual,,,FDA allowed other data to be leveraged to meet the study requirements,,,"[{'SeeAlsoLinkLabel': 'Lutonix® 035 Drug Coated Balloon PTA Catheter Instructions For Use', 'SeeAlsoLinkURL': 'http://www.bardpv.com/?portfolio=lutonix-035'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001157', 'ConditionMeshTerm': 'Arterial Occlusive Diseases'}, {'ConditionMeshId': 'D000003251', 'ConditionMeshTerm': 'Constriction, Pathologic'}]","[{'ConditionAncestorId': 'D000020763', 'ConditionAncestorTerm': 'Pathological Conditions, Anatomical'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}]","[{'ConditionBrowseLeafId': 'M5058', 'ConditionBrowseLeafName': 'Constriction, Pathologic', 'ConditionBrowseLeafAsFound': 'Stenosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3046', 'ConditionBrowseLeafName': 'Arterial Occlusive Diseases', 'ConditionBrowseLeafAsFound': 'Artery Occlusion', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21103', 'ConditionBrowseLeafName': 'Pathological Conditions, Anatomical', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}]",,,,,,,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'FlowGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementComment': 'Study was terminated and only some results at 1 month follow up are available.', 'FlowAchievementNumSubjects': '0'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Study terminated', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '4'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'BaselineGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '4'}]}}]","[{'BaselineMeasureTitle': 'Age, Customized', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': '≥18 years of age', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race (NIH/OMB)', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'American Indian or Alaska Native', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Asian', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Native Hawaiian or Other Pacific Islander', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Black or African American', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}]}}, {'BaselineCategoryTitle': 'White', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}]}}, {'BaselineCategoryTitle': 'More than one race', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Unknown or Not Reported', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Number of Participants With Freedom From the Following: All-cause Peri-operative Death at 30 Days, Index Limb Amputation Within 1 Year, Index Limb Re-intervention Within 1 Year, and Index-limb-Related Death Within 1 Year Post Index Procedure', 'OutcomeMeasureDescription': 'Index limb amputation includes above or below the ankle amputations.', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '12 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Effectiveness: Number of Participants With Primary Patency of the Target Lesion at 12 Month Post Index Procedure.', 'OutcomeMeasureDescription': 'Primary patency is defined as freedom from target lesion restenosis (TLR) and from binary restenosis. Binary restenosis is adjudicated by the independent Core Laboratory based on Peak Systolic Velocity Ratio (PSVR) ≥ 2.5 and / or abnormal waveforms, or based on angiographic ≥ 50% diameter stenosis.', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '12 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Freedom From All-cause Perioperative (≤ 30 Day) Death and Freedom From the Following: Index Limb Amputation, Index Limb Re-intervention, and Index-Limb-Related Death.', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '30 days post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Major Vascular Complications at 30 Days Post Index Procedure', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Complications', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Deaths (All Causes) at 30 Days Post Index Procedure', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': '30 days post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '4'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Clinically Driven Target Lesion Revascularization (TLR) at 1, 6, 12, and 24 Month Post Index Procedure', 'OutcomeMeasurePopulationDescription': 'Study terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Target Vessel Revascularization (TVR) at 1, 6, 12, and 24 Months Post Index Porcedure', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Reintervention for Treatment of Thrombosis of the Target Vessel or Embolization to Its Distal Vasculature at 1, 6, 12, and 24 Months Post Index Procedure', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Unanticipated and Anticipated Device Related Serious Adverse Events at 1, 6, 12, and 24 Months Post Index Procedure', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Amputation (Above the Ankle)-Free Survival (AFS) at 1, 6, 12, and 24 Months Post Index Procedure.', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change in Rutherford Classification Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Sustained Clinical Benefit at 1, 6, 12, and 24 Months Post Index Procedure', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Change of Resting Ankle Brachial Index (ABI) Scores at 1, 6, 12, and 24 Months Post Index Procedure Compared to Baseline', 'OutcomeMeasurePopulationDescription': 'Study was terminated.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureTimeFrame': '1, 6, 12 and 24 months post index procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'OutcomeGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '0'}]}}]}}]",0,At 1 month post-index procedure.,"Only the following type of endpoint related adverse events were reported:

Events leading to death
Target limb reintervention
Target limb amputation
Any event deemed to be device- or procedure-related
Major vascular complication within 30 days of the index procedure
Any event involving the target limb that requires treatment","[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Lutonix® 035 Drug Coated Balloon PTA Catheter', 'EventGroupDescription': 'This is a single-arm study. Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.\n\nLutonix® 035 Drug Coated Balloon PTA Catheter: Female subjects will receive the Lutonix® 035 Drug Coated Balloon PTA Catheter.', 'EventGroupDeathsNumAffected': '0', 'EventGroupDeathsNumAtRisk': '4', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '4', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '4'}]",,No,Yes,Anna Lovas,Becton Dickinson,anna.lovas@bd.com,763-445-2385,,OTHER,"Prior to PI publication of site results, sponsor requires publication of multi-centers results.",,,"[{'LargeDocTypeAbbrev': 'Prot_SAP', 'LargeDocHasProtocol': 'Yes', 'LargeDocHasSAP': 'Yes', 'LargeDocHasICF': 'No', 'LargeDocLabel': 'Study Protocol and Statistical Analysis Plan', 'LargeDocDate': 'December 1, 2017', 'LargeDocUploadDate': '04/10/2020 11:12', 'LargeDocFilename': 'Prot_SAP_000.pdf'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00666380,A-14620.a,U.S. Army Medical Research and Development Command,FED,A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya,"Phase 1a Open-label Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B in Healthy Malaria-Naïve Adults",May-15,Completed,No,Apr-08,,Dec-08,Actual,Jun-09,Actual,22-Apr-08,23-Apr-08,24-Apr-08,Estimate,27-May-15,29-May-15,Estimate,Sponsor,U.S. Army Medical Research and Development Command,FED,,,,,The purpose of this study is to determine whether an investigational malaria vaccine is safe and induces an immune response against malaria when tested in adults living in the United States.,['Malaria'],Interventional,['Phase 1'],Non-Randomized,Parallel Assignment,Prevention,None (Open Label),26,Actual,"[{'ArmGroupLabel': '10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Plasmodium falciparum Malaria Protein 010 (FMP010)']}}, {'ArmGroupLabel': '50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Plasmodium falciparum Malaria Protein 010 (FMP010)']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Plasmodium falciparum Malaria Protein 010 (FMP010)', 'InterventionDescription': 'Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['10 ug of FMP010 antigen in 0.5 mL AS01B adjuvant', '50 ug of FMP010 antigen in 0.5 mL AS01B adjuvant']}}]","[{'PrimaryOutcomeMeasure': 'Number of solicited adverse events', 'PrimaryOutcomeDescription': 'Occurrence and intensity of solicited symptoms on day of vaccination and Days 1-7 after each vaccination', 'PrimaryOutcomeTimeFrame': '7 days'}, {'PrimaryOutcomeMeasure': 'Number of unsolicited adverse events', 'PrimaryOutcomeDescription': 'Occurrence and intensity of unsolicited symptoms over a 30-day follow-up period (day of vaccination and 29 subsequent days) after each vaccination', 'PrimaryOutcomeTimeFrame': '30 days'}, {'PrimaryOutcomeMeasure': 'Number of serious adverse events', 'PrimaryOutcomeTimeFrame': '1 year'}]","[{'SecondaryOutcomeMeasure': 'Percent parasite growth inhibition', 'SecondaryOutcomeDescription': 'Functionality of antibodies elicited as measured by percent parasite growth inhibition in GIA against homologous (FVO) and heterologous (3D7) parasites', 'SecondaryOutcomeTimeFrame': 'Up to 112 days'}]","Inclusion Criteria:

A male or non-pregnant, non-lactating female 18 to 50 years of age (inclusive) at the time of screening
Free of significant health problems as established by medical history and clinical examination before entering into the study
Available to participate for duration of study (approximately seven months)
If the subject is female, she must be of non-childbearing potential (either surgically sterilized or one year post-menopausal) or, if of childbearing potential, she must be capable of preventing pregnancy, have a negative pregnancy test at the time of each vaccination, and must agree to continue such precautions for two months after completion of the vaccination series.
If the volunteer indicates he/she is active duty military (on the DCT sign-in page and intake form), approval from their supervisor through the Division Director using the Statement of Supervisor's Approval Form must be signed and on file prior to receipt of any test product
Written informed consent must be obtained from the subject before screening procedures.
Test of Understanding
Prior to entry into this study, subjects must score at least 80% correct on a 10- question multiple-choice quiz that assesses their understanding of this study. If they do not score 80% on the initial quiz, the protocol information will be reviewed with them to ensure comprehension, and they will have the opportunity to retest. If a volunteer fails to correctly answer 8 of 10 questions after two attempts they will be excluded from the study.

Exclusion Criteria:

Prior receipt of any investigational malaria vaccine
Prior receipt of a vaccine containing either QS-21, MPL or AS02 or AS01
Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the first dose of study vaccine, or planned use during the study period
Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of vaccination. For corticosteroids, this is defined as prednisone, or equivalent, 0.5 mg/kg/day. Inhaled and topical steroids are allowed.
Planned administration of a vaccine not foreseen by the study protocol within 30 days of the first dose of the study vaccine
Any past history of malaria
Planned travel to malarious areas during the study period
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
A family history of congenital or hereditary immunodeficiency
Chronic or active neurologic disease including seizure disorder
History of splenectomy

Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or abnormal baseline laboratory screening tests

ALT above normal range
Creatinine above normal range
Hemoglobin below normal range
Platelet count below normal range
Total white cell count below normal range
Acute disease at the time of enrollment (acute disease is defined as the presence of a moderate or severe illness with or without fever). All vaccines can be administered to persons with a minor illness, such as diarrhea or mild upper respiratory infection without fever, i.e., Oral temperature < 37.5°C.
Hepatomegaly, right upper quadrant abdominal pain or tenderness
Seropositive for HIV, Hepatitis C virus (antibodies to HCV) and/or HBsAg
Administration of immunoglobulins and/or any blood products within the three months preceding the first dose of study vaccine or planned administration during the study period
Pregnant or lactating female
Suspected or known current alcohol abuse/drug abuse as obtained by history and physical examination
Female who is willing or intends to become pregnant during the study
Any history of allergic reaction or anaphylaxis to previous vaccination
Inability to make follow-up visits or complete diary cards
Allergy to kanamycin, nickel, or imidazole
Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study",Accepts Healthy Volunteers,All,18 Years,50 Years,['Adult'],"[{'LocationFacility': 'Department of Clinical Trials, WRAIR', 'LocationCity': 'Silver Spring', 'LocationState': 'Maryland', 'LocationZip': '20910', 'LocationCountry': 'United States'}, {'LocationFacility': 'USAMRU-K/ KEMRI. Walter Reed Project', 'LocationCity': 'Kombewa, Kisumu', 'LocationState': 'Nyanza Province', 'LocationCountry': 'Kenya'}]","[{'CollaboratorName': 'GlaxoSmithKline', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'United States Agency for International Development (USAID)', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'Walter Reed Army Institute of Research (WRAIR)', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'Kenya Medical Research Institute', 'CollaboratorClass': 'OTHER'}]",Yes,"The study begins with the US phase in which 26 volunteers aged 18 to 50 years will be enrolled to receive an investigational malaria vaccine. The vaccine is made of a malaria protein FMP010 mixed in the adjuvant AS01B. Since this vaccine has not yet been in humans, first, 5 volunteers will get a small (10 µg) dose of FMP010 in AS01B. If it is safe, then 20 volunteers will get 50 µg FMP010 in AS01B. Vaccinations are given IM in the deltoid of the non-dominant arm, every month for 3 months. After each vaccination, the subjects will follow up at clinical trials for evaluation of any adverse events. There will be blood draws to assess safety of the vaccine as well as the level of immune response generated to the vaccine.

Upon receipt of preliminary safety results, the Kenya phase begins in which 30 volunteers who are randomized to receive either 50 µg FMP010 in AS01B (20) or the rabies vaccine (10). Vaccination and is on the same schedule as in the US phase and follow-up is for 112 days.","['Malaria', 'Vaccine', 'MSP-1 (merozoite surface protein-1)', 'Phase 1']",,,,,,"[{'SecondaryId': 'A-14620 (HSRRB)'}, {'SecondaryId': 'WRAIR 1417', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Walter Reed Army Institute of Research'}]",,,,,,,"[{'OverallOfficialName': 'Michele D Spring, MD, M.S.P.H.', 'OverallOfficialAffiliation': 'Walter Reed Army Institute of Research (WRAIR)', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Nekoye N. Otsyula, M.B. Ch. B.', 'OverallOfficialAffiliation': 'Kenya Medical Research Institute', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '23554856', 'ReferenceType': 'derived', 'ReferenceCitation': 'Bashir IM, Otsyula N, Awinda G, Spring M, Schneider P, Waitumbi JN. Comparison of PfHRP-2/pLDH ELISA, qPCR and microscopy for the detection of plasmodium events and prediction of sick visits during a malaria vaccine study. PLoS One. 2013;8(3):e56828. doi: 10.1371/journal.pone.0056828. Epub 2013 Mar 15.'}, {'ReferencePMID': '23342996', 'ReferenceType': 'derived', 'ReferenceCitation': 'Otsyula N, Angov E, Bergmann-Leitner E, Koech M, Khan F, Bennett J, Otieno L, Cummings J, Andagalu B, Tosh D, Waitumbi J, Richie N, Shi M, Miller L, Otieno W, Otieno GA, Ware L, House B, Godeaux O, Dubois MC, Ogutu B, Ballou WR, Soisson L, Diggs C, Cohen J, Polhemus M, Heppner DG Jr, Ockenhouse CF, Spring MD. Results from tandem Phase 1 studies evaluating the safety, reactogenicity and immunogenicity of the vaccine candidate antigen Plasmodium falciparum FVO merozoite surface protein-1 (MSP1(42)) administered intramuscularly with adjuvant system AS01. Malar J. 2013 Jan 23;12:29. doi: 10.1186/1475-2875-12-29.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17716', 'ConditionBrowseLeafName': 'Malaria, Falciparum', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01287247,MRZ 60201-4066-5,"Merz North America, Inc.",INDUSTRY,Trial Evaluating Xeomin® (incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States,"Prospective, Observational Trial Evaluating Xeomin®(incobotulinumtoxinA) for Cervical Dystonia or Blepharospasm in the United States",Apr-15,Completed,No,Feb-11,,Apr-13,Actual,Apr-13,Actual,28-Jan-11,31-Jan-11,01-Feb-11,Estimate,09-Apr-15,10-Apr-15,Estimate,Sponsor,"Merz North America, Inc.",INDUSTRY,,,,,"This is a prospective, observational trial evaluating the ""real world"" use of Xeomin®(incobotulinumtoxinA). Physicians may enroll patients who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon their clinical experience. The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study. Physicians may choose to treat their subjects with up to 2 treatment cycles (approximately 6 months/subject) of Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin. According and dependent on clinical practice, the investigators expect that subjects will be seen by the investigator for an average of 3 visits (two treatment cycles).","['Cervical Dystonia', 'Blepharospasm']",Observational,,,,,,688,Actual,"[{'ArmGroupLabel': 'Cervical Dystonia', 'ArmGroupDescription': 'The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of cervical dystonia.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Xeomin®']}}, {'ArmGroupLabel': 'Blepharospasm', 'ArmGroupDescription': 'The target populations for which the sample size calculations are based are adult subjects aged ≥ 18 years with clinical diagnoses of blepharospasm.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Xeomin®']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Xeomin®', 'InterventionDescription': 'Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Blepharospasm', 'Cervical Dystonia']}, 'InterventionOtherNameList': {'InterventionOtherName': ['incobotulinumtoxinA', 'botulinum toxin']}}]","[{'PrimaryOutcomeMeasure': 'Determination of injection patterns and techniques', 'PrimaryOutcomeDescription': 'To collect, evaluate and report observational data about the clinical use of Xeomin® in a ""real world"" setting to determine injection patterns and use of guidance techniques.', 'PrimaryOutcomeTimeFrame': 'Two treatment cycles (approximately 6 months/subject)'}]","[{'SecondaryOutcomeMeasure': 'To collect and evaluate efficacy of Xeomin®(incobotulinumtoxinA) including onset and offset of effect as well as improvement of disease specific and global illness severity', 'SecondaryOutcomeTimeFrame': 'Two treatment cycles (approximately 6 months/subject)'}]","Inclusion Criteria:

Subjects 18 years of age or older.
The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study.
Subjects who are eligible to be treated with a botulinum toxin for cervical dystonia or blepharospasm based upon the physicians' clinical experience. There are no restrictive subject entry criteria.
Subjects who are able to read, speak and understand English.

Exclusion Criteria:

Subjects who are enrolled in any clinical trial (currently or within the past 3 months) in which treatments are imposed by a protocol are not eligible for this trial.
Any subject for whom botulinum toxin treatment would be contraindicated; see Xeomin® Prescribing Information for further details.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Site #001052', 'LocationCity': 'Cullman', 'LocationState': 'Alabama', 'LocationZip': '35058', 'LocationCountry': 'United States'}, {'LocationCity': 'Scottsdale', 'LocationState': 'Arizona', 'LocationZip': '85258', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001974', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85713', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001046', 'LocationCity': 'Encinitas', 'LocationState': 'California', 'LocationZip': '92024', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001822', 'LocationCity': 'Fountain Valley', 'LocationState': 'California', 'LocationZip': '92708', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001852', 'LocationCity': 'La Jolla', 'LocationState': 'California', 'LocationZip': '92037', 'LocationCountry': 'United States'}, {'LocationFacility': 'Merz Investigative Site #001986', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90095', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001924', 'LocationCity': 'Los Gatos', 'LocationState': 'California', 'LocationZip': '95032', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001005', 'LocationCity': 'Newport Beach', 'LocationState': 'California', 'LocationZip': '92663', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001973', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95817', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001977', 'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001901', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20007', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001803', 'LocationCity': 'Boca Raton', 'LocationState': 'Florida', 'LocationZip': '33486', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001805', 'LocationCity': 'North Palm Beach', 'LocationState': 'Florida', 'LocationZip': '33408', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001823', 'LocationCity': 'Saint Petersburg', 'LocationState': 'Florida', 'LocationZip': '33713', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001955', 'LocationCity': 'Sarasota', 'LocationState': 'Florida', 'LocationZip': '34239', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001972', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60611', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001057', 'LocationCity': 'Glenview', 'LocationState': 'Illinois', 'LocationZip': '60026', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001978', 'LocationCity': 'Lake Bluff', 'LocationState': 'Illinois', 'LocationZip': '60044', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001820', 'LocationCity': 'Winfield', 'LocationState': 'Illinois', 'LocationZip': '60190', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001995', 'LocationCity': 'Munster', 'LocationState': 'Indiana', 'LocationZip': '46321', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001833', 'LocationCity': 'Overland Park', 'LocationState': 'Kansas', 'LocationZip': '66211', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001047', 'LocationCity': 'Baton Rouge', 'LocationState': 'Louisiana', 'LocationZip': '70810', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001849', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21287', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001053', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02114', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001816', 'LocationCity': 'Roseville', 'LocationState': 'Michigan', 'LocationZip': '48066', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001848', 'LocationCity': 'Warren', 'LocationState': 'Michigan', 'LocationZip': '48088', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001028', 'LocationCity': 'Bloomington', 'LocationState': 'Minnesota', 'LocationZip': '55431', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001834', 'LocationCity': 'Eagan', 'LocationState': 'Minnesota', 'LocationZip': '55122', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001957', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55455', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001802', 'LocationCity': 'Des Peres', 'LocationState': 'Missouri', 'LocationZip': '63131', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001838', 'LocationCity': 'St. Louis', 'LocationState': 'Missouri', 'LocationZip': '63141', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001010', 'LocationCity': 'Las Vegas', 'LocationState': 'Nevada', 'LocationZip': '89102', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001954', 'LocationCity': 'Reno', 'LocationState': 'Nevada', 'LocationZip': '89509', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001961', 'LocationCity': 'Toms River', 'LocationState': 'New Jersey', 'LocationZip': '08755', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001860', 'LocationCity': 'Kingston', 'LocationState': 'New York', 'LocationZip': '12401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001041', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10003', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001921', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10011', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001910', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10029', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001034', 'LocationCity': 'North Syracuse', 'LocationState': 'New York', 'LocationZip': '13212', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001013', 'LocationCity': 'Syracuse', 'LocationState': 'New York', 'LocationZip': '13210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001951', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27710', 'LocationCountry': 'United States'}, {'LocationFacility': 'Merz Investigative Site # 001840', 'LocationCity': 'Bellevue', 'LocationState': 'Ohio', 'LocationZip': '44811', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001812', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44195', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001826', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43215', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001815', 'LocationCity': 'Tulsa', 'LocationState': 'Oklahoma', 'LocationZip': '74136', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001916', 'LocationCity': 'Bend', 'LocationState': 'Oregon', 'LocationZip': '97701', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001839', 'LocationCity': 'Medford', 'LocationState': 'Oregon', 'LocationZip': '97504', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001000', 'LocationCity': 'Collegeville', 'LocationState': 'Pennsylvania', 'LocationZip': '19426', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001959', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19107', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001032', 'LocationCity': 'Wynnewood', 'LocationState': 'Pennsylvania', 'LocationZip': '19096', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001893', 'LocationCity': 'Spartanburg', 'LocationState': 'South Carolina', 'LocationZip': '29303', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001922', 'LocationCity': 'Chattanooga', 'LocationState': 'Tennessee', 'LocationZip': '37411', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001889', 'LocationCity': 'Columbia', 'LocationState': 'Tennessee', 'LocationZip': '38401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001831', 'LocationCity': 'Memphis', 'LocationState': 'Tennessee', 'LocationZip': '38163', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001836', 'LocationCity': 'Nashville', 'LocationState': 'Tennessee', 'LocationZip': '37203', 'LocationCountry': 'United States'}, {'LocationFacility': 'Merz Investigative Site # 001055', 'LocationCity': 'Bedford', 'LocationState': 'Texas', 'LocationZip': '76021', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001055', 'LocationCity': 'Bedford', 'LocationState': 'Texas', 'LocationZip': '76021', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001037', 'LocationCity': 'Bedford', 'LocationState': 'Texas', 'LocationZip': '76022', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001817', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75214', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001809', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75231', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001022', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001813', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001802', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001960', 'LocationCity': 'Tyler', 'LocationState': 'Texas', 'LocationZip': '75701', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001962', 'LocationCity': 'Alexandria', 'LocationState': 'Virginia', 'LocationZip': '22311', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001980', 'LocationCity': 'Fishersville', 'LocationState': 'Virginia', 'LocationZip': '22939', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site #001979', 'LocationCity': 'Virginia Beach', 'LocationState': 'Virginia', 'LocationZip': '23454', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001881', 'LocationCity': 'Kirkland', 'LocationState': 'Washington', 'LocationZip': '98034', 'LocationCountry': 'United States'}, {'LocationFacility': 'Site # 001800', 'LocationCity': 'Spokane', 'LocationState': 'Washington', 'LocationZip': '99204', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Registrat-Mapi', 'CollaboratorClass': 'OTHER'}]",No,"The primary objective of this trial is to collect, evaluate, and report observational data about the clinical use of Xeomin® in a ""real world"" setting to determine which muscles are injected, the dose used, and how doctors administer the injection.

The secondary objectives of this trial are: To collect and evaluate information about the efficacy of Xeomin®. To collect and evaluate information about the effect of Xeomin® on work productivity and quality of life. To monitor for any serious side effects and non-serious related side effects of Xeomin®","['Cervical dystonia', 'Blepharospasm']",,['Cohort'],['Prospective'],Subjects 18 years of age or older. The physician must have chosen to treat the patient with Xeomin® (incobotulinumtoxinA) prior to and independent of enrollment in this study.,Probability Sample,,XCiDaBLE,,,,,,"[{'OverallOfficialName': 'Hubert H. Fernandez, MD, FAAN', 'OverallOfficialAffiliation': 'Center for Neurological Restoration', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000004421', 'ConditionMeshTerm': 'Dystonia'}, {'ConditionMeshId': 'D000020821', 'ConditionMeshTerm': 'Dystonic Disorders'}, {'ConditionMeshId': 'D000014103', 'ConditionMeshTerm': 'Torticollis'}, {'ConditionMeshId': 'D000001764', 'ConditionMeshTerm': 'Blepharospasm'}]","[{'ConditionAncestorId': 'D000020820', 'ConditionAncestorTerm': 'Dyskinesias'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000009069', 'ConditionAncestorTerm': 'Movement Disorders'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000005141', 'ConditionAncestorTerm': 'Eyelid Diseases'}, {'ConditionAncestorId': 'D000005128', 'ConditionAncestorTerm': 'Eye Diseases'}]","[{'ConditionBrowseLeafId': 'M6178', 'ConditionBrowseLeafName': 'Dystonia', 'ConditionBrowseLeafAsFound': 'Dystonia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21159', 'ConditionBrowseLeafName': 'Dystonic Disorders', 'ConditionBrowseLeafAsFound': 'Dystonia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3627', 'ConditionBrowseLeafName': 'Blepharospasm', 'ConditionBrowseLeafAsFound': 'Blepharospasm', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15441', 'ConditionBrowseLeafName': 'Torticollis', 'ConditionBrowseLeafAsFound': 'Cervical Dystonia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21158', 'ConditionBrowseLeafName': 'Dyskinesias', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10612', 'ConditionBrowseLeafName': 'Movement Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6867', 'ConditionBrowseLeafName': 'Eyelid Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6854', 'ConditionBrowseLeafName': 'Eye Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1077', 'ConditionBrowseLeafName': 'Cervical Dystonia', 'ConditionBrowseLeafAsFound': 'Cervical Dystonia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T715', 'ConditionBrowseLeafName': 'Benign Essential Blepharospasm', 'ConditionBrowseLeafAsFound': 'Blepharospasm', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC11', 'ConditionBrowseBranchName': 'Eye Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]","[{'InterventionMeshId': 'D000001905', 'InterventionMeshTerm': 'Botulinum Toxins'}, {'InterventionMeshId': 'C000545476', 'InterventionMeshTerm': 'incobotulinumtoxinA'}]","[{'InterventionAncestorId': 'D000065087', 'InterventionAncestorTerm': 'Acetylcholine Release Inhibitors'}, {'InterventionAncestorId': 'D000049990', 'InterventionAncestorTerm': 'Membrane Transport Modulators'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000018678', 'InterventionAncestorTerm': 'Cholinergic Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000009465', 'InterventionAncestorTerm': 'Neuromuscular Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}]","[{'InterventionBrowseLeafId': 'M3765', 'InterventionBrowseLeafName': 'Botulinum Toxins', 'InterventionBrowseLeafAsFound': 'Solid', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M258642', 'InterventionBrowseLeafName': 'incobotulinumtoxinA', 'InterventionBrowseLeafAsFound': 'Recipes', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2054', 'InterventionBrowseLeafName': 'Acetylcholine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19342', 'InterventionBrowseLeafName': 'Cholinergic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'VaDiAg', 'InterventionBrowseBranchName': 'Vasodilator Agents'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04163341,IRB-300004217,University of Alabama at Birmingham,OTHER,Tailored Response to Psychiatric Comorbidity to Improve HIV Care Engagement in the United States,Tailored Response to Psychiatric Comorbidity to Improve HIV Care Engagement in the United States,Nov-19,Not yet recruiting,No,Sep-20,Anticipated,Nov-21,Anticipated,Nov-22,Anticipated,12-Nov-19,12-Nov-19,14-Nov-19,Actual,14-Nov-19,18-Nov-19,Actual,Sponsor-Investigator,"Michael J Mugavero, MD",OTHER,No,No,,,"This pilot randomized clinical trial will randomize 60 participants 1:1 to either enhanced usual care or to adapted CETA, a counseling intervention for HIV care engagement plus depression, anxiety, PTSD, and/or substance use.","['HIV/AIDS', 'Depression', 'Anxiety', 'Post-traumatic Stress Disorder', 'Substance Use Disorders']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,Double,60,Anticipated,"[{'ArmGroupLabel': 'CETA protocol', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Adapted Common Elements Treatment Approach']}}, {'ArmGroupLabel': 'Enhanced Usual Care', 'ArmGroupType': 'No Intervention'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Adapted Common Elements Treatment Approach', 'InterventionDescription': 'The intervention is a transdiagnostic cognitive behavioral therapy approach to treating any combination of depression, anxiety, post-traumatic stress, or substance use disorder that has been adapted the needs of adults with HIV and to additionally address HIV care engagement.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CETA protocol']}}]","[{'PrimaryOutcomeMeasure': 'Feasibility of recruitment', 'PrimaryOutcomeDescription': 'Number of patients approached in order to accrue the final sample', 'PrimaryOutcomeTimeFrame': 'Duration of recruitment phase (9 months)'}, {'PrimaryOutcomeMeasure': 'Client acceptability', 'PrimaryOutcomeDescription': 'Client Satisfaction Questionnaire-8', 'PrimaryOutcomeTimeFrame': 'At treatment exit (approximately 3 months post-baseline)'}, {'PrimaryOutcomeMeasure': 'Fidelity', 'PrimaryOutcomeDescription': 'Counselor adherence to CETA content and skill in delivery will be rated by supervisor based on review of audiorecordings of a subset of sessions', 'PrimaryOutcomeTimeFrame': ""At each CETA treatment session, over the approximately 3 months of each client's CETA treatment""}]","[{'SecondaryOutcomeMeasure': 'Suppressed HIV RNA viral load', 'SecondaryOutcomeDescription': 'HIV RNA viral load <200 copies/mL', 'SecondaryOutcomeTimeFrame': '3 months post-baseline'}, {'SecondaryOutcomeMeasure': 'Suppressed HIV RNA viral load', 'SecondaryOutcomeDescription': 'HIV RNA viral load <200 copies/mL', 'SecondaryOutcomeTimeFrame': '9 months post-baseline'}, {'SecondaryOutcomeMeasure': 'HIV appointment attendance', 'SecondaryOutcomeDescription': 'HRSA attendance measure: Engaged in care if attended >=2 HIV primary care visits >= 90 days apart in the 12 months after baseline.', 'SecondaryOutcomeTimeFrame': 'From baseline to 12 months post-baseline'}, {'SecondaryOutcomeMeasure': 'Depressive symptoms', 'SecondaryOutcomeDescription': 'Hamilton Rating Scale for Depression (HAM-D) score; minimum score is 0, maximum score is 52, with higher scores meaning a worse outcome.', 'SecondaryOutcomeTimeFrame': '3 months post-baseline'}, {'SecondaryOutcomeMeasure': 'Anxiety symptoms', 'SecondaryOutcomeDescription': 'Hopkins Symptom Checklist (HSCL) anxiety subscale score; minimum score is 1, maximum score is 4, with higher scores meaning a worse outcome.', 'SecondaryOutcomeTimeFrame': '3 months post-baseline'}, {'SecondaryOutcomeMeasure': 'Post-traumatic stress symptoms', 'SecondaryOutcomeDescription': 'Harvard Trauma Questionnaire (HTQ) score; minimum score is 1, maximum score is 4, with higher scores meaning a worse outcome.', 'SecondaryOutcomeTimeFrame': '3 months post-baseline'}, {'SecondaryOutcomeMeasure': 'Substance use symptoms', 'SecondaryOutcomeDescription': 'Timeline Follow-Back', 'SecondaryOutcomeTimeFrame': '3 months post-baseline'}, {'SecondaryOutcomeMeasure': 'HIV appointment attendance', 'SecondaryOutcomeDescription': 'Kept visit proportion: Total number of kept visits divided by total number of missed plus kept visits', 'SecondaryOutcomeTimeFrame': 'From baseline to 12 months post-baseline'}]","Inclusion Criteria:

Age >= 18 years. 2. Patient receiving HIV care at UAB 1917 Clinic. 3. Elevated symptoms of depression, anxiety, post-traumatic stress, or substance use disorder: At least one of the following:

Patient Health Questionnaire-9 score >= 10;
Generalized Anxiety Disorder 7-Item Scale score >= 10;
Post-Traumatic Stress Symptoms Checklist for DSM-5 score >= 33;
ASSIST score >=11 for alcohol or >=4 for any other substance 4. At risk for suboptimal HIV care engagement: At least one of the following:
Engaged in HIV care for the first time within the past 6 months;
Have an HIV RNA viral load >1,000 copies/mL within the past 6 months;
Antiretroviral regimen was changed due to treatment failure within the past 6 months;
No-showed to an HIV primary care appointment within the past year. 5. Willing to provide written informed consent.

Exclusion Criteria:

1. Non-English speaking 2. Unable to attend counseling sessions 3. Unwilling to provide informed consent",No,All,18 Years,,"['Adult', 'Older Adult']",,"[{'CollaboratorName': 'University of North Carolina, Chapel Hill', 'CollaboratorClass': 'OTHER'}]",No,"Patient participants in this study will be randomized 1:1 to either enhanced usual care or the adapted CETA intervention. Enhanced usual care will include provision of feedback about psychiatric diagnoses to the HIV provider and the clinic's behavioral health team for follow-up according to the clinic's standard care. Participants randomized to the adapted CETA arm will initiate CETA with the trained counselor. The number of CETA sessions will depend on the patient's presentation but will range from 7-13 weekly in-person 1-hour sessions.Before randomization, enrolled participants will complete a baseline assessment including sociodemographic information; self-reported health; standardized assessments of depressive, anxiety, and post-traumatic stress symptoms and substance use; and key related structural and psychosocial factors including housing stability,intimate partner violence (IPV), other violence in the home, coping, social support, and experiences of stigma related to mental health.

Participants in the Enhanced Contact arm will complete a follow-up research assessment at 3 months post baseline.Participants in the adapted CETA arm will complete this assessment after the final CETA session,also expected to be at approximately 3 months post-baseline. All participants will complete a final research assessment at 9 months post-baseline (approximately 6 months post-treatment exit for those in the adapted CETA arm). These follow-up assessments will assess the same domains as the baseline assessment.",,,,,,,,TRACE,"Michael J Mugavero, MD",Professor,University of Alabama at Birmingham,"['Investigator', 'Outcomes Assessor']",,"[{'OverallOfficialName': 'Brian Pence, PhD', 'OverallOfficialAffiliation': 'UNC-Chapel Hill', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Bradley Gaynes, MD', 'OverallOfficialAffiliation': 'UNC-Chapel Hill', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Doyane Darnell, PhD', 'OverallOfficialAffiliation': 'University of Washington', 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,,"[{'CentralContactName': 'Mariel Parman, MPH', 'CentralContactRole': 'Contact', 'CentralContactPhone': '205-996-6337', 'CentralContactEMail': 'marielparman@uabmc.edu'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000004194', 'ConditionMeshTerm': 'Disease'}, {'ConditionMeshId': 'D000019966', 'ConditionMeshTerm': 'Substance-Related Disorders'}, {'ConditionMeshId': 'D000040921', 'ConditionMeshTerm': 'Stress Disorders, Traumatic'}, {'ConditionMeshId': 'D000013313', 'ConditionMeshTerm': 'Stress Disorders, Post-Traumatic'}]","[{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000068099', 'ConditionAncestorTerm': 'Trauma and Stressor Related Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}, {'ConditionAncestorId': 'D000064419', 'ConditionAncestorTerm': 'Chemically-Induced Disorders'}]","[{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2905', 'ConditionBrowseLeafName': 'Anxiety Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23503', 'ConditionBrowseLeafName': 'Stress Disorders, Traumatic', 'ConditionBrowseLeafAsFound': 'Traumatic Stress Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14686', 'ConditionBrowseLeafName': 'Stress Disorders, Post-Traumatic', 'ConditionBrowseLeafAsFound': 'Post Traumatic Stress Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20421', 'ConditionBrowseLeafName': 'Substance-Related Disorders', 'ConditionBrowseLeafAsFound': 'Substance Use Disorders', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16268', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M222', 'ConditionBrowseLeafName': 'Trauma and Stressor Related Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M28889', 'ConditionBrowseLeafName': 'Chemically-Induced Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC25', 'ConditionBrowseBranchName': 'Substance Related Disorders'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02987335,2013-2191,Albert Einstein College of Medicine,OTHER,Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States,Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States,May-20,Not yet recruiting,No,Dec-20,Anticipated,Dec-22,Anticipated,Dec-22,Anticipated,02-Dec-16,06-Dec-16,08-Dec-16,Estimate,11-May-20,12-May-20,Actual,Principal Investigator,Albert Einstein College of Medicine,OTHER,Yes,No,,,"This purpose of this study is to define the metabolic characteristics of individuals with Lean Diabetes. We aim to determine whether differences in body composition, including any differences in lipid (fat) deposition, exist compared to individuals with either known forms of diabetes (eg, type 1 and type 2), or individuals without diabetes. Diabetes affects the ability of the body to process glucose (sugar). Therefore, we also plan to investigate the ability of the hormone insulin to regulate changes in glucose in these individuals. Developing a greater understanding of the features of this condition could have tremendous therapeutic benefit for these individuals.","['Malnutrition; Diabetes', 'Diabetes']",Observational,,,,,,80,Anticipated,"[{'ArmGroupLabel': 'Lean Diabetes Subjects', 'ArmGroupDescription': 'N=20 subjects with BMI 16-22.5 kg/m2, with a history of low birth weight and malnutrition documented on at least one occasion. Will undergo pancreatic clamp.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Pancreatic Clamp']}}, {'ArmGroupLabel': 'Type 2 Diabetes Mellitus Subjects', 'ArmGroupDescription': 'N=20 subjects with BMI 22.5-27 kg/m2. Will undergo pancreatic clamp', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Pancreatic Clamp']}}, {'ArmGroupLabel': 'Type 1 Diabetes Mellitus Subjects', 'ArmGroupDescription': 'N=20 subjects with BMI 16-22.5 kg/m2. Will undergo pancreatic clamp', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Pancreatic Clamp']}}, {'ArmGroupLabel': 'Nondiabetic Subjects', 'ArmGroupDescription': 'N=20 nondiabetic with BMI 16-22.5 kg/m2 subjects 19-45 years of age and in general good health, taking no medications, with normal glucose tolerance and no family history of diabetes. These subjects will be similar in age, ethnicity and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers. Will undergo pancreatic clamp', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Pancreatic Clamp']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Pancreatic Clamp', 'InterventionDescription': 'We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Lean Diabetes Subjects', 'Nondiabetic Subjects', 'Type 1 Diabetes Mellitus Subjects', 'Type 2 Diabetes Mellitus Subjects']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Clamp']}}]","[{'PrimaryOutcomeMeasure': 'Plasma insulin', 'PrimaryOutcomeDescription': 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'PrimaryOutcomeTimeFrame': '0 min to 360 min'}, {'PrimaryOutcomeMeasure': 'C-peptide', 'PrimaryOutcomeDescription': 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'PrimaryOutcomeTimeFrame': '0 min to 360 min'}, {'PrimaryOutcomeMeasure': 'Glucagon', 'PrimaryOutcomeDescription': 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'PrimaryOutcomeTimeFrame': '0 min to 360 min'}, {'PrimaryOutcomeMeasure': 'Growth Hormone', 'PrimaryOutcomeDescription': 'Measurements of plasma insulin, C-peptide, glucagon, and GH are taken throughout the study in order to evaluate the adequacy of the pancreatic clamp technique, i.e. the inhibitory effects of somatostatin on hormone secretion and the uniformity of hormone replacement.', 'PrimaryOutcomeTimeFrame': '0 min to 360 min'}]",,"Inclusion Criteria:

Age 19-45 yr
Diabetes duration at least one year (for the diabetes groups)
BMI range: 16-22.5 kg/m2 (individuals with lean and type 1 diabetes and non-diabetic controls); 22.5-27 kg/m2 in individuals with type 2 diabetes
Negative GAD antibodies
Present (>1.0pmol/l) C-peptide response to Sustacal challenge
Stable and moderate-to-poor glycemic control (HbA1c greater than 8%)
Able and willing to provide informed consent.

Exclusion Criteria:

Mentally disabled persons
Major psychiatric disorder on medication (excluding successfully treated depression)
HIV/AIDS
History of any cancer
Alcohol or substance abuse or toxin exposure which could be associated with neuropathy
Cushing's syndrome
Pregnancy or breast-feeding
Untreated or uncontrolled hypertension
Any Chronic illness requiring medication
History of bleeding disorder or with a prolonged PT or PTT
Renal disease
Liver impairment
Prisoners",Accepts Healthy Volunteers,All,19 Years,45 Years,['Adult'],,"[{'CollaboratorName': 'National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)', 'CollaboratorClass': 'NIH'}]",Yes,"India has the world's highest prevalence of diabetes, expected to rise to 80 million by 2030. This includes many patients with Lean Diabetes, which is a form of diabetes identified clinically by early onset, high insulin requirements, absence of other pancreatic disease, and low body mass index (typically ≤17 kg/m2) at presentation. Despite its prevalence, Lean Diabetes remains a relatively unknown disease that stirs conflicting opinions regarding its classification, diagnostic criteria, and pathogenesis.

In this study, the investigators will study individuals meeting the criteria for Lean Diabetes, Type 1 diabetes, Type 2 diabetes, and patients without diabetes using a procedure called a ""pancreatic clamp"" study. During the clamp procedure, glucose (a sugar) and insulin (a hormone produced in the pancreas that regulates the amount of glucose in the blood) are infused with an intravenous catheter, and blood samples are collected periodically throughout the procedure to measure blood sugar levels and the levels of several hormones that are found in the body and are related to glucose metabolism. Endogenous glucose production (a measure of the body's production of sugar) will also be measured. Participants will also have a fat biopsy, and will be given a mixed meal challenge which is a test that detects hyperglycemia and glucose intolerance.

The overall goal of this study is to define the metabolic characteristics of individuals with Lean Diabetes and to determine which differences exist compared to individuals with other known forms of diabetes or individuals without diabetes.","['Diabetes', 'Malnutrition']",No,['Case-Control'],['Prospective'],"Subjects with diabetes will be recruited from the community and outpatient diabetes practices at CMC India, Jacobi Medical Center, and North Central Bronx hospital. These subjects will meet the following criteria: Age 19-45 years, diabetes duration at least one year, negative GAD antibodies, >1.0 pmol/l C-peptide response to Sustacal challenge, stable and moderate-to-poor glycemic control (HbA1c between 8-11%), no pancreatic calcification on imaging, and not suffering from significant complications. Diabetic subjects will be otherwise in good health.

Subjects without diabetes: BMI 16-22.5 kg/m2, Age 19-45 years and in general good health, taking no medications, normal glucose tolerance, and no family history of diabetes. Subjects will be similar in age, ethnicity, and BMI with the lean DM group, and will be recruited through various means of community outreach, including notices in shops and newspapers.",Non-Probability Sample,"[{'SecondaryId': 'R01DK079974', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01DK079974&Fy=all'}, {'SecondaryId': 'R01DK069861', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01DK069861&Fy=all'}]",,Meredith Hawkins,Professor of Medicine,Albert Einstein College of Medicine,,,"[{'OverallOfficialName': 'Meredith Hawkins', 'OverallOfficialAffiliation': 'Albert Einstein College of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,"[{'CentralContactName': 'Meredith Hawkins', 'CentralContactRole': 'Contact', 'CentralContactPhone': '718-430-2903', 'CentralContactEMail': 'meredith.hawkins@einsteinmed.org'}]",,Samples Without DNA,"Plasma, Fat Biopsy",,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003920', 'ConditionMeshTerm': 'Diabetes Mellitus'}, {'ConditionMeshId': 'D000044342', 'ConditionMeshTerm': 'Malnutrition'}]","[{'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}, {'ConditionAncestorId': 'D000009748', 'ConditionAncestorTerm': 'Nutrition Disorders'}]","[{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafAsFound': 'Diabetes', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M23893', 'ConditionBrowseLeafName': 'Malnutrition', 'ConditionBrowseLeafAsFound': 'Malnutrition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23990', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11267', 'ConditionBrowseLeafName': 'Nutrition Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M8372', 'InterventionBrowseLeafName': 'Hormones', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02867722,2016P000913,Brigham and Women's Hospital,OTHER,Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States,Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States,Aug-16,Not yet recruiting,No,Sep-16,,Dec-21,Anticipated,Dec-22,Anticipated,18-Jul-16,12-Aug-16,16-Aug-16,Estimate,12-Aug-16,16-Aug-16,Estimate,Principal Investigator,Brigham and Women's Hospital,OTHER,,,,,"In this study, daylight PDT will be administered to interested patients at Dana-Farber/Brigham and Women's Cancer Center. Daylight PDT has been shown to be an effective and painless alternative to traditional PDT. Daylight PDT involves application of the photosensitizer in the physician's office followed by exposure to daylight.","['Actinic Keratosis', 'Non-melanoma Skin Cancer']",Interventional,['Not Applicable'],Non-Randomized,Single Group Assignment,Treatment,None (Open Label),40,Anticipated,"[{'ArmGroupLabel': 'Daylight PDT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patients will receive daylight-PDT treatment (aminolevulinic acid)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: aminolevulinic acid HCl']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'aminolevulinic acid HCl', 'InterventionDescription': 'Drug will be administered to consented patients', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Daylight PDT']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Levulan']}}]","[{'PrimaryOutcomeMeasure': 'Number of patients with reduction in the number of actinic keratoses after daylight PDT treatment', 'PrimaryOutcomeTimeFrame': '1 year and 5 years'}]","[{'SecondaryOutcomeMeasure': 'Number of non-melanoma skin cancers at 1- and 5-years compared to the number of skin', 'SecondaryOutcomeTimeFrame': '1 year and 5 years'}, {'SecondaryOutcomeMeasure': 'Number of patients with treatment related adverse events as assessed by CTCAE v4.0', 'SecondaryOutcomeTimeFrame': '5 years'}, {'SecondaryOutcomeMeasure': 'Measure patient satisfaction at 1- and 5- years using the Treatment Satisfaction Questionnaire for Medication', 'SecondaryOutcomeTimeFrame': '1 year and 5 years'}]","Inclusion Criteria:

Patients ≥ 18 years referred for the treatment of 5 or more visible or palpable actinic keratoses on one treatment area

Exclusion Criteria:

Age less than 18 years of age.
Pregnant women.
Non-English speaking patients.
Treatment of actinic keratoses with other modalities including topical 5-fluorouracil, topical imiquimod, conventional PDT, alpha-hydroxy-acids, and glycolic acids within 2 months
Use of retinoids within 1 month
Use of the following medications: griseofulvin, thiazide diuretics, sulfonyureas, phenothiazines, sulfonamides, and tetracyclines
History of cutaneous photosensitivity, lupus, porphyrias, or any other photosensitizing condition",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']",,,Yes,"The principal investigator will inform patients about the study during their initial consultation at the Mohs and Dermatologic Surgery Center, Dana-Farber/Brigham and Women's Cancer Center at Faulkner Hospital. The patients will be encouraged to make further inquiries about the study if they are interested. Informed consent will be obtained prior to initiating the treatment. If patients are interested in taking part in the study, the investigator will approach them in private to review the consent form and address any study-related questions.

A clinical examination along with photographs will be performed prior to application of the photosensitizer to determine the baseline number of actinic keratoses. The treatment steps were adapted from the daylight-PDT protocol presented in the phase III European multicenter study.9 The treatment will be performed if the temperature conditions are suitable to stay outdoors for 2.5 hours and not under any rainy weather conditions; however, treatment can be performed on overcast days. Suitable weather conditions include an outdoor temperature greater than 50 and between the months of April and November. This is based on a minimum of 8 J cm-2 (although other studies have shown that only 3.5 J cm-2) protoporphyrin IX light dose. A study of various geographic regions found this minimum dose was present in Turin, Italy, which is a similar latitude to Boston, MA.10 Weather conditions will be recorded on the day of treatment and final analysis will be stratified by temperature and weather conditions to evaluate whether this has impacted treatment. Subjects will be advised of the treatment requirements at the time of appointment booking and will be instructed to call the morning of their appointment to confirm that treatment can proceed. Subjects will scrub their faces with warm soapy water to clean and descale the skin and any hypertrophic AKs will be curetted. A chemical sunscreen will be applied to all sun exposed areas followed by one applicator of ALA (Levulan, DUSA pharmaceuticals, Wilmington, MA) to each treatment area. Subjects will be instructed to be exposed to daylight within 30-60 minutes of application and will remain outside in the shade for two and a half hours. Subjects will then remove the ALA and will be instructed to minimize sun exposure and to apply a physical sunscreen (zinc oxide or titanium dioxide) and wear protective clothing for the next 48 hours. This protocol will be repeated after one month unless complete response is documented at the month follow up. Subjects with a history of HSV infection will receive prophylaxis valtrex 500mg daily for 3 days.",,,,,,,,DaylightPDT,Emily Stamell Ruiz,Physician,Brigham and Women's Hospital,,,"[{'OverallOfficialName': 'Emily Stamell Ruiz, MD', 'OverallOfficialAffiliation': ""Brigham and Women's Hospital"", 'OverallOfficialRole': 'Principal Investigator'}]",No,,,,,,Data will be aggregated and analyzed,"[{'CentralContactName': 'Emily Stamell Ruiz, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '617-983-4626', 'CentralContactEMail': 'esruiz@partners.org'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000055623', 'ConditionMeshTerm': 'Keratosis, Actinic'}, {'ConditionMeshId': 'D000012878', 'ConditionMeshTerm': 'Skin Neoplasms'}, {'ConditionMeshId': 'D000007642', 'ConditionMeshTerm': 'Keratosis'}]","[{'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}, {'ConditionAncestorId': 'D000011230', 'ConditionAncestorTerm': 'Precancerous Conditions'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}]","[{'ConditionBrowseLeafId': 'M14264', 'ConditionBrowseLeafName': 'Skin Neoplasms', 'ConditionBrowseLeafAsFound': 'Skin Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M26855', 'ConditionBrowseLeafName': 'Keratosis, Actinic', 'ConditionBrowseLeafAsFound': 'Actinic Keratosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9251', 'ConditionBrowseLeafName': 'Keratosis', 'ConditionBrowseLeafAsFound': 'Keratosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14257', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12694', 'ConditionBrowseLeafName': 'Precancerous Conditions', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]","[{'InterventionMeshId': 'D000000622', 'InterventionMeshTerm': 'Aminolevulinic Acid'}]","[{'InterventionAncestorId': 'D000017319', 'InterventionAncestorTerm': 'Photosensitizing Agents'}, {'InterventionAncestorId': 'D000003879', 'InterventionAncestorTerm': 'Dermatologic Agents'}]","[{'InterventionBrowseLeafId': 'M2541', 'InterventionBrowseLeafName': 'Aminolevulinic Acid', 'InterventionBrowseLeafAsFound': 'Trimester', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M18191', 'InterventionBrowseLeafName': 'Photosensitizing Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M5657', 'InterventionBrowseLeafName': 'Dermatologic Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Derm', 'InterventionBrowseBranchName': 'Dermatologic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03276637,The MilSeq Project,Brigham and Women's Hospital,OTHER,Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force,The MilSeq Project: Enabling Personalized Medicine Through Exome Sequencing in the U.S. Air Force,May-19,"Active, not recruiting",No,23-Aug-17,Actual,31-Dec-19,Anticipated,31-Dec-19,Anticipated,31-Aug-17,06-Sep-17,08-Sep-17,Actual,15-May-19,17-May-19,Actual,Principal Investigator,Brigham and Women's Hospital,OTHER,No,No,,,"The MilSeq Project is a nonrandomized, prospective pilot study of whole exome sequencing (WES) in the U.S. Air Force. The purpose of this study is to explore the implementation of WES into clinical medical care in the military health system.","['Healthy Adults', 'Genetic Predisposition to Disease']",Interventional,['Not Applicable'],N/A,Single Group Assignment,Health Services Research,None (Open Label),75,Actual,"[{'ArmGroupLabel': 'Healthy Active-Duty Airmen Cohort', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics training will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Genetic: Whole exome sequencing']}}]","[{'InterventionType': 'Genetic', 'InterventionName': 'Whole exome sequencing', 'InterventionDescription': ""Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's CLIA certified laboratory on 75 enrolled individuals"", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Healthy Active-Duty Airmen Cohort']}}]","[{'PrimaryOutcomeMeasure': ""Change in military healthcare providers' genomic knowledge"", 'PrimaryOutcomeDescription': ""Novel and adapted (Kaphingst, K.A., et al. 2012; Bowling, B.V., et al. 2008) survey measures will assess military healthcare providers' genomic knowledge before and after receiving a genomic education primer, and after disclosing one or more whole exome sequencing result(s)"", 'PrimaryOutcomeTimeFrame': 'Baseline, after education (within 1 month of baseline), 6 months prior to study completion'}, {'PrimaryOutcomeMeasure': ""Change in active-duty Airmen's perceptions of military health system integration of genomic data on career status"", 'PrimaryOutcomeDescription': ""Novel survey measures will assess active-duty patient-participants' perceptions of military health system integration of genomic data on career status"", 'PrimaryOutcomeTimeFrame': 'Baseline, 6 weeks after results disclosure'}, {'PrimaryOutcomeMeasure': 'Genomic sequencing findings', 'PrimaryOutcomeDescription': 'Whole exome sequencing results will identify the counts and proportions of genomic findings in the active-duty patient-participant population', 'PrimaryOutcomeTimeFrame': 'Results disclosure (within 1 month of sequencing completion)'}, {'PrimaryOutcomeMeasure': 'Change in military healthcare utilization subsequent to introduction of genomic medicine', 'PrimaryOutcomeDescription': 'Novel survey measures and military medical record review by trained genetic professional(s) will assess the percentage of active-duty patient-participants who receive follow-up recommendations and healthcare interventions, as well as their appropriateness', 'PrimaryOutcomeTimeFrame': 'Within 2 weeks after results disclosure for military healthcare provider-participants, 6 weeks after results disclosure for active-duty patient-participants, 1 year after results disclosure'}]","[{'SecondaryOutcomeMeasure': ""Change in military healthcare providers' confidence with genomic data"", 'SecondaryOutcomeDescription': ""Novel and adapted (Kaphingst, K.A., et al. 2012; Gray S.W., et al., 2014) survey measures will assess military healthcare providers' confidence in receiving, interpreting, and returning whole exome sequencing results"", 'SecondaryOutcomeTimeFrame': 'Baseline, after education (within one month of baseline), 6 months prior to study completion'}, {'SecondaryOutcomeMeasure': ""Change in active-duty Airmen's perceptions and attitudes toward genomic sequencing"", 'SecondaryOutcomeDescription': ""Novel survey measures will assess active-duty patient-participants' perceptions and attitudes toward genomic sequencing"", 'SecondaryOutcomeTimeFrame': 'Baseline, 6 weeks after results disclosure'}, {'SecondaryOutcomeMeasure': ""Change in active-duty Airmen's health subsequent to introduction of genomic medicine"", 'SecondaryOutcomeDescription': 'Validated (Selim, A.J., et al. 2011) survey measures and military medical record review by trained genetic professional(s) will assess quality of life', 'SecondaryOutcomeTimeFrame': 'Baseline, 6 weeks after results disclosure, 1 year after results disclosure'}]","Patient-Participant Inclusion Criteria:

18 years or older
An active Air Force Airman
Fluent in English
Seen or eligible to be seen by a provider at Wilford Hall Ambulatory Surgical Center at Joint Base San Antonio (JBSA) Lackland Air Force Base

Healthcare Provider-Participant Inclusion Criterion

An active or Department of Defense civilian Primary Care, Internal Medicine, or Family Practice Healthcare Provider (Physician, Physician Assistant, or Nurse Practitioner) or resident practicing at Wilford Hall Ambulatory Surgical Center at JBSA Lackland Air Force Base

Patient-Participant Exclusion Criteria:

Those who do not meet the above inclusion criteria
Those with clinically concerning scores on anxiety and distress scales in baseline survey
Trainees (basic military training or tech school)
Airmen with an active change of duty station order or deployment order and expected to leave San Antonio in 6 months or less
Airmen expected to be discharged from the Air Force in 6 months or less

Healthcare Provider-Participant Exclusion Criteria:

Providers who do not meet the above inclusion criteria
Providers with an active change of duty station order or deployment order and expected to leave San Antonio in 6 months or less
Providers expected to be discharged from the Air Force in 6 months or less",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': ""Brigham and Women's Hospital"", 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02115', 'LocationCountry': 'United States'}, {'LocationFacility': 'Keesler Air Force Base', 'LocationCity': 'Biloxi', 'LocationState': 'Mississippi', 'LocationZip': '39530', 'LocationCountry': 'United States'}, {'LocationFacility': 'Baylor College of Medicine', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Joint Base San Antonio Lackland Air Force Base - 59th Medical Wing', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78236', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'United States Department of Defense', 'CollaboratorClass': 'FED'}]",Yes,"The objective of this effort is to investigate: (a) military healthcare providers' (HCPs') genomic knowledge before and after receiving a genomic educational primer and after disclosing whole exome sequencing (WES) results to begin to assess the genomic educational needs of military HCPs; (b) active-duty Airmen's knowledge and perceptions of genomic sequencing (GS); (c) reasons why active-duty Airmen choose to participate, or not to participate, in research involving GS; (d) how WES study participants, including HCPs and sequenced active-duty Airmen (patient-participants), respond to and use WES results; (e) the collection of medical, behavioral, and healthcare utilization outcomes related to the clinical integration of WES in the military; (f) how return of WES results and integration into the EMR (Electronic Medical Record) do or do not impact perceptions of mission readiness and duty assignments. Given the lack of prior research in this area in the Air Force and the broad number of topics of interest, the aims of the study are predominantly exploratory and results may be hypothesis generating.

The MilSeq Project will be conducted in two sequential phases. Phase I of the study will recruit, consent, and enroll approximately 750 ostensibly healthy active-duty Airmen who receive medical care in military Primary Care, Internal Medicine, and/or Family Practice settings to take a baseline survey. This survey will be administered to explore active-duty Airmen's perceptions of and preferences for GS, identify motivations and barriers to active-duty Airmen participating in a WES study, and assess interest in taking part in the WES study.

Phase II of the study will recruit, consent, and enroll 75 ostensibly healthy active-duty Airmen who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES through a research study. WES will be performed on each enrolled patient-participant. The result will be disclosed by an HCP-participant and permanently integrated into the patient-participant's EMR. Phase II will also recruit 10-20 military Primary Care, Internal Medicine, and/or Family Practice HCPs and consent them to participate in the study. The HCPs will receive an educational primer in genomics and will disclose WES results to Airmen participants.

There are a number of potential benefits and challenges to incorporating genomic medicine into the military, some that are relevant to the broader civilian community, but some that are unique to this population. Some of these challenges include: (a) how GS may or may not affect the perception of fitness for duty; (b) how genomic discrimination may or may not occur in the military setting; (c) how to best deal with unanticipated findings; and (d) how genomic results can be practically integrated into a military setting. In this pilot study, these potential opportunities and challenges will be explored, which will provide a basis for future study and begin to inform decisions regarding clinical care of active-duty service members.","['Genome Sequencing', 'Exome Sequencing', 'Military', 'Air Force']",,,,,,,MilSeq,"Robert C. Green, MD, MPH","Associate Professor of Medicine, Division of Genetics, Department of Medicine",Brigham and Women's Hospital,,,,Undecided,"[{'ReferenceType': 'background', 'ReferenceCitation': 'McMorrow D. The $100 genome: implications for the DoD. Technical Report. McLean, Virginia: The MITRE Corporation; 2010.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'De Castro M, Biesecker LG, Turner C, et al. Genomic medicine in the military. Genomic Medicine 2016;Epub ahead of print.'}, {'ReferencePMID': '11710899', 'ReferenceType': 'background', 'ReferenceCitation': 'Collins FS, Guttmacher AE. Genetics moves into the medical mainstream. JAMA. 2001 Nov 14;286(18):2322-4.'}, {'ReferencePMID': '12695777', 'ReferenceType': 'background', 'ReferenceCitation': 'Collins FS, Green ED, Guttmacher AE, Guyer MS; US National Human Genome Research Institute. A vision for the future of genomics research. Nature. 2003 Apr 24;422(6934):835-47. Epub 2003 Apr 14.'}, {'ReferencePMID': '23761042', 'ReferenceType': 'background', 'ReferenceCitation': 'McCarthy JJ, McLeod HL, Ginsburg GS. Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med. 2013 Jun 12;5(189):189sr4. doi: 10.1126/scitranslmed.3005785. Review.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Green RC, Rehm HL, Kohane IS. Clinical genome sequencing. In: Ginsburg GS, Willard HF, eds. Genomic and Personalized Medicine. 2nd ed. San Diego: Academic Press; 2013:102-22.'}, {'ReferencePMID': '26080898', 'ReferenceType': 'background', 'ReferenceCitation': 'Christensen KD, Vassy JL, Jamal L, Lehmann LS, Slashinski MJ, Perry DL, Robinson JO, Blumenthal-Barby J, Feuerman LZ, Murray MF, Green RC, McGuire AL; MedSeq Project Team. Are physicians prepared for whole genome sequencing? a qualitative analysis. Clin Genet. 2016 Feb;89(2):228-34. doi: 10.1111/cge.12626. Epub 2015 Jul 7.'}, {'ReferencePMID': '25642274', 'ReferenceType': 'background', 'ReferenceCitation': ""Vassy JL, Christensen KD, Slashinski MJ, Lautenbach DM, Raghavan S, Robinson JO, Blumenthal-Barby J, Feuerman LZ, Lehmann LS, Murray MF, Green RC, McGuire AL. 'Someday it will be the norm': physician perspectives on the utility of genome sequencing for patient care in the MedSeq Project. Per Med. 2015;12(1):23-32.""}, {'ReferencePMID': '24645908', 'ReferenceType': 'background', 'ReferenceCitation': 'Vassy JL, Lautenbach DM, McLaughlin HM, Kong SW, Christensen KD, Krier J, Kohane IS, Feuerman LZ, Blumenthal-Barby J, Roberts JS, Lehmann LS, Ho CY, Ubel PA, MacRae CA, Seidman CE, Murray MF, McGuire AL, Rehm HL, Green RC; MedSeq Project. The MedSeq Project: a randomized trial of integrating whole genome sequencing into clinical medicine. Trials. 2014 Mar 20;15:85. doi: 10.1186/1745-6215-15-85.'}, {'ReferencePMID': '26046366', 'ReferenceType': 'background', 'ReferenceCitation': 'Johnston JJ, Lewis KL, Ng D, Singh LN, Wynter J, Brewer C, Brooks BP, Brownell I, Candotti F, Gonsalves SG, Hart SP, Kong HH, Rother KI, Sokolic R, Solomon BD, Zein WM, Cooper DN, Stenson PD, Mullikin JC, Biesecker LG. Individualized iterative phenotyping for genome-wide analysis of loss-of-function mutations. Am J Hum Genet. 2015 Jun 4;96(6):913-25. doi: 10.1016/j.ajhg.2015.04.013.'}, {'ReferencePMID': '25629736', 'ReferenceType': 'background', 'ReferenceCitation': 'Green RC, Lautenbach D, McGuire AL. GINA, genetic discrimination, and genomic medicine. N Engl J Med. 2015 Jan 29;372(5):397-9. doi: 10.1056/NEJMp1404776.'}, {'ReferencePMID': '26928896', 'ReferenceType': 'background', 'ReferenceCitation': ""Robinson JO, Carroll TM, Feuerman LZ, Perry DL, Hoffman-Andrews L, Walsh RC, Christensen KD, Green RC, McGuire AL; MedSeq Project Team. Participants and Study Decliners' Perspectives About the Risks of Participating in a Clinical Trial of Whole Genome Sequencing. J Empir Res Hum Res Ethics. 2016 Feb;11(1):21-30. doi: 10.1177/1556264615624078. Epub 2016 Feb 28.""}, {'ReferencePMID': '25612602', 'ReferenceType': 'background', 'ReferenceCitation': 'Vassy JL, McLaughlin HM, MacRae CA, Seidman CE, Lautenbach D, Krier JB, Lane WJ, Kohane IS, Murray MF, McGuire AL, Rehm HL, Green RC. A one-page summary report of genome sequencing for the healthy adult. Public Health Genomics. 2015;18(2):123-9. doi: 10.1159/000370102. Epub 2015 Jan 21. Erratum in: Public Health Genomics. 2015 Apr;18(3):191. McLaughlin, Heather L [corrected to McLaughlin, Heather M].'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Krier J, McLaughlin HM, Lane WJ, et al. The return of pharmacogenomic variants in the MedSeq Project: reporting approach and physician response. Annual Meeting of the American Society of Human Genetics. Boston, MA2013'}, {'ReferencePMID': '26634332', 'ReferenceType': 'background', 'ReferenceCitation': 'Lane WJ, Westhoff CM, Uy JM, Aguad M, Smeland-Wagman R, Kaufman RM, Rehm HL, Green RC, Silberstein LE; MedSeq Project. Comprehensive red blood cell and platelet antigen prediction from whole genome sequencing: proof of principle. Transfusion. 2016 Mar;56(3):743-54. doi: 10.1111/trf.13416. Epub 2015 Dec 3.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Giovanni MA, Krier J, Vassy JL, Lautenbach DM, Green RC, Murray MF. A brief curriculum for physician orientation to clinical whole genome sequencing. American Society of Human Genetics Annual Meeting. Boston, MA2013.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Krier JB, Blout CB, D L, et al. Communication and management of genomic sequencing results by non-geneticist physicians. American Society of Human Genetics; 2015; Baltimore, MD.'}, {'ReferencePMID': '27181682', 'ReferenceType': 'background', 'ReferenceCitation': 'Green RC, Goddard KAB, Jarvik GP, Amendola LM, Appelbaum PS, Berg JS, Bernhardt BA, Biesecker LG, Biswas S, Blout CL, Bowling KM, Brothers KB, Burke W, Caga-Anan CF, Chinnaiyan AM, Chung WK, Clayton EW, Cooper GM, East K, Evans JP, Fullerton SM, Garraway LA, Garrett JR, Gray SW, Henderson GE, Hindorff LA, Holm IA, Lewis MH, Hutter CM, Janne PA, Joffe S, Kaufman D, Knoppers BM, Koenig BA, Krantz ID, Manolio TA, McCullough L, McEwen J, McGuire A, Muzny D, Myers RM, Nickerson DA, Ou J, Parsons DW, Petersen GM, Plon SE, Rehm HL, Roberts JS, Robinson D, Salama JS, Scollon S, Sharp RR, Shirts B, Spinner NB, Tabor HK, Tarczy-Hornoch P, Veenstra DL, Wagle N, Weck K, Wilfond BS, Wilhelmsen K, Wolf SM, Wynn J, Yu JH; CSER Consortium. Clinical Sequencing Exploratory Research Consortium: Accelerating Evidence-Based Practice of Genomic Medicine. Am J Hum Genet. 2016 Jun 2;98(6):1051-1066. doi: 10.1016/j.ajhg.2016.04.011. Epub 2016 May 12. Erratum in: Am J Hum Genet. 2016 Jul 7;99(1):246.'}, {'ReferencePMID': '28096516', 'ReferenceType': 'background', 'ReferenceCitation': 'Berg JS, Agrawal PB, Bailey DB Jr, Beggs AH, Brenner SE, Brower AM, Cakici JA, Ceyhan-Birsoy O, Chan K, Chen F, Currier RJ, Dukhovny D, Green RC, Harris-Wai J, Holm IA, Iglesias B, Joseph G, Kingsmore SF, Koenig BA, Kwok PY, Lantos J, Leeder SJ, Lewis MA, McGuire AL, Milko LV, Mooney SD, Parad RB, Pereira S, Petrikin J, Powell BC, Powell CM, Puck JM, Rehm HL, Risch N, Roche M, Shieh JT, Veeraraghavan N, Watson MS, Willig L, Yu TW, Urv T, Wise AL. Newborn Sequencing in Genomic Medicine and Public Health. Pediatrics. 2017 Feb;139(2). pii: e20162252. doi: 10.1542/peds.2016-2252. Epub 2017 Jan 17.'}, {'ReferencePMID': '22694298', 'ReferenceType': 'background', 'ReferenceCitation': 'Kaphingst KA, Facio FM, Cheng MR, Brooks S, Eidem H, Linn A, Biesecker BB, Biesecker LG. Effects of informed consent for individual genome sequencing on relevant knowledge. Clin Genet. 2012 Nov;82(5):408-15. doi: 10.1111/j.1399-0004.2012.01909.x. Epub 2012 Aug 7.'}, {'ReferencePMID': '18202354', 'ReferenceType': 'background', 'ReferenceCitation': 'Bowling BV, Acra EE, Wang L, Myers MF, Dean GE, Markle GC, Moskalik CL, Huether CA. Development and evaluation of a genetics literacy assessment instrument for undergraduates. Genetics. 2008 Jan;178(1):15-22. doi: 10.1534/genetics.107.079533.'}, {'ReferencePMID': '24663044', 'ReferenceType': 'background', 'ReferenceCitation': ""Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May 1;32(13):1317-23. doi: 10.1200/JCO.2013.52.4298. Epub 2014 Mar 24.""}, {'ReferencePMID': '21336657', 'ReferenceType': 'background', 'ReferenceCitation': 'Selim AJ, Rogers W, Qian SX, Brazier J, Kazis LE. A preference-based measure of health: the VR-6D derived from the veterans RAND 12-Item Health Survey. Qual Life Res. 2011 Oct;20(8):1337-47. doi: 10.1007/s11136-011-9866-y. Epub 2011 Feb 19.'}]",,,,,,,,,,,,,,,,,,,,,"Whole exome sequencing (WES) will be performed on 75 ostensibly healthy, active-duty Airmen (patient-participants) who receive medical care in military Primary Care, Internal Medicine and/or Family Practice settings who in their baseline survey expressed interest in receiving WES. Military healthcare providers who have received brief genomics traning will return results to the patient-participants and the WES reports will be permanently integrated into their electronic medical record.",,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000004198', 'ConditionMeshTerm': 'Disease Susceptibility'}, {'ConditionMeshId': 'D000020022', 'ConditionMeshTerm': 'Genetic Predisposition to Disease'}]","[{'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}]","[{'ConditionBrowseLeafId': 'M5963', 'ConditionBrowseLeafName': 'Disease Susceptibility', 'ConditionBrowseLeafAsFound': 'Predisposition', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20459', 'ConditionBrowseLeafName': 'Genetic Predisposition to Disease', 'ConditionBrowseLeafAsFound': 'Genetic Predisposition to Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21284', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M242928', 'InterventionBrowseLeafName': 'Acivicin', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03192891,SCMR_GRANT_002,Society for Cardiovascular Magnetic Resonance,OTHER,Stress CMR Perfusion Imaging in the United States (SPINS) Study,Stress CMR Perfusion Imaging in the United States (SPINS) Study. A Society for Cardiovascular Magnetic Resonance (SCMR) Registry Study,Sep-19,"Active, not recruiting",No,01-Mar-17,Actual,31-Mar-18,Actual,30-Nov-19,Anticipated,16-Jun-17,16-Jun-17,20-Jun-17,Actual,10-Sep-19,12-Sep-19,Actual,Sponsor,Society for Cardiovascular Magnetic Resonance,OTHER,No,No,,,"Numerous single-center studies have indicated gadolinium-enhanced stress CMR perfusion imaging has excellent diagnostic accuracy for coronary artery disease and negative clinical event rates, with its diagnostic accuracy exceeding nuclear scintigraphy. However, current prognostic evidence supporting clinical use of stress CMR is limited by study size, single-center settings with a predominance of academic centers, and a lack of ""real-world"" study design. Large-scale multicenter real-world evidence from a registry will provide the much needed information to guide evidence-based clinical adaptation that benefits patient care.",['Myocardial Ischemia'],Observational,,,,,,2200,Anticipated,,"[{'InterventionType': 'Diagnostic Test', 'InterventionName': 'Stress cardiac magnetic resonance (CMR) perfusion imaging', 'InterventionDescription': 'Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.'}]","[{'PrimaryOutcomeMeasure': 'Mortality', 'PrimaryOutcomeDescription': 'all-cause mortality', 'PrimaryOutcomeTimeFrame': 'from time of study to the date 4 years following'}, {'PrimaryOutcomeMeasure': 'AMI', 'PrimaryOutcomeDescription': 'Acute Myocardial Infarction', 'PrimaryOutcomeTimeFrame': 'from time of study to the date 4 years following'}, {'PrimaryOutcomeMeasure': 'Late coronary revascularization', 'PrimaryOutcomeDescription': 'PCI or CABG beyond 60 days after CMR', 'PrimaryOutcomeTimeFrame': 'from time of study to the date 4 years following'}]","[{'SecondaryOutcomeMeasure': 'Non-fatal cardiac events', 'SecondaryOutcomeDescription': 'cardiac hospitalizations for unstable angina or heart failure, heart transplant, significant ventricular arrhythmias, and strokes', 'SecondaryOutcomeTimeFrame': 'from time of study to the date 4 years following'}, {'SecondaryOutcomeMeasure': 'Cardiac event-weighted QALY', 'SecondaryOutcomeTimeFrame': 'from time of study to the date 4 years following'}]","Inclusion Criteria:

all of the following at time of imaging: a) male or female at age 35-85 years, b) presence of either of the following sign/symptom that led to stress CMR imaging

Symptoms suspicious of ischemia, or

abnormal ECG with a suspicion of coronary artery disease c) Intermediate or high risk of significant coronary disease based on at least 2 of the following conditions:

patient age > 50 for male, 60 for female
Diabetes: by either history or medical treatment
Hypertension: by either history or medical treatment
Hypercholesterolemia: by either history or medical treatment
family history of premature coronary disease: first degree relative at age <= 55 male and <=65 female
Body mass index > 30
Any medical documentation of peripheral artery disease
Any history of myocardial infarction or percutaneous coronary intervention

Exclusion Criteria:

Prior history of coronary artery bypass surgery (CABG)
Acute myocardial infarction within the past 30 days prior to CMR
any significant non-coronary cardiac conditions confirmed by medical documentation a. severe valvular heart disease, b. non-ischemic cardiomyopathy with LVEF <40%, c. infiltrative cardiomyopathy, d. hypertrophic cardiomyopathy, e. pericardial disease with significant constriction, or
active pregnancy,
any competing conditions leading to an expected survival of < 2 years
Known inability to follow-up due to logistical reasons (e.g. patient lives in another country where follow-up is not feasible)",,All,35 Years,85 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Illinois', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60612', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Chicago', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60637', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Kentucky', 'LocationCity': 'Lexington', 'LocationState': 'Kentucky', 'LocationZip': '40536', 'LocationCountry': 'United States'}, {'LocationFacility': 'National Heart, Lung, and Blood Institute (NHLBI)', 'LocationCity': 'Bethesda', 'LocationState': 'Maryland', 'LocationZip': '20824', 'LocationCountry': 'United States'}, {'LocationFacility': ""Brigham and Women's Hospital"", 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02115', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Minnesota', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55455', 'LocationCountry': 'United States'}, {'LocationFacility': 'New York-Presbyterian Brooklyn Methodist Hospital', 'LocationCity': 'Brooklyn', 'LocationState': 'New York', 'LocationZip': '11215', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ohio State University', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sharon Regional Health System', 'LocationCity': 'Hermitage', 'LocationState': 'Pennsylvania', 'LocationZip': '16148', 'LocationCountry': 'United States'}, {'LocationFacility': 'Houston Methodist', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'San Antonio Military Medical Center - Wilford Hall', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78219', 'LocationCountry': 'United States'}, {'LocationFacility': 'Revere Health', 'LocationCity': 'Provo', 'LocationState': 'Utah', 'LocationZip': '84604', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Siemens Healthcare', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Bayer', 'CollaboratorClass': 'INDUSTRY'}]",No,,,No,['Case-Only'],['Retrospective'],Consecutive patients who underwent stress CMR perfusion imaging for evaluation of myocardial ischemia between 2008-2013.,Non-Probability Sample,,SPINS,,,,,,,Undecided,"[{'ReferencePMID': '32819469', 'ReferenceType': 'derived', 'ReferenceCitation': 'Antiochos P, Ge Y, Steel K, Bingham S, Abdullah S, Mikolich JR, Arai AE, Bandettini WP, Patel AR, Farzaneh-Far A, Heitner JF, Shenoy C, Leung SW, Gonzalez JA, Shah DJ, Raman SV, Ferrari VA, Schulz-Menger J, Stuber M, Simonetti OP, Kwong RY; SPINS Study Investigators. Imaging of Clinically Unrecognized Myocardial Fibrosis in Patients With Suspected Coronary Artery Disease. J Am Coll Cardiol. 2020 Aug 25;76(8):945-957. doi: 10.1016/j.jacc.2020.06.063.'}, {'ReferencePMID': '32771575', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ge Y, Antiochos P, Steel K, Bingham S, Abdullah S, Chen YY, Mikolich JR, Arai AE, Bandettini WP, Shanbhag SM, Patel AR, Farzaneh-Far A, Heitner JF, Shenoy C, Leung SW, Gonzalez JA, Shah DJ, Raman SV, Ferrari VA, Schulz-Menger J, Stuber M, Simonetti OP, Kwong RY. Prognostic Value of Stress CMR Perfusion Imaging in Patients With Reduced Left Ventricular Function. JACC Cardiovasc Imaging. 2020 Oct;13(10):2132-2145. doi: 10.1016/j.jcmg.2020.05.034. Epub 2020 Aug 5.'}, {'ReferencePMID': '32417337', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ge Y, Pandya A, Steel K, Bingham S, Jerosch-Herold M, Chen YY, Mikolich JR, Arai AE, Bandettini WP, Patel AR, Farzaneh-Far A, Heitner JF, Shenoy C, Leung SW, Gonzalez JA, Shah DJ, Raman SV, Ferrari VA, Schulz-Menger J, Hachamovitch R, Stuber M, Simonetti OP, Kwong RY. Cost-Effectiveness Analysis of Stress Cardiovascular Magnetic Resonance Imaging for Stable Chest Pain Syndromes. JACC Cardiovasc Imaging. 2020 Jul;13(7):1505-1517. doi: 10.1016/j.jcmg.2020.02.029. Epub 2020 May 13.'}, {'ReferencePMID': '31582133', 'ReferenceType': 'derived', 'ReferenceCitation': 'Kwong RY, Ge Y, Steel K, Bingham S, Abdullah S, Fujikura K, Wang W, Pandya A, Chen YY, Mikolich JR, Boland S, Arai AE, Bandettini WP, Shanbhag SM, Patel AR, Narang A, Farzaneh-Far A, Romer B, Heitner JF, Ho JY, Singh J, Shenoy C, Hughes A, Leung SW, Marji M, Gonzalez JA, Mehta S, Shah DJ, Debs D, Raman SV, Guha A, Ferrari VA, Schulz-Menger J, Hachamovitch R, Stuber M, Simonetti OP. Cardiac Magnetic Resonance Stress Perfusion Imaging for Evaluation of Patients With Chest Pain. J Am Coll Cardiol. 2019 Oct 8;74(14):1741-1755. doi: 10.1016/j.jacc.2019.07.074.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000017202', 'ConditionMeshTerm': 'Myocardial Ischemia'}, {'ConditionMeshId': 'D000007511', 'ConditionMeshTerm': 'Ischemia'}]","[{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}]","[{'ConditionBrowseLeafId': 'M5129', 'ConditionBrowseLeafName': 'Coronary Artery Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18089', 'ConditionBrowseLeafName': 'Myocardial Ischemia', 'ConditionBrowseLeafAsFound': 'Myocardial Ischemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9126', 'ConditionBrowseLeafName': 'Ischemia', 'ConditionBrowseLeafAsFound': 'Ischemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03373045,D3250R00023,AstraZeneca,INDUSTRY,"Observational Study of Characteristics, Treatment and Outcomes With Severe Asthma in the United States (CHRONICLE)","The CHRONICLE Study: A Longitudinal Prospective Observational Study of the Characteristics, Treatment Patterns and Health Outcomes of Individuals With Severe Asthma in the United States",Oct-20,Recruiting,No,27-Feb-18,Actual,31-Jan-26,Anticipated,31-Jan-26,Anticipated,20-Nov-17,08-Dec-17,14-Dec-17,Actual,07-Oct-20,08-Oct-20,Actual,Sponsor,AstraZeneca,INDUSTRY,No,No,,,"The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose inhaled corticosteroid (ICS) therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. Data will be collected from the healthcare provider in a uniform manner for every patient enrolled using an electronic case report form (eCRF). Data will be collected monthly from patients via web-based surveys. Patients will be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.",['Asthma'],Observational,,,,,,4000,Anticipated,"[{'ArmGroupLabel': 'Cohort of US adults with severe asthma', 'ArmGroupDescription': 'To describe patient characteristics, treatment patterns, and health outcomes among a large, geographically diverse cohort of US adults with severe asthma who are not controlled on high-dose ICS with additional controllers and/or require chronic systemic corticosteroid or monoclonal antibody therapy.'}]",,"[{'PrimaryOutcomeMeasure': 'Healthcare utilization- hospitalizations, clinic Visits, and asthma exacerbations', 'PrimaryOutcomeDescription': ""Longitudinal changes of Healthcare utilization will be measured using directly collected information from medical, hospital, and pharmacy records to provide a supplementary comprehensive assessment of each patient's healthcare utilization during the study period."", 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Asthma treatment', 'PrimaryOutcomeDescription': 'Asthma medications with dose and start/stop dates including all FDA-approved and standard of care treatments for asthma will be assessed. Longitudinal changes in asthma treatment will also be assessed.', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Treatment adherence', 'PrimaryOutcomeDescription': ""Extraction of electronic medical, hospital, and pharmacy records will take place at study close and potentially at interim time points to provide a supplementary assessment of each patient's healthcare resource utilization. Longitudinal changes in patient reported treatment adherence will also be assessed."", 'PrimaryOutcomeTimeFrame': 'At baseline, every 1 month, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Asthma control test (ACT)', 'PrimaryOutcomeDescription': 'Patient-reported asthma symptoms and control will be collected via the ACT questionnaire; a 5 item, self-administered survey that is designed to help the patient describe their asthma and how it affects their daily activities. ACT questionnaire is a 5-point scale (for symptoms and activities: 1=all the time to 5= not at all; for asthma control rating: 1=not controlled at all to 5=completely controlled).', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 1 month, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Patient-reported asthma exacerbations', 'PrimaryOutcomeDescription': 'Asthma exacerbations, the primary analytical definition will be worsening of asthma that leads to any of the following: Use of systemic corticosteroids (or a temporary increase in a stable corticosteroid background dose) for at least 3 days; a single depo-injectable dose of corticosteroids will be considered equivalent to a 3-day course of systemic corticosteroids. An emergency department or urgent care visit (defined as evaluation and treatment for <24 hours in an emergency department or urgent care center) due to asthma that required systemic corticosteroids. An inpatient hospitalization (defined as admission to an inpatient facility and/or evaluation and treatment in a healthcare facility for ≥24 hours) due to asthma.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 1 month, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Work Productivity and Activity Impairment Asthma questionnaire (WPAI-Asthma)', 'PrimaryOutcomeDescription': ""Patient-reported productivity impairment assessment including work productivity, activity impairment, and disability will be collected via the WPAI-Asthma. Information will only be collected from procedures that are part of the patient's routine clinical care. WPAI Asthma questionnaire is calculated from 0 to 10 score (0 indicates-Asthma had no effect on my work/ daily activities and 10 indicates Asthma completely prevented me from working score/ doing my daily activities)."", 'PrimaryOutcomeTimeFrame': 'At baseline, every 3 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': ""St. George's Respiratory Questionnaire (SGRQ)"", 'PrimaryOutcomeDescription': 'Patient-reported assessment of asthma quality of life will be collected via the SGRQ. SGRQ, a disease specific health-related quality of life measure developed for both asthma and chronic obstructive pulmonary disease (COPD) patients. The SGRQ has 50 items and scores are calculated for 3 domains (symptoms, activity, and impact [psychosocial]) as well as total score.\n\nSymptoms - this component is concerned with the effect of respiratory symptoms, their frequency and severity.\n\nImpacts (psychosocial) - covers a range of aspects concerned with social functioning and psychological disturbances resulting from respiratory disease Activity - concerned with activities that cause or are limited by breathlessness. Total score summaries the impact of the disease on overall health status.\n\nThe score is expressed as a percentage of overall impairment, where 100 represents worst possible health status and 0 indicates best possible health status.', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Global evaluation of treatment effectiveness (GETE)', 'PrimaryOutcomeDescription': 'Patient evaluation of asthma treatment effectiveness will be measured using GETE; a simple measure of perceived treatment effectiveness. The patient will grade the overall treatment effectiveness using the following criteria: excellent (complete control of asthma); good (marked improvement of asthma); moderate (discernible, but limited improvement in asthma); poor (no appreciable change in asthma); or worsening (of asthma).', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed maximum up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Number of Participants With Adverse Events associated with corticosteroid therapy.', 'PrimaryOutcomeDescription': ""Frequency of relevant medical events such as weight gain (change in BMI), hypertension, dyslipidemia, pneumonia, bone densitometry results, osteoporosis / osteopenia, hip and spinal fractures, avascular necrosis, cataract, glaucoma, diabetes mellitus, cardiovascular disease, Cushing's syndrome, adrenal insufficiency, peptic ulcer disease, myopathy, pseudotumor cerebri, mood disturbance, and insomnia or sleep disturbance."", 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Relevant respiratory medical events', 'PrimaryOutcomeDescription': 'Frequency of relevant respiratory medical events such as pneumonia, pleural effusion, chronic bronchitis, allergic rhinitis.', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion,assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Respiratory comorbidities', 'PrimaryOutcomeDescription': 'Prevalence of respiratory comorbidities such as chronic obstructive pulmonary disease (COPD), bronchiectasis, alpha-1 anti-trypsin deficiency, Churg- Strauss syndrome (eosinophilic granulomatosis with polyangiitis [EGPA]), airway stenosis, cystic fibrosis, allergic bronchopulmonary aspergillosis,chronic eosinophilic pneumonia, bronchiolitis obliterans, immunodeficiency, primary ciliary dyskinesia, atelectasis, arterial hypertension, pulmonary hypertension, neuromuscular disease, allergic rhinitis, chronic rhinosinusitis, and pulmonary embolism.', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Non-respiratory comorbidities', 'PrimaryOutcomeDescription': 'Prevalence of non-respiratory comorbidities such as diabetes, thyroid disease, cardiac disease, etc.', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Events of special interest', 'PrimaryOutcomeDescription': 'Frequency of special interest events including new onset malignancy, severe infection, anaphylaxis, or mortality.', 'PrimaryOutcomeTimeFrame': 'At baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Complete blood count with differential including blood eosinophil count.', 'PrimaryOutcomeDescription': 'To assess complete blood count with differential including blood eosinophil count as a variable for asthma evaluation.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Total immunoglobulin E (IgE)', 'PrimaryOutcomeDescription': 'To assess total IgE as a variable for asthma evaluation.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Radiographic changes in asthma evaluation.', 'PrimaryOutcomeDescription': 'Radiographic changes in asthma evaluation included chest X-rays (dates, views, description of major chest findings), Chest computed tomography scan (dates, high resolution (yes/no), intravenous contrast (yes/no), description of major findings). Radiographic asthma evaluation conducted as part of routine care.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Forced Vital Capacity (FVC)', 'PrimaryOutcomeDescription': 'FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Forced Expiratory Volume in 1 second (FEV1)', 'PrimaryOutcomeDescription': 'FEV1 (liters and % predicted) will be assessed as a variable for asthma evaluation.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.'}, {'PrimaryOutcomeMeasure': 'Fractional exhaled nitric oxide (FENO)', 'PrimaryOutcomeDescription': 'To assess FENO as a variable for asthma evaluation.', 'PrimaryOutcomeTimeFrame': 'Change from baseline, every 6 months, through study completion, assessed up to 7 years.'}]",,"Inclusion Criteria:

1. Individuals with a diagnosis of severe asthma for at least 12 months prior to enrollment and confirmed by the Investigator not to be due to alternative diagnoses.

2. Currently receiving care from specialist physicians (eg, pulmonologists and or allergists) at the Investigator's or sub-investigator's site.

3. 18 years of age and older. 4. Meeting at least one of the following three criteria (a, b, or c):

a. Uncontrolled on asthma treatment consistent with GINA (Global Initiative for Asthma) Step 4 or 5, receiving high-dose ICS with additional controllers.

i. Uncontrolled is defined by meeting at least one of the following (as outlined by ATS/ERS [American Thoracic Society/European Respiratory Society] guidelines):

Poor symptom control: Asthma Control Questionnaire consistently ≥1.5, ACT <20 (or ""not well controlled"" by NAEPP [National Asthma Education and Prevention Program]/GINA guidelines).
Frequent severe exacerbations: two or more bursts of systemic corticosteroids (≥3 days each) in the previous 12 months.
Serious exacerbations: at least one hospitalization, intensive care unit stay or mechanical ventilation in the previous 12 months.
Airflow limitation: after appropriate bronchodilator withhold FEV1 <80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).

ii. For the purposes of this study, high-dose ICS will be defined as

1. ICS at a cumulative dose of >500 μg fluticasone propionate equivalents daily as defined in Appendix A, or 2. Highest labeled dose of a combination of ICS/LABA. b. Current use of a Food and Drug Administration (FDA)-approved monoclonal antibody agent for treatment of severe asthma (use is not primarily for an alternative condition).

c. Use of systemic corticosteroids or other systemic immunosuppressants (any dose level) for approximately 50% or more of the prior 12 months for treatment of severe asthma (use is not primarily for an alternative condition).

Exclusion Criteria

Not willing and able to sign written informed consent. Consent can be obtained from having a responsible, legally authorized representative acting on patient's behalf.
Not fluent in English or Spanish.
Inability to complete study follow-up or web-based PROs. If the patient does not have email or web access, minimal assistance from others to access the web-based PRO is permitted (ie receiving the email and/or assisting patient in navigating to the web page); PROs must be completed by the patient.

Received an investigational therapy for asthma, allergy, atopic disease, or eosinophilic disease as part of a clinical trial during the 6 months prior to enrollment.

Once enrolled in the CHRONICLE Study, patients can enroll in trials of investigational therapies (as well as other non-interventional studies) as long as they continue to complete study follow-up. If a patient enrolls in a trial of an investigational therapy, the identity (National Clinical Trial [NCT] number) of the study and dates of the first and last investigational therapy administrations will be collected. If a patient receives blinded therapy in a trial, the Investigator will request the identity of that therapy at trial conclusion so that treatment information collected for the current study may be updated accordingly.",No,All,18 Years,80 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35209', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35294', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hoover', 'LocationState': 'Alabama', 'LocationZip': '35244', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gilbert', 'LocationState': 'Arizona', 'LocationZip': '85234', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Little Rock', 'LocationState': 'Arkansas', 'LocationZip': '72205', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bakersfield', 'LocationState': 'California', 'LocationZip': '93301', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90025', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Redondo Beach', 'LocationState': 'California', 'LocationZip': '90277', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Riverside', 'LocationState': 'California', 'LocationZip': '92506', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Roseville', 'LocationState': 'California', 'LocationZip': '95661', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95819-3957', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Studio City', 'LocationState': 'California', 'LocationZip': '91607', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Ventura', 'LocationState': 'California', 'LocationZip': '93003', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Westminster', 'LocationState': 'California', 'LocationZip': '92683', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80045', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Danbury', 'LocationState': 'Connecticut', 'LocationZip': '06810', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Waterbury', 'LocationState': 'Connecticut', 'LocationZip': '06708', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Newark', 'LocationState': 'Delaware', 'LocationZip': '19713', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Clearwater', 'LocationState': 'Florida', 'LocationZip': '33765', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Coral Gables', 'LocationState': 'Florida', 'LocationZip': '33134', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gainesville', 'LocationState': 'Florida', 'LocationZip': '32608', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Kissimmee', 'LocationState': 'Florida', 'LocationZip': '33032', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lake Mary', 'LocationState': 'Florida', 'LocationZip': '32746', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Miami Beach', 'LocationState': 'Florida', 'LocationZip': '33140', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33175', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33176', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Plantation', 'LocationState': 'Florida', 'LocationZip': '33317', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Saint Petersburg', 'LocationState': 'Florida', 'LocationZip': '33704', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tallahassee', 'LocationState': 'Florida', 'LocationZip': '32308', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tampa', 'LocationState': 'Florida', 'LocationZip': '33613', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Albany', 'LocationState': 'Georgia', 'LocationZip': '31707', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Decatur', 'LocationState': 'Georgia', 'LocationZip': '30033', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Gainesville', 'LocationState': 'Georgia', 'LocationZip': '30501', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Boise', 'LocationState': 'Idaho', 'LocationZip': '83706', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60611', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60612', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Iowa City', 'LocationState': 'Iowa', 'LocationZip': '52242', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'West Des Moines', 'LocationState': 'Iowa', 'LocationZip': '50266', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Overland Park', 'LocationState': 'Kansas', 'LocationZip': '66210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Georgetown', 'LocationState': 'Kentucky', 'LocationZip': '40324', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lexington', 'LocationState': 'Kentucky', 'LocationZip': '40503', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lexington', 'LocationState': 'Kentucky', 'LocationZip': '40509', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationZip': '40215', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70112', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Orleans', 'LocationState': 'Louisiana', 'LocationZip': '70127', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Shreveport', 'LocationState': 'Louisiana', 'LocationZip': '71106', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Bangor', 'LocationState': 'Maine', 'LocationZip': '04401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Upper Marlboro', 'LocationState': 'Maryland', 'LocationZip': '20772', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wheaton', 'LocationState': 'Maryland', 'LocationZip': '20902', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Burlington', 'LocationState': 'Massachusetts', 'LocationZip': '01805', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48106', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Clinton Township', 'LocationState': 'Michigan', 'LocationZip': '48038', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hamtramck', 'LocationState': 'Michigan', 'LocationZip': '48212', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wyoming', 'LocationState': 'Michigan', 'LocationZip': '49519', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Maplewood', 'LocationState': 'Minnesota', 'LocationZip': '55109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lincoln', 'LocationState': 'Nebraska', 'LocationZip': '68505', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68114', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68198', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Las Vegas', 'LocationState': 'Nevada', 'LocationZip': '89106', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brick', 'LocationState': 'New Jersey', 'LocationZip': '08724', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Marlton', 'LocationState': 'New Jersey', 'LocationZip': '08053', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Brunswick', 'LocationState': 'New Jersey', 'LocationZip': '08901', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'North Bergen', 'LocationState': 'New Jersey', 'LocationZip': '07047', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Northfield', 'LocationState': 'New Jersey', 'LocationZip': '08225', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Toms River', 'LocationState': 'New Jersey', 'LocationZip': '08755', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Verona', 'LocationState': 'New Jersey', 'LocationZip': '07044', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Albuquerque', 'LocationState': 'New Mexico', 'LocationZip': '87109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bayside', 'LocationState': 'New York', 'LocationZip': '11361', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10458', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10459', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10461', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10465', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brooklyn', 'LocationState': 'New York', 'LocationZip': '11230', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Brooklyn', 'LocationState': 'New York', 'LocationZip': '11236', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Corning', 'LocationState': 'New York', 'LocationZip': '14830', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Great Neck', 'LocationState': 'New York', 'LocationZip': '11023', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mineola', 'LocationState': 'New York', 'LocationZip': '11501', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Hyde Park', 'LocationState': 'New York', 'LocationZip': '11042', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New Paltz', 'LocationState': 'New York', 'LocationZip': '12561', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10022', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '14642', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Rockville Centre', 'LocationState': 'New York', 'LocationZip': '11570', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Staten Island', 'LocationState': 'New York', 'LocationZip': '10305', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Valhalla', 'LocationState': 'New York', 'LocationZip': '10595', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Asheville', 'LocationState': 'North Carolina', 'LocationZip': '28801', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Charlotte', 'LocationState': 'North Carolina', 'LocationZip': '28204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27705', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fayetteville', 'LocationState': 'North Carolina', 'LocationZip': '28304', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Greenville', 'LocationState': 'North Carolina', 'LocationZip': '27834', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Winston-Salem', 'LocationState': 'North Carolina', 'LocationZip': '27157', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Fargo', 'LocationState': 'North Dakota', 'LocationZip': '58104', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Toledo', 'LocationState': 'Ohio', 'LocationZip': '43617', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Oklahoma City', 'LocationState': 'Oklahoma', 'LocationZip': '73120', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Corvallis', 'LocationState': 'Oregon', 'LocationZip': '97330', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97220', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97225', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Altoona', 'LocationState': 'Pennsylvania', 'LocationZip': '16601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'DuBois', 'LocationState': 'Pennsylvania', 'LocationZip': '15801', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Harrisburg', 'LocationState': 'Pennsylvania', 'LocationZip': '17109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19107', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15241', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sayre', 'LocationState': 'Pennsylvania', 'LocationZip': '18840', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Yardley', 'LocationState': 'Pennsylvania', 'LocationZip': '19067', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Warwick', 'LocationState': 'Rhode Island', 'LocationZip': '02886', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Clinton', 'LocationState': 'South Carolina', 'LocationZip': '29325', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Greenville', 'LocationState': 'South Carolina', 'LocationZip': '29607', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Mount Pleasant', 'LocationState': 'South Carolina', 'LocationZip': '29464', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Rock Hill', 'LocationState': 'South Carolina', 'LocationZip': '29732', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hendersonville', 'LocationState': 'Tennessee', 'LocationZip': '37075', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Aransas Pass', 'LocationState': 'Texas', 'LocationZip': '78336', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Beaumont', 'LocationState': 'Texas', 'LocationZip': '77702', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75426', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Denison', 'LocationState': 'Texas', 'LocationZip': '75020', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Duncanville', 'LocationState': 'Texas', 'LocationZip': '75116', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Fort Worth', 'LocationState': 'Texas', 'LocationZip': '76107', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77043', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77079', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Katy', 'LocationState': 'Texas', 'LocationZip': '77450', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Live Oak', 'LocationState': 'Texas', 'LocationZip': '78233', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'McKinney', 'LocationState': 'Texas', 'LocationZip': '75069', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78251', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Sugar Land', 'LocationState': 'Texas', 'LocationZip': '77478', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Murray', 'LocationState': 'Utah', 'LocationZip': '84107', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Lynchburg', 'LocationState': 'Virginia', 'LocationZip': '24501', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23507', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Richmond', 'LocationState': 'Virginia', 'LocationZip': '23229', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Richmond', 'LocationState': 'Virginia', 'LocationZip': '23235', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Williamsburg', 'LocationState': 'Virginia', 'LocationZip': '23188', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tacoma', 'LocationState': 'Washington', 'LocationZip': '98405', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Vancouver', 'LocationState': 'Washington', 'LocationZip': '98664', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Greenfield', 'LocationState': 'Wisconsin', 'LocationZip': '53228', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Onalaska', 'LocationState': 'Wisconsin', 'LocationZip': '54650', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wausau', 'LocationState': 'Wisconsin', 'LocationZip': '54401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guaynabo', 'LocationZip': '00968', 'LocationCountry': 'Puerto Rico'}]","[{'CollaboratorName': 'Parexel', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'MedImmune LLC', 'CollaboratorClass': 'INDUSTRY'}]",No,"The CHRONICLE Study is a multi-center, non-interventional, prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and/or require systemic corticosteroid or monoclonal antibody therapy. This study will provide a contemporary description of the epidemiology and medical management of United States adults with severe asthma who have not achieved control with high-dose ICS therapy and additional controllers. Additionally, the study will describe the use of and outcomes associated with recently approved monoclonal antibody therapies for severe asthma. Patients will be enrolled from a diverse population of academic and community-based specialist centers across the US. Data will be collected in a naturalistic manner and patient management will not be influenced by the study protocol. At least 1500 patients in the US with a confirmed diagnosis of severe asthma will be enrolled by a diverse set of asthma specialists (eg, allergists and pulmonologists who treat asthma) from academic and community-based centers. Basic de-identified information will be collected for all patients meeting study inclusion criteria, including those not approached for enrollment or who decline enrollment, to enable an assessment of the enrolled and non-enrolled populations. This information will include age, sex, insurance status, age at asthma diagnosis, class of asthma treatment per study inclusion criteria, number of asthma exacerbations in the past 12 months, study eligibility, whether the patient was approached for enrollment, study enrollment status, and reason for not enrolling for those who are approached but do not enroll. Patient-reported asthma control (Asthma Control Test [ACT]), asthma exacerbations, and treatment adherence will be solicited monthly. Patient-reported information on asthma-related healthcare utilization, global evaluation of treatment effectiveness (GETE), and work productivity (Work Productivity and Activity Impairment Asthma questionnaire [WPAI-Asthma]) will be collected at baseline and approximately every 3 months. Detailed information on asthma-related quality of life (Saint George's Respiratory Questionnaire [SGRQ]) as well as presence of an asthma treatment plan will be collected from patients approximately every 6 months. All of the questionnaires will be collected via web-based surveys. Patients will then be followed until study discontinuation or the patient withdraws from the study or death, whichever occurs first. The expectation is that patients will be followed for a period of at least 3 years.","['Severe asthma', 'Monoclonal antibody', 'Corticosteroid', 'Non-interventional']",Yes,['Cohort'],['Prospective'],"It is estimated that at least 1500 patients in the US with a confirmed diagnosis of severe asthma will be enrolled by a diverse set of asthma specialists (eg, allergists and pulmonologists who treat asthma) from academic and community-based centers.",Non-Probability Sample,,,,,,,,,No,"[{'ReferencePMID': '32765156', 'ReferenceType': 'derived', 'ReferenceCitation': 'Ambrose CS, Chipps BE, Moore WC, Soong W, Trevor J, Ledford DK, Carr WW, Lugogo N, Trudo F, Tran TN, Panettieri RA Jr. The CHRONICLE Study of US Adults with Subspecialist-Treated Severe Asthma: Objectives, Design, and Initial Results. Pragmat Obs Res. 2020 Jul 16;11:77-90. doi: 10.2147/POR.S251120. eCollection 2020.'}, {'ReferencePMID': '32304877', 'ReferenceType': 'derived', 'ReferenceCitation': 'Moore WC, Panettieri RA Jr, Trevor J, Ledford DK, Lugogo N, Soong W, Chipps BE, Carr W, Belton L, Gandhi H, Trudo F, Ambrose CS. Biologic and maintenance systemic corticosteroid therapy among US subspecialist-treated patients with severe asthma. Ann Allergy Asthma Immunol. 2020 Sep;125(3):294-303.e1. doi: 10.1016/j.anai.2020.04.004. Epub 2020 Apr 15.'}]",,,,,,"[{'CentralContactName': 'AstraZeneca Clinical Study Information Center', 'CentralContactRole': 'Contact', 'CentralContactPhone': '1-877-240-9479', 'CentralContactEMail': 'information.center@astrazeneca.com'}]",,,,,,,,,,,,,,5 Years,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001249', 'ConditionMeshTerm': 'Asthma'}]","[{'ConditionAncestorId': 'D000001982', 'ConditionAncestorTerm': 'Bronchial Diseases'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}, {'ConditionAncestorId': 'D000008173', 'ConditionAncestorTerm': 'Lung Diseases, Obstructive'}, {'ConditionAncestorId': 'D000008171', 'ConditionAncestorTerm': 'Lung Diseases'}, {'ConditionAncestorId': 'D000012130', 'ConditionAncestorTerm': 'Respiratory Hypersensitivity'}, {'ConditionAncestorId': 'D000006969', 'ConditionAncestorTerm': 'Hypersensitivity, Immediate'}, {'ConditionAncestorId': 'D000006967', 'ConditionAncestorTerm': 'Hypersensitivity'}, {'ConditionAncestorId': 'D000007154', 'ConditionAncestorTerm': 'Immune System Diseases'}]","[{'ConditionBrowseLeafId': 'M3137', 'ConditionBrowseLeafName': 'Asthma', 'ConditionBrowseLeafAsFound': 'Asthma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3840', 'ConditionBrowseLeafName': 'Bronchial Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9751', 'ConditionBrowseLeafName': 'Lung Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9753', 'ConditionBrowseLeafName': 'Lung Diseases, Obstructive', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8601', 'ConditionBrowseLeafName': 'Hypersensitivity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13550', 'ConditionBrowseLeafName': 'Respiratory Hypersensitivity', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8603', 'ConditionBrowseLeafName': 'Hypersensitivity, Immediate', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8783', 'ConditionBrowseLeafName': 'Immune System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M2806', 'InterventionBrowseLeafName': 'Antibodies', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8767', 'InterventionBrowseLeafName': 'Immunoglobulins', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2811', 'InterventionBrowseLeafName': 'Antibodies, Monoclonal', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04229212,B-BR-107-046-T,National Cheng-Kung University Hospital,OTHER,Effectiveness of Using Closed-suction Drainage in Treating Proximal Femur Fracture With Cephalomedullary Nail,Effectiveness of Using Closed-suction Drainage in Treating Proximal Femur Fracture With Cephalomedullary Nail,Jan-20,Completed,No,11-Dec-18,Actual,31-Dec-19,Actual,31-Dec-19,Actual,08-Jan-20,14-Jan-20,18-Jan-20,Actual,14-Jan-20,18-Jan-20,Actual,Sponsor,National Cheng-Kung University Hospital,OTHER,No,No,,,"Introduction: The closed suction drainage system is widely used in proximal femur surgeries. Recently, the proximal femoral nail antirotation (PFNA) system was advocated for treating intertrochanteric fractures (ITFs) in the elderly patients. However, the true effect of the closed suction drainage system with PFNA fixation on outcomes in ITFs is still unknown. This prospective randomized controlled trial aimed to examine whether routine drainage is useful for PFNA fixation in ITFs.

Methods: A total of 80 patients with acute ITFs were treated with closed or mini-open reduction with PFNA fixation at the National Cheng Kung University Hospital and 60 eligible patients (22 men and 38 women) were randomized for whether to receive suction drainage. In clinical outcomes, the visual analog scale (VAS), morphine equivalent dosage, injured thigh width, body temperature, and wound condition with specific reference to hematoma formation and wound infection were measured on postoperative days 1, 2, 4, and 10. In laboratory outcomes, the investigators evaluated hemoglobin and hematocrit levels postoperatively at different time points. Blood transfusion and total blood loss (TBL) were measured by Mercuriali's formula in millimeter.",['Intertrochanteric Fractures'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,Single,60,Actual,"[{'ArmGroupLabel': 'No drainage', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'No drainage'}, {'ArmGroupLabel': 'Drainage', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)']}}]","[{'InterventionType': 'Device', 'InterventionName': 'hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State)', 'InterventionDescription': 'In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Drainage']}}]","[{'PrimaryOutcomeMeasure': 'Blood transfusion', 'PrimaryOutcomeDescription': 'mL', 'PrimaryOutcomeTimeFrame': 'preoperation'}, {'PrimaryOutcomeMeasure': 'Blood transfusion', 'PrimaryOutcomeDescription': 'mL', 'PrimaryOutcomeTimeFrame': 'postoperative days 1'}, {'PrimaryOutcomeMeasure': 'Blood transfusion', 'PrimaryOutcomeDescription': 'mL', 'PrimaryOutcomeTimeFrame': 'postoperative days 2'}, {'PrimaryOutcomeMeasure': 'Blood transfusion', 'PrimaryOutcomeDescription': 'mL', 'PrimaryOutcomeTimeFrame': 'postoperative days 4'}, {'PrimaryOutcomeMeasure': 'Blood transfusion', 'PrimaryOutcomeDescription': 'mL', 'PrimaryOutcomeTimeFrame': 'postoperative days 10'}, {'PrimaryOutcomeMeasure': 'Total blood loss (TBL)', 'PrimaryOutcomeDescription': ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", 'PrimaryOutcomeTimeFrame': 'Pre-operation'}, {'PrimaryOutcomeMeasure': 'Total blood loss (TBL)', 'PrimaryOutcomeDescription': ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", 'PrimaryOutcomeTimeFrame': 'postoperative days 1'}, {'PrimaryOutcomeMeasure': 'Total blood loss (TBL)', 'PrimaryOutcomeDescription': ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", 'PrimaryOutcomeTimeFrame': 'postoperative days 2'}, {'PrimaryOutcomeMeasure': 'Total blood loss (TBL)', 'PrimaryOutcomeDescription': ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", 'PrimaryOutcomeTimeFrame': 'postoperative days 4'}, {'PrimaryOutcomeMeasure': 'Blood transfusion and total blood loss (TBL)', 'PrimaryOutcomeDescription': ""Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])"", 'PrimaryOutcomeTimeFrame': 'postoperative days 10'}]","[{'SecondaryOutcomeMeasure': 'body temperature', 'SecondaryOutcomeDescription': ""'C"", 'SecondaryOutcomeTimeFrame': 'preoperative'}, {'SecondaryOutcomeMeasure': 'body temperature', 'SecondaryOutcomeDescription': ""'C"", 'SecondaryOutcomeTimeFrame': 'postoperative days 1'}, {'SecondaryOutcomeMeasure': 'body temperature', 'SecondaryOutcomeDescription': ""'C"", 'SecondaryOutcomeTimeFrame': 'postoperative days 2'}, {'SecondaryOutcomeMeasure': 'body temperature', 'SecondaryOutcomeDescription': ""'C"", 'SecondaryOutcomeTimeFrame': 'postoperative days 4'}, {'SecondaryOutcomeMeasure': 'Secondary outcome-Pain', 'SecondaryOutcomeDescription': 'VAS score (0-10, while 0 is best, 10 is worst)', 'SecondaryOutcomeTimeFrame': 'postoperative days 1'}, {'SecondaryOutcomeMeasure': 'Secondary outcome-Pain', 'SecondaryOutcomeDescription': 'VAS score (0-10, while 0 is best, 10 is worst)', 'SecondaryOutcomeTimeFrame': 'postoperative days 2'}, {'SecondaryOutcomeMeasure': 'Secondary outcome-Pain', 'SecondaryOutcomeDescription': 'VAS score (0-10, while 0 is best, 10 is worst)', 'SecondaryOutcomeTimeFrame': 'postoperative days 4'}, {'SecondaryOutcomeMeasure': 'width of the injured proximal thigh', 'SecondaryOutcomeDescription': '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', 'SecondaryOutcomeTimeFrame': 'postoperative days 1'}, {'SecondaryOutcomeMeasure': 'width of the injured proximal thigh', 'SecondaryOutcomeDescription': '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', 'SecondaryOutcomeTimeFrame': 'Intraoperation'}, {'SecondaryOutcomeMeasure': 'width of the injured proximal thigh', 'SecondaryOutcomeDescription': '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', 'SecondaryOutcomeTimeFrame': 'postoperative days 2'}, {'SecondaryOutcomeMeasure': 'width of the injured proximal thigh', 'SecondaryOutcomeDescription': '20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]', 'SecondaryOutcomeTimeFrame': 'postoperative days 4'}, {'SecondaryOutcomeMeasure': 'wound condition', 'SecondaryOutcomeDescription': 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'SecondaryOutcomeTimeFrame': 'Intraoperation'}, {'SecondaryOutcomeMeasure': 'wound condition', 'SecondaryOutcomeDescription': 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'SecondaryOutcomeTimeFrame': 'postoperative days 1'}, {'SecondaryOutcomeMeasure': 'wound condition', 'SecondaryOutcomeDescription': 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'SecondaryOutcomeTimeFrame': 'postoperative days 2'}, {'SecondaryOutcomeMeasure': 'wound condition', 'SecondaryOutcomeDescription': 'Grade of hematoma (1-3, while 1 is best, 3 is worst)', 'SecondaryOutcomeTimeFrame': 'postoperative days 4'}]","Inclusion Criteria:

had an acute (injury less than 2 weeks) proximal femoral fracture, classified as Arbeitsgemeinschaft für Osteosynthesefragen (AO) 31A1, 31A2, and 31A314,
were treated with closed reduction or mini-open reduction, and
were followed-up for at least 2 weeks post-surgery.

Exclusion Criteria:

a history of muscular-skeletal disorder or inflammatory arthritis,
other combined injury,
a previous hip surgery,
an extensive open reduction of fracture site,
hemodynamic instability,
consumed non-steroid inflammatory drug, steroid, or morphine before treatment, and (7) abnormal preoperative laboratory data, especially anticoagulation data, including prothrombin time, activated partial thromboplastin time (aPTT), and platelet level.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Cheng Kung University Hospital', 'LocationCity': 'Tainan', 'LocationZip': '704', 'LocationCountry': 'Taiwan'}]",,No,"Participants This study protocol was approved by the Institutional Review Board of the National Cheng Kung University Hospital (IRB: B-BR-107-046-T). This single center study was performed between May 2018 and April 2019. All the 60 patients who were treated with a PFNA system (Depuy Synthes®, Proximal Femoral Nail Antirotation (II), Solothurn, Switzerland) were consecutively included. Patients were included in the study if they (1) had an acute (injury less than 2 weeks) proximal femoral fracture, classified as Arbeitsgemeinschaft für Osteosynthesefragen (AO) 31A1, 31A2, and 31A3, (2) were treated with closed reduction or mini-open reduction, and (3) were followed-up for at least 2 weeks post-surgery. Patients were excluded from the study if they had (1) a history of muscular-skeletal disorder or inflammatory arthritis, (2) other combined injury, (3) a previous hip surgery, (4) an extensive open reduction of fracture site, (5) hemodynamic instability, (6) consumed non-steroid inflammatory drug, steroid, or morphine before treatment, and (7) abnormal preoperative laboratory data, especially anticoagulation data, including prothrombin time, activated partial thromboplastin time (aPTT), and platelet level. The investigators established a table of random numbers, which was readily generated by computer 15, and divided participants into the drained and undrained groups based on their arrival time to the investigator's hospital.

Surgery procedure

Experienced trauma surgeons performed all the procedures. General or spinal anesthesia was determined by anesthesiologist. All patients received a single dose of 1 g cefazolin as preoperative prophylactic antibiotic. All the operations were performed on a traction table in supine position under fluoroscopic guidance. Reduction was achieved with closed reduction or mini-open reduction, including percutaneous Kapandji procedure or a minimally invasive procedure using the cerclage wire passer (Cerclage passer, DePuy Synthes, Solothurn, Switzerland). The reduction was regarded acceptable if no significant varus malalignment of the proximal fragment (neck-shaft angle more than 15°) existed or if less than 10 mm of translation existed between the main fragments as described previously. After achieving reduction, the skin was incised 3-5 cm proximal to the tip of the greater trochanter followed by straight longitudinal incision in the fascia of the gluteus muscle. The gluteus maximus muscle was split using the blunt dissection technique to gain access to the tip of the trochanter, which was followed by the insertion of the intramedullary guide wire. A protection drill sleeve was used to the trochanter and progressive reaming was performed until the diameter was 1 mm greater than that of the selected nail. After proximal reaming up to 16 mm, nail was manually inserted up to an adequate depth under fluoroscopic guidance, which was followed by positioning of blade guide wire. The blade was positioned in the center or distal third of the femoral neck on the anteroposterior view and in the middle third of the femoral neck on the lateral view. The blade was inserted and locked with the closure of fracture gap that was followed by application of a distal screw with gig and protection sleeve. End caps were not applied in all the cases because nearly none of the implants were to be removed. In the drained group, a hemovac drain (Zimmer Biomet, Autotransfusion System [HAS], United State) was placed beneath the fascia of the gluteus muscle, surrounding the entry point of the nail at the fracture site. The fascia of the gluteus muscle was repaired with absorbable sutures, Vicryl 1-0. The duration of operation was defined as the interval between the initiation of reduction and the wound closure.

Postoperative care All the patients received a prophylactic antibiotic therapy of 1 g cefazolin every 8 hours for 1 day after surgery. All wounds were covered with a surgical dressing only and wound care was practiced on postoperative days 1, 2, and 4. The drain was removed within 24 hours based on the drainage condition, except when more than 250 ml fluid was drained in 24 hours 2, 12. Hb and Hct were examined on postoperative days 1, 2, and 4. The criterion for postoperative BT was a hemoglobin level of less than 8 mg/dL or presence of symptoms indicative of hypoxia. To control postoperative pain due to the influence of different anesthetic methods, the investigators measured visual analog score (VAS) at rest from postoperative day 1. The basic regimen after surgery was a combination of oral analgesics, acetaminophen and etoricoxib. After receiving the combination therapy, if the VAS score was more than 5, the investigators administered a subcutaneous morphine injection for pain control.

Postoperative rehabilitation All the patients were encouraged to mobilize as early as possible to prevent complications associated with immobilization. Passive rehabilitation, including passive range of motion of the affected lower limb and practice for sitting at the edge of the bed, was initiated on postoperative day 1. Partial weight bearing ambulation and rehabilitation with walker was commenced on postoperative day 2. The extent of weight bearing was adjusted by the surgeon based on the stability of the fracture and the physical strength of the patient. Morphine was administered to patients when required during the rehabilitation period.

Data collection One independent observer who was not involved with the treatment performed the clinical assessments and laboratory data collection during the preoperative and intraoperative periods and on postoperative days 1, 2, and 4 (during admission) and on postoperative day 10 for suture removal.

Primary outcome The investigators defined TBL and BT as primary outcome variables that were calculated in millimeter. TBL was measured using the Mercuriali's formula because of its accuracy, which was based on previous studies. Mercuriali's formula: TBL = blood volume (BV) × (Hct [preop] - Hct [POD 4] + transfused RBC [mL])

Secondary outcome The clinical outcomes included body temperature, VAS (for pain assessment), opioid dosage (morphine equivalent), width of the injured proximal thigh (20 cm distal to the ipsilateral anterior superior iliac spine [ASIS]), wound condition, and the other laboratory data. The wound condition was assessed based on criteria described previously with specific reference to hematoma formation and wound infection. The severity of hematoma surrounding the wound site was classified into 3 grades as follows: none, moderate (ecchymosis without swelling), and severe (ecchymosis with swelling of the wound, resulting in tension on the skin sutures) [Fig. 2]. Wound infection was classified in 2 groups: superficial infection and deep infection. A wound infection was defined as superficial when 3 of the following symptoms occurred: fever, wound discharge, and wound redness, which usually could be controlled with antibiotic prescription. A deep wound infection involved the tissue beneath the fascia of the gluteus muscle and the implant, which usually required debridement or revision. The investigators recorded hemoglobin (Hb) and hematocrit (Hct) levels on postoperative days 1, 2, and 4 as secondary laboratory outcomes.

Statistical analysis The primary objective of the study was to determine whether routine drainage in PFNA fixation for ITFs is useful. Descriptive statistics, including estimated mean and standard deviation, for continuous variables and percentages and frequencies for categorical variables were tabulated and presented. Because the sample size of both the groups was small, a nonparametric method, the Wilcoxon rank-sum test was used for comparing continuous variables and the Fisher's exact test was used to analyze the categorical variables. Box and whisker plots were used to demonstrate the BT and TBL distribution between the drained and undrained groups for intertrochanteric fracture treated with PFNA. All statistical tests were 2-sided and a p value less than 0.05 was considered statistically significant. All statistical analysis was performed with R version 3.6.1 for Windows. The investigators calculated the required sample size that would provide 90% power (α = 0.05) to the trial for detecting the difference in TBL and BT based on previous studies 12, 21. Hence, the investigators enrolled 30 patients in each group.","['Intertrochanteric Fractures', 'Proximal Femoral Nail Antirotation (PFNA)', 'closed suction drainage system']",,,,,,,,,,,['Outcomes Assessor'],,,Undecided,"[{'ReferencePMID': '8583450', 'ReferenceType': 'result', 'ReferenceCitation': 'Varley GW, Milner SA. Wound drains in proximal femoral fracture surgery: a randomized prospective trial of 177 patients. J R Coll Surg Edinb. 1995 Dec;40(6):416-8.'}, {'ReferencePMID': '15589927', 'ReferenceType': 'result', 'ReferenceCitation': 'Tjeenk RM, Peeters MP, van den Ende E, Kastelein GW, Breslau PJ. Wound drainage versus non-drainage for proximal femoral fractures. A prospective randomised study. Injury. 2005 Jan;36(1):100-4.'}, {'ReferencePMID': '24114245', 'ReferenceType': 'result', 'ReferenceCitation': 'Zhou XD, Wu LD. Reply to Comment on Zhou et al.: Do we really need closed-suction drainage in total hip arthroplasty? A meta-analysis. Int Orthop. 2013 Dec;37(12):2531-2. doi: 10.1007/s00264-013-2125-9. Epub 2013 Oct 11.'}]",,,,,,,,,,,,,,,,,,,,,"This single center study was performed between May 2018 and April 2019. All the 60 patients who were treated with a PFNA system (Depuy Synthes®, Proximal Femoral Nail Antirotation (II), Solothurn, Switzerland) were consecutively included. The investigators established a table of random numbers, which was readily generated by computer 15, and divided participants into the drained and undrained groups based on their arrival time to our hospital.","One independent observer who was not involved with the treatment performed the clinical assessments and laboratory data collection during the preoperative and intraoperative periods and on postoperative days 1, 2, and 4 (during admission) and on postoperative day 10 for suture removal.",,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000050723', 'ConditionMeshTerm': 'Fractures, Bone'}, {'ConditionMeshId': 'D000005264', 'ConditionMeshTerm': 'Femoral Fractures'}, {'ConditionMeshId': 'D000006620', 'ConditionMeshTerm': 'Hip Fractures'}]","[{'ConditionAncestorId': 'D000014947', 'ConditionAncestorTerm': 'Wounds and Injuries'}, {'ConditionAncestorId': 'D000007869', 'ConditionAncestorTerm': 'Leg Injuries'}, {'ConditionAncestorId': 'D000025981', 'ConditionAncestorTerm': 'Hip Injuries'}]","[{'ConditionBrowseLeafId': 'M24957', 'ConditionBrowseLeafName': 'Fractures, Bone', 'ConditionBrowseLeafAsFound': 'Fracture', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M6985', 'ConditionBrowseLeafName': 'Femoral Fractures', 'ConditionBrowseLeafAsFound': 'Femur Fracture', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8279', 'ConditionBrowseLeafName': 'Hip Fractures', 'ConditionBrowseLeafAsFound': 'Intertrochanteric Fractures', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16268', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9464', 'ConditionBrowseLeafName': 'Leg Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21689', 'ConditionBrowseLeafName': 'Hip Injuries', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]","[{'InterventionMeshId': 'D000002927', 'InterventionMeshTerm': 'Cimetidine'}]","[{'InterventionAncestorId': 'D000000897', 'InterventionAncestorTerm': 'Anti-Ulcer Agents'}, {'InterventionAncestorId': 'D000005765', 'InterventionAncestorTerm': 'Gastrointestinal Agents'}, {'InterventionAncestorId': 'D000006635', 'InterventionAncestorTerm': 'Histamine H2 Antagonists'}, {'InterventionAncestorId': 'D000006633', 'InterventionAncestorTerm': 'Histamine Antagonists'}, {'InterventionAncestorId': 'D000018494', 'InterventionAncestorTerm': 'Histamine Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000065609', 'InterventionAncestorTerm': 'Cytochrome P-450 CYP1A2 Inhibitors'}, {'InterventionAncestorId': 'D000065607', 'InterventionAncestorTerm': 'Cytochrome P-450 Enzyme Inhibitors'}, {'InterventionAncestorId': 'D000004791', 'InterventionAncestorTerm': 'Enzyme Inhibitors'}]","[{'InterventionBrowseLeafId': 'M4748', 'InterventionBrowseLeafName': 'Cimetidine', 'InterventionBrowseLeafAsFound': 'Subarachnoid Hemorrhage', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2769', 'InterventionBrowseLeafName': 'Antacids', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2800', 'InterventionBrowseLeafName': 'Anti-Ulcer Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7464', 'InterventionBrowseLeafName': 'Gastrointestinal Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8291', 'InterventionBrowseLeafName': 'Histamine', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M219111', 'InterventionBrowseLeafName': 'Histamine phosphate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8294', 'InterventionBrowseLeafName': 'Histamine H2 Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8292', 'InterventionBrowseLeafName': 'Histamine Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M29124', 'InterventionBrowseLeafName': 'Cytochrome P-450 Enzyme Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02848781,IRB15-1739,University of Chicago,OTHER,Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial,PAUSE-SCD: Pan-Asia United States PrEvention of Sudden Cardiac Death Catheter Ablation Trial,Jun-19,Recruiting,No,30-Nov-15,Actual,Feb-21,Anticipated,Feb-23,Anticipated,26-Jul-16,27-Jul-16,28-Jul-16,Estimate,11-Jun-19,13-Jun-19,Actual,Sponsor,University of Chicago,OTHER,,,,,"The current standard of care for ventricular tachycardia (VT) includes the use of medicine called anti-arrhythmic drugs (AADs) and Implantable Cardioverter Defibrillator (ICD) therapy. These treatments are used to terminate the irregular heartbeats and bring the heart back to a normal rhythm. Catheter ablation is a procedure used to eliminate (damage) the heart cells causing the arrhythmia. Patients eligible for this may benefit from an ablation procedure in addition to an ICD to treat their VT condition or risk of developing VT. This study aims to show that treating VT with catheter ablation, if performed preemptively at the time of ICD implantation, will reduce subsequent recurrent VT, ICD shocks, and lead to improved survival.",['Ventricular Tachycardia (VT)'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),180,Anticipated,"[{'ArmGroupLabel': 'ICD with Ablation', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Patient will receive an implantable cardioverter defibrillator (ICD) with catheter ablation and standard medical management.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Implantable Cardioverter Defibrillator (ICD)', 'Procedure: Catheter Ablation']}}, {'ArmGroupLabel': 'ICD Only', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Patient will receive an implantable cardioverter defibrillator (ICD) and standard medical management.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: Implantable Cardioverter Defibrillator (ICD)']}}, {'ArmGroupLabel': 'Ablation Only (Registry)', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'The registry will enroll patients who refuse an implantable cardioverter defibrillator (ICD) and are thus not randomized. This arm will assess the efficacy of catheter ablation in the absence of background ICD therapy.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Catheter Ablation']}}]","[{'InterventionType': 'Device', 'InterventionName': 'Implantable Cardioverter Defibrillator (ICD)', 'InterventionDescription': 'An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['ICD Only', 'ICD with Ablation']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Catheter Ablation', 'InterventionDescription': ""Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm."", 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ablation Only (Registry)', 'ICD with Ablation']}}]","[{'PrimaryOutcomeMeasure': 'Freedom from recurrent VT, cardiovascular rehospitalization, and all-cause mortality', 'PrimaryOutcomeDescription': 'The primary endpoint is a composite.', 'PrimaryOutcomeTimeFrame': '2 years'}]","[{'SecondaryOutcomeMeasure': 'Freedom from recurrent VT', 'SecondaryOutcomeDescription': 'Recurrent VT is defined as any appropriate ICD therapy (shock or ATP) or documented sustained monomorphic VT >30 seconds.', 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'Freedom from cardiovascular rehospitalization', 'SecondaryOutcomeDescription': 'Cardiovascular rehospitalization is defined as a hospital admission after the randomized procedure for heart failure, procedure-associated complication, or arrhythmia-related causes during the follow-up period.', 'SecondaryOutcomeTimeFrame': '2 years'}, {'SecondaryOutcomeMeasure': 'Freedom from all-cause mortality', 'SecondaryOutcomeTimeFrame': '2 years'}]","Inclusion Criteria:

Patient is receiving a new implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy device (CRT-D) implant that has study required programing capabilities and is appropriate for remote monitoring. Patient who has received the ICD / CRT-D within 90 days of enrollment can also be enrolled.

Patient who has a high risk of ICD shock as shown by documented Monomorphic VT (MMVT) by one or more of the following:

Spontaneous MMVT
Inducible MMVT during electrophysiology study,
Inducible MMVT during noninvasive programmed stimulation study *Inducible MMVT is defined as MMVT > 30 seconds or requiring electrical termination (ATP or cardioversion)
Patient has ejection fraction < 50% or right ventricular dysfunction
Patient has a cardiomyopathy with structural heart disease of any cause

Exclusion Criteria:

Any history of debilitating stroke with neurologic deficit
ST-segment elevation myocardial infarction or previous cardiac surgery within 60 days prior to enrollment
Patient is pregnant or nursing
Patient has chronic New York Heart Association (NYHA) class IV heart failure
Patient has incessant VT necessitating immediate treatment
Patient has ventricular tachycardia/ventricular fibrillation thought to be from channelopathies
Limited life expectancy (less than one year)
Patient has current class IV angina
Recent coronary artery bypass graft or percutaneous coronary intervention (< 45 days)
Patient is currently participating in another investigational drug or device study
Known presence of intracardiac thrombi
Prosthetic mitral or aortic valve or mitral or aortic valvular heart disease requiring immediate surgical intervention
Major contraindication to anticoagulation therapy or coagulation disorder
Left Ventricular Ejection Fraction < 15%
Patient has had a previous ablation procedure for VT, excluding remote (> 3 months) outflow tract tachycardia
Patient has glomerular filtration rate (GFR) < 30 mL/min/1.73m2
Patient has peripheral vascular disease that precludes left ventricular access
Patient is thought to have idiopathic outflow VT as only VT
Patient has a premature ventricular contraction (PVC) or VT induced cardiomyopathy that is expected to resolve with ablation and will not require an ICD
Patient has reversible cause of VT
Patient does not meet criteria for ICD or CRT-D",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Fuwai Cardiovascular Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Beijing', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Yao Yan, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Huaxi Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chengdu', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jiang Jian, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Guangdong General Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Guangzhou', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shulin Wu, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Sir Run Run Shaw Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hangzhou', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Chenyang Jiang, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Nanjing First Affiliated Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Nanjing', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Minglong Chen, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'PLA Shenyang General Hospital', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Shenyang', 'LocationCountry': 'China', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Zulu Wang, MD, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Dokkyo Medical University, Saitama Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Saitama', 'LocationCountry': 'Japan', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shiro Nakahara, MD, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Kyorin University Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tokyo', 'LocationCountry': 'Japan', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Akiko Ueda, MD, PhD', 'LocationContactRole': 'Contact'}, {'LocationContactName': 'Kyoko Soejima, MD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Tsukuba University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tsukuba', 'LocationCountry': 'Japan', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Akihiko Nogami, MD, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Korea University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Seoul', 'LocationCountry': 'Korea, Republic of', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Young Hoon Kim, MD, PhD', 'LocationContactRole': 'Contact'}]}}, {'LocationFacility': 'Taipei Veterans General Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Taipei', 'LocationCountry': 'Taiwan', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shih-Ann Chen, MD', 'LocationContactRole': 'Contact'}]}}]","[{'CollaboratorName': 'Abbott Medical Devices', 'CollaboratorClass': 'INDUSTRY'}]",No,"Subjects who meet inclusion/exclusion criteria will be entered into the randomized trial. Randomization will be 1:1 between control group and ablation group. Those randomized to the control group will receive ICD therapy and routine drug therapy (including antiarrhythmic drugs as indicated). Subjects randomized to the ablation group will receive ablation therapy plus ICD for ventricular tachycardia. Patients that refuse ICD therapy and undergo ablation only will be enrolled in a prospective registry.

Follow-up will be performed prior to hospital discharge for incision check and device interrogation as is standard of care. In addition, routine device and clinical follow-up will be scheduled at 1, 3, 6, 12, 18, and 24 months. Electrocardiography (ECG) will be performed pre-implant and prior to hospital discharge. Echocardiography (TTE) will be performed pre-implant and at 12 and 24 months.

Patients that refuse ICD implantation will not be randomized and will be approached for inclusion into a registry if they undergo catheter ablation without an ICD. Basic demographics and medical history will be collected from registry subjects upon enrollment. Registry subjects will receive follow-up for routine clinical care every 6 months to check on their overall status.

120 subjects will be randomized. An additional 60 subjects will enrolled into the registry.

As of the time protocol revision C changes were made (07Nov2016), 33 subjects have been randomized. There has not been any preliminary or interim analysis of any data at this point. The study-sponsor has not had any access to any clinical follow-up for the patients enrolled to date.","['Sudden Cardiac Death', 'ICD Therapy', 'VT Ablation']",,,,,,,PAUSE-SCD,,,,,"[{'OtherOutcomeMeasure': 'Comparison of outcomes in ablation only registry with randomized patients', 'OtherOutcomeTimeFrame': '2 years'}]","[{'OverallOfficialName': 'Roderick Tung, MD', 'OverallOfficialAffiliation': 'University of Chicago', 'OverallOfficialRole': 'Study Director'}]",No,"[{'ReferencePMID': '31698933', 'ReferenceType': 'derived', 'ReferenceCitation': 'Kheiri B, Barbarawi M, Zayed Y, Hicks M, Osman M, Rashdan L, Kyi HH, Bachuwa G, Hassan M, Stecker EC, Nazer B, Bhatt DL. Antiarrhythmic Drugs or Catheter Ablation in the Management of Ventricular Tachyarrhythmias in Patients With Implantable Cardioverter-Defibrillators: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Circ Arrhythm Electrophysiol. 2019 Nov;12(11):e007600. doi: 10.1161/CIRCEP.119.007600. Epub 2019 Nov 8.'}]",,,,,,"[{'CentralContactName': 'Roderick Tung, MD', 'CentralContactRole': 'Contact', 'CentralContactPhone': '773-834-0455', 'CentralContactEMail': 'rodericktung@uchicago.edu'}]",,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000013610', 'ConditionMeshTerm': 'Tachycardia'}, {'ConditionMeshId': 'D000017180', 'ConditionMeshTerm': 'Tachycardia, Ventricular'}, {'ConditionMeshId': 'D000016757', 'ConditionMeshTerm': 'Death, Sudden, Cardiac'}, {'ConditionMeshId': 'D000003643', 'ConditionMeshTerm': 'Death'}]","[{'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000001145', 'ConditionAncestorTerm': 'Arrhythmias, Cardiac'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000075224', 'ConditionAncestorTerm': 'Cardiac Conduction System Disease'}, {'ConditionAncestorId': 'D000006323', 'ConditionAncestorTerm': 'Heart Arrest'}, {'ConditionAncestorId': 'D000003645', 'ConditionAncestorTerm': 'Death, Sudden'}]","[{'ConditionBrowseLeafId': 'M14967', 'ConditionBrowseLeafName': 'Tachycardia', 'ConditionBrowseLeafAsFound': 'Tachycardia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M18071', 'ConditionBrowseLeafName': 'Tachycardia, Ventricular', 'ConditionBrowseLeafAsFound': 'Ventricular Tachycardia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17701', 'ConditionBrowseLeafName': 'Death, Sudden, Cardiac', 'ConditionBrowseLeafAsFound': 'Sudden Cardiac Death', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5428', 'ConditionBrowseLeafName': 'Death', 'ConditionBrowseLeafAsFound': 'Cardiac Death', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5430', 'ConditionBrowseLeafName': 'Death, Sudden', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3034', 'ConditionBrowseLeafName': 'Arrhythmias, Cardiac', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M1472', 'ConditionBrowseLeafName': 'Cardiac Conduction System Disease', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7994', 'ConditionBrowseLeafName': 'Heart Arrest', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00385047,WRAIR 1280,U.S. Army Medical Research and Development Command,FED,"A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults","Phase I/IIa Study of the Safety, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge of FMP2.1/AS01B and FMP2.1/AS02A Candidate Malaria Vaccines Administered Intramuscularly at Months 0, 1, and 2 in Malaria-naive Adults Living in the United States",Jun-15,Completed,No,Sep-06,,Apr-07,Actual,Sep-07,Actual,04-Oct-06,04-Oct-06,06-Oct-06,Estimate,04-Jun-15,08-Jun-15,Estimate,Sponsor,U.S. Army Medical Research and Development Command,FED,,,,,The purpose of this study is to determine whether 2 investigational malaria vaccines are safe as well as protective against malaria in adults living in the United States,['Malaria'],Interventional,"['Phase 1', 'Phase 2']",Randomized,Parallel Assignment,Prevention,Quadruple,41,Actual,"[{'ArmGroupLabel': 'Group A', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'FMP 2.1 50 μg FMP2.1/AS01B', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Group A FMP2.1/AS01B']}}, {'ArmGroupLabel': 'Group B', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'FMP 2.1 50 μg FMP2.1/AS02A', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Group B FMP2.1/AS02A']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Group A FMP2.1/AS01B', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group A']}, 'InterventionOtherNameList': {'InterventionOtherName': ['FMP 2.1 50 μg FMP2.1/AS01B']}}, {'InterventionType': 'Biological', 'InterventionName': 'Group B FMP2.1/AS02A', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Group B']}, 'InterventionOtherNameList': {'InterventionOtherName': ['FMP 2.1 50 μg FMP2.1/AS02A']}}]","[{'PrimaryOutcomeMeasure': 'Number of adverse events', 'PrimaryOutcomeTimeFrame': 'Up to 1 year'}]","[{'SecondaryOutcomeMeasure': 'Anti-AMA-1 antibody titers during Immunization Phase', 'SecondaryOutcomeTimeFrame': 'Up to 70 days'}, {'SecondaryOutcomeMeasure': 'Anti-AMA-I antibody titers during Challenge Phase', 'SecondaryOutcomeTimeFrame': 'Up to 90 days'}, {'SecondaryOutcomeMeasure': 'Anti-AMA-I antibodies as percent parasite growth inhibition during Immunization Phase', 'SecondaryOutcomeTimeFrame': 'Up to 70 days'}, {'SecondaryOutcomeMeasure': 'Anti-AMA-I antibodies as percent parasite growth inhibition during Challenge Phase', 'SecondaryOutcomeTimeFrame': 'Up to 90 days'}, {'SecondaryOutcomeMeasure': 'Time to parasitemia development after primary challenge following administration of the FMP2.l/ASOIB and FMP2.l /AS02A', 'SecondaryOutcomeTimeFrame': 'Up to 1 Year'}]","Inclusion Criteria:

A male or non-pregnant female 18 to 50 years of age (inclusive) at the time of screening
Written informed consent obtained from the participant before screening procedures
Free of clinically significant health problems as established by medical history and clinical examination before entering into the study*
Available to participate for duration of study (approximately five months, not including screening)
If the participant is female, she must be of non-childbearing potential, i.e., either surgically sterilized or one year post-menopausal; or, if of childbearing potential, she must be abstinent or have used adequate contraceptive precautions (e.g., intrauterine contraceptive device; oral contraceptives; diaphragm or condom in combination with contraceptive jelly, cream or foam; Norplant® or Depo-Provera®) during this study, have a negative pregnancy test at the time of each immunization, and must agree to continue such precautions for two months after completion of the immunization series and the malaria challenge.
Prior to entry into this study, participants must score at least 80% correct on a short multiple-choice quiz that assesses their understanding of this study. If they do not score 80% on the initial quiz, the protocol information will be reviewed with them to ensure comprehension and they will have the opportunity to retest. Participants who fail the Comprehension Assessment for the second time will not be enrolled.

Exclusion Criteria:

Prior receipt of an investigational malaria vaccine
Use of any investigational or non-registered drug or vaccine other than the study vaccine(s) within 30 days preceding the first study immunization or planned use during the study period, or receipt of investigational vaccine containing 3-D MPL and/or QS-21 at any time in the past (Have you received an experimental vaccine with a GSK adjuvant in the past?)
Administration of chronic (defined as more than 14 days) immunosuppressants or other immune-modifying drugs within six months of immunization. (For corticosteroids, this will mean prednisone, or equivalent, greater than or equal to 0.5 mg/kg/day. Inhaled and topical steroids are allowed.)
Chronic use of antibiotics with anti-malarial effects (e.g., tetracyclines for dermatologic patients, sulfa for recurrent urinary tract infections, etc.)
Planned administration of a vaccine not foreseen by the study protocol 30 days prior to or after the first immunization
History of malaria chemoprophylaxis within 60 days prior to immunization
Any history of malaria
Known exposure to malaria within the previous 12 months
Planned travel to malarious areas during the study period
Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection
History of allergic disease or reactions to any vaccine
Chronic or active neurologic disorders including seizures, excluding a single febrile seizure as a child
History of splenectomy
Acute disease at the time of enrollment (Acute disease is defined as the presence of a moderate or severe illness with or without fever. All vaccines can be administered to persons with a minor illness such as diarrhea, mild upper respiratory infection with or without low-grade febrile illness, i.e., oral temperature < 37.5°C/99.5°F).
Acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests
Personal medical histories including the following diagnoses: systemic lupus erythematosus, rheumatoid arthritis, mixed connective tissue disease, scleroderma, vasculitis, and multiple sclerosis
Seropositive for hepatitis B surface antigen or hepatitis C antibody
Hepatomegaly, right upper quadrant abdominal pain or tenderness
Elevated serum creatinine, defined in this study as greater than or equal to 1.7 mg/dL in males and 1.4 mg/dL in females
Significant unexplained anemia: hematocrit < 35%
Administration of immunoglobulins and/or any blood products within the three months preceding the first study immunization or planned administration during the study period
Pregnant or lactating female or female who intends to become pregnant during the study
Suspected or known current alcohol abuse as defined by the American Psychiatric Association in DSM IV (Diagnostic and Statistical Manual of Mental Disorders- 4th edition)
Chronic or active illicit and/or intravenous drug use
History of severe anaphylactic reactions to mosquito bites
History of psoriasis (given its interaction with chloroquine)
Any history of anaphylaxis in reaction to immunization
History of allergy to nickel, imidazole or tetracycline group of antibiotics
History of sickle cell disease or sickle cell trait
Any other significant finding that in the opinion of the investigator would increase the risk of having an adverse outcome from participating in this study",Accepts Healthy Volunteers,All,18 Years,50 Years,['Adult'],"[{'LocationFacility': 'Clinical Trials Center, Walter Reed Army Institute of Research', 'LocationCity': 'Silver Spring', 'LocationState': 'Maryland', 'LocationZip': '20910', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'The PATH Malaria Vaccine Initiative (MVI)', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'GlaxoSmithKline', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'United States Agency for International Development (USAID)', 'CollaboratorClass': 'FED'}]",No,"35 volunteers aged 18 to 50 years will be enrolled to receive one of 2 investigational malaria vaccines. The vaccines are made of a malaria protein FMP2.1 mixed in 2 different adjuvants (AS01B and AS02A). Five volunteers will get a small (10 µg) dose of FMP2.1/AS01B since this vaccine has not yet been in humans. If it is safe, then 15 volunteers will get 50 µg FMP2.1 in AS02A and 15 will get 50 µg FMP2.1 in AS01B. All vaccines are given IM in the deltoid of the non-dominant arm, every 1 month for 3 months. After vaccination, the subjects will follow up at clinical trials for evaluation of any adverse events.

20 vaccinees (10 from each 50 µg vaccine group) will undergo primary sporozoite challenge 14-30 days after dose 3 via bite of 5 malaria-infected mosquitoes. All subjects will have a blood slide prepared and read to check for asexual P. falciparum parasitemia at least once daily beginning day 5 post challenge. Beginning on day 10 post challenge, subjects will check into a designated hotel, where 24 hour evaluation and care will be available for 10 nights. After this hotel phase, there will be follow-up visits to ensure there are no late developments of malaria in those who have not fallen ill (and thus are considered protected).

Any subject who tests positive for malaria will be treated with chloroquine. Efficacy readouts are complete protection or significant delay in patency defined as >2 days than the median prepatent period for the 6 infectivity controls. These 6 controls receive no vaccine and are enrolled for malaria-challenge only in order to provide comparison group for vaccinated individuals.","['malaria', 'vaccine', 'AMA-1 (apical membrane antigen-1)', 'efficacy']",,,,,,"[{'SecondaryId': 'A-13949', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'WRAIR Protocol ID'}, {'SecondaryId': 'ETrack Protocol No. 104936', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'E-Track'}, {'SecondaryId': 'MAL-045', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'GSK'}, {'SecondaryId': '#20060900', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Internal'}]",,,,,"['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']",,"[{'OverallOfficialName': 'Michele D. Spring, MD, M.S.P.H.', 'OverallOfficialAffiliation': 'Walter Reed Army Institute of Research (WRAIR)', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '12011004', 'ReferenceType': 'background', 'ReferenceCitation': 'Dutta S, Lalitha PV, Ware LA, Barbosa A, Moch JK, Vassell MA, Fileta BB, Kitov S, Kolodny N, Heppner DG, Haynes JD, Lanar DE. Purification, characterization, and immunogenicity of the refolded ectodomain of the Plasmodium falciparum apical membrane antigen 1 expressed in Escherichia coli. Infect Immun. 2002 Jun;70(6):3101-10.'}, {'ReferencePMID': '19390585', 'ReferenceType': 'derived', 'ReferenceCitation': 'Spring MD, Cummings JF, Ockenhouse CF, Dutta S, Reidler R, Angov E, Bergmann-Leitner E, Stewart VA, Bittner S, Juompan L, Kortepeter MG, Nielsen R, Krzych U, Tierney E, Ware LA, Dowler M, Hermsen CC, Sauerwein RW, de Vlas SJ, Ofori-Anyinam O, Lanar DE, Williams JL, Kester KE, Tucker K, Shi M, Malkin E, Long C, Diggs CL, Soisson L, Dubois MC, Ballou WR, Cohen J, Heppner DG Jr. Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A. PLoS One. 2009;4(4):e5254. doi: 10.1371/journal.pone.0005254. Epub 2009 Apr 23.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008288', 'ConditionMeshTerm': 'Malaria'}]","[{'ConditionAncestorId': 'D000011528', 'ConditionAncestorTerm': 'Protozoan Infections'}, {'ConditionAncestorId': 'D000010272', 'ConditionAncestorTerm': 'Parasitic Diseases'}]","[{'ConditionBrowseLeafId': 'M9863', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12971', 'ConditionBrowseLeafName': 'Protozoan Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11768', 'ConditionBrowseLeafName': 'Parasitic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3576', 'ConditionBrowseLeafName': 'Malaria', 'ConditionBrowseLeafAsFound': 'Malaria', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC03', 'ConditionBrowseBranchName': 'Parasitic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02993120,20150230,Amgen,INDUSTRY,Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States,Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States,Aug-20,"Active, not recruiting",No,06-Dec-16,Actual,06-Jul-21,Anticipated,06-Jul-21,Anticipated,02-Dec-16,12-Dec-16,15-Dec-16,Estimate,21-Aug-20,25-Aug-20,Actual,Sponsor,Amgen,INDUSTRY,,,,,"This is a multicenter observational cohort study with both retrospective and prospective data collection components in subjects with ASCVD.

The purpose of this study is to better understand cholesterol treatment patterns in the context of a changing landscape in subjects with ASCVD.","['Medical Conditions to be Studied', 'Dyslipidemia', 'ASCVD Management']",Observational,,,,,,5006,Actual,"[{'ArmGroupLabel': 'Cohort 1', 'ArmGroupDescription': 'For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary.'}, {'ArmGroupLabel': 'Cohort 2', 'ArmGroupDescription': '• For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥100 mg/dL with no change in LLT for 4 weeks.'}, {'ArmGroupLabel': 'Cohort 3', 'ArmGroupDescription': 'For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks'}]",,"[{'PrimaryOutcomeMeasure': 'Low-density lipoprotein (LDL) treatment patterns', 'PrimaryOutcomeDescription': 'Describe low-density lipoprotein (LDL) treatment patterns over time in subjects with clinical ASCVD', 'PrimaryOutcomeTimeFrame': 'Through study completion, an average of 3 years'}]","[{'SecondaryOutcomeMeasure': 'LDL-C levels and measurement patterns', 'SecondaryOutcomeDescription': 'Describe LDL-C levels and measurement patterns in subjects with clinical ASCVD', 'SecondaryOutcomeTimeFrame': 'Through study completion, an average of 3 years'}, {'SecondaryOutcomeMeasure': 'Subject Characteristics', 'SecondaryOutcomeDescription': 'Describe subject characteristics', 'SecondaryOutcomeTimeFrame': 'Through study completion, an average of 3 years'}, {'SecondaryOutcomeMeasure': 'Subject understanding of CV risk', 'SecondaryOutcomeDescription': 'Describe subject understanding of CV risk', 'SecondaryOutcomeTimeFrame': 'Through study completion, an average of 3 years'}, {'SecondaryOutcomeMeasure': 'Goals of Lipid Management', 'SecondaryOutcomeDescription': 'Describe subject goals of lipid management', 'SecondaryOutcomeTimeFrame': 'Through study completion, an average of 3 years'}, {'SecondaryOutcomeMeasure': 'Attitudes towards lipid lowering treatment (LLT)', 'SecondaryOutcomeDescription': 'Describe subject attitudes towards lipid lowering treatment (LLT)', 'SecondaryOutcomeTimeFrame': 'Through study completion, an average of 3 years'}, {'SecondaryOutcomeMeasure': 'Percentage of Subjects Achieving Pre-Specified Levels Low-Density Lipoprotein Cholesterol (LDL-C) Before and After Educational Intervention', 'SecondaryOutcomeDescription': 'The two levels of LDL-C that will be assessed are < 70 mg/dL and < 55 mg/dL.', 'SecondaryOutcomeTimeFrame': 'Up to 1 Year'}, {'SecondaryOutcomeMeasure': 'Number of Subjects who Experience an Intensification in Lipid-Lowering Therapy Before and After Educational Intervention', 'SecondaryOutcomeTimeFrame': 'Up to 1 Year'}, {'SecondaryOutcomeMeasure': 'Percentage of Subjects on Optimal Medical Therapy Before and After Educational Intervention', 'SecondaryOutcomeTimeFrame': 'Up to 1 Year'}, {'SecondaryOutcomeMeasure': 'Percentage of Physicians Stating a Specific Lipid Treatment Objective Before and After Educational Intervention', 'SecondaryOutcomeTimeFrame': 'Up to 1 Year'}]","Inclusion Criteria:

Subject

≥ 18 years of age at signing of informed consent
Undergoing treatment with a statin or other non-statin lipid lowering medication
at least 1 planned visit in the next 12 months
available for follow-up questionnaires

established ASCVD defined as meeting at least 1 of the following criteria:

coronary artery disease
prior history of myocardial infarction
coronary or other arterial revascularization
ischemic stroke or transient ischemic attack
documented peripheral arterial disease secondary to atherosclerosis (eg., aortic aneurysm, ankle brachial index < 0.9, imaging evidence of > 50% stenosis in any peripheral artery, or intermittent claudication)
carotid artery stenosis
LDL-C levels>69 mg/dL except in subjects assigned to the PCSK9i cohort Cohorts
Cohorts are assigned based upon most recent LDL-C level prior to enrollment
For the cohort of approximately 500 subjects taking a PCSK9i at baseline: proof consisting of a current prescription for an approved PCSK9i and subject confirmation that they have taken a PCSK9i within 30 days prior to enrollment is necessary
For the cohort of approximately 2000 subjects with LDL-C ≥ 100 mg/dL: confirmation of LDL-C ≥ 100 mg/dL with no change in LLT for 4 weeks.
For the cohort of approximately 2500 subjects with LDL-C 70-99 mg/dL: confirmation of LDL-C 70-99 mg/dL with no change in LLT for 4 weeks.

Exclusion Criteria:

Subject

Unable or unwilling to provide informed consent including but not limited to cognitive or language barriers
Current or planned participation in an interventional clinical study involving any investigational medical device or drug treatment at the time of enrollment or in the 6 months prior to enrollment. Subjects who chose to participate in an interventional clinical study of either device or drug treatment after enrollment will be removed from the GOULD study
Life expectancy < 12 months
Currently pregnant, breast feeding, or planning to become pregnant* *While subjects that are pregnant are not eligible for the study, if a site investigator has a subject that becomes pregnant while receiving evolocumab, they will be advised to refer the subject to Amgen's evolocumab pregnancy registry",No,All,18 Years,99 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'Research Site', 'LocationCity': 'Chandler', 'LocationState': 'Arizona', 'LocationZip': '85224', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Glendale', 'LocationState': 'Arizona', 'LocationZip': '85306', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85712', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85741', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85745', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Canoga Park', 'LocationState': 'California', 'LocationZip': '91303', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Cerritos', 'LocationState': 'California', 'LocationZip': '90703', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90048', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Oxnard', 'LocationState': 'California', 'LocationZip': '93030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Rancho Mirage', 'LocationState': 'California', 'LocationZip': '92270', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95823', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Wildomar', 'LocationState': 'California', 'LocationZip': '92595', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Colorado Springs', 'LocationState': 'Colorado', 'LocationZip': '80906', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Colorado Springs', 'LocationState': 'Colorado', 'LocationZip': '80909', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Lafayette', 'LocationState': 'Colorado', 'LocationZip': '80026', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Bloomfield', 'LocationState': 'Connecticut', 'LocationZip': '06002', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Bridgeport', 'LocationState': 'Connecticut', 'LocationZip': '06610', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Hartford', 'LocationState': 'Connecticut', 'LocationZip': '06102', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Stamford', 'LocationState': 'Connecticut', 'LocationZip': '06905', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Boca Raton', 'LocationState': 'Florida', 'LocationZip': '33434', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Brandon', 'LocationState': 'Florida', 'LocationZip': '33511', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Brooksville', 'LocationState': 'Florida', 'LocationZip': '34601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Daytona Beach', 'LocationState': 'Florida', 'LocationZip': '32114', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Hollywood', 'LocationState': 'Florida', 'LocationZip': '33021', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Homestead', 'LocationState': 'Florida', 'LocationZip': '33030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Jacksonville Beach', 'LocationState': 'Florida', 'LocationZip': '32250', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32256', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32277', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami Beach', 'LocationState': 'Florida', 'LocationZip': '33140', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33015', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33122', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33126', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33135', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33155', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33165', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Naples', 'LocationState': 'Florida', 'LocationZip': '34102', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Pembroke Pines', 'LocationState': 'Florida', 'LocationZip': '33028', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Pensacola', 'LocationState': 'Florida', 'LocationZip': '32504', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Rockledge', 'LocationState': 'Florida', 'LocationZip': '32955', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Winter Park', 'LocationState': 'Florida', 'LocationZip': '32792', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Cumming', 'LocationState': 'Georgia', 'LocationZip': '30041', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Smyrna', 'LocationState': 'Georgia', 'LocationZip': '30082', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Boise', 'LocationState': 'Idaho', 'LocationZip': '83712', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': ""Coeur d'Alene"", 'LocationState': 'Idaho', 'LocationZip': '83814', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Meridian', 'LocationState': 'Idaho', 'LocationZip': '83642', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Nampa', 'LocationState': 'Idaho', 'LocationZip': '83686', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Arlington Heights', 'LocationState': 'Illinois', 'LocationZip': '60005', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60604', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60637', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Evanston', 'LocationState': 'Illinois', 'LocationZip': '60201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Morton', 'LocationState': 'Illinois', 'LocationZip': '61550', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Evansville', 'LocationState': 'Indiana', 'LocationZip': '47713', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Michigan City', 'LocationState': 'Indiana', 'LocationZip': '46360', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Davenport', 'LocationState': 'Iowa', 'LocationZip': '52803', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Des Moines', 'LocationState': 'Iowa', 'LocationZip': '50309', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Covington', 'LocationState': 'Kentucky', 'LocationZip': '41011', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Alexandria', 'LocationState': 'Louisiana', 'LocationZip': '71301', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Eunice', 'LocationState': 'Louisiana', 'LocationZip': '70535', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Monroe', 'LocationState': 'Louisiana', 'LocationZip': '71201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Portland', 'LocationState': 'Maine', 'LocationZip': '04101', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Elkridge', 'LocationState': 'Maryland', 'LocationZip': '21075', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Great Barrington', 'LocationState': 'Massachusetts', 'LocationZip': '01230', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Natick', 'LocationState': 'Massachusetts', 'LocationZip': '01760', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Worcester', 'LocationState': 'Massachusetts', 'LocationZip': '01655', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Alpena', 'LocationState': 'Michigan', 'LocationZip': '49707', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48236', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Flint', 'LocationState': 'Michigan', 'LocationZip': '48504', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Grand Rapids', 'LocationState': 'Michigan', 'LocationZip': '49546', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Lansing', 'LocationState': 'Michigan', 'LocationZip': '48912', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Coon Rapids', 'LocationState': 'Minnesota', 'LocationZip': '55433', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55407', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Port Gibson', 'LocationState': 'Mississippi', 'LocationZip': '39150', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Columbia', 'LocationState': 'Missouri', 'LocationZip': '65212', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Saint Louis', 'LocationState': 'Missouri', 'LocationZip': '63141', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Lincoln', 'LocationState': 'Nebraska', 'LocationZip': '68510', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Lincoln', 'LocationState': 'Nebraska', 'LocationZip': '68526', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68144', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Las Vegas', 'LocationState': 'Nevada', 'LocationZip': '89117', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Cedar Knolls', 'LocationState': 'New Jersey', 'LocationZip': '07927', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Albany', 'LocationState': 'New York', 'LocationZip': '12206', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Buffalo', 'LocationState': 'New York', 'LocationZip': '14215', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Kingston', 'LocationState': 'New York', 'LocationZip': '12401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '14642', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Greensboro', 'LocationState': 'North Carolina', 'LocationZip': '27401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Wilmington', 'LocationState': 'North Carolina', 'LocationZip': '28401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Winston-Salem', 'LocationState': 'North Carolina', 'LocationZip': '27157', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Fargo', 'LocationState': 'North Dakota', 'LocationZip': '58103', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43205', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43214', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43231', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Dayton', 'LocationState': 'Ohio', 'LocationZip': '45406', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Downingtown', 'LocationState': 'Pennsylvania', 'LocationZip': '19335', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Doylestown', 'LocationState': 'Pennsylvania', 'LocationZip': '18901', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Jersey Shore', 'LocationState': 'Pennsylvania', 'LocationZip': '17740', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Levittown', 'LocationState': 'Pennsylvania', 'LocationZip': '19056', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Wynnewood', 'LocationState': 'Pennsylvania', 'LocationZip': '19096', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Providence', 'LocationState': 'Rhode Island', 'LocationZip': '02906', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Providence', 'LocationState': 'Rhode Island', 'LocationZip': '02908', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationZip': '29412', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Greer', 'LocationState': 'South Carolina', 'LocationZip': '29651', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Murrells Inlet', 'LocationState': 'South Carolina', 'LocationZip': '29576', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Summerville', 'LocationState': 'South Carolina', 'LocationZip': '29485', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Oak Ridge', 'LocationState': 'Tennessee', 'LocationZip': '37830', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75235', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77061', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Humble', 'LocationState': 'Texas', 'LocationZip': '77338', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Kingwood', 'LocationState': 'Texas', 'LocationZip': '77339', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Lufkin', 'LocationState': 'Texas', 'LocationZip': '75904', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'McKinney', 'LocationState': 'Texas', 'LocationZip': '75071', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Mesquite', 'LocationState': 'Texas', 'LocationZip': '75149', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Missouri City', 'LocationState': 'Texas', 'LocationZip': '77459', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Sugar Land', 'LocationState': 'Texas', 'LocationZip': '77478', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Tomball', 'LocationState': 'Texas', 'LocationZip': '77375', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Hopewell', 'LocationState': 'Virginia', 'LocationZip': '23860', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23510', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Winchester', 'LocationState': 'Virginia', 'LocationZip': '22601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Research Site', 'LocationCity': 'Bellevue', 'LocationState': 'Washington', 'LocationZip': '98004', 'LocationCountry': 'United States'}]",,No,"This is a prospective multicenter observational cohort study with retrospective component/chart review of ASCVD subjects that is designed to describe practice patterns of cholesterol management in such subjects in the US. Up to 1 year of retrospective lipid treatment, lipid measurement patterns, and CV data in subjects with ASCVD meeting inclusion/exclusion criteria at enrolled clinical sites will be captured. The retrospective data collection is being performed for the following reasons:

Capture relevant factors related to subject's CV risk and pertinent medical history.

Capture changes in LLT over time as related to the subject's clinical condition and medical history and adverse events to LLT Eligible subjects will be invited to enroll in chronological order of attending the clinic. The study will enroll 3 subject cohorts with the following rationale:

the first cohort will consist of approximately 500 subjects on PCSK9i at the time of enrollment. The goal is to include a large enough cohort of patients receiving PCSK9i in real world clinical practice; this will allow (for the first time) to better understand the characteristics of those patients whose treatment is escalated to include PCSK9i, the therapeutic effects of PCSK9i outside of the randomized clinical trial settings, and over a prolonged duration of follow up;
the second cohort will enroll approximately 2000 subjects with LDL-C levels greater than or equal to 100 mg/dL. The purpose is to include a large group of patients with established ASCVD and suboptimal LDL control in order to better understand the treatment patterns and rates of CV events in this group;
the third group will enroll approximately 2500 subjects with LDL-C levels between 70 and 99 mg/dL. The purpose is to include a large group of patients with established ASCVD and more optimal control of LDL.
To better understand patient characteristics, lipid-lowering treatment management, rates of CV events, and potential opportunities for further LLT optimization in this group. Interactive voice response system will be used to track the number of subjects in each cohort. Once a cohort is filled, no more subjects may be enrolled into it. After the first subject is enrolled and annually thereafter, physicians will fill out a questionnaire on their general use of LLT type and dose and their overall goals of lipid management. The study specific data collection points are aligned with the standard of care physician scheduled visits. Each subject will be followed through a systematic series of medical chart reviews conducted at participating clinical sites. Initial chart reviews will occur at subject enrollment with subsequent scanning of charts occurring at the site every 6 months thereafter. In addition, questionnaires will be administered to subjects every 6 months via a CATI system (wherein an interviewer will ask the subject a series of standard questions) to determine general perceptions and attitudes towards LLT. The order of questions in the questionnaire will be based on subject response. This will facilitate reports of the number of inpatient visits, outpatient visits, outpatient procedures, diagnostic tests, prescription and nonprescription medication use in the prior 6 months. Subjects will be asked to complete questionnaires even if they do not routinely see the enrolling physician or if they have switched providers.",,No,['Cohort'],['Other'],"Adults (18-44 years)
Adults (45-64 years)
Adults (65-74 years)
Adults (75 years and older)
Sex: Male and Female",Probability Sample,,,,,,,,"[{'OverallOfficialName': 'MD', 'OverallOfficialAffiliation': 'Amgen', 'OverallOfficialRole': 'Study Director'}]",Yes,"[{'ReferencePMID': '31174429', 'ReferenceType': 'background', 'ReferenceCitation': 'Arnold SV, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Mues KE, Alam S, Elliott-Davey M, Bhatt DL, Cannon CP, Kosiborod M; GOULD Investigators. Use of Guideline-Recommended Risk Reduction Strategies Among Patients With Diabetes and Atherosclerotic Cardiovascular Disease. Circulation. 2019 Aug 13;140(7):618-620. doi: 10.1161/CIRCULATIONAHA.119.041730. Epub 2019 Jun 7.'}, {'ReferencePMID': '31726422', 'ReferenceType': 'derived', 'ReferenceCitation': 'Cannon CP, de Lemos JA, Rosenson RS, Ballantyne CM, Liu Y, Yazdi D, Elliott-Davey M, Mues KE, Bhatt DL, Kosiborod MN; GOULD Investigators. Getting to an ImprOved Understanding of Low-Density Lipoprotein-Cholesterol and Dyslipidemia Management (GOULD): Methods and baseline data of a registry of high cardiovascular risk patients in the United States. Am Heart J. 2020 Jan;219:70-77. doi: 10.1016/j.ahj.2019.10.014. Epub 2019 Oct 31.'}]",,,,,De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request,,,,,"[{'SeeAlsoLinkLabel': 'AmgenTrials clinical trials website', 'SeeAlsoLinkURL': 'http://www.amgentrials.com'}]",,,,,,,,,,,,,,,"['Study Protocol', 'Statistical Analysis Plan (SAP)', 'Informed Consent Form (ICF)', 'Clinical Study Report (CSR)']",Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.,"Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.",https://www.amgen.com/datasharing,,26-Oct-20,"[{'ConditionMeshId': 'D000050171', 'ConditionMeshTerm': 'Dyslipidemias'}]","[{'ConditionAncestorId': 'D000052439', 'ConditionAncestorTerm': 'Lipid Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}]","[{'ConditionBrowseLeafId': 'M24768', 'ConditionBrowseLeafName': 'Dyslipidemias', 'ConditionBrowseLeafAsFound': 'Dyslipidemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M25616', 'ConditionBrowseLeafName': 'Lipid Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03045120,CA180-653,Bristol-Myers Squibb,INDUSTRY,Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States,Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States,Apr-20,Recruiting,No,29-Mar-17,Actual,31-Jan-21,Anticipated,31-Jul-21,Anticipated,31-Jan-17,03-Feb-17,07-Feb-17,Estimate,28-Apr-20,30-Apr-20,Actual,Sponsor,Bristol-Myers Squibb,INDUSTRY,,,,,"This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and initiating first-line TKIs in routine clinical practice in the US. All treatment decisions will be determined at the discretion of the treating physician(s) and data identifying the cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples (collected following 8 hours of fasting) will be collected during standard of care (SOC)/routine office visits. Additional research imaging will be performed and will be reviewed by core imaging laboratory. As the study is collecting data on management of CML, this study will not influence the prescribing or management practices at participating sites.",['Chronic Phase Chronic Myeloid Leukemia'],Observational,,,,,,200,Anticipated,"[{'ArmGroupLabel': 'dasatinib cohort', 'ArmGroupDescription': 'Intended to characterize the impact of dasatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.'}, {'ArmGroupLabel': 'imatinib cohort', 'ArmGroupDescription': 'Intended to characterize the impact of imatinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.'}, {'ArmGroupLabel': 'nilotinib cohort', 'ArmGroupDescription': 'Intended to characterize the impact of nilotinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.'}, {'ArmGroupLabel': 'bosutinib cohort', 'ArmGroupDescription': 'Intended to characterize the impact of bosutinib on cardiovascular and metabolic risk factors in CP-CML treated patients who are TKI naive and initiating first line TKIs in routine clinical practice in the US.'}]",,"[{'PrimaryOutcomeMeasure': 'changes in cardiovascular risk from baseline using the Framingham Coronary Heart Disease Score', 'PrimaryOutcomeTimeFrame': 'up to 24 months'}, {'PrimaryOutcomeMeasure': 'changes in metabolic risk from baseline using metabolic lab values', 'PrimaryOutcomeTimeFrame': 'up to 24 months'}]","[{'SecondaryOutcomeMeasure': 'echocardiography to assess left ventricular function', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'urinary protein excretion to assess early vascular endothelial changes', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'coronary calcium scoring to assess coronary artery narrowing', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'metabolic labs (Plasma Glucose, HbA1c, Fasting Lipids) for assessing the metabolic disease', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'safety and tolerability of first-line BCR-ABL TKIs in adults with CP-CML based on the number of treatment-related adverse events collected in the medical records', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'clinical outcomes as described by the number of deaths from clinical assessments of disease status and mutational analysis', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'clinical outcomes as described by the major molecular response from clinical assessments of disease status and mutational analysis', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'clinical outcomes as described by the cytogenetic response from clinical assessments of disease status and mutational analysis', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'time to development of clinical outcomes from baseline to time of clinical outcome event based on clinical assessments', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'description of treatment patterns based on the number of changes in treatment dosing, interruptions, changes in therapy, duration of therapy and treatment discontinuations through the management of adverse events and comorbid disease', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'description of the demographic and clinical patient characteristics associated with initial treatment choice and changes of treatment based on the medical records', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}, {'SecondaryOutcomeMeasure': 'measurement of serum biomarkers that are predictive of an increased risk for cardiovascular or metabolic disease', 'SecondaryOutcomeTimeFrame': 'up to 24 months'}]","Inclusion Criteria:

≥ 18 years at the time of Ph+ CP-CML diagnosis
Newly diagnosed chronic phase of Ph+ CP-CML, confirmed with cytogenetic and/or molecular testing at baseline
Treatment-naïve and initiating treatment with dasatinib, imatinib, nilotinib or bosutinib
Willingness and ability to comply with routine office visits

Exclusion Criteria:

Any other prior or active non-CML active malignancy for which the patient is receiving treatment
Participation in a therapeutic clinical trial for CML disease",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Arizona Cancer Center', 'LocationStatus': 'Withdrawn', 'LocationCity': 'Tucson', 'LocationState': 'Arizona', 'LocationZip': '85719', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mt. Sinai Hospital', 'LocationStatus': 'Recruiting', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60608', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Niraj Patel, 0008', 'LocationContactRole': 'Contact', 'LocationContactPhone': '872-222-7830', 'LocationContactEMail': 'nirajpatel@prismsgrp.com'}]}}, {'LocationFacility': 'Alexian Brothers Cancer Institute', 'LocationStatus': 'Recruiting', 'LocationCity': 'Elk Grove Village', 'LocationState': 'Illinois', 'LocationZip': '60007', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Karen Frezilis, 0001', 'LocationContactRole': 'Contact', 'LocationContactPhone': '630-269-2788', 'LocationContactEMail': 'Karen.Frizelis@amitahealth.org'}]}}, {'LocationFacility': 'Mid-Illinois Hematology & Oncology Associates, LTD', 'LocationStatus': 'Terminated', 'LocationCity': 'Normal', 'LocationState': 'Illinois', 'LocationZip': '61761', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oncology of Northshore (North Shore Community Hospital)', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Rolling Meadows', 'LocationState': 'Illinois', 'LocationZip': '60008', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Niraj Patel, 0036', 'LocationContactRole': 'Contact', 'LocationContactPhone': '872-222-7830', 'LocationContactEMail': 'nirajpatel@prismsgrp.com'}]}}, {'LocationFacility': 'Healthcare Research Network', 'LocationStatus': 'Recruiting', 'LocationCity': 'Tinley Park', 'LocationState': 'Illinois', 'LocationZip': '60487', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Brian Springer, 0006', 'LocationContactRole': 'Contact', 'LocationContactPhone': '314-972-9600', 'LocationContactEMail': 'bspringer@healthcareresearchnetwork.com'}, {'LocationContactName': 'Rosemary Beyer', 'LocationContactRole': 'Contact', 'LocationContactPhone': '314-972-9600', 'LocationContactEMail': 'rbeyer@healthcareresearchnetwork.com'}]}}, {'LocationFacility': 'American Health Network of IN, LLC', 'LocationStatus': 'Recruiting', 'LocationCity': 'Avon', 'LocationState': 'Indiana', 'LocationZip': '46123', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kisha Horan, 0034', 'LocationContactRole': 'Contact', 'LocationContactPhone': '317-462-1826', 'LocationContactEMail': 'Kisha_Horan@ahni.com'}]}}, {'LocationFacility': 'Cancer Center of Kansas', 'LocationStatus': 'Recruiting', 'LocationCity': 'Wichita', 'LocationState': 'Kansas', 'LocationZip': '67214', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Susan Davis, 0015', 'LocationContactRole': 'Contact', 'LocationContactPhone': '316-613-4318', 'LocationContactEMail': 'Susan.Davis@cancercenterofkansas.com'}]}}, {'LocationFacility': 'ARH Hazard', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hazard', 'LocationState': 'Kentucky', 'LocationZip': '41701', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Tracie McDaniel, 0024', 'LocationContactRole': 'Contact', 'LocationContactPhone': '606-487-7902', 'LocationContactEMail': 'tmcdaniel@arh.org'}]}}, {'LocationFacility': 'Willis Knighton Cancer Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Shreveport', 'LocationState': 'Louisiana', 'LocationZip': '71103', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Briana Barrow, 0023', 'LocationContactRole': 'Contact', 'LocationContactPhone': '318-212-8671', 'LocationContactEMail': 'bbarrow@wkhs.com'}]}}, {'LocationFacility': 'Saint Agnes Hospital', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21229', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Elizabeth Chandler, 0007', 'LocationContactRole': 'Contact', 'LocationContactPhone': '667-234-2966', 'LocationContactEMail': 'echandle@ascension.org'}]}}, {'LocationFacility': 'Frontier Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Billings', 'LocationState': 'Montana', 'LocationZip': '59101', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Heather Duyck, 0026', 'LocationContactRole': 'Contact', 'LocationContactPhone': '406-238-6288', 'LocationContactEMail': 'heather.duyck@sclhs.net'}]}}, {'LocationFacility': 'University of Nebraska Medical Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Omaha', 'LocationState': 'Nebraska', 'LocationZip': '68198', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Marie Witthoft, 0035', 'LocationContactRole': 'Contact', 'LocationContactPhone': '402-559-4828', 'LocationContactEMail': 'mwitthof@unmc.edu'}, {'LocationContactName': 'Krista Brown', 'LocationContactRole': 'Contact', 'LocationContactPhone': '402 559 4828', 'LocationContactEMail': 'krista.brown@unmc.edu'}]}}, {'LocationFacility': 'John Theurer Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Hackensack', 'LocationState': 'New Jersey', 'LocationZip': '07601', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kristen Marfino, 0016', 'LocationContactRole': 'Contact', 'LocationContactPhone': '551-996-3416', 'LocationContactEMail': 'kirsten.marfino@hackensackmeridian.org'}, {'LocationContactName': 'Diana Baumgardt', 'LocationContactRole': 'Contact', 'LocationContactEMail': 'Diana.Baumgardt@hackensackmeridian.org'}]}}, {'LocationFacility': 'Montefiore Medical Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10467', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ambar Baez, 0027', 'LocationContactRole': 'Contact', 'LocationContactPhone': '718-920-2006', 'LocationContactEMail': 'abaez@montefiore.org'}]}}, {'LocationFacility': 'Roswell Park Cancer Institute', 'LocationStatus': 'Recruiting', 'LocationCity': 'Buffalo', 'LocationState': 'New York', 'LocationZip': '14263', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Gretchen Watkins, 0005', 'LocationContactRole': 'Contact', 'LocationContactPhone': '716-845-1516', 'LocationContactEMail': 'Gretchen.Watkins@RoswellPark.org'}]}}, {'LocationFacility': 'Columbia University Medical Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Ryan Shelton, 0030', 'LocationContactRole': 'Contact', 'LocationContactPhone': '212-304-5485', 'LocationContactEMail': 'rs3323@cumc.columbia.edu'}]}}, {'LocationFacility': 'Memorial Sloan Kettering Cancer Center', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10065', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Jordan Chervin, 0019', 'LocationContactRole': 'Contact', 'LocationContactPhone': '646-888-1001', 'LocationContactEMail': 'greenea@mskcc.org'}]}}, {'LocationFacility': 'Weill Cornell Medicine', 'LocationStatus': 'Recruiting', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10065', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Gabrielle Gosciniak, 0011', 'LocationContactRole': 'Contact', 'LocationContactPhone': '646-962-9359', 'LocationContactEMail': 'gag2663@med.cornell.edu'}]}}, {'LocationFacility': 'Stony Brook Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Stony Brook', 'LocationState': 'New York', 'LocationZip': '11794', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Sebastian Munoz, 0012', 'LocationContactRole': 'Contact', 'LocationContactPhone': '631-638-2148', 'LocationContactEMail': 'Sebastian.Munoz@stonybrookmedicine.edu'}, {'LocationContactName': 'Jennifer Hofecker', 'LocationContactRole': 'Contact', 'LocationContactPhone': '631-638-2148'}]}}, {'LocationFacility': 'Leo W. Jenkins Cancer Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Greenville', 'LocationState': 'North Carolina', 'LocationZip': '27834', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Susan Eubanks, 0029', 'LocationContactRole': 'Contact', 'LocationContactPhone': '252-744-1015', 'LocationContactEMail': 'EUBANKSS@ecu.edu'}]}}, {'LocationFacility': 'Oncology Hematology Care', 'LocationStatus': 'Recruiting', 'LocationCity': 'Cincinnati', 'LocationState': 'Ohio', 'LocationZip': '45236', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Lisa Douglas, 0014', 'LocationContactRole': 'Contact', 'LocationContactPhone': '513-751-2273', 'LocationContactPhoneExt': '27111', 'LocationContactEMail': 'lisa.douglas@usoncology.com'}]}}, {'LocationFacility': 'Oregon Health and Science University', 'LocationStatus': 'Recruiting', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97239', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Diane Gasperin, 0002', 'LocationContactRole': 'Contact', 'LocationContactPhone': '503-418-9117', 'LocationContactEMail': 'gasperin@ohsu.edu'}]}}, {'LocationFacility': 'Huntsman Cancer Hospital', 'LocationStatus': 'Not yet recruiting', 'LocationCity': 'Salt Lake City', 'LocationState': 'Utah', 'LocationZip': '84093', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Spencer Thomas, 0033', 'LocationContactRole': 'Contact', 'LocationContactPhone': '801-213-4327', 'LocationContactEMail': 'Spencer.Thomas@hci.utah.edu'}]}}, {'LocationFacility': 'Providence Regional Cancer Partnership', 'LocationStatus': 'Recruiting', 'LocationCity': 'Everett', 'LocationState': 'Washington', 'LocationZip': '98201', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Heather Sights, 0009', 'LocationContactRole': 'Contact', 'LocationContactPhone': '425-297-5531', 'LocationContactEMail': 'Heather.Sights@providence.org'}]}}, {'LocationFacility': 'Fred Hutchinson Cancer Research Center', 'LocationStatus': 'Recruiting', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98109', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Kaysey Orlowski, 0003', 'LocationContactRole': 'Contact', 'LocationContactPhone': '206-667-1997', 'LocationContactEMail': 'korlowsk@fredhutch.org'}]}}]",,No,"This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and initiating first-line TKIs in routine clinical practice in the US. All treatment decisions will be determined at the discretion of the treating physician(s) and data identifying the cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples (collected following 8 hours of fasting) will be collected during standard of care (SOC)/routine office visits. Additional research imaging will be performed and will be reviewed by core imaging laboratory. As the study is collecting data on management of CML, this study will not influence the prescribing or management practices at participating sites.",,No,['Cohort'],['Prospective'],"Newly-diagnosed, treatment-naïve CP-CML patients who are ≥ 18 years at the time of CP-CML diagnosis who are scheduled to initiate treatment with dasatinib, imatinib, nilotinib or Bosutinib are eligible for enrollment. Enrolled patients (n=200) will be distributed across the 3 patient treatment groups of newly diagnosed CP-CML patients who will initiate their first- line TKI treatment.",Probability Sample,,,,,,,,"[{'OverallOfficialName': 'Bristol-Myers Squibb', 'OverallOfficialAffiliation': 'Bristol-Myers Squibb', 'OverallOfficialRole': 'Study Director'}]",No,,,,,,,"[{'CentralContactName': 'Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,', 'CentralContactRole': 'Contact', 'CentralContactPhone': 'please email:', 'CentralContactEMail': 'Clinical.Trials@bms.com'}, {'CentralContactName': 'First line of the email MUST contain NCT # and Site #.', 'CentralContactRole': 'Contact'}]",,Samples With DNA,biomarker analyses will be collected for metabolic panels,"[{'SeeAlsoLinkLabel': 'Investigator Inquiry Form', 'SeeAlsoLinkURL': 'http://www.bms.com/clinical_trials/pages/investigator_inquiry_form.aspx'}, {'SeeAlsoLinkLabel': 'FDA Safety Alerts and Recalls', 'SeeAlsoLinkURL': 'http://www.fda.gov/Safety/Recalls/'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007938', 'ConditionMeshTerm': 'Leukemia'}, {'ConditionMeshId': 'D000007951', 'ConditionMeshTerm': 'Leukemia, Myeloid'}, {'ConditionMeshId': 'D000015464', 'ConditionMeshTerm': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive'}, {'ConditionMeshId': 'D000015466', 'ConditionMeshTerm': 'Leukemia, Myeloid, Chronic-Phase'}]","[{'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000009196', 'ConditionAncestorTerm': 'Myeloproliferative Disorders'}, {'ConditionAncestorId': 'D000001855', 'ConditionAncestorTerm': 'Bone Marrow Diseases'}, {'ConditionAncestorId': 'D000006402', 'ConditionAncestorTerm': 'Hematologic Diseases'}]","[{'ConditionBrowseLeafId': 'M9528', 'ConditionBrowseLeafName': 'Leukemia', 'ConditionBrowseLeafAsFound': 'Leukemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9538', 'ConditionBrowseLeafName': 'Leukemia, Myeloid', 'ConditionBrowseLeafAsFound': 'Myeloid Leukemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16706', 'ConditionBrowseLeafName': 'Leukemia, Myelogenous, Chronic, BCR-ABL Positive', 'ConditionBrowseLeafAsFound': 'Chronic Myeloid Leukemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16708', 'ConditionBrowseLeafName': 'Leukemia, Myeloid, Chronic-Phase', 'ConditionBrowseLeafAsFound': 'Chronic Phase Chronic Myeloid Leukemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10898', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10732', 'ConditionBrowseLeafName': 'Myeloproliferative Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3716', 'ConditionBrowseLeafName': 'Bone Marrow Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8073', 'ConditionBrowseLeafName': 'Hematologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4006', 'ConditionBrowseLeafName': 'Myeloid Leukemia', 'ConditionBrowseLeafAsFound': 'Myeloid Leukemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T1314', 'ConditionBrowseLeafName': 'Chronic Myeloid Leukemia', 'ConditionBrowseLeafAsFound': 'Chronic Myeloid Leukemia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T1316', 'ConditionBrowseLeafName': 'Chronic Myeloproliferative Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M324', 'InterventionBrowseLeafName': 'Imatinib Mesylate', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M410', 'InterventionBrowseLeafName': 'Dasatinib', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T22', 'InterventionBrowseLeafName': 'Tyrosine', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AA', 'InterventionBrowseBranchName': 'Amino Acids'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01154296,AAAK3153,Columbia University,OTHER,HIV Rapid Testing & Counseling in Sexually Transmitted Disease (STD) Clinics in the U.S.,Project Aware: HIV Rapid Testing & Counseling in STD Clinics in the U.S. -- an Adaptation of CTN 0032,Sep-14,Completed,No,Apr-10,,Jul-11,Actual,Feb-12,Actual,29-Jun-10,29-Jun-10,30-Jun-10,Estimate,23-Sep-14,29-Sep-14,Estimate,Principal Investigator,Columbia University,OTHER,,,,,"Project Aware is a randomized controlled clinical trial in which individuals seeking medical or health services at sexually transmitted disease (STD) clinics are recruited to participate in a multi-center HIV testing and counseling study. The investigators will assess the relative effectiveness and cost-effectiveness of (1) on-site HIV rapid testing with brief, participant-tailored prevention counseling vs. (2) on-site HIV rapid testing with information only. The investigators will evaluate the effect of counseling on one primary outcome: STI incidence. Secondary outcomes will be reduction of sexual risk behaviors, substance use during sex (i.e., being under the influence during sex) and cost and cost effectiveness of counseling and testing. Participants will be assessed for sexually transmitted infections, HIV testing history and sexual and drug use risk behaviors at baseline and at 6-months follow-up. Approximately 5,000 individuals seeking medical or health services from approximately 9 STD clinics throughout the United States will be randomized. These individuals will be 18 years of age or older and efforts will be made to recruit a sample of study participants that reflects the proportion of minorities and gender in the STD clinic performance sites from which the investigators are recruiting.","['HIV/AIDS', 'Sexually Transmitted Infections']",Interventional,['Not Applicable'],Randomized,Parallel Assignment,Screening,Single,5012,Actual,"[{'ArmGroupLabel': 'Rapid HIV Testing w/ Counseling (Group 1)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: RESPECT-2 Counseling']}}, {'ArmGroupLabel': 'Rapid HIV Testing & Information Only (Group 2)', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'RESPECT-2 Counseling', 'InterventionDescription': 'Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Rapid HIV Testing w/ Counseling (Group 1)']}, 'InterventionOtherNameList': {'InterventionOtherName': ['RESPECT-2 Protocol']}}]","[{'PrimaryOutcomeMeasure': 'STI Incidence', 'PrimaryOutcomeDescription': 'Composite STI incidence (Yes/No) at 6-month follow-up in which a person is considered positive for STIs if they are positive on any tested STI.', 'PrimaryOutcomeTimeFrame': '6 months post randomization'}]","[{'SecondaryOutcomeMeasure': 'Sexual Risk Behavior -- # of Sex Acts', 'SecondaryOutcomeDescription': 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts.', 'SecondaryOutcomeTimeFrame': '6 months post randomization'}, {'SecondaryOutcomeMeasure': 'Sexual Risk Behavior -- # of Unprotected Sex Acts', 'SecondaryOutcomeDescription': 'Self-reported continuous variables to determine number of unprotected (vaginal and/or anal) sex acts', 'SecondaryOutcomeTimeFrame': '6 months post randomization'}, {'SecondaryOutcomeMeasure': 'Sexual Risk Behavior -- # of Partners', 'SecondaryOutcomeDescription': 'Self-reported continuous variables to determine number of partners with whom the participant had (vaginal and/or anal) sex.', 'SecondaryOutcomeTimeFrame': '6 months post randomization'}, {'SecondaryOutcomeMeasure': 'Sexual Risk Behavior -- # of Unprotected Partners', 'SecondaryOutcomeDescription': 'Self-reported continuous variables to determine number of partners with whom the participant had unprotected (vaginal and/or anal) sex.', 'SecondaryOutcomeTimeFrame': '6 months post randomization'}, {'SecondaryOutcomeMeasure': 'Sexual Risk Behavior -- # of Sex Acts With Substance Use', 'SecondaryOutcomeDescription': 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts in which the participant reported using substances before the sex act.', 'SecondaryOutcomeTimeFrame': '6 months post randomization'}]","Inclusion Criteria:

Site Eligibility:

high rates of STIs and HIV in their geographic target area,
sufficient number of patients so that they would be able to recruit the required 556 participants over the study time period,
prior participation in research and clinical studies, and
previous collaboration with investigators.

Participant eligibility:

be seeking medical or health services at the participating STD clinic,
be at least 18 years old,
report being HIV-negative or status unknown,
provide informed consent,
provide locator information,
be able to communicate in English,
agree to be tested for STIs/STDs and HIV;
sign a HIPAA form and/or medical record release form to permit medical record abstraction of HIV and STI/STD tests, results and treatment; and
report living in the vicinity of the clinic and being able to return to the clinic for the 6-month follow-up visit.

Exclusion Criteria:

Sites:

low rates of STIs and HIV in their geographic target area,
insufficient number of patients to meet study needs of 556 per site
no prior participation in research and clinical studies, and
no previous collaboration with investigators.

Participants:

Not seeking medical or health services at the participating STD clinic,
under 18 years old,
HIV positive,
unwilling to provide Informed Consent,
refuse to provide locator information,
not able to communicate in English,
Disagree to be tested for STIs/STDs and/or HIV, and
unwilling to sign a HIPAA form and/or medical record release form to permit medical record abstraction of HIV and STI/STD tests, results and treatment,
report living out of the vicinity and unable to return to the clinic for the 6-month follow-up visit.",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Los Angeles Gay & Lesbian Center', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90028', 'LocationCountry': 'United States'}, {'LocationFacility': 'San Francisco Department of Public Health', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94102', 'LocationCountry': 'United States'}, {'LocationFacility': 'Whitman-Walker Clinic', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20009', 'LocationCountry': 'United States'}, {'LocationFacility': 'Duval County Health Department', 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32206', 'LocationCountry': 'United States'}, {'LocationFacility': 'Miami-Dade County Health Department', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33125', 'LocationCountry': 'United States'}, {'LocationFacility': 'Multnomah County Health Department', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Allegheny County Health Department', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15213', 'LocationCountry': 'United States'}, {'LocationFacility': 'Richland County Health Department', 'LocationCity': 'Colombia', 'LocationState': 'South Carolina', 'LocationZip': '29204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Public Health Seattle & King County', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98107', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'National Institute on Drug Abuse (NIDA)', 'CollaboratorClass': 'NIH'}, {'CollaboratorName': 'University of Pittsburgh', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of California, San Francisco', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Oregon Health and Science University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Medical University of South Carolina', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Research Foundation for Mental Hygiene, Inc.', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Duke University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Emmes Company, LLC', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'San Francisco Department of Public Health', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'University of California', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Weill Medical College of Cornell University', 'CollaboratorClass': 'OTHER'}]",Yes,"An estimated 56,300 Americans are newly infected with HIV every year. In addition, of the more than one million Americans living with HIV, approximately one-fifth do not know they are infected. Identifying these individuals is among the biggest challenges for HIV prevention in the United States. Early diagnosis of such individuals, combined with prevention counseling and provision of health care, could decrease the spread of HIV and improve the survival of HIV-infected persons.

The recent introduction of rapid HIV testing offers a critical public health screening approach for facilitating earlier diagnoses of HIV infection. Rapid tests permit a sensitive and specific, fast, simple, minimally invasive, and cost-effective method to screen for HIV.

Project Aware expands on the CDC's Project RESPECT-2 study that was an expansion of the RESPECT study (a randomized controlled trial conducted in STD clinics in the mid-1990s before the advent of highly active antiretroviral therapy and before the advent of rapid testing). Project RESPECT demonstrated that a 2-session, client centered counseling session based on behavioral theory with HIV testing was superior to a program with HIV testing and information only. This project showed that the counseling arm had significant reduction of STIs compared to those in the information arm. However, RESPECT did not include men who have sex with men (who account for 53% of all new HIV infections in the U.S.) and did not examine the cost effectiveness of the intervention. RESPECT-2 did include MSM, but it only compared a 1-session counseling session with rapid testing to 2-session counseling with traditional testing and did not address the question of whether counseling and testing is more effective than testing alone.

Project Aware combines the RESPECT-2 counseling approach by adapting the HIV Rapid Testing and Counseling in Drug Abuse Treatment Study (CTN 0032), a NIDA-sponsored randomized controlled clinical trial being conducted in the NIDA Clinical Trials Network (CTN) to sexually transmitted disease (STD) clinics to provide important and timely data on the effect of counseling in high-risk populations tested in health care settings. In this adaptation of CTN 0032, we will assess the relative effectiveness of (1) on-site HIV rapid testing with brief, participant-tailored prevention counseling vs. (2) on-site HIV rapid testing with information only (as recommended in the CDC guidelines). Secondary outcomes are reduction of sexual risk behaviors, substance use during sex (i.e., being under the influence during sex) and cost and cost effectiveness of counseling and testing. Participants (approximately 5,000 from 9 STD clinics) will be assessed for STIs, HIV testing history and sexual and drug use risk behaviors at baseline and at 6-months follow-up. The battery of STI tests will screen for Neisseria gonorrhea (GC), Chlamydia trachomatis (CT), Trichomonas vaginalis, Herpes Simplex 2 (HSV-2) and Treponema pallidum (syphilis). HIV test results that yield a reactive result will receive a confirmatory HIV blood test that day, with results delivered 5-10 days later. All participants will be randomized into one of two arms: Group 1- HIV testing and brief, client-centered counseling or Group 2- HIV testing and information only. Group 1 will receive a rapid HIV test with brief prevention counseling that addresses risk reduction based on an evidence-based counseling approach (RESPECT-2 counseling), while Group 2 will receive a rapid HIV test with information only.

The primary outcome will be analyzed using logistic regression for the binary outcome, new diagnoses of STIs (Yes/No). The logistic regression analysis will predict 6-month STI incidence as a function of randomization group controlling for the baseline incidence of STI. ANCOVA will be used for the secondary continuous outcomes, number of sexual risk behaviors and number of sexual episodes involving substance use. Costs will be compared based on study records supplemented by site-level data collection. Primary analyses will be performed under intent-to-treat (ITT) criteria.","['HIV', 'Rapid Testing', 'Counseling', 'STD', 'U.S.']",,,,,,"[{'SecondaryId': '1RC2DA028973-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1RC2DA028973-01&Fy=all'}]",Aware,Lisa Metsch,"Stephen Smith Professor of Sociomedical Sciences and Chair, Department of Sociomedical Sciences",Columbia University,['Investigator'],,"[{'OverallOfficialName': 'Lisa R. Metsch, Ph.D.', 'OverallOfficialAffiliation': 'University of Miami', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Grant N Colfax, M.D.', 'OverallOfficialAffiliation': 'San Francisco Department of Public Health', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '24150466', 'ReferenceType': 'result', 'ReferenceCitation': 'Metsch LR, Feaster DJ, Gooden L, Schackman BR, Matheson T, Das M, Golden MR, Huffaker S, Haynes LF, Tross S, Malotte CK, Douaihy A, Korthuis PT, Duffus WA, Henn S, Bolan R, Philip SS, Castro JG, Castellon PC, McLaughlin G, Mandler RN, Branson B, Colfax GN. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013 Oct 23;310(16):1701-10. doi: 10.1001/jama.2013.280034.'}, {'ReferencePMID': '26071390', 'ReferenceType': 'derived', 'ReferenceCitation': 'Alcaide ML, Feaster DJ, Duan R, Cohen S, Diaz C, Castro JG, Golden MR, Henn S, Colfax GN, Metsch LR. The incidence of Trichomonas vaginalis infection in women attending nine sexually transmitted diseases clinics in the USA. Sex Transm Infect. 2016 Feb;92(1):58-62. doi: 10.1136/sextrans-2015-052010. Epub 2015 Jun 12.'}]",29-Jul-14,23-Sep-14,29-Sep-14,Estimate,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012749', 'ConditionMeshTerm': 'Sexually Transmitted Diseases'}]","[{'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000007239', 'ConditionAncestorTerm': 'Infection'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16833', 'ConditionBrowseLeafName': 'HIV Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2103', 'ConditionBrowseLeafName': 'Acquired Immunodeficiency Syndrome', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14141', 'ConditionBrowseLeafName': 'Sexually Transmitted Diseases', 'ConditionBrowseLeafAsFound': 'Sexually Transmitted Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC20', 'ConditionBrowseBranchName': 'Immune System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]",,,,,"Study personnel made 14,948 approaches to STD clinic patients; some were approached multiple times. Of the 6,239 consenting to be screened, 5028 were eligible (80.6%); 16 of these were not randomized due to: decision to decline (n=3), not returning (n=11), not testing with HIV/STD battery (n=1) and not completing baseline activities (n=1).","Individuals seeking services at 9 sexually transmitted disease (STD) clinics across the U.S. were recruited, screened and randomized between April 2010 - December 2010.","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'FlowGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'FlowGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]","[{'FlowPeriodTitle': 'Randomization and Intervention', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2505'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2507'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2500'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2505'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '5'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Decided to decline', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Declined by staff', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}, {'FlowDropWithdrawType': 'Did not return', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}, {'FlowDropWithdrawType': 'Left before test', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '0'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Left clinic early', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '2'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}]}}, {'FlowPeriodTitle': '6-month Follow-up', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2505'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2507'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2177'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '2179'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '328'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '328'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost contact', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '269'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '275'}]}}, {'FlowDropWithdrawType': 'Incarcerated', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '37'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '32'}]}}, {'FlowDropWithdrawType': 'Withdrew consent', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '14'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '15'}]}}, {'FlowDropWithdrawType': 'Death', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '2'}]}}, {'FlowDropWithdrawType': 'Declined by Study Coordinator', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '5'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'}]}}]}}]","6,239 patients approached provided consent to be screened. Of these, 5,028 were eligible (80.6%) and 5012 (99.5% of those eligible) were randomized; 16 screened eligible, but were not randomized due to: decision to decline (3), not returning (11), not testing with HIV/STD battery (1) and not completing baseline activities (1).","[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'BaselineGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'BaselineGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '2505'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '2507'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '5012'}]}}]","[{'BaselineMeasureTitle': 'Age, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': '<25 years', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1705'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1727'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '3432'}]}}]}}, {'BaselineClassTitle': '>=25 years', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '800'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '780'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1580'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex/Gender, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Male sex', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1655'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1653'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '3308'}]}}]}}, {'BaselineClassTitle': 'Female sex', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '850'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '854'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1704'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Black', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1045'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1053'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2098'}]}}]}}, {'BaselineClassTitle': 'Hispanic', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '382'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '385'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '767'}]}}]}}, {'BaselineClassTitle': 'White', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '798'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '794'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1592'}]}}]}}, {'BaselineClassTitle': 'Other', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '280'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '275'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '555'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2505'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2507'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '5012'}]}}]}}]}}, {'BaselineMeasureTitle': 'Men who have sex with men (MSM), #', 'BaselineMeasureDescription': 'Men were classified as MSM if, at study intake, they reported any previous anal or oral sex with males or if on the baseline sexual risk behavior questions they reported having anal or oral sexwith another male at any time during the study. All men who did not meet the definition of MSM were classified as men who have sex with women.', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '689'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '711'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1400'}]}}]}}]}}, {'BaselineMeasureTitle': 'Any STI, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1049'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1092'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2141'}]}}]}}]}}, {'BaselineMeasureTitle': 'Any STI excluding trichomoniasis, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1016'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1070'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2086'}]}}]}}]}}, {'BaselineMeasureTitle': 'Gonorrhea, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '137'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '145'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '282'}]}}]}}]}}, {'BaselineMeasureTitle': 'Chlamydia, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '238'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '254'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '492'}]}}]}}]}}, {'BaselineMeasureTitle': 'Trichomoniasis, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '126'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '119'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '245'}]}}]}}]}}, {'BaselineMeasureTitle': 'Syphilis, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '28'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '35'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '63'}]}}]}}]}}, {'BaselineMeasureTitle': 'HSV-2, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '758'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '793'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1551'}]}}]}}]}}, {'BaselineMeasureTitle': 'HIV, #', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '29'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '24'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '53'}]}}]}}]}}, {'BaselineMeasureTitle': '# of sex acts', 'BaselineMeasureDescription': 'Note that standard errors (not standard deviations) are presented below with the least squares means.', 'BaselineMeasureParamType': 'Least Squares Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'sex acts', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '34.6', 'BaselineMeasurementSpread': '1.0809'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '33.4', 'BaselineMeasurementSpread': '1.0431'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '34.0', 'BaselineMeasurementSpread': '0.751'}]}}]}}]}}, {'BaselineMeasureTitle': '# of unprotected sex acts', 'BaselineMeasureDescription': 'Note that standard errors (not standard deviations) are presented below with the least squares means.', 'BaselineMeasureParamType': 'Least Squares Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'unprotected sex acts', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '23.9', 'BaselineMeasurementSpread': '0.9578'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '22.6', 'BaselineMeasurementSpread': '0.9068'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '23.3', 'BaselineMeasurementSpread': '0.6594'}]}}]}}]}}, {'BaselineMeasureTitle': '# of partners', 'BaselineMeasureDescription': 'Note that standard errors (not standard deviations) are presented below with the least squares means.', 'BaselineMeasureParamType': 'Least Squares Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'partners', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4.7', 'BaselineMeasurementSpread': '0.1141'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '4.6', 'BaselineMeasurementSpread': '0.1135'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4.6', 'BaselineMeasurementSpread': '0.08047'}]}}]}}]}}, {'BaselineMeasureTitle': '# of unprotected partners', 'BaselineMeasureDescription': 'Note that standard errors (not standard deviations) are presented below with the least squares means.', 'BaselineMeasureParamType': 'Least Squares Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'unprotected partners', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2.1', 'BaselineMeasurementSpread': '0.05812'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2.1', 'BaselineMeasurementSpread': '0.05696'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2.1', 'BaselineMeasurementSpread': '0.04069'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'STI Incidence', 'OutcomeMeasureDescription': 'Composite STI incidence (Yes/No) at 6-month follow-up in which a person is considered positive for STIs if they are positive on any tested STI.', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': '6 months post randomization', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '2039'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2032'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '250'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '226'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'A total of 2039/2505 participants randomized to the counseling group and 2032/2507 to the information-only group had complete follow-up STI data. Cumulative STI incidence was 250/2039 (12.3%) in the counseling group and 226/2032 (11.1%) in the information-only group (aRR, 1.12; 95%CI, 0.94-1.33).', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValueComment': 'In the statistical tests of all hypotheses and calculation of the presented risk ratios, we used multiple imputations of data sets with all 5012 cases. The aRRs reported are based on the multiply imputed data. Counts are based on the observed data.', 'OutcomeAnalysisStatisticalMethod': 'Mantel Haenszel', 'OutcomeAnalysisParamType': 'adjusted risk ratio (aRR)', 'OutcomeAnalysisParamValue': '1.12', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.94', 'OutcomeAnalysisCIUpperLimit': '1.33'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Sexual Risk Behavior -- # of Sex Acts', 'OutcomeMeasureDescription': 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts.', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'sex acts', 'OutcomeMeasureTimeFrame': '6 months post randomization', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '2505'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2507'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '28.6', 'OutcomeMeasurementSpread': '1.1312'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '29.1', 'OutcomeMeasurementSpread': '1.1553'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'Analyses of sexual risk behaviors used zero-inflated negative binomial regressions (ZINB) including treatment group, baseline level of the risk behavior, site, and randomization stratum. (ZINB regression was used instead of ANCOVA because the outcome variable had an excessive number of zeroes and over dispersion.) Adjusted incidence rate ratios (IRR) from the models are presented.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Incidence rate ratio (IRR)', 'OutcomeAnalysisParamValue': '0.99', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.90', 'OutcomeAnalysisCIUpperLimit': '1.09', 'OutcomeAnalysisEstimateComment': 'In the statistical tests of all hypotheses and calculation of the presented IRR, we used multiple imputations of data sets with all 5012 cases. The adjusted IRRs reported are based on multiply imputed data. Counts are based on the observed data.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Sexual Risk Behavior -- # of Unprotected Sex Acts', 'OutcomeMeasureDescription': 'Self-reported continuous variables to determine number of unprotected (vaginal and/or anal) sex acts', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'unprotected sex acts', 'OutcomeMeasureTimeFrame': '6 months post randomization', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '2505'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2507'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '17.4', 'OutcomeMeasurementSpread': '0.9791'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '18.3', 'OutcomeMeasurementSpread': '1.0381'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'Analyses of sexual risk behaviors used zero-inflated negative binomial regressions (ZINB) including treatment group, baseline level of the risk behavior, site, and randomization stratum. (ZINB regression was used instead of ANCOVA because the outcome variable had an excessive number of zeroes and over dispersion.) Adjusted incidence rate ratios (IRR) from the models are presented.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Incidence Rate Ratio (IRR)', 'OutcomeAnalysisParamValue': '0.98', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.86', 'OutcomeAnalysisCIUpperLimit': '1.13', 'OutcomeAnalysisEstimateComment': 'In the statistical tests of all hypotheses and calculation of the presented IRR, we used multiple imputations of data sets with all 5012 cases. The adjusted IRRs reported are based on multiply imputed data. Counts are based on the observed data.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Sexual Risk Behavior -- # of Partners', 'OutcomeMeasureDescription': 'Self-reported continuous variables to determine number of partners with whom the participant had (vaginal and/or anal) sex.', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'partners', 'OutcomeMeasureTimeFrame': '6 months post randomization', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '2505'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2507'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.7', 'OutcomeMeasurementSpread': '0.07454'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '3.0', 'OutcomeMeasurementSpread': '0.08386'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'Analyses of sexual risk behaviors used zero-inflated negative binomial regressions (ZINB) including treatment group, baseline level of the risk behavior, site, and randomization stratum. (ZINB regression was used instead of ANCOVA because the outcome variable had an excessive number of zeroes and over dispersion.) Adjusted incidence rate ratios (IRR) from the models are presented.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Incidence Rate Ratio (IRR)', 'OutcomeAnalysisParamValue': '0.88', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.82', 'OutcomeAnalysisCIUpperLimit': '0.94', 'OutcomeAnalysisEstimateComment': 'In the statistical tests of all hypotheses and calculation of the presented IRR, we used multiple imputations of data sets with all 5012 cases. The adjusted IRRs reported are based on multiply imputed data. Counts are based on the observed data.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Sexual Risk Behavior -- # of Unprotected Partners', 'OutcomeMeasureDescription': 'Self-reported continuous variables to determine number of partners with whom the participant had unprotected (vaginal and/or anal) sex.', 'OutcomeMeasureParamType': 'Least Squares Mean', 'OutcomeMeasureDispersionType': 'Standard Error', 'OutcomeMeasureUnitOfMeasure': 'unprotected partners', 'OutcomeMeasureTimeFrame': '6 months post randomization', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '2505'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '2507'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.1', 'OutcomeMeasurementSpread': '0.03749'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1.1', 'OutcomeMeasurementSpread': '0.03845'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'Analyses of sexual risk behaviors used zero-inflated negative binomial regressions (ZINB) including treatment group, baseline level of the risk behavior, site, and randomization stratum. (ZINB regression was used instead of ANCOVA because the outcome variable had an excessive number of zeroes and over dispersion.) Adjusted incidence rate ratios (IRR) from the models are presented.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisParamType': 'Incidence Rate Ratio (IRR)', 'OutcomeAnalysisParamValue': '0.97', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.90', 'OutcomeAnalysisCIUpperLimit': '1.05', 'OutcomeAnalysisEstimateComment': 'In the statistical tests of all hypotheses and calculation of the presented IRR, we used multiple imputations of data sets with all 5012 cases. The adjusted IRRs reported are based on multiply imputed data. Counts are based on the observed data.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Sexual Risk Behavior -- # of Sex Acts With Substance Use', 'OutcomeMeasureDescription': 'Self-reported continuous variables to determine number of (vaginal and/or anal) sex acts in which the participant reported using substances before the sex act.', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'sex acts with substance use', 'OutcomeMeasureTimeFrame': '6 months post randomization', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'OutcomeGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '952'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '952'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '115'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '106'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValueComment': 'In the statistical tests of all hypotheses and calculation of the presented risk ratios, we used multiple imputations of data sets with all 5012 cases. The aRRs reported are based on the multiply imputed data. Counts are based on the observed data.', 'OutcomeAnalysisStatisticalMethod': 'Mantel Haenszel', 'OutcomeAnalysisParamType': 'Adjusted Risk Ratio (aRR)', 'OutcomeAnalysisParamValue': '1.14', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCILowerLimit': '0.89', 'OutcomeAnalysisCIUpperLimit': '1.46'}]}}]",1,Adverse events were captured post-randomization and were collected at each research visit. Other safety information is based on spontaneous reports and not specifically required by the study team.,Only the following events were required for reporting as AEs: medical events that are directly related to the collection of the HIV and STI test samples (e.g. irritation at the testing site); additional AE were assessed based on report of untoward events that participant or investigator believes are a direct result of the study.,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Rapid HIV Testing w/ Counseling (Group 1)', 'EventGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 1 will receive rapid HIV testing and RESPECT-2 counseling.\n\nRESPECT-2 Counseling: Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.', 'EventGroupSeriousNumAffected': '3', 'EventGroupSeriousNumAtRisk': '2505', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '2505'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Rapid HIV Testing & Information Only (Group 2)', 'EventGroupDescription': 'Individuals who screen as eligible will complete written informed consent procedures, be enrolled, be tested for STIs, and be asked to complete a baseline assessment using audio computer-assisted self interview (ACASI). Then participants randomized to group 2 will receive rapid HIV testing with information only.', 'EventGroupSeriousNumAffected': '2', 'EventGroupSeriousNumAtRisk': '2507', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '2507'}]",,No,No,"Lisa Metsch, PhD, Stephen Smith Professor and Chair of Sociomedical Sciences",Department of Sociomedical Sciences/Mailman School of Public Health/Columbia University,lm2892@columbia.edu,212-305-3577,"[{'SeriousEventTerm': 'Death, cause unknown', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA (Unspecified)', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventNotes': '""General disorders"" selected as default; cause of death is unknown', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2505'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2507'}]}}, {'SeriousEventTerm': 'victim of homicide, secondary to robbery', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA (Unspecified)', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventNotes': '""General disorders"" selected as default; cause is homicide', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2505'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2507'}]}}, {'SeriousEventTerm': 'Cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA (Unspecified)', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2505'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2507'}]}}, {'SeriousEventTerm': 'Heart failure', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA (Unspecified)', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2505'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2507'}]}}, {'SeriousEventTerm': 'Metastatic colon cancer', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA (Unspecified)', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2505'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2507'}]}}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02857764,RRA-17578,"Janssen Research & Development, LLC",INDUSTRY,Sodium-glucose Co-transporter 2 (SGLT2) Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States,SGLT2 Inhibitor Risk of Below-Knee Lower Extremity Amputation: A Retrospective Cohort Study Using a Large Claims Database in the United States,Aug-17,Completed,No,15-Feb-16,Actual,30-Jun-17,Actual,30-Jun-17,Actual,03-Aug-16,03-Aug-16,05-Aug-16,Estimate,29-Aug-17,30-Aug-17,Actual,Sponsor,"Janssen Research & Development, LLC",INDUSTRY,,,,,The purpose of the study is to estimate the incidence of below-knee lower extremity amputation in type 2 diabetes mellitus (T2DM) participants newly exposed to sodium-glucose co-transporter 2 inhibitors (SGLT2i)/ non-SGLT2i antihyperglycemic agents (AHA) overall and in the subgroup with high cardiovascular (CV) risk and to compare the hazards of below-knee lower extremity amputation in canagliflozin new users versus non-SGLT2i AHA new users.,"['Diabetes Mellitus, Type 2']",Observational,,,,,,127690,Actual,"[{'ArmGroupLabel': 'Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) New Users', 'ArmGroupDescription': 'Participants will not receive any intervention as a part of this study. SGLT2i includes canagliflozin, dapagliflozin, empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.'}, {'ArmGroupLabel': 'Canagliflozin New Users', 'ArmGroupDescription': 'Participants will not receive any intervention as a part of this study. This cohort contains new users of canagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 risk) and overall.'}, {'ArmGroupLabel': 'Dapagliflozin New Users', 'ArmGroupDescription': 'Participants will not receive any intervention as a part of this study. This cohort contains new users of dapagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.'}, {'ArmGroupLabel': 'Empagliflozin New Users', 'ArmGroupDescription': 'Participants will not receive any intervention as a part of this study. This cohort contains new users of empagliflozin as prescribed in clinical practice. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.'}, {'ArmGroupLabel': 'First-time Non-SGLT2i AHA New Users', 'ArmGroupDescription': 'Participants will not receive any intervention as a part of this study. Non-SGLT2i AHA include dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) agonists, thiazolidinediones (TZDs), Sulfonylureas, Insulin, and other AHAs. Participants will be evaluated in 2 sub-cohorts (with or without high CV risk) and overall.'}]",,"[{'PrimaryOutcomeMeasure': 'Incidence of Below-knee Lower Extremity Amputation in Type 2 Diabetes Mellitus (T2DM) Patients Newly Exposed to Sodium-glucose Co-transporter 2 Inhibitors (SGLT2i) Overall and in the Subgroup With High Cardiovascular (CV) Risk', 'PrimaryOutcomeDescription': 'The occurrence of a below-knee lower extremity amputation will be defined by observing an associated procedure code in the outpatient or inpatient medical service claims.', 'PrimaryOutcomeTimeFrame': 'up to 6 years (estimated study duration)'}, {'PrimaryOutcomeMeasure': 'Incidence of Below-Knee Lower Extremity Amputation in T2DM Patients Newly Exposed To non-SGLT2i Aha Overall And In The Subgroup With High CV Risk', 'PrimaryOutcomeDescription': 'The occurrence of a below-knee lower extremity amputation will be defined by observing an associated procedure code in the outpatient or inpatient medical service claims.', 'PrimaryOutcomeTimeFrame': 'up to 6 years (estimated study duration)'}, {'PrimaryOutcomeMeasure': 'Incidence of Below-Knee Lower Extremity Amputation in Canagliflozin New Users Versus non-SGLT2i Aha New Users', 'PrimaryOutcomeDescription': 'Hazard ratio will be estimated using a conditional Cox proportional hazards model based on propensity-matched cohorts.', 'PrimaryOutcomeTimeFrame': 'up to 6 years (estimated study duration)'}]",,"Inclusion Criteria:

First exposure to the particular drug in person's history
For the initial analysis, exposure start is between April 1, 2013 and January 31, 2015. For the ongoing repeat analysis per the protocol amendment, the study period ending date will vary depending on the time of each data extraction and analysis
At least 365 days of observation time prior to index
At least 1 condition occurrence of 'Type II diabetes' any time before or on index
Exactly 0 condition occurrences of 'Type I diabetes' any time before or on index

Exclusion Criteria:

Participants who had amputations prior to the index date were excluded.",No,All,18 Years,,"['Adult', 'Older Adult']",,,No,,,No,['Cohort'],['Retrospective'],"Participants who are new users (with at least 365 day of prior observation) to a drug exposure of interest between April 1, 2013 and January 31, 2015 and at least 1 condition occurrence of 'Type II diabetes' any time before or on index and no condition occurrences of 'Type I diabetes' or 'Secondary diabetes' any time before or on index date. January 31, 2015 reflects the data cutoff date for the initial analysis.",Non-Probability Sample,"[{'SecondaryId': 'RRA-17578', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Janssen Research & Development, LLC.'}]",,,,,,,"[{'OverallOfficialName': 'Janssen Research & Development, LLC Clinical Trial', 'OverallOfficialAffiliation': 'Janssen Research & Development, LLC', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003924', 'ConditionMeshTerm': 'Diabetes Mellitus, Type 2'}]","[{'ConditionAncestorId': 'D000003920', 'ConditionAncestorTerm': 'Diabetes Mellitus'}, {'ConditionAncestorId': 'D000044882', 'ConditionAncestorTerm': 'Glucose Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000004700', 'ConditionAncestorTerm': 'Endocrine System Diseases'}]","[{'ConditionBrowseLeafId': 'M5698', 'ConditionBrowseLeafName': 'Diabetes Mellitus', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5702', 'ConditionBrowseLeafName': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafAsFound': 'Diabetes Mellitus, Type 2', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23990', 'ConditionBrowseLeafName': 'Glucose Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6445', 'ConditionBrowseLeafName': 'Endocrine System Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC19', 'ConditionBrowseBranchName': 'Gland and Hormone Related Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M266956', 'InterventionBrowseLeafName': 'Empagliflozin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8948', 'InterventionBrowseLeafName': 'Insulin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M178017', 'InterventionBrowseLeafName': 'Insulin, Globin Zinc', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7626', 'InterventionBrowseLeafName': 'Glucagon', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M1691', 'InterventionBrowseLeafName': 'Sodium-Glucose Transporter 2 Inhibitors', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M25584', 'InterventionBrowseLeafName': 'Glucagon-Like Peptide 1', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M331', 'InterventionBrowseLeafName': 'Canagliflozin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M252914', 'InterventionBrowseLeafName': '2,4-thiazolidinedione', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Hypo', 'InterventionBrowseBranchName': 'Hypoglycemic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00412568,WRAMC WU # 04-2335-99d,Walter Reed Army Medical Center,FED,"Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel","Evaluation of Conventional Photorefractive Keratectomy (PRK) in U.S. Army Personnel, Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel",Nov-07,Completed,No,May-04,,,,Mar-08,,15-Dec-06,15-Dec-06,18-Dec-06,Estimate,31-Mar-08,01-Apr-08,Estimate,,Walter Reed Army Medical Center,FED,,,,,"The purpose of this study is to:

evaluate the safety and efficacy of conventional PRK in U.S. Army personnel who have naturally occurring myopia with or without astigmatism.
compare the data from this control group to study groups undergoing wavefront guided PRK.",['Myopia'],Interventional,['Not Applicable'],Non-Randomized,Single Group Assignment,Treatment,None (Open Label),150,Anticipated,"[{'ArmGroupLabel': '1', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'PRK control group', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Photorefractive Keratectomy (PRK)']}}]","[{'InterventionType': 'Procedure', 'InterventionName': 'Photorefractive Keratectomy (PRK)', 'InterventionDescription': 'vision correction with PRK', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}]","[{'PrimaryOutcomeMeasure': 'safety, efficacy, and refractive stability', 'PrimaryOutcomeTimeFrame': 'one year after procedure'}]",,"Inclusion Criteria:

Male or female, of any race, and at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
Manifest refractive spherical equivalent (MSE) of up to 6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00 D.
Manifest refraction and LADARWave™ refractions must be within 1.00 D.
Best spectacle corrected visual acuity of 20/20 or better in both eyes.
Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian; mires should be regular.
Located in the greater Washington DC area for a 12-month period.
Consent of the subject's command (active duty) to participate in the study.
Access to transportation to meet follow-up requirements.

Exclusion Criteria:

Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy.
Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity.
Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline.
Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye.
History of recurrent erosions or epithelial basement dystrophy.
Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
Any physical or mental impairment that would preclude participation in any of the examinations.",Accepts Healthy Volunteers,All,21 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Walter Reed Army Medical Center, Center For Refractive Surgery', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20302', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'United States Naval Medical Center, San Diego', 'CollaboratorClass': 'FED'}]",,,['Naturally occuring myopia with or without astigmatism.'],,,,,,[{'SecondaryId': 'WU #2335-99 (master protocol)'}],,,,,,,"[{'OverallOfficialName': 'KRAIG S. BOWER, MD', 'OverallOfficialAffiliation': 'Walter Reed Army Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000009216', 'ConditionMeshTerm': 'Myopia'}]","[{'ConditionAncestorId': 'D000012030', 'ConditionAncestorTerm': 'Refractive Errors'}, {'ConditionAncestorId': 'D000005128', 'ConditionAncestorTerm': 'Eye Diseases'}]","[{'ConditionBrowseLeafId': 'M10751', 'ConditionBrowseLeafName': 'Myopia', 'ConditionBrowseLeafAsFound': 'Myopia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3139', 'ConditionBrowseLeafName': 'Astigmatism', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13455', 'ConditionBrowseLeafName': 'Refractive Errors', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6854', 'ConditionBrowseLeafName': 'Eye Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC11', 'ConditionBrowseBranchName': 'Eye Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03353480,A0661212,Pfizer,INDUSTRY,Bioequivalence (BE) Study Comparing Azithromycin 250 mg Tablet Manufactured in China and in the United States,"AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, 3-WAY CROSSOVER BIOEQUIVALENCE STUDY COMPARING AZITHROMYCIN 250 MG TABLET (MANUFACTURED AT PFIZER DALIAN, CHINA) WITH AZITHROMYCIN 250 MG TABLET (MANUFACTURED AT PFIZER BARCELONETA, UNITED STATES) UNDER FASTED AND FED CONDITIONS IN HEALTHY CHINESE SUBJECTS",Feb-19,Completed,No,20-Dec-17,Actual,29-Jan-18,Actual,26-Feb-18,Actual,21-Nov-17,21-Nov-17,27-Nov-17,Actual,19-Feb-19,21-Feb-19,Actual,Sponsor,Pfizer,INDUSTRY,Yes,No,,Yes,"China Food and Drug Administration (CFDA) initiated a generic consistency evaluation program to evaluate the quality and efficacy of the products manufactured in China in 2016. This is a reference scaled bioequivalence study to support the program and to demonstrate the bioequivalence between the 250 mg azithromycin tablet manufactured at Pfizer Dalian, China (the localized originator, Test) and the 250 mg azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US (the originator, Reference) in healthy Chinese subjects under fasted and fed conditions. This open-lable, randomized, single-dose 3-way crossover study will enroll approximately 33 subjects for each condition. The primary endpoints are azithromycin area under the serum concentration-time curve from time zero to 72 hours post-dose (AUC72) and Cmax.",['Bioequivalence'],Interventional,['Phase 1'],Randomized,Crossover Assignment,Basic Science,None (Open Label),66,Actual,"[{'ArmGroupLabel': 'Reference', 'ArmGroupType': 'Other', 'ArmGroupDescription': '250mg Azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Azithromycin Tablet manufactured in US']}}, {'ArmGroupLabel': 'Experimental', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': '250mg Azithromycin tablet manufactured at Pfizer Dalian, China', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Azithromycin Tablet manufactured in China']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Azithromycin Tablet manufactured in China', 'InterventionDescription': '250 mg Azithromycin Tablet manufactured in China', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Experimental']}, 'InterventionOtherNameList': {'InterventionOtherName': ['The localized originator, Experimental']}}, {'InterventionType': 'Drug', 'InterventionName': 'Azithromycin Tablet manufactured in US', 'InterventionDescription': '250 mg Azithromycin Tablet manufactured in US', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Reference']}, 'InterventionOtherNameList': {'InterventionOtherName': ['The originator, Reference']}}]","[{'PrimaryOutcomeMeasure': 'AUC0-72', 'PrimaryOutcomeDescription': 'Area under the serum concentration-time profile from time zero to 72 hours post dose based on observed serum concentrations at time points 0 (prior-dose), 0.5, 1, 2, 3, 4, 5, 6,8, 10, 12, 24, 48 and 72 hours after dose using linear/log trapezoidal methods', 'PrimaryOutcomeTimeFrame': '0-72 hours'}, {'PrimaryOutcomeMeasure': 'Cmax', 'PrimaryOutcomeDescription': 'Maximum serum concentration among observed serum concentrations at time points 0 (prior-dose), 0.5, 1, 2, 3, 4, 5, 6,8, 10, 12, 24, 48 and 72 hours after dose', 'PrimaryOutcomeTimeFrame': '0-72 hours'}]","[{'SecondaryOutcomeMeasure': 'Adverse Events', 'SecondaryOutcomeDescription': 'All observed or volunteered safety events regardless of treatment group or suspected causal relationship to the investigational product(s) will be reported during study.', 'SecondaryOutcomeTimeFrame': 'Day 1 to Day 32 or early termination, plus at least 28 calendar days and up to 35 calendar days after the last administration of the investigational product'}]","Inclusion Criteria:

Subjects must meet all of the following inclusion criteria to be eligible for enrollment in the study:

Healthy Chinese male and female subjects, between the ages of 18 and 45 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure (BP) and pulse rate (PR) measurement, 12-lead ECG, or clinical laboratory tests.
BMI of 18 to 28 kg/m2; and a total body weight ≥50 kg for males and ≥45 kg for females.
Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the study.
Subjects who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures.
Subjects must be of Chinese ethnicity (individuals currently residing in mainland China who were born in China and have both parents of Chinese descent).

Exclusion Criteria:

Subjects with any of the following characteristics/conditions will not be included in the study:

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
Any condition possibly affecting drug absorption (eg, gastrectomy).
A positive urine drug screen, history of drug abuse within the past 5 years.
History of regular alcohol consumption exceeding 14 drinks/week (1 drink = 100 mL of wine or 285 mL of beer or 25 mL of hard liquor) within 3 months of Screening.
Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day within 3 months prior to Screening.
Treatment with an investigational drug within 3 months preceding the first dose of investigational product.
Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the subject's eligibility.
Screening supine 12-lead ECG demonstrating a corrected QT (QTc) interval >450 msec or a QRS complex >120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the subject's eligibility.
Female subjects of childbearing potential and fertile male subjects who are unwilling or unable to use a highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 28 days after the last dose of investigational product.
Female subjects who are breastfeeding or with positive pregnancy test at Screening and during the study period.
Use of prescription or nonprescription drugs, dietary supplements and herbal medicines within 14 days prior to Screening. As an exception, acetaminophen/paracetamol may be used at doses of ≤1 g/day. Limited use of nonprescription medications that are not believed to affect subject safety or the overall results of the study may be permitted on a case by case basis following approval by the sponsor. Taking any medicinal product that changes the activity of hepatic enzymes within 28 days prior to Screening, such as a strong CYP3A4 inducer (eg, St. John's Wort).
Blood donation (excluding plasma donations) or loss of blood of approximately 450 mL or more within 3 months prior to Screening.
History of hypersensitivity to azithromycin or any components of its formulation.
Use of special diet (including dragon fruit, mango, citrus, etc.), strenuous activities or other factors that may affect the disposition of the study medication within 14 days prior to Screening.
Use of chocolate, food or beverages containing caffeine or xanthine within 48 hours prior to dosing.
Use of products containing alcohol within 48 hours prior to dosing.
Intolerance of the standard high fat breakfast, which is only applicable to the subjects participating in Group 2 (fed condition).
History of HIV, hepatitis B, or hepatitis C; positive testing for HIV, HepBsAg, HepBcAb, HCVAb, or TPPA.
Unwilling or unable to comply with the criteria in the Lifestyle Requirements section.
Subjects who are investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or subjects who are Pfizer employees, including their family members, directly involved in the conduct of the study.
Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.",Accepts Healthy Volunteers,All,18 Years,45 Years,['Adult'],"[{'LocationFacility': 'The First Hospital of Jilin University/Phase I Clinical Trials Unit', 'LocationCity': 'Changchun', 'LocationState': 'Jilin', 'LocationZip': '130021', 'LocationCountry': 'China'}]",,No,"This is a reference scaled bioequivalence study to support a generic consistency evaluation program, initiated by CFDA in 2016, for the evaluation of quality and efficacy of the products manufactured in China. The selected strength of 250 mg tablet is the approved strength. The primary objective is to demonstrate the bioequivalence between the 250 mg azithromycin tablet manufactured at Pfizer Dalian, China (the localized originator, Test) and the 250 mg azithromycin tablet manufactured at Pfizer Barceloneta, Puerto Rico, US (the originator, Reference) in healthy Chinese subjects under fasted (Group 1) and fed (Group 2) conditions. Approximately 33 Chinese healthy subjects will be enrolled for each group.

The primary endpoints are azithromycin area under the serum concentration-time curve from time zero to 72 hours post-dose (AUC72) and Cmax.

The secondary objective is to evaluate the safety and tolerability of azithromycin administered as a single oral dose of 250 mg tablet manufactured at Pfizer Dalian, China and 250 mg tablet manufactured at Pfizer Barceloneta, Puerto Rico, US in healthy Chinese subjects under fasted and fed conditions. And the secondary endpoint is adverse events (AEs). Other endpoints include Tmax of azithromycin, safety laboratory tests and vital signs.

In each group, subjects will be randomized to one of the 3 treatment sequences. Each treatment sequence will consist of 3 periods, separated by a washout period of at least 14 days between each period.

On Day 1 of each period in both groups, each subject will be administered investigational product at approximately 8:00 AM (± 2 hours). Blood samples for the analysis of azithromycin in serum will be collected at pre-dose (within 30 minutes prior to dosing) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48 and 72 hours post dose in each period. Vital signs, physical examination, laboratory tests and 12-lead electrocardiogram (ECG) will be performed at specified times. Tolerability and safety will be assessed for all treatments by monitoring AEs.","['Azithromycin tablet, Bioequivalence, Phase I, Chinese, Healthy Subjects']",,,,,,,,,,,,,"[{'OverallOfficialName': 'Pfizer CT.gov Call Center', 'OverallOfficialAffiliation': 'Pfizer', 'OverallOfficialRole': 'Study Director'}]",No,,,,,,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",,,,,"[{'SeeAlsoLinkLabel': 'To obtain contact information for a study center near you, click here.', 'SeeAlsoLinkURL': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0661212&StudyName=An+Open-label%2C+Randomized%2C+Single-dose%2C+3-way+Crossover+Bioequivalence+Study+Comparing+Azithromycin+250+Mg+Tablet+%28manufactured+At+Pfizer+Dalian%2C+China%29+With+Azithromycin+250+Mg+Tablet+%28manufactured+At+Pfizer+Barceloneta%2C+United+States%29+Under+Fasted+And+Fed+Conditions+In+Healthy+Chinese+Subjects'}]",,,,,,,,,,,"This is an open-label, randomized, single-dose, 3-way crossover, reference scaled bioequivalence study under fasted and fed conditions in healthy Chinese subjects.

Under each condition, subjects will be randomized to one of the 3 treatment sequences. Each treatment sequence will consist of 3 periods, separated by a washout period of at least 14 days between each period. For sequence 1, first localized originator, then originator and finally originator will be administered. The order for sequence 2 is originator, localized originator and originator. The order for sequence 3 is originator, originator and localized originator.",,,,,,,,,26-Oct-20,,,,,"[{'InterventionMeshId': 'D000017963', 'InterventionMeshTerm': 'Azithromycin'}]","[{'InterventionAncestorId': 'D000000900', 'InterventionAncestorTerm': 'Anti-Bacterial Agents'}, {'InterventionAncestorId': 'D000000890', 'InterventionAncestorTerm': 'Anti-Infective Agents'}]","[{'InterventionBrowseLeafId': 'M18715', 'InterventionBrowseLeafName': 'Azithromycin', 'InterventionBrowseLeafAsFound': 'Anxiety', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2803', 'InterventionBrowseLeafName': 'Anti-Bacterial Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00800267,96TIPG005,Pfizer,INDUSTRY,A Study of Glaucoma or Ocular Hypertension in Patients Within the United States,"A 6-Month, Randomized, Double-Masked Comparison of Fixed Combination of Latanoprost and Timolol With the Individual Components, Continuing Into a 6-Month Open Label Safety Study of Fixed Combination in Patients With Glaucoma or Ocular Hypertension. A Multicenter Study in the United States",Mar-09,Completed,No,Jul-97,,Jun-99,Actual,Jun-99,Actual,03-Nov-08,01-Dec-08,02-Dec-08,Estimate,05-Mar-09,06-Mar-09,Estimate,,Pfizer,INDUSTRY,,,,,Safety and efficacy study comparing between fixed combination latanoprost-timolol and its component parts.,"['Ocular Hypertension', 'Glaucoma']",Interventional,['Phase 3'],Randomized,Parallel Assignment,Treatment,Double,418,Actual,"[{'ArmGroupLabel': 'Fixed combination of latanoprost 0.005% and timolol 0.5%', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: fixed combination latanoprost-timolol']}}, {'ArmGroupLabel': 'latanoprost 0.005%', 'ArmGroupType': 'Active Comparator', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: latanoprost 0.005%']}}, {'ArmGroupLabel': 'Timolol - 0.5%', 'ArmGroupType': 'Active Comparator', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: timolol 0.5%']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'latanoprost 0.005%', 'InterventionDescription': 'placebo in the morning and latanoprost .005% in the evening', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['latanoprost 0.005%']}}, {'InterventionType': 'Drug', 'InterventionName': 'fixed combination latanoprost-timolol', 'InterventionDescription': 'one drop in the morning and placebo in the evening', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Fixed combination of latanoprost 0.005% and timolol 0.5%']}}, {'InterventionType': 'Drug', 'InterventionName': 'timolol 0.5%', 'InterventionDescription': 'one drop in the morning and evening', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Timolol - 0.5%']}}]","[{'PrimaryOutcomeMeasure': 'The differences from baseline in diurnal IOP reduction after six months of treatment will be tested between the fixed combination and the monotherapy groups.', 'PrimaryOutcomeTimeFrame': '6 months'}, {'PrimaryOutcomeMeasure': 'Primary objective: to demonstrate that the fixed combination of latanoprost and timolol has a better IOP-reducing effect than the individual monotherapies.', 'PrimaryOutcomeTimeFrame': '6 months'}]","[{'SecondaryOutcomeMeasure': 'To examine, within treatment groups, the diurnal IOP reducing effect from baseline for all effect from baseline between the monotherapies latanoprost and timolol', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'To compare the diurnal IOP reducing effect from baseline between the monotherapies latanoprost and timolol at Week 26', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'To compared the number of treatment failures and patients withdrawn due to uncontrolled IOP from baseline to Week 26 between treatment groups', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'To describe the IOP development from baseline to Week 26 for all treatment groups', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'To compared the IOP reducing effect from baseline to Week 26 of the monotherapies with the IOP reducing effect from Week 26 to Week 52 of the fixed combination', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'To examine, within the fixed combination treatment group, the diurnal IOP reducing effect from baseline to Week 26 and Week 52', 'SecondaryOutcomeTimeFrame': '6 months'}, {'SecondaryOutcomeMeasure': 'To follow the safety variables throughout the study periods.', 'SecondaryOutcomeTimeFrame': '6 months'}]","Inclusion Criteria:

Unilateral or bilateral primary open angle glaucoma, capsular glaucoma, pigmentary glaucoma or ocular hypertension.
Patients currently on IOP reducing therapy: IOP greater than or equal to 25mmHg (Ltwo IOP determinations at pre-study separated by at least one hour) OR Patients without IOP reducing therapy: IOP greater than or equal to 30mmHg (two IOP determinations at pre-study separated by at least one hour).

Exclusion Criteria:

History of acute angle closure or closed/barely open anterior chamber angle.
Current use of contact lenses.
Ocular surgery or argon laser trabeculoplasty (ALT) within three months prior to pre-study visit.
Ocular inflammation/infection occurring within three months prior to pre-study visit.
Hypersensitivity to benzalkonium chloride or to any other component of the study drug solutions.
Other abnormal ocular condition or symptom preventing the patient from entering the study, according to the investigator's judgement.
Patients with conditions in which treatment with B-blocking agents are contraindicated: cardiac failure, sinus bradycardia, second and third degree atrio-ventricular block.
Patients with conditions in which treatment with B-blocking agents are contraindicated: bronchial asthma, history of bronchial asthma or chronic obstructive pulmonary disease.
Inability to adhere to treatment/visit plan.
Have participated in any other clinical study within one month prior to pre-study visit.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Anaheim', 'LocationState': 'California', 'LocationZip': '92801', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Anaheim', 'LocationState': 'California', 'LocationZip': '92807', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95819', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Sacramento', 'LocationState': 'California', 'LocationZip': '95823', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94115', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Boulder', 'LocationState': 'Colorado', 'LocationZip': '80304-3573', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Denver', 'LocationState': 'Colorado', 'LocationZip': '80210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Largo', 'LocationState': 'Florida', 'LocationZip': '34640', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Tampa', 'LocationState': 'Florida', 'LocationZip': '33613', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30322', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30342', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30349', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'East Point', 'LocationState': 'Georgia', 'LocationZip': '30223', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Griffin', 'LocationState': 'Georgia', 'LocationZip': '30223', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Morrow', 'LocationState': 'Georgia', 'LocationZip': '30260', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60612', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Wheaton', 'LocationState': 'Illinois', 'LocationZip': '60187', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Elkhart', 'LocationState': 'Indiana', 'LocationZip': '46515', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Mishawaka', 'LocationState': 'Indiana', 'LocationZip': '46545', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'South Bend', 'LocationState': 'Indiana', 'LocationZip': '46601', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'South Bend', 'LocationState': 'Indiana', 'LocationZip': '46617', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Iowa City', 'LocationState': 'Iowa', 'LocationZip': '52245', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationZip': '40207', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Owings Mills', 'LocationState': 'Maryland', 'LocationZip': '21117', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02111', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Golden Valley', 'LocationState': 'Minnesota', 'LocationZip': '55422', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Minneapolis', 'LocationState': 'Minnesota', 'LocationZip': '55421', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Kansas City', 'LocationState': 'Missouri', 'LocationZip': '64111', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Kansas City', 'LocationState': 'Missouri', 'LocationZip': '64114', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Warrenburg', 'LocationState': 'Missouri', 'LocationZip': '64093', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Concord', 'LocationState': 'New Hampshire', 'LocationZip': '03301', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'South Plainfield', 'LocationState': 'New Jersey', 'LocationZip': '07080', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Charlotte', 'LocationState': 'North Carolina', 'LocationZip': '28204', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Charlotte', 'LocationState': 'North Carolina', 'LocationZip': '28210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Charlotte', 'LocationState': 'North Carolina', 'LocationZip': '28260', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Matthews', 'LocationState': 'North Carolina', 'LocationZip': '28105', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Monroe', 'LocationState': 'North Carolina', 'LocationZip': '28112', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Wyomissing', 'LocationState': 'Pennsylvania', 'LocationZip': '19610', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Charleston', 'LocationState': 'South Carolina', 'LocationZip': '29412', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Mount Pleasant', 'LocationState': 'South Carolina', 'LocationZip': '29464-3245', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Memphis', 'LocationState': 'Tennessee', 'LocationZip': '38119', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationZip': '78731-4941', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Galveston', 'LocationState': 'Texas', 'LocationZip': '77555-1141', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Charlottesville', 'LocationState': 'Virginia', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Richmond', 'LocationState': 'Virginia', 'LocationZip': '23219', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Richmond', 'LocationState': 'Virginia', 'LocationZip': '23235', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Tacoma', 'LocationState': 'Washington', 'LocationZip': '98431', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Madison', 'LocationState': 'Wisconsin', 'LocationZip': '53705', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pfizer Investigational Site', 'LocationCity': 'Madison', 'LocationState': 'Wisconsin', 'LocationZip': '53715', 'LocationCountry': 'United States'}]",,No,,"['glaucoma', 'ocular hypertension', 'Fixed combination latanoprost-timolol', 'latanoprost', 'timolol']",,,,,,[{'SecondaryId': 'A6641006'}],,,,,"['Participant', 'Investigator']",,"[{'OverallOfficialName': 'Pfizer CT.gov Call Center', 'OverallOfficialAffiliation': 'Pfizer', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,,,,"[{'SeeAlsoLinkLabel': 'To obtain contact information for a study center near you, click here.', 'SeeAlsoLinkURL': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=96TIPG005&StudyName=A%20study%20of%20glaucoma%20or%20ocular%20hypertension%20in%20patients%20within%20the%20United%20States.'}]",,,,,,,"Director, Clinical Trial Disclosure Group","Pfizer, Inc.",,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000005901', 'ConditionMeshTerm': 'Glaucoma'}, {'ConditionMeshId': 'D000009798', 'ConditionMeshTerm': 'Ocular Hypertension'}, {'ConditionMeshId': 'D000006973', 'ConditionMeshTerm': 'Hypertension'}]","[{'ConditionAncestorId': 'D000014652', 'ConditionAncestorTerm': 'Vascular Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000005128', 'ConditionAncestorTerm': 'Eye Diseases'}]","[{'ConditionBrowseLeafId': 'M8607', 'ConditionBrowseLeafName': 'Hypertension', 'ConditionBrowseLeafAsFound': 'Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7596', 'ConditionBrowseLeafName': 'Glaucoma', 'ConditionBrowseLeafAsFound': 'Glaucoma', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M11314', 'ConditionBrowseLeafName': 'Ocular Hypertension', 'ConditionBrowseLeafAsFound': 'Ocular Hypertension', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15983', 'ConditionBrowseLeafName': 'Vascular Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6854', 'ConditionBrowseLeafName': 'Eye Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC11', 'ConditionBrowseBranchName': 'Eye Diseases'}]","[{'InterventionMeshId': 'D000013999', 'InterventionMeshTerm': 'Timolol'}, {'InterventionMeshId': 'D000077338', 'InterventionMeshTerm': 'Latanoprost'}]","[{'InterventionAncestorId': 'D000000319', 'InterventionAncestorTerm': 'Adrenergic beta-Antagonists'}, {'InterventionAncestorId': 'D000018674', 'InterventionAncestorTerm': 'Adrenergic Antagonists'}, {'InterventionAncestorId': 'D000018663', 'InterventionAncestorTerm': 'Adrenergic Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000000889', 'InterventionAncestorTerm': 'Anti-Arrhythmia Agents'}, {'InterventionAncestorId': 'D000000959', 'InterventionAncestorTerm': 'Antihypertensive Agents'}]","[{'InterventionBrowseLeafId': 'M1775', 'InterventionBrowseLeafName': 'Latanoprost', 'InterventionBrowseLeafAsFound': 'pH', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M15340', 'InterventionBrowseLeafName': 'Timolol', 'InterventionBrowseLeafAsFound': 'Progressive', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2252', 'InterventionBrowseLeafName': 'Adrenergic beta-Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19330', 'InterventionBrowseLeafName': 'Adrenergic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19339', 'InterventionBrowseLeafName': 'Adrenergic Antagonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2794', 'InterventionBrowseLeafName': 'Anti-Arrhythmia Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2858', 'InterventionBrowseLeafName': 'Antihypertensive Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'AnAg', 'InterventionBrowseBranchName': 'Antihypertensive Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AnArAg', 'InterventionBrowseBranchName': 'Anti-Arrhythmia Agents'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00601835,TDC01,Sanofi,INDUSTRY,Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td,Immunogenicity and Safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) for Adult Use Vaccine Compared With U.S. Manufactured Tetanus and Diphtheria Toxoids Adsorbed for Adult Use Vaccine In Persons 60 Years of Age and Older and Immunogenicity and Safety of Canadian Td Vaccine in Persons 11 Through 59 Years of Age,Apr-16,Completed,No,May-04,,Jul-05,Actual,Jul-05,Actual,15-Jan-08,25-Jan-08,28-Jan-08,Estimate,12-Apr-16,14-Apr-16,Estimate,Sponsor,"Sanofi Pasteur, a Sanofi Company",INDUSTRY,,,,,"To compare the seroprotection rates and booster responses to Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the seroprotection rates and booster responses to the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to subjects ≥ 60 years of age.

To compare the post-vaccination geometric mean titers of antibody (GMTs) to Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to the post-vaccination GMTs to the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine when administered to subjects ≥ 60 years of age.","['Diphtheria', 'Tetanus']",Interventional,['Phase 4'],Randomized,Parallel Assignment,Prevention,Quadruple,3651,Actual,"[{'ArmGroupLabel': 'Canadian Td Vaccine Group', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants received Canadian manufactured Td vaccine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine']}}, {'ArmGroupLabel': 'United States Td Vaccine Group', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants received US manufactured Td vaccine', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine', 'InterventionDescription': '0.5 mL, Intramuscular, single dose', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Canadian Td Vaccine Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['TENIVAC™']}}, {'InterventionType': 'Biological', 'InterventionName': 'Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine', 'InterventionDescription': '0.5 mL, Intramuscular, Single dose', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['United States Td Vaccine Group']}, 'InterventionOtherNameList': {'InterventionOtherName': ['DECAVAC®']}}]","[{'PrimaryOutcomeMeasure': 'Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria.', 'PrimaryOutcomeDescription': 'Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.', 'PrimaryOutcomeTimeFrame': '28 Days post-vaccination'}]","[{'SecondaryOutcomeMeasure': 'Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.', 'SecondaryOutcomeTimeFrame': '28 Days post-vaccination'}]","Inclusion Criteria:

Participant is healthy as per medical history reported by subject.
Participant is at least 11 years of age at the time of vaccination.
Participant has a signed Institutional Review Board (IRB)-approved informed assent/consent form. For subjects 11 to 17 years of age, a written informed consent must be obtained from parent(s) or legal guardian(s) and a written informed assent must be obtained from the subject
Participant provides history or documentation of primary or booster immunization with Diphtheria and Tetanus.
Female participants of childbearing potential must have a negative urine pregnancy test at the time of enrollment.

Exclusion Criteria:

Serious and uncontrolled chronic disease (i.e., cardiac, pulmonary, renal, neurologic, metabolic, rheumatologic, etc.).
Known or suspected impairment of immunologic function.
Acute medical illness with or without fever within the last 72 hours or an oral temperature ≥ 100.4°F (≥ 38°C) at the time of enrollment.
Administration of immune globulin or other blood products within the last three months; administration of corticosteroids (injected or oral) or other immunomodulatory therapy within six weeks of the study vaccine. However, individuals on a tapering dose schedule of oral steroids may be included in the trial, as long as steroids were discontinued more than two weeks prior to enrollment.
Received any vaccine, other than influenza vaccine, in the 28-day period prior to enrollment or scheduled to receive any vaccination, other than influenza prior to Visit 2 blood draw. For influenza vaccine only, exclude if received in the 14 day period prior to enrollment or scheduled to receive in the 14 day period after Visit 1.
Suspected or known hypersensitivity to Td components, thimerosal (for subjects > 60 years of age) or latex rubber.
Unable to attend scheduled visits or unable to comply with the study procedures.
Enrolled in another clinical trial.
Any condition that would pose a health risk to the participant or interfere with the evaluation of the vaccine in the opinion of the investigator.
A positive urine pregnancy test at the time of enrollment for all females of childbearing potential.
Female of childbearing potential who does not agree either to remain abstinent or to use effective birth control during the period of the trial.
Breast feeding during the period of the trial.
A history of Guillain- Barré syndrome within 6 weeks after a previous dose of a tetanus toxoid-containing vaccine.
Receipt of a tetanus or diphtheria vaccination within the 5 years prior to enrollment.
A previous history of diphtheria disease within the last 25 years or tetanus disease
History of Arthus-type hypersensitivity reaction or a temperature >103° F following a prior dose of tetanus toxoid, unless 10 years have elapsed since the previous dose.",Accepts Healthy Volunteers,All,11 Years,60 Years,"['Child', 'Adult']","[{'LocationCity': 'Oakland', 'LocationState': 'California', 'LocationZip': '94611', 'LocationCountry': 'United States'}, {'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15241', 'LocationCountry': 'United States'}]",,No,"This is a multi-center, partially open-label, partially randomized double blind trial for immunogenicity and safety in the United States. Participants will be enrolled to one of three treatment groups:

Subjects ages 11-59 years will receive Canadian manufactured Td vaccine on Day 0
Subjects 60 years or older will be randomized to receive either US manufactured Td on Day 0, or,
Subjects 60 years or older randomized to receive Canadian manufactured Td on Day 0

The trial is designed to assess the safety of Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in all trial participants 11 to 59 years of age and to describe the immune responses in subsets of adolescents (11-14, and 15-18 years of age) and in a subset of adults 19-59 years of age. The trial will also compare the immune responses and safety in subjects ≥ 60 years of age receiving Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine to an equal number of subjects ≥ 60 years of age receiving US Manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine.","['Diphtheria', 'Tetanus']",,,,,,,,,,,"['Participant', 'Care Provider', 'Investigator', 'Outcomes Assessor']","[{'OtherOutcomeMeasure': 'Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.', 'OtherOutcomeDescription': 'Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Chills, Diarrhea, Fever (temperature), Headache, Malaise, Muscle weakness, Nausea, Pain in joints, Rash, and Vomiting.', 'OtherOutcomeTimeFrame': '0-14 days post-vaccination'}]","[{'OverallOfficialName': 'Medical Director', 'OverallOfficialAffiliation': 'Sanofi Pasteur Inc.', 'OverallOfficialRole': 'Study Director'}]",,,16-Nov-09,21-Jan-11,18-Feb-11,Estimate,,,,,,"[{'SeeAlsoLinkLabel': 'http://www.sanofipasteur.com', 'SeeAlsoLinkURL': 'http://www.sanofipasteur.com'}, {'SeeAlsoLinkLabel': 'Related Info', 'SeeAlsoLinkURL': 'http://www.sanofi.com'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000013742', 'ConditionMeshTerm': 'Tetanus'}, {'ConditionMeshId': 'D000004165', 'ConditionMeshTerm': 'Diphtheria'}, {'ConditionMeshId': 'D000013746', 'ConditionMeshTerm': 'Tetany'}]","[{'ConditionAncestorId': 'D000003015', 'ConditionAncestorTerm': 'Clostridium Infections'}, {'ConditionAncestorId': 'D000016908', 'ConditionAncestorTerm': 'Gram-Positive Bacterial Infections'}, {'ConditionAncestorId': 'D000001424', 'ConditionAncestorTerm': 'Bacterial Infections'}, {'ConditionAncestorId': 'D000020879', 'ConditionAncestorTerm': 'Neuromuscular Manifestations'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000006996', 'ConditionAncestorTerm': 'Hypocalcemia'}, {'ConditionAncestorId': 'D000002128', 'ConditionAncestorTerm': 'Calcium Metabolism Disorders'}, {'ConditionAncestorId': 'D000008659', 'ConditionAncestorTerm': 'Metabolic Diseases'}, {'ConditionAncestorId': 'D000003354', 'ConditionAncestorTerm': 'Corynebacterium Infections'}, {'ConditionAncestorId': 'D000000193', 'ConditionAncestorTerm': 'Actinomycetales Infections'}]","[{'ConditionBrowseLeafId': 'M5930', 'ConditionBrowseLeafName': 'Diphtheria', 'ConditionBrowseLeafAsFound': 'Diphtheria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15094', 'ConditionBrowseLeafName': 'Tetanus', 'ConditionBrowseLeafAsFound': 'Tetanus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M15098', 'ConditionBrowseLeafName': 'Tetany', 'ConditionBrowseLeafAsFound': 'Tetanus', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4830', 'ConditionBrowseLeafName': 'Clostridium Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3303', 'ConditionBrowseLeafName': 'Bacterial Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17835', 'ConditionBrowseLeafName': 'Gram-Positive Bacterial Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21203', 'ConditionBrowseLeafName': 'Neuromuscular Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8629', 'ConditionBrowseLeafName': 'Hypocalcemia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10222', 'ConditionBrowseLeafName': 'Metabolic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3973', 'ConditionBrowseLeafName': 'Calcium Metabolism Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5157', 'ConditionBrowseLeafName': 'Corynebacterium Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T1891', 'ConditionBrowseLeafName': 'Diphtheria', 'ConditionBrowseLeafAsFound': 'Diphtheria', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T5618', 'ConditionBrowseLeafName': 'Tetanus', 'ConditionBrowseLeafAsFound': 'Tetanus', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC18', 'ConditionBrowseBranchName': 'Nutritional and Metabolic Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]","[{'InterventionMeshId': 'D000014612', 'InterventionMeshTerm': 'Vaccines'}]","[{'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]","[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafAsFound': 'Group', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M8784', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]","A total of 3,651 participants that met the inclusion and exclusion criteria were enrolled in the study. One participant declined vaccination.

The immunogenicity subsets consist of all participants ≥ 60 years of age; the safety subsets consist of all participants ≥ 60 years of age and one third of participants 11 to 59 years of age.","Participants were enrolled in the study from 06 May 2004 through 13 December 2004, in 2 medical sites (4 investigators) in the US.","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'Canadian Td Vaccine Group', 'FlowGroupDescription': 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'United States Td Vaccine Group', 'FlowGroupDescription': 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2950'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '700'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '2890'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '686'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '60'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '14'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '9'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '6'}]}}, {'FlowDropWithdrawType': 'Physician Decision', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}, {'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '37'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '5'}]}}, {'FlowDropWithdrawType': 'Adverse Event', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '1'}]}}, {'FlowDropWithdrawType': 'Relocate', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '12'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '2'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'Canadian Td Vaccine Group', 'BaselineGroupDescription': 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'United States Td Vaccine Group', 'BaselineGroupDescription': 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '2950'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '700'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '3650'}]}}]","[{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1501'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1501'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1000'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '257'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1257'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '449'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '443'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '892'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '33.6', 'BaselineMeasurementSpread': '23.49'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '69.3', 'BaselineMeasurementSpread': '7.89'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '40.5', 'BaselineMeasurementSpread': '25.60'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1629'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '403'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2032'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1321'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '297'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1618'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2950'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '700'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '3650'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants ≥ 60 Years of Age With Antibody Levels ≥ 0.10 IU/mL to Tetanus and Diphtheria.', 'OutcomeMeasureDescription': 'Seroprotection and booster responses for both tetanus and diphtheria were considered to be an antibody level of ≥ 0.10 IU/mL 28 days post-vaccination with either the Canadian-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine or the US-manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine in participants ≥ 60 years of age.', 'OutcomeMeasurePopulationDescription': 'Seroprotection and Booster Responses to Tetanus and Diphtheria were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants', 'OutcomeMeasureTimeFrame': '28 Days post-vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Canadian Td Vaccine Group', 'OutcomeGroupDescription': 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'United States Td Vaccine Group', 'OutcomeGroupDescription': 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '661'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '658'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Tetanus Post-vaccination Seroprotection', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '96'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '97'}]}}]}}, {'OutcomeClassTitle': 'Diphtheria Post-vaccination Seroprotection', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '71'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '71'}]}}]}}, {'OutcomeClassTitle': 'Tetanus Booster Response', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '82'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '84'}]}}]}}, {'OutcomeClassTitle': 'Diphtheria Booster Response', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '66'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '63'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Post-vaccination Geometric Mean Titer (GMT) to Tetanus and Diphtheria in Participants ≥ 60 Years Vaccinated With Canadian-manufactured or US-manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.', 'OutcomeMeasurePopulationDescription': 'Geometric mean titers were determined in subjects ≥ 60 years of age in the per-protocol immunogenicity population', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Geometric Mean', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Titers', 'OutcomeMeasureTimeFrame': '28 Days post-vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Canadian Td Vaccine Group', 'OutcomeGroupDescription': 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'United States Td Vaccine Group', 'OutcomeGroupDescription': 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '661'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '658'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Tetanus post-vaccination', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.83', 'OutcomeMeasurementLowerLimit': '6.01', 'OutcomeMeasurementUpperLimit': '7.77'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '7.35', 'OutcomeMeasurementLowerLimit': '6.54', 'OutcomeMeasurementUpperLimit': '8.26'}]}}]}}, {'OutcomeClassTitle': 'Diphtheria post-vaccination', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.459', 'OutcomeMeasurementLowerLimit': '0.371', 'OutcomeMeasurementUpperLimit': '0.567'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0.409', 'OutcomeMeasurementLowerLimit': '0.332', 'OutcomeMeasurementUpperLimit': '0.504'}]}}]}}]}}, {'OutcomeMeasureType': 'Other Pre-specified', 'OutcomeMeasureTitle': 'Number of Participants Reporting Solicited Injection Site and Systemic Reactions Post-vaccination With Canadian-Manufactured or US-Manufactured Tetanus and Diphtheria Toxoids Adsorbed Vaccine.', 'OutcomeMeasureDescription': 'Solicited injection site reactions: Pain, Redness, and Swelling. Solicited systemic reactions: Chills, Diarrhea, Fever (temperature), Headache, Malaise, Muscle weakness, Nausea, Pain in joints, Rash, and Vomiting.', 'OutcomeMeasurePopulationDescription': 'Solicited safety parameters were in all enrolled and vaccinated participants ≥ 60 years of age and one third of participants 11 to 59 years of age. A subset of the intend-to-treat population.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Participants', 'OutcomeMeasureTimeFrame': '0-14 days post-vaccination', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Canadian Td Vaccine Group', 'OutcomeGroupDescription': 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'United States Td Vaccine Group', 'OutcomeGroupDescription': 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '1450'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '700'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Any Injection site pain', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '832'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '209'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Injection site pain (require medical care)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '5'}]}}]}}, {'OutcomeClassTitle': 'Any Injection site redness', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '299'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '132'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Injection site redness (≥ 50 mm)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '28'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '20'}]}}]}}, {'OutcomeClassTitle': 'Any Injection site swelling', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '205'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '93'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Injection site swelling (≥ 50 mm)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '32'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '11'}]}}]}}, {'OutcomeClassTitle': 'Any Chills', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '80'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '32'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Chills (Incapacitating)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'Any Diarrhea', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '152'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '53'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Diarrhea (≥ 5 episodes)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Any Fever', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '95'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '40'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Fever (≥ 39.0 °C)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Any Headache', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '380'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '122'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Headache (Incapacitating)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '16'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '4'}]}}]}}, {'OutcomeClassTitle': 'Any Malaise', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '226'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '90'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Malaise (Incapacitating)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '13'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6'}]}}]}}, {'OutcomeClassTitle': 'Any Muscle weakness', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '267'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '61'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Muscle weakness (Incapacitating)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'Any Nausea', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '106'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '34'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Nausea (Incapacitating)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Any Pain in joints', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '201'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '74'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Pain in joints (Incapacitating)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}, {'OutcomeClassTitle': 'Any Vomiting', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '33'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '6'}]}}]}}, {'OutcomeClassTitle': 'Grade 3 Vomiting (≥ 3 episodes)', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '1'}]}}]}}]}}]",5,Adverse event data were collected for 6 months post-vaccination in all participants enrolled in the study.,,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Canadian Td Vaccine Group', 'EventGroupDescription': 'Participants received the Canadian manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (TENIVAC™)', 'EventGroupSeriousNumAffected': '58', 'EventGroupSeriousNumAtRisk': '2950', 'EventGroupOtherNumAffected': '832', 'EventGroupOtherNumAtRisk': '2950'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'United States Td Vaccine Group', 'EventGroupDescription': 'Participants received the US manufactured Tetanus and Diphtheria Toxoids Adsorbed vaccine for Adult Use (DECAVAC®)', 'EventGroupSeriousNumAffected': '44', 'EventGroupSeriousNumAtRisk': '700', 'EventGroupOtherNumAffected': '209', 'EventGroupOtherNumAtRisk': '700'}]","[{'OtherEventTerm': 'Injection site pain', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '832', 'OtherEventStatsNumAffected': '832', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '209', 'OtherEventStatsNumAffected': '209', 'OtherEventStatsNumAtRisk': '693'}]}}, {'OtherEventTerm': 'Injection site redness', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '299', 'OtherEventStatsNumAffected': '299', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '132', 'OtherEventStatsNumAffected': '132', 'OtherEventStatsNumAtRisk': '693'}]}}, {'OtherEventTerm': 'Injection site swelling', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '205', 'OtherEventStatsNumAffected': '205', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '93', 'OtherEventStatsNumAffected': '93', 'OtherEventStatsNumAtRisk': '693'}]}}, {'OtherEventTerm': 'Chills', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '80', 'OtherEventStatsNumAffected': '80', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '32', 'OtherEventStatsNumAffected': '32', 'OtherEventStatsNumAtRisk': '693'}]}}, {'OtherEventTerm': 'Diarrhea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '152', 'OtherEventStatsNumAffected': '152', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '53', 'OtherEventStatsNumAffected': '53', 'OtherEventStatsNumAtRisk': '693'}]}}, {'OtherEventTerm': 'Pyrexia', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '95', 'OtherEventStatsNumAffected': '95', 'OtherEventStatsNumAtRisk': '1427'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '40', 'OtherEventStatsNumAffected': '40', 'OtherEventStatsNumAtRisk': '687'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '380', 'OtherEventStatsNumAffected': '380', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '122', 'OtherEventStatsNumAffected': '122', 'OtherEventStatsNumAtRisk': '693'}]}}, {'OtherEventTerm': 'Malaise', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '226', 'OtherEventStatsNumAffected': '226', 'OtherEventStatsNumAtRisk': '1433'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '90', 'OtherEventStatsNumAffected': '90', 'OtherEventStatsNumAtRisk': '692'}]}}, {'OtherEventTerm': 'Muscle weakness', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '267', 'OtherEventStatsNumAffected': '267', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '61', 'OtherEventStatsNumAffected': '61', 'OtherEventStatsNumAtRisk': '692'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '106', 'OtherEventStatsNumAffected': '106', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '34', 'OtherEventStatsNumAffected': '34', 'OtherEventStatsNumAtRisk': '692'}]}}, {'OtherEventTerm': 'Pains in joints', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA 8.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '201', 'OtherEventStatsNumAffected': '201', 'OtherEventStatsNumAtRisk': '1434'}, {'OtherEventStatsGroupId': 'EG001', 'OtherEventStatsNumEvents': '74', 'OtherEventStatsNumAffected': '74', 'OtherEventStatsNumAtRisk': '693'}]}}]",No,Yes,Medical Director,Sanofi Pasteur Inc.,RegistryContactUs@sanofipasteur.com,,"[{'SeriousEventTerm': 'Anaemia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Thrombocytopenia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Acute myocardial infarction', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Angina pectoris', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Atrial fibrillation', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cardiac failure congestive', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cardio-respiratory arrest', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cardiomyopathy', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Myocardial infarction', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Moebius II syndrome', 'SeriousEventOrganSystem': 'Congenital, familial and genetic disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Thyroid mass', 'SeriousEventOrganSystem': 'Endocrine disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Retinal artery occlusion', 'SeriousEventOrganSystem': 'Eye disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Abdominal pain', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Colonic polyp', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Dysphagia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Gastric ulcer perforation', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Ileus', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Inguinal hernia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Oesophageal achalasia', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Peritonitis', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Rectocele', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Chest discomfort', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Chest pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Death', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Non-cardiac chest pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cholecystitis', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cholecystitis chronic', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cholelithiasis', 'SeriousEventOrganSystem': 'Hepatobiliary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Bronchitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Bronchitis acute', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cellulitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Cystitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Diverticulitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Gangrene', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Gastroenteritis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Infectious mononucleosis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Influenza', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Localised infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Pneumonia', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Septic shock', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Viral infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Contusion', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Femoral neck fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Fibula fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Head injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Hepatic trauma', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Hip Fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Joint dislocation', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Post procedural haematoma', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Rib fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Spinal compression fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Tibia fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Wound', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Wrist fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Dehydration', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Hyponatraemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Arthropathy', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Back Pain', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Lumbar spinal stenosis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 8.0', 'SeriousEventAssessmentType': 'Non-systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '2950'}, {'SeriousEventStatsGroupId': 'EG001', 'SeriousEventStatsNumEvents': '0', 'SeriousEventStatsNumAffected': '0', 'SeriousEventStatsNumAtRisk': '700'}]}}, {'SeriousEventTerm': 'Musculoskeletal chest pain', 'Se",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01087905,H2009-0074,"University of Wisconsin, Madison",OTHER,Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines,Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines,Oct-16,Completed,No,Apr-10,,Feb-11,Actual,Nov-11,Actual,15-Mar-10,15-Mar-10,16-Mar-10,Estimate,26-Oct-16,08-Dec-16,Estimate,Sponsor,"University of Wisconsin, Madison",OTHER,,,,,"Research shows that smoking cessation is the most significant preventable health behavior change that a person can make to lower cancer risk. In addition, telephone quitlines are an effective, science-based smoking cessation treatment that is universally accessible to smokers in the U.S. However, little research has explored promising approaches that could increase quitline use, improve quit rates, and inform resource allocation for quitline services. The proposed study will test three promising enhancements to the standard quitline treatment that typically consists of counseling and, possibly 2 weeks of a NRT medication. These enhancements are: 1) combination nicotine replacement therapy as recommended by the United States Public Health Service Clinical Practice Guideline on Treating Tobacco Use and Dependence; 2) extended duration of cessation medication use; and 3) an innovative counseling addition - cognitive medication adherence counseling - to optimize adherence to cessation medication. In addition, the cost-effectiveness of each intervention will be calculated. The findings of the proposed research have broad potential application and relevance to state quitlines, quitline service providers, and other purchasers of quitline services such as employers and insurers. Additionally, the study findings can potentially inform other telephone health behavior counseling programs.","['Smoking', 'Smoking Cessation']",Interventional,['Phase 4'],Randomized,Factorial Assignment,Treatment,Single,987,Actual,"[{'ArmGroupLabel': '2 Weeks of Nicotine Patch Only, No CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch']}}, {'ArmGroupLabel': '2 Weeks of Nicotine Patch Only plus CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 2 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch', 'Behavioral: CMAC']}}, {'ArmGroupLabel': '2 Wks Nicotine Patch+Nic Gum, No CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 2 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks\n\n2 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch', 'Drug: Nicotine gum']}}, {'ArmGroupLabel': '2 Wks Nicotine Patch+Nic Gum plus CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 2 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling\n\n2 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 2 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 2 weeks\n\n2 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 2 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch', 'Drug: Nicotine gum', 'Behavioral: CMAC']}}, {'ArmGroupLabel': '6 Weeks of Nicotine Patch Only, No CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch']}}, {'ArmGroupLabel': '6 Weeks of Nicotine Patch Only plus CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 6 weeks of nicotine patch and standard cessation counseling plus Cognitive Medication Adherence Counseling\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch', 'Behavioral: CMAC']}}, {'ArmGroupLabel': '6 Wks Nicotine Patch+Nic Gum, No CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 6 weeks of nicotine patch plus nicotine gum and standard cessation counseling (but no Cognitive Medication Adherence Counseling)\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks\n\n6 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch', 'Drug: Nicotine gum']}}, {'ArmGroupLabel': '6 Wks Nicotine Patch+Nic Gum plus CMAC', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants in this randomization arm received 6 weeks of nicotine patch and nicotine gum plus standard cessation counseling and Cognitive Medication Adherence Counseling\n\n6 Weeks of Nicotine patch dosed as follows:\n\nIf > 10 cigs/day: one 21 mg nicotine patch per day for 6 weeks\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day for 6 weeks\n\n6 Weeks of Nicotine gum dosed as follows:\n\nIf < 25 cigs/day, 2 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum for 6 weeks, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Nicotine patch', 'Drug: Nicotine gum', 'Behavioral: CMAC']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Nicotine patch', 'InterventionDescription': 'If > 10 cigs/day: one 21 mg nicotine patch per day\n\nIf < or = 10 cigs/day: one 14 mg nicotine patch per day', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2 Weeks of Nicotine Patch Only plus CMAC', '2 Weeks of Nicotine Patch Only, No CMAC', '2 Wks Nicotine Patch+Nic Gum plus CMAC', '2 Wks Nicotine Patch+Nic Gum, No CMAC', '6 Weeks of Nicotine Patch Only plus CMAC', '6 Weeks of Nicotine Patch Only, No CMAC', '6 Wks Nicotine Patch+Nic Gum plus CMAC', '6 Wks Nicotine Patch+Nic Gum, No CMAC']}}, {'InterventionType': 'Drug', 'InterventionName': 'Nicotine gum', 'InterventionDescription': 'If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.\n\nIf ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2 Wks Nicotine Patch+Nic Gum plus CMAC', '2 Wks Nicotine Patch+Nic Gum, No CMAC', '6 Wks Nicotine Patch+Nic Gum plus CMAC', '6 Wks Nicotine Patch+Nic Gum, No CMAC']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Nicotine polacrilex']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'CMAC', 'InterventionDescription': 'CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2 Weeks of Nicotine Patch Only plus CMAC', '2 Wks Nicotine Patch+Nic Gum plus CMAC', '6 Weeks of Nicotine Patch Only plus CMAC', '6 Wks Nicotine Patch+Nic Gum plus CMAC']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Cognitive Medication Adherence Counseling']}}]","[{'PrimaryOutcomeMeasure': '7-Day Point Prevalence Abstinence From Smoking by Intervention', 'PrimaryOutcomeDescription': 'Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'PrimaryOutcomeTimeFrame': '26 weeks after the target quit smoking date'}, {'PrimaryOutcomeMeasure': '7-Day Point Prevalence Abstinence From Smoking by Nicotine Replacement Therapy (NRT) Group', 'PrimaryOutcomeDescription': 'Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'PrimaryOutcomeTimeFrame': '26 weeks after the target quit smoking date'}]","[{'SecondaryOutcomeMeasure': 'Incremental Cost-Effectiveness Ratio for 7-Day Point Prevalence Abstinence From Smoking at 26 Weeks Post-Quit by Nicotine Replacement Therapy (NRT) Group', 'SecondaryOutcomeDescription': 'For cost analyses, we computed the costs of intervention per caller, the cost per quit based on the 6-month ITT 7-day PPA, and the incremental cost-effectiveness ratio (ICER. Intervention costs included direct costs associated with registration, provision of NRT and counseling (standard and MAC), and mailing of a quit guide (all participants) and a MAC information sheet (MAC participants only). Facility space, supplies, and physician supervision time were included in the call costs; research-related costs were excluded. ICER ratio is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; e.g., the ICER for the group that received 2 weeks of nicotine patch and nicotine gum = (213-178)/(.482-.384) = $357.', 'SecondaryOutcomeTimeFrame': '26 weeks after the target quit smoking date'}]","The only people eligible for this study are Wisconsin residents who contact the Wisconsin Tobacco Quit Line for smoking cessation services.

Inclusion Criteria:

Callers will be eligible to participate in the study if they are English speaking; are 18 years of age or older; smoke a minimum of 10 cigarettes per day; are interested in quitting and are willing to set a quit date; willing and able to use nicotine patch and nicotine gum; agree to receive four follow-up counseling calls from Free & Clear (the quitline vendor for the State of Wisconsin); provide verbal informed consent; and provide contact information and agree to take four study follow-up calls from staff at the University of Wisconsin Center for Tobacco Research and Intervention.

Exclusion Criteria:

Callers will be excluded if they are under the age of 18; are pregnant or breastfeeding; exclusively use other forms of tobacco (e.g., smokeless tobacco); are unwilling or unable to use study NRT medications; are currently using a cessation medication (NRT, bupropion, varenicline); or have medical exclusions as per FDA-approved product labeling.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Wisconsin Tobacco Quit Line (service provided by Free & Clear, Inc.)', 'LocationCity': 'Seattle', 'LocationState': 'Washington', 'LocationZip': '98104', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Wisconsin Center for Tobacco Research and Intervention', 'LocationCity': 'Madison', 'LocationState': 'Wisconsin', 'LocationZip': '53711', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Wisconsin Department of Health and Family Services', 'CollaboratorClass': 'OTHER_GOV'}, {'CollaboratorName': 'Alere Wellbeing', 'CollaboratorClass': 'INDUSTRY'}, {'CollaboratorName': 'Department of Health and Human Services', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'National Cancer Institute (NCI)', 'CollaboratorClass': 'NIH'}]",No,"The study design is a fully crossed 2x2x2 factorial design that tested the effect of two versus six weeks of nicotine replacement therapy (NRT), the effect of NRT monotherapy (nicotine patch alone) versus NRT combination therapy (nicotine patch + oral NRT), and the effect of cognitive medication adherence counseling (CMAC) versus no CMAC. A total of 987 smokers seeking cessation assistance from the Wisconsin Tobacco Quit Line (WTQL) were randomly assigned to the eight (2x2x2) different conditions generated by the three experimental factors. This design provides us with sufficient power to analyze each of our three main effects listed above. We will also test for two- and three-way interactions, but do not have sufficient data to make a priori assumptions about interaction effects. Finally, we will conduct a cost-effectiveness analysis for each of the three interventions to allow readers of this research to evaluate whether the additional costs of the interventions yield sufficient gains to warrant implementing them broadly.","['Smoking', 'Smoking cessation', 'Medication adherence']",,,,,,"[{'SecondaryId': '1RC1CA144382-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1RC1CA144382-01&Fy=all'}]",,,,,['Outcomes Assessor'],,"[{'OverallOfficialName': 'Stevens S Smith, PhD', 'OverallOfficialAffiliation': 'University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Paula A Keller, MPH', 'OverallOfficialAffiliation': 'University of Wisconsin Center for Tobacco Research and Intervention, School of Medicine and Public Health', 'OverallOfficialRole': 'Study Director'}]",Yes,"[{'ReferencePMID': '22992296', 'ReferenceType': 'result', 'ReferenceCitation': 'Smith SS, Keller PA, Kobinsky KH, Baker TB, Fraser DL, Bush T, Magnusson B, Zbikowski SM, McAfee TA, Fiore MC. Enhancing tobacco quitline effectiveness: identifying a superior pharmacotherapy adjuvant. Nicotine Tob Res. 2013 Mar;15(3):718-28. doi: 10.1093/ntr/nts186. Epub 2012 Sep 19.'}]",30-Jan-13,22-Apr-13,24-Apr-13,Estimate,"Upon request, clinical trial data will be shared with other investigators in the form of de-identified datasets. Requests can be sent to Stevens S. Smith, Ph.D., at sss@ctri.wisc.edu",,,,,"[{'SeeAlsoLinkLabel': 'University of Wisconsin Center for Tobacco Research and Intervention', 'SeeAlsoLinkURL': 'http://www.ctri.wisc.edu/'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,"[{'InterventionMeshId': 'D000009538', 'InterventionMeshTerm': 'Nicotine'}]","[{'InterventionAncestorId': 'D000005731', 'InterventionAncestorTerm': 'Ganglionic Stimulants'}, {'InterventionAncestorId': 'D000001337', 'InterventionAncestorTerm': 'Autonomic Agents'}, {'InterventionAncestorId': 'D000018373', 'InterventionAncestorTerm': 'Peripheral Nervous System Agents'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}, {'InterventionAncestorId': 'D000018722', 'InterventionAncestorTerm': 'Nicotinic Agonists'}, {'InterventionAncestorId': 'D000018679', 'InterventionAncestorTerm': 'Cholinergic Agonists'}, {'InterventionAncestorId': 'D000018678', 'InterventionAncestorTerm': 'Cholinergic Agents'}, {'InterventionAncestorId': 'D000018377', 'InterventionAncestorTerm': 'Neurotransmitter Agents'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}]","[{'InterventionBrowseLeafId': 'M11061', 'InterventionBrowseLeafName': 'Nicotine', 'InterventionBrowseLeafAsFound': 'Pilot', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2610', 'InterventionBrowseLeafName': 'Central Nervous System Stimulants', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19380', 'InterventionBrowseLeafName': 'Nicotinic Agonists', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19342', 'InterventionBrowseLeafName': 'Cholinergic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19088', 'InterventionBrowseLeafName': 'Neurotransmitter Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'CNSSti', 'InterventionBrowseBranchName': 'Central Nervous System Stimulants'}]",,"Adult smokers who called the Wisconsin Tobacco Quit Line (WTQL) from April 1, 2010 to June 15, 2010 were invited to participate in the study; no advertising or targeted recruitment was utilized.","[{'FlowGroupId': 'FG000', 'FlowGroupTitle': '2 Weeks of Nicotine Patch Only, No CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': '2 Weeks of Nicotine Patch Only Plus CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG002', 'FlowGroupTitle': '2 Weeks of Nicotine Patch+Nicotine Gum , No CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG003', 'FlowGroupTitle': '2 Weeks of Nicotine Patch+Nicotine Gum and CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG004', 'FlowGroupTitle': '6 Weeks of Nicotine Patch Only, No CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG005', 'FlowGroupTitle': '6 Weeks of Nicotine Patch Only Plus CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG006', 'FlowGroupTitle': '6 Weeks of Nicotine Patch+Nicotine Gum , No CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'FlowGroupId': 'FG007', 'FlowGroupTitle': '6 Weeks of Nicotine Patch+Nicotine Gum and CMAC', 'FlowGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '119'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '126'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '123'}, {'FlowAchievementGroupId': 'FG003', 'FlowAchievementNumSubjects': '122'}, {'FlowAchievementGroupId': 'FG004', 'FlowAchievementNumSubjects': '122'}, {'FlowAchievementGroupId': 'FG005', 'FlowAchievementNumSubjects': '127'}, {'FlowAchievementGroupId': 'FG006', 'FlowAchievementNumSubjects': '121'}, {'FlowAchievementGroupId': 'FG007', 'FlowAchievementNumSubjects': '127'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '90'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '94'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '101'}, {'FlowAchievementGroupId': 'FG003', 'FlowAchievementNumSubjects': '86'}, {'FlowAchievementGroupId': 'FG004', 'FlowAchievementNumSubjects': '91'}, {'FlowAchievementGroupId': 'FG005', 'FlowAchievementNumSubjects': '99'}, {'FlowAchievementGroupId': 'FG006', 'FlowAchievementNumSubjects': '98'}, {'FlowAchievementGroupId': 'FG007', 'FlowAchievementNumSubjects': '98'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '29'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '32'}, {'FlowAchievementGroupId': 'FG002', 'FlowAchievementNumSubjects': '22'}, {'FlowAchievementGroupId': 'FG003', 'FlowAchievementNumSubjects': '36'}, {'FlowAchievementGroupId': 'FG004', 'FlowAchievementNumSubjects': '31'}, {'FlowAchievementGroupId': 'FG005', 'FlowAchievementNumSubjects': '28'}, {'FlowAchievementGroupId': 'FG006', 'FlowAchievementNumSubjects': '23'}, {'FlowAchievementGroupId': 'FG007', 'FlowAchievementNumSubjects': '29'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '24'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '28'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '18'}, {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '31'}, {'FlowReasonGroupId': 'FG004', 'FlowReasonNumSubjects': '27'}, {'FlowReasonGroupId': 'FG005', 'FlowReasonNumSubjects': '25'}, {'FlowReasonGroupId': 'FG006', 'FlowReasonNumSubjects': '20'}, {'FlowReasonGroupId': 'FG007', 'FlowReasonNumSubjects': '24'}]}}, {'FlowDropWithdrawType': 'Withdrawal by Subject', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '5'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '4'}, {'FlowReasonGroupId': 'FG002', 'FlowReasonNumSubjects': '4'}, {'FlowReasonGroupId': 'FG003', 'FlowReasonNumSubjects': '5'}, {'FlowReasonGroupId': 'FG004', 'FlowReasonNumSubjects': '4'}, {'FlowReasonGroupId': 'FG005', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG006', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG007', 'FlowReasonNumSubjects': '5'}]}}]}}]","Baseline sample=987 adult smokers (at least 18 years of age) who called the Wisconsin Tobacco Quit Line (WTQL) from April 1, 2010 to June 15, 2010.","[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': '2 Weeks of Nicotine Patch Only, No CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': '2 Weeks of Nicotine Patch Only Plus CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': '2 Weeks of Nicotine Patch+Nicotine Gum , No CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG003', 'BaselineGroupTitle': '2 Weeks of Nicotine Patch+Nicotine Gum and CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 2 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG004', 'BaselineGroupTitle': '6 Weeks of Nicotine Patch Only, No CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG005', 'BaselineGroupTitle': '6 Weeks of Nicotine Patch Only Plus CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch only and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG006', 'BaselineGroupTitle': '6 Weeks of Nicotine Patch+Nicotine Gum , No CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls (but no Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG007', 'BaselineGroupTitle': '6 Weeks of Nicotine Patch+Nicotine Gum and CMAC', 'BaselineGroupDescription': 'Participants in this randomization group received 6 weeks of nicotine patch plus nicotine gum and standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC).'}, {'BaselineGroupId': 'BG008', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '119'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '126'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '123'}, {'BaselineDenomCountGroupId': 'BG003', 'BaselineDenomCountValue': '122'}, {'BaselineDenomCountGroupId': 'BG004', 'BaselineDenomCountValue': '122'}, {'BaselineDenomCountGroupId': 'BG005', 'BaselineDenomCountValue': '127'}, {'BaselineDenomCountGroupId': 'BG006', 'BaselineDenomCountValue': '121'}, {'BaselineDenomCountGroupId': 'BG007', 'BaselineDenomCountValue': '127'}, {'BaselineDenomCountGroupId': 'BG008', 'BaselineDenomCountValue': '987'}]}}]","[{'BaselineMeasureTitle': 'Age, Categorical', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': '<=18 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '2'}]}}, {'BaselineCategoryTitle': 'Between 18 and 65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '115'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '119'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '121'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '119'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '116'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '119'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '114'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '123'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '946'}]}}, {'BaselineCategoryTitle': '>=65 years', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '7'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '6'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '4'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '39'}]}}]}}]}}, {'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '42.33', 'BaselineMeasurementSpread': '12.99'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '43.35', 'BaselineMeasurementSpread': '12.61'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '41.39', 'BaselineMeasurementSpread': '11.24'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '40.84', 'BaselineMeasurementSpread': '11.96'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '41.74', 'BaselineMeasurementSpread': '14.19'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '43.18', 'BaselineMeasurementSpread': '13.627'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '42.61', 'BaselineMeasurementSpread': '13.51'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '40.03', 'BaselineMeasurementSpread': '13.31'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '41.93', 'BaselineMeasurementSpread': '12.96'}]}}]}}]}}, {'BaselineMeasureTitle': 'Gender', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '71'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '65'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '63'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '70'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '75'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '72'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '74'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '79'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '569'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '48'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '61'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '60'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '52'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '47'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '55'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '47'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '48'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '418'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '119'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '126'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '123'}, {'BaselineMeasurementGroupId': 'BG003', 'BaselineMeasurementValue': '122'}, {'BaselineMeasurementGroupId': 'BG004', 'BaselineMeasurementValue': '122'}, {'BaselineMeasurementGroupId': 'BG005', 'BaselineMeasurementValue': '127'}, {'BaselineMeasurementGroupId': 'BG006', 'BaselineMeasurementValue': '121'}, {'BaselineMeasurementGroupId': 'BG007', 'BaselineMeasurementValue': '127'}, {'BaselineMeasurementGroupId': 'BG008', 'BaselineMeasurementValue': '987'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': '7-Day Point Prevalence Abstinence From Smoking by Intervention', 'OutcomeMeasureDescription': 'Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'OutcomeMeasurePopulationDescription': 'The study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., 6 wks NRT); this effect size was based on prior quitline studies; we predicted that abstinence rates at 6 months would be approximately 12% in a standard intervention vs. 18.4% in an enhanced intervention.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants not smoking', 'OutcomeMeasureTimeFrame': '26 weeks after the target quit smoking date', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Two Weeks of Nicotine Replacement Therapy (NRT)', 'OutcomeGroupDescription': 'Participants in this intervention group received a two-week supply of Nicotine Replacement Therapy (NRT). This intervention is considered to be the standard intervention in terms of duration of NRT; it will be compared to the enhanced NRT duration intervention which is six weeks of NRT. Approximately half the total sample was randomized to the standard intervention (two weeks of NRT) and half to the enhanced intervention (six weeks of NRT).'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Six Weeks of Nicotine Replacement Therapy (NRT)', 'OutcomeGroupDescription': 'Participants in this intervention group received a six-week supply of Nicotine Replacement Therapy (NRT). This intervention is considered to be the enhanced intervention in terms of duration of NRT; it will be compared to the standard NRT duration intervention which is two weeks of NRT. Approximately half the total sample was randomized to the standard intervention (two weeks of NRT) and half to the enhanced intervention (six weeks of NRT).'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'NRT Monotherapy (Nicotine Patch Only)', 'OutcomeGroupDescription': 'Participants in this intervention group received a single Nicotine Replacement Therapy (NRT) consisting of the Nicotine Patch only. This intervention is considered to be the standard intervention in terms of type of NRT; it will be compared to the enhanced NRT type intervention which is combination NRT consisting of Nicotine Patch plus Nicotine Gum (Combo NRT). Approximately half the total sample was randomized to the standard intervention (Nicotine Patch Only) and half to the enhanced intervention (Nicotine Patch plus Nicotine Gum).'}, {'OutcomeGroupId': 'OG003', 'OutcomeGroupTitle': 'NRT Combination Therapy (Nicotine Patch Plus Nicotine Gum)', 'OutcomeGroupDescription': 'Participants in this intervention group received Combination Nicotine Replacement Therapy (NRT) consisting of the Nicotine Patch plus Nicotine Gum. This intervention is considered to be the enhanced intervention in terms of type of NRT; it will be compared to the standard NRT type intervention which is NRT Monotherapy consisting of the Nicotine Patch Only. Approximately half the total sample was randomized to the standard intervention (Nicotine Patch Only) and half to the enhanced intervention (Nicotine Patch plus Nicotine Gum).'}, {'OutcomeGroupId': 'OG004', 'OutcomeGroupTitle': 'Standard Cessation Counseling (No CMAC)', 'OutcomeGroupDescription': 'Participants in this intervention group received standard quitline cessation counseling consisting of 4 proactive counseling calls. This intervention is considered to be the standard intervention in terms of cessation counseling; it will be compared to the enhanced cessation counseling intervention which consists of Standard Cessation Counseling plus Cognitive Medication Adherence Counseling (CMAC). Approximately half the total sample was randomized to the standard intervention (Standard Cessation Counseling, No CMAC) and half to the enhanced intervention (Standard Cessation Counseling plus CMAC).'}, {'OutcomeGroupId': 'OG005', 'OutcomeGroupTitle': 'Standard Cessation Counseling Plus CMAC)', 'OutcomeGroupDescription': 'Participants in this intervention group received standard quitline cessation counseling consisting of 4 proactive counseling calls plus Cognitive Medication Adherence Counseling (CMAC). This intervention is considered to be the enhanced intervention in terms of cessation counseling; it will be compared to the standard cessation counseling intervention which consists of Standard Cessation Counseling only (no CMAC). Approximately half the total sample was randomized to the standard intervention (Standard Cessation Counseling, No CMAC) and half to the enhanced intervention (Standard Cessation Counseling plus CMAC).'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '490'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '497'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '494'}, {'OutcomeDenomCountGroupId': 'OG003', 'OutcomeDenomCountValue': '493'}, {'OutcomeDenomCountGroupId': 'OG004', 'OutcomeDenomCountValue': '485'}, {'OutcomeDenomCountGroupId': 'OG005', 'OutcomeDenomCountValue': '502'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '43.3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '48.9'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '42.3'}, {'OutcomeMeasurementGroupId': 'OG003', 'OutcomeMeasurementValue': '49.9'}, {'OutcomeMeasurementGroupId': 'OG004', 'OutcomeMeasurementValue': '47.6'}, {'OutcomeMeasurementGroupId': 'OG005', 'OutcomeMeasurementValue': '44.6'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG002']}, 'OutcomeAnalysisGroupDescription': 'Null hypothesis: No difference in abstinence rates for participants receiving Two Weeks of Nicotine Replacement Therapy (NRT) versus Six Weeks of Nicotine Replacement Therapy (NRT). We hypothesized that Six Weeks of NRT would result in statistically significantly higher abstinence rates compared to Two Weeks of NRT.\n\nThe study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., 6 wks NRT).', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '.076', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '1.26', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.98', 'OutcomeAnalysisCIUpperLimit': '1.61'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG002', 'OG003']}, 'OutcomeAnalysisGroupDescription': 'Null hypothesis: No difference in abstinence rates for participants receiving NRT Monotherapy (Nicotine Patch Only) versus NRT Combination Therapy (Nicotine Patch plus Nicotine Gum). We hypothesized that Combination NRT would result in statistically significantly higher abstinence rates compared to NRT Monotherapy.\n\nThe study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., Combination NRT).', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '.017', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '1.36', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '1.06', 'OutcomeAnalysisCIUpperLimit': '1.75'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG004', 'OG005']}, 'OutcomeAnalysisGroupDescription': 'Null hypothesis: No difference in abstinence rates for participants receiving Standard Cessation Counseling (No CMAC) versus Standard Cessation Counseling plus CMAC. We hypothesized that Standard Counseling plus CMAC would result in statistically significantly higher abstinence rates compared to Standard Counseling Only.\n\nThe study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., Standard Counseling plus CMAC).', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '.343', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '0.89', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.69', 'OutcomeAnalysisCIUpperLimit': '1.14'}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': '7-Day Point Prevalence Abstinence From Smoking by Nicotine Replacement Therapy (NRT) Group', 'OutcomeMeasureDescription': 'Self-reported total abstinence from any tobacco use (even a single puff) for the seven days preceding the target follow-up day.', 'OutcomeMeasurePopulationDescription': 'The study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention (e.g., 6 wks NRT); this effect size was based on prior quitline studies; we predicted that abstinence rates at 6 months would be approximately 12% in a standard intervention vs. 18.4% in an enhanced intervention.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants not smoking', 'OutcomeMeasureTimeFrame': '26 weeks after the target quit smoking date', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Two Weeks of Nicotine Patch Only', 'OutcomeGroupDescription': 'Participants in this treatment group received Two Weeks of Nicotine Patch Only.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Two Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'OutcomeGroupDescription': 'Participants in this treatment group received Two Weeks of Nicotine Patch plus Nicotine Gum.'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Six Weeks of Nicotine Patch Only', 'OutcomeGroupDescription': 'Participants in this treatment group received Six Weeks of Nicotine Patch Only.'}, {'OutcomeGroupId': 'OG003', 'OutcomeGroupTitle': 'Six Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'OutcomeGroupDescription': 'Participants in this treatment group received Six Weeks of Nicotine Patch plus Nicotine Gum.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '245'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '245'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '249'}, {'OutcomeDenomCountGroupId': 'OG003', 'OutcomeDenomCountValue': '248'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '38.4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '48.2'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '46.2'}, {'OutcomeMeasurementGroupId': 'OG003', 'OutcomeMeasurementValue': '51.6'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'Null hypothesis: No difference in abstinence rates for participants receiving Two Weeks of Nicotine Replacement Therapy (NRT) Monotherapy (Nicotine Patch Only) versus Two Weeks of Combination NRT (Patch+Gum). We hypothesized that Two Weeks of Combination NRT would result in statistically significantly higher abstinence rates compared to Two Weeks of NRT Monotherapy.\n\nThe study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '.029', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '1.49', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '1.04', 'OutcomeAnalysisCIUpperLimit': '2.14', 'OutcomeAnalysisEstimateComment': 'Inclusion of the Cognitive Medication Adherence Counseling (CMAC) factor (No CMAC versus CMAC) as a control variable did not change the results of this analysis.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG002']}, 'OutcomeAnalysisGroupDescription': 'Null hypothesis: No difference in abstinence rates for participants receiving Two Weeks of Nicotine Replacement Therapy (NRT) Monotherapy (Nicotine Patch Only) versus SIx Weeks of NRT Monotherapy. We hypothesized that Six Weeks of NRT Monotherapy would result in statistically significantly higher abstinence rates compared to Two Weeks of NRT Monotherapy.\n\nThe study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '.079', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '1.38', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '0.96', 'OutcomeAnalysisCIUpperLimit': '1.97', 'OutcomeAnalysisEstimateComment': 'Inclusion of the Cognitive Medication Adherence Counseling (CMAC) factor (No CMAC versus CMAC) as a control variable did not change the results of this analysis.'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG003']}, 'OutcomeAnalysisGroupDescription': 'Null hypothesis: No difference in abstinence rates for participants receiving Two Weeks of Nicotine Replacement Therapy (NRT) Monotherapy (Nicotine Patch Only) versus Six Weeks of Combination NRT (Patch+Gum). We hypothesized that Six Weeks of Combination NRT would result in statistically significantly higher abstinence rates compared to Two Weeks of NRT Monotherapy.\n\nThe study was originally powered to detect at least a 6.4% increase in the abstinence rate due to an enhanced intervention.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValue': '.003', 'OutcomeAnalysisStatisticalMethod': 'Regression, Logistic', 'OutcomeAnalysisParamType': 'Odds Ratio (OR)', 'OutcomeAnalysisParamValue': '1.71', 'OutcomeAnalysisCIPctValue': '95', 'OutcomeAnalysisCINumSides': '2-Sided', 'OutcomeAnalysisCILowerLimit': '1.20', 'OutcomeAnalysisCIUpperLimit': '2.45', 'OutcomeAnalysisEstimateComment': 'Inclusion of the Cognitive Medication Adherence Counseling (CMAC) factor (No CMAC versus CMAC) as a control variable did not change the results of this analysis.'}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Incremental Cost-Effectiveness Ratio for 7-Day Point Prevalence Abstinence From Smoking at 26 Weeks Post-Quit by Nicotine Replacement Therapy (NRT) Group', 'OutcomeMeasureDescription': 'For cost analyses, we computed the costs of intervention per caller, the cost per quit based on the 6-month ITT 7-day PPA, and the incremental cost-effectiveness ratio (ICER. Intervention costs included direct costs associated with registration, provision of NRT and counseling (standard and MAC), and mailing of a quit guide (all participants) and a MAC information sheet (MAC participants only). Facility space, supplies, and physician supervision time were included in the call costs; research-related costs were excluded. ICER ratio is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; e.g., the ICER for the group that received 2 weeks of nicotine patch and nicotine gum = (213-178)/(.482-.384) = $357.', 'OutcomeMeasurePopulationDescription': 'No ""a priori"" power analysis was conducted for this secondary outcome.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'U.S. Dollars', 'OutcomeMeasureTimeFrame': '26 weeks after the target quit smoking date', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'Two Weeks of Nicotine Patch Only', 'OutcomeGroupDescription': 'Participants in this treatment group received Two Weeks of Nicotine Patch Only.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'Two Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'OutcomeGroupDescription': 'Participants in this treatment group received Two Weeks of Nicotine Patch plus Nicotine Gum.'}, {'OutcomeGroupId': 'OG002', 'OutcomeGroupTitle': 'Six Weeks of Nicotine Patch Only', 'OutcomeGroupDescription': 'Participants in this treatment group received Six Weeks of Nicotine Patch Only.'}, {'OutcomeGroupId': 'OG003', 'OutcomeGroupTitle': 'Six Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'OutcomeGroupDescription': 'Participants in this treatment group received Six Weeks of Nicotine Patch plus Nicotine Gum.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '245'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '245'}, {'OutcomeDenomCountGroupId': 'OG002', 'OutcomeDenomCountValue': '249'}, {'OutcomeDenomCountGroupId': 'OG003', 'OutcomeDenomCountValue': '248'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '94'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '118'}, {'OutcomeMeasurementGroupId': 'OG002', 'OutcomeMeasurementValue': '115'}, {'OutcomeMeasurementGroupId': 'OG003', 'OutcomeMeasurementValue': '128'}]}}]}}]}, 'OutcomeAnalysisList': {'OutcomeAnalysis': [{'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG001']}, 'OutcomeAnalysisGroupDescription': 'In this analysis, the incremental cost-effectiveness ratio (ICER) is computed. ICER is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; ICER for the group that received 2 weeks of nicotine patch and nicotine gum = (213-178)/(.482-.384) = $357.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValueComment': 'There is no p-value for the incremental cost-effectiveness ratio (ICER).', 'OutcomeAnalysisStatisticalMethod': 'Incremental cost-effectiveness ratio', 'OutcomeAnalysisStatisticalComment': 'Unit of measurement for ICER is U.S. dollars.', 'OutcomeAnalysisParamType': 'incremental cost-effectiveness ratio', 'OutcomeAnalysisParamValue': '357', 'OutcomeAnalysisCIPctValue': '95'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG002']}, 'OutcomeAnalysisGroupDescription': 'In this analysis, the incremental cost-effectiveness ratio (ICER) is computed. ICER is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; ICER for the group that received 6 weeks of nicotine patch only = (233-178)/(.462-.384) = $712.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValueComment': 'There is no p-value for the incremental cost-effectiveness ratio (ICER).', 'OutcomeAnalysisStatisticalMethod': 'Incremental cost-effectiveness ratio', 'OutcomeAnalysisStatisticalComment': 'Unit of measurement for ICER is U.S. dollars.', 'OutcomeAnalysisParamType': 'Incremental cost-effectiveness ratio', 'OutcomeAnalysisParamValue': '712', 'OutcomeAnalysisCIPctValue': '95'}, {'OutcomeAnalysisGroupIdList': {'OutcomeAnalysisGroupId': ['OG000', 'OG003']}, 'OutcomeAnalysisGroupDescription': 'In this analysis, the Incremental cost-effectiveness ratio (ICER) is computed. ICER is a measure of the added cost per added quit for two treatments. ICER was computed as the cost difference between the least intensive treatment group (2 weeks of nicotine patch only) and a more intensive comparison group divided by the difference in the quit rates of the two groups being compared; ICER for the group that received 6 weeks of nicotine patch and nicotine gum = (348-178)/(.516-.384) = $1290.', 'OutcomeAnalysisTestedNonInferiority': 'No', 'OutcomeAnalysisNonInferiorityType': 'Superiority or Other', 'OutcomeAnalysisPValueComment': 'There is no p-value for the incremental cost-effectiveness ratio (ICER).', 'OutcomeAnalysisStatisticalMethod': 'Incremental cost-effectiveness ratio', 'OutcomeAnalysisStatisticalComment': 'Unit of measurement for ICER is U.S. dollars.', 'OutcomeAnalysisParamType': 'Incremental cost-effectiveness ratio', 'OutcomeAnalysisParamValue': '1290', 'OutcomeAnalysisCIPctValue': '95'}]}}]",5,"Information about adverse events was collected during the 6-week post-quit period of study interventions. The quitline vendor for the study, Free & Clear (Seattle, WA), dispensed all study medications and addressed adverse events.","This study used FDA-approved, over-the-counter nicotine replacement therapies (NRTs) that were dispensed according to standard protocols that were in use by Free & Clear at the time of the study. Free & Clear was responsible for assessing and managing any AEs related to study medication as per their existing Nicotine Replacement Therapy Protocols.","[{'EventGroupId': 'EG000', 'EventGroupTitle': 'Two Weeks of Nicotine Patch Only', 'EventGroupDescription': 'Participants in this treatment group received Two Weeks of Nicotine Patch Only.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '245', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '245'}, {'EventGroupId': 'EG001', 'EventGroupTitle': 'Two Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'EventGroupDescription': 'Participants in this treatment group received Two Weeks of Nicotine Patch plus Nicotine Gum.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '245', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '245'}, {'EventGroupId': 'EG002', 'EventGroupTitle': 'Six Weeks of Nicotine Patch Only', 'EventGroupDescription': 'Participants in this treatment group received Six Weeks of Nicotine Patch Only.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '249', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '249'}, {'EventGroupId': 'EG003', 'EventGroupTitle': 'Six Weeks of Combination NRT (Nicotine Patch + Nicotine Gum)', 'EventGroupDescription': 'Participants in this treatment group received Six Weeks of Nicotine Patch plus Nicotine Gum.', 'EventGroupSeriousNumAffected': '0', 'EventGroupSeriousNumAtRisk': '248', 'EventGroupOtherNumAffected': '0', 'EventGroupOtherNumAtRisk': '248'}]",,No,No,"Stevens S. Smith, Ph.D.",University of Wisconsin School of Medicine and Public Health,sss@ctri.medicine.wisc.edu,608-262-7563,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02616198,08-10.1/6,Ege University,OTHER,6-year Clinical Evaluation of Glass Ionomer Cements (GIS) With Resin Coating on Posterior Teeth,A Prospective 6-year Clinical Study Evaluating Reinforced Glass Ionomer Cements With Resin Coating on Posterior Teeth,Nov-15,Completed,No,Jan-09,,Sep-09,Actual,Sep-15,Actual,20-Nov-15,24-Nov-15,26-Nov-15,Estimate,24-Nov-15,26-Nov-15,Estimate,Principal Investigator,Ege University,OTHER,,,,,"The aim of this study was to evaluate the long-term clinical performance of two highly viscous encapsulated GICs (EquiaFil and Riva SC) covered with two different coatings (Equia Coat and Fuji Varnish) over 6-year using modified United State Public Health Service (USPHS) criteria.

A total of 256 restorations were made with EquiaFil and Riva SC. Equia Coat or Fuji Varnish was used randomly on the surface of the restorations. The restorations were evaluated at baseline, 6, 12, 18 months and 6 years after placement using modified USPHS criteria. The results were evaluated with Pearson Chi-Square and Mann Whitney U-test (p< 0.05).",['Dental Caries'],Interventional,['Not Applicable'],Randomized,Crossover Assignment,Treatment,Single,54,Actual,"[{'ArmGroupLabel': 'EquiaFil G-coat', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'EquiaFil G-coat combination was applied on one randomly selected cavity to be restored', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: EquiaFil Fuji Varnish', 'Other: Riva SC G-coat', 'Other: Riva SC Fuji Varnish']}}, {'ArmGroupLabel': 'EquiaFil Fuji Varnish', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'EquiaFil Fuji Varnish combination was applied on one randomly selected cavity to be restored', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: EquiaFil G-coat', 'Other: Riva SC G-coat', 'Other: Riva SC Fuji Varnish']}}, {'ArmGroupLabel': 'Riva SC G-coat', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'River SC G-coat combination was applied on one randomly selected cavity to be restored', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: EquiaFil G-coat', 'Other: EquiaFil Fuji Varnish', 'Other: Riva SC Fuji Varnish']}}, {'ArmGroupLabel': 'Riva SC Fuji Varnish', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'River SC Fuji Varnish combination was applied on one randomly selected cavity to be restored', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: EquiaFil G-coat', 'Other: EquiaFil Fuji Varnish', 'Other: Riva SC G-coat']}}]","[{'InterventionType': 'Other', 'InterventionName': 'EquiaFil G-coat', 'InterventionDescription': 'The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['EquiaFil Fuji Varnish', 'Riva SC Fuji Varnish', 'Riva SC G-coat']}}, {'InterventionType': 'Other', 'InterventionName': 'EquiaFil Fuji Varnish', 'InterventionDescription': 'The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['EquiaFil G-coat', 'Riva SC Fuji Varnish', 'Riva SC G-coat']}}, {'InterventionType': 'Other', 'InterventionName': 'Riva SC G-coat', 'InterventionDescription': 'The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['EquiaFil Fuji Varnish', 'EquiaFil G-coat', 'Riva SC Fuji Varnish']}}, {'InterventionType': 'Other', 'InterventionName': 'Riva SC Fuji Varnish', 'InterventionDescription': 'The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['EquiaFil Fuji Varnish', 'EquiaFil G-coat', 'Riva SC G-coat']}}]","[{'PrimaryOutcomeMeasure': 'Evaluating differently coated glass ionomer cements on posterior teeth with United State Public Health Service criteria regarding marginal adaptation by 2 independent evaluators', 'PrimaryOutcomeDescription': 'Marginal adaptation was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C and D score means that the restoration has failed and needs to be replaced. Alpha 1: Harmonious outline Alpha 2: Marginal gap (max 100µ) with discoloration (removable) Bravo: Marginal gap (> 100µ) with discoloration (unremovable) Charlie: The restoration is fractured or missed', 'PrimaryOutcomeTimeFrame': '6 years'}, {'PrimaryOutcomeMeasure': 'Evaluating differently coated glass ionomer cements on posterior teeth with United State Public Health Service criteria regarding marginal discolouration by 2 independent evaluators', 'PrimaryOutcomeDescription': 'Marginal discolouration was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C score means that the restoration has failed and needs to be replaced. Alpha: No discoloration anywhere along the margin between the restoration and the adjacent tooth.\n\nBravo: Slight discoloration along the margin between the restoration and the adjacent tooth.\n\nCharlie: The discoloration penetrated along the margin of the restorative material in a pulpal direction.', 'PrimaryOutcomeTimeFrame': '6 years'}, {'PrimaryOutcomeMeasure': 'Evaluating differently coated glass ionomer cements on posterior teeth with United State Public Health Service criteria regarding retention rate by 2 independent evaluators', 'PrimaryOutcomeDescription': 'Retention rate was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C and D score means that the restoration has failed and needs to be replaced. Alpha 1:Clinically excellent Alpha 2: Clinically good with slight deviations from ideal performance, correction possible without damage of tooth or restoration Bravo: Clinically sufficient with few defects, corrections or repair of the restoration possible Charlie: Restoration is partially missed Delta: Restoration is totally missed', 'PrimaryOutcomeTimeFrame': '6 years'}, {'PrimaryOutcomeMeasure': 'Evaluating differently coated glass ionomer cements on posterior teeth with United State Public Health Service criteria regarding anatomic form by 2 independent evaluators', 'PrimaryOutcomeDescription': 'Anatomic form was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C score means that the restoration has failed and needs to be replaced. Alpha 1: Continuous with existing anatomical form Alpha 2: Slightly discontinuous due to some chipping on the proximal ridge Bravo: Discontinuous with existing anatomical form due to material loss but proximal contact still present Charlie: Proximal contact is lost with ridge fracture', 'PrimaryOutcomeTimeFrame': '6 years'}, {'PrimaryOutcomeMeasure': 'Evaluating differently coated glass ionomer cements on posterior teeth with United State Public Health Service criteria regarding colour changes by 2 independent evaluators', 'PrimaryOutcomeDescription': 'Colour changes was evaluated by 2 independent clinicians. Visual inspection with a mirror at 18 inches was performed . A score means the higher score of clinical acceptability while C score means that the restoration has failed and needs to be replaced. Alpha: The restoration matches the adjacent tooth structure in color and translucency.\n\nBravo: Light mismatch in color, shade or translucency between the restoration and the adjacent tooth.\n\nCharlie: The mismatch in color and translucency is outside the acceptable range of tooth color and translucency.', 'PrimaryOutcomeTimeFrame': '6 years'}]","[{'SecondaryOutcomeMeasure': 'Effects of resin coating on the performance of glass ionomer cements according to the United State Public Health Service criteria regarding marginal adaptation, marginal discolouration, retention rate, and colour changes by 2 independent evaluators', 'SecondaryOutcomeDescription': 'The effect of different coatings on the clinical performance of the different glass ionomers tested was evaluated with United State Public Health Service criteria at baseline, 6-12-18 months and 6-years. For the evaluation 2 independent evaluators using dental problem and mirrors evaluated the resin coatings according to their retention, marginal adaptation, marginal discolouration, and colour match. There were 4 evaluation scores. Alpha meaning a perfect resin coating, Bravo meaning a coating partially effective but still clinically acceptable and Charlie and Delta meaning that the coating was partially to totally missed.', 'SecondaryOutcomeTimeFrame': '6 years'}]","Inclusion Criteria:

having good oral hygiene;
need for at least two or more posterior restorations in contact with neighbouring tooth and in occlusion with antagonist teeth;
teeth planned to be restore should be vital and symptomless;
the cavity isthmus size should be more than 1/3 of the intercuspal distance.

Exclusion Criteria:

absence of adjacent and antagonist teeth;
teeth with periodontal problems;
teeth with preoperative pain or pulpal inflammations;
teeth formerly subjected to direct pulp capping;
patients having severe systemic diseases, allergies or adverse medical history.",Accepts Healthy Volunteers,All,17 Years,55 Years,"['Child', 'Adult']",,,Yes,"The aim of this study was to evaluate the long-term clinical performance of two highly viscous encapsulated GICs (EquiaFil and Riva SC) covered with two different coatings (Equia Coat and Fuji Varnish) over 6-year using modified United State Public Health Service (USPHS) criteria.

Fifty-four patients having Class I and II restorations/caries were included in the study. A total of 256 restorations were made with EquiaFil (GC Corp, Japan) and Riva SC (SDI, Australia). Equia Coat or Fuji Varnish was used randomly on the surface of the restorations. After cavity preparations, the teeth were randomly restored with one glass ionomer cement and coated with Equia Coat or Fuji Varnish. The restorations were evaluated at baseline, 6, 12, 18 months and 6 years after placement using modified USPHS criteria. Two evaluators checked color-match, marginal discoloration, marginal adaptation, caries formation, anatomical form, postoperative sensitivity and retention rate and photographs were taken at each recalls. The results were evaluated with Pearson Chi-Square and Mann Whitney U-test (p< 0.05).

The 18-month results were presented at the CED IADR congress iheld in Barcelona in 2010 (Turkun LS, & Kanic O ,Clinical evaluation of new glass ionomer coating combined systems for 18-months Journal of Dental Research 89 (Special Issue B) Abstract #402.) Gurgan S et al. also mentioned our 18-month results in their published manuscript ( Gurgan S,Kutuk ZB, Ergin E, Oztas ZZ & Cakir FY (2015) Four-year randomized clinical trial to evaluate the clinical performance of a glass ionomer restorative system Operative Dentistry 40(2) 134-143).","['glass ionomers', 'surface coating', 'clinical trial']",,,,,,,GIS,Sebnem Turkun,Prof. Dr.,Ege University,['Participant'],,,,"[{'ReferencePMID': '21564113', 'ReferenceType': 'background', 'ReferenceCitation': 'Sidhu SK. Glass-ionomer cement restorative materials: a sticky subject? Aust Dent J. 2011 Jun;56 Suppl 1:23-30. doi: 10.1111/j.1834-7819.2010.01293.x. Review.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Lohbauer U (2010) Dental glass ionomer cements as permanent filling materials? Properties, limitations and future trends. Materials 3(1) 76-96.'}, {'ReferencePMID': '23832616', 'ReferenceType': 'background', 'ReferenceCitation': 'Diem VT, Tyas MJ, Ngo HC, Phuong LH, Khanh ND. The effect of a nano-filled resin coating on the 3-year clinical performance of a conventional high-viscosity glass-ionomer cement. Clin Oral Investig. 2014 Apr;18(3):753-9. doi: 10.1007/s00784-013-1026-z. Epub 2013 Jul 7.'}, {'ReferencePMID': '19089080', 'ReferenceType': 'background', 'ReferenceCitation': 'Tyas MJ. Clinical evaluation of glass-ionomer cement restorations. J Appl Oral Sci. 2006;14 Suppl:10-3.'}, {'ReferencePMID': '20339470', 'ReferenceType': 'background', 'ReferenceCitation': 'Frankenberger R, Garcia-Godoy F, Krämer N. Clinical Performance of Viscous Glass Ionomer Cement in Posterior Cavities over Two Years. Int J Dent. 2009;2009:781462. doi: 10.1155/2009/781462. Epub 2010 Feb 22.'}, {'ReferencePMID': '17082278', 'ReferenceType': 'background', 'ReferenceCitation': 'Ersin NK, Candan U, Aykut A, Onçağ O, Eronat C, Kose T. A clinical evaluation of resin-based composite and glass ionomer cement restorations placed in primary teeth using the ART approach: results at 24 months. J Am Dent Assoc. 2006 Nov;137(11):1529-36.'}, {'ReferencePMID': '17546060', 'ReferenceType': 'background', 'ReferenceCitation': 'Burke FJ, Siddons C, Cripps S, Bardha J, Crisp RJ, Dopheide B. Clinical performance of reinforced glass ionomer restorations placed in UK dental practices. Br Dent J. 2007 Jul 14;203(1):E2; discussion 40-1. Epub 2007 Jun 1. Erratum in: Br Dent J. 2007 Sep 22;203(6):369. Phipps, S [corrected to Cripps, S].'}, {'ReferencePMID': '22149968', 'ReferenceType': 'background', 'ReferenceCitation': 'Bonifácio CC, Werner A, Kleverlaan CJ. Coating glass-ionomer cements with a nanofilled resin. Acta Odontol Scand. 2012 Dec;70(6):471-7. doi: 10.3109/00016357.2011.639307. Epub 2011 Dec 12.'}, {'ReferencePMID': '21840585', 'ReferenceType': 'background', 'ReferenceCitation': 'Friedl K, Hiller KA, Friedl KH. Clinical performance of a new glass ionomer based restoration system: a retrospective cohort study. Dent Mater. 2011 Oct;27(10):1031-7. doi: 10.1016/j.dental.2011.07.004. Epub 2011 Aug 15.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Basso M, Brambilla E, Benites MG, Giovannardi M & Ionescu AC (2015) Glass ionomer cement for permanent dental restorations: a 48-months, multi-center, prospective clinical trial Stomatology Education Journal 2(1) 25-35.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Miletic I, Baraba A, Juic IB & Anic I (2013) Evaluation of a glass-ionomer based restoration system- a one year pilot study Journal of Minimum Intervention in Dentistry 6 87-95.'}, {'ReferencePMID': '25299703', 'ReferenceType': 'background', 'ReferenceCitation': 'Gurgan S, Kutuk ZB, Ergin E, Oztas SS, Cakir FY. Four-year randomized clinical trial to evaluate the clinical performance of a glass ionomer restorative system. Oper Dent. 2015 Mar-Apr;40(2):134-43. doi: 10.2341/13-239-C. Epub 2014 Oct 9.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003731', 'ConditionMeshTerm': 'Dental Caries'}]","[{'ConditionAncestorId': 'D000017001', 'ConditionAncestorTerm': 'Tooth Demineralization'}, {'ConditionAncestorId': 'D000014076', 'ConditionAncestorTerm': 'Tooth Diseases'}, {'ConditionAncestorId': 'D000009057', 'ConditionAncestorTerm': 'Stomatognathic Diseases'}]","[{'ConditionBrowseLeafId': 'M5511', 'ConditionBrowseLeafName': 'Dental Caries', 'ConditionBrowseLeafAsFound': 'Dental Caries', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17922', 'ConditionBrowseLeafName': 'Tooth Demineralization', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15414', 'ConditionBrowseLeafName': 'Tooth Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10600', 'ConditionBrowseLeafName': 'Stomatognathic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC07', 'ConditionBrowseBranchName': 'Mouth and Tooth Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M2688', 'InterventionBrowseLeafName': 'Anesthetics', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M20444', 'InterventionBrowseLeafName': 'Pharmaceutical Solutions', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'PhSol', 'InterventionBrowseBranchName': 'Pharmaceutical Solutions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00007540,709D,VA Office of Research and Development,FED,Study of Prostate Cancer in Black and White U.S. Veterans,Study of Prostate Cancer in Black and White U.S. Veterans,Feb-03,Completed,No,Apr-98,,,,Sep-00,,29-Dec-00,30-Dec-00,01-Jan-01,Estimate,20-Jan-09,21-Jan-09,Estimate,,US Department of Veterans Affairs,FED,,,,,"Prostate cancer is diagnosed in approximately 334,500 men each year and accounts for nearly 41,800 deaths in the United States. Prostate cancer is the leading cancer affecting veterans and the second leading cancer among all Americans. The causes of prostate cancer and, particularly, the reasons for the unusually high incidence rates in African-Americans remain obscure. Dietary factors likely play a role in fatal cases, while hormones are also important in regulating prostate cancer growth. Dr. Charles Huggins recognized this effect in the 1940?s, with androgen deprivation remaining as the cornerstone of therapy for advanced disease. Despite the strong circumstantial evidence, neither epidemiologic studies nor basic sciences have produced clear insight into the etiologic role of hormones. However, recent observations regarding androgen receptor gene polymorphisms and their relation to endocrine expression and prostate cancer risk may be providing important clues as to how an etiologic role might be mediated at the molecular level. Thus, it is important to attempt to identify genetic markers of high-risk cancer patients for necessary screening and counseling efforts.","['Prostate Cancer', 'Prostatic Neoplasms']",Observational,,,,,,,,,,,,Veterans who undergo prostate biopsy where biopsy results are positive or PSA less than 10Ng/ml.,No,Male,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Vamc - Chicago-Lakeside, Il', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60611', 'LocationCountry': 'United States'}]",,,"Primary Objectives: To evaluate the relationship between the length of the CAG repeat sequence occurring in the androgen receptor gene and major prostate cancer prognostic determinants (race, age, histologic grade and stage) at the time of diagnosis in black and white veterans.

Secondary Objectives: To create a secure, organized bank of DNA plasma samples obtained from newly diagnosed prostate cancer patients and assay the peripheral blood DNA for inherited polymorphisms of the androgen receptor gene.

Primary Outcomes: The primary outcomes are androgen receptor CAG repeat sequence length and stage of disease.

Intervention: N/A

Study Abstract: Prostate cancer is diagnosed in approximately 334,500 men each year and accounts for nearly 41,800 deaths in the United States. Prostate cancer is the leading cancer affecting veterans and the second leading cancer among all Americans. The causes of prostate cancer and, particularly, the reasons for the unusually high incidence rates in African-Americans remain obscure. Dietary factors likely play a role in fatal cases, while hormones are also important in regulating prostate cancer growth. Dr. Charles Huggins recognized this effect in the 1940's, with androgen deprivation remaining as the cornerstone of therapy for advanced disease. Despite the strong circumstantial evidence, neither epidemiologic studies nor basic sciences have produced clear insight into the etiologic role of hormones. However, recent observations regarding androgen receptor gene polymorphisms and their relation to endocrine expression and prostate cancer risk may be providing important clues as to how an etiologic role might be mediated at the molecular level. Thus, it is important to attempt to identify genetic markers of high-risk cancer patients for necessary screening and counseling efforts.

It has been recently demonstrated that the androgen receptor functions as a ligand-dependent transcriptional regulator, and that this regulation is important in controlling prostate growth and apoptosis. Heightened androgenic stimulation, a potential by-product of shortened CAG repeat length, could potentially increase the risk of prostate cancer development and progression. In particular, a shorter CAG repeat sequence may be associated with cancers that have features of higher histologic grade, extraprostatic extension, and distant metastases (stage C or D). Recent evidence indicates that men with shorter CAG repeats are at particularly higher risk for distant metastatic and fatal prostate cancer. The results demonstrated that a shorter CAG repeat sequence in the androgen receptor gene predicted higher grade and advanced state of prostate cancer at diagnosis, metastatic disease, and mortality. However, these studies have been limited to whites since only a small number of African American men with prostate cancer were included.

Prostate cancer incidence varies between African-American and white men. African-American men have the highest known incidence rates in the world, 66% higher than white men in the U.S. The genetic findings described above raise the possibility that racial differences in the distribution of androgen receptor polymorphisms may account for the higher rate of prostate cancer, the more advanced disease, and the younger age at presentation in African-Americans.

This study created a cohort of prostate cancer patients who are well characterized with respect to histology, stage of diagnosis, and (over time) mortality. This study is generating data regarding the length of the CAG repeat sequence occurring in the androgen receptor gene and major prostate cancer prognostic determinants (histologic grade and state) at the time of diagnosis in black and white veterans. CAG repeat lengths on the androgen receptor gene were evaluated for a cohort of 145 African American and 150 white veterans with prostate cancer.

Results: Mean androgen receptor gene CAG repeat lengths for Caucasians was 21.9 versus 19.8 for African Americans, p=0.0001. However, a truncated CAG repeat length (CAG <= 18 versus CAG > 18) was not associated with advanced stage of cancer at diagnosis, higher PSA at diagnosis, or higher Gleason score (each with p>0.5).

Conclusion: The mean androgen receptor CAG repeat length was 2 repeats shorter for African American versus white prostate cancer patients. These findings raise concern that prostate cancers in African American men may be less sensitive to hormonal therapy than those in white men. These findings provide biologic rationale for clinical trials that evaluate the joint administration of chemotherapy and hormone therapy for African American men with advanced prostate cancer.","['Prostate cancer', 'CAG repeat sequence']",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000011471', 'ConditionMeshTerm': 'Prostatic Neoplasms'}]","[{'ConditionAncestorId': 'D000005834', 'ConditionAncestorTerm': 'Genital Neoplasms, Male'}, {'ConditionAncestorId': 'D000014565', 'ConditionAncestorTerm': 'Urogenital Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000011469', 'ConditionAncestorTerm': 'Prostatic Diseases'}]","[{'ConditionBrowseLeafId': 'M12918', 'ConditionBrowseLeafName': 'Prostatic Neoplasms', 'ConditionBrowseLeafAsFound': 'Prostate Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M7529', 'ConditionBrowseLeafName': 'Genital Neoplasms, Male', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15898', 'ConditionBrowseLeafName': 'Urogenital Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M12916', 'ConditionBrowseLeafName': 'Prostatic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02163525,CP-00-0025,"Acessa Health, Inc.",INDUSTRY,Post Market TRUST - U.S.A. Study,The TRUST (Treatment Results of Uterine Sparing Technologies) U.S.A. Study,Jan-20,"Active, not recruiting",No,Jun-14,,Jul-19,Actual,Jun-24,Anticipated,11-Jun-14,11-Jun-14,13-Jun-14,Estimate,06-Jan-20,09-Jan-20,Actual,Sponsor,"Acessa Health, Inc.",INDUSTRY,,,,,"This Post Market study is being conducted to compare the direct and indirect cost of three approaches (GFA, myomectomy, and uterine artery embolization) for the treatment of symptomatic uterine fibroids. In addition, data from this study is being used to satisfy the requirements of the United States Food and Drug Administration's 522 (post market surveillance) order.",['Symptomatic Uterine Fibroids'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Treatment,None (Open Label),114,Actual,"[{'ArmGroupLabel': 'Ablation vs Embolization', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Women are randomized 1:1 to either global fibroid ablation (GFA) or uterine artery embolization (UAE)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Global Fibroid Ablation (GFA)', 'Procedure: Uterine Artery Embolization (UAE)']}}, {'ArmGroupLabel': 'Ablation vs Myomectomy', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Women are randomized 1:1 to either global fibroid ablation (GFA) or myomectomy (laparoscopic or abdominal)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Procedure: Global Fibroid Ablation (GFA)', 'Procedure: Abdominal or Laparoscopic Myomectomy']}}]","[{'InterventionType': 'Procedure', 'InterventionName': 'Global Fibroid Ablation (GFA)', 'InterventionDescription': 'GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ablation vs Embolization', 'Ablation vs Myomectomy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['GFA', 'Radiofrequency ablation', 'RFA', 'Radiofrequency volumetric fibroid ablation', 'Acessa procedure', 'Acessa treatment']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Abdominal or Laparoscopic Myomectomy', 'InterventionDescription': 'Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ablation vs Myomectomy']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Myomectomy']}}, {'InterventionType': 'Procedure', 'InterventionName': 'Uterine Artery Embolization (UAE)', 'InterventionDescription': 'UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Ablation vs Embolization']}, 'InterventionOtherNameList': {'InterventionOtherName': ['UAE', 'Uterine Fibroid Embolization', 'UFE']}}]","[{'PrimaryOutcomeMeasure': 'Compare direct cost of GFA compared to those of myomectomy and UAE', 'PrimaryOutcomeDescription': 'To compare medical, surgical, and hospitalization costs (including procedural complication costs) of Global Fibroid Ablation (GFA) compared to those of Myomectomy and Uterine Artery Embolization (UAE)at 3 months post procedure.', 'PrimaryOutcomeTimeFrame': '3 months post procedure'}, {'PrimaryOutcomeMeasure': 'Compare rates of acute and near-term serious complications to the acute and near-term treatment-related serious adverse events of pivotal study.', 'PrimaryOutcomeDescription': 'Overall rates of acute (within 48 hours post procedure) and near-term (between 2 and 30 days post procedure) serious complications in all GFA subjects compared to the acute and near-term treatment-related serious adverse event rates in the pivotal study.', 'PrimaryOutcomeTimeFrame': '30 days post procedure'}]","[{'SecondaryOutcomeMeasure': 'Assess the incidence and cost of post discharge procedure-related complications and reinterventions', 'SecondaryOutcomeDescription': 'Safety measures will be assessed by comparing the complication and reintervention rate for all three alternatives (GFA, Myomectomy, UAE).', 'SecondaryOutcomeTimeFrame': '60 months'}, {'SecondaryOutcomeMeasure': 'Assess factors that influence indirect costs of the three treatment alternatives', 'SecondaryOutcomeDescription': 'Compare incidence costs of post discharge procedure-related complications and re-interventions we well as indirect cost factors defined as days to return-to-work, return to normal activities of daily living, and cost of care up to 60 months post discharge.', 'SecondaryOutcomeTimeFrame': '60 months'}, {'SecondaryOutcomeMeasure': 'Assess Uterine Fibroid Symptom Severity and Quality of Life (UFS-QoL) pre-treatment to post treatment in all treatment groups', 'SecondaryOutcomeDescription': 'To compare fibroid symptom severity and quality of life scores at 3, 6, 12, 24, 36, 48, and 60 months post procedure as compared to baseline using the Uterine Fibroid Symptom and Health Related Quality of Life (UFS-QoL) assessment tool.', 'SecondaryOutcomeTimeFrame': '60 months'}, {'SecondaryOutcomeMeasure': 'Assess subjects menstrual bleeding using the MIQ', 'SecondaryOutcomeDescription': 'Compare subjects menstrual bleeding pre-treatment and up to 3, 6, 12, 24, 36, 48, and 60 months post treatment using the Menorrhagia Impact Questionnaire (MIQ).', 'SecondaryOutcomeTimeFrame': '60 months'}, {'SecondaryOutcomeMeasure': ""Assess subject's satisfaction with her treatment"", 'SecondaryOutcomeDescription': ""Assess the subject's satisfaction with her assigned procedure at 12 months post procedure using the Overall Treatment Effect questionnaire"", 'SecondaryOutcomeTimeFrame': '12 months'}, {'SecondaryOutcomeMeasure': ""Assess the subject's general health outcome"", 'SecondaryOutcomeDescription': 'General health outcome evaluation at 3, 6, 12, 24, 36, 48, and 60 months post procedure as compared to baseline using the EuroQol (EQ-5D), a standardized instrument for use as a measure of health outcome', 'SecondaryOutcomeTimeFrame': '60 months post procedure'}, {'SecondaryOutcomeMeasure': 'Assess the incidence of serious complications per investigator-surgeon during training and post training.', 'SecondaryOutcomeDescription': 'The incidence of acute and near-term serious complications following the GFA cases will also be analyzed by investigator-surgeon during the training and post training periods..', 'SecondaryOutcomeTimeFrame': '60 months'}]","Inclusion Criteria:

Are ≥ 18 years old and menstruating
Have symptomatic uterine fibroids
Have a uterine size ≤ 16 gestational weeks as determined by pelvic exam
Have all fibroids that are less than 10 cm in any diameter
Desire uterine conservation
Have had a normal Pap smear within the past 36 months defined as ""no untreated cervical malignancy or dysplasia.""
Are willing and able to comply with all study tests, procedures, and assessment tools
Are capable of providing informed consent.

Exclusion Criteria:

Have contraindications for laparoscopic surgery and/or general anesthesia.
Are expected to be high risk for, or are known to have, significant intra-abdominal adhesions (defined as adhesions that would require extensive dissection to mobilize and view all surfaces of the uterus)
Patients requiring major elective concomitant procedures (e.g., hernia repair)
Are pregnant or lactating
Have taken any depot gonadotropin releasing hormone (GnRh) agonist within three months prior to the screening procedures
Have an implanted intrauterine or fallopian tube device for contraception that cannot or will not be removed at least 10 days prior to treatment
Have chronic pelvic pain known to not be due to uterine fibroids
Have known or suspected endometriosis Stage 3 or 4, adenomyosis
Have active or history of pelvic inflammatory disease
Have a history of, or evidence of, gynecologic malignancy or pre-malignancy within the past five years
Have had pelvic radiation
Have a non-uterine pelvic mass over 3 cm
Have a cervical myoma
Have one or more completely intracavitary submucous fibroids (Type 0) or only Type 0/1 submucous fibroids that are better treated via hysteroscopic methods
In the medical judgment of the investigator should not participate in the study
Are not willing to be randomized to treatment.",No,Female,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of California, Los Angeles', 'LocationCity': 'Santa Monica', 'LocationState': 'California', 'LocationZip': '90401', 'LocationCountry': 'United States'}, {'LocationFacility': 'Aspen Surgery Center/John Muir Hospital', 'LocationCity': 'Walnut Creek', 'LocationState': 'California', 'LocationZip': '94598', 'LocationCountry': 'United States'}, {'LocationFacility': 'Augusta University', 'LocationCity': 'Augusta', 'LocationState': 'Georgia', 'LocationZip': '30912-3360', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Chicago Medicine and Biological Sciences', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60637', 'LocationCountry': 'United States'}, {'LocationFacility': ""Brigham and Women's Hospital"", 'LocationCity': 'Jamaica Plain', 'LocationState': 'Massachusetts', 'LocationZip': '02130', 'LocationCountry': 'United States'}, {'LocationFacility': 'Henry Ford Hospital', 'LocationCity': 'West Bloomfield', 'LocationState': 'Michigan', 'LocationZip': '48322', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Rochester Medical Center', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '14642', 'LocationCountry': 'United States'}, {'LocationFacility': 'Texas Fertility Center', 'LocationCity': 'Austin', 'LocationState': 'Texas', 'LocationZip': '78731', 'LocationCountry': 'United States'}, {'LocationFacility': 'INOVA', 'LocationCity': 'Falls Church', 'LocationState': 'Virginia', 'LocationZip': '60637', 'LocationCountry': 'United States'}]",,Yes,"The purpose of this study is to 1) evaluate the economic burden, safety and outcomes of three uterine-conserving treatment alternatives for symptomatic uterine fibroids: myomectomy, uterine artery embolization (UAE), and global fibroid ablation (GFA) using the Acessa™ System, and 2) meet the requirements of the U.S. Food and Drug Administration's 522 Order for post market surveillance In this study, subjects who have symptomatic uterine fibroids will be randomized to one of three uterine-conserving treatments based on the local standard of care.","['Fibroids', 'Myomas', 'leiomyomata', 'menorrhagia', 'Acessa Procedure', 'Radiofrequency Ablation (RFA)', 'GFA', 'Acessa']",,,,,,,,,,,,,"[{'OverallOfficialName': 'David Eisenstein, MD', 'OverallOfficialAffiliation': 'Henry Ford Hospital', 'OverallOfficialRole': 'Study Director'}]",Yes,"[{'ReferencePMID': '11814511', 'ReferenceType': 'background', 'ReferenceCitation': 'Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific symptom and health-related quality of life questionnaire for leiomyomata. Obstet Gynecol. 2002 Feb;99(2):290-300.'}, {'ReferencePMID': '18288885', 'ReferenceType': 'background', 'ReferenceCitation': 'Viswanathan M, Hartmann K, McKoy N, Stuart G, Rankins N, Thieda P, Lux LJ, Lohr KN. Management of uterine fibroids: an update of the evidence. Evid Rep Technol Assess (Full Rep). 2007 Jul;(154):1-122. Review.'}, {'ReferencePMID': '20471917', 'ReferenceType': 'background', 'ReferenceCitation': 'Twijnstra AR, Kolkman W, Trimbos-Kemper GC, Jansen FW. Implementation of advanced laparoscopic surgery in gynecology: national overview of trends. J Minim Invasive Gynecol. 2010 Jul-Aug;17(4):487-92. doi: 10.1016/j.jmig.2010.03.010. Epub 2010 May 14.'}, {'ReferencePMID': '16632830', 'ReferenceType': 'background', 'ReferenceCitation': 'Holzer A, Jirecek ST, Illievich UM, Huber J, Wenzl RJ. Laparoscopic versus open myomectomy: a double-blind study to evaluate postoperative pain. Anesth Analg. 2006 May;102(5):1480-4.'}, {'ReferencePMID': '17478371', 'ReferenceType': 'background', 'ReferenceCitation': 'Parker WH, Iacampo K, Long T. Uterine rupture after laparoscopic removal of a pedunculated myoma. J Minim Invasive Gynecol. 2007 May-Jun;14(3):362-4.'}, {'ReferencePMID': '16343253', 'ReferenceType': 'background', 'ReferenceCitation': ""Banas T, Klimek M, Fugiel A, Skotniczny K. Spontaneous uterine rupture at 35 weeks' gestation, 3 years after laparoscopic myomectomy, without signs of fetal distress. J Obstet Gynaecol Res. 2005 Dec;31(6):527-30.""}, {'ReferencePMID': '21481151', 'ReferenceType': 'background', 'ReferenceCitation': 'Moss JG, Cooper KG, Khaund A, Murray LS, Murray GD, Wu O, Craig LE, Lumsden MA. Randomised comparison of uterine artery embolisation (UAE) with surgical treatment in patients with symptomatic uterine fibroids (REST trial): 5-year results. BJOG. 2011 Jul;118(8):936-44. doi: 10.1111/j.1471-0528.2011.02952.x. Epub 2011 Apr 12.'}, {'ReferencePMID': '17943348', 'ReferenceType': 'background', 'ReferenceCitation': 'Mara M, Maskova J, Fucikova Z, Kuzel D, Belsan T, Sosna O. Midterm clinical and first reproductive results of a randomized controlled trial comparing uterine fibroid embolization and myomectomy. Cardiovasc Intervent Radiol. 2008 Jan-Feb;31(1):73-85. Epub 2007 Oct 18.'}, {'ReferencePMID': '21773858', 'ReferenceType': 'background', 'ReferenceCitation': 'Manyonda IT, Bratby M, Horst JS, Banu N, Gorti M, Belli AM. Uterine artery embolization versus myomectomy: impact on quality of life--results of the FUME (Fibroids of the Uterus: Myomectomy versus Embolization) Trial. Cardiovasc Intervent Radiol. 2012 Jun;35(3):530-6. doi: 10.1007/s00270-011-0228-5. Epub 2011 Jul 20.'}, {'ReferencePMID': '18687032', 'ReferenceType': 'background', 'ReferenceCitation': 'Carls GS, Lee DW, Ozminkowski RJ, Wang S, Gibson TB, Stewart E. What are the total costs of surgical treatment for uterine fibroids? J Womens Health (Larchmt). 2008 Sep;17(7):1119-32. doi: 10.1089/jwh.2008.0456.'}, {'ReferencePMID': '21779774', 'ReferenceType': 'background', 'ReferenceCitation': 'Nash K, Feinglass J, Zei C, Lu G, Mengesha B, Lewicky-Gaupp C, Lin A. Robotic-assisted laparoscopic myomectomy versus abdominal myomectomy: a comparative analysis of surgical outcomes and costs. Arch Gynecol Obstet. 2012 Feb;285(2):435-40. doi: 10.1007/s00404-011-1999-2. Epub 2011 Jul 22.'}, {'ReferencePMID': '12439538', 'ReferenceType': 'background', 'ReferenceCitation': 'Al-Fozan H, Dufort J, Kaplow M, Valenti D, Tulandi T. Cost analysis of myomectomy, hysterectomy, and uterine artery embolization. Am J Obstet Gynecol. 2002 Nov;187(5):1401-4.'}, {'ReferencePMID': '21043553', 'ReferenceType': 'background', 'ReferenceCitation': 'Bushnell DM, Martin ML, Moore KA, Richter HE, Rubin A, Patrick DL. Menorrhagia Impact Questionnaire: assessing the influence of heavy menstrual bleeding on quality of life. Curr Med Res Opin. 2010 Dec;26(12):2745-55. doi: 10.1185/03007995.2010.532200. Epub 2010 Nov 3.'}, {'ReferencePMID': '11406840', 'ReferenceType': 'background', 'ReferenceCitation': 'Hartung J, Knapp G. On tests of the overall treatment effect in meta-analysis with normally distributed responses. Stat Med. 2001 Jun 30;20(12):1771-82.'}, {'ReferencePMID': '23073229', 'ReferenceType': 'background', 'ReferenceCitation': 'Robles R, Aguirre VA, Argueta AI, Guerrero MR. Laparoscopic radiofrequency volumetric thermal ablation of uterine myomas with 12 months of follow-up. Int J Gynaecol Obstet. 2013 Jan;120(1):65-9. doi: 10.1016/j.ijgo.2012.07.023. Epub 2012 Oct 14.'}, {'ReferencePMID': '21545960', 'ReferenceType': 'background', 'ReferenceCitation': 'Garza Leal JG, Hernandez Leon I, Castillo Saenz L, Lee BB. Laparoscopic ultrasound-guided radiofrequency volumetric thermal ablation of symptomatic uterine leiomyomas: feasibility study using the Halt 2000 Ablation System. J Minim Invasive Gynecol. 2011 May-Jun;18(3):364-71. doi: 10.1016/j.jmig.2011.02.006.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Macer JA. For uterine-sparing fibroid treatment, consider laparoscopic ultrasound-guided radiofrequency ablation. obmanagement.com Vol 25 No. 11 November 2013'}, {'ReferencePMID': '23635746', 'ReferenceType': 'result', 'ReferenceCitation': 'Chudnoff SG, Berman JM, Levine DJ, Harris M, Guido RS, Banks E. Outpatient procedure for the treatment and relief of symptomatic uterine myomas. Obstet Gynecol. 2013 May;121(5):1075-82. doi: 10.1097/AOG.0b013e31828b7962.'}, {'ReferencePMID': '23941588', 'ReferenceType': 'result', 'ReferenceCitation': ""Guido RS, Macer JA, Abbott K, Falls JL, Tilley IB, Chudnoff SG. Radiofrequency volumetric thermal ablation of fibroids: a prospective, clinical analysis of two years' outcome from the Halt trial. Health Qual Life Outcomes. 2013 Aug 13;11:139. doi: 10.1186/1477-7525-11-139.""}, {'ReferencePMID': '24613404', 'ReferenceType': 'result', 'ReferenceCitation': 'Berman JM, Guido RS, Garza Leal JG, Pemueller RR, Whaley FS, Chudnoff SG; Halt Study Group. Three-year outcome of the Halt trial: a prospective analysis of radiofrequency volumetric thermal ablation of myomas. J Minim Invasive Gynecol. 2014 Sep-Oct;21(5):767-74. doi: 10.1016/j.jmig.2014.02.015. Epub 2014 Mar 5.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007889', 'ConditionMeshTerm': 'Leiomyoma'}]","[{'ConditionAncestorId': 'D000009379', 'ConditionAncestorTerm': 'Neoplasms, Muscle Tissue'}, {'ConditionAncestorId': 'D000018204', 'ConditionAncestorTerm': 'Neoplasms, Connective and Soft Tissue'}, {'ConditionAncestorId': 'D000009370', 'ConditionAncestorTerm': 'Neoplasms by Histologic Type'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}]","[{'ConditionBrowseLeafId': 'M9484', 'ConditionBrowseLeafName': 'Leiomyoma', 'ConditionBrowseLeafAsFound': 'Uterine Fibroids', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M24433', 'ConditionBrowseLeafName': 'Myofibroma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10161', 'ConditionBrowseLeafName': 'Menorrhagia', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10749', 'ConditionBrowseLeafName': 'Myoma', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18933', 'ConditionBrowseLeafName': 'Neoplasms, Connective and Soft Tissue', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10898', 'ConditionBrowseLeafName': 'Neoplasms by Histologic Type', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03310112,20170243,University of Miami,OTHER,Mindfulness Training in U.S. Army Cohorts,Mindfulness Training in U.S. Army Cohorts,Sep-18,Completed,No,09-Oct-17,Actual,27-Mar-18,Actual,27-Mar-18,Actual,03-Oct-17,12-Oct-17,16-Oct-17,Actual,14-Sep-18,18-Sep-18,Actual,Principal Investigator,University of Miami,OTHER,No,No,,,"This project aims to contextualize delivery of mindfulness training to U.S. Army personnel, evaluate its effectiveness on measures of executive functions and psychological well-being, and determine best practices for its delivery.","['Psychological Stress', 'Anxiety', 'Post Traumatic Stress Disorder', 'Depression', 'Cognitive Change']",Interventional,['Not Applicable'],Non-Randomized,Parallel Assignment,Basic Science,None (Open Label),120,Actual,"[{'ArmGroupLabel': '4-week MBAT', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 4 weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: 4-week MBAT']}}, {'ArmGroupLabel': '2-week MBAT', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Participants will engage in Mindfulness-Based Attention Training (MBAT) in 4, 2-hour training classes over 2 weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: 2-week MBAT']}}, {'ArmGroupLabel': 'No training control (NTC)', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Participants will receive no intervention but will be tested before and after a no-training interval.'}]","[{'InterventionType': 'Behavioral', 'InterventionName': '4-week MBAT', 'InterventionDescription': 'The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['4-week MBAT']}}, {'InterventionType': 'Behavioral', 'InterventionName': '2-week MBAT', 'InterventionDescription': 'The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2-week MBAT']}}]","[{'PrimaryOutcomeMeasure': 'Change in Sustained Attention to Response Task (SART)', 'PrimaryOutcomeDescription': 'The SART is used to assess attentional performance and mind wandering (i.e., off-task thinking which is typically self-generated and compromises the performance of the task at hand). The task uses a continuous performance paradigm involving button presses to frequently presented non-targets (numbers 1, 2, 4, 5, 6, 7, 8, and 9) but requires the participants to withhold their motor response to the infrequent target (number 3). Withholding responses only to infrequent targets encourages a pre-potent response and mind wandering. Real-time subjective experience of mind wandering during SART is assessed through experience-sampling probes randomly presented throughout the task.', 'PrimaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'PrimaryOutcomeMeasure': 'Change in Working Memory Task with Affective Distraction (WMDA)', 'PrimaryOutcomeDescription': 'The WMDA is used to assess the ability to hold information in working memory while overcoming emotional reactivity and distraction. Specifically, participants are presented with a memory item that they need to memorize and hold in memory during a delay interval. During the delay, emotionally negative or neutral scene images are presented. The negative images are combat scenes from Iraq or Afghanistan and the neutral images are non-combat scenes.', 'PrimaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}]","[{'SecondaryOutcomeMeasure': 'Change in Patient Health Questionnaire depression scale (PHQ)', 'SecondaryOutcomeDescription': 'PHQ is used as a valid diagnostic and severity measure for depressive disorders.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Generalized Anxiety Disorder assessment (GAD-7)', 'SecondaryOutcomeDescription': 'GAD is used as a screening tool and severity measure for generalized anxiety disorder.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in PTSD Checklist_Military (PCLM)', 'SecondaryOutcomeDescription': 'PCLM assesses the symptoms of Post-Traumatic Stress Disorder in military personnel.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in the Pittsburgh Sleep Quality Index (PSQI)', 'SecondaryOutcomeDescription': 'PSQI assesses sleep quality and disturbances in seven ""component"" scores: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)', 'SecondaryOutcomeDescription': 'AUDIT-C allows to identify people who are hazardous drinkers or have active alcohol use disorders.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Brief Resilience Scale (BRS)', 'SecondaryOutcomeDescription': 'BRS assesses the ability to bounce back or recover from stress.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Perceived Stress Scale (PSS)', 'SecondaryOutcomeDescription': ""PSS assesses the degree to which situations in one's life are viewed as stressful within the past month. Individual items assess feelings of stress, nervousness, irritation at life's hassles, and perceptions of one's own coping and control over a situation."", 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Positive and Negative Affect Scale (PANAS)', 'SecondaryOutcomeDescription': ""PANAS assesses positive and negative affect. It consists of a list of descriptors of positive (e.g., 'interested', 'enthusiastic') and negative (e.g., 'irritable', 'upset') affects. Items are rated on a 5-point scale (1 = very slightly or not at all, 5 = extremely), according to how participants feel. The Positive Affect scale reflects the extent to which a person feels enthusiastic, active, and alert; the Negative Affect scale reflects unpleasant mood states, such as anger, disgust, and fear."", 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Adult Decision-Making Competence scale (Sunk Costs questionnaire)', 'SecondaryOutcomeDescription': 'Sunk Costs assesses resistance to framing, recognizing social norms, under/overconfidence, applying decision rules, risk perception, resistance to sunk costs, and path independence. A variant of this measure assessing resistance to sunk costs in a military context may be used.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Cognitive Failures Questionnaire (CFQ)', 'SecondaryOutcomeDescription': 'CFQ assesses the frequency of committing minor, everyday mistakes.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the immediate post-intervention (testing 2; either 2 weeks or 4 weeks according to the group) and the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Five-Facet Mindfulness Questionnaire (5FMQ)', 'SecondaryOutcomeDescription': '5FMQ assesses five major measures of mindfulness, including non-judgment of experience, non-reactivity to inner experience, observing emotions, acting with awareness, and describing feelings in words.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Emotion Regulation Questionnaire (ERQ)', 'SecondaryOutcomeDescription': 'ERQ assesses individual differences in two emotion regulation strategies: expressive suppression and cognitive reappraisal.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Combat Experiences Scale (CES)', 'SecondaryOutcomeDescription': 'CES assesses how many different experiences someone had while deployed and in combat.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Rumination and Response Scale (RRS)', 'SecondaryOutcomeDescription': 'RRS assesses two aspects of rumination: brooding and reflective pondering', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Self-Compassion Questionnaire (SCQ)', 'SecondaryOutcomeDescription': 'SCQ assesses various facets of self-compassion', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Change in Mind Wandering Questionnaire (MWQ)', 'SecondaryOutcomeDescription': 'MWQ assesses common experiences related to distraction and mind-wandering.', 'SecondaryOutcomeTimeFrame': 'Change from the pre-intervention baseline (testing 1) to the long-term post-intervention (testing 3), which is an average of 8 weeks from the baseline.'}, {'SecondaryOutcomeMeasure': 'Practice logs', 'SecondaryOutcomeDescription': 'Practice logs will be used to keep track of participants daily mindfulness practice.', 'SecondaryOutcomeTimeFrame': 'Participants will complete paper practice logs tracking their daily practice (i.e., minutes) from the beginning of the MBAT through study completion (testing 3), which is an average of 8 weeks after beginning of the intervention.'}, {'SecondaryOutcomeMeasure': 'Motivation', 'SecondaryOutcomeDescription': 'Five questions regarding motivation to complete the testing session', 'SecondaryOutcomeTimeFrame': 'Participants answer the motivation questions during the long-term post-intervention (testing 3) testing session, which is an average of 8 weeks from the baseline.'}]","Inclusion Criteria:

English-speaking
U.S. Army personnel
Able to understand and provide signed informed consent

Exclusion Criteria

Non-controlled sever medical disease that might interfere with the performance in the study
Any other condition that the investigator might deem problematic for the inclusion of the volunteer in a training study of this nature",Accepts Healthy Volunteers,All,18 Years,65 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'University of Miami', 'LocationCity': 'Coral Gables', 'LocationState': 'Florida', 'LocationZip': '33146', 'LocationCountry': 'United States'}]",,No,"Background: An individual's success in the U.S. Army relies on many factors including the integrity of executive functions (EFs). EFs comprise a complex, multi-faceted brain system necessary to pay attention, overcome habitual and automatic behaviors, regulate mood, and ensure that current behavior is in line with short and long-term goals.Yet, protracted periods of high uncertainty, high demands, and high stress can lead to decreases in the efficiency and availability of EFs. Given the high demands and psychological vulnerabilities that U.S. Army personnel may face, it is critical to provide them with training programs to protect against degradation of EFs (particularly attention and working memory) over high-stress, high-demand intervals. Prior research on mindfulness training (MT) in civilians and military servicemembers showed that MT can effectively protect against degradation in attention and working memory and benefit psychological well-being over high-demand intervals.

Problem: While being successful, prior MT programs required a considerable amount of time dedicated to training (e.g., 24-hour training) and it is challenging to integrate these long programs into the busy schedule of the U.S. Army personnel. To accommodate the time constraints, the principal investigator together with a mindfulness expert developed a short-form mindfulness training program contextualized for the U.S. Army; the program consists of 8-hour training and is known as MBAT, Mindfulness-Based Attention Training.

Project Goal: The present study aims to investigate the best practices for delivery of a short-form mindfulness training to U.S. Army Cohorts. Specifically, the present study will examine the best delivery structure for the MBAT by comparing MBAT course delivered in 2 weeks vs. 4 weeks.",,,,,,,,,Amishi Jha,Associate Professor,University of Miami,,,"[{'OverallOfficialName': 'Amishi P Jha, Ph.D.', 'OverallOfficialAffiliation': 'University of Miami', 'OverallOfficialRole': 'Principal Investigator'}]",No,"[{'ReferencePMID': '25671579', 'ReferenceType': 'background', 'ReferenceCitation': 'Jha AP, Morrison AB, Dainer-Best J, Parker S, Rostrup N, Stanley EA. Minds ""at attention"": mindfulness training curbs attentional lapses in military cohorts. PLoS One. 2015 Feb 11;10(2):e0116889. doi: 10.1371/journal.pone.0116889. eCollection 2015.'}, {'ReferenceType': 'background', 'ReferenceCitation': 'Jha, AP, Morrison, AB, Parker, SC, & Stanley, EA. Practice is protective: Mindfulness training promotes cognitive resilience in high-stress cohorts. Mindfulness. 2016; 7(1), 1-13. doi: 10.1007/s12671-015-0465-9.'}, {'ReferencePMID': '17672382', 'ReferenceType': 'background', 'ReferenceCitation': 'Jha AP, Krompinger J, Baime MJ. Mindfulness training modifies subsystems of attention. Cogn Affect Behav Neurosci. 2007 Jun;7(2):109-19.'}, {'ReferencePMID': '20141302', 'ReferenceType': 'background', 'ReferenceCitation': 'Jha AP, Stanley EA, Kiyonaga A, Wong L, Gelfand L. Examining the protective effects of mindfulness training on working memory capacity and affective experience. Emotion. 2010 Feb;10(1):54-64. doi: 10.1037/a0018438.'}, {'ReferencePMID': '21732031', 'ReferenceType': 'background', 'ReferenceCitation': 'van Vugt MK, Jha AP. Investigating the impact of mindfulness meditation training on working memory: a mathematical modeling approach. Cogn Affect Behav Neurosci. 2011 Sep;11(3):344-53. doi: 10.3758/s13415-011-0048-8.'}, {'ReferencePMID': '30732844', 'ReferenceType': 'derived', 'ReferenceCitation': 'Zanesco AP, Denkova E, Rogers SL, MacNulty WK, Jha AP. Mindfulness training as cognitive training in high-demand cohorts: An initial study in elite military servicemembers. Prog Brain Res. 2019;244:323-354. doi: 10.1016/bs.pbr.2018.10.001. Epub 2018 Nov 27.'}]",,,,,,,,,,,,,,,,,,,,,"Participants will be assigned into three groups: (i) a 4-week MT group (MT4, n = 40) that will receive MBAT in 4, 2-hour sessions over 4 weeks; (ii) a 2-week MT group (MT2, n = 40) that will receive MBAT in 4, 2-hour sessions over 2 weeks; (iii) a no-training control group that will be tested before and after a no-training interval (NTC4, n = 40). After the end of the course sessions, participants from the training groups will still be assigned homework exercises until third testing session (T3). Hence, the MBAT program consists of delivery of the MBAT course, including homework mindfulness practice, and followed by an interval of homework mindfulness practice without course meetings.

The design relies on group randomization at the level of individual military cohort units. This is due to the military requirement that organic unit structure can be maintained during testing and course session scheduling.",,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000040921', 'ConditionMeshTerm': 'Stress Disorders, Traumatic'}, {'ConditionMeshId': 'D000013313', 'ConditionMeshTerm': 'Stress Disorders, Post-Traumatic'}, {'ConditionMeshId': 'D000013315', 'ConditionMeshTerm': 'Stress, Psychological'}]","[{'ConditionAncestorId': 'D000001526', 'ConditionAncestorTerm': 'Behavioral Symptoms'}, {'ConditionAncestorId': 'D000068099', 'ConditionAncestorTerm': 'Trauma and Stressor Related Disorders'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]","[{'ConditionBrowseLeafId': 'M5641', 'ConditionBrowseLeafName': 'Depression', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5644', 'ConditionBrowseLeafName': 'Depressive Disorder', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M2905', 'ConditionBrowseLeafName': 'Anxiety Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M23503', 'ConditionBrowseLeafName': 'Stress Disorders, Traumatic', 'ConditionBrowseLeafAsFound': 'Traumatic Stress Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14688', 'ConditionBrowseLeafName': 'Stress, Psychological', 'ConditionBrowseLeafAsFound': 'Psychological Stress', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14686', 'ConditionBrowseLeafName': 'Stress Disorders, Post-Traumatic', 'ConditionBrowseLeafAsFound': 'Post Traumatic Stress Disorder', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3399', 'ConditionBrowseLeafName': 'Behavioral Symptoms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16268', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M222', 'ConditionBrowseLeafName': 'Trauma and Stressor Related Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02766634,ZIN-FIL-1501,Pfizer,INDUSTRY,A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen),"A Randomized Open-label, Multiple-dose, Crossover Study Evaluatig The Pharmacodynamics And Pharmacokinetics Of Filgrastim Hospira Compared To Us-approved Neupogen (Registered) Following Subcutaneous Administration To Healthy Volunteers",Jul-16,Completed,No,Mar-16,,Jun-16,Actual,Jun-16,Actual,06-May-16,06-May-16,10-May-16,Estimate,20-Jul-16,21-Jul-16,Estimate,Sponsor,Pfizer,INDUSTRY,,,,,"This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as neutrophils. This type of white cell is important in fighting infections. A low neutrophil count is known as neutropenia. Both drugs work by increasing the number of neutrophils that are produced in the body.

This is important for patients who have low neutrophils due to chemotherapy, other treatments such as bone marrow transplant or certain other conditions with symptoms/problems related to low neutrophil counts. The main aim of the study is to test how Filgrastim Hospira works in the body compared to Neupogen®.",['Neutropenia (Low White Blood Cell Count)'],Interventional,['Phase 1'],Randomized,Crossover Assignment,Basic Science,None (Open Label),60,Actual,"[{'ArmGroupLabel': 'Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Filgrastim Hospira (US)', 'Biological: U.S.-approved Neupogen®']}}, {'ArmGroupLabel': 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Filgrastim Hospira (US)', 'Biological: U.S.-approved Neupogen®']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Filgrastim Hospira (US)', 'InterventionDescription': '5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']}}, {'InterventionType': 'Biological', 'InterventionName': 'U.S.-approved Neupogen®', 'InterventionDescription': '5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']}}]","[{'PrimaryOutcomeMeasure': 'The Area under the effect curve for CD34+ (AUECCD34+)', 'PrimaryOutcomeTimeFrame': 'prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period'}, {'PrimaryOutcomeMeasure': 'Maximum observed value for CD34+ (CD34+max)', 'PrimaryOutcomeTimeFrame': 'prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period'}, {'PrimaryOutcomeMeasure': 'Area under the serum filgrastim concentration versus time curve from time zero to 24 hours (AUC0-24)', 'PrimaryOutcomeTimeFrame': 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period'}, {'PrimaryOutcomeMeasure': 'Maximum serum filgrastim concentration (Cmax) following study drug administration on Day 5', 'PrimaryOutcomeTimeFrame': 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period'}]","[{'SecondaryOutcomeMeasure': 'Time to maximum CD34+ count (Tmax[CD34+])', 'SecondaryOutcomeTimeFrame': 'prior to study drug administration on Days 1, 2, 3, 4, 5, and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period'}, {'SecondaryOutcomeMeasure': 'The concentration prior to dose on Day 5 (Ctrough)', 'SecondaryOutcomeTimeFrame': 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period.'}, {'SecondaryOutcomeMeasure': 'Time to maximum serum filgrastim concentration (Tmax)', 'SecondaryOutcomeTimeFrame': 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period.'}, {'SecondaryOutcomeMeasure': 'Elimination half-life (t1/2) from serum filgrastim concentrations following dose administration on Day 5', 'SecondaryOutcomeTimeFrame': 'prior to study drug administration and 24, 48, 72, 96, and 120 hours after dose administration on Day 5 of each period.'}]","Inclusion Criteria:

A subject will be eligible for study participation if all of the following criteria are met at Screening:

Provides written informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB) prior to any study related activities
Healthy male or female volunteers between 18 and 65 years of age (both inclusive)
Body mass index (BMI) between 19 and 30 kg/m2, inclusive, and body weight of not < 50 kg or > 100 kg
Non smoker (defined as a subject who has not smoked and has not used nicotine containing products for at least 3 months prior to study drug administration and has a negative urine screen for cotinine) at Screening
Female subjects of childbearing potential and male subjects and their partners of childbearing potential, agree to pregnancy prevention throughout the duration of the study (through the Final Visit). Subjects and their partners must agree to use of an effective method of contraception, to avoid impregnation of females throughout the course of the study. Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior to Screening. While the best way to avoid pregnancy is to abstain from sexual activity, adequate forms of contraception to be used include oral contraception, depot contraception, intrauterine device (IUD), and barrier contraceptive methods, such as condoms and barrier creams/contraceptive jellies, and spermicidals. Subjects and their partners who can become pregnant must use contraception while on study drug from admission to the Final Visit. Male subjects must also refrain from donating sperm from admission to the Final Visit
Agrees to abstain from alcohol consumption throughout duration of the study and has a negative urine for alcohol at Screening

Exclusion Criteria:

A subject will NOT be eligible for study participation if any of the following criteria are met at Screening:

Any active systemic or immunologic disease or condition, including but not limited to the following general categories: cardiovascular/pulmonary, hepatorenal, or systemic infection, or lactation
Hematologic laboratory abnormalities including leukocytosis (defined as total leukocytes > 11,000/µL), leukopenia (defined as total leukocytes < 4000/μL), or neutropenia (defined as absolute neutrophil count [ANC] < 1500/µL) or thrombocytopenia (defined as platelet count of < 150/µL)
Clinically significant, as judged by the Investigator, vital sign, chest X-ray, or 12-lead electrocardiogram (ECG) abnormality
History of biological growth factor exposure, including but not limited to filgrastim and other granulocyte-colony stimulating factors (G-CSFs) in the context of treatment, prophylaxis, peripheral blood stem cell mobilization, or previous investigational study setting
Drug sensitivity, allergic reaction to, or known hypersensitivity/idiosyncratic reaction to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, other granulocyte colony-stimulating factors or any component of the product: Subjects with the rare heredity problem of fructose intolerance are excluded due to the excipient sorbitol
History of splenic rupture (or subject who is asplenic), pulmonary infiltrate or pneumonia, sickle cell disorders, chronic neutropenia, thrombocytopenia, or vasculitis",Accepts Healthy Volunteers,All,18 Years,65 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'SeaView Research, Inc.', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33126', 'LocationCountry': 'United States'}, {'LocationFacility': 'SeaView Research, Inc.', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33134', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Hospira, now a wholly owned subsidiary of Pfizer', 'CollaboratorClass': 'INDUSTRY'}]",No,"This is a randomized, open-label, multiple-dose, crossover study evaluating the pharmacodynamics and Pharmacokinetics equivalence following SC administration of test and reference product in healthy volunteers. The study will be conducted at a single Phase 1 unit. There will be 30 healthy subjects in each of the two sequences.

After meeting the selection criteria, subjects will be randomly assigned to 1 of the 2 treatment sequences:

Filgrastim Hospira (US) in Period 1 followed by US-approved Neupogen® in Period 2.
US-approved Neupogen® in Period 1 followed by Filgrastim Hospira (US) in Period 2.

Subjects will receive one of each of the drugs once a day for 5 days in each of the treatment sequences.",['filgrastim'],,,,,,"[{'SecondaryId': 'C1121003', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Alias Study Number'}]",,,,,,,"[{'OverallOfficialName': 'Pfizer CT.gov Call Center', 'OverallOfficialAffiliation': 'Pfizer', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '30900158', 'ReferenceType': 'derived', 'ReferenceCitation': 'Yao HM, Ottery FD, Borema T, Harris S, Levy J, May TB, Moosavi S, Zhang J, Summers M. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(®)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. BioDrugs. 2019 Apr;33(2):207-220. doi: 10.1007/s40259-019-00343-8.'}]",,,,,,,,,,"[{'SeeAlsoLinkLabel': 'To obtain contact information for a study center near you, click here.', 'SeeAlsoLinkURL': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=ZIN-FIL-1501&StudyName=A+Randomized+Open-label%2C+Multiple-dose%2C+Crossover+Study+Evaluatig+The+Pharmacodynamics+And+Pharmacokinetics+Of+Filgrastim+Hospira+Compared+To+Us-approved+Neupogen+%28registered%29+Following+Subcutaneous+Administration+To+Healthy+Volunteers'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000009503', 'ConditionMeshTerm': 'Neutropenia'}, {'ConditionMeshId': 'D000007970', 'ConditionMeshTerm': 'Leukopenia'}]","[{'ConditionAncestorId': 'D000000380', 'ConditionAncestorTerm': 'Agranulocytosis'}, {'ConditionAncestorId': 'D000007960', 'ConditionAncestorTerm': 'Leukocyte Disorders'}, {'ConditionAncestorId': 'D000006402', 'ConditionAncestorTerm': 'Hematologic Diseases'}]","[{'ConditionBrowseLeafId': 'M11026', 'ConditionBrowseLeafName': 'Neutropenia', 'ConditionBrowseLeafAsFound': 'Neutropenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9556', 'ConditionBrowseLeafName': 'Leukopenia', 'ConditionBrowseLeafAsFound': 'Low White Blood Cell Count', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2311', 'ConditionBrowseLeafName': 'Agranulocytosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9546', 'ConditionBrowseLeafName': 'Leukocyte Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8073', 'ConditionBrowseLeafName': 'Hematologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2612', 'ConditionBrowseLeafName': 'Granulocytopenia', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]","[{'InterventionMeshId': 'D000078224', 'InterventionMeshTerm': 'Lenograstim'}]","[{'InterventionAncestorId': 'D000000276', 'InterventionAncestorTerm': 'Adjuvants, Immunologic'}, {'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]","[{'InterventionBrowseLeafId': 'M1945', 'InterventionBrowseLeafName': 'Lenograstim', 'InterventionBrowseLeafAsFound': 'Prior to', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2209', 'InterventionBrowseLeafName': 'Adjuvants, Immunologic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8784', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02971709,CA140367,"Klein Buendel, Inc.",INDUSTRY,Use of Shade in U.S. and Australian City Parks,Norms and Built Environment: Use of Shade in U.S. and Australian City Parks,Jul-17,Completed,No,Jul-10,,31-May-17,Actual,31-May-17,Actual,21-Nov-16,21-Nov-16,23-Nov-16,Estimate,24-Jul-17,25-Jul-17,Actual,Sponsor,"Klein Buendel, Inc.",INDUSTRY,,,,,"Use of shade when outdoors is recommended by health authorities worldwide to reduce overall exposure to ultraviolet radiation. However, expensive physical environment changes are often required to provide shade and may be effective only when health education has created a social environment that motivate shade use. A multi-national research team will explore the use of built shade in passive recreation areas within public parks and compare use of built shade between the United States and Australia. The specific aims of the project are to: a) introduce built shade structures (i.e., shade sails) in public parks in Denver and Melbourne; b) compare the use of passive recreation areas with and without built shade; c) compare the change in use of the passive recreation areas in Denver and Melbourne after introduction of built shade, and d) examine the relationship among social environment and physical features of the environment and built shade.",['Skin Cancer'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Prevention,None (Open Label),144,Actual,"[{'ArmGroupLabel': 'Shade Sail', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Shade sails were constructed over passive recreation areas in public parks between pretest and posttest. Shade sails maximized available shade in the passive recreation areas from 11 am to 3 pm in the summer.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Shade Sail']}}, {'ArmGroupLabel': 'Unshaded Control', 'ArmGroupType': 'No Intervention', 'ArmGroupDescription': 'Passive recreation areas in public parks that remained unshaded at pretest and posttest.'}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Shade Sail', 'InterventionDescription': 'Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Shade Sail']}}]","[{'PrimaryOutcomeMeasure': 'Observed Use of Passive Recreation Area by Adults', 'PrimaryOutcomeDescription': 'Any use of each passive recreation, assessed by observing each passive recreation areas for 30 minutes on four weekend days between 11 am and 3 pm when forecast high temperatures were had forecast high temperature were between 72°F/22°C and 95°F/35°C over a 20-week period during two summers (pretest summer, posttest summer) by trained research assistants. Observations were suspended during rain.', 'PrimaryOutcomeTimeFrame': 'One-year'}]","[{'SecondaryOutcomeMeasure': 'Solar Ultraviolet Radiation Level', 'SecondaryOutcomeDescription': 'Average potential UV exposure for a user of the passive recreation area assessed in standard erythemal units, based on measurements from a handheld UV meter performed by trained research assistants during assessment of the primary outcome.', 'SecondaryOutcomeTimeFrame': 'One-year'}]","Inclusion Criteria:

Passive recreation areas had to be located in public parks in Denver, Colorado USA or Melbourne, Victoria Australia metropolitan area.
Parks had to contain at least two unshaded PRAs and be administered by the study municipalities,
Passive recreation areas had to meet the definition of a passive recreation area, i.e., areas for sitting/standing while socializing, preparing/eating a meal, watching or coaching sports, watching a concert, taking a class, or waiting, or areas where people stroll (walk slowly) for sightseeing while observing outdoor displays (e.g., festivals, gardens, zoo exhibits).
Passive recreation areas had to be in full sun (i.e. no shade) at pretest.
Passive recreation areas had to contain a space where a shade sail could be constructed, i.e., free from underground or above ground obstructions, relatively level, and large enough to accommodate the shade sail.
Passive recreation areas had to be approved by parks department staff for shade sail construction.
Adults had to appear to be 18 years of age or older.
Adults had to be in the public parks.

Exclusion Criteria:

Passive recreation areas where major construction/ redevelopment of the parks was planned within the study period.",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Klein Buendel, Inc.', 'LocationCity': 'Golden', 'LocationState': 'Colorado', 'LocationZip': '80403', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cancer Council Victoria', 'LocationCity': 'Melbourne', 'LocationState': 'Victoria', 'LocationZip': '3004', 'LocationCountry': 'Australia'}]","[{'CollaboratorName': 'Cancer Council Victoria', 'CollaboratorClass': 'OTHER'}]",No,"This study is designed to understand the value of shade development in skin cancer prevention and test predictions from social ecologic models that health behavior results from the interplay among the built environment, social environment, and setting features. Use of shade is recommended by health authorities worldwide. However, shade provision requires expensive physical environment changes and may be effective only when health education has created a social environment (e.g., norms) that motivates its use. A multi-national research team will explore the use of built shade in passive recreation areas (i.e., areas for sitting/ standing while socializing, preparing/eating a meal, watching/coaching sports, watching a concert, taking a class, or waiting, or areas where people stroll for sightseeing, while observing outdoor displays, or shopping) within public parks and compare use between the United States (i.e., Denver, Colorado) and Australia (i.e., Melbourne, Victoria) to prospectively test the moderating influence of social environment on the built environment. Pilot studies confirmed that adults in Melbourne had stronger sun protection habits and norms than adults in Denver. The specific aims of the project are to: a) introduce built shade structures (i.e., shade sails) in public parks in Denver and Melbourne; b) compare the use of passive recreation areas with and without built shade; c) compare the change in use of the passive recreation areas in Denver and Melbourne after introduction of built shade, and d) examine the relationship among social environment and physical features of the environment and built shade.The research team will build shade sails at passive recreation areas in public parks and compare use of the passive recreation areas to unshaded passive recreation areas in a randomized pretest-posttest controlled design. Passive recreation areas will be enrolled in one of three annual sample waves and stratified by location (72 in Denver and 72 in Melbourne). In each wave, passive recreation areas will be pretested in a first summer, further stratified based on baseline use, and randomized following pretest to construction of a shade sail or an untreated control group in a 1:3 ratio. Posttesting will occur the following summer, after construction of the shade sails. In total, 36 passive recreation areas will be randomized to the intervention group with shade sail construction (18 per city) and 108 passive recreation areas to the untreated control group with no shade sails (54 per city). The primary outcome measure will be use of the passive recreation areas, observed by trained research assistants. The secondary outcome measure will be the potential ultraviolet radiation exposure, assessed by hand-held meters during the observations of the passive recreation areas. Data collection will occur during 30-minute periods between 11 am and 3 pm on on 4 weekend days over 20-weeks in the summer. Primary analyses will be performed on the probability the passive recreation areas are in use when observed and secondary analysis, on estimated standard erythemal dose of ultraviolet radiation during 30 minutes, using intent-to-treat methods.",,,,,,,"[{'SecondaryId': '0265', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Klein Buendel, Inc.'}]",Shade,,,,,,"[{'OverallOfficialName': 'David Buller, PhD', 'OverallOfficialAffiliation': 'Klein Buendel, Inc.', 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '29048958', 'ReferenceType': 'derived', 'ReferenceCitation': 'Buller DB, English DR, Buller MK, Simmons J, Chamberlain JA, Wakefield M, Dobbinson S. Shade Sails and Passive Recreation in Public Parks of Melbourne and Denver: A Randomized Intervention. Am J Public Health. 2017 Dec;107(12):1869-1875. doi: 10.2105/AJPH.2017.304071. Epub 2017 Oct 19.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012878', 'ConditionMeshTerm': 'Skin Neoplasms'}]","[{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]","[{'ConditionBrowseLeafId': 'M14264', 'ConditionBrowseLeafName': 'Skin Neoplasms', 'ConditionBrowseLeafAsFound': 'Skin Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14257', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M4854', 'InterventionBrowseLeafName': 'Cocaine', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'VaCoAg', 'InterventionBrowseBranchName': 'Vasoconstrictor Agents'}, {'InterventionBrowseBranchAbbrev': 'CNSDep', 'InterventionBrowseBranchName': 'Central Nervous System Depressants'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03801928,C1231006,Pfizer,INDUSTRY,"Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease","OBSERVATIONAL, REAL WORLD STUDY OF INFLECTRA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE (IBD) IN THE UNITED STATES AND CANADA",Jun-20,Completed,No,23-Feb-18,Actual,07-Feb-20,Actual,07-Feb-20,Actual,11-Dec-18,09-Jan-19,14-Jan-19,Actual,11-Jun-20,16-Jun-20,Actual,Sponsor,Pfizer,INDUSTRY,,,,,"This is a prospective, observational, multicenter study conducted in adult patients with ulcerative colitis (UC) or Crohn's disease (CD). The study plans to recruit 300 subjects in the United States and Canada in which the participating physician has decided to treat with INFLECTRA. The study will evaluate treatment patterns, adherence, disease activity, remission status, relapse status, treatment satisfaction, and healthcare resource utilization. Patient outcomes will be assessed at four time points (quarterly) for approximately 52 weeks after the decision to initiate treatment with INFLECTRA.","['Inflammatory Bowel Disease (IBD)', ""Crohn's Disease (CD)"", 'Ulcerative Colitis (UC)']",Observational,,,,,,118,Actual,"[{'ArmGroupLabel': 'Ulcerative Colitis', 'ArmGroupDescription': 'Group treated with Inflectra for Ulcerative Colitis', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Inflectra']}}, {'ArmGroupLabel': ""Crohn's Disease"", 'ArmGroupDescription': ""Group treated with Inflectra for Crohn's Disease"", 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Inflectra']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Inflectra', 'InterventionDescription': 'The study plans to recruit 300 subjects in the United States and Canada initiating or switching to treatment with INFLECTRA over an 8 month period. The decision to start INFLECTRA will be entirely a clinical decision made by the participating physician irrespective of this study.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': [""Crohn's Disease"", 'Ulcerative Colitis']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Infliximab']}}]","[{'PrimaryOutcomeMeasure': 'Duration of Remicade and/or Inflectra therapy and time between lines of therapy', 'PrimaryOutcomeTimeFrame': 'From Baseline through 12 months'}, {'PrimaryOutcomeMeasure': 'Proportion of patients who change dosing and/or dosing schedule', 'PrimaryOutcomeTimeFrame': 'From Baseline thtough 12 months'}, {'PrimaryOutcomeMeasure': 'Proportion of patients who discontinue treatment and the rationale', 'PrimaryOutcomeTimeFrame': 'From Baseline through 12 months'}, {'PrimaryOutcomeMeasure': 'Proportion of patients adhering to treatment regimen', 'PrimaryOutcomeTimeFrame': 'From Baseline through 12 months'}, {'PrimaryOutcomeMeasure': 'Number of health care related visits for all indications', 'PrimaryOutcomeTimeFrame': 'From Baseline through 12 months'}]","[{'SecondaryOutcomeMeasure': ""Crohn's disease response and remission based on Harvey Bradshaw Index score"", 'SecondaryOutcomeDescription': ""Crohn's disease remission indicated by Harvey Bradshaw Index score <5. Crohn's disease response if reduction of Harvey Bradshaw Score of ≥3 points from baseline."", 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months'}, {'SecondaryOutcomeMeasure': 'Ulcerative colitis response and remission based on Partial Mayo score', 'SecondaryOutcomeDescription': 'Ulcerative colitis remission indicated by partial Mayo score <3 points. Ulcerative colitis response if reduction of partial Mayo score of ≥3 points from baseline.', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months'}, {'SecondaryOutcomeMeasure': ""Short Inflammatory Bowel Disease Questionnaire (SIBDQ) for Chron's disease and ulcerative colitis"", 'SecondaryOutcomeDescription': 'All indications - Short Inflammatory Bowel Disease Questionnaire (SIBDQ) Score. Score ranges from 10-70, with higher scores being better.', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months'}, {'SecondaryOutcomeMeasure': 'Quality of Life Visual Analog Scale (VAS)', 'SecondaryOutcomeDescription': 'All indications - Change in Quality of Life Visual Analog Scale (VAS), from baseline. VAS ranges from 0-100, with higher scores being better.', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months'}, {'SecondaryOutcomeMeasure': 'Score on Treatment Satisfaction Questionnaire for Medication (TSQM)', 'SecondaryOutcomeDescription': 'All indications - Treatment Satisfaction Questionnaire for Medication (TSQM) is a generic instrument with a total score and four domain scores: side effects (5 items), effectiveness (3 items), convenience (3 items), and global satisfaction (3 items).', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months'}, {'SecondaryOutcomeMeasure': 'Count of health care related resource utilizations at each study visit', 'SecondaryOutcomeDescription': 'For all indications - Count of health care related visits at each time point, including hospitalizations, Emergency Department visits, office visits and infusion clinic visits', 'SecondaryOutcomeTimeFrame': 'From Baseline through 12 months'}, {'SecondaryOutcomeMeasure': 'Work Productivity and Activity Impairment (WPAI)', 'SecondaryOutcomeDescription': 'All indications - Work Performance and Activity Impairment (WPAI) has 6 questions, related to the preceding 7 days. The questions consider hours missed from work due to health, hours missed because of other reasons (e.g., holidays), hours worked and productivity while working. Scores are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.', 'SecondaryOutcomeTimeFrame': 'Baseline, 3 months, 6 months, 12 months'}]","Inclusion Criteria:

Patients must meet all of the following criteria to be eligible for inclusion in the study:

Patients with confirmed diagnosis of Ulcerative Colitis or Crohn's Disease.
Evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study.
Patient eligible to receive INFLECTRA for the treatment of their disease per approved drug label (patients with fistula, or stoma are eligible).

Exclusion Criteria:

-Patients meeting any of the following criteria will not be included in the study:

Patient previously failed treatment with REMICADE or INFLECTRA/CT P13.
Any reported contraindications for INFLECTRA/CT P13 or REMICADE.
Known hypersensitivity (including severe, acute infusion reactions) to infliximab, its excipients or other murine proteins, at the time of enrolment.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'San Diego Clinical Trials', 'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92120', 'LocationCountry': 'United States'}, {'LocationFacility': 'Medical Research Center Of Connecticut, LLC', 'LocationCity': 'Hamden', 'LocationState': 'Connecticut', 'LocationZip': '06518', 'LocationCountry': 'United States'}, {'LocationFacility': 'Suncoast Research Group, LLC', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33135', 'LocationCountry': 'United States'}, {'LocationFacility': 'Illinois Gastroenterology Group', 'LocationCity': 'Gurnee', 'LocationState': 'Illinois', 'LocationZip': '60031', 'LocationCountry': 'United States'}, {'LocationFacility': 'Indiana University Health Division of Gastroenterology/Hepatology', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46202', 'LocationCountry': 'United States'}, {'LocationFacility': 'Gastro Center of Maryland', 'LocationCity': 'Columbia', 'LocationState': 'Maryland', 'LocationZip': '21045', 'LocationCountry': 'United States'}, {'LocationFacility': 'Infusion Associates N.E.', 'LocationCity': 'Grand Rapids', 'LocationState': 'Michigan', 'LocationZip': '49525', 'LocationCountry': 'United States'}, {'LocationFacility': 'Trinity Health Center Medical Arts', 'LocationCity': 'Minot', 'LocationState': 'North Dakota', 'LocationZip': '58701', 'LocationCountry': 'United States'}, {'LocationFacility': 'Dayton Gastroenterology, Inc.', 'LocationCity': 'Beavercreek', 'LocationState': 'Ohio', 'LocationZip': '45440', 'LocationCountry': 'United States'}, {'LocationFacility': 'Paramount Medical Research & consulting, LLC', 'LocationCity': 'Middleburg Heights', 'LocationState': 'Ohio', 'LocationZip': '44130', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Vancouver Clinic Research', 'LocationCity': 'Vancouver', 'LocationState': 'Washington', 'LocationZip': '98664', 'LocationCountry': 'United States'}, {'LocationFacility': 'Aspen Woods Clinic', 'LocationCity': 'Calgary', 'LocationState': 'Alberta', 'LocationZip': 'T3H 0V5', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Brennan Walters Professional Corporation', 'LocationCity': 'Edmonton', 'LocationState': 'Alberta', 'LocationZip': 'T5R 1W2', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Fraser Clinical Trials', 'LocationCity': 'New Westminster', 'LocationState': 'British Columbia', 'LocationZip': 'V3L 3W5', 'LocationCountry': 'Canada'}, {'LocationFacility': 'Montreal IBD Center (CMIIM)', 'LocationCity': 'Montreal', 'LocationState': 'Quebec', 'LocationZip': 'H2V 2X1', 'LocationCountry': 'Canada'}]",,No,,"['Inflectra', 'Remicade']",No,['Case-Only'],['Prospective'],"A total of 300 patients are planned to be enrolled from approximately 30 40 physician clinics. Enrollment is planned to be competitive, but an upper limit of 20 patients per site per cohort will be applied to maintain the generalizability of the study. This is an observational study; therefore the decision to treat a patient with INFLECTRA must be made prior to a decision to enroll them in this study. Patients are eligible to participate if they have:

Initiated therapy with INFLECTRA as their first biologic;
Switched to INFLECTRA while in remission on a stable dose of REMICADE; or,
Switched to INFLECTRA from another biologic, due to non responsiveness, intolerance, or other reasons.",Non-Probability Sample,"[{'SecondaryId': 'ONWARD', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Alias Study Number'}]",ONWARD,,,,,,"[{'OverallOfficialName': 'Pfizer CT.gov Call Center', 'OverallOfficialAffiliation': 'Pfizer', 'OverallOfficialRole': 'Study Director'}]",No,,,,,,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",,,,,"[{'SeeAlsoLinkLabel': 'To obtain contact information for a study center near you, click here.', 'SeeAlsoLinkURL': 'https://pmiform.com/clinical-trial-info-request?StudyID=C1231006'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003424', 'ConditionMeshTerm': 'Crohn Disease'}, {'ConditionMeshId': 'D000003093', 'ConditionMeshTerm': 'Colitis, Ulcerative'}, {'ConditionMeshId': 'D000007410', 'ConditionMeshTerm': 'Intestinal Diseases'}, {'ConditionMeshId': 'D000015212', 'ConditionMeshTerm': 'Inflammatory Bowel Diseases'}]","[{'ConditionAncestorId': 'D000005759', 'ConditionAncestorTerm': 'Gastroenteritis'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000003092', 'ConditionAncestorTerm': 'Colitis'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}]","[{'ConditionBrowseLeafId': 'M9027', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafAsFound': 'Bowel Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16500', 'ConditionBrowseLeafName': 'Inflammatory Bowel Diseases', 'ConditionBrowseLeafAsFound': 'Inflammatory Bowel Disease', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5221', 'ConditionBrowseLeafName': 'Crohn Disease', 'ConditionBrowseLeafAsFound': ""Crohn's Disease"", 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4904', 'ConditionBrowseLeafName': 'Colitis, Ulcerative', 'ConditionBrowseLeafAsFound': 'Ulcerative Colitis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4903', 'ConditionBrowseLeafName': 'Colitis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15789', 'ConditionBrowseLeafName': 'Ulcer', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7458', 'ConditionBrowseLeafName': 'Gastroenteritis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4919', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}]","[{'InterventionMeshId': 'D000069285', 'InterventionMeshTerm': 'Infliximab'}]","[{'InterventionAncestorId': 'D000003879', 'InterventionAncestorTerm': 'Dermatologic Agents'}, {'InterventionAncestorId': 'D000005765', 'InterventionAncestorTerm': 'Gastrointestinal Agents'}, {'InterventionAncestorId': 'D000018501', 'InterventionAncestorTerm': 'Antirheumatic Agents'}]","[{'InterventionBrowseLeafId': 'M375', 'InterventionBrowseLeafName': 'Infliximab', 'InterventionBrowseLeafAsFound': 'Lateral', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M5657', 'InterventionBrowseLeafName': 'Dermatologic Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M7464', 'InterventionBrowseLeafName': 'Gastrointestinal Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M19188', 'InterventionBrowseLeafName': 'Antirheumatic Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'ARhu', 'InterventionBrowseBranchName': 'Antirheumatic Agents'}, {'InterventionBrowseBranchAbbrev': 'Derm', 'InterventionBrowseBranchName': 'Dermatologic Agents'}, {'InterventionBrowseBranchAbbrev': 'Gast', 'InterventionBrowseBranchName': 'Gastrointestinal Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT01641029,11H-770351,Olive View-UCLA Education & Research Institute,OTHER,Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis,Surveillance and Risk Factor Analysis of Community-Associated Uropathogen Antimicrobial Resistance Among Emergency Department Patients With Acute Pyelonephritis in the United States,Apr-15,Completed,No,Jul-13,,Dec-14,Actual,Dec-14,Actual,12-Jul-12,13-Jul-12,16-Jul-12,Estimate,23-Apr-15,24-Apr-15,Estimate,Sponsor,Olive View-UCLA Education & Research Institute,OTHER,,,,,"Pyelonephritis is a serious infection that manifests with fever, back pain, nausea, and vomiting. In the U.S., it is estimated that there are 20 cases of pyelonephritis per 10,000 annually, with the highest incidence in young women. Escherichia coli (E. coli) causes over 80% of these infections. Over the last two decades, E. coli resistance has emerged to commonly prescribed antimicrobials, such as ampicillin and trimethoprim-sulfamethoxazole (TMP/SMX). Most recently, resistance to fluoroquinolones and strains producing extended-spectrum beta-lactamases (ESBL) have been observed. In order to better understand the evolution and current state of antibiotic resistance among E. coli urinary tract isolates so as to better inform treatment decisions, the investigators propose to conduct an investigation to: a) determine the prevalence of antimicrobial resistance among E. coli causing acute pyelonephritis in various patient groups, and specifically healthy community-dwellers with uncomplicated infections, b) determine the specific prevalence of fluoroquinolone-resistance and ESBL-producing E. coli, and c) determine potential risk factors for fluoroquinolone and ESBL-producing E. coli infections.",['Pyelonephritis'],Observational,,,,,,720,Actual,"[{'ArmGroupLabel': 'pyelonephritis', 'ArmGroupDescription': 'Patients > 18 years of age with flank pain and/or costovertebral angle tenderness, documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement, and clinically suspected acute pyelonephritis. Patients will be identified by their emergency department treating physicians.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: No intervention']}}]","[{'InterventionType': 'Other', 'InterventionName': 'No intervention', 'InterventionDescription': 'There is no intervention', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['pyelonephritis']}}]","[{'PrimaryOutcomeMeasure': 'Prevalence of antimicrobial resistant E. coli in the U.S.', 'PrimaryOutcomeTimeFrame': 'July 2013-July 2014'}]",,"Inclusion Criteria:

patients > 18 years of age with flank pain and/or costovertebral angle tenderness
documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement,
documented temperature in the emergency department of ≥38°C/100.4°F by any method of measurement,

Exclusion Criteria:

complicated pyelonephritis",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Olive View-UCLA Medical Center', 'LocationCity': 'Sylmar', 'LocationState': 'California', 'LocationZip': '91342', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Centers for Disease Control and Prevention', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'Merck Sharp & Dohme Corp.', 'CollaboratorClass': 'INDUSTRY'}]",No,,,No,['Case-Only'],['Prospective'],"Patients will be recruited from ten U.S. university-affiliated medical center emergency departments participating in a CDC-collaborative emerging infections sentinel network, EMERGEncy ID NET. Patients presenting with symptoms of acute uncomplicated pyelonephritis will be enrolled by treating physicians or study coordinators.",Non-Probability Sample,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000011704', 'ConditionMeshTerm': 'Pyelonephritis'}, {'ConditionMeshId': 'D000004630', 'ConditionMeshTerm': 'Emergencies'}]","[{'ConditionAncestorId': 'D000020969', 'ConditionAncestorTerm': 'Disease Attributes'}, {'ConditionAncestorId': 'D000010335', 'ConditionAncestorTerm': 'Pathologic Processes'}, {'ConditionAncestorId': 'D000009395', 'ConditionAncestorTerm': 'Nephritis, Interstitial'}, {'ConditionAncestorId': 'D000009393', 'ConditionAncestorTerm': 'Nephritis'}, {'ConditionAncestorId': 'D000007674', 'ConditionAncestorTerm': 'Kidney Diseases'}, {'ConditionAncestorId': 'D000014570', 'ConditionAncestorTerm': 'Urologic Diseases'}, {'ConditionAncestorId': 'D000011702', 'ConditionAncestorTerm': 'Pyelitis'}]","[{'ConditionBrowseLeafId': 'M6379', 'ConditionBrowseLeafName': 'Emergencies', 'ConditionBrowseLeafAsFound': 'Emergency', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M13140', 'ConditionBrowseLeafName': 'Pyelonephritis', 'ConditionBrowseLeafAsFound': 'Pyelonephritis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M21284', 'ConditionBrowseLeafName': 'Disease Attributes', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10921', 'ConditionBrowseLeafName': 'Nephritis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10923', 'ConditionBrowseLeafName': 'Nephritis, Interstitial', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9281', 'ConditionBrowseLeafName': 'Kidney Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M15902', 'ConditionBrowseLeafName': 'Urologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BXS', 'ConditionBrowseBranchName': 'Urinary Tract, Sexual Organs, and Pregnancy Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M2803', 'InterventionBrowseLeafName': 'Anti-Bacterial Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02128542,GS-US-334-1379,Gilead Sciences,INDUSTRY,Efficacy and Safety of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis,"A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV",Jun-16,Completed,No,Jun-14,,Jun-15,Actual,Jun-15,Actual,29-Apr-14,29-Apr-14,01-May-14,Estimate,21-Jun-16,03-Aug-16,Estimate,Sponsor,Gilead Sciences,INDUSTRY,,,,,"This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV infection.",['Hepatitis C Virus Infection'],Interventional,['Phase 4'],N/A,Single Group Assignment,Treatment,None (Open Label),66,Actual,"[{'ArmGroupLabel': 'Sofosbuvir+RBV 12 weeks', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Participants will receive sofosbuvir+RBV for 12 weeks.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Sofosbuvir', 'Drug: RBV']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Sofosbuvir', 'InterventionDescription': 'Sofosbuvir 400 mg tablet administered orally once daily', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sofosbuvir+RBV 12 weeks']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Sovaldi®', 'GS-7977', 'PSI-7977']}}, {'InterventionType': 'Drug', 'InterventionName': 'RBV', 'InterventionDescription': 'Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Sofosbuvir+RBV 12 weeks']}}]","[{'PrimaryOutcomeMeasure': 'Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy', 'PrimaryOutcomeDescription': 'SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.', 'PrimaryOutcomeTimeFrame': 'Posttreatment Week 12'}, {'PrimaryOutcomeMeasure': 'Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event', 'PrimaryOutcomeTimeFrame': 'Up to 12 weeks'}]","[{'SecondaryOutcomeMeasure': 'Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)', 'SecondaryOutcomeDescription': 'SVR4 was defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.', 'SecondaryOutcomeTimeFrame': 'Posttreatment Week 4'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants Experiencing Viral Breakthrough', 'SecondaryOutcomeDescription': 'Viral breakthrough was defined as either:\n\nHCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while receiving treatment\nHCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values', 'SecondaryOutcomeTimeFrame': 'Up to Posttreatment Weak 12'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants Experiencing Viral Relapse', 'SecondaryOutcomeDescription': 'Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA < LLOQ at end of treatment.', 'SecondaryOutcomeTimeFrame': 'Up to Posttreatment Week 12'}, {'SecondaryOutcomeMeasure': 'Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment', 'SecondaryOutcomeDescription': 'Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.', 'SecondaryOutcomeTimeFrame': 'Pretreatment and Posttreatment Week 12'}]","Inclusion Criteria:

Willing and able to provide written informed consent.
Treatment-naive or treatment-experienced adult, U.S. Veteran

Chronic genotype 2 (GT2) HCV infection Classified as:

Eligible for treatment with interferon (IFN)-based therapy
Ineligible for IFN treatment
Intolerant to IFN.
Cirrhosis determination
Laboratory parameters within prespecified ranges at screening:
A negative serum pregnancy test is required for females of childbearing potential
Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
Lactating females must agree to discontinue nursing before study drug is administered.
Males must agree to refrain from sperm donation from the date of screening until at least 7 months after the last dose of RBV, or 90 days after their last dose of study drug if not taking RBV.
Must be able to comply with the dosing instructions for study drug administration and able to complete the study schedule of assessments.
Must be of generally good health as determined by the Investigator.

Exclusion Criteria:

Current participation in an interventional clinical trial.
Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV).
History of any other clinically significant chronic liver disease (e.g., hemochromatosis; Wilson's disease; α1-antitrypsin deficiency), except nonalcoholic steatohepatitis (NASH).
Decompensated liver
History of hemoglobinopathies
Contraindication or hypersensitivity to RBV
History or current evidence of any condition, therapy, laboratory abnormality or other circumstance that might confound the results of the study, or interfere with the participation for the full duration of the study, such that it is not in the best interest of the individual to participate.
Clinically significant ECG abnormality at screening.
History of solid organ transplantation.
Presence of hepatocellular carcinoma (HCC) Malignancy within 5 years prior to screening, with the exception of specific cancers that are entirely cured by surgical resection (basal cell skin cancer and prostate cancer in remission). Individuals under evaluation for possible malignancy are not eligible.
Prior treatment with an NS5B polymerase inhibitor.
Chronic use of systemic immunosuppressive agents or immunomodulatory agents (e.g., prednisone equivalent > 10 mg/day).
Concomitant disallowed as per the Sovaldi Packet Insert.
Known hypersensitivity to the study drug, the metabolites, or formulation excipient.
History of difficulty with blood collection and/or poor venous access for the purposes of phlebotomy.
Use of any prohibited concomitant medications as described in the study protocol
Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug.
Male with pregnant female partner.
In the judgment of the investigator any clinically-relevant drug or alcohol abuse within 12 months of screening that may interfere with treatment, assessment or compliance with the protocol.",No,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationCity': 'Long Beach', 'LocationState': 'California', 'LocationZip': '90822', 'LocationCountry': 'United States'}, {'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90073', 'LocationCountry': 'United States'}, {'LocationCity': 'Palo Alto', 'LocationState': 'California', 'LocationZip': '94394', 'LocationCountry': 'United States'}, {'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92102', 'LocationCountry': 'United States'}, {'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94121', 'LocationCountry': 'United States'}, {'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520', 'LocationCountry': 'United States'}, {'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33125', 'LocationCountry': 'United States'}, {'LocationCity': 'Decatur', 'LocationState': 'Georgia', 'LocationZip': '30033', 'LocationCountry': 'United States'}, {'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21201', 'LocationCountry': 'United States'}, {'LocationCity': 'Kansas City', 'LocationState': 'Missouri', 'LocationZip': '64128', 'LocationCountry': 'United States'}, {'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27705', 'LocationCountry': 'United States'}, {'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97239', 'LocationCountry': 'United States'}, {'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19104', 'LocationCountry': 'United States'}, {'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15240', 'LocationCountry': 'United States'}, {'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75216', 'LocationCountry': 'United States'}, {'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationCity': 'Richmond', 'LocationState': 'Virginia', 'LocationZip': '23249', 'LocationCountry': 'United States'}]",,No,,['Veterans HCV'],,,,,,,VALOR-HCV,,,,,,"[{'OverallOfficialName': 'Lorenzo Rossaro, MD', 'OverallOfficialAffiliation': 'Gilead Sciences', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '27237429', 'ReferenceType': 'result', 'ReferenceCitation': 'Ho SB, Monto A, Peyton A, Kaplan DE, Byrne S, Moon S, Copans A, Rossaro L, Roy A, Le H, Dvory-Sobol H, Zhu Y, Brainard DM, Guyer W, Shaikh O, Fuchs M, Morgan TR; VALOR study team. Efficacy of Sofosbuvir Plus Ribavirin in Veterans With Hepatitis C Virus Genotype 2 Infection, Compensated Cirrhosis, and Multiple Comorbidities. Clin Gastroenterol Hepatol. 2017 Feb;15(2):282-288. doi: 10.1016/j.cgh.2016.05.024. Epub 2016 May 27.'}]",21-Jun-16,21-Jun-16,03-Aug-16,Estimate,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006526', 'ConditionMeshTerm': 'Hepatitis C'}]","[{'ConditionAncestorId': 'D000006505', 'ConditionAncestorTerm': 'Hepatitis'}, {'ConditionAncestorId': 'D000008107', 'ConditionAncestorTerm': 'Liver Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000006525', 'ConditionAncestorTerm': 'Hepatitis, Viral, Human'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000018178', 'ConditionAncestorTerm': 'Flaviviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8175', 'ConditionBrowseLeafName': 'Hepatitis A', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8194', 'ConditionBrowseLeafName': 'Hepatitis C', 'ConditionBrowseLeafAsFound': 'Hepatitis C Virus Infection', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8174', 'ConditionBrowseLeafName': 'Hepatitis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9686', 'ConditionBrowseLeafName': 'Liver Cirrhosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9690', 'ConditionBrowseLeafName': 'Liver Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8193', 'ConditionBrowseLeafName': 'Hepatitis, Viral, Human', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18907', 'ConditionBrowseLeafName': 'Flaviviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}]","[{'InterventionMeshId': 'D000069474', 'InterventionMeshTerm': 'Sofosbuvir'}]","[{'InterventionAncestorId': 'D000000998', 'InterventionAncestorTerm': 'Antiviral Agents'}, {'InterventionAncestorId': 'D000000890', 'InterventionAncestorTerm': 'Anti-Infective Agents'}]","[{'InterventionBrowseLeafId': 'M443', 'InterventionBrowseLeafName': 'Sofosbuvir', 'InterventionBrowseLeafAsFound': 'Acetaminophen', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M13666', 'InterventionBrowseLeafName': 'Ribavirin', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2895', 'InterventionBrowseLeafName': 'Antiviral Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",113 participants were screened.,Participants were enrolled at a total of 15 study sites in the United States The first participant was screened on 04 June 2014. The last study visit occurred on 22 June 2015.,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'SOF+RBV 12 Weeks (TN)', 'FlowGroupDescription': 'Treatment-naive (TN) participants received sofosbuvir (Sovaldi®; SOF) 400 mg tablet once daily + ribavirin (RBV) tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'FlowGroupId': 'FG001', 'FlowGroupTitle': 'SOF+RBV 12 Weeks (TE)', 'FlowGroupDescription': 'Treatment-experienced participants received sofosbuvir (Sovaldi®; SOF) 400 mg tablet once daily + ribavirin (RBV) tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]","[{'FlowPeriodTitle': 'Overall Study', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '47'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '19'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '43'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '19'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4'}, {'FlowAchievementGroupId': 'FG001', 'FlowAchievementNumSubjects': '0'}]}}]}, 'FlowDropWithdrawList': {'FlowDropWithdraw': [{'FlowDropWithdrawType': 'Lost to Follow-up', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '3'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}, {'FlowDropWithdrawType': 'Withdrew Consent', 'FlowReasonList': {'FlowReason': [{'FlowReasonGroupId': 'FG000', 'FlowReasonNumSubjects': '1'}, {'FlowReasonGroupId': 'FG001', 'FlowReasonNumSubjects': '0'}]}}]}}]",Safety analysis set: participants who received at least 1 dose of study drug,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'SOF+RBV 12 Weeks (TN)', 'BaselineGroupDescription': 'Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'BaselineGroupId': 'BG001', 'BaselineGroupTitle': 'SOF+RBV 12 Weeks (TE)', 'BaselineGroupDescription': 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'BaselineGroupId': 'BG002', 'BaselineGroupTitle': 'Total', 'BaselineGroupDescription': 'Total of all reporting groups'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '47'}, {'BaselineDenomCountGroupId': 'BG001', 'BaselineDenomCountValue': '19'}, {'BaselineDenomCountGroupId': 'BG002', 'BaselineDenomCountValue': '66'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'Years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '64', 'BaselineMeasurementSpread': '6.0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '62', 'BaselineMeasurementSpread': '5.4'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '63', 'BaselineMeasurementSpread': '5.8'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '47'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '66'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race/Ethnicity, Customized', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Black or African American', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '10'}]}}]}}, {'BaselineClassTitle': 'White', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '37'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '54'}]}}]}}, {'BaselineClassTitle': 'Hawaiian or Pacific Islander', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}]}}, {'BaselineClassTitle': 'Other', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '1'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '47'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '66'}]}}]}}]}}, {'BaselineMeasureTitle': 'IL28b Status', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'CC', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '25'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '33'}]}}]}}, {'BaselineClassTitle': 'CT', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '10'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '29'}]}}]}}, {'BaselineClassTitle': 'TT', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '3'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '1'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}]}}]}}, {'BaselineMeasureTitle': 'HCV RNA', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'log10 IU/mL', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '5.9', 'BaselineMeasurementSpread': '0.89'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '6.6', 'BaselineMeasurementSpread': '0.48'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '6.1', 'BaselineMeasurementSpread': '0.87'}]}}]}}]}}, {'BaselineMeasureTitle': 'HCV RNA Category', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': '< 800,000 IU/mL', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '21'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '23'}]}}]}}, {'BaselineClassTitle': '≥ 800,000 IU/mL', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '26'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '43'}]}}]}}]}}, {'BaselineMeasureTitle': 'HCV Genotype', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'Genotype 2', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '2'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '4'}]}}]}}, {'BaselineClassTitle': 'Genotype 2b', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '37'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '17'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '54'}]}}]}}, {'BaselineClassTitle': 'Genotype 2a/2c', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '8'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '8'}]}}]}}]}}, {'BaselineMeasureTitle': 'Cirrhosis Status', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'No', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '0'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '0'}]}}]}}, {'BaselineClassTitle': 'Yes', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '47'}, {'BaselineMeasurementGroupId': 'BG001', 'BaselineMeasurementValue': '19'}, {'BaselineMeasurementGroupId': 'BG002', 'BaselineMeasurementValue': '66'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy', 'OutcomeMeasureDescription': 'SVR12 was defined as HCV RNA < the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.', 'OutcomeMeasurePopulationDescription': 'Full Analysis Set: participants who were enrolled into the study and received at least 1 dose of study drug', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants', 'OutcomeMeasureTimeFrame': 'Posttreatment Week 12', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TN)', 'OutcomeGroupDescription': 'Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TE)', 'OutcomeGroupDescription': 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '47'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '76.6', 'OutcomeMeasurementLowerLimit': '62.0', 'OutcomeMeasurementUpperLimit': '87.7'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '84.2', 'OutcomeMeasurementLowerLimit': '60.4', 'OutcomeMeasurementUpperLimit': '96.6'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event', 'OutcomeMeasurePopulationDescription': 'Safety Analysis Set: participants who received at least 1 dose of study drug', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants', 'OutcomeMeasureTimeFrame': 'Up to 12 weeks', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (All)', 'OutcomeGroupDescription': 'All participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '66'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '4.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)', 'OutcomeMeasureDescription': 'SVR4 was defined as HCV RNA < LLOQ at 4 weeks following the last dose of study drug.', 'OutcomeMeasurePopulationDescription': 'Full Analysis Set', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Posttreatment Week 4', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TN)', 'OutcomeGroupDescription': 'Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TE)', 'OutcomeGroupDescription': 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '47'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '78.7', 'OutcomeMeasurementLowerLimit': '64.3', 'OutcomeMeasurementUpperLimit': '89.3'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '89.5', 'OutcomeMeasurementLowerLimit': '66.9', 'OutcomeMeasurementUpperLimit': '98.7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants Experiencing Viral Breakthrough', 'OutcomeMeasureDescription': 'Viral breakthrough was defined as either:\n\nHCV RNA ≥ LLOQ after having previously had HCV RNA < LLOQ while receiving treatment\nHCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values', 'OutcomeMeasurePopulationDescription': 'Full Analysis Set', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants', 'OutcomeMeasureTimeFrame': 'Up to Posttreatment Weak 12', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TN)', 'OutcomeGroupDescription': 'Treatment-naive participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TE)', 'OutcomeGroupDescription': 'Treatment-experienced participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '47'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants Experiencing Viral Relapse', 'OutcomeMeasureDescription': 'Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA < LLOQ at end of treatment.', 'OutcomeMeasurePopulationDescription': 'Participants in the Full Analysis Set with available data were analyzed\n\n.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'Percentage of participants', 'OutcomeMeasureTimeFrame': 'Up to Posttreatment Week 12', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TN)', 'OutcomeGroupDescription': 'SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}, {'OutcomeGroupId': 'OG001', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (TE)', 'OutcomeGroupDescription': 'SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '46'}, {'OutcomeDenomCountGroupId': 'OG001', 'OutcomeDenomCountValue': '19'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '17.4'}, {'OutcomeMeasurementGroupId': 'OG001', 'OutcomeMeasurementValue': '15.8'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment', 'OutcomeMeasureDescription': 'Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.', 'OutcomeMeasurePopulationDescription': 'Participants who relapsed and qualified for sequencing analysis were analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'participants', 'OutcomeMeasureTimeFrame': 'Pretreatment and Posttreatment Week 12', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'SOF+RBV 12 Weeks (All)', 'OutcomeGroupDescription': 'All participants received SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '10'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'NS5B NI RAV Pretreatment', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2'}]}}]}}, {'OutcomeClassTitle': 'NS5B NI RAV Posttreatment', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5'}]}}]}}, {'OutcomeClassTitle': 'NS5B RBV RAV Pretreatment', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}, {'OutcomeClassTitle': 'NS5B RBV RAV Posttreatment', 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0'}]}}]}}]}}]",5,Up to12 weeks plus 30 days,Safety Analysis Set,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'SOF+RBV 12 Weeks (All Participants)', 'EventGroupDescription': 'SOF 400 mg tablet once daily + RBV tablets (1000 or 1200 mg daily based on weight) for 12 weeks.', 'EventGroupSeriousNumAffected': '8', 'EventGroupSeriousNumAtRisk': '66', 'EventGroupOtherNumAffected': '45', 'EventGroupOtherNumAtRisk': '66'}]","[{'OtherEventTerm': 'Anaemia', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '16', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Diarrhoea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Dyspepsia', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Nausea', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Vomiting', 'OtherEventOrganSystem': 'Gastrointestinal disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Fatigue', 'OtherEventOrganSystem': 'General disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '22', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Musculoskeletal pain', 'OtherEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Dizziness', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Headache', 'OtherEventOrganSystem': 'Nervous system disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '11', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Depression', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Insomnia', 'OtherEventOrganSystem': 'Psychiatric disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Dyspnoea', 'OtherEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '66'}]}}, {'OtherEventTerm': 'Rash', 'OtherEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'OtherEventSourceVocabulary': 'MedDRA Version 18.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '66'}]}}]",No,Yes,Clinical Trial Disclosures,Gilead Sciences,ClinicalTrialDisclosures@gilead.com,,"[{'SeriousEventTerm': 'Anaemia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Cardiac failure congestive', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Nausea', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Oesophageal varices haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Chest pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Bacteraemia', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Endocarditis staphylococcal', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Sepsis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Rhabdomyolysis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Drug withdrawal convulsions', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Chronic obstructive pulmonary disease', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}, {'SeriousEventTerm': 'Hyperhidrosis', 'SeriousEventOrganSystem': 'Skin and subcutaneous tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA Version 18.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '66'}]}}]",OTHER,"After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:

The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or
The study has been completed at all study sites for at least 2 years",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00573976,OCRT07019,"University of California, Irvine",OTHER,Study to Assess the Validity and Reliability of the Spinal Cord Independence Measure (SCIM III),United States Multi-Center Study to Assess the Validity and Reliability of the Spinal Cord Independence Measure (SCIM III),Nov-10,Completed,No,Sep-07,,,,Sep-10,Actual,12-Dec-07,13-Dec-07,14-Dec-07,Estimate,02-Nov-10,04-Nov-10,Estimate,,"University of California, Irvine",OTHER,,,,,"In the past two decades there have been great strides made in understanding the biological changes resulting from spinal cord injury (SCI). The future holds promise of the development of therapies that will promote degrees of repair and recovery of function for people living with SCI. Lessons learned from past ""failed"" SCI clinical trials, however, demonstrate that, in order to accurately evaluate the overall effectiveness of SCI therapies, more sensitive outcomes measures are needed. Specifically, and reflecting the ultimate goal of clinical interventions - inducing functional recovery - the Spinal Cord Independence Measure (SCIM), has been recommended for further testing and development for use as a measure of functional ability in future SCI clinical studies. The SCIM is a very simple questionnaire and score sheet that an evaluator uses to determine how independently a person with SCI can perform certain tasks.

A panel of SCI researchers recommended the SCIM as the most suitable among four candidate measures of functional recovery reviewed at a special meeting sponsored by the National Institute on Disability and Rehabilitation Research (NIDRR) at a joint meeting of the American Spinal Injury Association and the International Spinal Cord Society (ASIA-ISCoS) in Boston, MA, in June 2006. It was recommended that a large-scale, multi-center, prospective trial be conducted in the United States, which would mirror a recently published multi-site international study.

The proposed research on the SCIM III, the latest and most sensitive version of the SCIM, would test the hypothesis that the SCIM III is a valid, reliable, and sensitive measure of functional ability in persons with SCI. Twenty-two rehabilitation centers throughout the United States will enroll a maximum of 660 subjects. Functional ability will be measured with the SCIM III during the first week of admittance into inpatient acute rehabilitation and within one week of discharge from the same rehabilitation program. Statistical analyses will be used to test the validity, reliability, and sensitivity of the SCIM III. The results will demonstrate whether the SCIM III is a suitable outcome measure to assess SCI specific functional ability in future clinical trials.",['Spinal Cord Injury'],Observational,,,,,,660,Anticipated,,,,,"Inclusion Criteria:

Any level SCI
Traumatic or non-traumatic cause of spinal injury
ASIA Impairment Scale grade A, B, C, or D
Males and females 18 years of age or older

Exclusion Criteria:

Cognitive impairments
Any additional condition, other than SCI and SCI-related secondary conditions, that may influence everyday function",No,All,18 Years,,"['Adult', 'Older Adult']",,"[{'CollaboratorName': 'University of Pittsburgh', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Texas Southwestern Medical Center', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Rancho Los Amigos National Rehabilitation Center', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Missouri-Columbia', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'James A. Haley Veterans Administration Hospital', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'VA Long Beach Healthcare System', 'CollaboratorClass': 'FED'}, {'CollaboratorName': 'Allina Health System', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Kentucky', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Mayo Clinic', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'University of Louisville', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Shirley Ryan AbilityLab', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Atrium Health', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Kessler Foundation', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'MedStar National Rehabilitation Network', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'MetroHealth Rehabilitation Institute of Ohio', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Touro Rehabilitation Center', 'CollaboratorClass': 'UNKNOWN'}, {'CollaboratorName': 'Icahn School of Medicine at Mount Sinai', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Medical College of Wisconsin', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'St. Joseph Hospital Health Center', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Thomas Jefferson University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'The Institute for Rehabilitaion and Research Foundation', 'CollaboratorClass': 'OTHER'}]",No,"STUDY PURPOSE This clinical research study will be performed to assess the validity, reliability, and sensitivity of the Spinal Cord Independence Measure (SCIM III) in measuring functional ability in persons with spinal cord injury (SCI).

Aims and Hypothesis:

Overall hypothesis - The SCIM III is a valid, reliable, and sensitive measure of functional ability in persons with SCI.

Aim 1: Examine the validity of the SCIM III as an outcome measure to assess functional ability in persons with SCI.

Criterion-related validity
Construct validity of components

Aim 2: Examine the reliability of SCIM III evaluations.

Inter-rater reliability
Internal consistency

Aim 3: Examine the sensitivity of the SCIM III to functional change.

Sensitivity to functional change compared to the Functional Independence Measure (FIM).
Sensitivity to functional change over time

STUDY DESIGN This is a multi-center, prospective clinical research study performed to assess the validity, reliability, and sensitivity of the Spinal Cord Independence Measure (SCIM III) in measuring functional ability in persons with spinal cord injury (SCI).

UCI will act as the coordinating center for this study, collecting and performing statistical data analysis. There will be approximately 22 rehabilitation centers participating in this study. De-identified data will be transferred from these sites to Dr. Kim Anderson at UCI.","['SCIM', 'SCIM III', 'Multi-Center', 'United States']",,['Case-Control'],['Prospective'],"The characteristics of the proposed subject population include:

Males and females 18 years of age or older
Adults who are competent to give informed consent
Subjects who are able to read or speak English",Non-Probability Sample,[{'SecondaryId': '2007-5854'}],,,,,,,"[{'OverallOfficialName': 'Kimberly D Anderson, Ph.D.', 'OverallOfficialAffiliation': 'University of California, Irvine', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,"Kimberly D. Anderson, Ph.D","University of California, Irvine",,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000013119', 'ConditionMeshTerm': 'Spinal Cord Injuries'}]","[{'ConditionAncestorId': 'D000013118', 'ConditionAncestorTerm': 'Spinal Cord Diseases'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000020196', 'ConditionAncestorTerm': 'Trauma, Nervous System'}, {'ConditionAncestorId': 'D000014947', 'ConditionAncestorTerm': 'Wounds and Injuries'}]","[{'ConditionBrowseLeafId': 'M14499', 'ConditionBrowseLeafName': 'Spinal Cord Injuries', 'ConditionBrowseLeafAsFound': 'Spinal Cord Injury', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M14498', 'ConditionBrowseLeafName': 'Spinal Cord Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16268', 'ConditionBrowseLeafName': 'Wounds and Injuries', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20607', 'ConditionBrowseLeafName': 'Trauma, Nervous System', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC26', 'ConditionBrowseBranchName': 'Wounds and Injuries'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00306007,H1179-27236-01A,"University of California, San Francisco",OTHER,"Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women","Evaluation of the Reliability, Validity, and Acceptability of the London Measure of Unplanned Pregnancy in a U.S. Population of Women",Jun-13,Completed,No,Nov-05,,Aug-07,Actual,Aug-07,Actual,17-Mar-06,21-Mar-06,22-Mar-06,Estimate,23-Jun-13,25-Jun-13,Estimate,Sponsor,"University of California, San Francisco",OTHER,,,,,"The aim of the study is to evaluate the reliability, validity, and acceptability of the London Measure of Unplanned Pregnancy (LMUP) in a U.S. population of women. The researchers hypothesize that the LMUP will be acceptable to a U.S. population and will be reliable and valid.",['Unplanned Pregnancy'],Observational,,,,,,320,Actual,"[{'ArmGroupLabel': 'English prenatal', 'ArmGroupDescription': 'English speaking women recruited from the general OB/GYN clinic'}, {'ArmGroupLabel': 'Spanish prenatal', 'ArmGroupDescription': 'Spanish speaking (monolingual) women recruited from the general OB/GYN clinic'}, {'ArmGroupLabel': 'English abortion clinic', 'ArmGroupDescription': 'English speaking women recruited from the abortion clinic'}, {'ArmGroupLabel': 'Spanish abortion clinic', 'ArmGroupDescription': 'Spanish speaking (monolingual) women recruited from the abortion clinic'}]",,,,"Inclusion Criteria:

Pregnant women
Basic literacy in English or Spanish needed to participate.

Exclusion Criteria:

Literacy level lower than 11 years of age",Accepts Healthy Volunteers,Female,15 Years,45 Years,"['Child', 'Adult']","[{'LocationFacility': 'San Francisco General Hospital', 'LocationCity': 'San Francisco', 'LocationState': 'California', 'LocationZip': '94110', 'LocationCountry': 'United States'}]",,No,"The concept of ""unplanned pregnancy"" is used frequently in health research and policy. The majority of tools used to assess unplanned pregnancy planning have not been validated. Recently the London Measure of Unplanned Pregnancy (LMUP) has been developed and validated. The LMUP had been found to be valid and reproducible, but has not been studied outside of the United Kingdom. If we are able to validate this measure in a U.S. population, its use in studies will improve the quality of data about family planning in U.S. women.","['Pregnancy', 'Unplanned pregnancy', 'Psychosocial', 'Measure']",No,['Cohort'],['Prospective'],"target population for this study is pregnant women who present to san Francisco General Hospital (SFGH) Women's Options Center (WOC) for abortion and to the Women's Health Center for prenatal care. The population is racially and ethnically diverse, and the majority are financially challenged and have no insurance or Medicaid.",Non-Probability Sample,,LMUP,,,,,,"[{'OverallOfficialName': 'Jody Steinauer, MD, MAS', 'OverallOfficialAffiliation': 'University of California, San Francisco', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Diane Morof, MD, MSc', 'OverallOfficialAffiliation': 'University of California, San Francisco', 'OverallOfficialRole': 'Study Director'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02766647,ZIN-FIL-1502,Pfizer,INDUSTRY,A Research Study To Test How Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given By Subcutaneous Injection (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen),"A Randomized Open-Label, Single-Dose, Crossover Study Evaluating The Pharmacokinetics And Pharmacodynamics Of Filgrastim Hospira Compared To U.S.-Approved Neupogen® (Amgen) Following Subcutaneous Administration To Healthy Volunteers",May-16,Completed,No,Dec-15,,Feb-16,Actual,Mar-16,Actual,06-May-16,06-May-16,10-May-16,Estimate,06-May-16,10-May-16,Estimate,Sponsor,Pfizer,INDUSTRY,,,,,"This is a study comparing two study drugs, Filgrastim Hospira and Neupogen®. Neupogen® is approved by the US Food and Drug Administration (FDA) to treat low numbers of specific kinds of white blood cells (WBC) known as neutrophils. This type of white cell is important in fighting infections. A low neutrophil count is known as neutropenia. Both drugs work by increasing the number of neutrophils that are produced in the body.

This is important for patients who have low neutrophils due to chemotherapy, other treatments such as bone marrow transplant or certain other conditions with symptoms/problems related to low neutrophil counts. The main aim of the study is to test how Filgrastim Hospira works in the body compared to Neupogen®.",['Neutropenia (Low White Blood Cell Count)'],Interventional,['Phase 1'],Randomized,Crossover Assignment,Basic Science,None (Open Label),24,Actual,"[{'ArmGroupLabel': 'Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Filgrastim Hospira (US)', 'Biological: US-approved Neupogen®']}}, {'ArmGroupLabel': 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)', 'ArmGroupType': 'Experimental', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Filgrastim Hospira (US)', 'Biological: US-approved Neupogen®']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Filgrastim Hospira (US)', 'InterventionDescription': '5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']}}, {'InterventionType': 'Biological', 'InterventionName': 'US-approved Neupogen®', 'InterventionDescription': '5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Filgrastim Hospira (US) followed by U.S.-approved Neupogen®', 'U.S.-approved Neupogen® followed by Filgrastim Hospira (US)']}}]","[{'PrimaryOutcomeMeasure': 'Area under the serum filgrastim concentration versus time curve from zero to infinity (AUC0-∞)', 'PrimaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}, {'PrimaryOutcomeMeasure': 'Maximum serum filgrastim concentration (Cmax)', 'PrimaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}, {'PrimaryOutcomeMeasure': 'Area under the effect curve for Absolute Neutrophil Count (ANC) (AUEC ANC)', 'PrimaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration'}, {'PrimaryOutcomeMeasure': 'Maximum observed ANC ( ANC max)', 'PrimaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration'}]","[{'SecondaryOutcomeMeasure': 'Time to maximum serum filgrastim concentration (Tmax)', 'SecondaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}, {'SecondaryOutcomeMeasure': 'Elimination half-life (t ½)', 'SecondaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}, {'SecondaryOutcomeMeasure': 'Area under the serum filgrastim concentration versus time curve from time zero to the time of the last measurable concentration versus time curve from time zero to the time of the last measurable concentration (AUC0-t)', 'SecondaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}, {'SecondaryOutcomeMeasure': 'Clearance (CL)', 'SecondaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}, {'SecondaryOutcomeMeasure': 'Time to maximum ANC (Tmax[ANC])', 'SecondaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.5, 1, 2, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dose administration'}, {'SecondaryOutcomeMeasure': 'Volume of distribution (Vd)', 'SecondaryOutcomeTimeFrame': '1 hour prior to dose administration and 0.25, 0.5, 0.75, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, and 48 hours after dose administration'}]","Inclusion Criteria:

Provides written informed consent, approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB) prior to any study related activities
Healthy male or female volunteers between 18 and 65 years of age (both inclusive)
Body mass index (BMI) between 19 and 30 kg/m2, inclusive, and body weight of not < 50 kg or > 100 kg
Non smoker (defined as a subject who has not smoked and has not used nicotine containing products for at least 3 months prior to study drug administration and has a negative urine screen for cotinine) at Screening
Female subjects of childbearing potential, and male subjects and their partners of childbearing potential, agree to pregnancy prevention throughout the duration of the study (through the Final Visit). Subjects and their partners must agree to use of an effective method of contraception, to avoid impregnation of females throughout the course of the study. Subjects using oral contraceptives must be on a stable regimen for at least 3 months prior to Screening. While the best way to avoid pregnancy is to abstain from sexual activity, adequate forms of contraception to be used include oral contraception, depot contraception, intrauterine device (IUD), and barrier contraceptive methods, such as condoms and barrier creams/contraceptive jellies, and spermicidals. Subjects and their partners who can become pregnant must use contraception while on study drug from admission to the Final Visit. Male subjects must also refrain from donating sperm from admission to the Final Visit
Agrees to abstain from alcohol consumption throughout duration of the study and has a negative urine for alcohol at Screening

Exclusion Criteria:

Any active systemic or immunologic disease or condition, including but not limited to the following general categories: cardiovascular/pulmonary, hepatorenal, or systemic infection, or lactation
Hematologic laboratory abnormalities including leukocytosis (defined as total leukocytes > 11,000/µL), leukopenia (defined as total leukocytes < 4000/μL), or neutropenia (defined as absolute neutrophil count [ANC] < 1500/µL) or thrombocytopenia (defined as platelet count of < 150/µL)
Clinically significant, as judged by the Investigator, vital sign, chest X-ray, or 12-lead ECG abnormality
History of biological growth factor exposure, including but not limited to filgrastim and other G-CSFs in the context of treatment, prophylaxis, peripheral blood stem cell mobilization, or previous investigational study setting
Drug sensitivity, allergic reaction to, or known hypersensitivity/idiosyncratic reaction to Escherichia coli-derived proteins, filgrastim, pegfilgrastim, other granulocyte colony-stimulating factors or any component of the product. Subjects with the rare heredity problem of fructose intolerance are excluded due to the excipient sorbitol
History of splenic rupture (or subject who is asplenic), pulmonary infiltrate or pneumonia, sickle cell disease, chronic neutropenia, thrombocytopenia, or vasculitis",Accepts Healthy Volunteers,All,18 Years,65 Years,"['Adult', 'Older Adult']","[{'LocationFacility': 'SeaView Research, Inc', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33126', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Hospira, now a wholly owned subsidiary of Pfizer', 'CollaboratorClass': 'INDUSTRY'}]",No,"This is a randomized, open-label, single-dose, two-way crossover study evaluating the PK and PD equivalence following SC administration of test and reference product in healthy volunteers. The study will be conducted at a single Phase 1 unit.

After meeting the selection criteria, subjects will be randomly assigned to 1 of the 2 treatment sequences:

Filgrastim Hospira (US) followed by US-approved Neupogen®
US-approved Neupogen® followed by Filgrastim Hospira (US)

Subjects will receive one of the drugs in the first Period and the other drug in the other Period.",['Filgrastim'],,,,,,"[{'SecondaryId': 'C1121002', 'SecondaryIdType': 'Other Identifier', 'SecondaryIdDomain': 'Alias Study Number'}]",,,,,,,"[{'OverallOfficialName': 'Pfizer CT.Gov Call Center', 'OverallOfficialAffiliation': 'Pfizer', 'OverallOfficialRole': 'Study Director'}]",,"[{'ReferencePMID': '30900158', 'ReferenceType': 'derived', 'ReferenceCitation': 'Yao HM, Ottery FD, Borema T, Harris S, Levy J, May TB, Moosavi S, Zhang J, Summers M. PF-06881893 (Nivestym™), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen(®)): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers. BioDrugs. 2019 Apr;33(2):207-220. doi: 10.1007/s40259-019-00343-8.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000009503', 'ConditionMeshTerm': 'Neutropenia'}, {'ConditionMeshId': 'D000007970', 'ConditionMeshTerm': 'Leukopenia'}]","[{'ConditionAncestorId': 'D000000380', 'ConditionAncestorTerm': 'Agranulocytosis'}, {'ConditionAncestorId': 'D000007960', 'ConditionAncestorTerm': 'Leukocyte Disorders'}, {'ConditionAncestorId': 'D000006402', 'ConditionAncestorTerm': 'Hematologic Diseases'}]","[{'ConditionBrowseLeafId': 'M11026', 'ConditionBrowseLeafName': 'Neutropenia', 'ConditionBrowseLeafAsFound': 'Neutropenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9556', 'ConditionBrowseLeafName': 'Leukopenia', 'ConditionBrowseLeafAsFound': 'Low White Blood Cell Count', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M2311', 'ConditionBrowseLeafName': 'Agranulocytosis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9546', 'ConditionBrowseLeafName': 'Leukocyte Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8073', 'ConditionBrowseLeafName': 'Hematologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T2612', 'ConditionBrowseLeafName': 'Granulocytopenia', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC15', 'ConditionBrowseBranchName': 'Blood and Lymph Conditions'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]","[{'InterventionMeshId': 'D000078224', 'InterventionMeshTerm': 'Lenograstim'}]","[{'InterventionAncestorId': 'D000000276', 'InterventionAncestorTerm': 'Adjuvants, Immunologic'}, {'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]","[{'InterventionBrowseLeafId': 'M1945', 'InterventionBrowseLeafName': 'Lenograstim', 'InterventionBrowseLeafAsFound': 'Prior to', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2209', 'InterventionBrowseLeafName': 'Adjuvants, Immunologic', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8784', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT04460898,A5481123,Pfizer,INDUSTRY,RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.,"Real-World Treatment Patterns and Outcomes in Postmenopausal, Hormone-Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative, Metastatic Breast Cancer Patients Treated With Palbociclib Plus an Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.",Jul-20,Completed,No,04-Jan-19,Actual,24-Jun-19,Actual,24-Jun-19,Actual,06-Jul-20,06-Jul-20,08-Jul-20,Actual,06-Jul-20,08-Jul-20,Actual,Sponsor,Pfizer,INDUSTRY,,,,,"This is a retrospective, observational study that will document treatment patterns and clinical outcomes of postmenopausal patients diagnosed with HR+/HER2- mBC who received Palbociclib plus Letrozole as initial endocrine-based therapy in US community oncology network settings.",['Breast Cancer'],Observational,,,,,,1,Actual,"[{'ArmGroupLabel': 'Breast Cancer Patients', 'ArmGroupDescription': 'HR+/HER2- metastatic breast cancer patients in the US.'}]",,"[{'PrimaryOutcomeMeasure': 'Progression Free Survival (PFS)', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}, {'PrimaryOutcomeMeasure': 'Tumor response', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}, {'PrimaryOutcomeMeasure': 'Proportion of patients receiving various cancer treatment regimens', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}, {'PrimaryOutcomeMeasure': 'Proportion of patients receiving each therapy sequence across lines', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}, {'PrimaryOutcomeMeasure': 'Proportion of patients receiving each starting dose and end dose for those on palbociclib combination therapy', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}, {'PrimaryOutcomeMeasure': 'Proportion of patients that experienced dose adjustment', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}, {'PrimaryOutcomeMeasure': 'Proportion of patients that discontinued therapy', 'PrimaryOutcomeTimeFrame': 'mBC diagnosis through end of study (assessed up to 24 months)'}]",,"Inclusion Criteria:

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

Diagnosed with locoregional recurrent or metastatic female breast cancer.
Pathologically confirmed HR-positive/HER2-negative diagnosis.

Received treatment with palbociclib in combination with letrozole as initial endocrine-based therapy for advanced/metastatic breast cancer:

Initiated treatment with palbociclib at least 3 months following the provider's first use of palbociclib following its FDA approval.
At least 1 month of follow-up (at least one visit with the provider) after initiation of palbociclib.
Postmenopausal (or receiving surgical or medical treatment to induce menopause) at the time of initiation of palbociclib.

≥18 year old at initiation of palbociclib.

Exclusion Criteria:

No exclusion criteria will be imposed for the selection of patients.",No,Female,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Pfizer United States', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10017', 'LocationCountry': 'United States'}]",,,,,No,['Cohort'],['Retrospective'],"The study will include adult patients aged 18 years and older, diagnosed with HR+/HER2- mBC and received treatment with Palbociclib in combination with letrozole as initial endocrine-therapy for advanced/metastatic breast cancer.",Non-Probability Sample,,,,,,,,"[{'OverallOfficialName': 'Pfizer CT.gov Call Center', 'OverallOfficialAffiliation': 'Pfizer', 'OverallOfficialRole': 'Study Director'}]",No,,,,,,"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.",,,,,"[{'SeeAlsoLinkLabel': 'To obtain contact information for a study center near you, click here.', 'SeeAlsoLinkURL': 'https://pmiform.com/clinical-trial-info-request?StudyID=A5481123'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001943', 'ConditionMeshTerm': 'Breast Neoplasms'}]","[{'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000001941', 'ConditionAncestorTerm': 'Breast Diseases'}, {'ConditionAncestorId': 'D000012871', 'ConditionAncestorTerm': 'Skin Diseases'}]","[{'ConditionBrowseLeafId': 'M3802', 'ConditionBrowseLeafName': 'Breast Neoplasms', 'ConditionBrowseLeafAsFound': 'Breast Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3800', 'ConditionBrowseLeafName': 'Breast Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14257', 'ConditionBrowseLeafName': 'Skin Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC17', 'ConditionBrowseBranchName': 'Skin and Connective Tissue Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'M1743', 'InterventionBrowseLeafName': 'Letrozole', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M231444', 'InterventionBrowseLeafName': 'Palbociclib', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M10483', 'InterventionBrowseLeafName': 'Mitogens', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M8372', 'InterventionBrowseLeafName': 'Hormones', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'ANeo', 'InterventionBrowseBranchName': 'Antineoplastic Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00413517,WRAMC WU # 06-23020,Walter Reed Army Medical Center,FED,Evaluation of Epi-lasik in U.S. Army Personnel,Evaluation of Epi-lasik in U.S. Army Personnel,Jul-10,Completed,No,Nov-06,,,,Sep-09,Actual,18-Dec-06,18-Dec-06,19-Dec-06,Estimate,15-Jul-10,16-Jul-10,Estimate,,Walter Reed Army Medical Center,FED,,,,,"The purpose of this study is to evaluate the safety and efficacy of Epi-Lasik in U.S. Army personnel who have naturally occurring myopia with or without astigmatism. The data from this control group will be collected in such a way as to be comparable to data sets from study groups undergoing wavefront guided PRK, conventional PRK, and related laser refractive surgery procedures.",['Myopia'],Interventional,['Not Applicable'],Non-Randomized,Single Group Assignment,Treatment,None (Open Label),150,Anticipated,,"[{'InterventionType': 'Procedure', 'InterventionName': 'Epi-Lasik', 'InterventionDescription': 'A vision correcting surgery'}]","[{'PrimaryOutcomeMeasure': 'Safety and efficacy of Epi-LASIK', 'PrimaryOutcomeTimeFrame': '12 months after procedure'}]",,"Inclusion Criteria:

Active duty US Army Soldiers eligible for care at WRAMC
Male or female, of any race, and at least 21 years old at the time of the pre-operative examination, and have signed an informed consent. The lower age limit of 21 years is intended to ensure documentation of refractive stability.
Manifest refractive spherical equivalent (MSE) of up to 6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00 D.
Manifest refraction and LADARWave™ refractions must be within 1.00 D.
Best spectacle corrected visual acuity of 20/20 or better in both eyes.
Demonstrated refractive stability, confirmed by clinical records. Neither the spherical nor the cylindrical portion of the refraction may have changed more than 0.50D during the 12-month period immediately preceding the baseline examination, as confirmed by clinical records.
Soft contact lens users must have removed their lenses at least 2 weeks before baseline measurements. Hard contact lens users (PMMA or rigid gas permeable lenses) must have removed their lenses at least 4 weeks prior to baseline measurements and have 2 central keratometry readings and 2 manifest refractions taken at least 1 week apart that do not differ by more than 0.50 D in either meridian; mires should be regular.
Subject must expect to be located in the greater Washington DC area for a 12 month period post-operatively.
Consent of the subject's command (active duty) to participate in the study.
Access to transportation to meet follow-up requirements

Exclusion Criteria:

Female subjects who are pregnant, breast-feeding or intend to become pregnant during the study. Female subjects will be given a urine pregnancy test prior to participating in the study to rule out pregnancy. [Pregnancy and breastfeeding are contraindications to refractive surgery in general, including epi-lasik, whether participating in this study or not]
Concurrent topical or systemic medications that may impair healing, including corticosteroids, antimetabolites, isotretinoin (Accutane), amiodarone hydrochloride (Cordarone) and/or sumatripin (Imitrex).
Medical condition(s), which, in the judgment of the investigator, may impair healing, including but not limited to: collagen vascular disease, autoimmune disease, immunodeficiency diseases, and ocular herpes zoster or simplex.
Active ophthalmic disease, neovascularization of the cornea within 1mm of the intended ablation zone, or clinically significant lens opacity.
Evidence of glaucoma or an intraocular pressure greater than 22 mm Hg at baseline.
Evidence of keratoconus, corneal irregularity, or abnormal videokeratography in either eye.
History of recurrent erosions or epithelial basement dystrophy.
Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the post-operative course.
Any physical or mental impairment that would preclude participation in any of the examinations.",Accepts Healthy Volunteers,All,21 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Walter Reed Army Medical Center, Center for Refractive Surgery', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20307', 'LocationCountry': 'United States'}]",,,,['Naturally occurring myopia with or without astigmatism'],,,,,,,,,,,,,"[{'OverallOfficialName': 'KRAIG S. BOWER, MD', 'OverallOfficialAffiliation': 'Walter Reed Army Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000009216', 'ConditionMeshTerm': 'Myopia'}]","[{'ConditionAncestorId': 'D000012030', 'ConditionAncestorTerm': 'Refractive Errors'}, {'ConditionAncestorId': 'D000005128', 'ConditionAncestorTerm': 'Eye Diseases'}]","[{'ConditionBrowseLeafId': 'M10751', 'ConditionBrowseLeafName': 'Myopia', 'ConditionBrowseLeafAsFound': 'Myopia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3139', 'ConditionBrowseLeafName': 'Astigmatism', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13455', 'ConditionBrowseLeafName': 'Refractive Errors', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6854', 'ConditionBrowseLeafName': 'Eye Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC11', 'ConditionBrowseBranchName': 'Eye Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02882100,INSI-201603,"Insight Therapeutics, LLC",OTHER,Adjuvanted Influenza Vaccination in U.S. Nursing Homes,Adjuvanted Influenza Vaccination and Morbidity and Mortality in U.S. Nursing Homes,Jun-20,"Active, not recruiting",No,Apr-16,Actual,04-Oct-18,Actual,01-Sep-20,Anticipated,24-Aug-16,24-Aug-16,29-Aug-16,Estimate,11-Jun-20,12-Jun-20,Actual,Sponsor,"Insight Therapeutics, LLC",OTHER,,,,,"This study is powered to prospectively evaluate the relative effectiveness of adjuvanted trivalent influenza vaccine (aTIV; FLUAD) in preventing influenza mortality, hospitalization, and functional decline in a nursing home population in the U.S., compared to the commercially available, standard dose trivalent seasonal influenza vaccine (TIV; Fluvirin).","['Influenza', 'Influenza-like Illness']",Interventional,['Phase 4'],Randomized,Parallel Assignment,Prevention,Single,823,Actual,"[{'ArmGroupLabel': 'aTIV', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'NH facilities randomized to receive adjuvanted trivalent influenza vaccine (aTIV, FLUAD) for the residents', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: adjuvanted trivalent influenza vaccine', 'Biological: trivalent influenza vaccine']}}, {'ArmGroupLabel': 'TIV', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'NH facilities randomized to receive standard trivalent influenza vaccine (TIV, Fluvirin) for the residents', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: trivalent influenza vaccine']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'adjuvanted trivalent influenza vaccine', 'InterventionDescription': 'Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['aTIV']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Fluad', 'aTIV']}}, {'InterventionType': 'Biological', 'InterventionName': 'trivalent influenza vaccine', 'InterventionDescription': 'Nursing home residents are allocated to receive standard trivalent vaccine (TIV).', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['TIV', 'aTIV']}, 'InterventionOtherNameList': {'InterventionOtherName': ['Fluvirin', 'TIV']}}]","[{'PrimaryOutcomeMeasure': 'Hospitalization for a respiratory-related Illness', 'PrimaryOutcomeDescription': 'Time to first occurrence of hospitalization for a respiratory-related Illness based upon Medicare inpatient hospital claims', 'PrimaryOutcomeTimeFrame': 'up to 1 year'}, {'PrimaryOutcomeMeasure': 'Hospitalization for all causes', 'PrimaryOutcomeDescription': 'Time to first occurrence of hospitalization for all-causes', 'PrimaryOutcomeTimeFrame': 'up to 1 year'}]","[{'SecondaryOutcomeMeasure': 'Activities of daily living (ADL) scores', 'SecondaryOutcomeDescription': 'Change in activities of daily living (ADL) scores', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}, {'SecondaryOutcomeMeasure': 'Mortality', 'SecondaryOutcomeDescription': 'Difference in mortality rate', 'SecondaryOutcomeTimeFrame': 'up to 1 year'}]","Inclusion Criteria:

Long-term care facilities within 75 miles of one of the 121 cities that serve as CDC surveillance sites

Exclusion Criteria:

Facilities that used high dose influenza vaccine in residents over age 65 in previous influenza season (2015-16)
Facilities having fewer than 50 long-stay residents
Hospital-based facilities
Facilities with more than 20% of the population under age 65
Facilities not submitting Minimum Data Set (MDS) data",No,All,65 Years,,['Older Adult'],"[{'LocationFacility': 'Insight Therapeutics, LLC', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23510', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Case Western Reserve University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Brown University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Seqirus', 'CollaboratorClass': 'INDUSTRY'}]",No,"SUMMARY: A random study sample of up to 1000 NHs within 75 miles of the local area of the 121 cities where the CDC performs weekly influenza surveillance (estimated N= 11,239) may be offered the opportunity for participation; the first 1000 eligible to participate and accepting the offer will be enrolled. Participating facilities will be offered vaccine education for residents and staff, but will be randomly allocated to receive aTIV (FLUAD) vaccine or usual care (TIV) vaccination for their residents.

BACKGROUND: Lower respiratory tract infection (LRI), including pneumonia, bronchitis, and tracheobronchitis, is the leading cause of infectious mortality and hospitalization in older adults , and nursing home (NH) residents. Pneumonia and infection often produce attenuated signs and symptoms in older adults, leading to delayed or even misdiagnosis for this population. Diagnosis is further compromised due to few and sporadic clinician visits with nursing home residents, and reduced access to radiology. LRI may or may not directly lead to hospitalization, but LRIs are associated with considerable other morbidity than can result in hospitalization, including exacerbation of underlying cardiopulmonary diseases. Hospitalization rates for NH residents vary considerably between facilities, but the majority of hospitalizations occur during the 12 weeks during which influenza peaks each year.

OBJECTIVES: The primary objective is to estimate the differences in hospitalization rates during influenza season experienced by long-stay nursing home residents, between facilities using adjuvanted trivalent vaccine vs. standard trivalent vaccine. The secondary objective is to estimate the differences in the likelihood of Activities of Daily Living (ADL) functional decline and mortality rates in the study nursing homes, and influenza outbreaks.","['influenza', 'vaccine', 'vaccination', 'nursing home', 'cluster randomized trial', 'respiratory-related hospitalization']",,,,,,,,,,,['Outcomes Assessor'],"[{'OtherOutcomeMeasure': 'Influenza outbreaks', 'OtherOutcomeDescription': 'Difference in occurrence of documented influenza outbreaks', 'OtherOutcomeTimeFrame': 'up to 1 year'}]","[{'OverallOfficialName': 'Stefan Gravenstein, MD, MPH', 'OverallOfficialAffiliation': 'Case Western Reserve Univsity', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'Vincent Mor, PhD', 'OverallOfficialAffiliation': 'Brown University', 'OverallOfficialRole': 'Principal Investigator'}, {'OverallOfficialName': 'H. Edward Davidson, PharmD, MPH', 'OverallOfficialAffiliation': 'Insight Therapeutics, LLC', 'OverallOfficialRole': 'Principal Investigator'}]",No,"[{'ReferencePMID': '12517228', 'ReferenceType': 'background', 'ReferenceCitation': 'Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003 Jan 8;289(2):179-86.'}, {'ReferencePMID': '15367555', 'ReferenceType': 'background', 'ReferenceCitation': 'Thompson WW, Shay DK, Weintraub E, Brammer L, Bridges CB, Cox NJ, Fukuda K. Influenza-associated hospitalizations in the United States. JAMA. 2004 Sep 15;292(11):1333-40.'}, {'ReferencePMID': '17142257', 'ReferenceType': 'background', 'ReferenceCitation': 'Hayward AC, Harling R, Wetten S, Johnson AM, Munro S, Smedley J, Murad S, Watson JM. Effectiveness of an influenza vaccine programme for care home staff to prevent death, morbidity, and health service use among residents: cluster randomised controlled trial. BMJ. 2006 Dec 16;333(7581):1241. Epub 2006 Dec 1.'}, {'ReferencePMID': '32882710', 'ReferenceType': 'derived', 'ReferenceCitation': 'McConeghy KW, Davidson HE, Canaday DH, Han L, Saade E, Mor V, Gravenstein S. Cluster-randomized trial of adjuvanted vs. non-adjuvanted trivalent influenza vaccine in 823 U.S. nursing homes. Clin Infect Dis. 2020 Sep 4. pii: ciaa1233. doi: 10.1093/cid/ciaa1233. [Epub ahead of print]'}]",,,,,,,,,,"[{'SeeAlsoLinkLabel': 'FDA approves first seasonal influenza vaccine containing an adjuvant', 'SeeAlsoLinkURL': 'https://wayback.archive-it.org/7993/20170111160747/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm474295.htm'}]",,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000007251', 'ConditionMeshTerm': 'Influenza, Human'}]","[{'ConditionAncestorId': 'D000009976', 'ConditionAncestorTerm': 'Orthomyxoviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000012141', 'ConditionAncestorTerm': 'Respiratory Tract Infections'}, {'ConditionAncestorId': 'D000012140', 'ConditionAncestorTerm': 'Respiratory Tract Diseases'}]","[{'ConditionBrowseLeafId': 'M8878', 'ConditionBrowseLeafName': 'Influenza, Human', 'ConditionBrowseLeafAsFound': 'Influenza', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11485', 'ConditionBrowseLeafName': 'Orthomyxoviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13561', 'ConditionBrowseLeafName': 'Respiratory Tract Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13560', 'ConditionBrowseLeafName': 'Respiratory Tract Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC08', 'ConditionBrowseBranchName': 'Respiratory Tract (Lung and Bronchial) Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]","[{'InterventionMeshId': 'D000014612', 'InterventionMeshTerm': 'Vaccines'}]","[{'InterventionAncestorId': 'D000007155', 'InterventionAncestorTerm': 'Immunologic Factors'}, {'InterventionAncestorId': 'D000045505', 'InterventionAncestorTerm': 'Physiological Effects of Drugs'}]","[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafAsFound': 'Group', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M8784', 'InterventionBrowseLeafName': 'Immunologic Factors', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00533975,71015,"University of California, San Diego",OTHER,A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy,A Prospective Study of a New Immunochemical Fecal Occult Blood Test in U.S. Veteran Patients Undergoing Colonoscopy,Jun-07,Unknown status,No,Sep-07,,,,Dec-08,Anticipated,20-Sep-07,20-Sep-07,24-Sep-07,Estimate,20-Sep-07,24-Sep-07,Estimate,,"University of California, San Diego",OTHER,,,,,The purpose of our study is to evaluate the diagnostic validity of a new immunofecal occult blood test (IFOBT) (Teco Diagnostics) in U.S. veterans and to compare it with the guaiac based FOBT.,['Colon Cancer'],Observational,,,,,,500,Anticipated,,,,,"Inclusion Criteria:

Patients (men or women) that are >18 years of age undergoing colonoscopy for a variety of indications (bleeding, diarrhea, weight loss, anemia, abdominal pain, etc)

Exclusion Criteria:

concurrent hospitalization
visible rectal bleeding
known diagnosis of inflammatory bowel disease
hematuria
menstruation at the time of obtaining a stool specimen and performing the tests
inability to prepare the 3 different IFOBT or 3 different FOBT kits",Accepts Healthy Volunteers,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Veteran Affairs Medical Center San Diego', 'LocationCity': 'San Diego', 'LocationState': 'California', 'LocationZip': '92161', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Samuel B Ho, M.D.', 'LocationContactRole': 'Principal Investigator'}]}}]",,No,"Colorectal cancer (CRC) is the third most common cancer in men and women in the United States with an estimated 147,000 new cases and more than 56,000 deaths each year. Early detection of colon cancer and removal of precancerous adenomatous polyps have been shown to reduce its morbidity, mortality and incidence. There are several recommended CRC screening tests, including fecal occult blood test (FOBT), flexible sigmoidoscopy, air-contrast barium enema, and colonoscopy. In the VA, FOBT is the predominant screening test for CRC. Numerous randomized controlled trials have established the efficacy of FOBT in CRC screening. Its advantages include privacy, noninvasiveness, and cost-effectiveness. Use of guaiac-based testing, however, is hampered by low patient compliance, sensitivity, specificity, and positive predictive value. The poor patient compliance, and low specificity and positive predictive value, may be related to the testing procedure. For example, dietary and medication restrictions are recommended to decrease false-negative and false-positive tests. Such restrictions may impede patient compliance. Recently, several studies have evaluated the effectiveness immunochemical-based testing as a potential alternative, with reportedly better compliance, sensitivity, and specificity than guaiac-based tests. The purpose of our study is to evaluate the diagnostic validity of a new IFOBT (Teco Diagnostics) in U.S. veterans and to compare it with the guaiac based FOBT.","['Colon Cancer screening', 'immunofecal occult blood test', 'colonoscopy', 'diagnostic validity']",,['Defined Population'],['Prospective'],,,,,,,,,,"[{'OverallOfficialName': 'Samuel B Ho, M.D.', 'OverallOfficialAffiliation': 'UCSD, VA San Diego', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,"[{'CentralContactName': 'Jeffrey K Lee, B.A.', 'CentralContactRole': 'Contact', 'CentralContactPhone': '510-847-1198', 'CentralContactEMail': 'jklee@ucsd.edu'}]",,,,,,Not yet recruiting,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000003110', 'ConditionMeshTerm': 'Colonic Neoplasms'}]","[{'ConditionAncestorId': 'D000015179', 'ConditionAncestorTerm': 'Colorectal Neoplasms'}, {'ConditionAncestorId': 'D000007414', 'ConditionAncestorTerm': 'Intestinal Neoplasms'}, {'ConditionAncestorId': 'D000005770', 'ConditionAncestorTerm': 'Gastrointestinal Neoplasms'}, {'ConditionAncestorId': 'D000004067', 'ConditionAncestorTerm': 'Digestive System Neoplasms'}, {'ConditionAncestorId': 'D000009371', 'ConditionAncestorTerm': 'Neoplasms by Site'}, {'ConditionAncestorId': 'D000009369', 'ConditionAncestorTerm': 'Neoplasms'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000005767', 'ConditionAncestorTerm': 'Gastrointestinal Diseases'}, {'ConditionAncestorId': 'D000003108', 'ConditionAncestorTerm': 'Colonic Diseases'}, {'ConditionAncestorId': 'D000007410', 'ConditionAncestorTerm': 'Intestinal Diseases'}]","[{'ConditionBrowseLeafId': 'M4921', 'ConditionBrowseLeafName': 'Colonic Neoplasms', 'ConditionBrowseLeafAsFound': 'Colon Cancer', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M16473', 'ConditionBrowseLeafName': 'Colorectal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9031', 'ConditionBrowseLeafName': 'Intestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7469', 'ConditionBrowseLeafName': 'Gastrointestinal Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5839', 'ConditionBrowseLeafName': 'Digestive System Neoplasms', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4919', 'ConditionBrowseLeafName': 'Colonic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M9027', 'ConditionBrowseLeafName': 'Intestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC04', 'ConditionBrowseBranchName': 'Cancers and Other Neoplasms'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,"[{'InterventionBrowseLeafId': 'T120', 'InterventionBrowseLeafName': 'Cola', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'HB', 'InterventionBrowseBranchName': 'Herbal and Botanical'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02109757,FWR20130114H,United States Air Force,FED,Evaluation of Hearing Protection Fit Testing Program,Evaluation of Hearing Protection Fit Testing Program,Apr-14,Unknown status,No,Mar-14,,Oct-15,Anticipated,,,09-Jan-14,07-Apr-14,10-Apr-14,Estimate,07-Apr-14,10-Apr-14,Estimate,Principal Investigator,United States Air Force,FED,,,,,"The specific aim of this research is to evaluate the performance, effectiveness, and long-term training benefits of a formal hearing protection fit testing program. This study may provide preliminary evidence on the benefits of direct education/training combined with a formal hearing protection device (HPD) fit testing on HPD fittings on United States Air Force (USAF) employees. Currently, Public Health provides informal, subjective training to employees; this practice may be altered by the results of this study.",['Hearing Loss'],Interventional,['Not Applicable'],Randomized,Parallel Assignment,Prevention,Single,200,Anticipated,"[{'ArmGroupLabel': 'Software intervention and education', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'This group will receive software intervention and education before and after receiving one-on-one education, thus showing if benefit or effect occurs simply due to having the software input before receiving education.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Software intervention and education']}}, {'ArmGroupLabel': 'Education only', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'This group will not receive software intervention prior to and after one-on-one education, only afterwards.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Other: Education only']}}]","[{'InterventionType': 'Other', 'InterventionName': 'Software intervention and education', 'InterventionDescription': 'Personal attenuation rating measurements will be taken before and after educating the patient using software program', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Software intervention and education']}}, {'InterventionType': 'Other', 'InterventionName': 'Education only', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Education only']}}]","[{'PrimaryOutcomeMeasure': 'Degree of earplug fit for participants in the Air Force Hearing Conservation Program as a measure of education and personnal attenuation rating.', 'PrimaryOutcomeDescription': 'The experimental group will show an increase, larger than the control group, in the amount of personal attenuation rating measurement shown by the software program as a result of software intervention used before and after education at the initial and follow-up visits.', 'PrimaryOutcomeTimeFrame': '6 mos after intial subject visit'}]",,"Inclusion Criteria:

Subjects must be enrolled in the hearing conservation program, and can be civilian or active duty/uniformed. Subjects must be currently using some form of in-the-ear hearing protection device on a regular basis and have ear canals free of cerumen, infection, or any other obstruction.

Exclusion Criteria:

Not enrolled in the hearing conservation program. Not using in-the-ear hearing protection device on a regular basis. Ear canals containing cerumen, infection, or other obstructions.",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Elmendorf Air Force Base', 'LocationStatus': 'Recruiting', 'LocationCity': 'Elemendorf Air Force Base', 'LocationState': 'Alaska', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Shannon Hunt, Au.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '907-580-5804', 'LocationContactEMail': 'shannon.hunt.3@us.af.mil'}, {'LocationContactName': 'Shannon Hunt, Au.D.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Daniel Williams, Au.D.', 'LocationContactRole': 'Sub-Investigator'}]}}, {'LocationFacility': 'Wright-Patterson Air Force Base', 'LocationStatus': 'Recruiting', 'LocationCity': 'Dayton', 'LocationState': 'Ohio', 'LocationZip': '45433', 'LocationCountry': 'United States', 'LocationContactList': {'LocationContact': [{'LocationContactName': 'Quintin A Hecht, Au.D.', 'LocationContactRole': 'Contact', 'LocationContactPhone': '937-938-3201', 'LocationContactEMail': 'quintin.hecht.1@us.af.mil'}, {'LocationContactName': 'Quintin A Hecht, Au.D.', 'LocationContactRole': 'Principal Investigator'}, {'LocationContactName': 'Elizabeth A McKenna, Au.D.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'April Taylor, Au.D.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Malisha Martukovich, Au.D.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Matthew Williams, Au.D.', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Katie Tastad, MPH', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Christina Waldrop, Associates', 'LocationContactRole': 'Sub-Investigator'}, {'LocationContactName': 'Michelle LeMond, Associates', 'LocationContactRole': 'Sub-Investigator'}]}}]",,Yes,,"['Hearing conservation', 'Personal attenuation rating', 'earplug']",,,,,,,,Quintin Hecht,"Hearing Conservation Program Manager, Doctor of Audiology",United States Air Force,['Participant'],,"[{'OverallOfficialName': 'Quintin A Hecht, Au.D.', 'OverallOfficialAffiliation': 'United States Air Force School of Aerospace Medicine', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,Recruiting,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000034381', 'ConditionMeshTerm': 'Hearing Loss'}]","[{'ConditionAncestorId': 'D000006311', 'ConditionAncestorTerm': 'Hearing Disorders'}, {'ConditionAncestorId': 'D000004427', 'ConditionAncestorTerm': 'Ear Diseases'}, {'ConditionAncestorId': 'D000010038', 'ConditionAncestorTerm': 'Otorhinolaryngologic Diseases'}, {'ConditionAncestorId': 'D000012678', 'ConditionAncestorTerm': 'Sensation Disorders'}, {'ConditionAncestorId': 'D000009461', 'ConditionAncestorTerm': 'Neurologic Manifestations'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]","[{'ConditionBrowseLeafId': 'M23007', 'ConditionBrowseLeafName': 'Hearing Loss', 'ConditionBrowseLeafAsFound': 'Hearing Loss', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5423', 'ConditionBrowseLeafName': 'Deafness', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7983', 'ConditionBrowseLeafName': 'Hearing Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M6184', 'ConditionBrowseLeafName': 'Ear Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M11544', 'ConditionBrowseLeafName': 'Otorhinolaryngologic Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14073', 'ConditionBrowseLeafName': 'Sensation Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10987', 'ConditionBrowseLeafName': 'Neurologic Manifestations', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC09', 'ConditionBrowseBranchName': 'Ear, Nose, and Throat Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00959933,P1BH01001,Sandoz,INDUSTRY,Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions,"A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Non-Fasting Conditions.",Aug-09,Completed,No,Apr-01,,May-01,Actual,May-01,Actual,13-Aug-09,14-Aug-09,17-Aug-09,Estimate,27-Mar-17,28-Mar-17,Actual,,Sandoz,INDUSTRY,,,,,The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under non-fasting conditions.,['Chronic Hepatitis C'],Interventional,['Phase 1'],Randomized,Crossover Assignment,Treatment,None (Open Label),24,Actual,"[{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Rebetol 200 Capsules (Schering Corporation, U.S.A.)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Rebetol 200 Capsules (Schering Corporation, U.S.A.)']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Drug', 'InterventionName': 'Rebetol 200 Capsules (Schering Corporation, U.S.A.)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]","[{'PrimaryOutcomeMeasure': 'Bioequivalence based on AUC and Cmax', 'PrimaryOutcomeTimeFrame': '30 days'}]",,"Inclusion Criteria:

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.",Accepts Healthy Volunteers,Female,18 Years,65 Years,"['Adult', 'Older Adult']",,,,,,,,,,,,,,,,,,"[{'OverallOfficialName': 'Piyush Patel, M.D.', 'OverallOfficialAffiliation': 'Allied Clinical Research', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,"Eric Mittleberg, Ph.D, VP of Product Development",Sandoz Inc.,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006526', 'ConditionMeshTerm': 'Hepatitis C'}, {'ConditionMeshId': 'D000019698', 'ConditionMeshTerm': 'Hepatitis C, Chronic'}]","[{'ConditionAncestorId': 'D000006505', 'ConditionAncestorTerm': 'Hepatitis'}, {'ConditionAncestorId': 'D000008107', 'ConditionAncestorTerm': 'Liver Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000006525', 'ConditionAncestorTerm': 'Hepatitis, Viral, Human'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000018178', 'ConditionAncestorTerm': 'Flaviviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000006521', 'ConditionAncestorTerm': 'Hepatitis, Chronic'}]","[{'ConditionBrowseLeafId': 'M8175', 'ConditionBrowseLeafName': 'Hepatitis A', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8194', 'ConditionBrowseLeafName': 'Hepatitis C', 'ConditionBrowseLeafAsFound': 'Hepatitis C', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8174', 'ConditionBrowseLeafName': 'Hepatitis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8190', 'ConditionBrowseLeafName': 'Hepatitis, Chronic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20197', 'ConditionBrowseLeafName': 'Hepatitis C, Chronic', 'ConditionBrowseLeafAsFound': 'Chronic Hepatitis C', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9690', 'ConditionBrowseLeafName': 'Liver Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8193', 'ConditionBrowseLeafName': 'Hepatitis, Viral, Human', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18907', 'ConditionBrowseLeafName': 'Flaviviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]","[{'InterventionMeshId': 'D000012254', 'InterventionMeshTerm': 'Ribavirin'}]","[{'InterventionAncestorId': 'D000000963', 'InterventionAncestorTerm': 'Antimetabolites'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000000998', 'InterventionAncestorTerm': 'Antiviral Agents'}, {'InterventionAncestorId': 'D000000890', 'InterventionAncestorTerm': 'Anti-Infective Agents'}]","[{'InterventionBrowseLeafId': 'M13666', 'InterventionBrowseLeafName': 'Ribavirin', 'InterventionBrowseLeafAsFound': 'Artery', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2862', 'InterventionBrowseLeafName': 'Antimetabolites', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2895', 'InterventionBrowseLeafName': 'Antiviral Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT00960479,P1BH00001,Sandoz,INDUSTRY,Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions,"A Relative Bioavailability Study of Ribavirin (Geneva Pharmaceutical Technology Corporation, N.J., U.S.A.) 200 Capsules and Rebetol (Schering Corporation, N.J., U.S.A.) 200 mg Capsules in Females Under Fasting Conditions.",Aug-09,Completed,No,Jan-01,,Feb-01,Actual,Feb-01,Actual,13-Aug-09,14-Aug-09,17-Aug-09,Estimate,27-Mar-17,28-Mar-17,Actual,,Sandoz,INDUSTRY,,,,,The purpose of this study is to demonstrate the relative bioavailability of Ribavirin 200 capsules and Rebetol 200 mg capsules in females under fasting conditions.,['Chronic Hepatitis C'],Interventional,['Phase 1'],Randomized,Crossover Assignment,Treatment,None (Open Label),38,Actual,"[{'ArmGroupLabel': '1', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)']}}, {'ArmGroupLabel': '2', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Drug: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)']}}]","[{'InterventionType': 'Drug', 'InterventionName': 'Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['1']}}, {'InterventionType': 'Drug', 'InterventionName': 'Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['2']}}]","[{'PrimaryOutcomeMeasure': 'Bioequivalence based on AUC and Cmax', 'PrimaryOutcomeTimeFrame': '30 days'}]",,"Inclusion Criteria:

No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.

Exclusion Criteria:

Positive test results for HIV or hepatitis B or C.
Treatment for drug or alcohol dependence.",Accepts Healthy Volunteers,Female,18 Years,65 Years,"['Adult', 'Older Adult']",,,,,,,,,,,,,,,,,,"[{'OverallOfficialName': 'Piyush Patel, M.D.', 'OverallOfficialAffiliation': 'Allied Clinical Research', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,,,,,,,,"Eric Mittleberg, Ph.D, VP of Product Development",Sandoz Inc.,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000006526', 'ConditionMeshTerm': 'Hepatitis C'}, {'ConditionMeshId': 'D000019698', 'ConditionMeshTerm': 'Hepatitis C, Chronic'}]","[{'ConditionAncestorId': 'D000006505', 'ConditionAncestorTerm': 'Hepatitis'}, {'ConditionAncestorId': 'D000008107', 'ConditionAncestorTerm': 'Liver Diseases'}, {'ConditionAncestorId': 'D000004066', 'ConditionAncestorTerm': 'Digestive System Diseases'}, {'ConditionAncestorId': 'D000006525', 'ConditionAncestorTerm': 'Hepatitis, Viral, Human'}, {'ConditionAncestorId': 'D000014777', 'ConditionAncestorTerm': 'Virus Diseases'}, {'ConditionAncestorId': 'D000018178', 'ConditionAncestorTerm': 'Flaviviridae Infections'}, {'ConditionAncestorId': 'D000012327', 'ConditionAncestorTerm': 'RNA Virus Infections'}, {'ConditionAncestorId': 'D000006521', 'ConditionAncestorTerm': 'Hepatitis, Chronic'}]","[{'ConditionBrowseLeafId': 'M8175', 'ConditionBrowseLeafName': 'Hepatitis A', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8194', 'ConditionBrowseLeafName': 'Hepatitis C', 'ConditionBrowseLeafAsFound': 'Hepatitis C', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8174', 'ConditionBrowseLeafName': 'Hepatitis', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8190', 'ConditionBrowseLeafName': 'Hepatitis, Chronic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20197', 'ConditionBrowseLeafName': 'Hepatitis C, Chronic', 'ConditionBrowseLeafAsFound': 'Chronic Hepatitis C', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M9690', 'ConditionBrowseLeafName': 'Liver Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M7466', 'ConditionBrowseLeafName': 'Gastrointestinal Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M5838', 'ConditionBrowseLeafName': 'Digestive System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8193', 'ConditionBrowseLeafName': 'Hepatitis, Viral, Human', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16105', 'ConditionBrowseLeafName': 'Virus Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M18907', 'ConditionBrowseLeafName': 'Flaviviridae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13732', 'ConditionBrowseLeafName': 'RNA Virus Infections', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC02', 'ConditionBrowseBranchName': 'Viral Diseases'}, {'ConditionBrowseBranchAbbrev': 'BC06', 'ConditionBrowseBranchName': 'Digestive System Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}]","[{'InterventionMeshId': 'D000012254', 'InterventionMeshTerm': 'Ribavirin'}]","[{'InterventionAncestorId': 'D000000963', 'InterventionAncestorTerm': 'Antimetabolites'}, {'InterventionAncestorId': 'D000045504', 'InterventionAncestorTerm': 'Molecular Mechanisms of Pharmacological Action'}, {'InterventionAncestorId': 'D000000998', 'InterventionAncestorTerm': 'Antiviral Agents'}, {'InterventionAncestorId': 'D000000890', 'InterventionAncestorTerm': 'Anti-Infective Agents'}]","[{'InterventionBrowseLeafId': 'M13666', 'InterventionBrowseLeafName': 'Ribavirin', 'InterventionBrowseLeafAsFound': 'Artery', 'InterventionBrowseLeafRelevance': 'high'}, {'InterventionBrowseLeafId': 'M2862', 'InterventionBrowseLeafName': 'Antimetabolites', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2895', 'InterventionBrowseLeafName': 'Antiviral Agents', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M2795', 'InterventionBrowseLeafName': 'Anti-Infective Agents', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'Infe', 'InterventionBrowseBranchName': 'Anti-Infective Agents'}, {'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03266497,R01HL115189,Tufts University,OTHER,Diet Quality Among U.S.-Born and Foreign-born Non-Hispanic Blacks,Diet Quality Among U.S.-Born and Foreign-born Non-Hispanic Blacks: NHANES 2003-2012 Data,Aug-17,Completed,No,Jan-03,Actual,Dec-12,Actual,Dec-12,Actual,28-Aug-17,28-Aug-17,30-Aug-17,Actual,28-Aug-17,30-Aug-17,Actual,Sponsor-Investigator,Sara C. Folta,OTHER,No,No,,,This study compares the diet quality between U.S.-born and foreign-born non-Hispanic Blacks using pooled NHANES data.,['Diet Habit'],Observational,,,,,,4243,Actual,,,"[{'PrimaryOutcomeMeasure': 'Adapted AHEI-2010', 'PrimaryOutcomeDescription': 'Components include: fruit (excluding fruit juice) (s/d); vegetables (excluding white potatoes) (s/d); whole grains (oz-equivalents/d); sugar-sweetened beverages (s/d); nuts, legumes, and vegetable protein (oz-equivalents/d); red/processed meat (s/d); long-chain omega-3 fats (EPA+DHA; mg/d); polyunsaturated fats (PUFA; % kcal/d); sodium (mg/d); and alcohol (drinks/d). Potential range of 0-100 points and higher scores indicative of higher diet quality', 'PrimaryOutcomeTimeFrame': '2003-2012'}]","[{'SecondaryOutcomeMeasure': 'Adapted DASH score', 'SecondaryOutcomeDescription': 'Quintile-, food-based dietary score assessing adherence to the DASH diet, which was developed as a dietary approach to prevent and treat hypertension. Components of the revised score include vegetables, fruit, whole grains, nuts and legumes, sodium, red and processed meat, and sugar-sweetened beverages.', 'SecondaryOutcomeTimeFrame': '2003-2012'}]","Inclusion Criteria:

22-79

Exclusion Criteria:

Pregnant subjects
Energy intakes of ≤600 kcal and ≥ 4800 kcal
No dietary data available",Accepts Healthy Volunteers,All,22 Years,79 Years,"['Adult', 'Older Adult']",,"[{'CollaboratorName': 'Harvard School of Public Health', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'Albert Einstein College of Medicine', 'CollaboratorClass': 'OTHER'}]",No,"This study uses the Alternative Healthy Eating Index-2010 (AHEI-2010) and Dietary Approach to Stop Hypertension (DASH) scores to compare diet quality between U.S.-born (n=3,837) and foreign-born (n=406) non-Hispanic Black adults aged 22-79y, based on pooled nationally representative data (NHANES 2003-2012); as well as by length of U.S. residency. Association between nativity and diet quality was done using multivariable-adjusted linear regression for the continuous total diet quality scores and their components, or multinomial (polytomous) logistic regression for categorical tertiles (low, medium, or high) of the total scores and their components. The study found that foreign-born Blacks had significantly higher AHEI-2010 and DASH scores compared to U.S-born Blacks, and more favorable intakes for many of the score components. Among foreign-born Blacks, diet quality did not significantly differ by length of residency. Foreign-born Blacks were more likely to be in the high than low tertile for fruit (including and excluding fruit juice), vegetables (excluding starchy vegetables), percent whole grains, and omega-3 fatty acids. Overall, the study suggests that foreign-born Blacks have better diet quality compared to their U.S.-born counterparts. Considering nativity among U.S. Blacks in nutrition research and public health efforts may therefore improve accuracy of characterizing dietary intakes and facilitate development of targeted nutrition interventions to reduce diet-related diseases in the diverse Black population in the U.S.","['diet quality', 'health disparities', 'immigrants', 'foreign-born', 'Blacks/African Americans', 'place of birth/nativity', 'length of residency', 'NHANES', 'acculturation']",No,['Other'],['Cross-Sectional'],"The study population comprised 4,243 non-Hispanic Blacks, including 3,837 U.S.-born (90.4%) and 406 foreign-born (9.6%). Compared to U.S.-born Blacks, a higher proportion of foreign-born Blacks were male, had attained a higher level of education, were classified as normal or overweight, had never been a smoker, engaged in physical activity, and had lower energy intake. In comparison to those who were in the U.S. for <10 years, more foreign-born Blacks who were in the U.S. for ≥30 years were current smokers (14.8% vs. 5.0%, respectively), had higher income (IPR of ≥4.00: 43.5% vs 7.9%, respectively), and a higher percent with a college degree or higher (39.4% vs. 18.3%, respectively). Foreign-born Blacks residing in the U.S. for ≥30 years reported higher BMI in comparison to those residing in the U.S. for <10 years (28.8 vs. 26.7 kg/m2).",Probability Sample,,,Sara C. Folta,Associate Professor,Tufts University,,,,No,,,,,,,,,,,,,,,,,,,,,,,,U.S. NIH Grant/Contract,https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=R01HL115189&Fy=all,,,,,,26-Oct-20,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02207569,10126779DOC,Medtronic Cardiovascular,INDUSTRY,Medtronic CoreValve Evolut R U.S. Clinical Study,Medtronic CoreValve Evolut R United States IDE Clinical Study,Oct-20,"Active, not recruiting",No,Aug-14,,Aug-15,Actual,Dec-20,Anticipated,24-Jul-14,31-Jul-14,04-Aug-14,Estimate,20-Oct-20,22-Oct-20,Actual,Sponsor,Medtronic Cardiovascular,INDUSTRY,,,,,The study objectives are to assess the safety and efficacy of the CoreValve Evolut R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis are considered at high or extreme risk for surgical aortic valve replacement.,['Aortic Stenosis'],Interventional,['Not Applicable'],N/A,Single Group Assignment,Treatment,None (Open Label),241,Actual,"[{'ArmGroupLabel': 'CoreValve Evolut R TAVR system', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\nEnVeo R Loading System (LS)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: CoreValve Evolut R TAVR system']}}]","[{'InterventionType': 'Device', 'InterventionName': 'CoreValve Evolut R TAVR system', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CoreValve Evolut R TAVR system']}}]","[{'PrimaryOutcomeMeasure': 'All-cause Mortality at 30 Days by Percent', 'PrimaryOutcomeDescription': 'Percentage of patients that died by any cause at 30 days', 'PrimaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'PrimaryOutcomeMeasure': 'Percentage of Patients With Disabling Stroke at 30 Days', 'PrimaryOutcomeDescription': 'Stroke Diagnostic Criteria:\n\n>\n\nAcute episode of focal or global neurological deficit with at least 2 of the following:\n\nchange in level of consciousness >\nhemiplegia, hemiparesis\nnumbness or sensory loss affecting 1 side >\ndysphasia or aphasia\nhemianopia\namaurosis fugax >\n\nother neurological signs or symptoms consistent with stroke\n\n2.) No other readily identifiable non-stroke cause or the clinical presentation, to be determined by or in conjunctions with the designated neurologist\n\n3.) Confirmation of the diagnosis by at least 1 of the following:\n\nNeurological specialist >\nNeuroimaging procedure, or on clincial grounds alone > Stroke: durations of neural deficit > 24 h if available neuroimaging documents a new hemofrrhage or infarct; or the neurological deficit results in death\n\nDefined by VARC II:\n\n> An mRS (Modified Rankin Score) of 2 or more at 90 days and an increase in at least 1 mRS category from pre-stroke baseline', 'PrimaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'PrimaryOutcomeMeasure': 'Percent Device Success Rate Between 24 and 7 Day', 'PrimaryOutcomeDescription': 'Percentage of patients with Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single Evolut R valve into the proper anatomical location, AND\nAbsence of patient-prosthesis mismatch, and mean gradient , 20 mm Hg (or peak velocity < 3m/sec, AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'PrimaryOutcomeTimeFrame': 'Assessed at 24 hours to seven days post implantation'}, {'PrimaryOutcomeMeasure': 'Percentage of Patients With Less Than Moderate Prosthetic Regurgitation at Early Post Procedure Echocardiogram (24 Hours to 7 Days)', 'PrimaryOutcomeDescription': 'Percentage of patience with none, trace or mild total prosthetic regurgitation at early post procedure echo cardiogram (24 hours to 7 days) as evaluated by echo core lab.', 'PrimaryOutcomeTimeFrame': 'Assessed at 24 hours to 7 days post implantation'}]","[{'SecondaryOutcomeMeasure': 'Individual Component of VARC II Safety Endpoint: Percentage of People Requiring Valve-related Dysfunction Requiring Repeat Procedure (BAV, TAVI, or SAVR)', 'SecondaryOutcomeDescription': 'Percentage of patients with any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVI, or surgical AVR), per VARC II definition.', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Coronary Artery Obstruction Requiring Intervention.', 'SecondaryOutcomeDescription': 'Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut R prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure.', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Percent VARC II Combined Safety Endpoint at 30 Days', 'SecondaryOutcomeDescription': 'VARC II composite safety endpoint rate includes percent freedom from the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Percent of Patients With Acute Kidney Injury: Stage 2 or 3 (Including Renal Replacement Therapy).', 'SecondaryOutcomeDescription': 'Stage 2\n\nIncrease in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR\n\n>\n\nUrine output <0.5 mL/kg/h for >12 but <24 h > Stage 3 >\n\n1) Increase in serum creatinine to ≥300% (>3 x increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR\n\nUrine output <0.3 ml/kg/h for ≥24 h OR\n\n>\n\nAnuria for ≥12 h', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Percentage of Patients With Life-threatening or Disabling Bleeding Event Rate', 'SecondaryOutcomeDescription': 'Fatal bleeding (BARC type 5) OR\n\n>\n\nBleeding in a critical organs, such as intracranial, intraspinal,\n\n> intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR\n\n>\n\nBleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR\n\n>\n\nOvert source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* > (BARC type 3b)', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Percent Rate of Patients Who Received New Permanent Pacemaker Implant at 30 Days', 'SecondaryOutcomeDescription': 'Percent of patients who underwent implantation of new permanent pacemaker or ICD during or after index procedure', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days'}, {'SecondaryOutcomeMeasure': 'Percent Resheath and Recapture Success Rate', 'SecondaryOutcomeDescription': 'Resheath or recapture success rate (where attempted) where a successful resheath is defined as the intended portion of the Evolut R is resheathed into the capsule of the delivery catheter to the intended amount, as verified by flouroscopy; and a successful recapture is defined as the entire Evolut R TAV (including the frame) is full resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip , as verified by flouroscopy. Resheath or recapture wa attempted in a subset of patients. Success rate is calculated as successful resheath or recaputure events in the number of total events. Resheath anad recapture is only possible during the index procedure.', 'SecondaryOutcomeTimeFrame': 'Assessed intra-procedurally'}, {'SecondaryOutcomeMeasure': 'Hemodynamic Performance -Mean Gradient', 'SecondaryOutcomeDescription': 'Mean gradient by Doppler echocardiography.', 'SecondaryOutcomeTimeFrame': 'Assessed at baseline, 30 days, 6 months, and 1 year'}, {'SecondaryOutcomeMeasure': 'Major Vascular Complication', 'SecondaryOutcomeDescription': 'Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR\n\n>\n\nAccess-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment OR\n\n>\n\nDistal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR\n\n>\n\nThe use of unplanned endovascular or surgery associated with death, major bleeding, visceral ischemia or neurological impairment OR\n\n>\n\nAny new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR\n\n>\n\nSurgery for access site nerve injury OR\n\n>\n\nPermanent access related nerve injury', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Hemodynamic Performance - Aortic Valve Area', 'SecondaryOutcomeDescription': 'Hemodynamic performance by Doppler echocardiography - Aortic Valve Area cm2', 'SecondaryOutcomeTimeFrame': 'Assessed at baseline, 30 days, 6 months, and 1 year'}, {'SecondaryOutcomeMeasure': 'Hemodynamic Performance: Total Prosthetic Valve Regurgitation Graded as Moderate or Severe', 'SecondaryOutcomeDescription': 'Hemodynamic performance: the percent of patients who have a degree of total prosthetic valve regurgitation that is moderate or severe.', 'SecondaryOutcomeTimeFrame': 'Assessed at 30 days, 6 months, and 1 year'}]","Inclusion Criteria - Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.

Subjects with low-flow/low gradient severe aortic stenosis can be included, provided low-dose dobutamine or exercise stress echocardiography demonstrates a mean gradient of >40 mmHg or a maximal aortic valve velocity of >4.0 m/sec, AND aortic valve area of <1.0cm2 (or aortic valve area index of <0.6 cm2/m2).

STS score of ≥ 8 OR documented heart team agreement of ≥ high risk for AVR due to frailty or co-morbidities.
Symptoms of aortic stenosis, AND NYHA Functional Class II or greater
The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria

Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. subject is indicated for mechanical prosthetic valve).
A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated: aspirin or heparin (HIT/HITTS) and bivalirudin, ticlopidine and clopidogrel, Nitinol (titanium or nickel), contrast media
Blood dyscrasias as defined: leukopenia (WBC < 1000 mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states.
Untreated clinically significant coronary artery disease requiring revascularization.
Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.
End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min.
Ongoing sepsis, including active endocarditis.
Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to the study procedure.
Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment.
Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
Gastrointestinal (GI) bleeding that would preclude anticoagulation.
Subject refuses a blood transfusion.
Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions.
Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-ups exams.
Currently participating in an investigational drug or another device study (excluding registries).
Evidence of an acute myocardial infarction ≤ 30 days before the study procedure.
Need for emergency surgery for any reason.
Liver failure (Child-Pugh class C).
Subject is pregnant or breast feeding.

Anatomical exclusion criteria:

Pre-existing prosthetic heart valve in any position.
Mixed aortic valve disease (aortic stenosis with severe aortic regurgitation).
Severe mitral regurgitation.
Severe tricuspid regurgitation.
Moderate or severe mitral stenosis.
Hypertrophic obstructive cardiomyopathy.
Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus, or vegetation.
Congenital bicuspid or unicuspid valve verified by echocardiography.

For transfemoral or transaxillary (subclavian) acess:

- Access vessel diameter <5.0mm or <6.0mm for patent LIMA",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Banner Good Samaritan Medical Center', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85006', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Southern California', 'LocationCity': 'Los Angeles', 'LocationState': 'California', 'LocationZip': '90033', 'LocationCountry': 'United States'}, {'LocationFacility': 'Yale New Haven Hospital', 'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520', 'LocationCountry': 'United States'}, {'LocationFacility': 'Washington Hospital Center/Medstar', 'LocationCity': 'Washington', 'LocationState': 'District of Columbia', 'LocationZip': '20010', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Vincent Heart Center of Indiana/The Care Group, LLC', 'LocationCity': 'Indianapolis', 'LocationState': 'Indiana', 'LocationZip': '46290', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Kansas', 'LocationCity': 'Kansas City', 'LocationState': 'Kansas', 'LocationZip': '66160', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Johns Hopkins University', 'LocationCity': 'Baltimore', 'LocationState': 'Maryland', 'LocationZip': '21287', 'LocationCountry': 'United States'}, {'LocationFacility': 'Beth Israel Deaconcess Medical Center', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02215', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Michigan Health Systems', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Detroit Medical Center Cardiovascular Institute', 'LocationCity': 'Detroit', 'LocationState': 'Michigan', 'LocationZip': '48201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Spectrum Health', 'LocationCity': 'Grand Rapids', 'LocationState': 'Michigan', 'LocationZip': '49503', 'LocationCountry': 'United States'}, {'LocationFacility': 'Morristown Memorial Hospital', 'LocationCity': 'Morristown', 'LocationState': 'New Jersey', 'LocationZip': '07962', 'LocationCountry': 'United States'}, {'LocationFacility': 'New York Langone Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10016', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Mount Sinai Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10029', 'LocationCountry': 'United States'}, {'LocationFacility': 'Columbia University Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Francis Hospital', 'LocationCity': 'Roslyn', 'LocationState': 'New York', 'LocationZip': '11576', 'LocationCountry': 'United States'}, {'LocationFacility': 'Duke University Medical Center', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27710', 'LocationCountry': 'United States'}, {'LocationFacility': 'Riverside Methodist Hospital/Ohio Health Research Institute', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43214', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Pittsburg Medical Center', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15213', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pinnacle Health', 'LocationCity': 'Wormleysburg', 'LocationState': 'Pennsylvania', 'LocationZip': '17043', 'LocationCountry': 'United States'}, {'LocationFacility': 'Baylor Heart and Vascular Hospital', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75225', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Methodist DeBakey Heart & Vasc Ctr/The Methodist Hosp', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77030', 'LocationCountry': 'United States'}, {'LocationFacility': ""Aurora Health Care/St Luke's Medical Center"", 'LocationCity': 'Milwaukee', 'LocationState': 'Wisconsin', 'LocationZip': '53215', 'LocationCountry': 'United States'}]",,Yes,"This objective will be accomplished by a prospective, single arm, historical controlled, multi-site study involving a minimum of 150 implanted subjects with no more than 250 implanted subjects at up to 25 study sites in the United States. Procedural and 30 day safety and efficacy results from this study will be compared to appropriate historical control data for the Medtronic CoreValve System. Subjects will be followed up to 5 years following implantation.

The enrollment phase of the study is estimated to take approximately 6-9 months. As each implanted subject is to be followed up to 5 years, the estimated study duration is approximately 66-69 months, excluding the time required for preparing the final report.",,,,,,,,,,,,,,"[{'OverallOfficialName': 'Mathew R Williams, MD', 'OverallOfficialAffiliation': 'New York Langone Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]",Undecided,"[{'ReferencePMID': '28183466', 'ReferenceType': 'derived', 'ReferenceCitation': 'Popma JJ, Reardon MJ, Khabbaz K, Harrison JK, Hughes GC, Kodali S, George I, Deeb GM, Chetcuti S, Kipperman R, Brown J, Qiao H, Slater J, Williams MR. Early Clinical Outcomes After Transcatheter Aortic Valve Replacement Using a Novel Self-Expanding Bioprosthesis in Patients With Severe Aortic Stenosis Who Are Suboptimal for Surgery: Results of the Evolut R U.S. Study. JACC Cardiovasc Interv. 2017 Feb 13;10(3):268-275. doi: 10.1016/j.jcin.2016.08.050.'}]",30-Sep-16,13-Nov-17,12-Dec-17,Actual,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001024', 'ConditionMeshTerm': 'Aortic Valve Stenosis'}]","[{'ConditionAncestorId': 'D000006349', 'ConditionAncestorTerm': 'Heart Valve Diseases'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000014694', 'ConditionAncestorTerm': 'Ventricular Outflow Obstruction'}]","[{'ConditionBrowseLeafId': 'M2921', 'ConditionBrowseLeafName': 'Aortic Valve Stenosis', 'ConditionBrowseLeafAsFound': 'Aortic Stenosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5058', 'ConditionBrowseLeafName': 'Constriction, Pathologic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8020', 'ConditionBrowseLeafName': 'Heart Valve Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16023', 'ConditionBrowseLeafName': 'Ventricular Outflow Obstruction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T449', 'ConditionBrowseLeafName': 'Aortic Valve Stenosis', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'CoreValve Evolut R TAVR System', 'FlowGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]","[{'FlowPeriodTitle': 'Enrolled to Implant', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementComment': '241 entered procedure room for implant', 'FlowAchievementNumSubjects': '241'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementComment': '237 actual implants', 'FlowAchievementNumSubjects': '237'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4'}]}}]}}, {'FlowPeriodTitle': 'Implant to 30 Days', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '237'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '233'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '4'}]}}]}}, {'FlowPeriodTitle': '30 Days to 6 Months', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '233'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '222'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '11'}]}}]}}, {'FlowPeriodTitle': '6 Months - 1 Year', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '222'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '213'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '9'}]}}]}}]",241 attempted implant 237 implanted,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'CoreValve Evolut R TAVR System', 'BaselineGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:>\n\nEvolut R Transcatheter Aortic Valve (TAV)>\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath>\nEnVeo R Loading System (LS)> > CoreValve Evolut R TAVR system'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '241'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '84.4', 'BaselineMeasurementSpread': '6.8'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '165'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '76'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Number', 'BaselineMeasureUnitOfMeasure': 'participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '241'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'All-cause Mortality at 30 Days by Percent', 'OutcomeMeasureDescription': 'Percentage of patients that died by any cause at 30 days', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of partcipants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.5', 'OutcomeMeasurementLowerLimit': '1.1', 'OutcomeMeasurementUpperLimit': '5.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Patients With Disabling Stroke at 30 Days', 'OutcomeMeasureDescription': 'Stroke Diagnostic Criteria:\n\n>\n\nAcute episode of focal or global neurological deficit with at least 2 of the following:\n\nchange in level of consciousness >\nhemiplegia, hemiparesis\nnumbness or sensory loss affecting 1 side >\ndysphasia or aphasia\nhemianopia\namaurosis fugax >\n\nother neurological signs or symptoms consistent with stroke\n\n2.) No other readily identifiable non-stroke cause or the clinical presentation, to be determined by or in conjunctions with the designated neurologist\n\n3.) Confirmation of the diagnosis by at least 1 of the following:\n\nNeurological specialist >\nNeuroimaging procedure, or on clincial grounds alone > Stroke: durations of neural deficit > 24 h if available neuroimaging documents a new hemofrrhage or infarct; or the neurological deficit results in death\n\nDefined by VARC II:\n\n> An mRS (Modified Rankin Score) of 2 or more at 90 days and an increase in at least 1 mRS category from pre-stroke baseline', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '3.3', 'OutcomeMeasurementLowerLimit': '1.7', 'OutcomeMeasurementUpperLimit': '6.6'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percent Device Success Rate Between 24 and 7 Day', 'OutcomeMeasureDescription': 'Percentage of patients with Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single Evolut R valve into the proper anatomical location, AND\nAbsence of patient-prosthesis mismatch, and mean gradient , 20 mm Hg (or peak velocity < 3m/sec, AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'OutcomeMeasurePopulationDescription': 'All subjects implanted with the Evolut R TAV, defined as the Evolut R TAV is placed in the aortic annulus and completely released from the Enveo catheter delivery system', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of overall device success', 'OutcomeMeasureTimeFrame': 'Assessed at 24 hours to seven days post implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '237'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '69.2', 'OutcomeMeasurementLowerLimit': '62.3', 'OutcomeMeasurementUpperLimit': '75.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Patients With Less Than Moderate Prosthetic Regurgitation at Early Post Procedure Echocardiogram (24 Hours to 7 Days)', 'OutcomeMeasureDescription': 'Percentage of patience with none, trace or mild total prosthetic regurgitation at early post procedure echo cardiogram (24 hours to 7 days) as evaluated by echo core lab.', 'OutcomeMeasurePopulationDescription': 'Subset includes all subjects who are implanted with the Evolut R TAV, defined as the Evolut R TAV is placed in the aortic annulus and completely released from the Enveo catheter delivery system', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of partcipants', 'OutcomeMeasureTimeFrame': 'Assessed at 24 hours to 7 days post implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '237'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '96.5', 'OutcomeMeasurementLowerLimit': '93.3', 'OutcomeMeasurementUpperLimit': '98.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Individual Component of VARC II Safety Endpoint: Percentage of People Requiring Valve-related Dysfunction Requiring Repeat Procedure (BAV, TAVI, or SAVR)', 'OutcomeMeasureDescription': 'Percentage of patients with any valve dysfunction that requires repeat procedure (e.g. balloon valvuloplasty, TAVI, or surgical AVR), per VARC II definition.', 'OutcomeMeasurePopulationDescription': 'The safety subset includes all subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of overall patients', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.0', 'OutcomeMeasurementLowerLimit': '0.0', 'OutcomeMeasurementUpperLimit': '1.6'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Coronary Artery Obstruction Requiring Intervention.', 'OutcomeMeasureDescription': 'Angiographic or echocardiographic evidence of a new, partial or complete, obstruction of a coronary ostium, either by the Evolut R prosthesis itself, the native leaflets, calcifications, or dissection, occurring during or after the TAVI procedure.', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.4', 'OutcomeMeasurementLowerLimit': '0.1', 'OutcomeMeasurementUpperLimit': '3.0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percent VARC II Combined Safety Endpoint at 30 Days', 'OutcomeMeasureDescription': 'VARC II composite safety endpoint rate includes percent freedom from the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVI, or SAVR)', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '14.5', 'OutcomeMeasurementLowerLimit': '10.6', 'OutcomeMeasurementUpperLimit': '19.7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percent of Patients With Acute Kidney Injury: Stage 2 or 3 (Including Renal Replacement Therapy).', 'OutcomeMeasureDescription': 'Stage 2\n\nIncrease in serum creatinine to 200%-299% (2.0%-2.99% increase compared with baseline) OR\n\n>\n\nUrine output <0.5 mL/kg/h for >12 but <24 h > Stage 3 >\n\n1) Increase in serum creatinine to ≥300% (>3 x increase compared with baseline) OR serum creatinine of ≥4.0 mg/dL (≥354 mmol/L) with an acute increase of at least 0.5 mg/dL (44 mmol/L) OR\n\nUrine output <0.3 ml/kg/h for ≥24 h OR\n\n>\n\nAnuria for ≥12 h', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.3', 'OutcomeMeasurementLowerLimit': '0.4', 'OutcomeMeasurementUpperLimit': '3.9'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Patients With Life-threatening or Disabling Bleeding Event Rate', 'OutcomeMeasureDescription': 'Fatal bleeding (BARC type 5) OR\n\n>\n\nBleeding in a critical organs, such as intracranial, intraspinal,\n\n> intraocular, or pericardial necessitating pericardiocentesis, or intramuscular with compartment syndrome (BARC type 3b and 3c) OR\n\n>\n\nBleeding causing hypovolemic shock or severe hypotension requiring vasopressors or surgery (BARC type 3b) OR\n\n>\n\nOvert source of bleeding with drop in hemoglobin ≥5 g/dL or whole blood or packed red blood cells (RBCs) transfusion ≥4 units* > (BARC type 3b)', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.1', 'OutcomeMeasurementLowerLimit': '4.4', 'OutcomeMeasurementUpperLimit': '11.2'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percent Rate of Patients Who Received New Permanent Pacemaker Implant at 30 Days', 'OutcomeMeasureDescription': 'Percent of patients who underwent implantation of new permanent pacemaker or ICD during or after index procedure', 'OutcomeMeasurePopulationDescription': 'All subjects who are brought into the procedure room and any of the following have occurred: anesthesia administered, vascular line placed, TEE placed, or any monitoring line placed. Additionally, these patients did NOT have ICD or PPM at the time of the index procedure.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '201'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '19.7', 'OutcomeMeasurementLowerLimit': '14.7', 'OutcomeMeasurementUpperLimit': '26.0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percent Resheath and Recapture Success Rate', 'OutcomeMeasureDescription': 'Resheath or recapture success rate (where attempted) where a successful resheath is defined as the intended portion of the Evolut R is resheathed into the capsule of the delivery catheter to the intended amount, as verified by flouroscopy; and a successful recapture is defined as the entire Evolut R TAV (including the frame) is full resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip , as verified by flouroscopy. Resheath or recapture wa attempted in a subset of patients. Success rate is calculated as successful resheath or recaputure events in the number of total events. Resheath anad recapture is only possible during the index procedure.', 'OutcomeMeasurePopulationDescription': '65 patients had resheath or recapture feature used during the 241 attempted procedures.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percentage of resheath or recapture', 'OutcomeMeasureTimeFrame': 'Assessed intra-procedurally', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '65'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '96.9'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hemodynamic Performance -Mean Gradient', 'OutcomeMeasureDescription': 'Mean gradient by Doppler echocardiography.', 'OutcomeMeasurePopulationDescription': 'The Implanted population consisted of all As Treated Subjects who underwent an index procedure and were implanted with the Evolut R system. Only subjects with echo can be analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'mmHg', 'OutcomeMeasureTimeFrame': 'Assessed at baseline, 30 days, 6 months, and 1 year', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '237'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'baseline', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '237'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '48.2', 'OutcomeMeasurementSpread': '10'}]}}]}}, {'OutcomeClassTitle': '30 days', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '229'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.8', 'OutcomeMeasurementSpread': '3.1'}]}}]}}, {'OutcomeClassTitle': '6 months', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '208'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '8.4', 'OutcomeMeasurementSpread': '3.8'}]}}]}}, {'OutcomeClassTitle': '1 year', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '188'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '9.0', 'OutcomeMeasurementSpread': '4.8'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Major Vascular Complication', 'OutcomeMeasureDescription': 'Any aortic dissection, aortic rupture, annulus rupture, left ventricle perforation, or new apical aneurysm/pseudoaneurysm OR\n\n>\n\nAccess-related vascular injury (dissection, stenosis, perforation, rupture, arterio-venous fistula, pseudoaneurysm, hematoma, irreversible nerve injury, compartment syndrome, percutaneous closure device failure) leading to death, life-threatening or major bleeding, visceral ischemia, or neurological impairment OR\n\n>\n\nDistal embolization (noncerebral) from a vascular source requiring surgery or resulting in amputation or irreversible end-organ damage OR\n\n>\n\nThe use of unplanned endovascular or surgery associated with death, major bleeding, visceral ischemia or neurological impairment OR\n\n>\n\nAny new ipsilateral lower extremity ischemia documented by patient symptoms, physical exam, and/or decreased or absent blood flow on lower extremity angiogram OR\n\n>\n\nSurgery for access site nerve injury OR\n\n>\n\nPermanent access related nerve injury', 'OutcomeMeasurePopulationDescription': 'The Implanted population consisted of all As Treated Subjects who underwent an index procedure and were implanted with the Evolut R system.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '241'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '7.5', 'OutcomeMeasurementLowerLimit': '4.8', 'OutcomeMeasurementUpperLimit': '11.7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hemodynamic Performance - Aortic Valve Area', 'OutcomeMeasureDescription': 'Hemodynamic performance by Doppler echocardiography - Aortic Valve Area cm2', 'OutcomeMeasurePopulationDescription': 'The hemodynamic performance subset includes all subjects implanted with the Evolut R TAV for more than 24 hours post implantation - only subjects with echo can be analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'cm²', 'OutcomeMeasureTimeFrame': 'Assessed at baseline, 30 days, 6 months, and 1 year', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '237'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'baseline', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '237'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.6', 'OutcomeMeasurementSpread': '0.2'}]}}]}}, {'OutcomeClassTitle': '30 days', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '229'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.9', 'OutcomeMeasurementSpread': '0.5'}]}}]}}, {'OutcomeClassTitle': '6 months', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '208'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.8', 'OutcomeMeasurementSpread': '0.5'}]}}]}}, {'OutcomeClassTitle': '1 year', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '188'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.8', 'OutcomeMeasurementSpread': '0.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hemodynamic Performance: Total Prosthetic Valve Regurgitation Graded as Moderate or Severe', 'OutcomeMeasureDescription': 'Hemodynamic performance: the percent of patients who have a degree of total prosthetic valve regurgitation that is moderate or severe.', 'OutcomeMeasurePopulationDescription': 'The hemodynamic performance subset includes all subjects implanted with the Evolut R TAV for more than 24 hours post implantation. Only subjects with echo can be analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Assessed at 30 days, 6 months, and 1 year', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut R TAVR System', 'OutcomeGroupDescription': 'The CoreValve Evolut R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)\n\n>\n\n> CoreValve Evolut R TAVR system'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '237'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '30 days', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'Ou",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02569632,ChildrensHRCOakland,UCSF Benioff Children's Hospital Oakland,OTHER,Investigating the Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba),Immunogenicity of a U.S.-Licensed Meningococcal Serogroup B Vaccine (Trumenba) in Adults at Increased Risk of Meningococcal Disease Because of Occupational Exposure,Oct-15,Unknown status,No,Jan-15,,May-17,Anticipated,May-17,Anticipated,30-Sep-15,06-Oct-15,07-Oct-15,Estimate,28-Sep-16,30-Sep-16,Estimate,Sponsor,UCSF Benioff Children's Hospital Oakland,OTHER,,,,,"This study will investigate the breadth of protection against meningococcal disease in humans immunized with a newly FDA approved meningococcal B vaccine, trade name ""Trumenba®"" manufactured by Pfizer Vaccines. As a secondary goal the investigators will investigate underlying mechanisms by which human anti-FHbp antibodies elicit complement-mediated bactericidal activity.",['Meningococcal Infections'],Interventional,['Phase 4'],N/A,Single Group Assignment,,None (Open Label),18,Anticipated,"[{'ArmGroupLabel': 'Open Label: MenB-FHbp', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Trumenba Meningococcal Group B Vaccine (Wyeth/Pfizer Pharmaceuticals)', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Biological: Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)']}}]","[{'InterventionType': 'Biological', 'InterventionName': 'Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)', 'InterventionDescription': 'All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Open Label: MenB-FHbp']}, 'InterventionOtherNameList': {'InterventionOtherName': ['MenB-FHbp']}}]","[{'PrimaryOutcomeMeasure': 'Breadth of protective activity of serum anti-FHbp antibody responses of adults immunized with Trumenba vaccine as assessed by serum bactericidal titers', 'PrimaryOutcomeDescription': 'Determine the percentage of subjects achieving serum bactericidal titers of 1:4 or greater in serum obtained 1 month after doses 2 and 3 as measured against a panel of 15 genetically diverse meningococcal strains.', 'PrimaryOutcomeTimeFrame': '18 months'}]","[{'SecondaryOutcomeMeasure': 'Antibody repertoire to FHbp', 'SecondaryOutcomeDescription': 'Determine the percentage of recombinant anti-FHbp Fabs isolated from B cells of each subject that react with 3 FHbp amino acid sequence variants representative of FHbp variant groups 1, 2 and 3', 'SecondaryOutcomeTimeFrame': '1 year'}]","Inclusion Criteria:

Adults in the following risk groups: physicians, nurses, respiratory therapists, microbiology laboratory personnel working at UCSF Benioff Children's Hospital Oakland or the University of Massachusetts Medical School as well as medical students attending accredited U.S. medical schools
Able to comprehend and follow all required study procedures
In good health as determined by a brief medical history
For females of child bearing age a negative urine pregnancy test will be required

Exclusion Criteria:

Are not in the risk groups summarized above
Have not given or are unable to give written informed consent to participate in the study
Females of child bearing potential who are pregnant, or planning on becoming pregnant during the study period.
Persons with a past history of having Guillain-Barré Syndrome (GBS), or a family history of GBS in a parent or sibling.
Persons with presence or suspected presence of serious chronic disease including but not limited to: chronic cardiac disease, autoimmune disease, diabetes, hepatitis B/C, HIV, progressive neurological disease or seizure, leukemia, lymphomas, or neoplasm.
Have participated in any other investigational drug or received any other vaccine within the last 30 days.
Received a dose of a meningococcal serogroups A, C, Y, W conjugate vaccine within the previous 30 days or wish to receive a dose of this vaccine during the six month study period.
Have a history of anaphylactic shock, asthma, urticaria or other allergic reaction after previous dose of Trumenba
Have experienced fever (oral temperature above 38.0°C) within the past 3 days or are suffering from a present acute infectious disease
Are planning to leave the area of the study site before the end of the study period
Have obesity (BMI higher than 33); or 11.
With any condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.",Accepts Healthy Volunteers,All,18 Years,65 Years,"['Adult', 'Older Adult']","[{'LocationFacility': ""UCSF Benioff Children's Hospital Oakland"", 'LocationCity': 'Oakland', 'LocationState': 'California', 'LocationZip': '94609', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Massachusetts Medical School', 'LocationCity': 'Worcester', 'LocationState': 'Massachusetts', 'LocationZip': '01655', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'University of Massachusetts, Worcester', 'CollaboratorClass': 'OTHER'}]",No,"Neisseria meningitidis causes meningitis and severe infections of the blood stream. The incidence of serogroup B meningococcal disease however is too low to conduct a randomized, controlled trial to determine the actual efficacy of the new serogroup B vaccines. Instead vaccine efficacy was inferred from serum bactericidal antibody responses using four test strains. However, because of strain variability of FHbp amino acid sequence (there are more than 800 sequence variants described) and strain variability of FHbp expression, bactericidal data on only four strains are unlikely to be sufficient to predict the actual strain coverage by the vaccine. There also are gaps in knowledge about the underlying mechanisms by which human antibodies to FHbp elicit complement mediated bactericidal activity. For example, binding of FH to FHbp is specific for human FH. Therefore in vaccinated humans the vaccine antigen is expected to form a complex with FH right after immunization. The investigators' hypothesis is that binding of human FH to the vaccine antigen skews the antibody repertoire to FHbp epitopes located outside of the FH combining site. The resulting antibodies would be expected not to inhibit binding of FH to the bacteria. This hypothesis will be investigated in Trumenba-immunized humans as part of studies in Aim 1 (and in future studies of recombinant human anti-FHbp Fabs that will be enabled by obtaining DNA from individual B cells, described in Aim 2).","['Meningococcal Vaccines', 'Neisseria Meningitidis', 'Factor H-binding Protein']",,,,,,,,,,,,,"[{'OverallOfficialName': 'Dan Granoff, MD', 'OverallOfficialAffiliation': ""Children's Hospital Oakland Research Institute, Center for Immunobiology and Vaccine Development"", 'OverallOfficialRole': 'Principal Investigator'}]",,"[{'ReferencePMID': '28566335', 'ReferenceType': 'derived', 'ReferenceCitation': 'Lujan E, Partridge E, Giuntini S, Ram S, Granoff DM. Breadth and Duration of Meningococcal Serum Bactericidal Activity in Health Care Workers and Microbiologists Immunized with the MenB-FHbp Vaccine. Clin Vaccine Immunol. 2017 Aug 4;24(8). pii: e00121-17. doi: 10.1128/CVI.00121-17. Print 2017 Aug.'}]",,,,,,,,,,,,"Active, not recruiting",,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000008589', 'ConditionMeshTerm': 'Meningococcal Infections'}, {'ConditionMeshId': 'D000008581', 'ConditionMeshTerm': 'Meningitis'}]","[{'ConditionAncestorId': 'D000016870', 'ConditionAncestorTerm': 'Neisseriaceae Infections'}, {'ConditionAncestorId': 'D000016905', 'ConditionAncestorTerm': 'Gram-Negative Bacterial Infections'}, {'ConditionAncestorId': 'D000001424', 'ConditionAncestorTerm': 'Bacterial Infections'}, {'ConditionAncestorId': 'D000002493', 'ConditionAncestorTerm': 'Central Nervous System Diseases'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}]","[{'ConditionBrowseLeafId': 'M4951', 'ConditionBrowseLeafName': 'Communicable Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8866', 'ConditionBrowseLeafName': 'Infection', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M10147', 'ConditionBrowseLeafName': 'Meningitis', 'ConditionBrowseLeafAsFound': 'Meningococcal Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M10155', 'ConditionBrowseLeafName': 'Meningococcal Infections', 'ConditionBrowseLeafAsFound': 'Meningococcal Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M17801', 'ConditionBrowseLeafName': 'Neisseriaceae Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3303', 'ConditionBrowseLeafName': 'Bacterial Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M17832', 'ConditionBrowseLeafName': 'Gram-Negative Bacterial Infections', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M4325', 'ConditionBrowseLeafName': 'Central Nervous System Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T3714', 'ConditionBrowseLeafName': 'Meningococcal Infection', 'ConditionBrowseLeafAsFound': 'Meningococcal Infections', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'T4068', 'ConditionBrowseLeafName': 'Neisseria Meningitidis Infection', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BC01', 'ConditionBrowseBranchName': 'Bacterial and Fungal Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,"[{'InterventionBrowseLeafId': 'M15943', 'InterventionBrowseLeafName': 'Vaccines', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'M18123', 'InterventionBrowseLeafName': 'Complement Factor H', 'InterventionBrowseLeafRelevance': 'low'}, {'InterventionBrowseLeafId': 'T8', 'InterventionBrowseLeafName': 'Histidine', 'InterventionBrowseLeafRelevance': 'low'}]","[{'InterventionBrowseBranchAbbrev': 'All', 'InterventionBrowseBranchName': 'All Drugs and Chemicals'}, {'InterventionBrowseBranchAbbrev': 'AA', 'InterventionBrowseBranchName': 'Amino Acids'}]",,,,,,,,,,,,,,,,,,,,,,,,UCSF Benioff Children's Hospital Oakland,"[{'UnpostedEventType': 'Release', 'UnpostedEventDate': 'May 10, 2017'}, {'UnpostedEventType': 'Reset', 'UnpostedEventDate': 'June 9, 2017'}, {'UnpostedEventType': 'Release', 'UnpostedEventDate': 'September 25, 2020'}, {'UnpostedEventType': 'Unrelease', 'UnpostedEventDate': 'September 25, 2020'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02069925,1310012846,Yale University,OTHER,STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.,STEP-ED: Reducing Duration of Untreated Psychosis and Its Impact in the U.S.,May-20,"Active, not recruiting",No,01-Feb-14,,27-Feb-20,Actual,29-Oct-20,Anticipated,20-Feb-14,21-Feb-14,24-Feb-14,Estimate,07-May-20,11-May-20,Actual,Sponsor,Yale University,OTHER,,,,,"The guiding questions for this study are: can a U.S. adaptation of a successful Scandinavian approach (TIPS) to early detection substantially reduce the duration of untreated psychosis (DUP) and improve outcomes beyond an established first-episode service (FES)?

The primary aim of this study is:

To determine whether an early detection intervention can reduce DUP in the US, as compared to usual detection. Early detection (ED) will be implemented in one US community (New Haven, CT), and usual detection efforts will continue in another (Boston, MA). DUP will be measured at admission to the corresponding first-episode services (STEP & PREP) in each community, over one year before and throughout ED implementation. The investigators hypothesize that DUP will be reduced significantly in the early detection site compared to the usual detection site;
A secondary aim is to determine whether DUP reduction can augment the outcomes of established FES on outcomes in the U.S. The investigators will measure symptoms, functioning and engagement with treatment at entry and over 1 year at each site. The investigators hypothesize that shorter DUP at one FES (STEP) will predict reduced distress and illness severity at entry and better early outcomes at STEP compared to PREP.","['Psychosis', 'Schizophrenia']",Interventional,['Not Applicable'],Non-Randomized,Parallel Assignment,Treatment,None (Open Label),224,Anticipated,"[{'ArmGroupLabel': 'Early Detection (ED)', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Early Detection (ED)', 'Behavioral: Usual Detection']}}, {'ArmGroupLabel': 'Usual Detection', 'ArmGroupType': 'Active Comparator', 'ArmGroupDescription': 'This intervention will provide equivalent best practice care without the benefit of an early detection campaign', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Behavioral: Usual Detection']}}]","[{'InterventionType': 'Behavioral', 'InterventionName': 'Early Detection (ED)', 'InterventionDescription': 'This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Early Detection (ED)']}}, {'InterventionType': 'Behavioral', 'InterventionName': 'Usual Detection', 'InterventionDescription': 'This intervention will provide equivalent best practice care without the benefit of an early detection campaign', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['Early Detection (ED)', 'Usual Detection']}}]","[{'PrimaryOutcomeMeasure': 'Proportion of Participants with Duration of Untreated Psychosis (DUP)', 'PrimaryOutcomeDescription': 'The primary outcome of interest, proportion of participants at each site with DUP < 3 months, will be calculated for the ""pre period"" (first year of the study, prior to initiation of ED intervention at STEP)', 'PrimaryOutcomeTimeFrame': '3 months'}, {'PrimaryOutcomeMeasure': 'Proportion of Participants with Duration of Untreated Psychosis DUP', 'PrimaryOutcomeTimeFrame': '3 years'}]",,"Inclusion Criteria:

16 to 35 years old,
Within first 3 years of psychosis onset (per pre-defined SOS threshold criteria)
Willing travel to local First Episode Service (STEP, New Haven or PREP, Boston) for treatment;
Must live in target catchment towns for New Haven site (New Haven, East Haven, West Haven, North Haven, Hamden, Bethany, Orange, Woodbridge, Milford, and Branford) and Boston site (anywhere in Commonwealth of MA)

Exclusion Criteria:

Established diagnosis of affective psychotic illness (Bipolar disorder or MDD with psychotic features) or psychosis secondary to substance use or a medical illness
Unable to communicate in English
IQ<70 or eligible for DDS (Department of Developmental Services) care
legally mandated to enter treatment or otherwise unable to give free, informed consent
Unable to reliably determine DUP
Unstable medical illness",No,All,16 Years,35 Years,"['Child', 'Adult']","[{'LocationFacility': 'Yale University', 'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520-8234', 'LocationCountry': 'United States'}, {'LocationFacility': 'Massachusetts Mental Health Center', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02115', 'LocationCountry': 'United States'}]","[{'CollaboratorName': 'Harvard University', 'CollaboratorClass': 'OTHER'}, {'CollaboratorName': 'National Institute of Mental Health (NIMH)', 'CollaboratorClass': 'NIH'}]",Yes,"Early detection, or reducing the duration of untreated psychosis (DUP) can substantially ameliorate the distress and disability caused by psychotic illnesses. The TIPS project in Scandinavia used a combination of public and targeted education campaigns coupled with rapid availability of comprehensive services to improve the identification, referral and early treatment of psychotic illness. By targeting the dual 'bottlenecks' of inadequate mental health literacy and delayed access to effective treatment, TIPS significantly reduced DUP2 and experimentally demonstrated improved clinical presentations and outcomes.

Effective service models for new onset psychosis exist in the U.S. Multi-element specialty 'first-episode' services (FES), highlighted in this FOA, provide care that is adapted to the specific needs of younger patients and their families and can improve symptoms and functional outcomes during the critical early phase of psychotic illnesses. The NIH-funded Specialized Treatment in Early Psychosis (STEP, New Haven) project, included the first U.S.-based randomized controlled trial to establish the feasibility and effectiveness of a public-sector approach to FES.5 The Prevention and Recovery in Early Psychosis (PREP, Boston) clinic has advanced a similar model of care within an analogous public-academic collaboration.

What is required, as the next logical step, is a test of the effectiveness of TIPS' powerful approach to early detection in a policy-relevant U.S. setting, where relatively fragmented pathways to care raise both the challenges and potential public health impact of early detection. The expertise within the investigators investigative team in the design of early detection and the presence of 2 similar, effective, geographically separated and collaborative FES programs (STEP and PREP) presents an excellent opportunity to conduct such a test and thereby advance secondary prevention for psychotic illnesses in the U.S.",,,,,,,"[{'SecondaryId': '1R01MH103831-01', 'SecondaryIdType': 'U.S. NIH Grant/Contract', 'SecondaryIdLink': 'https://projectreporter.nih.gov/reporterapi.cfm?PROJECTNUM=1R01MH103831-01&Fy=all'}]",,,,,,,"[{'OverallOfficialName': 'Vinod Srihari, MD', 'OverallOfficialAffiliation': 'Yale University', 'OverallOfficialRole': 'Principal Investigator'}]",No,"[{'ReferencePMID': '25023923', 'ReferenceType': 'background', 'ReferenceCitation': 'Annamalai A, Palmese LB, Chwastiak LA, Srihari VH, Tek C. High rates of obstructive sleep apnea symptoms among patients with schizophrenia. Psychosomatics. 2015 Jan-Feb;56(1):59-66. doi: 10.1016/j.psym.2014.02.009. Epub 2014 Mar 2.'}, {'ReferencePMID': '25454802', 'ReferenceType': 'background', 'ReferenceCitation': 'Tek C, Palmese LB, Krystal AD, Srihari VH, DeGeorge PC, Reutenauer EL, Guloksuz S. The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. Schizophr Res. 2014 Dec;160(1-3):180-5. doi: 10.1016/j.schres.2014.10.002. Epub 2014 Oct 29.'}, {'ReferencePMID': '25962699', 'ReferenceType': 'background', 'ReferenceCitation': 'Tek C, Kucukgoncu S, Guloksuz S, Woods SW, Srihari VH, Annamalai A. Antipsychotic-induced weight gain in first-episode psychosis patients: a meta-analysis of differential effects of antipsychotic medications. Early Interv Psychiatry. 2016 Jun;10(3):193-202. doi: 10.1111/eip.12251. Epub 2015 May 12. Review.'}, {'ReferencePMID': '29764759', 'ReferenceType': 'background', 'ReferenceCitation': 'Kline ER, DeTore NR, Keefe K, Seidman LJ, Srihari VH, Keshavan MS, Guyer M. Development and validation of the client engagement and service use scale: A pilot study. Schizophr Res. 2018 Nov;201:343-346. doi: 10.1016/j.schres.2018.05.006.'}, {'ReferencePMID': '28864280', 'ReferenceType': 'background', 'ReferenceCitation': 'Kline E, Thomas L. Cultural factors in first episode psychosis treatment engagement. Schizophr Res. 2018 May;195:74-75. doi: 10.1016/j.schres.2017.08.035. Epub 2017 Aug 30.'}, {'ReferencePMID': '25663602', 'ReferenceType': 'background', 'ReferenceCitation': 'van Schalkwyk GI, Davidson L, Srihari V. Too Late and Too Little: Narratives of Treatment Disconnect in Early Psychosis. Psychiatr Q. 2015 Dec;86(4):521-32. doi: 10.1007/s11126-015-9348-4.'}, {'ReferencePMID': '27691379', 'ReferenceType': 'background', 'ReferenceCitation': 'Steiner JL, Anez-Nava L, Baranoski M, Cole R, Davidson L, Delphin-Rittmon M, Dike C, DiLeo PJ, Duman RS, Kirk T Jr, Krystal J, Malison RT, Rohrbaugh RM, Sernyak MJ, Srihari V, Styron T, Tebes JK, Woods S, Zonana H, Jacobs SC. The Connecticut Mental Health Center: Celebrating 50 Years of a Successful Partnership Between the State and Yale University. Psychiatr Serv. 2016 Dec 1;67(12):1286-1289. Epub 2016 Oct 3.'}, {'ReferencePMID': '28434615', 'ReferenceType': 'background', 'ReferenceCitation': 'Foss-Feig JH, Adkinson BD, Ji JL, Yang G, Srihari VH, McPartland JC, Krystal JH, Murray JD, Anticevic A. Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders. Biol Psychiatry. 2017 May 15;81(10):848-861. doi: 10.1016/j.biopsych.2017.03.005. Epub 2017 Mar 14. Review.'}, {'ReferencePMID': '29328779', 'ReferenceType': 'background', 'ReferenceCitation': 'Dixon LB, Goldman HH, Srihari VH, Kane JM. Transforming the Treatment of Schizophrenia in the United States: The RAISE Initiative. Annu Rev Clin Psychol. 2018 May 7;14:237-258. doi: 10.1146/annurev-clinpsy-050817-084934. Epub 2018 Jan 12.'}, {'ReferencePMID': '27745755', 'ReferenceType': 'background', 'ReferenceCitation': 'Starc M, Murray JD, Santamauro N, Savic A, Diehl C, Cho YT, Srihari V, Morgan PT, Krystal JH, Wang XJ, Repovs G, Anticevic A. Schizophrenia is associated with a pattern of spatial working memory deficits consistent with cortical disinhibition. Schizophr Res. 2017 Mar;181:107-116. doi: 10.1016/j.schres.2016.10.011. Epub 2016 Oct 10.'}, {'ReferencePMID': '24976861', 'ReferenceType': 'background', 'ReferenceCitation': 'Breitborde NJ, Kleinlein P, Srihari VH. Causality Orientations among Individuals with First-Episode Psychosis. Psychosis. 2014 Jun 1;6(2):177-180.'}, {'ReferencePMID': '25603283', 'ReferenceType': 'background', 'ReferenceCitation': 'Hay RA, Roach BJ, Srihari VH, Woods SW, Ford JM, Mathalon DH. Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients. Biol Psychol. 2015 Feb;105:130-7. doi: 10.1016/j.biopsycho.2015.01.004. Epub 2015 Jan 17.'}, {'ReferencePMID': '27580422', 'ReferenceType': 'background', 'ReferenceCitation': 'Guloksuz S, Li F, Tek C, Woods SW, McGlashan TH, Friis S, Srihari VH. Analyzing the Duration of Untreated Psychosis: Quantile Regression. JAMA Psychiatry. 2016 Oct 1;73(10):1094-1095. doi: 10.1001/jamapsychiatry.2016.2013.'}, {'ReferencePMID': '28859587', 'ReferenceType': 'background', 'ReferenceCitation': 'Wasser T, Pollard J, Fisk D, Srihari V. First-Episode Psychosis and the Criminal Justice System: Using a Sequential Intercept Framework to Highlight Risks and Opportunities. Psychiatr Serv. 2017 Oct 1;68(10):994-996. doi: 10.1176/appi.ps.201700313. Epub 2017 Sep 1. Review.'}, {'ReferencePMID': '24050720', 'ReferenceType': 'background', 'ReferenceCitation': 'Perez VB, Woods SW, Roach BJ, Ford JM, McGlashan TH, Srihari VH, Mathalon DH. Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity. Biol Psychiatry. 2014 Mar 15;75(6):459-69. doi: 10.1016/j.biopsych.2013.07.038. Epub 2013 Sep 16.'}, {'ReferencePMID': '25471062', 'ReferenceType': 'background', 'ReferenceCitation': 'Srihari VH, Tek C, Pollard J, Zimmet S, Keat J, Cahill JD, Kucukgoncu S, Walsh BC, Li F, Gueorguieva R, Levine N, Mesholam-Gately RI, Friedman-Yakoobian M, Seidman LJ, Keshavan MS, McGlashan TH, Woods SW. Reducing the duration of untreated psychosis and its impact in the U.S.: the STEP-ED study. BMC Psychiatry. 2014 Dec 4;14:335. doi: 10.1186/s12888-014-0335-3.'}, {'ReferencePMID': '26747524', 'ReferenceType': 'background', 'ReferenceCitation': 'Srihari VH, Jani A, Gray M. Early Intervention for Psychotic Disorders: Building Population Health Systems. JAMA Psychiatry. 2016 Feb;73(2):101-2. doi: 10.1001/jamapsychiatry.2015.2821. Review.'}, {'ReferencePMID': '28779850', 'ReferenceType': 'background', 'ReferenceCitation': 'Srihari VH. Working toward changing the Duration of Untreated Psychosis (DUP). Schizophr Res. 2018 Mar;193:39-40. doi: 10.1016/j.schres.2017.07.045. Epub 2017 Aug 3.'}, {'ReferencePMID': '29927083', 'ReferenceType': 'background', 'ReferenceCitation': 'Mathis WS, Woods S, Srihari V. Blind Spots: Spatial analytics can identify nonrandom geographic variation in first episode psychosis program enrollments. Early Interv Psychiatry. 2018 Dec;12(6):1229-1234. doi: 10.1111/eip.12681. Epub 2018 Jun 21.'}, {'ReferencePMID': '30488086', 'ReferenceType': 'background', 'ReferenceCitation': 'Kline E, Hendel V, Friedman-Yakoobian M, Mesholam-Gately RI, Findeisen A, Zimmet S, Wojcik JD, Petryshen TL, Woo TW, Goldstein JM, Shenton ME, Keshavan MS, McCarley RW, Seidman LJ. A comparison of neurocognition and functioning in first episode psychosis populations: do research samples reflect the real world? Soc Psychiatry Psychiatr Epidemiol. 2019 Mar;54(3):291-301. doi: 10.1007/s00127-018-1631-x. Epub 2018 Nov 28.'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000012559', 'ConditionMeshTerm': 'Schizophrenia'}, {'ConditionMeshId': 'D000011618', 'ConditionMeshTerm': 'Psychotic Disorders'}, {'ConditionMeshId': 'D000001523', 'ConditionMeshTerm': 'Mental Disorders'}]","[{'ConditionAncestorId': 'D000019967', 'ConditionAncestorTerm': 'Schizophrenia Spectrum and Other Psychotic Disorders'}]","[{'ConditionBrowseLeafId': 'M13959', 'ConditionBrowseLeafName': 'Schizophrenia', 'ConditionBrowseLeafAsFound': 'Schizophrenia', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafAsFound': 'Psychosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafAsFound': 'Psychosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M20422', 'ConditionBrowseLeafName': 'Schizophrenia Spectrum and Other Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}]","[{'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT03433131,HBS-101-CL-001,"Harmony Biosciences, LLC",INDUSTRY,Expanded Access Program to Provide Treatment With Pitolisant to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy,An Open Label Expanded Access Program Intended to Provide Treatment With HBS-101 (Pitolisant) to Adult Patients in the U.S. With Excessive Daytime Sleepiness Associated With Narcolepsy With or Without Cataplexy,Aug-19,No longer available,,,,,,,,07-Feb-18,07-Feb-18,14-Feb-18,Actual,22-Aug-19,28-Aug-19,Actual,Sponsor,"Harmony Biosciences, LLC",INDUSTRY,,,,,"This EAP will be open to provide access to treatment with pitolisant while a U.S. New Drug Application (NDA) is being prepared and submitted for review for marketing approval. This program will be open to adult patients in the U.S. with Excessive Daytime Sleepiness (EDS) associated with narcolepsy, with or without cataplexy. Pitolisant will be made available through treating physicians participating in the program.","['Narcolepsy Without Cataplexy', 'Narcolepsy With Cataplexy']",Expanded Access,,,,,,,,,"[{'InterventionType': 'Drug', 'InterventionName': 'Pitolisant', 'InterventionDescription': 'Tablets', 'InterventionOtherNameList': {'InterventionOtherName': ['Wakix']}}]",,,"Inclusion Criteria:

In the opinion of the treating physician, the patient is capable of understanding and complying with protocol and program requirements, oral drug administration and care instructions.
The patient or, when applicable, the patient's legally acceptable representative, signs and dates a written, ICF and any required privacy authorization prior to the initiation of any program procedures.
Men or women, 18 years of age and over.
Patients with a diagnosis of narcolepsy with or without cataplexy according to the ICSD or DSM criteria at the time of diagnosis.
Patients should be free of prohibited treatments or have discontinued them for at least 7 days prior to the start of treatments.
Women of child-bearing potential must have a negative serum pregnancy test performed at the screening visit.
Due to the effectiveness of hormonal contraceptives potentially being reduced when used with pitolisant, alternative or concomitant barrier methods of contraception are required for patients taking hormonal contraceptives (e.g., ethinyl estradiol) when taking pitolisant and for at least 21 days after discontinuation of pitolisant treatment.

Exclusion Criteria:

The patient has severe hepatic impairment (Child-Pugh C).
The patient is a woman who is breastfeeding or plans to breastfeed during their participation.
The patient has, in the judgment of the treating physician, a history or current medical condition that could affect safety or poses an additional risk to the patient by their participation in the program.
The patient is at high risk for suicide defined as a suicide attempt within the past year, significant risk determined by the investigator interview, or use of the Columbia Suicide Severity Rating Scale (C-SSRS).
The patient has a history of hypersensitivity or allergic reaction to pitolisant or any inactive ingredient of the formulation.
Current or recent (within one year) history of a substance abuse or dependence disorder including alcohol abuse as defined in Diagnostic and Statistical Manual of Mental Disorders (DSM-V).
Patients with a known history of long QTc syndrome (e.g. syncope or arrhythmia) or any significant history of a serious abnormality of the ECG (e.g. recent myocardial infarction), or QTc Fridericia higher than 450 ms for male and 470 ms for female (electrocardiogram Fridericia's corrected QT interval = QT / 3√ RR).
Significant abnormality in the physical examination or clinical laboratory results.
Prior severe adverse reactions to CNS stimulants.",,All,18 Years,,"['Adult', 'Older Adult']","[{'LocationFacility': 'Sleep Disorders Center of Alabama', 'LocationCity': 'Birmingham', 'LocationState': 'Alabama', 'LocationZip': '35213', 'LocationCountry': 'United States'}, {'LocationFacility': 'CPC', 'LocationCity': 'Cullman', 'LocationState': 'Alabama', 'LocationZip': '35058', 'LocationCountry': 'United States'}, {'LocationFacility': 'Xenoscience', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85004-1150', 'LocationCountry': 'United States'}, {'LocationFacility': 'Xenoscience', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85004', 'LocationCountry': 'United States'}, {'LocationFacility': 'Foothills Neurology', 'LocationCity': 'Phoenix', 'LocationState': 'Arizona', 'LocationZip': '85048', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mayo Clinic', 'LocationCity': 'Scottsdale', 'LocationState': 'Arizona', 'LocationZip': '85259', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sleep Medicine Specialists of California', 'LocationCity': 'San Ramon', 'LocationState': 'California', 'LocationZip': '94583', 'LocationCountry': 'United States'}, {'LocationFacility': 'Santa Monica Sleep Disorders Center', 'LocationCity': 'Santa Monica', 'LocationState': 'California', 'LocationZip': '90404', 'LocationCountry': 'United States'}, {'LocationFacility': ""Children's Hospital Colorado"", 'LocationCity': 'Aurora', 'LocationState': 'Colorado', 'LocationZip': '80045', 'LocationCountry': 'United States'}, {'LocationFacility': 'Colorado Sleep Institute', 'LocationCity': 'Boulder', 'LocationState': 'Colorado', 'LocationZip': '80301', 'LocationCountry': 'United States'}, {'LocationFacility': 'Norwalk Hospital Sleep Disorders Center', 'LocationCity': 'Norwalk', 'LocationState': 'Connecticut', 'LocationZip': '06850', 'LocationCountry': 'United States'}, {'LocationFacility': 'Clinical Neurosciences fo Tampa Bay', 'LocationCity': 'Clearwater', 'LocationState': 'Florida', 'LocationZip': '33756', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mayo Clinic', 'LocationCity': 'Jacksonville', 'LocationState': 'Florida', 'LocationZip': '32224', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sleep Medicine Specialists of South Florida, PA', 'LocationCity': 'Miami', 'LocationState': 'Florida', 'LocationZip': '33126', 'LocationCountry': 'United States'}, {'LocationFacility': 'Child Lung, Asthma Sleep Specialists', 'LocationCity': 'Winter Park', 'LocationState': 'Florida', 'LocationZip': '32789', 'LocationCountry': 'United States'}, {'LocationFacility': 'Emory University', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30329', 'LocationCountry': 'United States'}, {'LocationFacility': 'NeuroTrials Research Center', 'LocationCity': 'Atlanta', 'LocationState': 'Georgia', 'LocationZip': '30342', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Neurological Center of North Georgia', 'LocationCity': 'Gainesville', 'LocationState': 'Georgia', 'LocationZip': '30501', 'LocationCountry': 'United States'}, {'LocationFacility': 'Critical Healthcare Decisions', 'LocationCity': 'Savannah', 'LocationState': 'Georgia', 'LocationZip': '31419', 'LocationCountry': 'United States'}, {'LocationFacility': 'Northwestern Medical Group', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60611', 'LocationCountry': 'United States'}, {'LocationFacility': 'Rush University Medical Center', 'LocationCity': 'Chicago', 'LocationState': 'Illinois', 'LocationZip': '60637', 'LocationCountry': 'United States'}, {'LocationFacility': 'NorthShore Uni HealthSys-Glenbrook Hospital', 'LocationCity': 'Glenview', 'LocationState': 'Illinois', 'LocationZip': '60026', 'LocationCountry': 'United States'}, {'LocationFacility': 'Northshore Sleep Medicine', 'LocationCity': 'Northbrook', 'LocationState': 'Illinois', 'LocationZip': '60062', 'LocationCountry': 'United States'}, {'LocationFacility': 'Indiana Internal Medicine Consultants', 'LocationCity': 'Greenwood', 'LocationState': 'Indiana', 'LocationZip': '46143', 'LocationCountry': 'United States'}, {'LocationFacility': 'The University of Kansas Health System', 'LocationCity': 'Fairway', 'LocationState': 'Kansas', 'LocationZip': '66205', 'LocationCountry': 'United States'}, {'LocationFacility': 'Norton Pulmonary Specialists', 'LocationCity': 'Louisville', 'LocationState': 'Kentucky', 'LocationZip': '40218', 'LocationCountry': 'United States'}, {'LocationFacility': 'Maine Medical Partners - Neurology', 'LocationCity': 'Scarborough', 'LocationState': 'Maine', 'LocationZip': '04074', 'LocationCountry': 'United States'}, {'LocationFacility': 'The Center for Sleep and Wake Disorders', 'LocationCity': 'Chevy Chase', 'LocationState': 'Maryland', 'LocationZip': '20815', 'LocationCountry': 'United States'}, {'LocationFacility': ""Boston Children's Hospital"", 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02115', 'LocationCountry': 'United States'}, {'LocationFacility': 'The University of Michigan', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Henry Ford Health System', 'LocationCity': 'Novi', 'LocationState': 'Michigan', 'LocationZip': '48377', 'LocationCountry': 'United States'}, {'LocationFacility': 'Bronson Sleep Health', 'LocationCity': 'Portage', 'LocationState': 'Michigan', 'LocationZip': '49024', 'LocationCountry': 'United States'}, {'LocationFacility': 'Alliance Health Shelby Family Medicine', 'LocationCity': 'Shelby', 'LocationState': 'Michigan', 'LocationZip': '48317', 'LocationCountry': 'United States'}, {'LocationFacility': 'Fairview Health Services', 'LocationCity': 'Brooklyn Park', 'LocationState': 'Minnesota', 'LocationZip': '55443', 'LocationCountry': 'United States'}, {'LocationFacility': 'Mayo Clinic', 'LocationCity': 'Rochester', 'LocationState': 'Minnesota', 'LocationZip': '55905', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Lukes Hospital, Sleep Medicine', 'LocationCity': 'Chesterfield', 'LocationState': 'Missouri', 'LocationZip': '63017', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Missouri', 'LocationCity': 'Columbia', 'LocationState': 'Missouri', 'LocationZip': '65212', 'LocationCountry': 'United States'}, {'LocationFacility': ""Saint Luke's Hospital of Kansas City"", 'LocationCity': 'Kansas City', 'LocationState': 'Missouri', 'LocationZip': '64111', 'LocationCountry': 'United States'}, {'LocationFacility': 'Montefiore Medical Center', 'LocationCity': 'Bronx', 'LocationState': 'New York', 'LocationZip': '10467', 'LocationCountry': 'United States'}, {'LocationFacility': 'Norwell Health', 'LocationCity': 'New Hyde Park', 'LocationState': 'New York', 'LocationZip': '11042', 'LocationCountry': 'United States'}, {'LocationFacility': 'NYU-FGP Comphrenhensive Epilepsy Center-Sleep Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10016', 'LocationCountry': 'United States'}, {'LocationFacility': 'Columbia University', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10032', 'LocationCountry': 'United States'}, {'LocationFacility': 'Unity Sleep Disorders Center', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '14618', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Rochester Sleep Center', 'LocationCity': 'Rochester', 'LocationState': 'New York', 'LocationZip': '35058', 'LocationCountry': 'United States'}, {'LocationFacility': 'Duke University Medical Center', 'LocationCity': 'Durham', 'LocationState': 'North Carolina', 'LocationZip': '27710', 'LocationCountry': 'United States'}, {'LocationFacility': 'Excel Psychiatric Associates, PA', 'LocationCity': 'Huntersville', 'LocationState': 'North Carolina', 'LocationZip': '28078', 'LocationCountry': 'United States'}, {'LocationFacility': 'Raleigh Neurology Assoc., PA', 'LocationCity': 'Raleigh', 'LocationState': 'North Carolina', 'LocationZip': '27607', 'LocationCountry': 'United States'}, {'LocationFacility': 'Neurology & Neuroscience Associates, Inc.', 'LocationCity': 'Akron', 'LocationState': 'Ohio', 'LocationZip': '44320', 'LocationCountry': 'United States'}, {'LocationFacility': 'Intrepid Research, LLC', 'LocationCity': 'Cincinnati', 'LocationState': 'Ohio', 'LocationZip': '45245', 'LocationCountry': 'United States'}, {'LocationFacility': 'Cleveland Clinic', 'LocationCity': 'Cleveland', 'LocationState': 'Ohio', 'LocationZip': '44195', 'LocationCountry': 'United States'}, {'LocationFacility': 'Ohio Sleep Medicine Institute', 'LocationCity': 'Dublin', 'LocationState': 'Ohio', 'LocationZip': '43017', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oklahoma Heart Institute', 'LocationCity': 'Tulsa', 'LocationState': 'Oklahoma', 'LocationZip': '74104', 'LocationCountry': 'United States'}, {'LocationFacility': 'Oklahoma Heart Institute', 'LocationCity': 'Tulsa', 'LocationState': 'Oklahoma', 'LocationZip': '74133', 'LocationCountry': 'United States'}, {'LocationFacility': 'Legacy Medical Group Sleep Medicine', 'LocationCity': 'Portland', 'LocationState': 'Oregon', 'LocationZip': '97210', 'LocationCountry': 'United States'}, {'LocationFacility': 'Collegeville Family Practice', 'LocationCity': 'Berwyn', 'LocationState': 'Pennsylvania', 'LocationZip': '19426', 'LocationCountry': 'United States'}, {'LocationFacility': 'Paoli Sleep Center', 'LocationCity': 'Paoli', 'LocationState': 'Pennsylvania', 'LocationZip': '19301', 'LocationCountry': 'United States'}, {'LocationFacility': 'Thomas Jefferson University', 'LocationCity': 'Philadelphia', 'LocationState': 'Pennsylvania', 'LocationZip': '19107', 'LocationCountry': 'United States'}, {'LocationFacility': 'Maria J. Sunseri, MD, LLC', 'LocationCity': 'Pittsburgh', 'LocationState': 'Pennsylvania', 'LocationZip': '15224', 'LocationCountry': 'United States'}, {'LocationFacility': 'Abington Neurological Associates', 'LocationCity': 'Willow Grove', 'LocationState': 'Pennsylvania', 'LocationZip': '19090', 'LocationCountry': 'United States'}, {'LocationFacility': 'Respitory Specialists', 'LocationCity': 'Wyomissing', 'LocationState': 'Pennsylvania', 'LocationZip': '19610', 'LocationCountry': 'United States'}, {'LocationFacility': 'Brown Medicine/Rhode Island Hospital', 'LocationCity': 'West Warwick', 'LocationState': 'Rhode Island', 'LocationZip': '02893', 'LocationCountry': 'United States'}, {'LocationFacility': 'Bogan Sleep Consultants', 'LocationCity': 'Columbia', 'LocationState': 'South Carolina', 'LocationZip': '29201', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sleep Medicine Associates of Texas', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75231', 'LocationCountry': 'United States'}, {'LocationFacility': 'Houston Neurology & Sleep Center', 'LocationCity': 'Houston', 'LocationState': 'Texas', 'LocationZip': '77063', 'LocationCountry': 'United States'}, {'LocationFacility': 'Sleep Therapy & Research Center', 'LocationCity': 'San Antonio', 'LocationState': 'Texas', 'LocationZip': '78229', 'LocationCountry': 'United States'}, {'LocationFacility': 'Comprehensive Sleep Medicine Associates', 'LocationCity': 'Sugar Land', 'LocationState': 'Texas', 'LocationZip': '77478', 'LocationCountry': 'United States'}, {'LocationFacility': 'Chalottesville Neurology and Sleep Medicine', 'LocationCity': 'Charlottesville', 'LocationState': 'Virginia', 'LocationZip': '22911', 'LocationCountry': 'United States'}, {'LocationFacility': ""Children's Hospital of The King's Daughters"", 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23507', 'LocationCountry': 'United States'}, {'LocationFacility': 'Eastern Virginia Medical School', 'LocationCity': 'Norfolk', 'LocationState': 'Virginia', 'LocationZip': '23507', 'LocationCountry': 'United States'}, {'LocationFacility': 'Stultz Sleep and Behavioral Health', 'LocationCity': 'Barboursville', 'LocationState': 'West Virginia', 'LocationZip': '25504', 'LocationCountry': 'United States'}, {'LocationFacility': 'Medical College of Wisonsin', 'LocationCity': 'Milwaukee', 'LocationState': 'Wisconsin', 'LocationZip': '53226', 'LocationCountry': 'United States'}]",,,,,,,,,,,,,,,,,"[{'OverallOfficialName': 'Michael Thorpy, MD', 'OverallOfficialAffiliation': 'Albert Einstein College of Medicine', 'OverallOfficialRole': 'Principal Investigator'}]",,,,,,,,,,,,"[{'SeeAlsoLinkLabel': 'Program website to provide information to both prosective patients and physicians', 'SeeAlsoLinkURL': 'http://thepeacenarcolepsyprogram.com'}]",,,,,,,,,,,,,,,,,,,Yes,26-Oct-20,"[{'ConditionMeshId': 'D000009290', 'ConditionMeshTerm': 'Narcolepsy'}, {'ConditionMeshId': 'D000002385', 'ConditionMeshTerm': 'Cataplexy'}, {'ConditionMeshId': 'D000077260', 'ConditionMeshTerm': 'Sleepiness'}]","[{'ConditionAncestorId': 'D000006970', 'ConditionAncestorTerm': 'Disorders of Excessive Somnolence'}, {'ConditionAncestorId': 'D000020919', 'ConditionAncestorTerm': 'Sleep Disorders, Intrinsic'}, {'ConditionAncestorId': 'D000020920', 'ConditionAncestorTerm': 'Dyssomnias'}, {'ConditionAncestorId': 'D000012893', 'ConditionAncestorTerm': 'Sleep Wake Disorders'}, {'ConditionAncestorId': 'D000009422', 'ConditionAncestorTerm': 'Nervous System Diseases'}, {'ConditionAncestorId': 'D000001523', 'ConditionAncestorTerm': 'Mental Disorders'}]","[{'ConditionBrowseLeafId': 'M10824', 'ConditionBrowseLeafName': 'Narcolepsy', 'ConditionBrowseLeafAsFound': 'Narcolepsy', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M1717', 'ConditionBrowseLeafName': 'Sleepiness', 'ConditionBrowseLeafAsFound': 'Sleepiness', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M4220', 'ConditionBrowseLeafName': 'Cataplexy', 'ConditionBrowseLeafAsFound': 'Cataplexy', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M8604', 'ConditionBrowseLeafName': 'Disorders of Excessive Somnolence', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M20826', 'ConditionBrowseLeafName': 'Parasomnias', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21238', 'ConditionBrowseLeafName': 'Sleep Disorders, Intrinsic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M21239', 'ConditionBrowseLeafName': 'Dyssomnias', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M14279', 'ConditionBrowseLeafName': 'Sleep Wake Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M3396', 'ConditionBrowseLeafName': 'Mental Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M13056', 'ConditionBrowseLeafName': 'Psychotic Disorders', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T4055', 'ConditionBrowseLeafName': 'Narcolepsy', 'ConditionBrowseLeafAsFound': 'Narcolepsy', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC10', 'ConditionBrowseBranchName': 'Nervous System Diseases'}, {'ConditionBrowseBranchAbbrev': 'BXM', 'ConditionBrowseBranchName': 'Behaviors and Mental Disorders'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
NCT02746809,10211838DOC,Medtronic Cardiovascular,INDUSTRY,Medtronic CoreValve Evolut R U.S. Clinical Study (Evolut 34R Addendum),Medtronic CoreValve Evolut R United States Clinical Study (Evolut 34R Addendum),Oct-20,"Active, not recruiting",No,Jun-16,,Nov-16,Actual,Nov-21,Anticipated,18-Apr-16,18-Apr-16,21-Apr-16,Estimate,20-Oct-20,22-Oct-20,Actual,Sponsor,Medtronic Cardiovascular,INDUSTRY,,,,,The study objectives are to assess the safety and efficacy of the CoreValve Evolut 34R transcatheter aortic valve replacement (TAVR) system in patients with severe symptomatic aortic stenosis who are considered at high or extreme risk for surgical aortic valve replacement.,['Aortic Valve Stenosis'],Interventional,['Not Applicable'],N/A,Single Group Assignment,Treatment,None (Open Label),60,Actual,"[{'ArmGroupLabel': 'CoreValve Evolut 34R TAVR system', 'ArmGroupType': 'Experimental', 'ArmGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.', 'ArmGroupInterventionList': {'ArmGroupInterventionName': ['Device: CoreValve Evolut 34R TAVR system']}}]","[{'InterventionType': 'Device', 'InterventionName': 'CoreValve Evolut 34R TAVR system', 'InterventionDescription': 'The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\nEnVeo R Loading System (LS)', 'InterventionArmGroupLabelList': {'InterventionArmGroupLabel': ['CoreValve Evolut 34R TAVR system']}}]","[{'PrimaryOutcomeMeasure': 'Percentage of Participants With All-cause Mortality', 'PrimaryOutcomeDescription': 'Percentage of participants with all-cause mortality at 30 days', 'PrimaryOutcomeTimeFrame': '30 Days'}, {'PrimaryOutcomeMeasure': 'Percentage of Participants With Stroke (Disabling)', 'PrimaryOutcomeDescription': 'Percentage of participants with disabling stroke (VARC-II definitions) at 30 days', 'PrimaryOutcomeTimeFrame': '30 Days'}, {'PrimaryOutcomeMeasure': 'Device Success Rate', 'PrimaryOutcomeDescription': 'Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location, AND\nIntended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient < 20 mmHg (or peak velocity < 3 m/sec), AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'PrimaryOutcomeTimeFrame': '24 hours to 7 days post implantation'}, {'PrimaryOutcomeMeasure': 'The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram', 'PrimaryOutcomeDescription': 'The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory', 'PrimaryOutcomeTimeFrame': '24 hours to 7 days post implantation'}]","[{'SecondaryOutcomeMeasure': 'Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days', 'SecondaryOutcomeDescription': 'VARC II composite safety endpoint includes the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)', 'SecondaryOutcomeTimeFrame': '30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With Life Threatening or Disabling Bleeding', 'SecondaryOutcomeDescription': 'Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details', 'SecondaryOutcomeTimeFrame': '30 days post-implantation'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With Major Vascular Complication', 'SecondaryOutcomeDescription': 'Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With Acute Kidney Injury: Stage 2 or 3', 'SecondaryOutcomeDescription': 'Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Percentage of Participants With Coronary Artery Obstruction', 'SecondaryOutcomeDescription': 'Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure', 'SecondaryOutcomeDescription': 'Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Percentage of Subjects With Permanent Pacemaker Implant at 30 Days', 'SecondaryOutcomeDescription': 'Percentage of subjects with new permanent pacemaker implant at 30 days.', 'SecondaryOutcomeTimeFrame': '30 days'}, {'SecondaryOutcomeMeasure': 'Percentage of Resheath and Recapture Success', 'SecondaryOutcomeDescription': 'Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.\n\nSuccessful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.', 'SecondaryOutcomeTimeFrame': 'Implant procedure'}, {'SecondaryOutcomeMeasure': 'Hemodynamic Performance Metrics - Mean Gradient', 'SecondaryOutcomeDescription': 'Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'SecondaryOutcomeTimeFrame': 'Baseline, 30 days, and 6 months'}, {'SecondaryOutcomeMeasure': 'Hemodynamic Performance Metrics- Aortic Valve Area', 'SecondaryOutcomeDescription': 'Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'SecondaryOutcomeTimeFrame': 'Baseline, 30 Days, and 6 Months'}, {'SecondaryOutcomeMeasure': 'Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace', 'SecondaryOutcomeDescription': 'Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'SecondaryOutcomeTimeFrame': '30 days and 6 months'}]","Inclusion Criteria:

Severe aortic stenosis, defined as aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2) by the continuity equation, AND mean gradient > 40 mmHg or maximal aortic valve velocity > 4.0 m/sec by resting echocardiogram.

Subjects with low-flow/low gradient severe aortic stenosis can be included, provided low-dose dobutamine or exercise stress echocardiography demonstrates a mean gradient of > 40 mmHg or a maximal aortic valve velocity of > 4.0 m/sec, AND aortic valve area of < 1.0 cm2 (or aortic valve area index of < 0.6 cm2/m2).

Society of Thoracic Surgeons (STS) score of ≥ 8 OR documented heart team agreement of ≥ high risk for aortic valve replacement due to frailty or co-morbidities.
Symptoms of aortic stenosis, AND New York Heart Association (NYHA) Functional Class II or greater.

The subject and the treating physician agree that the subject will return for all required post-procedure follow-up visits.

Exclusion Criteria:

Any condition considered a contraindication for placement of a bioprosthetic valve (e.g. subject is indicated for mechanical prosthetic valve).

A known hypersensitivity or contraindication to any of the following which cannot be adequately pre-medicated:

aspirin or heparin (HIT/HITTS) and bivalirudin
ticlopidine and clopidogrel
Nitinol (titanium or nickel)
contrast media
Blood dyscrasias as defined: leukopenia (WBC < 1000 mm3), thrombocytopenia (platelet count <50,000 cells/mm3), history of bleeding diathesis or coagulopathy, or hypercoagulable states.
Untreated clinically significant coronary artery disease requiring revascularization.
Severe left ventricular dysfunction with left ventricular ejection fraction (LVEF) < 20% by echocardiography, contrast ventriculography, or radionuclide ventriculography.
End stage renal disease requiring chronic dialysis or creatinine clearance < 20 cc/min.
Ongoing sepsis, including active endocarditis.
Any percutaneous coronary or peripheral interventional procedure with a bare metal or drug eluting stent performed within 30 days prior to study procedure.
Symptomatic carotid or vertebral artery disease or successful treatment of carotid stenosis within 10 weeks of Heart Team assessment.
Cardiogenic shock manifested by low cardiac output, vasopressor dependence, or mechanical hemodynamic support.
Recent (within 6 months of Heart Team assessment) cerebrovascular accident (CVA) or transient ischemic attack (TIA).
Gastrointestinal (GI) bleeding that would preclude anticoagulation.
Subject refuses a blood transfusion.
Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).
Estimated life expectancy of less than 12 months due to associated non-cardiac co-morbid conditions.
Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-ups exams.
Currently participating in an investigational drug or another device study (excluding registries).
Evidence of an acute myocardial infarction ≤ 30 days before the study procedure.
Need for emergency surgery for any reason.
Liver failure (Child-Pugh class C).

Subject is pregnant or breast feeding.

Anatomical exclusion criteria:

Pre-existing prosthetic heart valve in any position.
Mixed aortic valve disease (aortic stenosis with severe aortic regurgitation).
Severe mitral regurgitation.
Severe tricuspid regurgitation.
Moderate or severe mitral stenosis.
Hypertrophic obstructive cardiomyopathy.
Echocardiographic or Multi-Slice Computed Tomography (MSCT) evidence of intracardiac mass, thrombus, or vegetation.

Congenital bicuspid or unicuspid valve verified by echocardiography.

For transfemoral or transaxillary (subclavian) access:

Access vessel diameter < 5.5 mm or <6.0 mm for patent left internal mammary artery (LIMA)",No,All,,,"['Child', 'Adult', 'Older Adult']","[{'LocationFacility': 'Yale New Haven Hospital', 'LocationCity': 'New Haven', 'LocationState': 'Connecticut', 'LocationZip': '06520', 'LocationCountry': 'United States'}, {'LocationFacility': 'Beth Israel Deaconess Medical Center', 'LocationCity': 'Boston', 'LocationState': 'Massachusetts', 'LocationZip': '02215', 'LocationCountry': 'United States'}, {'LocationFacility': 'University of Michigan Health Systems', 'LocationCity': 'Ann Arbor', 'LocationState': 'Michigan', 'LocationZip': '48109', 'LocationCountry': 'United States'}, {'LocationFacility': 'Spectrum Health Hospitals', 'LocationCity': 'Grand Rapids', 'LocationState': 'Michigan', 'LocationZip': '49503', 'LocationCountry': 'United States'}, {'LocationFacility': 'New York Langone Medical Center', 'LocationCity': 'New York', 'LocationState': 'New York', 'LocationZip': '10016', 'LocationCountry': 'United States'}, {'LocationFacility': 'St. Francis Hospital', 'LocationCity': 'Roslyn', 'LocationState': 'New York', 'LocationZip': '11576', 'LocationCountry': 'United States'}, {'LocationFacility': 'Riverside Methodist Hospital', 'LocationCity': 'Columbus', 'LocationState': 'Ohio', 'LocationZip': '43214', 'LocationCountry': 'United States'}, {'LocationFacility': 'Pinnacle Health/Moffitt Heart and Vascular Institute', 'LocationCity': 'Harrisburg', 'LocationState': 'Pennsylvania', 'LocationZip': '17104', 'LocationCountry': 'United States'}, {'LocationFacility': 'Baylor Heart and Vascular Hospital', 'LocationCity': 'Dallas', 'LocationState': 'Texas', 'LocationZip': '75225', 'LocationCountry': 'United States'}, {'LocationFacility': ""Aurora Health Care/St Luke's Medical Center"", 'LocationCity': 'Milwaukee', 'LocationState': 'Wisconsin', 'LocationZip': '53215', 'LocationCountry': 'United States'}]",,Yes,"This objective will be accomplished by a prospective, single arm, historical controlled, multi-site study involving up to 60 implanted subjects at up to 15 study sites in the United States. Procedural and 30 day safety and efficacy results from this study will be compared to appropriate historical control data for the Medtronic CoreValve System. Subjects will be followed up to 5 years following implantation.",,,,,,,,,,,,,,"[{'OverallOfficialName': 'Mathew R Williams, MD', 'OverallOfficialAffiliation': 'NYU Langone Medical Center', 'OverallOfficialRole': 'Principal Investigator'}]",Undecided,,28-Nov-17,28-Nov-17,29-Dec-17,Actual,,,,,,,,,,,,,,,,,,,,,,,,,,26-Oct-20,"[{'ConditionMeshId': 'D000001024', 'ConditionMeshTerm': 'Aortic Valve Stenosis'}]","[{'ConditionAncestorId': 'D000006349', 'ConditionAncestorTerm': 'Heart Valve Diseases'}, {'ConditionAncestorId': 'D000006331', 'ConditionAncestorTerm': 'Heart Diseases'}, {'ConditionAncestorId': 'D000002318', 'ConditionAncestorTerm': 'Cardiovascular Diseases'}, {'ConditionAncestorId': 'D000014694', 'ConditionAncestorTerm': 'Ventricular Outflow Obstruction'}]","[{'ConditionBrowseLeafId': 'M2921', 'ConditionBrowseLeafName': 'Aortic Valve Stenosis', 'ConditionBrowseLeafAsFound': 'Aortic Valve Stenosis', 'ConditionBrowseLeafRelevance': 'high'}, {'ConditionBrowseLeafId': 'M5058', 'ConditionBrowseLeafName': 'Constriction, Pathologic', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8020', 'ConditionBrowseLeafName': 'Heart Valve Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M8002', 'ConditionBrowseLeafName': 'Heart Diseases', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'M16023', 'ConditionBrowseLeafName': 'Ventricular Outflow Obstruction', 'ConditionBrowseLeafRelevance': 'low'}, {'ConditionBrowseLeafId': 'T449', 'ConditionBrowseLeafName': 'Aortic Valve Stenosis', 'ConditionBrowseLeafAsFound': 'Aortic Valve Stenosis', 'ConditionBrowseLeafRelevance': 'high'}]","[{'ConditionBrowseBranchAbbrev': 'BC14', 'ConditionBrowseBranchName': 'Heart and Blood Diseases'}, {'ConditionBrowseBranchAbbrev': 'All', 'ConditionBrowseBranchName': 'All Conditions'}, {'ConditionBrowseBranchAbbrev': 'BC23', 'ConditionBrowseBranchName': 'Symptoms and General Pathology'}, {'ConditionBrowseBranchAbbrev': 'Rare', 'ConditionBrowseBranchName': 'Rare Diseases'}]",,,,,,,"[{'FlowGroupId': 'FG000', 'FlowGroupTitle': 'CoreValve Evolut R TAVR System 34R Valve', 'FlowGroupDescription': 'The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R 20Fr Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]","[{'FlowPeriodTitle': 'Baseline- 30 Days', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '60'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '59'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '1'}]}}]}}, {'FlowPeriodTitle': 'Baseline-6 Months', 'FlowMilestoneList': {'FlowMilestone': [{'FlowMilestoneType': 'STARTED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '59'}]}}, {'FlowMilestoneType': 'COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '54'}]}}, {'FlowMilestoneType': 'NOT COMPLETED', 'FlowAchievementList': {'FlowAchievement': [{'FlowAchievementGroupId': 'FG000', 'FlowAchievementNumSubjects': '5'}]}}]}}]",,"[{'BaselineGroupId': 'BG000', 'BaselineGroupTitle': 'CoreValve Evolut 34R TAVR System', 'BaselineGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.>\n\n> CoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:>\n\nEvolut 34R Transcatheter Aortic Valve (TAV)>\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath>\nEnVeo R Loading System (LS)'}]","[{'BaselineDenomUnits': 'Participants', 'BaselineDenomCountList': {'BaselineDenomCount': [{'BaselineDenomCountGroupId': 'BG000', 'BaselineDenomCountValue': '60'}]}}]","[{'BaselineMeasureTitle': 'Age, Continuous', 'BaselineMeasureParamType': 'Mean', 'BaselineMeasureDispersionType': 'Standard Deviation', 'BaselineMeasureUnitOfMeasure': 'years', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '60'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '81.8', 'BaselineMeasurementSpread': '8.2'}]}}]}}]}}, {'BaselineMeasureTitle': 'Sex: Female, Male', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '60'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineCategoryTitle': 'Female', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '2'}]}}, {'BaselineCategoryTitle': 'Male', 'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '58'}]}}]}}]}}, {'BaselineMeasureTitle': 'Race and Ethnicity Not Collected', 'BaselineMeasurePopulationDescription': 'Race and Ethnicity were not collected from any participant.', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '0'}]}}]}}]}}, {'BaselineMeasureTitle': 'Region of Enrollment', 'BaselineMeasureParamType': 'Count of Participants', 'BaselineMeasureUnitOfMeasure': 'Participants', 'BaselineClassList': {'BaselineClass': [{'BaselineClassTitle': 'United States', 'BaselineClassDenomList': {'BaselineClassDenom': [{'BaselineClassDenomUnits': 'Participants', 'BaselineClassDenomCountList': {'BaselineClassDenomCount': [{'BaselineClassDenomCountGroupId': 'BG000', 'BaselineClassDenomCountValue': '60'}]}}]}, 'BaselineCategoryList': {'BaselineCategory': [{'BaselineMeasurementList': {'BaselineMeasurement': [{'BaselineMeasurementGroupId': 'BG000', 'BaselineMeasurementValue': '60'}]}}]}}]}}]","[{'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants With All-cause Mortality', 'OutcomeMeasureDescription': 'Percentage of participants with all-cause mortality at 30 days', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 Days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.7', 'OutcomeMeasurementLowerLimit': '0.2', 'OutcomeMeasurementUpperLimit': '11.2'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Percentage of Participants With Stroke (Disabling)', 'OutcomeMeasureDescription': 'Percentage of participants with disabling stroke (VARC-II definitions) at 30 days', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 Days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.0', 'OutcomeMeasurementLowerLimit': '0.0', 'OutcomeMeasurementUpperLimit': '6.1'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'Device Success Rate', 'OutcomeMeasureDescription': 'Device Success defined as:\n\nAbsence of procedural mortality, AND\nCorrect positioning of a single prosthetic heart valve into the proper anatomical location, AND\nIntended performance of the prosthetic heart valve, defined as the absence of patient prosthesis-mismatch and mean gradient < 20 mmHg (or peak velocity < 3 m/sec), AND\nAbsence of moderate or severe prosthetic valve regurgitation', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '24 hours to 7 days post implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '79.2', 'OutcomeMeasurementLowerLimit': '65.9', 'OutcomeMeasurementUpperLimit': '89.2'}]}}]}}]}}, {'OutcomeMeasureType': 'Primary', 'OutcomeMeasureTitle': 'The Percentage of Subjects With no More Than Mild Prosthetic Regurgitation at Early Post Procedure Echocardiogram', 'OutcomeMeasureDescription': 'The percentage of subjects with no more than mild prosthetic regurgitation at early post procedure echocardiogram as assessed by echo core laboratory', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '24 hours to 7 days post implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '100.0', 'OutcomeMeasurementLowerLimit': '93.9', 'OutcomeMeasurementUpperLimit': '100.0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With VARC II Combined Safety Endpoint Event at 30 Days', 'OutcomeMeasureDescription': 'VARC II composite safety endpoint includes the following components:\n\nAll-cause mortality\nAll stroke (disabling and non-disabling)\nLife-threatening bleeding\nAcute kidney injury: stage 2 or 3 (including renal replacement therapy).\nCoronary artery obstruction requiring intervention.\nMajor vascular complication.\nValve-related dysfunction requiring repeat procedure (BAV, TAVR, or SAVR)', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '5.0', 'OutcomeMeasurementLowerLimit': '1.6', 'OutcomeMeasurementUpperLimit': '14.7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With Life Threatening or Disabling Bleeding', 'OutcomeMeasureDescription': 'Percentage of participants with life threatening or disabling bleeding - see VARC-2 definitions for classification details', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days post-implantation', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.7', 'OutcomeMeasurementLowerLimit': '0.2', 'OutcomeMeasurementUpperLimit': '11.4'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With Major Vascular Complication', 'OutcomeMeasureDescription': 'Percentage of participants with Major vascular complication - see VARC-2 definitions for additional details', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '1.7', 'OutcomeMeasurementLowerLimit': '0.2', 'OutcomeMeasurementUpperLimit': '11.4'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With Acute Kidney Injury: Stage 2 or 3', 'OutcomeMeasureDescription': 'Percentage of participants with Acute Kidney Injury: Stage 2 or 3 - see VARC-2 definitions for additional details', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.0', 'OutcomeMeasurementLowerLimit': '0.0', 'OutcomeMeasurementUpperLimit': '6.1'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Participants With Coronary Artery Obstruction', 'OutcomeMeasureDescription': 'Percentage of participants with coronary artery obstruction - see VARC-2 definitions for additional details', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.0', 'OutcomeMeasurementLowerLimit': '0.0', 'OutcomeMeasurementUpperLimit': '6.1'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Subjects With Valve-related Dysfunction Requiring Repeat Procedure', 'OutcomeMeasureDescription': 'Percentage of subjects with valve-related dysfunction requiring repeat procedure - see VARC-2 definitions for additional details', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.0', 'OutcomeMeasurementLowerLimit': '0.0', 'OutcomeMeasurementUpperLimit': '6.1'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Subjects With Permanent Pacemaker Implant at 30 Days', 'OutcomeMeasureDescription': 'Percentage of subjects with new permanent pacemaker implant at 30 days.', 'OutcomeMeasurePopulationDescription': 'Subjects with pre-existing pacemaker or internal cardiac defibrillator were excluded from analysis.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureDispersionType': '95% Confidence Interval', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '42'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '20.8', 'OutcomeMeasurementLowerLimit': '12.1', 'OutcomeMeasurementUpperLimit': '34.3'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Percentage of Resheath and Recapture Success', 'OutcomeMeasureDescription': 'Successful resheathing is defined as Evolut R TAV (including frame) was resheathed into the capsule of the delivery cathether to the desired amount intended, as verified by fluoroscopy.\n\nSuccessful recapture is defined as the entire Evolut R TAV (including frame) is resheathed into the capsule of the delivery catheter until there is no gap between the capsule and the tip, as verified by fluoroscopy.', 'OutcomeMeasurePopulationDescription': 'Success could only be analyzed in subjects where the resheath/recapture feature was used.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': 'Implant procedure', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '26'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '100.0'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hemodynamic Performance Metrics - Mean Gradient', 'OutcomeMeasureDescription': 'Mean gradient (mmHg) as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'OutcomeMeasurePopulationDescription': 'Only participants with echo could be analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'mmHg', 'OutcomeMeasureTimeFrame': 'Baseline, 30 days, and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'Baseline', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '60'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '41.5', 'OutcomeMeasurementSpread': '10.3'}]}}]}}, {'OutcomeClassTitle': '30 days', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '58'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.4', 'OutcomeMeasurementSpread': '3.2'}]}}]}}, {'OutcomeClassTitle': '6 Months', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '53'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '6.7', 'OutcomeMeasurementSpread': '3.5'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hemodynamic Performance Metrics- Aortic Valve Area', 'OutcomeMeasureDescription': 'Aortic valve area as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'OutcomeMeasurePopulationDescription': 'Only participants with echo could be analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Mean', 'OutcomeMeasureDispersionType': 'Standard Deviation', 'OutcomeMeasureUnitOfMeasure': 'cm2', 'OutcomeMeasureTimeFrame': 'Baseline, 30 Days, and 6 Months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '60'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': 'baseline', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '60'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '0.8', 'OutcomeMeasurementSpread': '0.2'}]}}]}}, {'OutcomeClassTitle': '30 days', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '58'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.6', 'OutcomeMeasurementSpread': '0.7'}]}}]}}, {'OutcomeClassTitle': '6 months', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '53'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '2.3', 'OutcomeMeasurementSpread': '0.7'}]}}]}}]}}, {'OutcomeMeasureType': 'Secondary', 'OutcomeMeasureTitle': 'Hemodynamic Performance Metrics - Total Prosthetic Regurgitation Graded as None/Trace', 'OutcomeMeasureDescription': 'Total prosthetic regurgitation (none/trace) as measured by transthoracic echocardiogram and assessed by echo core laboratory', 'OutcomeMeasurePopulationDescription': 'Only participants with echo could be analyzed.', 'OutcomeMeasureReportingStatus': 'Posted', 'OutcomeMeasureParamType': 'Number', 'OutcomeMeasureUnitOfMeasure': 'percentage of participants', 'OutcomeMeasureTimeFrame': '30 days and 6 months', 'OutcomeGroupList': {'OutcomeGroup': [{'OutcomeGroupId': 'OG000', 'OutcomeGroupTitle': 'CoreValve Evolut 34R TAVR System', 'OutcomeGroupDescription': 'Treatment of Aortic Stenosis with Medtronic CoreValve Evolut R 34R TAVR System.\n\n>\n\n>\n\nCoreValve Evolut 34R TAVR system: The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:\n\nEvolut 34R Transcatheter Aortic Valve (TAV)\n\n>\n\nEnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath\n\n>\n\nEnVeo R Loading System (LS)'}]}, 'OutcomeDenomList': {'OutcomeDenom': [{'OutcomeDenomUnits': 'Participants', 'OutcomeDenomCountList': {'OutcomeDenomCount': [{'OutcomeDenomCountGroupId': 'OG000', 'OutcomeDenomCountValue': '58'}]}}]}, 'OutcomeClassList': {'OutcomeClass': [{'OutcomeClassTitle': '30 days', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '58'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '60.3'}]}}]}}, {'OutcomeClassTitle': '6 months', 'OutcomeClassDenomList': {'OutcomeClassDenom': [{'OutcomeClassDenomUnits': 'Participants', 'OutcomeClassDenomCountList': {'OutcomeClassDenomCount': [{'OutcomeClassDenomCountGroupId': 'OG000', 'OutcomeClassDenomCountValue': '53'}]}}]}, 'OutcomeCategoryList': {'OutcomeCategory': [{'OutcomeMeasurementList': {'OutcomeMeasurement': [{'OutcomeMeasurementGroupId': 'OG000', 'OutcomeMeasurementValue': '72.0'}]}}]}}]}}]",5,6 months,,"[{'EventGroupId': 'EG000', 'EventGroupTitle': 'EVOLUTR 34R', 'EventGroupDescription': 'Participants implanted with EVOLUTR 34R device', 'EventGroupDeathsNumAffected': '5', 'EventGroupDeathsNumAtRisk': '60', 'EventGroupSeriousNumAffected': '34', 'EventGroupSeriousNumAtRisk': '60', 'EventGroupOtherNumAffected': '48', 'EventGroupOtherNumAtRisk': '60'}]","[{'OtherEventTerm': 'Anaemia', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Leukocytosis', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '8', 'OtherEventStatsNumAffected': '8', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Thrombocytopenia', 'OtherEventOrganSystem': 'Blood and lymphatic system disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '15', 'OtherEventStatsNumAffected': '15', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Atrial Fibrillation', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Atrioventricular Block First Degree', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '13', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Bundle Branch Block Left', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '17', 'OtherEventStatsNumAffected': '17', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Extrasystoles', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Sinus Bradycardia', 'OtherEventOrganSystem': 'Cardiac disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Urinary Tract Infection', 'OtherEventOrganSystem': 'Infections and infestations', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Myocardial Necrosis Marker Increased', 'OtherEventOrganSystem': 'Investigations', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Hyperglycaemia', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Hypervolaemia', 'OtherEventOrganSystem': 'Metabolism and nutrition disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '12', 'OtherEventStatsNumAffected': '12', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Haematuria', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '5', 'OtherEventStatsNumAffected': '5', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Renal Failure', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Urinary Retention', 'OtherEventOrganSystem': 'Renal and urinary disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Hypertension', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '6', 'OtherEventStatsNumAffected': '6', 'OtherEventStatsNumAtRisk': '60'}]}}, {'OtherEventTerm': 'Hypotension', 'OtherEventOrganSystem': 'Vascular disorders', 'OtherEventSourceVocabulary': 'MedDRA 10.0', 'OtherEventAssessmentType': 'Systematic Assessment', 'OtherEventStatsList': {'OtherEventStats': [{'OtherEventStatsGroupId': 'EG000', 'OtherEventStatsNumEvents': '4', 'OtherEventStatsNumAffected': '4', 'OtherEventStatsNumAtRisk': '60'}]}}]",No,No,Sara Saul,Medtronic,sara.m.saul@medtronic.com,763-526-1965,"[{'SeriousEventTerm': 'Anaemia', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Coagulopathy', 'SeriousEventOrganSystem': 'Blood and lymphatic system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Acute Myocardial Infarction', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Atrioventricular Block', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Atrioventricular Block Complete', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '8', 'SeriousEventStatsNumAffected': '8', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Atrioventricular Block First Degree', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Bundle Branch Block Left', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Cardiac Arrest', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Cardiac Failure Acute', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Cardiac Failure Congestive', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Cardio-Respiratory Arrest', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Cardiogenic Shock', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Conduction Disorder', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Nodal Rhythm', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Pulseless Electrical Activity', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Supraventricular Tachycardia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Ventricular Tachycardia', 'SeriousEventOrganSystem': 'Cardiac disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Vision Blurred', 'SeriousEventOrganSystem': 'Eye disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Rectal Haemorrhage', 'SeriousEventOrganSystem': 'Gastrointestinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Chest Pain', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Device Embolisation', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Generalised Oedema', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Pyrexia', 'SeriousEventOrganSystem': 'General disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Bronchitis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Pneumonia', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Sepsis', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Viral Infection', 'SeriousEventOrganSystem': 'Infections and infestations', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Arterial Injury', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Compression Fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Concussion', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Hip Fracture', 'SeriousEventOrganSystem': 'Injury, poisoning and procedural complications', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Hyperglycaemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Hypomagnesaemia', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Malnutrition', 'SeriousEventOrganSystem': 'Metabolism and nutrition disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Rhabdomyolysis', 'SeriousEventOrganSystem': 'Musculoskeletal and connective tissue disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Lung Neoplasm Malignant', 'SeriousEventOrganSystem': 'Neoplasms benign, malignant and unspecified (incl cysts and polyps)', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Cerebrovascular Accident', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Dizziness', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Hypoxic-Ischaemic Encephalopathy', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Syncope', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Transient Ischaemic Attack', 'SeriousEventOrganSystem': 'Nervous system disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Confusional State', 'SeriousEventOrganSystem': 'Psychiatric disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Glomerulonephritis Membranous', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Haematuria', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Urinary Retention', 'SeriousEventOrganSystem': 'Renal and urinary disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '4', 'SeriousEventStatsNumAffected': '4', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Acute Respiratory Failure', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Bronchiectasis', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Pleural Effusion', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Pulmonary Embolism', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Pulmonary Oedema', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Respiratory Failure', 'SeriousEventOrganSystem': 'Respiratory, thoracic and mediastinal disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Deep Vein Thrombosis', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '3', 'SeriousEventStatsNumAffected': '3', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Femoral Artery Dissection', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Hypertension', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Hypotension', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '2', 'SeriousEventStatsNumAffected': '2', 'SeriousEventStatsNumAtRisk': '60'}]}}, {'SeriousEventTerm': 'Peripheral Ischaemia', 'SeriousEventOrganSystem': 'Vascular disorders', 'SeriousEventSourceVocabulary': 'MedDRA 10.0', 'SeriousEventAssessmentType': 'Systematic Assessment', 'SeriousEventStatsList': {'SeriousEventStats': [{'SeriousEventStatsGroupId': 'EG000', 'SeriousEventStatsNumEvents': '1', 'SeriousEventStatsNumAffected': '1', 'SeriousEventStatsNumAtRisk': '60'}]}}]",,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
